gemcitabine has been researched along with Pancreatic Neoplasms in 4415 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 73 (1.65) | 18.2507 |
| 2000's | 1118 (25.32) | 29.6817 |
| 2010's | 2458 (55.67) | 24.3611 |
| 2020's | 766 (17.35) | 2.80 |
| Authors | Studies |
|---|---|
| Iovanna, JL; Liu, Y; Neyts, J; Peng, L; Qu, F; Rocchi, P; Wan, J; Wang, M; Xia, Y; Yao, J | 1 |
| Iovanna, JL; Liu, Y; Peng, L; Qu, F; Rocchi, P; Wan, J; Wang, M; Xia, Y | 1 |
| Fan, Y; Iovanna, JL; Liu, Y; Maggiani, A; Peng, L; Qu, F; Rocchi, P; Xia, Y | 1 |
| Fan, Y; Iovanna, JL; Peng, L; Qu, F; Rocchi, P; Wang, M; Xia, Y | 1 |
| Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU | 1 |
| Bourguignon, JJ; Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Abdelhamed, S; Athikomkulchai, S; Awale, S; Miyatake, R; Saiki, I; Ueda, JY; Yokoyama, S | 1 |
| Abdelhamed, S; Athikomkulchai, S; Awale, S; Dibwe, DF; Miyatake, R; Saiki, I; Ueda, JY; Yokoyama, S | 1 |
| Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mantelas, A; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Chin, J; Choi, H; Chun, T; Ekins, M; Hahn, D; Han, C; Kang, H; Kim, H; Mun, B; Nam, SJ; Park, S; Wang, W; Won, DH; Yoon, D | 1 |
| Aboukameel, A; Banerjee, S; Khan, EM; Khatal, S; Mohammad, M; Padhye, S; Sarkar, FH; Venkateswara Swamy, K; Yusufi, M | 1 |
| Gately, S; Gonzales, P; Sepulveda, M; Wang, T | 1 |
| Awale, S; Shakya, B; Ueda, JY; Yadav, PN | 1 |
| Awale, S; Do, TN; Esumi, H; Le, TH; Nguyen, HX; Nguyen, MT; Nguyen, NT | 1 |
| Abbe, P; Benhida, R; Cavazza, E; Cerezo, M; Jaune, E; Millet, A; Plaisant, M; Rocchi, S; Ronco, C | 1 |
| Chun, KH; Kim, J; Kim, Y; Lim, JW; Yoon, Y | 1 |
| Kuang, Y; Ljungman, M; Neamati, N; Nurra, S; Sechi, M | 1 |
| Ahmed, AA; Andrade, ACG; Balasubramanian, S; Besser, RJ; Di Vita, G; Diocou, S; Evans, TRJ; Gunaratnam, M; Haider, SM; Laughlin-Toth, S; Marchetti, C; Marsico, G; Morton, JP; Neidle, S; Ohnmacht, SA; Pazitna, I; Pedley, RB; Pike, JA; Robson, M; Tannahill, D; Vo, T; Wilson, WD; Zyner, KG | 1 |
| Bai, C; Chen, J; Chen, Y; Chong, C; Ding, Y; Gao, Y; Geng, Y; Li, J; Wang, M; Wu, L; Yu, J; Zhang, Q | 1 |
| Aboelela, A; Ali, U; Apte, M; Bachovchin, DA; Buckley, BJ; Cheung, CY; Cook, GM; Cook, SM; Fildes, K; Huang, M; Jiang, LX; Johnson, DC; Kelso, MJ; Minaei, E; Ranson, M; Xu, Z | 1 |
| Cui, W; Li, JX; Liu, CX; Shen, Q; Wang, J; Wang, Y; Wu, J; Zhang, L; Zhang, YC | 1 |
| Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y | 1 |
| Bergonzini, C; Carbone, D; Cascioferro, S; Cirrincione, G; Dekker, H; Diana, P; Funel, N; Geerke, D; Giovannetti, E; Mantini, G; Parrino, B; Peters, GJ; Petri, GL | 1 |
| Beauregard, J; Collins, L; Dostie, S; Guindon, Y; Labbé, MO; Lefebvre, CA; Maharsy, W; Nemer, M; Prévost, M | 1 |
| Augustin, E; Borowa-Mazgaj, B; Horowska, B; Konopa, J; Mazerska, Z; Paluszkiewicz, E; Paradziej-Łukowicz, J; Peszyńska-Sularz, G | 1 |
| Awolade, P; Gummidi, L; Kerru, N; Raza, A; Sharma, AK; Singh, P | 1 |
| Gao, Y; Han, X; Hao, M; Hou, S; Kang, Z; Li, Y; Tong, Y; Wang, B; Wang, C; Wang, Q; Zhang, C | 1 |
| Ganapathi, T; Kamal, A; Khan, I; Kumar, CG; Rehman, MM; Shareef, MA | 1 |
| Contreras, JI; Ezell, EL; Garrison, JC; Kizhake, S; Mallareddy, JR; Napoleon, JV; Natarajan, A; Radhakrishnan, P; Rajesh, C; Rana, S; Sagar, S; Singh, S; Sonawane, YA | 1 |
| Che, Q; Li, D; Li, J; Liu, X; Shah, M; Sun, C; Sun, N; Zhang, G; Zhang, X; Zhu, T | 1 |
| Chen, H; Kuang, Y; Kyani, A; Ljungman, M; Neamati, N; Paulsen, M; Wild, C; Ye, N; Zhou, J; Zhou, M | 1 |
| Avan, A; Bononi, G; Brai, A; Caligiuri, I; Chicca, A; Di Stefano, M; Dreassi, E; Gertsch, J; Giovannetti, E; Granchi, C; Macchia, M; Masetto, F; Meier, P; Minutolo, F; Ortore, G; Poli, G; Rizzolio, F; Tuccinardi, T; Vagaggini, C; Valoti, M | 1 |
| Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q | 1 |
| Dotan, E; Handorf, E; Winer, A | 1 |
| Atri, P; Batra, SK; Bhatia, R; Cox, JL; Ganguly, K; Kaur, S; Kisling, A; Kumar, S; Mallya, K; Ram Krishn, S; Rauth, S; Shinde, D; Thomas, V; Thompson, C; Vengoji, R | 1 |
| AlMasri, SS; Bahary, N; Bartlett, DL; Boone, BA; Desilva, A; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Nassour, I; Paniccia, A; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Jin, X; Ren, D; Shen, J; Sun, Y; Wu, H; Zhou, Y | 1 |
| Chen, D; Chen, Q; He, C; Hu, P; Hu, Y; Huang, K; Huang, M; Niu, Y; Tang, J; Wang, C; Wang, F; Xu, F; Zeng, Z; Zhao, G; Zhao, Y | 1 |
| Au, T; Biskupiak, J; Kharat, AA; Nelson, R | 1 |
| Chambers, CR; Chen, A; Ghosh, S; Ha, VH; Sawyer, MB | 1 |
| Chen, C; Cui, F; Lin, K; Peng, L; Sun, L; Yao, Y; Yu, Q; Zhang, Y; Zhuang, L | 1 |
| Huang, H; Wang, C | 1 |
| Chassagnon, G; Ginestet, C; Sabat, C | 1 |
| Amundsen, T; Doyle, J; Hall, JA; Raiyani, C; Wong, L | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Jensen, E; Nalluri, H; Staley, C | 1 |
| Gong, Y; Hou, B; Huang, B; Huang, S; Li, Z; Liu, C; Ma, Z; Yang, L; Zhang, C; Zheng, Z; Zhou, Q; Zhou, Z; Zhuang, H; Zou, Y | 1 |
| Wang, Q; Xie, S; Xu, M; Yang, C; Zhang, D; Zhang, J; Zhong, W; Zhou, L | 1 |
| Hua, J; Liang, C; Liu, J; Meng, Q; Shi, S; Tan, Z; Wang, W; Xu, J; Yang, J; Yu, X; Zhang, B | 1 |
| Ding, L; Hang, Y; Oupický, D; Sil, D; Tang, S; Tang, W; Xie, Y; Yu, A; Zhang, C | 1 |
| Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Holmes, B; Hossain, MA; Mukherjee, P; Tarannum, M; Vivero-Escoto, JL; Yan, S | 1 |
| Chao, Y; Lee, CY; Li, CP; Lin, LG; Yu, HY | 1 |
| Arias, J; Beca, J; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Forbes, L; Gavura, S; Habbous, S; Raphael, MJ; Raskin, W; Tai, X | 1 |
| Dai, GH; Deng, GC; Han, QL; Lv, Y; Pan, YT; Qu, TT; Sun, DC; Yan, H | 1 |
| Hwang, HK; Kang, CM; Lee, SH; Lee, WJ | 1 |
| Kaneyasu, T; Morimoto, K; Moriwaki, K; Nakayama, H; Shimozuma, K | 1 |
| Furukawa, M; Hisano, T; Lee, L; Miki, M; Sugimoto, R | 1 |
| Guo, X; Qin, R; Wang, M; Yu, S; Zhang, H | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Andolfo, A; Federici, F; Latiano, TP; Laura, M; Panebianco, C; Pazienza, V; Perri, F; Pisati, F; Potenza, A; Rizzi, E; Tripodo, C; Ulaszewska, M; Villani, A | 1 |
| Chen, Q; Gao, G; Go, VLW; Guo, J; Li, K; Li, N; Liu, J; Pan, Y; Tao, X; Xiao, GG; Zhao, Y | 1 |
| Barrera, LN; Brumskill, S; Calcraft, P; Costello, E; Phillips, C | 1 |
| Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D | 1 |
| Bauer, K; Henne-Bruns, D; Manzini, G | 1 |
| Che, JX; Dong, XW; Gu, YQ; Lin, NM; Lin, X; Teng, F; Yan, YY; Zhang, B; Zhou, LX; Zhou, XL | 1 |
| Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW | 1 |
| Komatsu, Y; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Uchiyama, K | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Endo, I; Hiratani, S; Homma, Y; Kumamoto, T; Matsuyama, R; Miyake, K; Mori, R; Murakami, T; Ota, Y; Sawada, Y; Shimizu, Y; Yabusita, Y | 1 |
| Andrén, PE; Atkinson, J; Barnes, J; Barry, ST; Brais, R; Bunch, J; Dunlop, CR; Goodwin, RJA; Gopinathan, A; Hamm, G; Jodrell, DI; Johnson, TI; Kaistha, BP; Lau, A; Ling, S; Maglennon, G; Nilsson, A; Race, AM; Richards, FM; Sansom, OJ; Serra, MP; Smith, A; Strittmatter, N; Sutton, D; Takats, Z; Wallez, Y; Wilson, J; Wong, E | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Arıkan, R; Atcı, MM; Ay, S; Doğan, İ; Dülgar, Ö; Gümüş, M; Öven, BB; Öztosun, B; Özyükseler, DT; Paksoy, N; Taştekin, D | 1 |
| Chen, R; He, R; Hu, C; Li, G; Li, T; Li, Z; Lin, Q; Xia, R; Ye, Y; Zhang, X; Zheng, S | 1 |
| Hao, S; Li, S; Liu, Z; Lu, W; Ouyang, G; Pan, G; Wu, Y | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Ohata, C; Shimizu, Y | 1 |
| Bai, Y; Guo, H; Guo, Y; Huang, Y; Lin, M; Xiao, Y; Yang, X; Yuan, Z; Zhang, Q; Zhu, H | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Fukumoto, T; Matsuo, Y; Nanno, Y; Ogura, Y; Okimoto, T; Park, S; Suga, M; Sulaiman, NS; Takahashi, D; Terashima, K; Tokumaru, S; Toyama, H | 1 |
| Alemany, R; Álvarez, R; Bazan-Peregrino, M; Blasco, C; Blasi, E; Capella, G; Cascallo, M; Garcia-Carbonero, R; Gimenez-Alejandre, M; Ginestà, MM; Gornals, JB; Hidalgo, M; Laquente, B; Maliandi, MV; Mato-Berciano, A; Moreno, R; Morgado, S; Perea, S; Perez-Carreras, M; Prados, S; Riesco, MC; Rodríguez-García, A; Salazar, R | 1 |
| Li, N; Qi, Y; Yu, D; Zhan, J; Zhang, G; Zhao, Q | 1 |
| Chen, K; Chen, Z; Li, J; Ma, J; Ma, Q; Qian, W; Qin, T; Wang, Z; Wu, E; Wu, Z; Xiao, Y | 1 |
| Cai, C; Dong, P; Gong, W; Li, ML; Liang, HB; Liu, SL; Wu, XS; Wu, ZY; Yang, ZY; Zheng, L | 1 |
| Abdul Majid, AMS; Asif, M; Oon, CE; Yehya, AHS | 1 |
| Abi Jaoude, J; Delahoussaye, AM; Feng, N; Fowlkes, N; Fujimoto, TN; Garcia Garcia, CJ; Gay, JP; Green, M; Marszalek, J; Molkentine, J; Taniguchi, CM | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 2 |
| Enomoto, A; Fujishiro, M; Iida, T; Imai, M; Ishikawa, T; Kawashima, H; Kinoshita, F; Kuwatsuka, Y; Mizutani, Y; Ohno, E; Shimizu, S; Tsuruta, T | 1 |
| Abe, Y; Daiku, K; Fujita, M; Fukutake, N; Higashi, S; Hiraga, E; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Cao, Y; Jiang, L; Jin, G; Ju, X; Liu, W; Ye, Y; Zhang, H; Zhao, X; Zhu, X | 2 |
| Hong, SS; Kang, CM; Kim, D; Kim, S; Lee, J; Lee, JH; Lee, S; Lee, SH; Park, H | 1 |
| Kashima, H; Kimura, Y; Kusumi, F; Matsumoto, A; Minami, R; Ohana, M; Okano, A; Ozawa, T; Takeda, Y; Ueo, T | 1 |
| Cheuk, W; Cho, WCS; Huang, QH; Li, Y; Lin, ZX; Xian, YF; Xu, HX; Yang, W; Zhang, J | 1 |
| Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y | 2 |
| Carson, JA; Chaib, M; Glazer, ES; Hayes, DN; Kansal, R; Makowski, L; Morrrison, M; Rana, M; Shibata, D; Stanfill, AG; Teng, B | 1 |
| Cutillas, PR; de Luxán-Delgado, B; Dormann, C; Drake, RJG; Géraud, C; Gómez-Escudero, J; Hodivala-Dilke, K; Maiques, O; Meng, YM; Newport, E; Rajeeve, V; Reynolds, LE; Richards, FM; Roy-Luzarraga, M; Sanz-Moreno, V; Saur, D; Vermeulen, PB; Weller, C; Wisniewski, L; Wong, PP | 1 |
| Hou, Y; Li, C; Liu, H; Zhang, L; Zhu, J | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Kawano, R; Kondo, N; Murakami, Y; Okada, K; Otsuka, H; Seo, S; Sumiyoshi, T; Takahashi, S; Uemura, K | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Higashino, N; Ikoma, A; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Abe, Y; Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Kang, FP; Liao, CY; Lin, CF; Tian, YF; Wang, ZW | 1 |
| Aissa, AF; Benevolenskaya, EV; Ke, R; Kumar, S; Munshi, HG; Nair, R; Pham, TND; Principe, DR; Rana, A; Rana, B; Trevino, JG; Underwood, PW | 1 |
| Li, X; Lu, W; Tang, K; Wang, L | 1 |
| Cao, C; Han, S; Hu, C; Li, M; Liu, R; Pan, L; Xu, M; Yuan, Y; Zhang, X | 1 |
| Allard, J; Bonnet, M; Bouattour, M; Gagaille, MP; Laurent, L; Leclerc, V | 1 |
| Cai, CY; Chen, ZS; Fan, Y; Gu, J; Huang, W; Li, J; Liu, S; Tao, T; Wang, H; Wang, X; Yang, J; Zhang, J; Zheng, Y | 1 |
| Furukawa, K; Gocho, T; Hamura, R; Ikegami, T; Onda, S; Sakamoto, T; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Liao, CY; Pan, JJ; Shen, BY; Tian, YF; Wang, YD; Wang, ZW; Yang, C; Zhang, JQ | 1 |
| Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G | 2 |
| Du, H; Epps, J; Johnson, S; Karki, K; Safe, S; Shrestha, R; Suva, L; Vaziri-Gohar, A; Yu, Z; Zarei, M | 1 |
| Boeck, S; Engel, J; Gil, L; Guenther, M; Heinemann, V; Mayerle, J; Ormanns, S; Palm, MA; Surendran, SA; von Bergwelt-Baildon, M; Werner, J | 1 |
| Feng, M; Gu, Z; He, Y; Kong, X; Mao, H; Wu, L | 1 |
| Bu, F; Chen, L; Hu, Z; Li, Q; Lin, K; Luo, C; Peng, X; Wang, K; Yu, X; Yuan, R; Zhang, W; Zhao, J; Zhu, J; Zhu, X; Zhu, Z | 1 |
| Andolfo, A; Latiano, TP; Orsenigo, F; Panebianco, C; Pazienza, V; Perri, F; Pisati, F; Potenza, A; Terracciano, F; Tripodo, C; Ulaszewska, M; Villani, A | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Chen, Y; Liu, M; Lu, P; Niu, N; Shen, X; Shi, J; Sun, Y; Tang, Y; Xu, D; Xue, J; Yang, X; Yao, H | 1 |
| Kong, R; Qian, X; Ying, W | 1 |
| Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Chen, SY; Li, ZY; Weng, MH; Yen, GC | 1 |
| Huang, B; Li, C; Yan, Y; Yang, X | 1 |
| Fu, L; Jiang, J; Li, J; Liu, M; Liu, Q; Song, C; Zeng, Z; Zhu, H | 1 |
| Arciero, V; Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Isaranuwatchai, W; Luo, J; Mittmann, N; Parmar, A; Raphael, MJ; Tadrous, M | 1 |
| Chen, G; Liu, Y; Qiu, J; Su, D; Tao, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Furuse, J; Gondo, K; Kogure, M; Matsuki, R; Nagashima, F; Ochiai, K; Okano, N; Sakamoto, Y; Shibahara, J; Sugiyama, M; Suzuki, Y; Tateishi, H; Toki, M; Watanabe, S | 1 |
| Chen, T; Geng, Y; Gu, Y; Li, Y; Liu, K; Sun, L; Wang, L; Wu, S; Xu, F; Xu, H; Zhao, Z; Zou, M | 1 |
| Lou, J; Lu, W; Tang, K; Wang, L | 1 |
| Ananda, S; Burge, M; Chee, CE; Clarke, K; Cooray, P; Fox, A; Gibbs, P; Harris, M; Knowles, B; Lee, B; Lipton, L; Mclachlan, SA; Nagrial, A; Nikfarjam, M; Pattison, S; Shapiro, J; Tebbutt, N; Thomson, B; Usatoff, V; Walpole, I; Wong, R; Zielinski, R | 1 |
| Esposito, F; Font, C; Garcia de Herreros, M; Sauri, T | 1 |
| Elia, A; Kraev, I; Miralles, F; Rashid, S; Rimmer, E | 1 |
| Fujii, K; Fujiwara-Tani, R; Kishi, S; Kuniyasu, H; Mori, S; Nishiguchi, Y; Ohmori, H; Sasaki, T; Takagi, T | 1 |
| Chen, C; Chen, H; Chen, X; Jian, Y; Xiu, Z; Yang, S; Yin, L; Yu, Q; Zeng, W; Zhou, J | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Hamauchi, S; Kawakami, T; Nakase, H; Ohwada, S; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Chen, JA; Gandara, DR; Huynh, JC; Kelly, KL; Kim, EJ; Li, T; Mack, PC; Mahaffey, N; Martinez, A; Matsukuma, K; Riess, JW; Semrad, TJ; Tam, K; Wu, CY; Yu, AM | 1 |
| Asagi, A; Hiasa, Y; Hino, K; Hyodo, I; Imamura, Y; Inoue, T; Kajiwara, T; Kanemitsu, K; Koizumi, M; Kokubu, M; Kumagi, T; Marui, K; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Numata, Y; Okujima, Y; Sakaguchi, C; Terao, T; Yoshimatsu, M | 1 |
| Chen, L; Gong, Q; Li, H; Tang, Z; Tao, J; Zhang, Z; Zhao, C | 1 |
| Hou, Y; Li, C; Liu, H; Wang, Y; Zhang, L | 1 |
| Chen, JY; Jiang, JL; Ma, T; Qi, WX; Xu, HP | 1 |
| Cong, M; Li, C; Li, F; Pang, H; Wang, Y; Xu, G; Yang, S; Zhao, W | 1 |
| Cai, Z; Cao, D; Chang, C; Cheng, K; Li, R; Li, X; Lv, W; Xiong, J; Zhang, P | 1 |
| He, J; Kong, W; Liang, M; Liu, P; Ren, P; Tang, S; Wei, D; Xu, L; Yang, H; Zhang, T | 1 |
| Cao, L; Chen, C; Freeman, JW; Karnad, A; Kumar, AP; Zhao, S; Zhao, X | 1 |
| Bai, X; Chen, W; Gao, S; Huang, B; Lao, M; Liang, T; Ma, T; Que, R; Shui, Y; Wang, J; Wei, Q; Zhang, Y | 1 |
| Arima, S; Doi, K; Furuse, J; Hayashi, H; Higuchi, H; Hisano, T; Imaoka, H; Ishii, H; Ishii, S; Kawabe, K; Kitano, Y; Kobayashi, S; Kojima, Y; Maruki, Y; Misumi, T; Miwa, H; Nagano, H; Naganuma, A; Nakashima, K; Okano, N; Ozaka, M; Shioji, K; Suzuki, M; Suzuki, R; Tanaka, K; Todaka, A; Tsuji, K; Tsumura, H; Ueno, M; Umemoto, K; Yamaguchi, H; Yamashita, T | 1 |
| Guo, YC; Jian, WZ; Qiu, XY; Xue, JS; Yao, QY; Yao, Y; Zhang, RW; Zhou, J; Zhou, TY | 1 |
| Cui, J; Gou, S; Guo, Y; Peng, T; Wu, H; Xiong, J | 1 |
| Chang, A; Gao, S; Ge, Y; Hao, J; Huang, C; Li, H; Liu, J; Sun, H; Wang, X; Wang, Y; Wu, L; Xu, C; Yuan, Y; Zhao, T | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Chang, JS; Chen, HA; Chiu, CF; Hsu, TW; Lin, CY; Park, JM; Peng, JM; Saengboonmee, C; Shan, YS; Shen, YS; Su, YH | 1 |
| Aucoin, N; Couture, F; Du, P; Gill, S; Harb, M; Jia, S; Jonker, D; Kavan, P; Kim, CA; Knox, JJ; Ko, YJ; Lemay, F; Loree, JM; Meyers, BM; O'Callaghan, CJ; Ramjeesingh, R; Renouf, DJ; Schaeffer, DF; Tang, PA; Tehfe, M; Topham, JT; Tu, D; Welch, S | 1 |
| Hou, X; Li, JH; Li, SJ; Li, YX; Ni, X; Wu, X; Yin, XY; Zhao, W; Zhu, XX | 1 |
| Artru, P; Assenat, E; Bauguion, L; Ben Abdelghani, M; Biagi, JJ; Bouché, O; Castan, F; Conroy, T; Evesque, L; Hammel, P; Lambert, A; Lecomte, T; Lopez, A; Mitry, E; Monard, L; Turpin, A; Wei, AC; Ychou, M | 1 |
| Chen, L; Chen, WJ; Chen, WQ; Hong, RQ; Wang, HP; Yu, Y; Zou, YF | 1 |
| Bertram, M; Binninger, A; Chiabudini, M; Hegewisch-Becker, S; Hollerbach, SH; Jänicke, M; Kaiser-Osterhues, A; Kreher, S; Marschner, N; Reiser, M; von der Heyde, E; Wolf, T | 1 |
| Brown, J; Correa Ordonez, I; Davis, M; Vanenkevort, E; Varun, S; Wojtowicz, M; Young, A | 1 |
| Algül, H; Braren, RF; Crone, B; Harder, FN; Heid, I; Jungmann, F; Kaissis, G; Karst, U; Liotta, L; Lohöfer, F; Makowski, MR; Mayer, M; Siveke, JT; Steiger, K; Topping, GJ; Trajkovic-Arsic, M; Weichert, W; Wildgruber, M; Yen, HY | 1 |
| Jusko, WJ; Kandel, ES; Lin, Q; Qian, Z; Qu, J; Rasam, SS; Serratore, A; Shen, S; Straubinger, RM | 1 |
| Chang, Q; Chen, Q; Huang, X; Jiang, H; Li, K; Li, R; Liu, G; Liu, X; Shi, P; Tu, Q; Xu, G; Yao, X; Zhao, B; Zhu, H | 1 |
| Du, S; Fan, L; Li, Y; Liu, Y; Wang, J | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T | 1 |
| Dong, LP; Liu, YM; Lu, WJ; Tang, KZ | 1 |
| Jiménez-Luna, C; Melguizo, C; Mesas, C; Muñoz-Gámez, JA; Ortiz, R; Perazzoli, G; Prados, J; Quiñonero, F | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Cao, R; Chen, H; Li, L; Li, R; Li, Y; Liu, X; Shao, R; Shi, Y; Song, W; Wang, J; Yao, H; Ye, C; Zhang, L; Zhou, X | 1 |
| Jiang, Y; Sohal, DPS | 1 |
| Abdul Majid, AMS; Asif, M; Kaur, G; Oon, CE; Subramaniam, AV; Yehya, AHS | 1 |
| Abuelafia, AM; Bigonnet, M; Chanez, B; Chuluyan, E; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Roques, J | 1 |
| Endo, I; Fujii, S; Hata, M; Homma, Y; Kumamoto, T; Matsuyama, R; Misumi, T; Miyake, K; Yabushita, Y; Yamanaka, S | 1 |
| Goršić, I; Kekez, D; Librenjak, N; Pleština, S; Prejac, J; Tomek Hamzić, D | 1 |
| Chiao, PJ; Fu, J; Furukawa, K; Ling, J; Lu, YU; Marukuchi, R; Sun, Y | 1 |
| Chen, Q; Gao, W; Li, W; Zeng, H | 1 |
| Adachi, T; Baba, H; Eguchi, S; Hisaka, T; Ikenaga, N; Inomata, M; Ishigami, K; Kurahara, H; Miyasaka, Y; Nagano, H; Nakamura, M; Nakata, K; Nishihara, K; Noshiro, H; Ohtsuka, T; Tokunaga, S; Ueki, T | 1 |
| Deng, J; Du, J; Fu, D; Gu, J; Guo, Y; Hu, X; Kong, L; Li, J; Tao, B; Ying, T | 1 |
| Cai, J; Li, J; Luo, S; Peng, C; Yu, P | 1 |
| Allen, M; Biagi, J; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Grant, RC; Hutchinson, S; Jang, GH; Kelly, D; Knox, JJ; Lam, B; Notta, F; O'Kane, GM; Perera, S; Ramjeesingh, R; Ramotar, S; Tehfe, M; Wang, Y; Wilson, J; Zhang, A; Zogopoulos, G | 1 |
| Andou, M; Furuse, J; Kitamura, H; Nagashima, F; Nakazawa, J | 1 |
| Abdiannia, M; Acharya, A; Aranha, O; Belle, JI; Bogner, SJ; Boice, N; Breden, M; Brown, A; DeNardo, DG; Gao, F; Hawkins, WG; Herndon, J; Herzog, BH; Lim, KH; Lockhart, AC; McWilliams, R; Pedersen, K; Ratner, L; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A; Yoon, HH; Zhu, M | 1 |
| Bai, C; Cheng, Y; Dai, M; Guo, J; Lu, J; Qiao, C; Tang, H; Wang, Y; Zhang, T | 1 |
| Dutta, M; Mohapatra, AP; Mohapatra, D; Roychowdhury, A; Senapati, S | 1 |
| Hiratsuka, M; Inoue, Y; Ito, H; Matsueda, K; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Takeda, T | 1 |
| Chai, T; Lu, JJ; Ma, JY; Ma, LM; Naghavi, MR; Sang, CY; Yang, JL; Zheng, YD | 1 |
| Hu, Z; Jing, W; Liu, J; Lu, H; Wang, T | 1 |
| Chen, S; Cortez, NE; Hong, BV; Hwang, CI; Mackenzie, GG; Matsukuma, K; Müller, M; Pontifex, MG; Ramsey, JJ; Rodriguez Lanzi, C; Vahmani, P; Vauzour, D; Wang, F; Xu, J | 1 |
| Huang, CS; Lai, JM; Liu, Q; Liu, ZD; Shi, YH; Su, Q; Wang, JQ; Wang, XY; Xu, QC; Xu, X; Yin, XY; Zhao, GY; Zhu, YQ | 1 |
| Dong, Y; Lai, S; Lin, C; Wang, L; Wang, Y; Weng, S; Zhang, X | 1 |
| Chen, Y; Lin, L; Lin, X; Ou, G; Pan, L; Su, M; Tan, Y; Tian, Z | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Aldakkak, M; AlMasri, S; Bahary, N; Ellsworth, SG; Evans, DB; Hammad, AY; Hodges, JC; Lee, KK; Paniccia, A; Singhi, AD; Tsai, S; Zureikat, A | 1 |
| Azizian, A; Cawley, H; Gaedcke, J; Ghadimi, BM; Hanna, N; Hussain, SP; Lal, T; Ohara, Y; Rupin, E; Sinha, S; Ströbel, P; Tang, W; Valenzuela, P; Wang, L; Yang, S; Zhang, L | 1 |
| Amin, MA; Der, CJ; Grierson, PM; Knoerzer, D; Kreider, B; Lim, KH; Liu, J; Park, H; Pedersen, KS; Reddy, A; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Cai, C; Cheng, M; Lin, K; Liu, Z; Miao, R; Qi, D; Song, X; Xue, C; Yao, W; Yu, H; Zhang, Z; Zhu, N | 1 |
| Cheon, J; Choi, SH; Chon, HJ; Kang, B; Kang, I; Kim, DJ; Kim, G; Ko, KH; Kwon, CI; Lee, SH | 1 |
| Fujiwara, T; Fushimi, T; Kagawa, S; Kajiwara, Y; Kanaya, N; Kikuchi, S; Kuroda, S; Noma, K; Ohara, T; Tazawa, H; Umeda, Y; Urata, Y; Yamada, M; Yoshida, R | 1 |
| Cao, Z; Feng, M; Liu, Y; Qiu, J; Yang, G; You, L; Zhang, T | 1 |
| Couturier, F; Graff, V; Herrscher, H; Moussouni, M | 1 |
| Akashi, T; Fujimori, N; Matsumoto, K; Miyagahara, T; Niina, Y; Ogawa, Y; Omori, K; Oono, T; Shimokawa, Y; Suehiro, Y; Tachibana, Y; Takamatsu, Y; Takaoka, T; Teramatsu, K; Ueda, K | 1 |
| Chanez, B; Dusetti, NJ; Fraunhoffer, N; Iovanna, JL; Mitry, E; Teyssedou, C | 1 |
| Banavath, HN; Gupta, S; Tejavath, KK | 1 |
| Balconi, F; Berardi, R; Cimbro, E; Donisi, C; Giampieri, R; Lai, E; Lupi, A; Murgia, S; Pecci, F; Persano, M; Pozzari, M; Pretta, A; Pusceddu, V; Puzzoni, M; Scartozzi, M; Spanu, D; Ziranu, P | 1 |
| Gao, J; Li, Y; Luan, Y; Wang, R | 1 |
| Agyare, E; Bulusu, R; Ebesoh, D; Frimpong, E; Han, B; Inkoom, A; Ndemazie, NB; Trevino, J; Zhu, X | 1 |
| Artru, P; Auvray Kuentz, M; Coutzac, C; de Mestier, L; Drouillard, A; Hammel, P; Hautefeuille, V; Lecomte, T; Lièvre, A; Malka, D; Nardon, V; Pernot, S; Taieb, J; Touchefeu, Y; Tran-Minh, ML; Trouilloud, I; Turpin, A; Williet, N; Zaanan, A | 1 |
| Chang, A; Chen, Y; Feng, Y; Hao, J; Huang, C; Huang, Z; Li, MJ; Li, S; Li, X; Liu, W; Qi, L; Shi, L; Tang, B; Wang, Z; Wu, C; Xie, P; Yu, X; Yuan, Y | 1 |
| Arora, P; Boyne, DJ; Brenner, DR; Cheung, WY; Gupta, A; Hernán, MA; Mackay, E; Wasiak, R | 1 |
| Amir, SS; Behrens, A; Khan, OM; Kohil, A | 1 |
| Beutel, AK; Halbrook, CJ | 1 |
| Kamitani, N; Kato, JY; Nakamae, I; Sho, M; Yoneda-Kato, N | 1 |
| Chen, P; Guo, G; Huang, J; Jiang, C; Jiang, Q; Li, S; Li, X; Quan, Q | 1 |
| Fagone, P; He, J; Li, Q; Li, S; Lu, Y; Nicoletti, F; Tian, C; Xiang, M; Yang, J; Yuan, H | 1 |
| Chu, C; Geng, S; Gong, P; Jiang, M; Luo, T; Wu, L; Zhang, X; Zhou, W | 1 |
| Betts, C; Bridge, M; Chen, B; Cheung, A; Coussens, LM; Crocker, M; Dragomanovich, H; Fahlman, A; Fong, L; Griffith, MJ; Lerner, K; Liu, E; Lopez, CD; Marquez, J; Pener, D; Rajagopalan, B; Sinha, M; Sivagnanam, S; Solman, I; Stultz, J; Sudduth-Klinger, J; Taber, E; Tamaki, W; Tempero, M; Todd, K; Vaccaro, G; Vo, J; Ware, C; Zhang, L | 1 |
| Ahn, E; Ahn, T; Bang, S; Choi, J; Han, JM; Hwang, GS; Kim, K; Kim, Y; Lee, HS; Luo, E; Min, DS; Park, SJ; Sung, Y; Yoo, HC; Yu, YC | 1 |
| Arlen, P; Basu Mallick, A; Beg, MS; Cleary, JM; Horick, NK; Hosein, PJ; Huffman, BM; Lacy, J; Manz, C; Mavroukakis, S; Morse, MA; Murphy, JE; Sanoff, H; Schlechter, BL; Wang-Gillam, A; Wolpin, BM; Zaki, A | 1 |
| Albers, D; Herold, T; Kasper, S; Linden, G; Markus, P; Prasnikar, N; Radunz, S; Schmidt, H; Schuler, M; Schumacher, B; Siveke, J; Ting, S; Treckmann, JW; Virchow, I; Wiesweg, M | 1 |
| Hu, Q; Huang, Y; Li, B; Liang, T; Ping, Y; Shao, S; Tang, H; Wang, M; Yao, Z; Zhang, F | 1 |
| Benguigui, M; Cooper, TJ; Haj-Shomaly, J; Levin, S; Manobla, B; Menachem, R; Raviv, Z; Shaked, Y; Timaner, M; Vorontsova, A | 1 |
| Araujo, R; Dallaston, M; Jenner, AL; Kelly, W; Kim, PS; Parfitt, I; Pooladvand, P; Steinitz, D; Vine, KL; Wade, SJ | 1 |
| Fujimori, N; Fukuda, H; Furukawa, M; Furuse, J; Ikeda, M; Imaoka, H; Ishii, H; Kamata, K; Katanuma, A; Kataoka, T; Katayama, H; Kobayashi, S; Komatsu, Y; Miwa, H; Mizukoshi, E; Mizuno, N; Mizusawa, J; Nakachi, K; Ohba, A; Okano, N; Okusaka, T; Ozaka, M; Sasahira, N; Takayama, Y; Terashima, T; Todaka, A; Tsumura, H; Ueno, M; Yamamoto, T | 1 |
| Chang, CD; Chao, MW; Hsu, KC; Huang, SH; Lee, HY; Lien, ST; Lin, TE; Liu, YT; Pan, SL; Sung, TY; Tu, HJ; Yen, SC | 1 |
| Guo, W; Huang, JH; Liu, Z | 1 |
| Su, J; Wang, W; Yang, L; Zhou, F | 1 |
| Altaner, C; Altanerova, U; Jakubechova, J; Klimova, D; Nicodemou, A; Repiska, V; Styk, J; Szemes, T | 1 |
| Albers, D; Kasper, S; Kostbade, K; Laue, K; Liffers, ST; Markus, M; Markus, P; Maßmann, M; Mende, B; Pogorzelski, M; Reissig, TM; Roehrle, J; Rosery, V; Schildhaus, HU; Schmid, K; Schuler, M; Schumacher, B; Siveke, JT; Ting, S; Treckmann, JW; Virchow, I; Wendling, J; Wiesweg, M; Zaun, G | 1 |
| Aprile, G; Bergamo, F; Bernardini, I; Bozzarelli, S; Cardellino, GG; Cavanna, L; Cordio, S; De Simone, I; Di Marco, MC; Ghidini, M; Giommoni, E; Macchini, M; Maiello, E; Milella, M; Orsi, G; Pinto, C; Porcu, L; Reni, M; Rulli, E; Spada, M; Torri, V | 1 |
| Asonuma, S; Doi, K; Goto, H; Hiramoto, K; Kimura, O; Masuda, K; Miyazaki, S; Muto, M; Nakagawa, K; Okata, H; Ototake, H; Sato, H; Satoh, A; Shimosegawa, T; Ueno, T | 1 |
| Endo, S; Fujiwara, Y; Higashida, M; Ito, Y; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Sanuki, F; Tanaka, H; Ueno, M; Ueno, T; Yoshimatsu, K | 1 |
| Akiyama, N; Fujita, Y; Ikeshita, T; Iwamoto, R; Kawaoka, T; Miyahara, M; Sakai, B; Sato, T; Suto, Y; Suzuki, A; Tamesa, T; Tokunou, K; Umeno, H; Yamamoto, S | 1 |
| Fujisaki, S; Okamura, Y; Sakurai, K; Takashina, M; Takayama, T; Tomita, R | 1 |
| Asaka, S; Kono, T; Kuhara, K; Nakayasu, Y; Nomura, T; Ohigashi, S; Shimakawa, T; Shimojima, Y; Shiozawa, S; Takano, K; Usui, T; Yokomizo, H | 1 |
| Aono, T; Hasegawa, M; Ichikawa, H; Kaneko, K; Maruyama, T; Muneoka, Y; Muto, I; Nakajima, K; Okada, T; Sakata, J; Sato, T; Shimada, Y; Suzuki, S; Tajima, Y; Wakai, T | 1 |
| Ho, B; Li, CG; Mitchell, A; Ponomarova, O; Rosener, B; Sayin, S; Walhout, AJM; Ward, DV | 1 |
| Doolin, JW; Paredes de la Fuente, R; Peters, ML | 1 |
| Huang, X; Jin, C; Li, H; Wang, W; Yang, C; Yu, X | 1 |
| Amano, H; Dash, S; Honda, M; Kawazu, M; Komuro, A; Okada, H; Ueda, T | 1 |
| Doi, T; Enoki, M; Gotoh, K; Hamakawa, T; Hirao, M; Katoh, T; Kawai, K; Miyo, M; Sakai, K; Takahashi, Y; Takami, K; Takeno, A; Toshiyama, R; Yanagisawa, K | 1 |
| Aldakkak, M; Christians, KK; Clarke, CN; Erickson, BA; Evans, DB; George, B; Hall, WA; Kamgar, M; Smith, ZL; Thalji, SZ; Tolat, PP; Tsai, S | 1 |
| Gao, W; Han, D; Huang, H; Li, X; Li, Z; Liu, L; Peng, C; Yu, X; Zhang, X; Zhu, H | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Furukawa, T; Ishitsuka, T; Kasuga, A; Matsuyama, M; Mie, T; Nakagawa, H; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, M | 1 |
| Aoki, S; Douchi, D; Hirano, N; Inoue, K; Iseki, M; Ishida, M; Kamei, T; Miura, T; Mizuma, M; Morikawa, T; Nakagawa, K; Nakayama, S; Ohnuma, S; Ohtsuka, H; Unno, M | 1 |
| Abrams, T; Aguirre, AJ; Bakir, B; Blaszkowsky, L; Brais, L; Chiarella, AM; Cleary, JM; Das, K; Enzinger, P; Germon, V; Giannakis, M; Giantonio, BJ; Goessling, W; Goyal, L; Horick, N; Meyerhardt, JA; Needle, M; Perez, K; Pitarresi, JR; Raghavan, S; Rubinson, D; Rustgi, AK; Stonely, D; Weekes, C; Wolpin, BM; Yurgelun, MB | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Marukawa, D; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Bolm, L; Braun, R; Busch, H; Castven, D; Drenckhan, M; Färber, B; Gorantla, SP; Hael, AAM; Honselmann, KC; Keck, T; Konukiewitz, B; Künstner, A; Lapshyna, O; Marquardt, JU; Spielmann, M; Ungefroren, H; Watzelt, J; Wellner, UF | 1 |
| Guan, J; Guan, X; Jiang, X; Jiao, Z; Li, L; Long, B; Ma, Y; Qin, L; Shi, W; Wang, J; Wang, K; Wang, T; Yang, J; Ye, H; Yu, Z; Zhou, H | 1 |
| Manji, GA | 1 |
| Fujishiro, M; Hakuta, R; Hamada, T; Ishigaki, K; Kanai, S; Nakai, Y; Oyama, H; Saito, K; Saito, T; Sato, T; Suzuki, T; Suzuki, Y; Takahara, N; Tateishi, R | 1 |
| Liu, X; Ma, X; Tian, W; Wang, R; Zhang, L | 1 |
| Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Coburn, N; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Raphael, M; Saluja, R | 1 |
| Akahoshi, K; Akiyama, Y; Asano, D; Ishikawa, Y; Kato, T; Kudo, A; Murase, Y; Ogawa, K; Ono, H; Tanabe, M; Tanaka, S; Ueda, H; Watanabe, S; Yamashita, H | 1 |
| He, Z; Jiang, Y; Li, X; Qi, K; Tong, L; Wang, X; Xing, Y; Xu, J; Xu, W; Zhang, L | 1 |
| de Geus, SWL; Sachs, TE | 1 |
| Alemanno, F; Barra, A; Cavo, M; D'Amone, E; Del Mercato, LL; Delle Cave, D; Fachechi, A; Gigli, G; Lonardo, E; Rizzo, R | 1 |
| Li, T; Li, Z; Qin, C; Wang, W; Wang, Y; Yang, X; Zhao, B; Zhao, Y | 1 |
| Akamune, A; Johira, H; Kagajo, Y; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Yunoki, S | 1 |
| Chen, S; Chen, Y; Dong, A; Jin, M; Li, J; Liu, Z; Peng, Z; Wang, Y; Wei, G; Wu, S; Zhu, M | 1 |
| Chen, Y; Huang, K; Xia, C; Xu, D; Yang, F; Yang, H | 1 |
| Aronson, A; Cohen, DJ; Fulop, DJ; Labiner, AJ; Lucas, AL; Sigel, KM; Wisnivesky, J; Wu, YL; Zylberberg, HM | 1 |
| Furuya, N; Hamada, T; Ito, T; Kato, N; Kido, M; Kohno, H; Kouno, H; Kuraoka, K; Kusunoki, R; Kuwai, T; Mizumoto, T; Sugata, S; Tamaru, Y; Yamaguchi, A | 1 |
| Boutin, R; Catalano, P; Dotan, E; Ioffe, D; Lenchik, L; Li, D; Marques, HS; O'Dwyer, PJ; Simon, MA; Wagner, LI; Wong, TZ; Yao, X; Zhen, DB | 1 |
| Hu, Q; Huang, J; Liang, T; Shao, S; Wang, M; Yao, Z; Zhang, F; Zhao, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Guo, Z; Huang, Y; Lai, S; Li, T; Lin, C; Wang, Y; Weng, S; Zhang, X | 1 |
| Chen, Y; Hu, Q; Jin, P; Liang, T; Que, R; Xu, M; Yao, Z; Zhang, F | 1 |
| Liu, S; Xu, C; Ye, C; Ye, Q | 1 |
| Gao, S; Jiang, CF; Wang, W; Yin, HS; Yu, BP | 1 |
| Bai, Y; Dal, E; Li, K; Li, X; Lin, R; Liu, N; Liu, Z; Qi, R; Shi, B; Wang, H; Wang, X; Wang, Y; Xu, Y | 1 |
| Abdallah, R; Ahmad, SA; Aminjonov, B; Boyer, E; Choi, YJ; Clavien, PA; Eshmuminov, D; He, J; Held, U; Helton, S; Hoffe, SE; Jang, JY; Katz, MHG; Kim, H; Lehmann, K; Lopez-Lopez, V; Maggino, L; Malinka, T; Malleo, G; Maloney, S; Palm, RF; Park, JY; Patel, S; Prakash, L; Rangelova, E; Rose, JB; Rössler, F; Sahora, K; Salvia, R; Schmocker, RK; Schneider, MA; Shaib, WL; Taieb, J; Timmermann, L; Wilson, GC; Yoo, C | 1 |
| Bhargava, P; Das, S; Kannan, S; Ostwal, V; Ramaswamy, A; Shah, D; Shah, M; Srinivas, S; Suman, M; Trikha, M | 1 |
| Bhambhvani, H; Collisson, EA; Fountzilas, C; Hendifar, A; Johansen, JS; Joshi, A; Krishna, V; Makawita, S; Mehta, A; Musher, B; Nimgaonkar, V; Rajpurkar, P; Singhi, A; Smith, K; Sohal, D; Tiu, E; Vrabac, D; Wainberg, Z | 1 |
| Brender, JR; Chandramouli, GVR; Devasahayam, N; Kishimoto, S; Krishna, MC; Mitchell, JB; Otowa, Y; Saida, Y; Yamamoto, K; Yamashita, K | 1 |
| Ch'ang, HJ; Chen, JS; Chen, LT; Chiu, YF; Ho, CL; Hsieh, RK; Hwang, TL; Li, CP; Liu, TW; Shan, YS | 1 |
| Adair, S; Bauer, TW; Honrado, C; Moore, J; Salahi, A; Swami, NS | 1 |
| Bresalier, RS; Hafley, MA; Liu, Y; Lorenzi, PL; Tan, L; Wang, L; Wei, D; Yang, P; Zuo, X | 1 |
| Aminjonov, B; Eshmuminov, D; Lehmann, K; Palm, RF | 1 |
| Fujisawa, T; Fukuma, T; Fukumura, Y; Isayama, H; Ishii, S; Ito, K; Nagahara, A; Suzuki, A; Takahashi, S; Takasaki, Y; Tomishima, K; Ushio, M; Yao, T | 1 |
| Akdeniz, N; Beşiroğlu, M; Demirci, A; Ergün, Y; İnanç, M; Işikdoğan, A; Kaplan, MA; Kiliçkap, S; Küçüköner, M; Şendur, MAN; Topçu, A; Uncu, D; Urakçi, Z; Yerlikaya, H | 1 |
| Cho, IR; Choi, JH; Hong, JM; Kim, YT; Lee, SH; Nam, GH; Paik, WH; Ryu, JK | 1 |
| Cho, YJ; Han, BS; Hong, SS; Jung, KH; Kim, DK; Kim, SE; Ko, S; Lee, JE; Lee, P; Lee, YJ; Lim, JH; Park, MS; Ryu, JK; Shim, S; Yoon, YC | 1 |
| Huang, K; Yang, G | 1 |
| Ha Hwang, J; Khokhlova, TD; Son, H; Totten, S; Wang, YN; Whang, S | 1 |
| Hsu, CP; Hwang, TL; Kou, HW; Kuo, YC; Lo, CH | 1 |
| Bhawal, UK; Fujiwara-Tani, R; Ikemoto, A; Kishi, S; Kuniyasu, H; Luo, Y; Mori, S; Nishiguchi, Y; Ogata, R; Ohmori, H; Sasaki, R; Sasaki, T; Sho, M; Takagi, T | 1 |
| Araki, K; Batbayar, C; Erkhem-Ochir, B; Gantumur, D; Gombodorj, N; Hagiwara, K; Harimoto, N; Hoshino, K; Hosouchi, Y; Ishii, N; Muranushi, R; Saito, H; Shirabe, K; Tsukagoshi, M; Watanabe, A; Yamanaka, T; Yokobori, T | 1 |
| Baba, H; Inoue, Y; Ito, H; Kitano, Y; Oba, A; Ono, Y; Ozaka, M; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Takeda, T | 1 |
| Boeck, S; Engel, J; Guenther, M; Haas, M; Heinemann, V; Ormanns, S; Surendran, SA; von Bergwelt-Baildon, M; Werner, J | 1 |
| Bai, W; Chang, A; Fu, D; Gao, S; Hao, J; Hou, X; Huang, C; Jiang, W; Li, X; Liu, J; Liu, Z; Man, Q; Sun, H; Sun, J; Wang, H; Wang, X; Wang, Y; Xie, Y; Yan, J; Yang, S; Zhang, X; Zhang, Z; Zhao, T; Zhou, T | 1 |
| Besselink, MG; Brosens, LAA; de Hingh, IHJT; de Vos-Geelen, J; Hopstaken, JS; Quispel, R; Stommel, MWJ; van der Geest, LG; van Laarhoven, KJHM; Vissers, PAJ | 1 |
| Amador, Y; Arguelles, O; Concepción, ML; Guerra, PP; Leblanch, L; Leyva, A; Martorell, B; Moret, S; Piriz, A; Rabassa, R; Rivero, G; Sánchez, L; Sánchez, Y; Saumell, Y; Valls, AR; Vasallo, AL | 1 |
| Aquilini Mummolo, A; Bruno, G; Cincione, RI; Conteduca, V; Giordano, G; Landriscina, M; Lizzi, V; Losavio, F; Pacilli, M; Piscazzi, A; Senia, T | 1 |
| Cappetta, A; Catalano, M; Conca, R; D'Angelo, A; Petrioli, R; Ramello, M; Roviello, G; Siminonato, F | 1 |
| Bae, JH; Kim, J; Koh, EK; Lee, HR; Park, GY; Park, YS; Son, WC | 1 |
| Agyare, E; Bulusu, R; Frimpong, E; Han, B; Inkoom, A; Ndemazie, NB; Poku, R; Smith, T; Trevino, J; Zhu, X | 1 |
| Fu, X; Hao, Z; Hua, X; Jiao, A; Li, S; Wang, K | 1 |
| Fu, L; Han, W; Lv, K; Tian, Y; Zhou, X | 1 |
| Govindarajan, R; Nayak, D; Weadick, B | 1 |
| Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N | 1 |
| Han, C; Hu, D; Wang, H; Wang, M; Zhang, L; Zheng, H | 1 |
| Akashi, K; Arima, S; Baba, E; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Aguirre, AJ; Ali, LR; Bello, E; Cardot-Ruffino, V; Castillo, JI; Cremasco, V; Dougan, M; Dougan, SK; Hoffman, MT; Kageler, L; Lenehan, P; Pelletier, M; Qiang, L; Raghavan, S; Temesgen, A; Uribe, GA; Wang, SJ; Yang, A | 1 |
| Bhoopathi, P; Das, SK; Emdad, L; Fisher, PB; Mannangatti, P | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Cooper, SJ; Gordon, ER; James, M; Wright, CA | 1 |
| Bajwa, A; Bisunke, B; Fang, J; Glazer, ES; Kansal, RG; Rana, M; Shibata, D; Yang, J | 1 |
| Beaman, C; Hurtado de Mendoza, T; Ishfaq, M; Joshi, S; Lowy, AM; Madheswaran, S; Park, IH; Patel, J; Pham, TV; Rohila, D; Sun, S; Tamayo, P; Tapia, E; Weitz, J | 1 |
| Niu, J; Qian, S; Qu, J; Shen, S; Straubinger, RM; Wang, X | 1 |
| Beebe, J; Dong, Z; Hao, Y; He, Z; Huang, C; Liu, H; Liu, JY; Liu, Y; Qin, L; Subramaniyan, B; Zhang, JT | 1 |
| Chang, YC; Chen, MH; Chou, WC; Huang, SC; Huang, WK; Hung, TH; Jung, SM; Lin, SH; Pan, YR; Wu, CE; Yeh, CN; Yu, AL | 1 |
| Bai, R; Chen, R; Chen, Z; Deng, S; He, X; Huang, X; Li, M; Li, R; Lin, D; Liu, J; Liu, S; Su, J; Xu, Z; Xue, C; Zeng, L; Zhang, J; Zhang, S; Zhao, H; Zhao, S; Zheng, J; Zhou, Q; Zhou, Y; Zhuang, L | 1 |
| Chen, IM; Christensen, S; Detlefsen, S; Egendal, I; Johansen, JS; Ladekarl, M; Liposits, G; Pfeiffer, P; Rasmussen, LS; Shim, S; Ventzel, L; Weber, B; Winther, SB | 1 |
| Abrams, TA; Biller, LH; Bollenrucher, N; Brais, LK; Cardot-Ruffino, V; Cleary, JM; Delius, L; Dougan, M; Dougan, SK; Enzinger, PC; Keheler, CE; McCleary, NJ; Ng, K; Patel, AK; Perez, K; Remland, J; Rubinson, DA; Schlechter, B; Singh, H; Slater, S; Sullivan, KM; Wang, SJ; Wolpin, BM; Yurgelun, MB | 1 |
| Cao, Y; Chen, D; Chen, H; Deng, X; Jiang, L; Jiang, Y; Liu, Y; Peng, C; Shen, B; Shi, M; Tang, H; Wang, W; Wen, C; Yao, N; Zang, L; Zhai, S; Zhao, S; Zhu, Y | 1 |
| Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ | 1 |
| Bhardwaj, N; Chen, KT; Ebot, E; Fabrizio, D; Fleischmann, Z; Frampton, G; He, J; Hegde, P; Jin, D; Lofgren, KT; Madison, R; Moore, J; Newberg, J; Pishvaian, MJ; Schrock, A; Singhi, A; Sokol, E | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Chang, A; Ding, J; Feng, Y; Fu, D; Gao, C; Gao, S; Hao, J; Huang, C; Liu, J; Liu, Y; Ma, X; Ma, Y; Tang, B; Wang, H; Wang, X; Yan, J; Yang, S; Zhang, Z; Zhao, R; Zhao, T | 1 |
| Maithel, SK | 1 |
| Doi, M; Endo, M; Furuya, K; Hasegawa, N; Hashimoto, S; Hoshiai, S; Kobayashi, M; Makishima, H; Mathis, BJ; Miyazaki, Y; Mizumoto, M; Mori, K; Moriwaki, T; Nakai, K; Nakajima, T; Niisato, Y; Numajiri, H; Oda, T; Saida, T; Saito, T; Sakurai, H; Shimomura, O; Takahashi, K; Tsuchiya, K; Yamada, T; Yamamoto, Y | 1 |
| Agirman, F; Arsenijevic, T; Azurmendi Senar, O; Bellahcène, A; Crake, R; D'Haene, N; Dehaye, J; Gasmi, I; Koopmansch, B; Lambert, F; Lardinois, F; Maloujahmoum, N; Peiffer, R; Peulen, O; Van Laethem, JL | 1 |
| Dumke, C; Eberle, F; Engenhart-Cabillic, R; Exeli, L; Hauswald, H; Lautenschlaeger, S | 1 |
| Cho, JM; Choi, YW; Jin, CE; Jo, MJ; Kim, H; Kim, JS; Kim, SY; Lee, JM; Oh, JG; Park, CW; Park, H; Shin, DH; Shin, HJ; Shin, YB; Yoon, MS | 1 |
| Jiang, X; Lee, MJ; Lin, W; Luo, T; Tillman, L | 1 |
| Baar, K; Chen, S; Cortez, NE; Crone, R; Gomes, AV; Hong, BV; Mackenzie, GG; Pathak, S; Rodriguez Lanzi, C; Sule, R; Wang, F | 1 |
| Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T | 1 |
| Akce, M; Cao, HST; Cleary, SP; Javle, MM; Keilson, JM; Lin, BS; Mahipal, A; Maithel, SK; Rocha, FG; Rupji, M; Switchenko, JM | 1 |
| Anttila, M; Arias, V; Basnet, S; Cervera-Carrascon, V; Clubb, JHA; Grönberg-Vähä-Koskela, S; Havunen, R; Haybout, L; Heiniö, C; Hemminki, A; Jirovec, E; Kudling, TV; Pakola, S; Quixabeira, DCA; Santos, JM | 1 |
| Aoyama, Y; Denda, Y; Hayashi, Y; Imafuji, H; Kato, T; Kimura, M; Matsuo, Y; Mitsui, A; Morimoto, M; Murase, H; Nonoyama, K; Ogawa, R; Saito, K; Takahashi, H; Takiguchi, S | 1 |
| Hei, Y; Hou, D; Tian, S; Wang, B; Wang, F; Wang, Y; Xu, X; Zhang, J; Zhang, Y | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Nishi, H; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Jiang, H; Liao, X; Ning, J; Qin, S; Yang, D | 1 |
| Bai, Y; Chen, C; Chen, J; Gao, Y; Guo, H; Guo, Y; Hu, Z; Xie, L; Yang, X; Yuan, Z | 1 |
| Gallinger, S; Grant, R; Grunwald, B; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Perera, S | 1 |
| Chen, G; Cheng, H; Deng, T; Gong, P; Jiang, S; Liu, W; Ma, L; Shi, D; Zhang, X | 1 |
| Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L | 1 |
| Chong, D; Gu, Y; Guan, X; Jiang, T; Lu, Z; Song, N; Wang, JY; Wang, X; Wang, Y; Yu, R; Yu, W; Zhang, S | 1 |
| Hu, H; Ma, Y; Xiong, S; Zhu, C; Zhu, D | 1 |
| Chen, B; Cheng, H; Deng, T; Gong, P; He, Z; Jiang, S; Liu, W; Ma, L; Shi, D; Wang, W; Yuan, J; Zhang, X | 1 |
| Curtis, A; Hoskins, C; Lindsay, S; Oluwasanmi, A; Perrie, Y | 1 |
| Besselink, MG; Busch, OR; Doppenberg, D; Farina, A; Kazemier, G; Mebius, RE; Meijer, LL; van Ee, T; van Kooyk, Y; Versteijne, E; Wilmink, JW; Zwart, ES | 1 |
| Alves, F; Feldmann, C; Ischyropoulou, M; Napp, J; Niemeyer, CM; Sabljo, K; Schneider, L | 1 |
| Gao, W; Lin, K; Pan, Y; Shi, T; Yu, Y; Zhang, J; Zhang, S; Zheng, Z; Zhou, E | 1 |
| Cao, M; Cao, P; Gu, H; Guo, Z; Han, X; Huang, C; Lv, Y; Qiu, Z; Wang, X; Wei, Q; Weng, L; Yang, Y; Zhang, K | 1 |
| Cui, J; Gou, S; Guo, Y; Liang, X; Lu, C; Peng, T; Xiong, J; Yin, T | 1 |
| Biankin, AV; Blackwell, A; Chambers, CR; Charlton, B; Chitty, JL; Clark, SJ; Cox, TR; Croucher, DR; Da Silva, AM; Filipe, EC; Findlay, AD; Gill, AJ; Grant, RD; Grimmond, SM; Hastings, JF; Herrmann, D; Jarolimek, W; Johns, AL; Latham, SL; Lucas, MC; Major, G; Melenec, P; Mok, ETY; Murphy, KJ; Nadalini, A; Nagrial, A; Nobis, M; Pajic, M; Papanicolaou, M; Parker, AL; Pereira, BA; Perryman, L; Phillips, PA; Pidsley, R; Ratnaseelan, S; Reed, DA; Ritchie, SC; Russo, A; Setargew, YFI; Sharbeen, G; Skhinas, JN; Stoehr, J; Tayao, M; Timpson, P; Tran, E; Trpceski, M; Velayuthar, S; Vennin, C; Wyllie, K; Yam, M; Youkhana, J; Zaratzian, A | 1 |
| Bai, C; Cheng, Y; Tang, H; Wang, X; Wang, Y; Ying, J; Zhu, Z | 1 |
| Bai, X; Bai, Y; Chen, D; Chen, J; Chen, Z; Cheng, Y; Fu, D; Hao, C; Li, J; Liu, T; Pan, H; Qin, B; Qin, S; Shen, L; Wang, Q; Wang, Z; Xu, J; Xu, R; Yang, J; Yang, L; Yuan, Y; Zhang, H; Zhang, J; Zheng, Q; Zhong, H | 1 |
| Chen, J; Ke, Z; Li, T; Li, W; Liang, X; Liu, C; Liu, J; Luo, F; Luo, X; Luo, Y; Wang, S; Wang, Y; Wu, T; Wu, Y; Yan, J; Yang, D; Zhang, S; Zhang, Y; Zhao, Z | 1 |
| Nagaraju, GP; Natu, J | 1 |
| Ariake, K; Douchi, D; Furukawa, T; Hirose, K; Ishida, M; Miura, T; Mizuma, M; Morikawa, T; Nakagawa, K; Nakayama, S; Ohtsuka, H; Unno, M; Xun, J | 1 |
| Bartkeviciene, A; Dambrauskas, Z; Gulbinas, A; Jasukaitiene, A; Jaudzems, K; Maimets, T; Matthews, J; Stukas, D; Teino, I | 1 |
| Cao, P; Chang, A; Feng, Y; Guo, W; Hao, J; Li, H; Li, S; Liu, W; She, C; Wang, X; Wu, C; Xie, Y; Xu, C; Yang, Y | 1 |
| Hayashi, H; Kubota, K; Masuo, H; Miyazaki, S; Notake, T; Sakai, H; Shimizu, A; Soejima, Y; Yoshizawa, T | 1 |
| Aşkin Çelik, T; Aslantürk, ÖS | 1 |
| Bridgewater, JA; Cubillo, A; Hédouin-Biville, F; Macarulla, T; Palmer, DH; Prager, GW; Reni, M; Seufferlein, T; Taieb, J; Teng, Z; Vermeire, A | 1 |
| Characiejus, D; Janiulioniene, A; Jasiunaite, E; Matuzeviciene, R; Radzevicius, M; Sileikis, A; Tulyte, S; Zvirblis, T | 1 |
| Bailey, MJ; Costa, C; Gupta, P; Lewis, HM; Saunders, KDG; Spick, M; Velliou, E; von Gerichten, J | 1 |
| Borbath, I; Bouchart, C; Closset, J; Demetter, P; Geboes, K; Moretti, L; Navez, J; Paesmans, M; Van Laethem, JL; Vandamme, T | 1 |
| Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Lee, YS; Park, JS | 1 |
| Du, J; Hou, G; Li, M; Liang, J; Shao, Y; Silli, EK; Wang, Y; Zhang, Y | 1 |
| Dai, C; Gong, T; Guo, Y; Huang, Y; Pan, H; Wu, D; Yan, J; Yang, Y; Zhao, Y; Zhu, S | 1 |
| Amin, M; Bansod, S; Boice, N; Brown, A; Grierson, PM; Lim, KH; Liu, J; Park, H; Pedersen, KS; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Bouchekioua-Bouzaghou, K; Chen, J; Griera, JB; Jiang, X; Kong, X; Meng, YM; Qin, H; Wang, M; Wong, PP; Xu, Q | 1 |
| Çubukçu, E; Dede, DŞ; Deligönül, A; Dizdar, Ö; Doğan, A; Emre Yildirim, M; Eraslan, E; Erol, C; Esen, SA; Günel, N; Odabaş, H; Öksüzoğlu, ÖB; Özdemir, N; Özet, A; Şahin, AB; Şahin, TK; Sütcüoğlu, O; Turan, N; Uçar, G; Üner, A; Yazici, O; Yilmaz, F | 1 |
| Chen, M; Liu, X; Liu, Y; Lu, J; Teng, H; Yu, C; Zheng, Y | 1 |
| Ko, AH | 2 |
| Ashrafizadeh, M; Luo, K; Reza Aref, A; Zhang, W; Zhang, X | 1 |
| Chen, Q; He, J; Liu, L; Lou, W; Pu, N; Shi, C; Wang, W; Wu, W; Xie, Y; Xu, H; Yin, H; Yu, J; Zhang, L | 1 |
| Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Park, JS | 1 |
| Lin, Q; Qu, J; Rasam, S; Shen, S; Straubinger, RM | 1 |
| Chen, M; Gan, L; Hong, P; Jin, J; Li, D; Liu, W; Wei, X; Wong, W; Wu, M; Wu, P; Wu, R; Xu, X; Zhang, K; Zheng, X | 1 |
| Chen, X; Liu, X; Liu, Z; Lu, J; Song, W; Yang, Y | 1 |
| Fang, S; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, MJ; Lee, BE; Lee, DE; Lee, KJ; Lee, YS; Park, JS; Yoo, J | 1 |
| Dutta, M; Kar, S; Minz, AP; Mishra, S; Mohapatra, AP; Mohapatra, D; Parida, D; Sasmal, PK; Senapati, S; Sethi, M | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Miwa, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N; Ushijima, T | 1 |
| Baines, AT; Bialkowska, AB; Graves, LM; Ingle, K; LaComb, JF | 1 |
| Biswas, R; Bugde, P; He, J; Li, J; Li, S; Li, Y; Tian, F; Wu, Z; Yang, X | 1 |
| Bai, X; Feng, L; Lan, Z; Li, D; Ren, H; Wang, C; Wang, P; Wang, S; Xiao, Q; Zhang, J; Zhang, S | 1 |
| Chen, H; Gan, L; Han, L; Jiang, L; Jiang, Y; Lin, X; Shen, B; Shi, M; Wang, T; Wu, Z; Xiong, C; Xue, M; Zhu, Y | 1 |
| Augustinus, S; Besselink, MG; Bonsing, BA; Bruno, MJ; Busch, OR; de Groot, JWB; Groot Koerkamp, B; Intven, MPW; Köhler, F; Molenaar, Q; Wilmink, JW | 1 |
| Busch, OR; de Wilde, RF; Molenaar, IQ; Seelen, LWF; van Santvoort, HC; Wilmink, JW | 1 |
| Agostini, A; Alfieri, S; Arena, S; Bizzozero, L; Bria, E; Caggiano, A; Carbone, C; Corbo, V; De Sanctis, F; Esposito, A; Guerriero, I; Larghi, A; Lucchetti, D; Musella, M; Piro, G; Priori, L; Quero, G; Rizzatti, G; Roberto, L; Scaglione, G; Sgambato, A; Sistigu, A; Tortora, G; Ugel, S | 1 |
| Feng, X; Gong, S; Guo, J; Ma, X; Ren, Z; Wu, N; Xu, L; Zhang, C; Zhang, P; Zhang, X; Zhang, Y; Zhao, M | 1 |
| Al-Hawaray, M; Cho, CS; Cuneo, KC; Devasia, T; Lawrence, TS; Maybaum, J; Morgan, MA; Nathan, H; Parsels, JD; Parsels, LA; Sahai, V; Schipper, MJ; Zalupski, MM | 1 |
| Hackman, RM; Mackenzie, GG; Penso, NEC; Wang, Y; Wei, R | 1 |
| Chen, Y; Huang, Y; Liu, J; Liu, Y | 1 |
| Berlin, J; Carrero, X; Deshpande, V; Evans, DB; Goff, LW; Kindler, HL; Merchant, N; Meyerhardt, J; Misdraji, J; Moore, M; Newman, E; O'Reilly, EM; Ou, FS; Pisters, P; Posner, MC; Sahani, D; Shi, Q; Tamm, E; Wei, AC; Wolff, RA | 1 |
| Cheng, H; Fan, K; Fan, Z; Huang, Q; Jin, K; Liu, C; Luo, G; Yang, C; Yu, X | 1 |
| Schwartz, PB; Uboha, NV; Weber, SM | 1 |
| Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| Sidaway, P | 1 |
| Cao, Z; Feng, M; Liu, Y; Luan, J; Luo, W; Qiu, J; Yang, G; You, L; Zhang, T; Zhang, Y; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Benhadji, KA; Cleverly, A; Gueorguieva, I; Lahn, MM; Macarulla, T; Melisi, D; Merz, V; Miles, C; Tabernero, J; Waterhouse, TH | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Dalin, S; Fenoglio, S; Grauman-Boss, B; Hemann, MT; Kreidl, E; Lau, AN; Lauffenburger, DA; Lees, JA; Luengo, A; Mueller, HS; Sullivan, MR; Vander Heiden, MG | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Chen, J; Vermolen, FJ; Weihs, D | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Grützmann, R; Lan, B; Pilarsky, C; Pöttler, M; Yang, H; Zeng, S | 1 |
| Feng, M; Hu, Y; Liu, C; Wang, X; Xiong, G; Xu, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L; Zhou, L | 1 |
| Bansal, R; Bijlsma, MF; De Geus, SWL; Kuninty, PR; Kuppen, PJK; Mardhian, DF; Metselaar, JM; Östman, A; Prakash, J; Schnittert, J; Sier, CFM; Storm, G; Vahrmeijer, AL; van Baarlen, J; van Laarhoven, HW | 1 |
| Chin, SY; Hii, LW; Lai, KS; Leong, CO; Lim, SE; Mai, CW; Tan, NP | 1 |
| Dou, J; Ma, L; Shen, B; Shen, W; Xie, X; Xu, D; Zhou, C; Zhou, Y | 1 |
| Iyikesici, MS | 1 |
| Ando, K; Iwata, T; Mishima, H | 1 |
| Bai, Y; Du, L; Gao, F; Jin, L; Li, F; Lin, L; Niu, S; Shi, Q; Sun, T; Wu, J; Zhu, LM | 1 |
| Miyasaka, Y; Nakamura, M | 1 |
| Haan, L; Hankemeier, T; Joore, J; Kramer, B; Lanz, HL; Olivier, T; Vermeer, M; Vulto, P | 1 |
| Li, P; Li, Y; Liu, B; Wang, W; Wang, Y | 1 |
| Cardoso, ACF; Florez Bedoya, CA; Fogelman, D; Katz, MHG; Kim, MP; Ngo-Huang, A; Park, M; Parker, N; Petzel, MQ; Romero, SG; Schadler, KL; Wang, H | 1 |
| Berkenstam, A; Dai, B; DiLorenzo, S; Fleming, J; Hases, L; Ibrahim, A; Jafferali, MH; Jose Augustine, J; Kang, Y; Kim, M; Lin, CY; Mesmar, F; Wang, J; Williams, C; Zhao, Y | 1 |
| Chen, HY; Chou, CJ; Hsieh, YY; Lee, KH; Liu, TP; Yang, PM | 1 |
| Bouvet, M; Chawla, SP; Higuchi, T; Hoffman, RM; Kawaguchi, K; Miyake, K; Oshiro, H; Park, JH; Singh, SR; Sugisawa, N; Unno, M; Zhang, Z | 1 |
| Fushida, S; Gabata, R; Harmon, JW; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Shimbashi, H; Tajima, H; Takamura, H | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Banerjee, RK; Caulfield, TR; Dutta, SK; Huang, HS; Madamsetty, VS; Mody, K; Mukhopadhyay, D; Pal, K; Thompson, JR; Wang, E; Yen, Y | 1 |
| Digiovanni, MG; Lacomb, JF; Luo, D; Mackenzie, GG; Rigas, B; Wei, R; Williams, JL | 1 |
| Chen, ZM; Huang, H; Ji, B; Jiang, CX; Mukaida, N; Song, Y; Yao, NH | 1 |
| Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Gou, H; Huang, J; Li, Q; Liao, W; Wang, X; Wen, F; Wu, Q; Zhang, P; Zhou, J; Zhou, K; Zhu, G | 1 |
| Chen, J; Chen, ZH; Huang, JL; Ma, XK; Wei, L; Wen, JY; Wu, DH | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Kubo, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Chen, H; Chen, Z; Hua, YQ; Liu, LM; Meng, ZQ; Ning, ZY; Sheng, J; Xie, GQ; Zhang, K; Zhu, YD; Zhu, ZF | 1 |
| Li, Y; Wang, Q; Xie, S; Xu, M; Zhang, H; Zhou, L | 1 |
| Cai, JX; Hu, XB; Li, YJ; Wang, JM; Wu, JY; Xiang, DX | 1 |
| Bandyopadhyaya, R; Prabhuraj, RS; Saini, K | 1 |
| Boeck, S; Crispin, A; D'Haese, JG; Gebauer, L; Haas, M; Heinemann, V; Ilmer, M; Kirchner, T; Kobold, S; Kruger, S; Kunz, WG; Mayerle, J; Ormanns, S; Ricke, J; Schirle, K; Schirra, J; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Chen, L; Feng, D; Gu, M; Qian, Y; Wu, Y; Xiong, Y; Zhang, X | 1 |
| Kee, JY; Kim, M; Lee, HJ; Lee, MJ; Mun, JG; Son, SR | 1 |
| Eguchi, H; Kubo, M | 1 |
| Huang, GC; Ji, XQ; Jiang, CC; Li, AM; Li, B; Shen, ZT; Yuan, X; Zhou, H; Zhu, XX | 1 |
| Georgikou, C; Gladkich, J; Gretz, N; Gross, W; Herr, I; Karakhanova, S; Schäfer, M; Sticht, C; Torre, C; Xiao, X; Yin, L | 1 |
| Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W | 1 |
| Hussein, A; Razavi, M; Ren, G; Rezaee, M; Thakor, AS; Ullah, M; Wang, J; Zheng, F | 1 |
| Chen, Q; Dai, S; Hou, C; Liu, T; Miao, Y; Peng, Y; Wu, J; Xu, D; Xu, W; Zhu, F; Zhu, X; Zhu, Y | 1 |
| Hashimoto, M; Hikichi, T; Irie, H; Konno, N; Nakamura, J; Ohira, H; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Cai, Q; Hu, Z; Tang, Y; Wang, Y; Xu, J; Yang, D; Zhu, Z | 1 |
| Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B | 1 |
| Hara, R; Ishii, H; Kita, E; Nakamura, K; Sudo, K; Takayama, W; Tsujimoto, A; Yamaguchi, T | 1 |
| Daunys, S; Matulis, D; Petrikaitė, V | 1 |
| Chikhladze, S; Fichtner-Feigl, S; Kousoulas, L; Lederer, AK; Reinmuth, M; Sick, O; Wittel, UA | 1 |
| Bami, H; Boldt, G; Goodman, C; Vincent, M | 1 |
| Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z | 1 |
| Cui, J; Peng, T; Wu, H; Xiong, J; Yang, Z; Zhao, N | 1 |
| Arias, J; Beca, JM; Berry, SR; Biagi, JJ; Chan, KKW; Cheng, S; Coburn, N; Dai, WF; Earle, C; Gavura, S; Guo, H; Isaranuwatchai, W; Kennedy, ED; McLeod, R; Meyers, BM; Mittmann, N; Qiao, L; Redmond-Misner, R; Schwartz, D; Welch, S | 1 |
| Ghanem, NB; Jamshed, MB; Li, X; Muhammad, SA; Munir, F; Sadiq, U; Shahid, N; Zhang, Q; Zhong, H | 1 |
| Benson, A; Fought, AJ; Kalyan, A; Kamath, SD; Kircher, S; Mulcahy, M; Nimeiri, H | 1 |
| Fu, CX; Li, HM; Liu, W; Peng, WJ; Tang, W; Wang, QF; Wang, XH; Zhou, LP | 1 |
| Knudsen, ES; Kumarasamy, V; Nambiar, R; Ruiz, A; Witkiewicz, AK | 1 |
| Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
| Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C | 1 |
| Abe, R; Izumi, H; Makuuchi, H; Mukai, M; Nomura, E; Tajiri, T; Yoshii, H | 1 |
| Cao, M; Chen, Y; Hu, R; Li, T; Wang, K; Wang, R; Yang, M; Zhou, Y | 1 |
| Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K | 1 |
| Li, F; Li, W; Liu, Y; Shi, C; Wang, X; Yang, J; Zang, R; Zhao, J; Zhong, L | 1 |
| El Hassouni, B; Giovannetti, E; Immordino, B; Mantini, G; Peters, GJ | 1 |
| Ding, Y; Ge, W; Huang, Y; Kong, Y; Wang, W; Yan, Y; Zhang, L; Zheng, H; Zhou, J; Zhou, X; Zhu, W | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Chouzenoux, S; Jeljeli, M; Lafon, C; Leenhardt, R; Mestas, JL; Nicco, C; Prat, F | 1 |
| Akita, H; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Mori, M; Nagano, H; Noda, T; Tomimaru, Y | 1 |
| Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
| Chen, XD; Qiao, ZG; Tang, JM; Wu, XY; Yao, XM; Zhou, HY | 1 |
| Aburatani, H; Masoudi, M; Seki, M; Yachie, N; Yazdanparast, R | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Deng, LD; Hu, LJ; Jiang, X; Ren, ZP; Wang, YP; Yang, L; Zhao, HJ | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Chen, LT; Cunningham, D; Dean, A; Lee, KH; Li, CP; Macarulla Mercadé, T; Siveke, JT; Wang-Gillam, A | 1 |
| Frank, RC; Lee, R; Levy, G; Lo, T; Lobo, S; Martino, C; Pandya, D | 1 |
| Brunetti, O; Silvestris, N | 1 |
| Anders, R; Batukbhai, B; Begum, A; De Jesus-Acosta, A; de Wilde, RF; Laheru, DA; Maitra, A; McAllister, F; O'Dwyer, PJ; Rajeshkumar, NV; Ramanathan, RK; Rasheed, Z; Sahin, I; Sugar, EA; Von Hoff, DD; Yabuuchi, S; Zheng, L | 1 |
| de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R | 1 |
| Blanco, A; Li, J; Norgard, RJ; Stanger, BZ; Yamazoe, T; Yan, F; Yuan, S | 1 |
| Bjånes, TK; Cros-Perrial, E; Jordheim, LP; Kamceva, T; Kotopoulis, S; Langer, A; McCormack, E; Riedel, B; Ruiz de Garibay, G; Schjøtt, J | 1 |
| Chen, X; Li, T; Wan, J; Wang, H; Wang, Y; Wu, L; Zhang, F | 1 |
| Chen, L; Chen, Z; Cheng, CS; Liu, W; Meng, Z; Tang, W; Zhong, A; Zhou, L | 1 |
| Kawashiri, T; Kobayashi, D; Shimazoe, T; Tokunaga, A | 1 |
| Chauhan, B; Chauhan, N; Chauhan, SC; Halaweish, FT; Jaggi, M; Khan, P; Khan, S; Kumari, S; Malik, S; Sikander, M; Yallapu, MM | 1 |
| Gong, JH; Liu, XJ; Miao, QF; Wang, RH; Wang, YX; Yang, SQ; Zhang, MR; Zhen, YS; Zheng, YB | 1 |
| Adiseshaiah, PP; Burgan, W; Goswami, D; Guerin, TM; Kozlov, SV; McCormick, F; Mukhopadhyay, S; Nissley, DV; Yi, M | 1 |
| Bansal, R; Mardhian, DF; Prakash, J; Storm, G; Vrynas, A | 1 |
| Ahn, ER; Algül, H; Askoxylakis, V; Bendell, J; Charu, V; Gracian, AC; Ko, AH; Kuesters, G; Kundranda, M; Meiri, E; Pelzer, U; Pipas, JM; Rivera, F; Santillana, S; Watkins, D; Zafar, SF; Zalutskaya, A | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Beh, I; Brais, R; Connell, CM; Corrie, P; Janowitz, T; Jodrell, DI; Risdall, J; Upponi, S; Whitaker, H | 1 |
| Caprioli, R; Dai, X; Dosch, AR; Kashikar, N; Kwon, D; Mehra, S; Merchant, NB; Nagathihalli, NS; Reyzer, ML; Srinivasan, S; Willobee, BA | 1 |
| Segar, J; Shroff, RT | 1 |
| Abrams, RA; Berger, AC; Corn, BW; Crane, CH; DiPetrillo, TA; Fisher, BJ; Gillin, MT; Goodman, KA; Haddock, MG; Jiang, Y; Katz, AW; Lowy, AM; Mehta, S; Philip, PA; Regine, WF; Safran, H; Seaward, SA; Song, S; Willett, CG; Winter, KA; Wu, A | 1 |
| Jia, Y; Liu, B; Ma, J; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xue, L; Yin, X | 1 |
| Honda, Y; Inaba, T; Kim, J; Liu, X; Matsui, M; Nishiyama, N; Nomoto, T; Takemoto, H; Taniwaki, K; Tomoda, K; Toyoda, M; Yamada, N | 1 |
| Beumer, JH; Chen, Y; Diao, D; Li, S; Lu, B; Luo, Z; Parise, RA; Ren, P; Sun, J; Wan, Z; Xu, J | 1 |
| Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I | 1 |
| Garcia-Cremades, M; Magni, P; Melillo, N; Troconiz, IF | 1 |
| Beringer, A; Groschek, M; Heinemann, V; Hoeffkes, HG; Marschner, N; Schulze, M; Tessen, HW; Waldschmidt, D; Westphalen, CB | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Aksnes, AK; Amund Eriksen, J; Dueland, S; Faluyi, O; Iversen, B; Jensen Gjertsen, T; Ma, YT; Miller, R; Møller, AS; Neoptolemos, JP; Palmer, DH; Valle, JW | 1 |
| Chen, X; Gao, M; Han, H; Hou, Y; Ji, J; Jin, Q; Kang, M; Zhang, P | 1 |
| Beringer, A; Fuchs, M; Garlipp, B; Hahn, L; Heinemann, V; Kukiolka, T; Kütting, F; Malfertheiner, P; Reiser, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Gibbs, SL; King, D; Solanki, A; Thibault, G; Wang, L | 1 |
| Ding, X; Huang, W; Jiang, C; Li, F; Sun, T; Wang, Q; Wang, Z; Wu, Z; Zhu, X | 1 |
| Bhattacharya, R; Elechalawar, CK; Figg, WD; Hossen, MN; Mukherjee, P; Peer, CJ; Robertson, JD; Shankarappa, P | 1 |
| Fei, Z; Liang, X; Su, H; Zou, C; Zou, J | 1 |
| Akkermans-Vogelaar, JM; Besselink, MG; Bonsing, BA; Buijsen, J; Busch, OR; Creemers, GM; de Groot, JWB; de Hingh, IH; de Vos-Geelen, J; Eskens, FALM; Festen, S; Groot Koerkamp, B; Groothuis, K; Homs, MYV; Kerver, ED; Luelmo, SAC; Neelis, KJ; Nuyttens, J; Paardekooper, GMRM; Patijn, GA; Punt, CJ; Suker, M; van Dam, RM; van der Sangen, MJC; van Eijck, CH; van Hooft, JE; van Tienhoven, G; Versteijne, E; Wilmink, JW; Zwinderman, AH | 1 |
| Baek, YY; Fang, S; Jang, SI; Lee, DH; Lee, DK; Lee, SY; Na, K | 1 |
| Li, W; Lin, H; Peng, Y; Sun, J; Wu, W; Yu, X; Zhang, K; Zhu, Y | 1 |
| Crane, CH; Gusani, NJ; Lehrer, EJ; Sharma, NK; Tchelebi, LT; Trifiletti, DM; Zaorsky, NG | 1 |
| Dahabreh, IJ; García-Albéniz, X; Hernán, MA; Howlader, N; Logan, RW; Mariotto, AB; Petito, LC | 1 |
| Garcia, PL; Miller, AL; Yoon, KJ | 1 |
| Amaravadi, RK; Bahary, N; Bartlett, DL; Boone, BA; Espina, V; Hogg, ME; Lee, KK; Liotta, L; Lotze, MT; Marsh, JW; Miller-Ocuin, JL; Murthy, P; Normolle, DP; Seiser, N; Singhi, AD; Tang, D; Tsung, A; Zeh, HJ; Zureikat, AH | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Buse, JB; Corty, RW; Fine, JP; Langworthy, BW; Lund, JL; Sanoff, HK | 1 |
| Li, B; Li, T; Liu, MF; Xi, Y; Yuan, P; Zhang, M | 1 |
| Drexler, R; Feyerabend, B; Kleine, M; Küchler, M; Oldhafer, KJ; Wagner, KC | 1 |
| Apte, MV; Goldstein, D; Liu, AC; Mekapogu, AR; Murakami, T; Pang, TCY; Perera, CJ; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Abdelrahman, L; Banerjee, S; Kesh, K; Mendez, R | 1 |
| D'Haese, JG; Maisonneuve, P; Miksch, RC; Weniger, M; Werner, J | 1 |
| Ilbasmis-Tamer, S; Takka, S; Yalcin, TE | 1 |
| Hamada, Y; Hattori, A; Kawabata, H | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Gao, S; Hao, J; Huang, C; Jin, F; Liu, J; Wang, H; Wang, X; Xiao, D; Yang, S; Zhao, T | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Chiaradonna, F; De Vitto, H; Gang, Y; Giampà, M; Gu, J; Guan, W; La Ferla, B; Li, Q; Palorini, R; Ricciardiello, F; You, L; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Dorman, MJ; Fishel, ML; Grippo, PJ; Hwang, RF; Kamath, SD; Kumar, S; Munshi, HG; Narbutis, M; Park, A; Principe, DR; Rana, A; Thummuri, D; Trevino, JG; Underwood, PW; Viswakarma, N | 1 |
| Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ | 1 |
| Damarla, V; Dobrosotskaya, I; Khan, G; Kwon, D; Li, J; Raoufi, M; Seixas, T; Siddiqui, F; Thanikachalam, K; Winters, K; Wollner, I | 1 |
| Chiba, M; Honma, S; Imazu, H; Ito, M; Shimamoto, N; Sumiyama, K | 1 |
| Gao, LF; Han, J; Li, XL; Liu, QY; Liu, ZJ; Wang, XH; Xu, W | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Cui, M; Dai, M; Gao, J; Guo, J; Kleeff, J; Li, T; Li, Y; Liao, Q; Liu, J; Liu, Q; Lu, Z; Pan, B; Wang, W; Wu, H; Wu, W; Zhang, R; Zhang, T; Zhang, X; Zhao, Y; Zhou, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Bäsecke, J; Schoel, G; Schrader, J | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Bottinor, W; Das, S; Nunnery, S | 1 |
| Anthoney, A; Arif, S; Basu, B; Bax, L; Brais, R; Bridgewater, J; Bundi, P; Chhabra, A; Corrie, PG; Cummins, S; Dalchau, K; Dayim, A; Ellis, R; Evans, J; Falk, S; Gillmore, R; Gopinathan, A; Isherwood, C; Jodrell, DI; Lwuji, C; Ma, YT; Machin, A; McAdam, K; Neesse, A; Palmer, D; Propper, D; Qian, W; Scott-Brown, M; Skells, R; Tuveson, D; Valle, JW; Wadsley, J; Wall, L; Wasan, H | 1 |
| Arora, S; Carter, JE; Gorman, GS; Khan, MA; Khushman, M; Patel, GK; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Barone, D; Bekaii-Saab, T; Flaherty, KT; Krause, S; Mahalingam, D; O'Reilly, EM; Richards, DA; Roach, JM; Rosano, M; Ryan, DP; Shao, SH; Wolf, J; Yu, KH | 1 |
| Chen, SY; Hsu, YH; Lin, JA; Wang, SY; Yen, GC | 1 |
| Dwarkasing, RS; Eskens, FALM; Groot Koerkamp, B; Homs, MYV; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Bhutia, YD; Cai, A; Chen, R; Chen, Z; Ganapathy, V; Kou, L; Li, C; Lin, X; Yao, Q; Zheng, H | 1 |
| Fazio, N | 1 |
| Abushahin, L; Alexandra Diaz, D; Chen, W; Cloyd, JM; Dillhoff, M; Frankel, WL; Miller, ED; Noonan, A; Prabhakar, D; Williams, TM; Wolfe, AR; Yildiz, VO | 1 |
| Ahn, HM; Kim, DG; Kim, YJ | 1 |
| Aceti, M; Bayle, S; Duckett, D; Frydman, SM; Grant, W; McDonald, P; Monastyrskyi, A; Nieto, A; Quereda, V; Roush, WR; Sansil, SS; Teng, M; Vena, F | 1 |
| Fujimoto, D; Goi, T; Iida, A; Ishida, M; Kimura, T; Sato, Y; Togawa, T | 1 |
| Chen, ZN; Jiang, JL; Liu, Z; Tang, J; Yang, H; Zheng, M; Zhou, Y; Zhu, P | 1 |
| Kim, JH; Lee, J | 1 |
| Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A | 1 |
| Chen, D; Chen, J; Hao, Q; Huag, Y; Jiang, L; Kong, Y; Li, W; Liu, R; Lu, Y; Tang, Y; Tao, W; Yang, X; Yu, H; Zhang, H; Zhang, Y; Zhu, X; Zou, H | 1 |
| Ahmad, SA; Bogdanov, VY; Chu, Z; Davis, HW; Franco, RS; Lewis, CS; N'Guessan, KF; Olowokure, O; Qi, X; Vallabhapurapu, SD; Yeh, JJ | 1 |
| Chen, S; Chen, Y; Huang, K; Li, X; Lian, G; Tan, Y; Tian, Z; Zou, J | 1 |
| Cui, Y; Huang, P; Ji, D; Kang, P; Leng, K; Wang, Z; Xu, Y; Zheng, W; Zhong, X | 1 |
| Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Bazan, D; Cavaliere, A; Deiana, M; Fedele, V; Lonardi, S; Mangiameli, D; Melisi, D; Merz, V; Piro, G; Sabbadini, F; Santoro, R; Simionato, F; Valenti, MT; Zecchetto, C | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Aly, A; Botteman, M; Chiorean, EG; Goldstein, D; Lee, CK; Louis, CU; Lu, B; Margunato-Debay, S; McGovern, D; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD | 1 |
| Bean, PA; Bulanadi, JC; de Campo, L; Gong, X; Julovi, SM; Moghaddam, MJ; Smith, RC; Xue, A | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Casey, PJ; Chai, TF; Manu, KA; Wang, M | 1 |
| Asukai, K; Hara, H; Haraguchi, N; Hasegawa, S; Ishikawa, O; Miyata, H; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shinno, N; Sugimura, K; Takahashi, H; Ushigome, H; Wada, H; Yamada, D; Yamamoto, K; Yano, M; Yasui, M | 1 |
| Chen, HB; Gu, DN; Jiang, MJ; Mei, Z; Ye, ZQ; Zou, CL | 1 |
| Bao, M; Das, M; Huang, L; Li, J | 1 |
| Li, PC; Lin, GH; Wang, BC; Xiao, BY | 1 |
| Ibusuki, M; Inoue, T; Ito, K; Kimoto, S; Kitano, R; Kobayashi, Y; Nakade, Y; Ohashi, T; Sakamoto, K; Sumida, Y; Yoneda, M | 2 |
| Bullock, A; Chiorean, EG; Oestreicher, N; Rowan, CG; Yeganegi, H | 1 |
| Chen, M; Goodin, S; Li, D; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, P; Xu, X; Zhang, K; Zheng, X; Zhou, R | 1 |
| Balourdas, DI; Berger, BT; Cheung, PF; Hahn, SA; Hamdan, FH; Joerger, AC; Johnsen, SA; Knapp, S; Ladigan, S; Liffers, ST; Lucas, R; Scheffler, B; Siveke, JT; Trajkovic-Arsic, M; Weiser, T; Zegar, T; Zhang, X | 1 |
| Chen, R; Chen, Y; Feng, H; Fung, FKC; Li, CH; Li, G; To, KF; Tong, JH; Wong, CH; Xia, T; Zhu, YX | 1 |
| Capacio, BA; Carr, MJ; Chai, LF; Cox, BF; Erdem, S; Jaroch, DB; Katz, SC; Ray, P; Shankara Narayanan, JS; Vicente, DA; White, RR | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Akagi, N; Burns, ST; Damon, L; Ko, AH; Laszik, Z | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Chen, Y; Di, YS; He, L; Lam, LM; Liang, ST; Liao, Y; Tsang, YS; Xia, Q | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Cao, D; Cheng, K; Guo, F; Li, J; Li, S; Li, X; Peng, Y; Shui, L; Shui, P; Yi, C | 1 |
| Abolmaali, N; Baumann, M; Blum, S; Distler, M; Folprecht, G; Grützmann, R; Jentsch, C; Polster, H; Saeger, HD; Troost, EGC; Weitz, J; Zimmermann, C; Zöphel, K | 1 |
| Moir, JAG; Severs, GR; Tingle, SJ; White, SA | 1 |
| Bendell, J; Feeney, K; Gracián, AC; Hecht, JR; Hung, A; Lee, MA; Lin, Y; Lonardi, S; Muñoz, A; Ryoo, BY; Wainberg, ZA | 1 |
| Boggio, V; Catrinacio, C; Gonzalez, CD; Orquera, T; Renna, FJ; Ropolo, A; Vaccaro, MI | 1 |
| Evans, DB | 1 |
| Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J | 1 |
| Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y | 1 |
| Hines, OJ; Ye, L | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Iede, K; Ikenaga, M; Kato, R; Matsuyama, J; Nakashima, S; Ohta, K; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 3 |
| Du, J; Gu, J; Li, J | 1 |
| Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q | 1 |
| Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C | 1 |
| Ahmed, AA; Marchetti, C; Neidle, S; Ohnmacht, SA | 1 |
| Cordelier, P; Lumeau, A | 1 |
| Cao, J; Chen, J; Diao, F; Huang, P; Qiu, F | 1 |
| Arshad, A; Dennison, AR; Isherwood, JD; Jones, DJL; Ng, LL; Runau, F; Sandhu, JK | 1 |
| Han, Y; Ma, J; Qian, J; Shi, Y; Wang, Y; Yan, X; Yao, N | 1 |
| Ali, DW; Chen, XZ; Dong, X; Huang, Y; Michalak, M; Qin, W; Tang, J; Wei, J; Yan, Y; Yi, C; Yi, Y; Zhang, R; Zhang, X; Zhou, C | 1 |
| Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M | 2 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Bernaldo de Quirós Fernández, S; Cadogan, EB; Dunlop, CR; Durant, ST; Jodrell, DI; Johnson, TI; Lau, A; Richards, FM; Wallez, Y | 1 |
| Andrikou, K; Bernardini, L; Casadei-Gardini, A; Catanese, S; Falcone, A; Formica, V; Fornaro, L; Lencioni, M; Massa, V; Pecora, I; Rapposelli, GI; Riggi, L; Rovesti, G; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Carpenter, ES; Pasca di Magliano, M; Steele, NG | 1 |
| Lam, LL; Levingston, R; O'Neill, RS; Solanki, P; Thomas, D | 1 |
| Dash, AK; Deodhar, S; Hulce, M; North, EJ | 1 |
| Chie, EK; Jang, JY; Kim, BH; Kim, H; Kim, K; Kwon, W; Lee, KB; Lee, KH; Oh, DY | 1 |
| Bendell, J; Berlin, J; Bhargava, P; Brachmann, CB; Chaves, J; Gordon, M; Khan, SA; Liu, J; Patel, MR; Shah, MA; Sharma, S; Starodub, A; Thai, D; Wainberg, ZA; Windsor, KS; Zavodovskaya, M | 1 |
| Agarwal, C; Agarwal, R; Bagby, SM; Dhar, D; Kumar, D; Messersmith, WA; Orlicky, DJ; Pitts, TM; Raina, K; Wempe, MF | 1 |
| Alseidi, A; Carney, M; Carrier, E; Glaspy, J; Kouchakji, E; Larson, T; Matrana, M; Mody, K; Picozzi, V; Pishvaian, M; Porter, S; Rocha, F; Winter, J | 1 |
| Cui, C; Feng, Y; Hao, C; Kong, D; Su, H; Tian, X; Xue, J; Yan, L; Yao, Q; Yao, Y; Zhou, T | 1 |
| Arpicco, S; Chegaev, K; Donadelli, M; Fruttero, R; Gazzano, E; Masetto, F; Mullappilly, N; Riganti, C; Rolando, B | 1 |
| Hatano, H; Imura, S; Johira, H; Kagajo, Y; Kashu, N; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Watanabe, R; Yunoki, S | 1 |
| Bakhtiyari, S; Gheysarzadeh, A; Mofid, MR | 1 |
| Boeck, S; Guenther, M; Haas, M; Heinemann, V; Kirchner, T; Kruger, S; Mayerle, J; Ormanns, S; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Hoffman, RM; Huang, J; Shen, L; Sun, YU; Tong, Z; Yang, H | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Li, J; Liu, J; Liu, Y; Qi, Z; Shen, Y; Tian, W; Yang, L; Yang, Y; Zhang, Q; Zhu, M | 1 |
| Ding, J; He, L; Pang, S; Shen, B; Xie, X; Xu, D; Zhou, C; Zhou, Y | 1 |
| Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA | 1 |
| Ferrara, KW; Ingham, ES; Kakwere, H; Tumbale, SK | 1 |
| Bu, LP; Li, XY; Liu, H; Liu, P; Shao, L; Ying, Q; Yu, SQ | 1 |
| Bulanadi, JC; Gill, AJ; Gong, X; Hugh, T; Julovi, SM; Moghaddam, MJ; Phillips, L; Proschogo, N; Rye, KA; Smith, RC; Smith, SF; Xue, A | 1 |
| Baltatzis, M; De Liguori Carino, N; Rodriquenz, MG; Siriwardena, AK | 1 |
| Blaauboer, A; Booy, S; Dogan, F; Hofland, LJ; Karels, B; van Eijck, CHJ; van Koetsveld, PM; van Zwienen, S | 1 |
| Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Bolidong, D; Domoto, T; Minamoto, T; Miyashita, T; Takenaka, S; Takeuchi, O; Uehara, M | 1 |
| Ito, K; Kawamoto, Y; Komatsu, Y; Nakano, S; Nakatsumi, H; Saito, R; Sakamoto, N; Yuki, S | 1 |
| Aghmesheh, M; Foroughi, J; Moulton, SE; Piper, AK; Sahin, Z; Talebian, S; Vine, KL; Wade, SJ; Wallace, GG | 1 |
| Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V | 1 |
| Abe, Y; Ashida, R; Fukutake, N; Ikezawa, K; Imai, T; Katayama, K; Kato, K; Kiyota, R; Kukita, Y; Nawa, T; Ohkawa, K; Takada, R; Yamai, T | 1 |
| Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
| Björnsson, B; Blomstrand, H; Elander, NO; Fredrikson, M; Gränsmark, E; Green, H | 1 |
| El-Husseiny, AA; El-Mahdy, HA; Gamal El-Din, AM; Kandil, YI | 1 |
| Arcucci, S; Barentin, C; Ben-Mériem, Z; Delanoë-Ayari, H; Delarue, M; Guillermet-Guibert, J; Hatzikirou, H; Mascheroni, P; Prunet, A; Rivière, C; Rizzuti, IF | 1 |
| Al-Batran, SE; Aldaoud, A; Behringer, DM; Bildat, S; Blau, W; Büchner-Steudel, P; Däßler, KU; Dörfel, S; Eschenburg, H; Ettrich, TJ; Feustel, HP; Fietz, T; Forstbauer, H; Gallmeier, E; Götze, TO; Groschek, M; Hahn, L; Harich, HD; Hausen, GZ; Höffkes, HG; Hofheinz, RD; Homann, N; Jacobasch, L; Koenigsmann, M; Kretzschmar, A; Kunzmann, V; Mahlmann, S; Messmann, H; Papke, J; Pauligk, C; Peters, U; Pink, D; Reichart, A; Schaaf, M; Schlag, R; Schönherr, C; Schubert, J; Schuch, G; Schulz, H; Schwindel, U; Siegler, G; Springfeld, C; Stauch, M; Trojan, J; Uhlig, J; Vehling-Kaiser, U; Vogel, A; von Weikersthal, LF; Waibel, K; Waidmann, O; Wehmeyer, J; Weniger, J; Wierecky, J; Wolf, M; Wörns, MA; Zahn, MO | 1 |
| Cao, S; Liu, S; Xu, J; Yang, X; Zhou, Y | 1 |
| Jiang, W; Li, H; Li, T; Liu, L; Liu, X; Yu, X; Zhang, J; Zhang, W | 1 |
| Benkirane-Jessel, N; Chalhoub, S; Fuhrmann, G; Hassan, S; Idoux Gillet, Y; Peluso, J; Rochel, N; Ubeaud-Sequier, G | 1 |
| Cha, J; Hsu, S; Huang, S; Jennings, E; Lee, JB | 1 |
| Inoue, Y; Ito, H; Mise, Y; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Takahashi, Y | 1 |
| Cheng, WC; Chiang, CM; Hsu, KW; Liu, YH; Peng, PH; Tsai, LH; Wu, HH; Yang, HJ; Yang, SF | 1 |
| Abushahin, L; Chakravarti, A; Cruz-Monserrate, Z; Hegazi, A; Jacob, JR; Palanichamy, K; Robb, R; Shyu, DL; Trevino, JG; Williams, TM; Wolfe, AR; Yang, L | 1 |
| Adair, SJ; Adli, M; Bauer, TW; Demirlenk, YM; Dutta, A; Habieb, AH; Kane, WJ; Kuscu, C; Lee, KY; Liu, D; O'Hara, PE; Ozturk, H; Wei, X; Yang, J; Yilmaz, E | 1 |
| Chugh, P; Furukawa, M; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Kanai, M; Kawabe, K; Komatsu, Y; Nakamori, S; Okusaka, T; Ozaka, M; Sato, A; Shimizu, S; Sugimori, K; Tang, R; Ueno, M | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| Abraham, AG; Cox, CM; Hughes, DLI; Hurt, CN; Jones, CM; Maughan, T; Mukherjee, S; O'Neill, EE; Owens, R; Parkes, EE; Sabbagh, A; Wilhelm-Benartzi, CS; Willenbrock, F | 1 |
| Arai, T; Fukumura, Y; Hirabayashi, K; Kawanishi, A; Kojima, M; Matsuda, Y; Mino-Kenudson, M; Nakano-Narusawa, Y; Ohkubo, S; Sahara, Y; Takahashi, S; Yamaguchi, H | 1 |
| Batra, SK; C Caffrey, T; Chhonker, YS; Chirravuri, R; Chugh, S; Grandgenett, PM; Gupta, R; Hollingsworth, MA; L Grem, J; Lele, SM; Leon, F; Mallya, K; Marimuthu, S; Murry, DJ; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Prajapati, DR; Rachagani, S; Rauth, S; Shailendra, GK | 1 |
| Lv, X; Yin, N; Yu, H; Zhang, X | 1 |
| Kawai, S; Kikuchi, S; Lin, Y; Suzuki, T; Ueno, M | 1 |
| Cui, JX; Qin, Y; Xu, J; Xu, Y | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Capone, A; Capurso, G; de Latouliere, L; Di Agostino, S; Manni, I; Montori, A; Naro, C; Panzeri, V; Piaggio, G; Pilozzi, E; Sacconi, A; Sette, C | 1 |
| Fukutomi, A; Furuse, J; Hara, H; Hiraoka, N; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Ito, Y; Katayama, H; Kawashima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Nakamori, S; Nakamura, S; Okano, N; Okusaka, T; Ozaka, M; Sata, N; Shimizu, K; Sugimori, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, T; Yanagimoto, H | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 2 |
| Chen, HA; Chiu, CF; Chuang, TH; Hsieh, CL; Hsu, TW; Huang, MT; Leo Su, J; Su, CM; Su, YH | 1 |
| Ho, TTB; Honda, M; Inui, H; Kaneko, S; Kawaguchi, K; Kitamura, Y; Komura, T; Kozaka, T; Mizukoshi, E; Nasti, A; Sakai, Y; Seki, A; Shiba, K; Wada, T; Yamashita, T | 1 |
| Armenoult, L; Arsenijevic, T; Augustin, J; Ayadi, M; Bachet, JB; Bigonnet, M; Blum, Y; Cros, J; Dahan, L; de Reyniès, A; Duconseil, P; Dusetti, NJ; Elarouci, N; Emile, JF; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Hammel, P; Iovanna, J; Moutardier, V; Nicolle, R; Puleo, F; Roques, J; Svrcek, M; Van Laethem, JL; Vanbrugghe, C | 1 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Gao, S; Xu, Y; Zhang, Z; Zhao, C | 1 |
| Caires, HR; Castro, I; Cavadas, B; Ferreira, D; Oliveira, MJ; Pereira, L; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
| Wang, F; Zhang, Z | 1 |
| Real, FX; Siveke, JT | 1 |
| Ahmed, AA; Neidle, S | 1 |
| Deng, D; El Hassouni, B; Giovannetti, E; Gregori, A; Kazemier, G; Puik, JR | 1 |
| Banerjee, S; Banerjee, SK; Dutta, D; Haque, I; Jain, P; Kale, N; Kambhampati, S; Mallik, S; Mohammed, J; Nair, G; Orr, M; Parmer, M; Quadir, M; Ray, P; Reindl, KM | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Azevedo-Pouly, AC; Brekken, RA; Girard, L; Huang, H; Kantheti, HS; Layeghi-Ghalehsoukhteh, S; MacDonald, RJ; Niederstrasser, H; Ocal, O; Pal Choudhuri, S; Pashkov, V; Posner, BA; Wilkie, TM; Zolghadri, Y | 1 |
| Fujiwara, H; Ijichi, H; Isayama, H; Kim, J; Kimura, G; Koike, K; Kudo, Y; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Nakatsuka, T; Sano, M; Soma, K; Takahashi, R; Takeda, N; Tanaka, Y; Tateishi, K; Yamamoto, K | 1 |
| Hsia, RC; Kambhampati, SP; Kannan, RM; Kokkoli, E; Shabana, AM | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Batra, SK; Chirravuri-Venkata, R; Foster, JM; Jain, M; Kaushik, G; Lele, SM; Ly, QP; Malafa, MP; Mallya, K; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Rachagani, S; Rauth, S; Seshacharyulu, P; Singh, AB; Smith, LM; Vengoji, R | 1 |
| Abdel Hadi, N; Borge, L; Carrier, A; Cormareche, L; Diémé, B; Dou, S; Dusetti, N; El Kaoutari, A; Garcia, J; Gayet, O; Gicquel, T; Iovanna, J; Lac, S; Masoud, R; Pasquier, E; Reyes-Castellanos, G; Shintu, L; Tranchida, F | 1 |
| Andel, J; Arnold-Schrauf, C; Djanani, A; Eisterer, W; Gerger, A; Gruenberger, B; Heibl, S; Hubmann, E; Korger, M; Laengle, F; Mlineritsch, B; Neumann, HJ; Oehler, L; Pecherstorfer, M; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Prager, GW; Sliwa, T; Trondl, R; Wilthoner, K; Winder, T; Wöll, E | 1 |
| Jiang, Z; Liu, Y; Tao, L; Zhao, Y | 1 |
| Inoue, Y; Ito, H; Mise, Y; Oba, A; Ono, Y; Saiura, A; Sato, T; Takahashi, Y; Ushida, Y | 1 |
| Hirokawa, T; Masutani, T; Sakamoto, K | 1 |
| Karaca, M; Kayahan, N; Özet, A; Satış, H; Yapar, D | 1 |
| Arumugam, T; Fujii, T; Huang, H; Ji, B; Jiang, H; Jin, Z; Li, Z; Lin, K; Logsdon, C; Peng, L; Sun, L; Yao, Y; Zhang, Y; Zhuang, L | 1 |
| Cao, D; Hu, Q; Wang, X; Xu, H; Zhou, S | 1 |
| Hua, YQ; Meng, ZQ; Ning, ZY; Shen, YH; Sheng, J; Wang, P; Xu, LT; Yan, X; Zhu, ZF; Zhuang, LP | 1 |
| Che, G; Chen, Y; Huang, C; Li, T; Li, Y; Lin, Y; Luo, L; Peng, S; Ren, T; Yang, P; Zeng, L | 1 |
| Gan, Y; Jiang, W; Li, X; Zhou, W | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Bai, LY; Chen, CY; Chen, LT; Chiang, NJ; Chiu, CF; Liang, SH; Su, YY; Wang, HC | 1 |
| Aoyama, T; Kamiya, M; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Numata, M; Oshima, T; Rino, Y; Sawazaki, S; Shiozawa, M; Tamagawa, H; Ueno, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Ak, H; Atay, S; Aydin, HH; Rüstem, DG | 1 |
| Assenat, E; Boissière-Michot, F; de Forges, H; Dupuy, M; Ho-Pun-Cheung, A; Lombard-Bohas, C; Lopez-Crapez, E; Mazard, T; Mineur, L; Mollevi, C; Portales, F; Samalin, E; Walter, T; Ychou, M | 1 |
| Dehdashti, F; Detering, L; Greco, S; Grierson, PM; Heo, GS; Laforest, R; Li, L; Lim, KH; Liu, Y; Lou, L; Luehmann, H; Ruzinova, M; Sultan, D; Zhang, X | 1 |
| Deng, ZH; Hong, X; Hou, J; Li, ZX; Pang, LH; Sun, H; Wang, T; Zhang, CY; Zhang, HY; Zhang, J | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, SW; Im, SA; Jang, JY; Kim, JH; Kim, JS; Kim, SW; Kim, TY; Kwon, J; Lee, KH; Oh, DY | 1 |
| Aoki, Y; Hirose, Y; Ishimoto, U; Kinoshita, A; Koike, K; Mizuno, Y; Ohsawa, A; Saruta, M; Satou, N; Satou, Y | 1 |
| Bogeski, I; Ellenrieder, V; Gaedcke, J; Gibhardt, CS; Hamdan, FH; Hessmann, E; Johnsen, SA; Kopp, W; Kutschat, AP; Najafova, Z; Ströbel, P; Wang, X; Wixom, AQ | 1 |
| Kaneko, T; Kobayashi, S; Miwa, H; Morimoto, M; Ohkawa, S; Sugimori, K; Taguri, M; Ueno, M; Yamanaka, T | 1 |
| Deep, A; Kaur, M; Kim, KH; Kumar, P; Kush, P; Madan, J; Sharma, M | 1 |
| Betancourt, O; Cazes, A; Esparza, E; Gymnopoulos, M; Jaquish, D; Lowy, AM; Mose, ES; Tiriac, H; Wascher, AA; Wong, E | 1 |
| Choi, MH; Hong, TH; Kim, IH; Lee, IS; Lee, MA | 1 |
| Arrigoni, E; Catanese, S; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Fornaro, L; Massa, V; Morganti, R; Pecora, I; Rofi, E; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Hayashi, H; Ishida, M; Kamei, T; Miyazaki, K; Mizuma, M; Morikawa, T; Motoi, F; Nakagawa, K; Ohtsuka, H; Shinoto, M; Takiyama, H; Unno, M; Yamada, S | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Caffrey, TC; Clausen, H; Hollingsworth, MA; Leiphrakpam, PD; McAndrews, KL; Radhakrishnan, P; Sagar, S; Swanson, BJ; Thomas, D; Wandall, HH | 1 |
| Beatty, GL; Carpenter, EL; Giannone, MA; Gladney, WL; Herrera, VM; Wattenberg, MM | 1 |
| Cheng, K; Li, G; Li, Y; Lin, CY; Liu, Y; Staveley-OCarroll, KF; Zhao, Z | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Bjånes, TK; Riedel, B; Schjøtt, J | 1 |
| Akahori, T; Ikeda, N; Kunishige, T; Nagai, M; Nakagawa, K; Nakamura, K; Nishiwada, S; Sho, M; Takagi, T; Terai, T | 1 |
| Fu, JY; Mai, CW; Maniam, G; Zulkefeli, M | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Higa, N; Hirano, H; Kitanaka, C; Okada, M; Sanomachi, T; Seino, S; Sonoda, Y; Sugai, A; Suzuki, S; Takajo, T; Togashi, K; Uchida, H; Yamada, Y; Yamamoto, M; Yonezawa, H; Yoshimoto, K | 1 |
| Li, X; Li, ZQ; Liu, YF; Luo, D; Yu, X; Zhu, HW | 1 |
| Hua, YQ; Li, Y; Liu, LM; Ning, ZY; Sheng, J; Shi, WD; Zhang, K | 1 |
| Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
| Gao, W; Li, X; Liu, Y; Luo, D; Yu, L; Yu, X; Zhu, H | 1 |
| Furukawa, T; Higuchi, R; Izumo, W; Matsunaga, Y; Shiihara, M; Uemura, S; Yamamoto, M; Yazawa, T | 1 |
| Abdul-Ahad, A; Boeck, S; Dechow, T; Fischer von Weikersthal, L; Freiberg-Richter, J; Frickhofen, N; Haas, M; Heinemann, V; Held, S; Illerhaus, G; Kaiser, F; Kanzler, S; Kruger, S; Kubicka, S; Mahlberg, R; Malfertheiner, P; Reinacher-Schick, A; Seufferlein, T; Snijder, R; Stahl, M; von Bergwelt-Baildon, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Ergözen, S; Gümüş, T | 1 |
| Philip, PA | 5 |
| Baba, H; Goel, A; Nishiwada, S; Okada, Y; Sho, M; Takayama, T; Yamamura, K | 1 |
| Liu, B; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xu, G; Yin, X; Zou, X | 1 |
| Al-Rajabi, R; Balducci, L; Banks, J; Brenner, W; Coveler, AL; Elquza, E; George, TJ; Hatoum, H; Hewitt, DB; Kennedy, E; Lavu, H; Leiby, B; Link, C; LoConte, N; Musher, B; Nissen, N; Rossi, G; Seng, J; Vaccaro, G; Vahanian, N; Yeo, CJ | 1 |
| Einama, T; Fujii, Y; Fukai, M; Hatanaka, Y; Kamachi, H; Kawamata, F; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Cho, SK; Ediriweera, MK; Kim, HY; Moon, JY; Ryu, JY | 1 |
| Choi, KY; Han, G; Lee, SH; Ryu, WJ | 1 |
| Atlı Şekeroğlu, Z; Aydın, B; Işık, S; Şekeroğlu, V | 1 |
| Cao, Z; Feng, M; Gu, J; Guan, W; Guo, W; Liu, Y; Qiu, J; Xiong, G; Yang, G; You, L; Zhang, MQ; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Fan, F; Jin, L; Yang, L | 1 |
| Chen, X; Guo, G; He, W; Quan, Q; Wang, F; Wang, Y; Zhang, B; Zhang, D | 1 |
| Ariake, K; Douchi, D; Fukase, K; Hayashi, H; Kawasaki, S; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Nakagawa, K; Ohtsuka, H; Sato, M; Sato, Y; Unno, M | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| He, Y; Wei, X; Weng, Z; Xu, C; Zhao, Y; Zhou, X | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, JS; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Seo, MS; Shin, SM; Son, MK; Woo, MG; Yan, HH; Yoon, YC | 1 |
| Jusko, WJ; Lin, Q; Ma, WW; Mager, DE; Qian, Z; Straubinger, RM | 1 |
| Besselink, MG; Bonsing, BA; Bos, H; Bosscha, KP; Coene, PPLO; de Hingh, IHJT; de Vos-Geelen, J; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Karsten, TM; Liem, MSL; Loosveld, OJL; Patijn, GA; van Dam, JL; van der Kolk, MB; van Eijck, CHJ; van Santvoort, HC; van Tienhoven, G; Wilmink, JW; Zonderhuis, BM | 1 |
| Chung, N; Han, TY; Jung, SH; Lee, DG; Pak, PJ; Park, SH; Sung, JH | 1 |
| Chen, R; Fu, Z; Huang, L; Li, G; Lin, Q; Lu, Y; Wei, L; Zhou, Q | 1 |
| Dedonyte, V; Kurlinkus, B; Schemmer, P; Sileikis, A; Valius, M; Zalyte, E | 1 |
| Han, HS; Hwang, JH; Kim, H; Kim, J; Lee, JC; Shin, DW; Yoon, YS | 1 |
| Beg, MS; Brekken, RA; Du, W; Huang, H; Lorens, JB; Phinney, NZ; Toombs, JE; Wang, Z; Westcott, J; Wilkie, TM; Zhang, Y | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| MacCuaig, WM; McNally, LR | 1 |
| Aoki, T; Iso, Y; Kubota, K; Matsumoto, T; Mori, S; Park, KH; Sakuraoka, Y; Shimizu, T; Shiraki, T; Yamaguchi, T | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Berger, AK; Bougatf, N; Busch, E; Hackert, T; Jäger, D; Springfeld, C; Werft, W | 1 |
| Furukawa, K; Gocho, T; Onda, S; Sakamoto, T; Shiba, H; Shiozaki, H; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Cui, J; Guo, Y; Peng, T; Wu, H; Xiong, J | 1 |
| Bischoff, S; Blau, O; Briest, F; Bullinger, L; Christen, F; Damm, F; Hablesreiter, R; Hoyer, K; Hummel, M; Inoue, Y; Kakiuchi, N; Keilholz, U; Lohneis, P; Ogawa, S; Pelzer, U; Putter, H; Riess, H; Shiozawa, Y; Shiraishi, Y; Sinn, M; Striefler, JK; Yoshida, K; Yoshizato, T | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Fujii, Y; Fukai, M; Kamachi, H; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Caffrey, TC; Crawford, A; Grunkemeyer, J; Hollingsworth, MA; Leclerc, E; Neville, T; O'Connell, KA; Patil, P; Radhakrishnan, P; Shin, S; Swami, P; Thiyagarajan, S; Vetter, SW | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Binda, E; Latiano, TP; Panebianco, C; Pazienza, V; Perri, F; Potenza, A; Terracciano, F; Trivieri, N; Villani, A | 1 |
| Emamzadeh, M; Pasparakis, G | 1 |
| Hamura, R; Horiuchi, T; Ikegami, T; Kanegae, Y; Ohashi, T; Saito, N; Shimada, Y; Shirai, Y; Takada, N; Taniai, T; Yanaga, K | 1 |
| Leung, E; Lozano Hernandez, L; Reginald-Opara, JN; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Bahra, M; Bischoff, S; Kruger, S; Kurreck, A; Modest, DP; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Weckwerth, J | 1 |
| Barrios-Anderson, A; Radhakrishnan, R; Shimanovsky, A; Yu, E | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR | 1 |
| Hagiwara, S; Higuchi, T; Hori, R; Ioroi, T; Kano, M; Kato, Y; Kitahara, H; Kitahashi, T; Komori, T; Kori, H; Matsumoto, T; Ono, K; Sakabe, M; Yoshino, Y | 1 |
| Eurola, A; Haglund, C; Hagström, J; Mustonen, H; Nurmi, AM; Ristimäki, A; Seppänen, H | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Liu, A; Tang, X; Xu, J; Zhao, T; Zhou, B; Zhou, Y | 1 |
| Fukahori, M; Kakuma, T; Miwa, K; Murotani, K; Nagasu, S; Naito, Y; Okabe, Y; Sakaue, T; Suga, H; Tanaka, T; Torimura, T; Ushijima, T | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Callan, B; Callan, JF; Gao, J; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Bhutkar, S; Dukhande, V; Patel, K; Patki, M; Saraswat, A | 1 |
| Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Chen, G; Deng, T; Ding, X; Li, J; Wang, Y; Wu, L; Xie, X; Yang, Z; Ye, L; Yu, H; Yu, Z; Zheng, Y; Zhu, Q | 1 |
| Brody, JR; Brown, D; Delaney, LJ; Eisenbrey, JR; Forsberg, F; Jimbo, M; Liu, JB; Oeffinger, BE; Stanczak, M; Wheatley, MA | 1 |
| Hashimoto, D; Hirooka, S; Inoue, K; Ishida, M; Ryota, H; Sakaguchi, T; Satoi, S; Sekimoto, M; Yamaki, S; Yamamoto, T | 1 |
| Shang, H; Sun, L; Wu, Y; Xin, X | 1 |
| Minomi, K; Tamura, Y; Yoneda, A | 1 |
| Akahoshi, K; Ban, D; Fujii, M; Kato, T; Kudo, A; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Gotoda, T; Hemmi, A; Iwatsuka, K; Kikuta, D; Moriyama, M; Nakagawara, H; Ogawa, M; Shibuya, H; Yamao, K | 1 |
| Wu, Y; Xu, W; Yang, Y; Zhang, Z | 1 |
| Asby, S; Beatty, M; Blauvelt, J; Innamarato, P; Kidd, S; Mackay, A; Morse, J; Mullinax, JE; Pilon-Thomas, S; Sarnaik, AA | 1 |
| Li, Y; Paxton, JW; Wu, Z; Xu, H | 1 |
| Chen, H; Cheng, T; Cheng, Z; Wang, L; Xie, P; Yang, Y; Zhou, J | 1 |
| Amé, JC; Burckel, H; Mura, C; Noël, G; Waissi, W | 1 |
| Bokas, A; Felekouras, E; Karamouzis, MV; Koustas, E; Papadimitropoulou, A; Papakotoulas, P; Papalampros, A; Papavassiliou, AG; Sarantis, P; Schizas, D; Theocharis, S | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Kawaguchi, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Murayama, K; Nakashita, S; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Oza, N; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Takahashi, H; Ueda, Y; Ureshino, N | 1 |
| Arima, S; Fukahori, M; Hashimoto, S; Honda, T; Ide, Y; Ido, A; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Fujii, H; Iihara, H; Iwashita, T; Kato-Hayashi, H; Kobayashi, R; Ohata, K; Sadaka, S; Shimizu, M; Suzuki, A; Uemura, S | 1 |
| Attri, KS; Auwerx, J; Chaika, NV; Chaudhary, S; Fu, X; He, C; High, RR; Hu, T; Jha, K; King, RJ; Lan, P; Lazenby, A; Mai, A; Mehla, K; Mulder, SE; Mullen, NJ; Murthy, D; Pacheco, CG; Rotili, D; Shukla, SK; Siddhanta, K; Singh, PK; Steegborn, C; Tafani, M; Thakur, R; Tuveson, D; Valente, S; Verdin, E; Vernucci, E; Wang, D; Yu, F | 1 |
| Baydogan, S; Dong, W; Fogelman, DR; Hasanov, M; Javle, MM; Katz, MHG; Kim, MP; Lotze, MT; McAllister, F; Mizrahi, JD; Mohindroo, C; Overman, MJ; Pant, S; Prakash, LR; Rogers, JE; Tzeng, CD; Varadhachary, GR; Wolff, RA | 1 |
| Furukawa, T; Kasuga, A; Kawano, F; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ono, Y; Ozaka, M; Sasahira, N; Sasaki, T; Takahashi, Y; Takamatsu, M; Takeda, T; Yamada, Y | 1 |
| Ay, C; Barth, DA; Djanani, A; Fandler-Höfler, S; Gantschnigg, A; Gary, T; Gerger, A; Greil, R; Gressenberger, P; Hatzl, S; Horvath, L; Jost, PJ; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Schlick, K; Schwarzenbacher, E; Stotz, M | 1 |
| Aoyama, T; Hama, T; Hashiguchi, M; Hori, S; Ito, G; Kawakami, K; Kizaki, H; Nakamura, M; Ozaka, M; Sasahira, N; Yokokawa, T | 1 |
| Hayuka, K; Murakami, A; Nishiuchi, T; Okano, K; Okita, Y; Okuyama, H; Suzuki, Y; Tsuji, A | 1 |
| Bae, SB; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MY; Lee, N; Lee, SC; Lee, YN; Lim, SH; Moon, JH; Park, SK; Yun, J | 1 |
| David, KI; Krishnan, UM; Ravikumar, TS; Sethuraman, S | 1 |
| Chen, J; Hua, Q; Lin, Z; Pi, G; Wang, H; Yu, D; Zhang, D; Zhang, T; Zhao, L | 1 |
| Gao, S; Hao, J; Huang, C; Li, X; Liu, J; Liu, W; Ma, Y; Wang, H; Wang, X; Wang, Z; Wu, L; Yang, S; Yu, X; Zhao, T | 1 |
| Arscott, WT; Bear, A; Ben-Josef, E; Drebin, J; Lee, MK; Loaiza-Bonilla, A; Lukens, JN; Metz, J; Nead, KT; O'Hara, M; Plastaras, JP; Reiss, KA; Shabason, J; Shroff, SG; Teitelbaum, U; Venigalla, S; Wojcieszynski, A | 1 |
| Bai, Y; Chen, D; Deng, J; Guo, H; Guo, Y; Lan, J; Liu, X; Wang, J; Xiao, Y; Zhang, Q; Zhu, H | 1 |
| Hamada, S; Masamune, A; Matsumoto, R; Taguchi, K; Tanaka, Y; Yamamoto, M | 1 |
| Hua, J; Liang, C; Liu, J; Lu, SY; Meng, QC; Shi, S; Wang, W; Wei, MY; Xu, J; Yu, XJ; Zhang, B | 1 |
| Barman, S; Batra, SK; Chauhan, S; Dhawan, P; Fatima, I; Ponnusamy, MP; Rachagani, S; Rauth, S; Singh, AB; Smith, L; Talmon, G; Uppada, J | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Han, BR; Jung, HA; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Chambers, C; Chen, A; Eurich, DT; Ha, V; McCall, M; Sawyer, MB; Youn, S | 1 |
| Bi, R; Li, L; Wang, L; Yin, H; Zhou, K | 1 |
| Bapiro, TE; Bautista, W; Chen, V; Gilbert, DJ; Guerin, TM; Jodrell, DI; Kim, SJ; Kozlov, S; Kumar, P; Li, D; Mehta, M; Ock, CY; Palena, C; Pate, N; Richards, FM; Rudloff, U; Schaub, N; Schlomer, JJ; Sorber, R; Talsania, K; Teper, Y; Zhao, Y | 1 |
| Akshinthala, D; Clohessy, JG; Gaglia, G; Gray, NS; Hidalgo, M; Ke, S; Kibe, S; Kim, N; Koikawa, K; Lee, TH; London, N; Lu, KP; Manz, TD; Muthuswamy, SK; Nakamura, M; Nezu, Y; Oda, Y; Ohuchida, K; Pinch, BJ; Qiu, C; Santagata, S; Sekino, N; Suizu, F; Verma, A; Wegiel, B; Wulf, GM; Zhou, XZ | 1 |
| Croagh, D; Deswaerte, V; Gao, H; Gearing, LJ; Hertzog, PJ; Jenkins, BJ; Lundy, J; McLeod, L; Pajic, M; Porazinski, S; West, AC; Yu, L | 1 |
| Guo, J; Shang, Y; Song, J; Wang, J; Wang, T; Xu, J | 1 |
| Carvalho, T; Castillo Martin, M; Costa, B; Couto, N; Fior, R; Rebelo de Almeida, C; Tavares Barroso, M | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Hashimoto, K; Kim, Y; Kobayashi, S; Morimoto, O; Murakami, M; Nakahira, S; Shimizu, J; Sugimoto, K; Takahashi, H; Takeda, Y; Tanemura, M; Tomokuni, A; Tsujie, M; Yamada, D; Yamada, T; Yokoyama, S | 1 |
| Al-Radhi, M; Awsh, M; Baldi, S; Chu, P; Fang, J; Jia, J; Li, X; Ma, X; Peng, J; Safi, M; Shopit, A; Shu, X; Tang, Z; Wang, F; Wang, S | 1 |
| Benz, D; Chen, S; Cruise, GM; Lopez-Benitez, R; Wu, X; Wu, Y | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Okada, K; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Ahn, HM; Choi, IK; Hong, J; Hong, SS; Jung, KH; Lee, HS; Son, MK; Yan, HH; Yun, CO | 1 |
| Li, M; Li, X; Liu, N; Meng, F; Song, S; Wu, X | 1 |
| Chen, J; Gao, W; Guo, F; Jiang, K; Li, H; Lu, Z; Lv, N; Miao, Y; Song, G; Tu, M; Wei, J; Xi, C | 1 |
| Bel, A; Buijsen, J; Ebrahimi, G; Gurney-Champion, OJ; Kolff, MW; Lens, E; Neelis, KJ; Rasch, CR; Stoker, J; van der Horst, A; van Herk, M; van Tienhoven, G; Versteijne, E | 1 |
| Chen, H; Chen, Z; Geng, YW; Meng, ZQ; Qi, Q; Wang, P; Xu, LT; Yu, SL | 1 |
| Abakar-Mahamat, A; Ciccolini, J; Dahan, L; Deplanque, G; Fein, F; François, E; Gagnière, J; Gattacceca, F; Lacarelle, B; Rachid, M; Seitz, JF; Serdjebi, C | 1 |
| Beg, MS; Bolluyt, J; Boothman, DA; Deberardinis, RJ; Fattah, F; Gerber, DE; Huang, X; Laheru, D; Leff, R; Merritt, ME; Sarode, V; Silvers, MA; Xie, XJ | 1 |
| Desai, P; Haimovitz-Friedman, A; Humm, JL; Kramer, RM; Lowery, MA; Pillarsetty, N; Romesser, PB; Russell, J | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Cao, YB; Li, Q; Ma, YX; Sun, Y; Xu, CA; Zhang, XW | 1 |
| Chen, Y; Hu, Q; Li, L; Li, Y; Lou, Z; Luo, K; Nowsheen, S; Wu, C; Yin, Y; Yuan, J; Zhang, L | 1 |
| Bugde, P; Hawkins, BC; Li, Y; Paxton, JW; Revalde, JL; Rosengren, RJ; Wijeratne, TS | 1 |
| Xiao, J; Yu, H | 1 |
| Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK | 1 |
| Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
| Caputo, D; Coppola, R; D'Angelillo, RM; Fiore, M; Floreno, B; Ramella, S; Trecca, P; Trodella, L; Trodella, LE; Valeri, S | 1 |
| Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Berlin, J; Engebretson, A; Hong, TS; Katz, MHG; Khorana, AA; Maitra, A; Mangu, PB; Mohile, SG; Mumber, M; Schulick, R; Shapiro, M; Urba, S; Zeh, HJ | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Abe, T; Endo, S; Hashizume, M; Iwamoto, C; Koikawa, K; Manabe, T; Miura, D; Miyasaka, Y; Mizumoto, K; Mizuuchi, Y; Moriyama, T; Nagai, E; Nakamura, M; Nakata, K; Oda, Y; Ohtsuka, T; Ohuchida, K; Okumura, T; Sada, M | 1 |
| Batist, G; Chanez, B; Gilabert, M; Giovanini, M; Kavan, P; Raoul, JL; Rho, YS; Turrini, O | 1 |
| Chen, H; Deng, X; Fang, Y; Huo, Z; Li, H; Lu, X; Peng, C; Shen, B; Shi, M; Tang, X; Wang, X; Wen, C; Xie, J | 1 |
| Amada, K; Itoh, H; Nakahara, R; Ono, H; Sato, Y | 1 |
| Edwards, H; Ge, Y; Jiang, Y; Liu, S; Quan, C; Ren, Q; Wang, G; Wang, T | 1 |
| Chen, S; Chen, Y; Huang, C; Huang, K; Li, J; Li, Y; Lian, G; Lin, Y; Wang, L; Yang, K; Zeng, L; Zhang, Z | 1 |
| Baechmann, S; Boeck, S; Clemens, MR; Esposito, I; Haas, M; Heinemann, V; Jung, A; Kettner, E; Kirchner, T; Kruger, S; Laubender, RP; Ormanns, S; Quietzsch, D; Remold, A; Schlitter, AM; Siveke, JT; Wenzel, P; Westphalen, CB | 1 |
| Benhadji, KA; Fujii, H; Ikeda, M; Kondo, S; Lahn, MMF; Ogasawara, K; Takahashi, H; Ueno, H | 1 |
| Li, J; Liu, B; Liu, F; Ma, Z; Qian, J; Wu, G | 1 |
| Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
| Endo, I; Kubota, K; Kumamoto, T; Matsuyama, R; Mori, R; Sakamaki, K; Taniguchi, K; Yabushita, Y | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Li, W; Yao, J; Zhang, C; Zhang, L | 1 |
| Hirai, K; Inoue, K; Itoh, K; Kawasaki, Y; Matsumoto, M; Nakamori, H; Osada, M; Otake, A; Taku, K; Tsuji, D; Yokoi, M | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Abou-Khalil, J; Rocha, FG | 1 |
| Bjerregaard, JK; Detlefsen, S; Graversen, M; Mortensen, MB; Pfeiffer, P | 1 |
| Azemoto, N; Hasebe, A; Hiasa, Y; Imai, Y; Imamura, Y; Inada, N; Kawamura, T; Koizumi, M; Kumagi, T; Kuroda, T; Miyata, H; Nishiyama, M; Ohno, Y; Seike, H; Shibata, N; Tanaka, Y; Terao, T; Ueno-Toshimori, A; Yamanishi, H; Yokota, T | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kirchner, T; Kruger, S; Ormanns, S; Remold, A | 1 |
| Chaudhary, AK; Kattel, K; Kumar, V; Mahato, RI; Mondal, G | 1 |
| Bouvet, M; Clary, BM; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Murakami, T; Unno, M | 1 |
| Furuse, J; Gemma, A; Ichikawa, W; Ishii, T; Okusaka, T; Seki, A | 1 |
| Baechmann, S; Boeck, S; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Modest, DP; Ormanns, S; Remold, A; Werner, J | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Büchler, MW; Strobel, O | 3 |
| Abu-Suboh, M; Allende, E; Arribas, J; Balsells, J; Bernadó Morales, C; Bilal, F; Carreras, MJ; Macarulla, T; Massó-Vallés, D; Mohan, V; Pedersen, K; Sagi, I; Salcedo, MT; Serres, X; Soucek, L; Tabernero, J; Vivancos, A | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Hara, R; Kita, E; Nakamura, K; Sudo, K; Tsujimoto, A; Yamaguchi, T | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Bentrem, DJ; Cho, CS; Ethun, CG; Hanseman, DJ; Kooby, DA; Maithel, SK; Salem, A; Stocker, SJ; Talamonti, MS; Weber, SM; Xia, BT | 1 |
| Du, C; Guo, H; Kornmann, M; Liu, X; Ma, L; Tian, X; Wang, F; Yang, Y; Zhang, Z | 1 |
| Fan, ZK; Jin, LM; Jin, SF; Pan, L | 1 |
| Corr, SJ; Curley, SA; Curtis, LT; Frieboes, HB; Godin, B; Ho, JC; Ware, MJ; Wu, M | 1 |
| Feygenzon, V; Klausner, JM; Lahat, G; Loewenstein, S; Lubezky, N; Pasmanic-Chor, M; Sher, O | 1 |
| Barni, S; Ghidini, A; Inno, A; Labianca, R; Petrelli, F; Rimassa, L; Tomasello, G | 1 |
| Arai, D; Chen, LT; Furuse, J; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Li, CP; Matsuyama, Y; Mizuno, N; Oh, DY; Okusaka, T; Park, YS; Ueno, M; Yamaguchi, T | 1 |
| Hiramoto, H; Ichikawa, D; Inazawa, J; Muramatsu, T; Otsuji, E; Tanimoto, K; Yasukawa, S | 1 |
| Adamska, A; Domenichini, A; Falasca, M | 1 |
| Blanco, FF; Brody, JR; Chand, SN; Cozzitorto, JA; Dukleska, K; Jiang, W; Jimbo, M; Lal, S; Londin, ER; Mambelli-Lisboa, NC; Metallo, CM; Moffat, C; Nevler, A; Parker, SJ; Seifert, EL; Vaziri-Gohar, A; Winter, JM; Yeo, CJ; Zarei, M | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Abraham, T; Adair, JH; Butler, PJ; Clawson, GA; Fox, T; Gigliotti, CM; Kester, M; Linton, SS; Loc, WS; Martin, JA; Matters, GL; McGovern, CO; Smith, JP; Tabakovic, A; Tang, X; Wilczynski, ZR | 1 |
| Cheng, AL; Guo, JC; Kuo, SH; Kuo, TC; Lee, JC; Tien, YW; Yang, SH; Yeh, KH | 1 |
| Achiwa, K; Fujita, M; Kataoka, K; Matsubara, H; Minami, Y; Naitoh, T; Urano, F; Yamada, M; Yamamoto, H | 1 |
| Bahary, N; Epelboym, I; Hamad, A; Hogg, ME; Lee, KK; Steve, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Huang, WF; Jiang, JH; Nie, J; Tan, DW; Wang, XF; Zhou, Y | 1 |
| Alexander, JF; Borsoi, C; Elganainy, D; Ferrari, M; Godin, B; Kai, M; Kang, Y; Koay, EJ; Lee, Y; Leonard, F; Liu, X; Liu, YT; Yokoi, K; Zaid, M | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Carlan, SJ; Guzman, A; Holloman, C; Madruga, M; Sundharkrishnan, L | 1 |
| Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Nakashima, M; Oka, M; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Ueno, T; Yoshimura, K; Yoshino, S | 1 |
| Abrego, J; Asara, JM; Attri, KS; Augustine, JJ; Berim, L; Cantley, LC; Chaika, NV; Dai, B; Dasgupta, A; Fleming, JB; Gebregiworgis, T; Goode, GD; Grandgenett, PM; Grem, JL; Gunda, V; Hankins, JH; Hollingsworth, MA; Illies, AL; Kim, JW; King, RJ; Lazenby, AJ; Ly, QP; Lyssiotis, CA; Mashadova, O; Matés, JM; Mehla, K; Murthy, D; Oliveto, JM; Powers, R; Purohit, V; Sasson, AR; Serkova, NJ; Shukla, SK; Singh, PK; Vernucci, E; Weekes, C; Yu, F | 1 |
| Aloia, TA; Cloyd, JM; Das, P; Egger, ME; Fleming, JB; Fogelman, D; Herman, JM; Javle, M; Katz, MHG; Kim, MP; Koay, EJ; Lee, JE; Maitra, A; Overman, MJ; Prakash, LR; Shroff, R; Tzeng, CD; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Ding, M; Gao, Y; Gong, L; Hong, C; Huang, X; Li, K; Yang, H; Yang, Q; Zhang, Z | 1 |
| Sohal, DPS | 1 |
| Boggi, U; Cernusco, NLV; Coppola, M; Falcone, A; Gonnelli, A; Montrone, S; Morganti, R; Paiar, F; Panichi, M; Pasqualetti, F; Sainato, A; Vasile, E | 1 |
| Ilic, D; Ilic, I; Radojkovic, M | 1 |
| Cheng, H; Guo, M; Jin, K; Liu, C; Lu, Y; Luo, G; Ni, Q; Yu, X | 1 |
| Bayerl, C; Breitenstein, S; Frei, L; Staerkle, RF; Stieger, R | 1 |
| Almawash, S; Chaudhary, AK; Mahato, RI; Mondal, G | 1 |
| Doi, M; Eguchi, H; Hirono, S; Kawai, M; Matsumoto, I; Murakami, Y; Okada, KI; Satoi, S; Shimokawa, T; Sho, M; Yamada, S; Yamaue, H | 1 |
| Billadeau, DD; Huang, H; Jin, X; Ma, T; Pan, Y; Tang, AH; Wang, L; Wu, H; Zhang, L | 1 |
| Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
| Dora, CP; Jain, S; Katiyar, SS; Kumar, P; Kushwah, V; Pillay, V; Suresh, S | 1 |
| Hori, Y; Kuki, K; Shiomi, Y; Tanaka, T; Yoshimura, M | 1 |
| Ge, L; Qie, S; Wang, Z; Yan, Q; Yang, L; Zhong, S | 1 |
| Hu, Q; Ji, S; Liang, C; Liang, D; Ni, Q; Qin, Y; Shi, S; Xiang, J; Xu, J; Xu, W; Yu, X; Zhang, B | 1 |
| Chen, T; Han, H; Ji, J; Jin, Q; Qin, Z; Teng, W; Zhao, J | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Jöhrens, K; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Algül, H; Azoitei, N; Bohnenberger, H; Frappart, PO; Gaedcke, J; Gieldon, L; Hampp, S; Hessmann, E; Hohwieler, M; Ihle, M; Kleger, A; Lechel, A; Lesina, M; Liebau, S; Lin, Q; Perkhofer, L; Reinhardt, HC; Romero Carrasco, MC; Ruess, DA; Russell, R; Schmitt, A; Schröck, E; Seufferlein, T; Sipos, B; Wagner, M; Wiesmüller, L | 1 |
| Agrawal, AK; Dora, CP; Gupta, RC; Jain, S; Kushwah, V; Lamprou, DA; Mallinson, D | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Amidon, GL; Drelich, AJ; Smith, DE; Tsume, Y | 1 |
| Huang, X; Meng, Q; Song, Z; Wang, H; Xia, G | 1 |
| Chen, T; Han, H; Ji, J; Jin, Q; Wang, J; Yin, L | 1 |
| Brentnall, TA; Chen, R; Jung, L; Lai, LA; Pan, S; Pillarisetty, VG; Riddell, J; Sullivan, Y; Wang, L; Wong, M | 1 |
| Ancrile, BB; Birkholz, JH; Blandford, JT; Dye, CE; Gusani, NJ; Headlee, BD; Heisey, HD; Levenick, JM; Maranki, JL; Mathew, A; McGarrity, TJ; Moyer, MT; Sharzehi, S | 1 |
| Cai, R; Hao, J; Ji, T; Lang, J; Nie, G; Qi, F; Qin, Z; Wang, J; Wu, W; Zhang, L; Zhang, Y; Zhao, X; Zhao, Y | 1 |
| Abrego, J; Berim, L; Chaika, NV; Grem, J; Gunda, V; King, RJ; Lazenby, AJ; Sasson, AR; Shukla, SK; Singh, PK; Tadros, S; Vernucci, E; Yu, F | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Dörken, B; Gellert, K; Ghadimi, M; Grützmann, R; Jacobasch, L; Liersch, T; Maschmeyer, G; Messmann, H; Oettle, H; Pelzer, U; Rau, BM; Riess, H; Sinn, M; Stieler, JM; Striefler, JK; Waldschmidt, D; Weinmann, A; Wilhelm, M | 1 |
| Chen, Y; Cui, X; Lin, Y; Qin, C; Wang, X; Wang, Z; Xian, G; Zhang, Z | 1 |
| Chen, Y; Tian, B; Wang, L; Wang, W; Zhang, Y; Zhu, Y | 1 |
| Bajwa, R; Daily, K; Starr, J | 1 |
| Adamian, Y; Brambilla, D; Gharibi, A; Hong, J; Hoover, M; Kelber, JA; La Kim, S; Lin, J; Molnar, J; Wolfenden, L | 1 |
| Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N | 1 |
| Boroujerdi, M; Gilzad-Kohan, H; Sani, S | 1 |
| Afgar, A; Mahmoodzadeh, H; Radfar, JE; Rajabpour, A; Rajaei, F; Teimoori-Toolabi, L | 1 |
| Gilabert, M; Raoul, JL; Rousseau, F | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Fu, XB; He, JP; Jiao, H; Li, CL; Li, W; Liao, ZY; Liu, XR; Yang, B; Yi, C; You, X; Yuan, ML; Zhao, J | 1 |
| Avraham, R; Barshack, I; Barzily-Rokni, M; Bhatia, SN; Brandis, A; Bu, J; Chatman, K; Cooper, ZA; Danino, T; Ferrone, CR; Flaherty, KT; Fleming, J; Frederick, DT; Fuks, G; Garrett, WS; Gavert, N; Geller, LT; Gevers, D; Golan, T; Golub, TR; Gopalakrishnan, V; Gurbatri, C; Hurd, MW; Huttenhower, C; Johnston, SE; Jonas, OH; Katz, M; Kim, M; Ligorio, M; Livny, J; Maitra, A; Mandinova, A; Michaud, M; Mosher, CM; Nejman, D; Reuben, A; Sandbank, J; Shee, K; Shental, N; Skalak, M; Smith, DA; Straussman, R; Thaiss, CA; Thayer, SP; Trauger, SA; Wargo, JA; Zwang, Y | 1 |
| Choi, HG; Gupta, B; Jeong, JH; Kim, JO; Oh, KT; Pathak, S; Poudel, BK; Ramasamy, T; Thapa, RK; Yong, CS | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Conroy, T; Gourgou Bourgade, S; Jarlier, M; Lambert, A | 1 |
| Coppola, L; D'Andrea, MR; Di Raimo, T; Giordano, G; Olivieri, N; Pancione, M; Parcesepe, P; Toffoli, G; Velocci, M | 1 |
| Affram, K; Agyare, E; Krishnan, S; Reams, R; Rosenberg, J; Singh, M; Udofot, O | 1 |
| Al-Hazzouri, A; Bendell, JC; DeBusk, LM; Earwood, C; Guo, S; Ko, AH; Lane, CM; Murphy, PB; Peyton, JD; Rodriguez, FA; Shipley, DL; Tempero, MA; Waterhouse, DM; Womack, MS; Xiong, HQ | 1 |
| Saung, MT; Zheng, L | 1 |
| Kim, JH; Kuh, HJ; Lee, J; Park, WS; Shin, BC | 1 |
| Al-Shakarchi, W; Albusair, MK; Aldebasi, MH; Curtis, ADM; Elsini, RS; Haxton, KJ; Hoskins, C; Manzur, A; Oluwasanmi, A | 1 |
| Chen, L; Hu, Z; Ju, B; Song, W; Sun, Q; Wang, W; Xie, H; Yang, Q; Yao, H; Zhang, L; Zheng, S; Zhou, D; Zhou, L | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Iida, T; Ju, H; Lee, H; Li, H; Ling, J; Lu, Y; Sun, Y; Wu, M; Zhuang, Z | 1 |
| Anand, S; Badhe, B; Chandrasekar, S; Pottakkat, B; Rajagopal, MD | 1 |
| Wang, X; Xiao, G; Yu, Y | 1 |
| Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK | 1 |
| Furukawa, K; Kagawa, S; Miyazaki, M; Nishino, H; Ohtsuka, M; Shimazaki, R; Shimizu, H; Suzuki, K; Takano, S; Yoshitomi, H | 1 |
| Behringer, DM; Berdel, WE; Bulitta, M; De Dosso, S; Dommach, M; Ebert, MP; Goker, E; Hofheinz, R; Kerkhoff, A; Kneba, M; Overkamp, F; Reuter, D; Rohrberg, R; Schlegel, F; Schmidt, WE; Schultheis, B; Siveke, J; Steinmetz, T; Strumberg, D; Yalcin, S | 1 |
| Di, Y; Fu, D; Gu, J; Guo, Z; Jin, C; Li, H; Yu, X; Zhu, W | 1 |
| Bachmann, H; Knuth, A; Nguyen-Kim, TDL; Pascolo, S; Samaras, P; Seifert, B; Tusup, M; von Moos, R | 1 |
| Bennouna, J; Bouché, O; Conroy, T; Desseigne, F; Gourgou, S; Jarlier, M; Juzyna, B; Robert, M; Ychou, M | 1 |
| Chang, A; Gao, S; Hao, J; Huang, C; Li, N; Li, Y; Li, Z; Ren, H; Wang, H; Wang, X; Yang, S; Zhao, T | 1 |
| Al-Suraih, F; Bhattacharya, S; Caulfield, TR; Coffer, JL; Dutta, SK; Gonzalez-Rodriguez, R; Kwak, HS; Pal, K; Wang, E | 1 |
| Ji, S; Liang, C; Liang, D; Meng, Q; Ni, Q; Qin, Y; Shi, S; Xu, J; Yu, X; Zhang, B | 2 |
| Duan, Q; Li, H; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 2 |
| Thomas, H | 1 |
| Beeharry, N; Bhattacharjee, V; Fink, L; Fraenkel, E; Gosline, SJC; Huang, SC; Ursu, O; Yen, T; Zhou, Y | 1 |
| An, MJ; Cha, YH; Gee, HY; Han, JW; Jeung, HC; Jun, I; Jung, J; Lee, MG; Park, HS; Park, JS; Piao, H; Shin, YK; Yook, JI; Yoon, DS; Yun, BG; Zhang, X | 1 |
| Chen, H; Ji, W; Jin, X; Lin, X; Pan, B; Song, H; Xiao, J; Yu, H | 1 |
| Chen, W; Feng, J; Huang, X; Liu, P; Shao, L; Sun, M; Sun, Q; Xiao, R; Xiong, J; Xiong, M; Yu, X; Yuan, W; Zhang, Q; Zhao, X | 1 |
| Fang, Y; Qin, YX; Shen, BY; Shi, MM; Tang, XM; Wen, CL; Zhang, YJ | 1 |
| Abbruzzese, JL; Benson, AB; Berlin, JD; Blackstock, AW; Catalano, P; Feng, Y; Lowy, AM; McWilliams, RR; Philip, PA | 1 |
| Chen, W; Huang, S; Liu, Q; Long, MM; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M; Zhou, J; Zhu, J | 1 |
| Goel, A; Han, H; Ravindranathan, P; Toden, S; Yoshida, K | 1 |
| Hamano, K; Harada, E; Hosoyama, T; Kawamura, D; Kugimiya, N; Nishimoto, A; Shirasawa, B; Takemoto, Y; Tanaka, T; Ueno, K | 1 |
| Abdel-Wahab, M; Berriochoa, CA; Khorana, A; Kumar, AMS; Leyrer, CM; Matthew Walsh, R | 1 |
| Andersson, B; Andersson, R; Ansari, D; Hilmersson, KS; Urey, C | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Cox, TF; Deakin, M; Dervenis, C; Ghaneh, P; Glimelius, B; Goldstein, D; Halloran, CM; Izbicki, JR; Jackson, R; Jones, O; Kleeff, J; Lerch, MM; Mayerle, J; McDonald, AC; Melling, J; Neoptolemos, JP; O'Reilly, DA; Oláh, A; Padbury, R; Palmer, DH; Raraty, M; Rawcliffe, CL; Scarfe, AG; Shannon, J; Smith, CJ; Strobel, O; Tebbutt, NC; Valle, JW | 1 |
| Fujii, Y; Hamada, T; Hiyoshi, M; Imamura, N; Nanashima, A; Tsuchimochi, Y; Wada, T; Yano, K | 1 |
| Dhayat, SA; Mardin, WA; Senninger, N | 1 |
| Attwood, K; Balachandar, S; Chandra, D; Chaudhary, AK; Hochwald, S; Inigo, JR; Kumar, R; Kumar, S; O'Malley, J; Wang, J; Wang, X; Yadav, N | 1 |
| Alvarez, R; Caruso, R; Cubillo, A; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ielpo, B; Kalivaci, D; Lazzaro, S; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X | 1 |
| Beck, J; Blaydorn, L; Bornemann-Kolatzki, K; Khemka, V; Schütz, E; Urnovitz, H; Weiss, GJ | 1 |
| Bielli, P; Capurso, G; Farini, D; Fave, GD; Panzeri, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| Itai, R; Yamashita, Y; Yokode, M; Zen, Y | 1 |
| Deshmukh, SP; Epstein, JD; Keith, SW; Kozak, GM; Lavu, H; Scott, BB; Winter, JM; Yeo, CJ | 1 |
| Camateros, P; Cheung, WY; Wang, Y | 1 |
| Bao, YT; Li, CM; Liu, ZC; Sun, XD; Wang, LL | 1 |
| Inui, M; Ishiguro, S; Kawabata, A; Monson, K; Ohta, N; Pappas, CG; Tamura, M; Tzakos, AG; Uppalapati, D; Zulbaran-Rojas, A | 1 |
| Bodis, S; Clavien, PA; Datta, NR; Khan, S; Knuchel, J; Mamot, C; Pestalozzi, B; Puric, E; Reiner, CS; Riesterer, O; Siebenhüner, A | 1 |
| Allen-Petersen, BL; Amery, TS; Crawford, HC; Egbukichi, N; Farrell, AS; Heiser, LM; Hoffman, MT; Jenny, ZP; Joly, MM; Kendsersky, ND; Lanciault, C; Link, J; Manning, SL; Morton, JP; Murphy, DJ; Muthalagu, N; Pelz, C; Pratt, ED; Rhim, AD; Sansom, OJ; Sauer, D; Sears, RC; Sheppard, BC; Thoma, MC; Worth, PJ | 1 |
| Brekken, RA; Cruz, VH; Du, W; Lorens, JB; Ludwig, KF; Maitra, A; Rajeshkumar, NV; Sorrelle, NB; Toombs, JE; Topalovski, M; Wnuk-Lipinska, K; Yabuuchi, S | 1 |
| Armbrecht, N; Bernhardt, G; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Fleischmann-Mundt, B; Gürlevik, E; Kubicka, S; Kühnel, F; Manns, MP; Niemann, J; Peters, K; Ribback, S; Smyth, MJ; Wirth, TC; Woller, N | 1 |
| Puls, TJ; Tan, X; Voytik-Harbin, SL; Whittington, CF | 1 |
| Bellis, SL; Bonner, JA; Buchsbaum, DJ; Chakraborty, A; Dorsett, KA; Oliver, PG; Trummell, HQ; Yang, ES | 1 |
| Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM | 1 |
| Caffrey, TC; Grunkemeyer, JA; Hollingsworth, MA; Madiyalakan, R; Mehla, K; Nicodemus, CF; O'Connell, KA; Schultes, BC; Singh, PK; Steele, MM; Tremayne, J; Yu, F; Zhu, X | 1 |
| Dai, GH; Han, QL; Lyu, Y; Yan, H; Zhou, YH | 1 |
| Li, X; Niu, Q; Song, W; Tian, Z; Wu, J; Xie, M; Xu, Y; Yang, L; Zhang, C; Zhang, Q; Zhao, X; Zhou, B | 1 |
| Chen, P; Chen, Q; Dong, R; Drisko, JA; Fan, F; Godwin, AK; Levine, M; Pessetto, Z; Polireddy, K; Reed, G; Violet, PC; Williamson, S; Yu, J | 1 |
| Abdol Razak, NB; Adamska, A; Elaskalani, O; Emmanouilidi, A; Falasca, M; Kim, M; Metharom, P | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Alcindor, T; Chan, E; Chao, R; Chiorean, EG; Gabrail, NY; Hurwitz, H; O'Dwyer, PJ; Potvin, D | 1 |
| Liang, J; Ma, Y; Tian, X; Wang, F; Xie, X; Yang, C; Yang, Y; Zhang, Z | 1 |
| Hamada, S; Masamune, A; Shimosegawa, T; Taguchi, K; Yamamoto, M | 1 |
| Casadei, R; Chen, X; Chu, T; Dantes, Z; Di Marco, M; Friedman, RA; Habenicht, AJR; Hayakawa, Y; Ilmer, M; Iuga, AC; Jiang, Z; Kleespies, A; Macchini, M; Maurer, HC; Middelhoff, M; Mohanta, SK; Nagar, K; Neumann, J; Olive, KP; Reichert, M; Remotti, H; Renz, BW; Tailor, Y; Takahashi, R; Tanaka, T; Valenti, G; Wang, TC; Werner, J; Westphalen, CB; Worthley, DL | 1 |
| Gourd, E | 1 |
| Fushida, S; Harmon, JW; Hayashi, H; Kishimoto, K; Makino, I; Miyashita, T; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okazaki, M; Tajima, H; Takamura, H; Yamaguchi, T | 1 |
| Guo, Y; Liang, M; Ma, L; Zhao, T | 1 |
| Altomare, DA; Copik, AJ; Gitto, SB; Hogan, FC; Oyer, JL; Pandey, V; Phanstiel, O | 1 |
| Benguigui, M; Beyar-Katz, O; Bronshtein, T; Kotsofruk, R; Letko-Khait, N; Machluf, M; Rachman-Tzemah, C; Raviv, Z; Shaked, Y; Timaner, M | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Du, C; Gao, H; Guo, H; Kornmann, M; Ma, L; Tian, X; Wang, F; Xie, X; Yang, Y; Zhang, Z; Zhuang, Y | 1 |
| Chen, L; Chen, Z; Guo, Y; Huang, X; Kang, Y; Liu, Q; Liu, Z; Sun, C; Zhou, D; Zhu, H | 1 |
| Cai, H; Chen, J; Chen, Q; Guo, Q; Huang, S; Jiang, B; Kang, M; Li, P; Lu, W; Qin, W; Rao, J; Wan, D; Wang, L; Wu, Y; Zheng, W; Zhou, Y | 1 |
| Friess, H; Goess, R | 1 |
| Brenner, R; Capanu, M; Chen, AP; Dhani, N; Do, RK; Epstein, AS; Estrella, H; Golan, T; Kelsen, DP; Kindler, HL; Lee, JW; Lowery, MA; Maynard, H; Moore, MJ; O'Reilly, EM; Salo-Mullen, EE; Segal, A; Segal, M; Stadler, ZK; Tang, LH; Yu, KH | 1 |
| Hayashi, K; Inoue, T; Joh, T; Kato, A; Kondo, H; Naiki-Ito, A; Naitoh, I; Nakazawa, T; Nishi, Y; Okumura, F; Shimizu, S; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Chen, S; Chen, Y; Huang, K; Li, J; Li, Y; Lian, G; Yang, K; Zeng, L | 1 |
| Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
| Asai, A; Doki, Y; Ishii, H; Konno, M; Koseki, J; Mori, M; Ogawa, K; Satoh, T; Taketo, K; Toratani, M | 1 |
| Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Chen, D; Jing, FC; Liu, HQ; Yan, X; Yang, XH; Zhang, QA; Zhang, R | 1 |
| Head, R; Jiang, H; Li, L; Li, Q; Lim, KH; Liu, J; Ruzinova, MB; Wang-Gillam, A; Yu, J; Zhang, D | 1 |
| Garcia-Cremades, M; Iversen, PW; Pitou, C; Troconiz, IF | 2 |
| Cai, MH; Sun, Z; Tu, YX; Wang, BK; Xu, XG; Yan, SL; Ying, Y | 1 |
| Hu, C; Hui, K; Jiang, X; Liang, L; Qiao, Y; Ren, Y; Wang, L; Xia, Y; Zhu, P | 1 |
| Fujioka, T; Hayama, T; Nakashima, M; Nohta, H; Todoroki, K; Tomita, R; Yamaguchi, M; Yoshida, H | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Church, KJ; Fagnan, M; Harding, JW; Harris, PH; LeValley, JC; Mateo-Victoriano, B; Riggers, RR; Vanderwerff, BR | 1 |
| Ariake, K; Fukase, K; Hayashi, H; Ishida, M; Maeda, S; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Takadate, T; Unno, M | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Kinami, S; Kosaka, T; Miura, S; Motoo, Y; Nakano, Y; Ohnishi, T; Omote, K; Tomita, Y; Ueda, N | 1 |
| Deguchi, M; Ishida, M; Kaizaki, Y; Kitajima, T; Ohnishi, K; Ohno, N; Sawai, K; Tabata, S | 1 |
| Fujiyama, J; Hiramoto, H; Kawamura, Y; Masuyama, M; Nakashima, S; Nishida, M; Ochi, F; Shibamoto, J; Takashima, Y; Tsujiura, M | 1 |
| Hosoda, Y; Katayama, H; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sasaki, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ichikawa, Y; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Takeyari, M; Tatsumi, M; Wada, H; Yamada, D | 1 |
| Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
| Colby, AH; Grinstaff, MW; Liu, K; Lu, C; Oberlies, NH; Pearce, C; Sabbatini, ME; Yang, D | 1 |
| Anthoney, DA; Basu, B; Cook, N; Evans, J; Farmer-Hall, H; Gopinathan, A; Halford, S; Hampson, LV; Hategan, M; Jodrell, D; McLeod, R; Nebozhyn, M; Palmer, D; Propper, D; Smith, DM; Steward, WP; Turner, H; Tuveson, D; Venugopal, B | 1 |
| Chen, L; Cheng, X; Feng, H; Fu, Z; Jin, Z; Kuang, J; Liang, J; Peng, C; Qiu, W; Shen, B; Shen, X; Yuen, S | 1 |
| Chie, EK; Choi, SH; Han, Y; Heo, JS; Jang, JY; Kim, SH; Kim, SW; Koh, YH; Kwon, W; Lee, H; Lee, IJ; Lee, JM; Lee, KH; Lee, WJ; Lim, DH; Oh, DY; Park, JO; Park, JS; Park, SJ; Yoon, DS | 1 |
| Adamberg, K; Adamberg, S; Andriulli, A; Copetti, M; Fontana, A; Jaagura, M; Kolk, K; Panebianco, C; Pazienza, V; Vilu, R | 1 |
| Boku, N; Fukutomi, A; Hagiwara, Y; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Nishikura, K; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A; Watanabe, G | 1 |
| Cheng, JX; Li, J; Qu, X; Tian, J; Zhang, JT | 1 |
| An, M; Cuneo, KC; Lubman, DM; Wu, J; Zhu, J | 1 |
| Anthoney, A; Aughton, K; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Elander, NO; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Lerch, MM; Mackey, JR; Mayerle, J; McDonald, AC; Neoptolemos, JP; Oláh, A; Palmer, DH; Scarfe, AG; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Hu, HJ; Li, FY; Liu, F; Wang, JK; Zhou, RX | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Bu, Y; Ozaki, T; Sang, M; Sun, D; Yin, D; Yu, M; Zhu, Y | 1 |
| Jin, J; Li, T; Teng, C | 1 |
| Jin, H; Ma, S; Yang, J; Zhang, S; Zhang, X; Zhao, Y | 1 |
| Aoki, Y; Hamamoto, Y; Hirata, K; Kanai, T; Kasuga, A; Kawasaki, K; Okano, N; Sukawa, Y; Suzuki, T; Takaishi, H; Takeuchi, A; Togasaki, K | 1 |
| Chen, Y; Ji, Y; Jin, Y; Yu, Y; Zhang, X; Zhou, J; Zhu, J | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Blair, AB; Burkhart, RA; Cameron, JL; Fishman, EK; Gemenetzis, G; Groot, VP; He, J; Hruban, RH; Laheru, DA; Narang, AK; Weiss, MJ; Wolfgang, CL; Yu, J; Zheng, L | 1 |
| Boichard, A; Bush, KT; Tsigelny, IF | 1 |
| Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Bardini, R; Buda, A; D'Ippolito, S; Da Dalt, G; Fabricio, ASC; Fiduccia, P; Gion, M; Giovanis, P; Pastorelli, D; Rainato, G; Soldà, C; Sperti, C; Ursini, F | 1 |
| Chang, HM; Hong, SM; Hwang, DW; Hwang, I; Jeong, JH; Kang, J; Kim, KP; Kim, MH; Kim, SC; Lee, JH; Lee, SK; Lee, SS; Park, DH; Ryoo, BY; Seo, DW; Shin, SH; Song, KB; Song, TJ; Yoo, C | 1 |
| Han, L; Jiang, J; Ma, Q; Wang, Z; Wu, Z | 1 |
| Nakamura, M; Nikaido, T; Ogata, T; Ozaki, T; Sang, M; Shimozato, O; Sun, D | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Lwin, TM; Miyake, K; Miyake, M; Oshiro, H; Tan, Y; Unno, M | 1 |
| Bauer, N; Gladkich, J; Gretz, N; Gross, W; Hackert, T; Herr, I; Liu, L; Nwaeburu, CC; Sticht, C; Strobel, O; Yin, L; Yin, Y; Zhao, Z | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Endo, T; Hasegawa, K; Isogai, J; Kamiya, A; Kaneko, J; Kobayashi, K; Kondoh, I; Maejima, K; Maejima, S; Takatsuno, Y | 1 |
| Beguin, E; Callan, B; Callan, JF; Kamila, S; Kelly, P; Logan, K; Love, M; McHale, AP; Nesbitt, H; O'Rourke, D; Sheng, Y; Stride, E; Taylor, MA; Thomas, K | 1 |
| Fujiwara, H; Higuchi, T; Ishino, M; Iwamura, H; Kakinuma, C; Kito, N; Kuniyoshi, H; Matsumoto, T; Mima, S; Nishikawa, H; Paradiso, LJ; Saeki, K; Shimada, Y; Uematsu, R; Yamada, T | 1 |
| Dorjee, P; Long, ZW | 1 |
| Katz, MH; Kim, MP; Lee, JE; Tzeng, CW | 1 |
| Akashita, G; Hioki, M; Miyamoto, KI; Nakanishi, T; Ohta, T; Sai, Y; Sawamoto, K; Shimada, T; Tajima, H; Takabayashi, M; Tamai, I; Yamazaki, M; Yokono, R; Yuan, T | 1 |
| Kim, DU | 1 |
| Adham, M; Boschetti, G; Castel-Kremer, E; Charlois, AL; Chopin-Laly, X; Comte, B; De Talhouet, S; Graillot, E; Lombard-Bohas, C; Walter, T | 1 |
| Hu, H; Huang, CX; Li, D; Tong, MT; Wang, J; Xing, HB; Zhai, CY | 1 |
| Hu, Q; Ji, S; Liu, J; Liu, W; Ni, Q; Qin, Y; Sun, Q; Xiang, J; Xu, J; Xu, W; Yu, X; Zhang, B; Zhang, Z | 1 |
| Dobbelstein, M; Köpper, F; Li, Y | 1 |
| Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y | 1 |
| Cassoni, A; Di Benedetto, G; Fadda, MT; Raponi, I; Terenzi, V; Valentini, V | 1 |
| Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E | 1 |
| Chen, B; Chen, Z; Shi, K; Zhao, L | 1 |
| Cai, S; Chen, X; Lao, Y; Li, Y; Liang, C; Tan, H; Wang, Z; Xi, Z; Xu, H | 1 |
| Hou, XF; Li, K; Li, S; Wang, JF; Wu, C; Xu, SN | 1 |
| Hu, Q; Liu, H; Xu, Y; Yang, W; Zhong, L | 1 |
| Bazin, I; Canon, JL; Cubillo, A; Hammel, P; Hidalgo, M; Macarulla, T; Manojlovic, N; Poddubskaya, E; Radenkovic, D; Raymond, E; Schueler, A; Van Cutsem, E; Verslype, C; Zhao, C | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Kirouac, DC | 1 |
| Cao, J; Chen, K; Cheng, L; Jiang, Z; Li, J; Ma, J; Ma, Q; Qian, W; Sha, H; Sun, L; Yan, B; Zhou, C | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
| Cao, J; Jiang, T; Luo, G; Qiu, Z; Wang, X; Xia, X; Zhang, K; Zhao, Q | 1 |
| Coe, IR; Karshafian, R; Mariglia, J; Momin, S | 1 |
| Ding, F; Xu, C; Yu, Y | 1 |
| Devasahayam, N; Gillies, RJ; Hart, CP; Kishimoto, S; Krishna, MC; Matsumoto, S; Mitchell, JB; Munasinghe, JP; Saito, K; Takakusagi, Y | 1 |
| Goto, H; Hirooka, Y; Ichinose, T; Ishikawa, T; Kasuya, H; Kawashima, H; Kodera, Y; Koyama, N; Naoe, Y; Ohno, E; Tanaka, M; Villalobos, IB | 1 |
| Duran, H; Ielpo, B; Quijano, Y; Vicente, E | 1 |
| Cao, H; Chen, H; Hu, C; Huang, L; Li, H; Lu, H; Wang, R; Wu, X | 1 |
| Abdel-Wahab, R; Bhosale, PR; Fogelman, DR; Javle, M; Overman, MJ; Shroff, RT; Varadhachary, GR; Wang, X; Wolff, RA | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Kang, MJ; Kim, N; Kim, YT; Lee, JE; Lee, SH; Paik, WH; Ryu, JK; Son, JH | 1 |
| Chen, B; Chen, H; Deng, T; Huang, C; Lou, B; Shi, K; Xiang, Y; Ye, W; Yu, D; Zhang, F; Zhang, J; Zhou, M | 1 |
| Esumi, H; Fujioka, R; Ikeda, M; Kishino, S; Mochizuki, N; Nomura, S; Owada, S; Sato, A; Tsuchihara, K; Yomoda, S | 1 |
| Bouvet, M; Clary, B; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Miyake, K; Miyake, M; Murakami, T; Singh, SR; Unno, M | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM | 1 |
| Fung, KP; Han, QB; Lau, CBS; Leung, PC; Leung, PS; Li, L; Pu, JX; Sun, HD; Wong, TP; Yue, GGL; Zhao, SL | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Tan, Y; Unno, M; Wangsiricharoen, S; Zhang, Z | 1 |
| Chen, S; Guo, Y; Sun, C; Yu, C | 1 |
| Che, X; Cheng, X; Du, Z; Huang, X; Li, J; Lin, D; Shao, M; Tan, W; Wang, C; Wu, C; Zhao, Y; Zheng, J | 1 |
| Aly, A; Asghari, G; Beale, P; Botteman, M; Clingan, P; Ferrara, S; Harris, M; Mainwaring, P; Margunato-Debay, S; Parnis, FX; Romano, A; Young, R | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| De Haes, P; Morren, MA; Noë, E; Van Cutsem, E; Van den Oord, JJ; Verhulst, L; Verslype, C | 1 |
| Chen, LH; Feng, L; Hu, CY; Mostofa, AGM; Suthe, SR; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 2 |
| Jusko, WJ; Molins, EAG | 1 |
| Cheng, L; Li, X; Yang, F; Zhang, L | 1 |
| Gwynne, SH; Quinton, AE; Yim, KL | 1 |
| Borowicz, P; Confeld, M; Gange, K; Haldar, MK; Hossain, R; Karandish, F; Kulkarni, P; Mallik, S; Sarkar, K; Xia, L | 1 |
| Chandimali, N; Huynh, DL; Jin, WY; Kwon, T | 1 |
| Anthony, L; Desimone, P; Dineen, S; Goel, G; Hosein, PJ; Husnain, M; Kudrimoti, M; Loaiza-Bonilla, A; Peterson, SL; Pimentel, A; Pollack, T; Ratermann, K; Tzeng, CD; Westendorf-Overley, C | 1 |
| Canale, TD; Cheung, WY; Cho, H | 1 |
| Abrams, SL; Candido, S; Cervello, M; Cocco, L; Falasca, M; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Ratti, S; Rosalen, PL; Steelman, LS; Yang, LV | 1 |
| Hua, J; Liang, C; Liang, D; Meng, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Halldén, G; Nattress, CB | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Bahary, N; Matsuda, R; Miller-Ocuin, JL; Nguyen, K; Singhi, AD; Thakur, PC; Zeh, HJ | 1 |
| Ji, L; Ke, M; Li, Y; Liu, G; Ou, Z; Tang, N | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Bahra, M; Denecke, T; Jühling, A; Klein, F; Pelzer, U; Riess, H; Roemmler-Zehrer, J; Sinn, M; Striefler, J; Wislocka, L | 1 |
| Hu, W; Liu, Q; Pan, J; Sui, Z | 1 |
| Belle, S; Betge, J; Burgermeister, E; Chi-Kern, J; Ebert, MP; Gutting, T; Haertel, N; Jesenofsky, R; Maenz, M; Schulte, N; Wedding, U | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Nishibuchi, I; Wadasaki, K | 1 |
| Saito, K; Sato, A; Takahata, T; Yu, C | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Huang, WW; McGregor, S; Nyckowski, T | 1 |
| Ben David, G; Binenbaum, Y; Fridman, E; Gil, Z; Milman, N; Schroeder, A; Shlomi, T; Yaari, Z | 1 |
| Cao, J; Chen, K; Cheng, L; Duan, W; Jiang, Z; Li, J; Ma, Q; Qian, W; Yan, B; Zhou, C | 1 |
| Chang, S; Choi, EA; Choi, YS; Kim, I; Kim, SC; Lee, EJ; Park, S; Rhee, JK; Song, JH | 1 |
| Ichimiya, S; Imaizumi, A; Morisaki, T; Murahashi, M; Nagai, S; Nakamura, K; Ogata, H; Onishi, H; Umebayashi, M; Yamasaki, A; Yanai, K | 1 |
| Cheng, R; Cui, W; Deng, L; Huang, X; Santos, HA; Song, Z; Wang, H; Xia, G; Zhang, H | 1 |
| Aiken, T; Anderson, A; Avital, I; Li, D; Mullinax, JE; Rudloff, U; Thorgeirsson, S; Wiegand, G; Xin, H | 1 |
| Jusko, WJ; Straubinger, RM; Trueman, S; Zhu, X | 1 |
| Einama, T; Kamachi, H; Kamiyama, T; Katoh, N; Mitsuhashi, T; Orimo, T; Sakamoto, Y; Sakata, T; Shibuya, K; Shimada, S; Taketomi, A; Tsuruga, Y; Uchinami, Y; Wakayama, K; Yokoo, H | 1 |
| Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M | 1 |
| Jusko, WJ; Qu, J; Shen, X; Straubinger, RM; Zhu, X | 1 |
| Bilalis, P; Dimas, K; Iatrou, H; Karatzas, A; Marakis, J; Sereti, E; Skoulas, D; Stamogiannos, A; Stratikos, E; Tsimblouli, C; Vlassopoulos, D | 1 |
| Al-Ghadhban, A; Carter, JE; Deshmukh, SK; Dugger, K; Khan, MA; Singh, AP; Singh, S; Srivastava, SK; Tyagi, N | 1 |
| Barbie, D; Chaves, J; Fuchs, CS; Hahn, WC; Hendifar, A; Koh, B; Ng, K; Starodub, A; Yang, Y | 1 |
| Bamlet, WR; Bentrem, DJ; Etheridge, AS; Glubb, D; Gordân, R; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, H; McWilliams, RR; Mulkey, F; Nakamura, Y; Neel, N; Niedzwiecki, D; Owzar, K; Petersen, GM; Ratain, MJ; Seiser, E; Sibley, AB; Talamonti, MS; Van Loon, K; Venook, AP; Yeh, JJ | 1 |
| Chen, BW; Chen, W; Hu, L; Li, H; Liang, T; Liu, H; Ma, T; Shen, J; Zhang, B; Zhang, S; Zheng, X; Zhi, X; Zhou, Y | 1 |
| Berlin, J; Cardin, D; Das, S | 1 |
| Akita, H; Asukai, K; Ioka, T; Ishikawa, O; Ohue, M; Takahashi, H; Tomokoni, A; Wada, H; Yano, M | 1 |
| Cabeza-Morales, M; Garcia-Carbonero, N; Garcia-Foncillas, J; Li, W; Martinez-Useros, J | 1 |
| Bhowmick, NA; Boros, LG; Chheda, C; Edderkaoui, M; Habtezion, A; Hu, RW; Lewis, M; Madhav, A; Murali, R; Pan, X; Pandol, SJ; Ramanujan, VK; Soufi, B; Tajbakhsh, J; Tuli, R; Wang, Q; Zayou, F | 1 |
| Akita, H; Asukai, K; Ishikawa, O; Matsunaga, T; Miyata, H; Nakanishi, M; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shirayanagi, M; Sugimura, K; Takahashi, H; Takahashi, Y; Tomokuni, A; Wada, H; Yamamoto, K; Yamamoto, T; Yamasaki, T; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Liu, H; Tang, W; Xue, R; Zhang, S; Zhou, Y | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Di, Y; Fu, D; Guo, Z; Jin, C; Li, J; Wang, F; Yao, L; Yu, X | 1 |
| Borbath, I; Conroy, T; Malka, D | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Shin, SM; Son, MK; Woo, MG; Yan, HH | 1 |
| Hu, M; Nijampatnam, B; Qin, JJ; Ruan, KH; Velu, SE; Voruganti, S; Wang, W; Zhang, R; Zhou, J | 1 |
| Chiou, SH; Dorsch, M; Grüner, BM; Koong, AC; Kozak, MM; Kusch, E; Naranjo, S; Winslow, MM | 1 |
| Babazono, A; Fujita, T; Harano, Y; Jiang, P | 1 |
| Cai, Q; Fu, H; Hu, Z; Tang, Y; Xu, J; Yang, D; Zhang, Y | 1 |
| Bahra, M; Neumann, CCM; Pratschke, J; Reutzel-Selke, A; Sauer, IM; Schmuck, RB; Seidel, E; von Hörschelmann, E | 1 |
| Arroyo-Conde, C; Casanova-Martinez, C; González-Costas, S; Piñeiro-Corrales, G; Romero-Ventosa, EY | 1 |
| Alexander, MS; Allen, BG; Berg, DJ; Bodeker, KL; Brown, HA; Buatti, JM; Buettner, GR; Cullen, JJ; Du, J; Gibson-Corley, K; O'Leary, BR; Schroeder, SR; Spitz, DR; Vollstedt, S; Wagner, BA; Wilkes, JG | 1 |
| Ge, C; Ge, J | 1 |
| Akhtar, S; David, D; Geamanu, A; Goja, A; Gupta, SV; Razalli, NH; Saadat, N; Shen, Y | 1 |
| Higashi, T; Koizumi, M; Kurosawa, G; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y | 1 |
| Bansal, R; Mardhian, DF; Prakash, J; Storm, G | 1 |
| Bruno, S; Butera, G; Conti, P; Donadelli, M; Margiotta, M; Mullappilly, N; Pacchiana, R; Riganti, C | 1 |
| Akahori, T; Hasegawa, M; Ikeda, N; Kichikawa, K; Mitoro, A; Nagai, M; Nakagawa, K; Nakamura, K; Nishiwada, S; Sho, M; Tamamoto, T; Tanaka, T; Yoshiji, H | 1 |
| Copolla, D; Goyal, G; Kim, J; Kim, R; Kommalapati, A; Mahipal, A; Neuger, A; Soares, H; Tella, SH | 1 |
| Dhir, M; Zureikat, AH | 1 |
| Bonior, J; Góralska, M; Jastrzębska, M; Jaworek, J; Leja-Szpak, A; Link-Lenczowski, P; Nawrot-Porąbka, K; Pierzchalski, P | 1 |
| Gou, H; Yi, C; Zhao, Y; Zhu, H | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, HY; Maeng, HJ; Yoon, JH | 1 |
| Gong, Y; Hao, W; He, B; He, Z; Hu, G; Li, W; Liu, J; Liu, Y; Yu, Q | 1 |
| Jin, R; Wang, GJ; Yan, L; Zhang, M | 1 |
| Benhadji, KA; Blunt, A; Cleverly, A; Deplanque, G; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Gueorguieva, I; Kozloff, M; Lahn, MMF; Macarulla, T; Melisi, D; Oettle, H; Pezet, D; Smith, C; Tabernero, J; Trojan, J | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Bhosale, P; Fogelman, D; Gulhati, P; Javle, M; Katz, MHG; Koay, EJ; Lee, JE; Lee, JH; Maitra, A; Prakash, L; Shroff, R; Tamm, E; Tzeng, CD; Varadhachary, GR; Wang, H; Wang, X; Weston, B; Wolff, RA | 1 |
| Biondi, M; Botti, G; Fusco, S; Iaffaioli, RV; Mayol, L; Quagliariello, V; Serri, C | 1 |
| Chen, R; Li, G; Li, Z; Lin, Q; Liu, Y; Lu, Y; Wei, L; Ye, H; Zheng, S; Zhou, Q | 1 |
| Cao, J; Cheng, L; Duan, W; Jiang, Z; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Sun, L; Wang, F; Wu, E; Wu, Z; Yan, B; Zhou, C | 1 |
| Liang, Z; Liu, C; Liu, Z; Wang, H; Yang, G; You, L; Zhang, J; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ | 1 |
| Boeck, S; Diehl, F; Haas, M; Heinemann, V; Holdenrieder, S; Jung, A; Kirchner, T; Kruger, S; Liebmann, S; Nagel, D; Ormanns, S; Prinz-Bravin, I; Ross, C; von Bergwelt-Baildon, M; Westphalen, CB | 1 |
| Chen, H; He, R; Qin, R; Shi, X; Zhang, H; Zhao, C; Zhou, M | 1 |
| Araki, K; Gantumur, D; Hagiwara, K; Handa, T; Harimoto, N; Igarashi, T; Ishii, N; Kubo, N; Kuwano, H; Masamune, A; Shirabe, K; Tsukagoshi, M; Umezawa, K; Watanabe, A; Yamanaka, T; Yokobori, T | 1 |
| Arumugam, T; Chiao, P; Curran, MA; Deng, D; Hung, MC; Husted, H; Hwang, RF; Lee, JE; Ling, J; Liu, Y; Logsdon, CD; Lu, M; Maitra, A; Moore, T; Niehrs, C; Ramachandran, V; Wang, H; Zhou, L | 1 |
| Choi, YJ; Kang, EJ; Kim, DS; Kim, HJ; Kim, JS; Lee, SY; Oh, SC; Seo, JH | 1 |
| Chen, W; Fan, W; Huang, F; Lu, X; Mou, X; Ru, G; Wang, S; Zhang, X | 1 |
| Guo, K; Liu, Z; Ma, G; Song, S; Wu, X | 1 |
| Goodwin, ML; Simeone, DM; Urs, SK | 1 |
| Chiorean, EG; Gu, D; Jia, Y; Wan, J; Wang, Y; Xie, J; Yu, B; Zhang, X | 1 |
| Gao, D; Qian, SY; Xu, Y; Yang, L; Yang, X | 1 |
| Bi, H; Bold, RJ; Gonzalez, FJ; Ho, PY; Jian, C; Kim, EJ; Qiu, JX; Tu, MJ; Yu, AM; Zhang, QY | 1 |
| Carnevale, I; Choy, ATF; Coppola, S; Deng, D; Giovannetti, E; Kazemier, G; Meijer, LL; Zaura, E | 1 |
| Hung, WS; Lee, IC; Wu, YC | 1 |
| Baron, B; Hamada, JI; Harada, K; Kitagawa, T; Kobayashi, M; Kuhara, K; Kuramitsu, Y; Nagayasu, H; Ohta, T; Shimo, T; Takai, R; Terasaki, M; Tokuda, K; Tokunaga, M; Uehara, O | 1 |
| Liu, C; Lou, C; Lu, H; Ma, Z; Zhang, Y | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Tian, Q; Wang, Y; Zhang, F | 1 |
| An, N; Cheng, D | 1 |
| Anderson, GJ; Du, C; Han, X; Lang, J; Min, H; Nie, G; Qi, Y; Qin, H; Shi, Q; Tian, X; Wang, Y; Yang, Y; Zhang, Y; Zhang, Z; Zhao, X; Zhao, Y | 1 |
| D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P | 1 |
| Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Braiteh, FS; Chen, LT; Chiu, CF; Cunningham, D; de Jong, FA; Dean, AP; Hubner, RA; Jameson, GS; Lee, KH; Li, CP; Macarulla, T; Mamlouk, K; Schwartsmann, G; Shan, YS; Siveke, JT; Wang-Gillam, A | 1 |
| Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
| Kumar, L; Tiwari, A | 1 |
| Gupta, S; Nayak, L; Ostwal, V; Ramaswamy, A; Sahu, A; Shetty, N; Shrikhande, SV; Zanwar, S | 1 |
| Borowicz, P; Confeld, M; Mallik, S; Quadir, M; Ray, P; Wang, T | 1 |
| Akce, M; Alese, OB; El-Rayes, BF; Kane, SR; Kooby, DA; Maithel, SK; Narayan, AS; Patel, PR; Sarmiento, JM; Shaib, WL; Switchenko, JM; Wu, C | 1 |
| Amundadottir, L; Clarke, WR; James, MA | 1 |
| Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
| Guo, Z; He, S; Hu, Z; Jiang, K; Lin, C; Su, H; Yuan, G; Zeng, Y; Zhong, F | 1 |
| Han, H; Rong, Y; Tang, Z; Tao, J; Xiong, C; Zhang, Z; Zhu, K; Zhu, Z | 1 |
| Adeva, J; Alés-Díaz, I; Buxò, E; Cañabate, M; Carmona-Bayonas, A; De la Cámara, J; Fernández, A; Gallardo, E; Gallego, J; García, A; González, P; Guillén, C; Jiménez-Fonseca, P; Llorca, C; López, C; López, LJ; Muñoz, A; Navarro-Pérez, V; Pazo-Cid, RA; Quintero, G; Ramírez, P; Reboredo, M; Ruiz-Miravet, N; Salgado, M; Sanchez-Cánovas, M; Vera, R | 1 |
| Kim, DH; McCaw, ZR; Tian, L; Wei, LJ | 1 |
| Arima, K; Baba, H; Chikamoto, A; Fukuzawa, K; Hashimoto, D; Hirata, T; Hirota, M; Inomata, M; Maehara, Y; Nakagawa, S; Negoro, Y; Ohga, T; Oki, E; Saeki, H; Yamashita, YI | 1 |
| Cai, YL; Li, J; Shen, ZP; Song, Y; Wu, XD; Zou, L | 1 |
| Choi, YJ; Kang, EJ; Kim, DS; Kim, HJ; Kim, JS; Lee, SY; Seo, HY | 1 |
| Cao, D; Chen, X; Feng, Y; Gong, C; Haydon, RC; He, TC; Huang, B; Huang, S; Lei, Y; Liu, B; Liu, W; Liu, X; Luo, W; Luu, HH; Ma, C; Peng, B; Shen, Y; Tang, S; Wang, X; Wu, T; Wu, X; Yang, L; Ye, Z; Yuan, C; Zeng, Z; Zhang, B; Zhang, L; Zhang, Z; Zhao, L | 1 |
| Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O | 1 |
| Kindler, HL | 6 |
| Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M | 1 |
| Batra, SK; Ju, J; Junker, WM; Kalaga, M; Mallapragada, S; Pothuraju, R; Rachagani, S; Uz, M | 1 |
| Chen, Y; Kadam, SM; Kelly, LE; Liu, L; Rapp, CM; Sahu, RP; Thyagarajan, A | 1 |
| Chen, J; Hu, P; Wu, G; Zhou, H | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Lafon, C; Mestas, JL; Prat, F | 1 |
| Furuse, J; Honda, G; Kosuge, T; Matsumoto, I; Matsuyama, Y; Motoi, F; Satoi, S; Sho, M; Ueno, H; Unno, M; Wada, K; Yamaue, H | 1 |
| Shi, S; Yu, X | 1 |
| Bernard, PW; Fan, J; Han, H; Hu, Y; Katz, MH; Koay, EJ; Liu, Y; Ning, B; Wei, Q; Zhang, N; Zhao, Z | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Funamizu, N; Kamada, M; Lacy, CR; Manome, Y; Yanaga, K | 1 |
| Azumi, Y; Fujii, T; Hayasaki, A; Iizawa, Y; Isaji, S; Kato, H; Kishiwada, M; Kuriyama, N; Mizuno, S; Murata, Y; Sakurai, H; Takeuchi, T; Tanemura, A; Usui, M | 1 |
| Buyse, M; Giai, J; Maucort-Boulch, D; Péron, J | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Aamir Mirza, M; Alshahrani, SM; Alshetaili, AS; Anwer, MK; Iqbal, Z; Jamil, A; Panda, AK; Telegaonkar, S; Thakur, PS | 1 |
| Bryant, M; Davis, MJ; Hendifar, A; Hoffman, D; Jamil, L; Kim, S; Klempner, SJ; Lo, S; Nissen, N; Noe, P; Osipov, A; Piantadosi, S; Placencio-Hickok, V; Ristow, L; Rokhsar, S; Sandler, H; Scher, K; Shiao, SL; Tighiouart, M; Tuli, R; Wachsman, A | 1 |
| Boige, V; Conroy, T; Ducreux, M; Hollebecque, A; Laurent-Puig, P; Malka, D; Seufferlein, T; Smolenschi, C; Van Laethem, JL | 1 |
| Du, G; Fan, Z; Ma, L; Wang, H | 1 |
| Abdalla, MY; Ahmad, IM; Bailey, KL; Banerjee, K; Britigan, BE; Kumar, S; Maurer, HC; Olive, KP; Rachagani, S; Thompson, CM | 1 |
| Ho, TTB; Honda, M; Kaneko, S; Kawaguchi, K; Komura, T; Miyazawa, M; Mizukoshi, E; Nasti, A; Okuzono, M; Sakai, Y; Takabatake, H; Wada, T; Yamada, T; Yamashita, T; Yamato, M; Yoshida, K | 1 |
| Romero, D | 1 |
| Thoma, C | 1 |
| Soefje, SA | 1 |
| Bronich, TK; Caffrey, T; Hollingsworth, MA; Lei, F; Lele, SM; Mehla, K; O'Connell, KA; Radhakrishnan, P; Sagar, S; Soni, KS; Thomas, D | 1 |
| Bi, T; Gao, Q; Liu, L; Liu, Y; Qin, L; Shen, G | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Tajima, H; Takamura, H; Terai, S | 1 |
| Amagasa, H; Ami, K; Andou, M; Fukuda, A; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kakuta, R; Kawaguchi, M; Maeda, S; Motoyama, K; Shibuya, G; Yamada, A | 1 |
| Alexandre, J; Bellesoeur, A; Blanchet, B; Cessot, A; Cohen, R; Curis, E; Desaulle, D; Goldwasser, F; Huillard, O; Joste, V; Jouinot, A; Narjoz, C; Nicolis, I; Preta, LH; Quilichini, J; Thomas-Schoemann, A; Tiako Meyo, M; Vidal, M | 1 |
| Laczkó, D; Marchand, B; Pitarresi, JR; Reichert, M; Rustgi, AK; Suzuki, K | 1 |
| Brunner, M; Ellenrieder, V; Gaedcke, J; Goetze, RG; Gruetzmann, R; Hamdan, FH; Hessmann, E; Jodrell, DI; Johnsen, SA; Kari, V; Kitz, J; Knösel, T; Neesse, A; Patil, S; Patzak, MS; Pilarsky, C; Richards, FM; Rümmele, P | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Dede, I; Demirci, NS; Engin, H; Eren, T; Ergun, Y; Esin, E; Guner, EK; Koksoy, EB; Oksuzoglu, B; Ozdemir, NY; Sendur, MA; Sezer, A; Urun, Y; Utkan, G; Yalcin, B; Zengin, N | 1 |
| Dong, M; Li, X; Sheng, W; Shi, X; Wang, G; Zhou, J | 1 |
| Carugo, A; Corti, D; Deem, AK; Del Poggetto, E; Draetta, GF; Fleming, J; Futreal, A; Genovese, G; Giuliani, V; Heffernan, TP; Ho, IL; Jiang, S; Kang, Y; Karpinets, T; Kim, M; Kumar, T; Li, CY; Loponte, S; Maitra, A; Peoples, M; Robinson, FS; Sapio, L; Seth, S; Song, X; Viale, A; Yen, EY; Zhang, J | 1 |
| Chen, L; Chen, Z; Hua, Y; Li, Y; Liu, L; Meng, Z; Ning, Z; Shi, W; Zhang, C | 1 |
| Wang, C; Xin, B; Zhang, X; Zhao, P | 1 |
| Han, L; Jiang, J; Qin, T; Wang, Z; Xiao, Y | 1 |
| Akiyama, T; Fukada, T; Kametaka, H; Makino, H; Miyazaki, M; Okura, R; Oya, M; Saitou, M; Seike, K; Tabe, S; Yoshitomi, H | 1 |
| Ahn, DH; Bekaii-Saab, T; Goldstein, D; Li, CP; Macarulla, T; O'Neil, B; Okusaka, T; Reni, M; Sonbol, MB; Tabernero, J; Van Cutsem, E | 1 |
| Bai, Z; Chen, G; Chen, Y; Guo, W; Ma, X; Pei, H; Peng, Y; Wang, T; Yang, Y; Zhang, Z | 1 |
| Hu, W; Li, M; Lu, H; Lu, S; Yang, D; Ye, J; Zhang, L | 1 |
| Fang, L; Guan, X; Li, Q; Li, Z; Lian, J; Liu, C; Lou, C; Shi, J; Wang, B; Wang, Y; Yao, Y; Zhan, F; Zhang, Y; Zhao, Q; Zhou, B; Zhu, Y | 1 |
| Araujo-Gutierrez, R; Bryan, NS; Fernandez-Moure, JS; Fleming, JB; Kang, Y; Kirui, D; Van Eps, JL | 1 |
| Bekaii-Saab, T | 2 |
| Bosch, R; Brú, A; Brú, I; Carmona-Güedes, S; Céspedes, MV; Pascual, E; Souto, JC | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Biankin, A; Chang, D; Crawford, HC; Dreyer, S; Frankel, TL; Halbrook, CJ; Hong, HS; Kemp, S; Kovalenko, I; Kremer, DM; Lapienyte, L; Lazarus, J; Lee, HJ; Lyssiotis, CA; Morton, JP; Nelson, BS; Pasca di Magliano, M; Pontious, C; Sajjakulnukit, P; Shi, J; Thurston, G; Zhang, L; Zhang, Y | 1 |
| Bhinderwala, F; Chaika, NV; Gebregiworgis, T; Powers, R; Purohit, V; Singh, PK | 1 |
| Bordon, Y | 1 |
| Conroy, T; Van Laethem, JL | 1 |
| Baldwin, GS; He, H; Nikfarjam, M; Wang, K | 1 |
| Cole, G; Gabrail, NY; James, D; Khorana, AA; Ramanathan, RK; Shah, S; Thomas, GW; Wong, S; Zhou, C | 1 |
| Lubgan, D; Semrau, S | 1 |
| Higashi, T; Matsumoto, H; Nagatsu, K; Oe, Y; Sugyo, A; Tsuji, AB; Yoshii, Y; Yoshimoto, M; Zhang, MR | 1 |
| Guo, JC; Li, BQ; Liang, ZY; Liu, QF; Seery, S; You, L; Zhang, TP; Zhao, YP | 1 |
| Lin, J; Ma, L; Su, GH; Wei, J | 1 |
| Fujimori, N; Kakihara, D; Kimura, R; Matsuda, R; Miyasaka, Y; Mori, Y; Nakamura, M; Nakata, K; Oda, Y; Ohno, T; Ohtsuka, T | 1 |
| Billig, AM; Jordan, VC; Medarova, Z; Pantazopoulos, P; Ross, A; Sheedy, P; Yoo, B | 1 |
| Benhadji, KA; Cleverly, A; Deplanque, G; Driscoll, KE; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Kozloff, M; Lahn, MMF; Macarulla, T; Man, M; Melisi, D; Pezet, D; Simionato, F; Smith, C; Tabernero, J; Trojan, J; Wang, S | 1 |
| Crona, DJ; Denning, S; Etheridge, AS; Furukawa, Y; Hatch, AJ; Hurwitz, HI; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, HL; Niedzwiecki, D; Nixon, AB; Owzar, K; Ratain, MJ; Sibley, AB; Watson, D | 1 |
| Gao, F; He, M; Jiang, X; Kuai, Q; Nie, G; Pan, Y; Ren, S; Shi, W; Wang, Y; Yu, Q; Zhao, X | 1 |
| Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Shan, Y; Sun, Y; Wang, P; Wu, H; Yang, W; Zhang, Q | 1 |
| Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X | 1 |
| Ray, K | 1 |
| Cao, L; Chen, Y; Ding, G; Jia, S; Wang, W; Wu, Z; Yu, W; Zhang, M; Zhou, L | 1 |
| Cheng, SH; Cheng, YJ; Jin, ZY; Xue, HD | 1 |
| Alcalá, S; Alonso-Nocelo, M; Carrato, A; Cassiano, C; D'Errico, G; Earl, J; Feliu, J; García, CP; García-Bermejo, L; Hermann, PC; Lombardia, L; Martin-Hijano, L; Martinelli, P; Monti, MC; Sainz, B; Seufferlein, T; Valle, S; Vallespinos, M | 1 |
| Aires, A; Cortajarena, AL; Couleaud, P; Courty, J; Göring, J; Hilger, I; Latorre, A; Ludwig, R; Miranda, R; Prina-Mello, A; Sanhaji, M; Somoza, Á; Stapf, M; Volkov, Y | 1 |
| Arteta, B; Benedicto, A; Hernandez-Unzueta, I; Herrero, A; Márquez, J; Olaso, E; Romayor, I; Sanz, E | 1 |
| Clay, T; Das, A; Dean, A | 1 |
| Apisarnthanarax, S; Hallemeier, CL; Huguet, F; Jabbour, SK; Murphy, JD; Olsen, JR; Tait, D | 1 |
| Chen, Q; Fu, Y; Shi, W; Tang, L; Yao, N | 1 |
| Angelini, G; Ciferri, E; Cornacchia, C; Filauro, M; Rutigliani, M; Serventi, A | 1 |
| Fukushima, T; Kaneko, T; Maeda, S; Oka, H; Okada, K; Okazaki, H; Sugimori, K; Tozuka, Y | 1 |
| Conroy, T; Ducreux, M | 1 |
| Alabkaa, A; Behrman, S; Chauhan, SC; Dan, N; Ganju, A; Hafeez, BB; Jaggi, M; Khan, S; Kumari, S; Massey, A; Setua, S; Stiles, ZE; Yallapu, MM; Yue, J | 1 |
| Hara, M; Hayashi, Y; Imafuji, H; Koide, S; Matsuo, Y; Morimoto, M; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Chen, L; Fang, K; Fang, Z; Liu, T; Wang, L | 1 |
| Li, PW; Luo, S; Tian, BL; Wang, L; Xiao, LY; Zeng, YC; Zhang, ZR | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M | 1 |
| Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H | 1 |
| Dart, A | 1 |
| Chen, Q; Chen, X; Guo, Q; Jiang, C; Li, C; Liang, C; Lu, Y; Shi, S; Sun, T; Yu, X; Zhang, Y; Zhou, W | 1 |
| Kanamala, M; Leung, E; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S | 1 |
| Chen, C; Chen, H; Chen, Y; Lu, Y; Luo, Z; Peng, J; Wang, Z; Xu, D; Yin, P; Zheng, M | 1 |
| Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH | 1 |
| Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y | 1 |
| Amaravadi, RK; Borazanci, E; Burrell, JA; De Jesus-Acosta, A; Drebin, JA; Karasic, TB; Laheru, DA; Loaiza-Bonilla, A; O'Dwyer, PJ; O'Hara, MH; Redlinger, C; Reiss, KA; Teitelbaum, UR; Von Hoff, DD | 1 |
| Bai, J; Chen, YS; Hou, PF; Liu, QH; Yong, HM; Zhang, XP; Zhu, MH; Zhuang, QX | 1 |
| Jin, HB; Lu, L; Ma, SL; Xie, L; Yang, JF; Zhang, XF | 1 |
| Chang, S; Khawar, IA; Kuh, HJ; Nam, S; Park, JK | 1 |
| Chen, P; Wang, C; Wang, M | 1 |
| Awasthi, N; Hassan, MS; Kronenberger, D; Schwarz, MA; Schwarz, RE; Stefaniak, A; von Holzen, U | 1 |
| Ishigaki, A; Kainuma, O; Kato, M; Kuwayama, N; Maruyama, T; Matsumoto, Y; Miyazaki, A; Mizumoto, H; Natsume, T; Note, H; Oshima, S; Sato, Y; Shimizu, S; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Branstrom, A; Cao, L; Decker, AR; Eberle-Singh, JA; Hu, J; Kim, MJ; Maurer, HC; Mollin, A; Olive, KP; Palermo, CF; Sagalovskiy, I; Sastra, SA; Sheedy, J; Weetall, M | 1 |
| Hashimoto, Y; Iizumi, S; Ikeda, M; Imaoka, H; Kondo, S; Kuchiba, A; Mitsunaga, S; Morizane, C; Ohashi, K; Ohno, I; Okusaka, T; Osame, K; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Ferraro, M; Haag, R; Quadir, M; Ray, P | 1 |
| Eid, R; Haddad, FG; Hajjar, AH; Kourie, HR | 1 |
| Hidalgo, M; Macarulla, T | 1 |
| Catanese, S; Fornaro, L; Pecora, I; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Akita, H; Asai, A; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ishii, H; Iwagami, Y; Kasahara, Y; Kawamoto, K; Kobayashi, S; Konno, M; Koseki, J; Matsushita, K; Mori, M; Mori, S; Morihiro, K; Noda, T; Obika, S; Okuda, T; Satoh, T; Yamada, D | 1 |
| Aasrum, M; Amrutkar, M; Gladhaug, IP; Verbeke, CS | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Asanuma, H; Hayashi, H; Hirata, K; Hirohashi, Y; Imai, K; Ito, YM; Kanaseki, T; Kimura, Y; Kubo, T; Kutomi, G; Miyakoshi, T; Mizuguchi, T; Murai, A; Nakae, Y; Nakatsugawa, M; Ota, Y; Sato, N; Shima, H; Sugita, O; Takemasa, I; Tokita, S; Torigoe, T; Tsukahara, T; Tsurita, G; Wada, S; Watanabe, K; Yasui, H | 1 |
| Hirose, Y; Ishii, A; Ishimoto, U; Iwaku, A; Kinoshita, A; Koike, K; Mizuno, Y; Saruta, M; Shibata, K; Shoji, R; Yokota, T | 1 |
| Kocher, HM; North, B; Sasieni, P | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nagashima, F; Nakajima, TE; Ohkawa, S; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Fu, DL; Jin, C; Warshaw, AL; Yang, F | 1 |
| Burge, M; Cohen, J; Cooray, P; Gibbs, P; Goldstein, D; Harris, M; Haydon, A; Javed, AA; Kinzler, KW; Lawrence, B; Lee, B; Lennon, AM; Li, L; Lipton, L; Nagrial, A; Nikfarjam, M; Papadopoulos, N; Simons, K; Tai, DWM; Tebbutt, NC; Thomson, B; Tie, J; Tomasetti, C; Vogelstein, B; Wolfgang, CL | 1 |
| Castellanos, K; Cordoba-Chacon, J; Dawson, D; Dorman, MJ; Grimaldo, S; Grippo, PJ; Hirsch, E; Kumar, S; Mancinelli, G; McKinney, R; Munshi, HG; Principe, D; Rana, A; Torres, C; Viswakarma, N | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Bhattacharya, S; Caplette, JR; Dutta, SK; Gong, X; Mukhopadhyay, D; Nguyen, FT; Son, M; Strano, MS; Wang, E | 1 |
| Collisson, EA; Fer, N; Galeas, J; Kim, SE; McCormick, F; Sharib, J; Wang, MT | 1 |
| Chen, Q; Qiu, J; Tao, M; Xie, Y; Yu, D; Zhao, Y | 1 |
| Baikoghli, M; Borowsky, AD; Cheng, RH; Ferrara, KW; Foiret, J; Hubbard, NE; Ingham, ES; Kheirolomoom, A; Mahakian, LM; Tam, SM; Tucci, ST | 1 |
| Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H | 1 |
| Anota, A; Aparicio, T; Bachet, JB; Bonnetain, F; Charton, E; Chibaudel, B; Cohen, R; Dauba, J; Debourdeau, P; Desramé, J; Guerin-Meyer, V; Hammel, P; Lecomte, T; Louvet, C; Seitz, JF; Taieb, J; Tournigand, C; Volet, J | 1 |
| Alfaro-Olea, A; Casajús-Navasal, A; Marín-Gorricho, R; Nebot-Villacampa, MJ; Uriarte-Pinto, M; Zafra-Morales, R | 1 |
| Berlin, J; Cardin, DB; Cohen, SJ; Davis, SL; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, WA; O'Neil, BH; Shahda, S; Stagg, RJ | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Bendell, JC; Bullock, A; Dupont, J; Firdaus, I; Hatoum, H; Holmgren, E; Hool, H; Hu, ZI; Kapoun, AM; Leach, JW; LoConte, NK; O'Reilly, EM; Patel, R; Picozzi, V; Ritch, P; Sahai, V; Sanchez, J; Sohal, DPS; Strickler, J; Wang-Gillam, A; Yu, KH; Zhou, L | 1 |
| Corfiotti, F; Corvaisier, M; Deshorgues, AC; El Amrani, M; Fulbert, M; Gnemmi, V; Huet, G; Lahdaoui, F; Pruvot, FR; Skrzypczyk, C; Truant, S; Tulasne, D; Van Seuningen, I; Vasseur, R; Vincent, A | 1 |
| Fang, Y; Kuang, T; Lou, W; Rong, Y; Wang, D; Wu, W; Xu, X; Zhou, W | 1 |
| Büchler, MW; Hackert, T; Heger, U; Hinz, U; Klaiber, U; Liu, B; Michalski, CW; Sachsenmaier, M; Springfeld, C; Sun, H; Tanaka, M | 1 |
| Dvorak, P; Ehrlichova, M; Flasarova, D; Hlavac, V; Kocik, M; Mohelnikova-Duchonova, B; Ojima, I; Oliverius, M; Soucek, P; Strouhal, O | 1 |
| Chang, CF; Chang, PH; Chen, JS; Chen, YY; Chou, WC; Hsueh, SW; Huang, PW; Hung, CY; Hung, YS; Lu, CH; Yeh, KY | 1 |
| Lee, GY; Mao, H; Nie, S; Qian, WP; Satpathy, M; Staley, CA; Wang, L; Wang, YA; Yang, L | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S | 1 |
| Chikano, Y; Endo, Y; Higashi, T; Hirose, M; Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Miyamoto, K; Motoo, Y; Nakada, M; Sai, Y; Sato, H; Shimasaki, T; Takino, T | 1 |
| Bevan, P; Boeck, S; Ebert, MP; Heinemann, V; Laubender, RP; Mala, C | 1 |
| Arshad, A; Chung, W; Dennison, A; Isherwood, J; Metcalfe, M; Steward, W | 1 |
| Bekaii-Saab, TS; Chidiac, TA; Criswell, T; Fernandez, SA; Guttridge, D; Villalona-Calero, M; Wu, C | 1 |
| Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M | 1 |
| An, Y; Cai, B; Chen, J; Jiang, K; Lv, N; Miao, Y; Sun, J; Tu, M; Wei, J; Wu, P | 1 |
| Blaszkowsky, LS; Chan, E; Hartford, A; Hidalgo, M; Jackson, L; Ko, YJ; Lichinitser, M; Macarulla, T; McWhirter, E; Morrison, K; O'Reilly, EM; Pezet, D; Rarick, M; Reyno, L; Ritch, P; Rocha-Lima, CM; Roman, L; Spratlin, J; Vincent, M; Wolpin, BM | 1 |
| Berzcel, L; Charabaty, A; Collins, SP; Gurka, MK; Haddad, N; Jackson, P; Jha, R; Johnson, CD; Lei, S; Ley, L; Marshall, JL; Pishvaian, MJ; Slack, R; Suy, S; Tse, G | 1 |
| Arshad, A; Chung, WY; Dennison, AR; Metcalfe, MS; Steward, W | 1 |
| Calvo, EL; Dusetti, N; Fernandez-Zapico, ME; Garcia, S; Gilabert, M; Iovanna, JL; Lomberk, G; Moutardier, V; Secq, V; Turrini, O; Urrutia, R; Vaccaro, MI | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Chen, X; Li, J; Ouyang, X; Wang, W; Xie, F; Xue, Z; Yu, Z; Zheng, P | 1 |
| Camp, ER; Chang, EH; Cole, DJ; Little, EC; Pirollo, KF; Rait, A; Wang, C; Watson, DK; Watson, PM | 1 |
| Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY | 1 |
| Büchler, MW; Combs, SE; Diener, MK | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Harada, N; Hayashi, T; Kaji, S; Koike, N; Ozaki, Y; Saida, S; Suzuki, M; Suzuki, S | 1 |
| Li, YH; Luo, HY; Qiu, MZ; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS | 1 |
| Bhattacharya, R; Khan, JA; Kudgus, RA; Mukherjee, P; Reid, JM; Robertson, JD; Szabolcs, A; Walden, CA | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Abe, Y; Asaka, M; Eto, K; Fukuoka, M; Kawahata, S; Kawakami, H; Kudo, T; Kuwatani, M; Matsuno, Y; Sakamoto, N; Takasawa, A | 1 |
| Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Daneker, GW; Kim, B; McDonald, JF; Mezencev, R; Sulchek, TA; Wang, L; Xu, W | 1 |
| Drebin, JA; Feldman, MD; Giantonio, BJ; Ginsberg, G; Harlacker, K; Heitjan, DF; Kochman, ML; Metz, JM; O'Dwyer, PJ; Plastaras, JP; Sohal, DP; Sun, W; Teitelbaum, UR | 1 |
| Barzotti, E; Drudi, F; Fantini, M; Gianni, L; Giuliani, J; Lotti, N; Ravaioli, A; Ridolfi, C; Santelmo, C; Tamburini, E; Tassinari, D | 1 |
| Ge, Y; Guo, Y; He, M; He, Y; Li, W; Qiao, Z; Ren, S; Sun, L; Wang, X; Yu, Q | 1 |
| O'Reilly, EM | 2 |
| Baba, H; Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fukutomi, A; Funakoshi, A; Furuse, J; Hatori, T; Ikeda, M; Ioka, T; Kitano, M; Mizumoto, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Shimamura, T; Sho, M; Sugimori, K; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K; Yanagimoto, H | 1 |
| Endo, I; Hosono, K; Kobayashi, N; Kubota, K; Matsuyama, R; Mori, R; Nakajima, A; Sato, T; Taniguchi, K; Watanabe, S | 1 |
| Bouvet, M; Hoffman, RM; Liu, F; Wu, C; Zhang, L; Zhang, Y; Zhao, M | 1 |
| Endoh, T; Ikeda, K; Iwata, N; Minami, T; Sasano, H; Sugawara, N; Yoshida, Y | 1 |
| Hwang, JH; Kim, HR; Lee, SH; Paik, WH; Park, JK; Song, BJ | 1 |
| Chen, G; Cui, QC; Du, X; Shi, J; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Jiang, Y; Jiao, X; Sun, S; Zheng, C | 1 |
| Scheithauer, W; Van Cutsem, E | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Alvarez, E; Campos, MD; Cavaliere, V; Costantino, S; Kaiser, CM; Lombardo, T; Papademetrio, DL; Simunovich, T | 1 |
| Hao, K; Qin, C; Tian, X; Xie, K; Xie, X; Yang, Y | 1 |
| Agaram, N; Crooks, PA; Schmidt, CM; Stantz, K; Wu, H; Yip-Schneider, MT | 1 |
| Furuse, J; Higashi, S; Ikeda, M; Inagaki, M; Kato, H; Mitsunaga, S; Ochiai, A; Ohno, I; Shimizu, S; Terao, K | 1 |
| patel, J | 1 |
| Ghansah, T; Kinney, K; Kodumudi, K; Pilon-Thomas, S; Sarnaik, AA; Springett, G; Vohra, N; Weber, A | 1 |
| El-Hadaad, HA; Wahba, HA | 1 |
| Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T | 1 |
| Chabot, JA; Hershman, DL; Insel, BJ; Khanna, LG; Neugut, AI; Oberstein, PE | 1 |
| Cheng, X; Ji, Z; Lu, M; Mei, F; Ou, Y; Peng, Z | 1 |
| Assadourian, S; Barone, C; Hatteville, L; Humblet, Y; Karasek, P; Manges, R; Philip, PA; Riess, H; Rougier, P; Santoro, A | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Wang, J; Xu, Q; Xu, S; Zhang, L; Zhang, N; Zhou, J | 1 |
| Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
| Maréchal, R; Van Laethem, JL | 2 |
| Fu, Z; Han, B; Han, H; He, Q; Tang, K; Wang, X; Xu, J; Yin, H; Zhang, X | 1 |
| Giese, N; Giese, T; Gladkich, J; Hage, C; Herr, I; Labsch, S; Mattern, J; Nwaeburu, C; Rausch, V; Schönsiegel, F | 1 |
| Horiguchi, S; Ichimura, K; Iwamuro, M; Kataoka, J; Kato, H; Matsubara, M; Nagahara, T; Nishina, S; Nouso, K; Shiraha, H; Takaki, A; Tanaka, T; Yagi, T; Yamamoto, K | 1 |
| Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM | 1 |
| Chen, Q; Drisko, J; Yu, J | 1 |
| Artru, P; Bachet, JB; Bidard, FC; Bouché, O; Chibaudel, B; Desseigne, F; Hammel, P; Huguet, F; Louvet, C; Mathiot, C; Mineur, L; Pierga, JY | 1 |
| Boettcher, M; Fredebohm, J; Hoheisel, JD; Wolf, J | 1 |
| Arizumi, T; Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Yagioka, H; Yamamoto, K; Yamamoto, N | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Kosuge, T; Morizane, C; Nara, S; Okusaka, T; Otsuka, T; Shimada, K; Ueno, H | 1 |
| Ai, Y; Brody, JR; Burkhart, RA; Cozzitorto, JA; Gehrmann, M; Lal, S; Liang, Q; Miller, K; Napper, A; Norris, ZA; Peng, Y; Sawicki, JA; Talbott, VA; Tholey, RM; Winter, JM; Witkiewicz, AK; Yeo, CJ; Zhuang, Z | 1 |
| Dangi-Garimella, S; Ebine, K; Kumar, K; Munshi, HG; Sahai, V | 1 |
| Fleming, J; Jiang, ZQ; Katz, M; Kopetz, S; Lee, JE; Overman, MJ; Shroff, R; Varadhachary, G; Wang, H; Wang, X; Wolff, RA | 1 |
| Bekaii-Saab, T; Ben-Josef, E; Bloomston, M; Dawson, LA; Francis, IR; Greenson, JK; Griffith, KA; Herman, JM; Kim, EJ; Laheru, D; Lawrence, TS; Moore, MJ; Simeone, DM; Wei, A; Williams, T; Wolfgang, CL; Zalupski, MM | 1 |
| Bansal, SS; Celia, C; Ferrari, M; Ferrati, S; Grattoni, A; Palapattu, G; Zabre, E | 1 |
| Arora, S; Bhardwaj, A; Grizzle, WE; McClellan, S; Nirodi, CS; Owen, LB; Piazza, GA; Singh, AP; Singh, S; Srivastava, SK | 1 |
| Badola, S; Chen, L; Deng, H; Fuchs, CS; Gansert, JL; Kindler, HL; Loh, E; McCaffery, I; Patterson, SD; Suzuki, S; Tang, R; Tudor, Y | 1 |
| Fu, Z; Wang, X; Yin, H; Zhang, X | 1 |
| Behrman, SW; Chitkara, D; Kumar, N; Mahato, RI; Mittal, A | 1 |
| Baines, AT; Baldwin, AS; Bednarski, BK; Cobb, MG; Gavilano, L; Kim, HJ; Taverna, P; White, CD; Williams, D; Witherspoon, SM; Xu, D | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Fujikawa, T; Maekawa, H; Shimoike, N; Tanaka, A | 1 |
| Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S | 1 |
| Gotoh, K; Ioka, T; Ishikawa, O; Marubashi, S; Murata, M; Ohigashi, H; Takahashi, H; Uehara, H; Yamada, T; Yano, M | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Alongi, F; Clerici, E; Comito, T; Cozzi, L; Fogliata, A; Iftode, C; Mancosu, P; Navarria, P; Reggiori, G; Rimassa, L; Scorsetti, M; Tomatis, S; Tozzi, A; Zerbi, A | 1 |
| Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
| Davis, MA; Engelke, CG; Greenson, JK; Karnak, D; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Qian, Y; Robertson, JR; Tanska, DM; Wei, D; Zhang, Q; Zhao, L | 1 |
| Dimcevski, G; Gilja, OH; Hoem, D; Kotopoulis, S; Postema, M | 1 |
| Brons, S; Combs, SE; Debus, J; El Shafie, RA; Haberer, T; Habermehl, D; Mairani, A; Orschiedt, L; Rieken, S; Weber, KJ | 1 |
| Bakker, A; Balic, A; Garcia, E; Hahn, SA; Heeschen, C; Hermann, PC; Hidalgo, M; Sahoo, SK; Sainz, B; Trabulo, SM; Tunici, P; Vandana, M | 1 |
| Hashimoto, J; Hosoi, H; Koizumi, F; Kondo, S; Morizane, C; Okusaka, T; Tamura, K; Ueno, H | 1 |
| Hamed, SS; Jusko, WJ; Straubinger, RM | 1 |
| Beasley, TM; Boothman, DA; Buchsbaum, DJ; Kim, H; Lee, SK; Li, LS; Martin, A; Rigell, CJ; Samuel, SL; Stockard, CR; Umphrey, HR; Zhai, G; Zinn, KR | 1 |
| Bapiro, TE; Frese, KK; Jodrell, DI; Nakagawa, T; Neesse, A; Pilarsky, C; Seeley, TW; Spong, SM; Sternlicht, MD; Tuveson, DA | 1 |
| Ciccolini, J; Dahan, L; Duluc, M; Fina, F; Lacarelle, B; Norguet, E; Ouafik, L; Seitz, JF; Serdjebi, C | 1 |
| Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Bao, GQ; Pan, CP; Peng, CH; Shen, BY; Shi, MM; Zhang, YJ | 1 |
| Demizu, Y; Fuwa, N; Horai, A; Kinoshita, Y; Kitajima, N; Ose, T; Satake, S; Takatori, K; Terashima, K; Yoshida, R | 1 |
| Chaulagain, CP; Rothschild, J; Saif, MW | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Jarboe, J; Saif, MW | 1 |
| Saif, MW; Strimpakos, AS | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 4 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Ducreux, M; Heinemann, V; Macarulla, T; Reni, M; Richel, DJ; Ychou, M | 1 |
| Boeck, S; Haas, M; Heinemann, V | 1 |
| Hamada, C; Nagashima, K; Noma, H; Sato, Y | 1 |
| Bae, I; Cho, CH; Duong, HQ; Hong, YB; Kim, JS; Kim, YJ; Lee, HS; Seong, YS; Wang, A; Yi, YW; Zhao, W | 1 |
| Cheng, AL; Hsu, CH; Kuo, SH; Lee, JC; Tien, YW; Yang, SH | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K | 1 |
| Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Asuthkar, S; Cines, DB; Estes, N; Gondi, CS; Holterman, AL; Lebedeva, T; Rao, JS; Stepanova, V | 1 |
| Gonzalez de Mejia, E; Johnson, JL | 1 |
| Chang, X; Fan, X; Guo, Q; Huang, Y; Li, X; Lu, J; Lu, Y; Shan, H; Wang, L; Wang, Y; Wang, Z; Zhu, H; Zhu, M; Zhu, S | 1 |
| Delalande, A; Dimcevski, G; Gilja, OH; Gjertsen, BT; Kotopoulis, S; Mamaeva, V; McCormack, E; Popa, M; Postema, M | 1 |
| Kimura, S; Kitahara, K; Komiya, K; Noshiro, H; Sueoka-Aragane, N; Sugioka, T; Yakabe, T | 1 |
| Barth, PJ; Bartsch, DK; Brendel, C; Ebert, MP; Endlicher, E; Fass, J; Fensterer, H; Gress, TM; Hofheinz, R; Kornmann, M; Lindig, U; Märten, A; Michl, P; Müller, HH; Schade-Brittinger, C; Schmidt, WE; Settmacher, U; Tebbe, S | 1 |
| Akada, J; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Suenaga, S; Tanaka, T; Tokuda, K; Wang, Y | 1 |
| Gong, DJ; Guo, QQ; Yu, M; Zhang, JM; Zhuang, B | 1 |
| Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Wada, H | 1 |
| Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V | 1 |
| Hu, Y; Liao, Q; Wen, Z; You, L; Zhao, Y; Zhou, L | 1 |
| Abood, GJ; Bahary, N; Bartlett, DL; Krasinskas, AM; Lembersky, BC; Moser, AJ; Potter, DM; Ramanathan, RK; Shuai, Y; Smith, RP; Van Buren, G; Zeh, HJ; Zureikat, AH | 1 |
| Dumontet, C; Jordheim, LP | 1 |
| Alvarez, R; Barbacid, M; Cubillo, A; de Vicente, E; Garcia-Garcia, E; Guerra, C; Hidalgo, M; Lopez-Casas, PP; Lopez-Rios, F; Megias, D; Muñoz, M; Musteanu, M; Plaza, C; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Tabernero, S | 1 |
| Chao, Y; Lee, RC; Lee, WP; Li, CP; Wang, JP; Wu, CY | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B | 1 |
| Gog, C; Heinrich, S; Kraft, D; Lorenz, M; Schwarz, W; Staib-Sebler, E; Vogl, T | 1 |
| Tan, ZM; Wang, LY; Yu, Z; Yuan, YH; Zhong, W | 1 |
| Abo, R; Bamlet, W; Brisbin, A; Carlson, E; Eckloff, BW; Ellsworth, KA; Fridley, BL; Jenkins, GD; Li, L; Moon, I; Petersen, G; Wang, L; Wieben, ED | 1 |
| Bhutia, YD; Cho, JH; Chu, CK; Davis, F; Dhar, S; Govindarajan, R; Hung, SW; Marrache, S; Mody, H; Zastre, J | 1 |
| Chen, MC; Eibl, G; Hines, OJ; Ishiguro, H; Matsuo, Y; Pham, H; Reber, HA; Takahashi, H; Takeyama, H | 1 |
| Centeno, BA; Chen, DT; Hingorani, SR; Husain, K; Malafa, MP; Sebti, SM | 1 |
| Choi, BI; Choi, Y; Han, JK; Kim, H; Lee, ES; Lee, JY; Park, J | 1 |
| Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
| Alavi, A; Beatty, GL; Brothers, A; Chiorean, EG; O'Dwyer, PJ; Saboury, B; Sun, W; Teitelbaum, UR; Torigian, DA; Troxel, AB; Vonderheide, RH | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Fichtner-Feigl, S; Kesselring, R; Knoop, R; Plassmeier, L; Waldmann, J | 1 |
| Chen, RX; Jiang, ZD; Jin, FS; Wang, EF; Wang, YN; Zhang, LG; Zhang, X; Zhao, JH | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nagata, C; Nagumo, Y; Nishiyama, H; Oikawa, T; Suetomi, T; Uchida, M | 1 |
| Amit, M; Binenbaum, Y; Gil, Z; Krelin, Y; Shabtay-Orbach, A; Weizman, N; Wong, RJ | 1 |
| Clements, D; Giacomantonio, CA; Gujar, SA; Hill, R; Lee, PW; Madureira, PA; Rabb, M; Waisman, DM | 1 |
| Padmanabhan, J; Woods, NK | 1 |
| Du, QH; He, CY; Xu, YB; Yun, P; Zhang, MY | 1 |
| Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q | 1 |
| Bartholin, L; Calvo, E; Cano, CE; Dusetti, N; Garcia, MN; Garcia, S; Grasso, D; Hamidi, T; Iovanna, JL; Lomberk, G; Loncle, C; Urrutia, R | 1 |
| Büchler, MW; Combs, SE; Debus, J; Dreher, C; Habermehl, D; Haselmann, R; Jäger, D; Jäkel, O; Kieser, M; Werner, J | 1 |
| Bahra, M; Bischoff, S; Denkert, C; Dörken, B; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Sallmon, D; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Buckway, B; Ghandehari, H; Ray, A; Wang, Y | 1 |
| Hilger, RA; Hoheisel, JD; Holtrup, F; Werner, J; Wolf, RJ | 1 |
| Berrevoet, F; De Bosschere, K; Ferdinande, L; Geboes, K; Hav, M; Ky, V; Laurent, S; Monsaert, E; Troisi, RI; Van Damme, N; Vanderstraeten, E | 1 |
| Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| England, CG; Frieboes, HB; Huang, J; Lee, JJ; McNally, LR | 1 |
| Guo, JC; Yang, SH | 1 |
| Daignault, S; Healy, P; O'Malley, M; Ramnath, N | 1 |
| Gansauge, F; Kleef, R; Poch, B; Schwarz, M | 1 |
| Avan, A; Boggi, U; Campani, D; Caretti, V; Fuchs, D; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Lagerweij, T; Maftouh, M; Peters, GJ; Schuurhuis, GJ; Van Tellingen, O; Verheul, HM; Würdinger, T | 1 |
| Bertagnolli, MM; Friedman, PN; Goldberg, RM; Hurwitz, HI; Kindler, HL; Nixon, AB; Pang, H; Starr, MD; Venook, AP | 1 |
| Arning, MB; Fahlke, J; Gellert, K; Hartmann, JT; Hinke, A; Hochhaus, A; Neuhaus, P; Niedergethmann, M; Oettle, H; Ridwelski, K; Riess, H; Sinn, M; Zülke, C | 1 |
| Centeno, BA; Chellappan, SP; Lawrence, NJ; Pernazza, D; Pillai, S; Sebti, SM; Singh, S; Treviño, JG; Verma, M; Zhang, D | 1 |
| Dwinell, MB; Hauser, AD; Roy, I; Williams, CL; Wilson, JM; Zimmerman, NP | 1 |
| Goecke, H; Méndez, GP; Parodi, C; Vega, J | 1 |
| Qi, JL; Shi, SB; Tang, XY; Tian, J; Wang, M | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Al-Leswas, D; Arshad, A; Chung, WY; Dennison, AR; Isherwood, J; Mann, CD; Metcalfe, MS; Steward, WP | 1 |
| Fillat, C; Mato-Berciano, A; Mazo, A; Sobrevals, L; Urtasun, N | 1 |
| Bai, L; Jiao, SC; Li, J; Long, YY; Shi, WW; Su, D; Wang, LJ | 1 |
| Brinker, CJ; Chang, CH; Dong, J; Ji, Z; Lin, YS; Mai, WX; Meng, H; Nel, AE; Xue, M; Zhang, H; Zhao, Y; Zink, JI | 1 |
| Donahue, TR; Elashoff, DA; Farrell, JJ; Gorgan, TR; Hines, OJ; Wei, CH | 1 |
| Choi, SH; Heo, JS; Hong, JY; Kang, WK; Lee, J; Lee, SC; Lim, HY; Nam, EM; Park, JO; Park, SH; Park, YS; Song, SY | 1 |
| Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH | 1 |
| Bahary, N; Brand, R; Burton, SA; Heron, DE; Krasinskas, AM; Lembersky, B; Moser, AJ; Quinn, AE; Rajagopalan, MS; Wegner, RE; Zeh, HJ | 1 |
| Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Honeywell, R; Leon, LG; Maftouh, M; Minutolo, F; Peters, GJ; Rani, R; Sciarrillo, R; Smid, K | 1 |
| Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Schlaich, F; Weber, KJ | 1 |
| Chung, C; Kim, H; Kim, SK; Kim, T; Kim, TS; Koh, GY; Lee, DH; Lim, DS | 1 |
| Biasco, G; Brandi, G; De Rosa, F; Di Girolamo, S; Di Marco, M; Guarnieri, T; Macchini, M; Papi, A; Paterini, P; Tavolari, S | 1 |
| Kim, S; Li, X; Lin, L; Liu, C; Okunieff, P; Su, Y; Sun, W; Wang, W; Yang, S; Zhang, H; Zhang, L; Zhang, M; Zhang, Z | 1 |
| Lecca, P | 2 |
| Aprahamian, M; Bour, G; Giese, NA; Grekova, SP; Lehn, JM; Nicolau, C; Raykov, Z | 1 |
| Amadori, D; Aquilina, M; Burgio, MA; Carloni, S; Casadei Gardini, A; Frassineti, GL; Lucchesi, A; Oboldi, D; Tenti, E | 1 |
| John, P; McConnell, K; Saif, MW | 1 |
| Saif, MW | 13 |
| Hamada, S; Masamune, A; Miura, S; Satoh, K; Shimosegawa, T | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Akada, J; Baron, B; Kaino, S; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Sakaida, I; Suenaga, S; Tokuda, K; Wang, Y | 1 |
| Bassi, C; Bosco, G; Bosio, C; Camporesi, E; Cannato, M; Casarotto, A; Chen, C; Garetto, G; Guizzon, L; Mangar, D; Nasole, E; Toniolo, L; Yang, Z | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Abe, M; Azemoto, N; Furukawa, S; Hiasa, Y; Hirooka, M; Ikeda, Y; Imai, Y; Imamine, S; Inada, N; Koizumi, M; Kumagi, T; Kuroda, T; Matsuura, B; Miyaike, J; Miyake, T; Nishiyama, M; Ohno, Y; Okada, S; Onji, M; Seike, H; Shibata, N; Tanaka, Y; Tatsukawa, H; Utsunomiya, H; Yamanishi, H; Yokota, T | 1 |
| Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Maithel, SK; Pantazides, BG; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Volkan Adsay, N; Warren, MD; Yu, DS | 1 |
| Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN | 1 |
| Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V | 1 |
| Chiba, S; Hori, Y; Shimizu, K | 1 |
| Annels, NE; Billingham, L; Corrie, P; Cunningham, D; Eatock, M; Gabitass, RF; Middleton, G; Neoptolemos, JP; Pandha, H; Shaw, VE; Smith, D; Valle, J; Wadsley, J | 1 |
| Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Furuse, J | 2 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Chun, HJ; Hyun, JJ; Jeen, YT; Keum, B; Kim, CD; Lee, HS; Seo, YS; Um, SH | 1 |
| Chen, G; Du, X; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Hazama, S; Iida, M; Matsui, H; Oka, M; Shindo, Y; Suzuki, N; Takeda, K; Ueno, T; Yoshimura, K; Yoshino, S | 1 |
| Azemoto, R; Hara, T; Hirata, N; Ishihara, T; Mikata, R; Nakagawa, A; Nakaji, S; Nakamura, K; Nihei, T; Nishino, T; Ohshima, T; Ozawa, F; Shimura, K; Sudo, K; Tada, M; Tawada, K; Yamaguchi, T; Yokosuka, O | 1 |
| Arra, C; Barbieri, A; Bimonte, S; Luciano, A; Palma, G; Rea, D | 1 |
| Hong, SK; Yang, KX; Yang, SY; Yin, SH | 1 |
| Chen, Y; Ouyang, J; Ouyang, L; Yang, J | 1 |
| Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| Chung, I; Eastman, A; Hou, H; Khan, N; Montano, R; Thompson, R | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Bae, I; Duong, HQ; Hong, YB; Kang, HJ; Seong, YS; Tang, W; Wang, A; Yi, YW | 1 |
| Fang, L; Hu, H; Li, F; Liu, L; Mao, Y; Zhu, H | 1 |
| Horiguchi, S; Iwamuro, M; Kataoka, J; Kato, H; Kumon, H; Nagahara, T; Nasu, Y; Nouso, K; Shiraha, H; Takaki, A; Uchida, D; Watanabe, M; Yagi, T; Yamamoto, K | 1 |
| Bauer, C; Bauernfeind, F; Conrad, C; Dauer, M; Duewell, P; Eigler, A; Endres, S; Kiefl, R; Schnurr, M; Sterzik, A | 1 |
| Etienne, E; Geny, B; Gottenberg, JE; Lannes, B; Messer, L; Meyer, A; Meyer, C; Moreau, P; Sibilia, J; Spielmann, L | 1 |
| Ding, X; Liu, W; Luo, H; Lv, Y; Pan, J; Pei, Q; Zhu, H; Zou, X | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Ohta, T; Sakai, S; Shoji, M; Tajima, H; Takamura, H | 1 |
| Desaki, R; Higashi, M; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Gabata, T; Hayashi, H; Kinoshita, J; Kitagawa, H; Koda, W; Makino, I; Minami, T; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ohta, T; Okamoto, K; Oyama, K; Sai, Y; Sakai, S; Sanada, J; Shoji, M; Tajima, H; Takamura, H | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Ohira, M; Otani, H; Tanaka, H; Toyokawa, T | 1 |
| Aoki, S; Egawa, S; Fukase, K; Hayashi, H; Katayose, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, T; Sakata, N; Unno, M; Yoshida, H | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tanizaki, K; Tomimaru, Y; Wada, H | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Toyoki, Y; Wakiya, T | 1 |
| Doi, T; Fujishima, F; Kawaguchi, K; Kuroda, F; Motoi, F; Nozawa, Y; Takemura, S; Unno, M; Yokoyama, S | 1 |
| Aoki, T; Chohno, T; Hyuga, S; Kobayashi, K; Matsumoto, T; Nishioka, K; Takachi, K; Takemoto, H; Uemura, Y; Watanabe, R | 1 |
| Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Funamizu, N; Hiyoshi, Y; Lacy, CR; Parpart, ST; Takai, A; Yanaga, K | 1 |
| Bhuvaneshwar, K; Deeken, J; Filice, R; Harris, M; Madhavan, S; Natarajan, T; Pishvaian, MJ; Sheahan, L; Shoulson, I; Steadman, K; Tadesse, MG; Wang, D | 1 |
| Arrowsmith, E; Austin, T; Beckman, R; Forero-Torres, A; Greenberg, J; Hart, L; He, AR; Infante, JR; Jin, X; Rosen, M; Saleh, M; Trent, D; Vickers, S; von Roemeling, R; Wade, J; Wang, Q; Waterhouse, D; Wong, L | 1 |
| Kaino, S; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Sakaida, I; Suenaga, S | 1 |
| Avan, A; Giovannetti, E; Orsini, V; Peters, GJ; Ruiz, MG; Smit, EF | 1 |
| Gore, AJ; Korc, M; Liu, F; Wilson, JL | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Garcon, MC; Kaley, K; Rodriguez, T; Saif, MW | 1 |
| Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Butturini, G; Carter, R; Cox, T; Cunningham, D; Dervenis, C; Ghaneh, P; Goldstein, D; Izbicki, JR; Jackson, R; Karapetis, C; Lacaine, F; Lind, PA; Mayerle, J; Middleton, MR; Neoptolemos, JP; O'Reilly, D; Oláh, A; Palmer, D; Rawcliffe, CL; Robinson, BA; Sand, J; Scarfe, A; Stocken, DD; Sumpter, K; Valle, JW | 1 |
| Jiang, L; Li, P; Ma, J; Qi, L; Xu, X; Zhou, L; Zhou, P | 1 |
| Bouvet, M; Chishima, T; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, A; Miwa, S; Momiyama, M; Suetsugu, A; Tanaka, K; Uehara, F; Yano, S; Zhang, Y; Zhao, M | 1 |
| Aberson, HL; Duitman, J; Queiroz, KC; Richel, DJ; Shi, K; Spek, CA; van Noesel, CJ; Wilmink, JW | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Cai, X; Cui, JJ; Huang, WY; Song, WF; Wang, L; Wang, LW | 1 |
| Brade, A; Brierley, J; Cummings, B; Dawson, LA; Gallinger, S; Hashem, S; Hedley, D; Jiang, H; Kim, J; Krzyzanowska, MK; Ringash, J; Wong, R; Youl, M | 1 |
| Adem, A; Adrian, TE; Al Shemaili, J; Attoub, S; Collin, P; Hellman, B; Mensah-Brown, E; Nyberg, F; Parekh, K; Thomas, SA | 1 |
| Jaiyesimi, I; Kizilbash, SH; Liang, JJ; Lipscomb, J; Ward, KC | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Chen, YJ; Chu, L; Fang, JM; Han, YC; Liu, ZQ; Xu, Q; Zhang, X; Zhao, HX | 1 |
| Cheng, J; Hong, DF; Liu, JW; Shen, GL; Shi, Y; Sun, XD; Wang, CY; Wang, ZF; Zhang, CW; Zhang, JG; Zhang, YB; Zhao, G | 1 |
| Baldwin, GS; Beutler, JA; Christophi, C; He, H; Huynh, N; Nikfarjam, M; Shulkes, A; Yeo, D | 1 |
| Briggs, K; Curley, SA; Koshkina, NV; Palalon, F | 1 |
| Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J | 1 |
| Amiji, MM; Singh, A; Xu, J | 1 |
| Choi, H; Choi, YJ; Chung, MJ; Han, SH; Kang, H; Kim, JS; Lee, HW; Lee, KJ; Lee, SW; Song, SY | 1 |
| Fujimura, Y; Hashizume, M; Ikenaga, N; Irie, M; Miura, D; Mizumoto, K; Murata, M; Ohuchida, K; Setoyama, D; Tanaka, M; Wariishi, H | 1 |
| Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Han, B; Ji, L; Jia, G; Jiang, H; Li, Y; Liu, J; Lv, J; Pan, S; Song, Z; Sun, B; Teng, Y; Wang, Y; Zhou, Y | 1 |
| Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K | 1 |
| Bierwirth, C; Binkowski, AM; Dobbelstein, M; Köpper, F | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Dietel, M; Dörken, B; Lindner, JL; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Guo, Y; Kim, DH; Larson, AC; Nicolai, J; Omary, RA; Procissi, D; Zhang, Z | 1 |
| Cheng, L; Wang, R; Wang, Z; Wu, Q; Xia, J | 1 |
| Kondratska, K; Kondratskyi, A; Lemonnier, L; Lepage, G; Morabito, A; Prevarskaya, N; Skryma, R; Yassine, M | 1 |
| Hiraoka, M; Itasaka, S; Kawaguchi, Y; Matsuo, Y; Mizowaki, T; Nakamura, A; Shibuya, K; Takaori, K; Uemoto, S; Yoshimura, M | 1 |
| Ko, AH; Walker, EJ | 1 |
| Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Becker, G; Gaertner, J | 1 |
| Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W | 1 |
| Abbruzzese, JL; Bhosale, PR; Chatterjee, D; Chen, R; Chen, Y; Crane, CH; Cristini, V; Ferrari, M; Fleming, JB; Gottumukkala, VN; Javle, M; Kang, Y; Katz, MH; Koay, EJ; Lee, JE; Plunkett, W; Rozner, MA; Shen, H; Tamm, EP; Thomas, RM; Truty, MJ; Varadhachary, GR; Wang, H; Wolff, RA | 1 |
| Choi, M; Kim, R; Saif, MW | 2 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Abdelmohsen, K; Acosta, Ade J; Brody, JR; Burkhart, RA; Gorospe, M; Iacobuzio-Donahue, CA; Jimbo, M; Laheru, D; Lal, S; Lankapalli, RH; McAllister, F; Moughan, J; Pineda, DM; Winter, JM; Winter, KA; Witkiewicz, AK; Yeo, CJ | 1 |
| Jin, X; Wu, Y | 1 |
| Kajihara, M; Koido, S; Matsudaira, H; Matsumoto, K; Mitobe, J; Nagatsuma, K; Odahara, S; Ohkusa, T; Tajiri, H; Takahara, A; Takakura, K; Tsukinaga, S; Uchiyama, K; Yukawa, T | 1 |
| Bekaii-Saab, T; Espinoza, AM; Fogelman, DR; Foster, NR; Iyer, RV; Javle, MM; Kim, GP; Ko, AH; Martin, LK; Picozzi, VJ; Tempero, MA; Van Loon, K; Wolff, RA | 1 |
| Ii, N; Inoue, H; Isaji, S; Kishiwada, M; Kobayashi, M; Mizuno, S; Murata, Y; Sakurai, H; Shiraishi, T; Tabata, M; Usui, M; Yamada, T; Yamakado, K | 1 |
| Di, XY; Guo, JM; Jiang, HT; Yu, Q; Yu, YP; Zhu, Y | 1 |
| Bai, G; Hua, L; Lao, L; Qi, M; Wang, W; Zhu, Y | 1 |
| Adsay, NV; Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Liu, EA; Madden, MZ; Maithel, SK; Nagaraju, GP; Pan, Y; Pantazides, BG; Pauly, R; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Warren, MD; Yu, DS | 1 |
| Dohmen, T; Goto, T; Kamada, K; Mashima, H; Ohnishi, H; Sakai, T; Sato, W; Uchinami, H; Yamada, Y; Yamamoto, Y; Yoshioka, M | 1 |
| Greten, TF | 1 |
| Bekaii-Saab, T; Fogelman, D; Geyer, S; Iyer, R; Ko, AH; Martin, LK; Pant, S; Sommovilla, N; Van Loon, K; Wei, L; Zalupski, M | 2 |
| Duxfield, L; Li, Y; Lim, J; Paxton, J; Wu, Z; Xu, H; Zhang, W | 1 |
| Bahra, M; Dörken, B; Gebauer, B; Hilbig, A; Pelzer, U; Riess, H; Sinn, M; Stieler, JM | 1 |
| Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsui, H; Nakai, Y; Sasaki, T; Tada, M; Takagi, K; Takahara, N; Tsujino, T; Watanabe, T; Yagioka, H; Yamamoto, N; Yasunaga, H | 1 |
| Blanco Codesido, M; García Alfonso, P; Martín Jiménez, M; Muñoz Martín, AJ; Pérez Ramírez, S; Rupérez Blanco, AB | 1 |
| Ciftci, R; Disci, R; Duranyildiz, D; Karabulut, S; Sakar, B; Sen, F; Tas, F | 1 |
| Botteman, M; Ji, X; Reni, M; Solem, C; Wan, Y; Whiting, S | 1 |
| Audebert, S; Baudelet, E; Bidaut, G; Bonacci, T; Borg, JP; Camoin, L; Garcia, M; Iovanna, JL; Perkins, ND; Soubeyran, P; Witzel, II | 1 |
| Shu, H; Wang, TX; Xu, JW; You, L; Zhang, TP; Zhao, YP; Zheng, LF | 1 |
| Bae, I; Duong, HQ; Jang, YJ; Kang, HJ; Kwak, SJ; Seong, YS; Yi, YW | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Raucher, D; Ryu, JS | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Liu, Q; Liu, Y; Su, Z; Wang, D; Xie, X; Zhang, L; Zhang, Z; Zhou, Y; Zhu, H; Zhu, Y | 1 |
| Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A | 1 |
| Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ | 1 |
| Chen, SH; Jiang, Y; Li, DL; Wu, Z; Yang, F; Zhao, YY | 1 |
| Forster, T; Gebhard, MM; Gerhauser, C; Giese, N; Gladkich, J; Gross, W; Heilmann, K; Herr, I; Isayev, O; Labsch, S; Liu, L; Mattern, J; Nessling, M; Nwaeburu, CC; Rausch, V; Richter, K; Schaefer, M; Schemmer, P; Schoensiegel, F; Werner, J; Zhang, Y | 1 |
| Chang, DT; Chaudhry, M; Dholakia, AS; Griffith, ME; Hacker-Prietz, A; Herman, JM; Koong, AC; Laheru, DA; Leal, JP; Oteiza, KE; Pai, J; Pawlik, T; Raman, SP; Su, Z; Tryggestad, E; Wahl, RL; Wolfgang, CL | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Chen, Q; Yu, J | 1 |
| Arumugam, T; Elmetwally, AM; Lin, HY; Mousa, SA; Nazeer, T; Phillips, P; Sudha, T; Yalcin, M | 1 |
| Bockorny, B; Dasanu, CA | 1 |
| Ba'ssalamah, A; Brostjan, C; Eisenhut, A; Gnant, M; Kuehrer, I; Sahora, K; Schindl, M; Schoppmann, SF; Stift, J; Telek, B; Werba, G | 1 |
| Iida, T; Nakabayashi, Y; Okui, N; Otsuka, M; Shiba, H; Yanaga, K | 1 |
| Fukutomi, A; Gansert, J; Ikeda, M; Kobayashi, Y; Okusaka, T; Shibayama, K; Takubo, T | 1 |
| Avan, A; Boggi, U; Campani, D; Cantore, M; Caponi, S; Faviana, P; Funel, N; Giovannetti, E; Maftouh, M; Mambrini, A; Milella, M; Pacetti, P; Paolicchi, E; Peters, GJ; Reni, M; Vaccaro, V; Vasile, E | 1 |
| Chen, Y; Cheng, JM; Gong, GQ; Li, CY; Li, GP; Liu, LX; Wang, JH; Wang, XL; Yan, ZP | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, KH; Lee, H; Son, MK; Yan, HH | 1 |
| Ambre, AH; Borowicz, PP; Guo, B; Haldar, MK; Katti, KS; Katti, P; Kulkarni, PS; Mallik, S; Muhonen, WW; Nahire, RR; Padi, SK; Reindl, K; Shabb, JB; Shrivastava, DK; Singh, RK | 1 |
| Behrman, SW; Chitkara, D; Mahato, RI; Mittal, A | 1 |
| Al-Ejeh, F; Biankin, AV; Brown, MP; Chou, A; Grimmond, SM; Kalimutho, M; Khanna, KK; Miranda, M; Nagrial, AM; Pajic, M; Shi, W | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Cui, J; Du, Y; Huang, S; Jia, Z; Jiang, W; Kong, X; Li, L; Li, Z; Wei, D; Xie, D; Xie, K | 1 |
| Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Frese, KK; Griffiths, JR; Jodrell, DI; Madhu, B; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Bekaii-Saab, T; Bloomston, M; Chen, CS; Chou, CC; Fang, CS; Kulp, SK; Lai, IL; Lai, PT; Mo, X; Shirley, LA; Yan, R | 1 |
| Borazanci, E; Von Hoff, DD | 1 |
| Chung, N; Park, SH; Sung, JH | 1 |
| Abou-Alfa, GK; Allen, PJ; Brennan, MF; Capanu, M; Coit, DG; DeMatteo, RP; DʼAngelica, M; Gerdes, H; Jarnagin, WR; Kingham, TP; Klimstra, DS; Kurtz, RC; LaValle, J; Lowery, MA; OʼReilly, EM; Perelshteyn, A; Reidy, DL; Schattner, M; Tang, LH; Winston, C | 1 |
| Aglietta, M; Bagalà, C; Barone, C; Cagnazzo, C; Colombi, F; Fly, KD; Gioeni, L; Huang, B; Leone, F; Miller, WH; Moore, MJ; Sawyer, MB; Wang, E | 1 |
| Infante, JR; Kasubhai, SM; Le, N; Li, CP; Liu, Y; Oh, DY; Park, JO; Redhu, S; Scheulen, ME; Somer, BG; Steplewski, K | 1 |
| Bang, S; Chung, MJ; Park, JY; Park, SW; Song, SY | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Ide, T; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, J; Noshiro, H | 1 |
| Katsuno, A; Matsushita, A; Nakamura, Y; Sumiyoshi, H; Uchida, E; Yamahatsu, K | 1 |
| Frödin, JE; Liljefors, M; Mellstedt, H; Mozaffari, F; Staff, C | 1 |
| Ikari, T; Ioka, T; Isayama, H; Ishii, H; Koike, K; Kwon, AH; Nakai, Y; Okusaka, T; Ozaka, M; Satoi, S; Shimokawa, T; Sho, M; Tanaka, M; Ueno, H; Yanagimoto, H | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Avan, A; Castellano, L; Fiuji, H; Frampton, AE; Funel, N; Galla, V; Giovannetti, E; Maftouh, M; Pelliccioni, S; Peters, GJ | 1 |
| Hazama, S; Hinoda, Y; Iida, M; Maeda, Y; Matsui, H; Oka, M; Sakai, K; Shindo, Y; Suehiro, Y; Suzuki, N; Ueno, T; Yamasaki, T; Yoshimura, K; Yoshino, S | 1 |
| Blum, H; Bruns, CJ; Camaj, P; Ellwart, JW; Ischenko, I; Jäckel, C; Jauch, KW; Krebs, S; Mysliwietz, J; Nelson, PJ; Niess, H; Renner, A; Zhao, Y | 1 |
| Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J | 1 |
| Kornmann, M; Liu, X; Ma, Y; Tian, X; Wang, F; Yang, Y | 1 |
| Bartsch, DK; Fendrich, V; Hudemann, C; Knoop, RF; Lauth, M; Plassmeier, L; Sparn, M; Waldmann, J | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Andrake, M; Astsaturov, I; Banina, E; Beeharry, N; Deacon, S; Egleston, BL; Hittle, J; Khazak, V; Peterson, JR; Skobeleva, N; Yen, TJ | 1 |
| Alishekevitz, D; Bril, R; Fremder, E; Gingis-Veltski, S; Hasnis, E; Karban, A; Raviv, Z; Shaked, Y; Voloshin, T | 1 |
| Boyella, R; Gottesman, S; Juneman, E; Khan, MF | 1 |
| Brunner, TB; Chu, KY; Hawkins, M; Mukherjee, S; Partridge, M; Wilson, JM | 1 |
| Choi, BI; Han, JK; Kim, H; Kim, JH; Kim, YJ; Lee, JY | 1 |
| Chen, B; Liu, LL; Lou, HZ; Pan, HM; Pan, Q; Sun, P; Weng, XC | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Bischoff, S; Dörken, B; Görner, M; Greten, TF; Heil, G; Lakner, V; Mölle, M; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Sinn, M; Stieler, JM | 1 |
| Cattel, L; Couvreur, P; Desmaële, D; Giraudo, E; Maione, F; Mura, S; Noiray, M; Stella, B; Valetti, S; Vauthier, C; Vergnaud, J | 1 |
| Cao, B; Li, Q; Wen, Z; Yan, H; Yuan, Z; Zhang, R | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Chen, ZX; Cheng, Z; Du, X; Hu, JK; Li, Y; Wang, YH; Wang, ZQ; Zhou, ZG | 1 |
| Barth, RJ; Colacchio, TA; Gardner, TB; Gordon, SR; Hessami, N; Klibansky, DA; Mody, K; Pipas, JM; Putra, J; Ripple, GH; Smith, KD; Suriawinata, AA; Tsapakos, MJ; Tsongalis, GJ; Zaki, B | 1 |
| Batra, SK; Dey, P; Ganti, AK; Ponnusamy, MP; Rachagani, S; Vaz, AP | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Gladkich, J; Gross, W; Haberkorn, U; Herr, I; Isayev, O; Liu, L; Mattern, J; Mollenhauer, M; Nwaeburu, CC; Rausch, V; Rückert, F; Schönsiegel, F; Zach, S; Zhang, Y | 1 |
| Andersson, R; Ansari, D; Nordh, S | 1 |
| Jeong, KS; Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ; Yoon, YB | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Fan, X; Jiang, H; Liu, Y; Mao, Z; Wang, X; Wang, Y; Zhang, J | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| Arakawa, H; Gong, J; Hayashi, K; Homma, S; Ikegami, M; Imazu, H; Ishidao, T; Ito, M; Kajihara, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Koyama, S; Misawa, T; Mori, M; Odahara, S; Ohkusa, T; Okamoto, M; Shimodaira, S; Sugiyama, H; Tajiri, H; Takakura, K; Toyama, Y; Tsukinaga, S; Uchiyama, K; Yanagisawa, S; Yoshizaki, S; Yusa, S | 1 |
| Brekken, RA; Carroll, KD; Cenik, BK; Hagopian, MM; Nugent, D; Ostapoff, KT; Rivera, LB; Topalovski, M; Wang, M; Xu, X; Ye, R | 1 |
| Guo, Z; Hu, H; Jiao, F; Jin, Z; Wang, L; Yuan, C | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Huber, K; Saif, MW; Yu, E | 1 |
| Peponi, E; Saif, MW; Syrigos, KN; Tourkantonis, IS | 1 |
| Kaddis, N; Saif, MW | 1 |
| Bhalla, A; Saif, MW | 1 |
| Daoud, V; Goodman, M; Saif, MW | 1 |
| Li, J; Saif, MW | 3 |
| DeNardo, DG; Goedegebuure, SP; Knolhoff, BL; Linehan, DC; Luo, J; Meyer, MA; Nywening, TM; Wang-Gillam, A; West, BL; Zhu, Y | 1 |
| Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P | 1 |
| de Sousa Cavalcante, L; Monteiro, G | 1 |
| Oettle, H | 2 |
| Barzi, A; Beckett, L; Burich, RA; Gong, IY; Holland, W; Hutchins, IM; Kim, EJ; Lara, PN; Lenz, HJ; Mack, P; Semrad, T; Snyder-Solis, L; Tanaka, M | 1 |
| Cao, B; Li, Q; Liu, W; Yan, H; Yang, Y; Zhen, H | 1 |
| Fuchs, C; Innocenti, F; Jiang, C; Kindler, HL; Mulcahy, MF; Niedzwiecki, D; O'Reilly, EM; Owzar, K; Van Loon, K; Venook, AP | 1 |
| Bekaii-Saab, TS; Ben-Josef, E; Dawson, LA; Griffith, KA; Herman, JM; Kim, EJ; Ringash, J; Serrano, PE; Wei, AC; Zalupski, MM | 1 |
| Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Erkan, M; Gündüz, U; Kleeff, J; Parsian, M; Ünsoy, G; Yalçin, S | 1 |
| Cheung, TT; Chiu, JW; Fan, ST; Leung, R; Pang, R; Poon, R; Wong, H; Yau, T | 1 |
| Doki, Y; Eguchi, H; Gotoh, N; Hama, N; Hasegawa, S; Ishii, H; Kawamoto, K; Kobayashi, S; Konno, M; Koseki, J; Mori, M; Nagano, H; Nishida, N; Nishimura, T; Nojima, H; Ohno, S; Tomimaru, Y; Wada, H; Yabuta, N | 1 |
| Burns, M; Cardenes, HR; Chiorean, EG; Howard, T; Khawaja, MR; Kleyman, S; Loehrer, PJ; Nakeeb, A; Yu, Z | 1 |
| Aggarwal, S; Alkharfy, KM; Baral, A; Chowdhury, S; Dutta, SK; Krishnaswamy, S; Mukhopadhyay, D; Pal, K; Pletnev, AA; Spaller, MR; Wang, E; Yadav, VK; Zhao, R | 1 |
| Chen, L; Luo, S; Zhang, M | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
| Gu, Y; Hu, B; Hu, H; Li, J; Qian, Y; Wang, G; Zhu, C | 1 |
| Chen, Y; Jiang, T; Jin, C; Mao, A; Sun, X | 1 |
| Bruchertseifer, F; Bryan, RA; Dadachova, E; Epstein, AL; Jandl, T; Jiang, Z; Koba, W; Morgenstern, A; Onyedika, C; Strauss, J | 1 |
| Held-Warmkessel, J | 1 |
| Addanki, S; Bollu, LR; Candelaria, NR; Dey, P; Fisher, WE; Gabbi, C; Gustafsson, JÅ; Hodges, SE; Issazadeh, MA; Ittmann, MM; Jonsson, PK; Karaboga, H; Lin, CY; Lin, JZ; Liu, K; McElhany, AL; Nguyen-Vu, T; Steffensen, KR; Su, F; Vedin, LL; Wu, W; Zheng, J | 1 |
| Asanuma, F; Atsuda, K; Suzuki, Y; Takeuchi, O; Takizawa-Hashimoto, A; Watanabe, Y; Yamada, Y; Yoneyama, H | 1 |
| Dong, Z; Qin, L; Zhang, JT | 2 |
| Bamezai, RN; Kumar, B; Manvati, S; Pandita, A; Singh, SK; Vaishnavi, S | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Cooper, AJ; Keshavarz, S; Lwaleed, BA; Rooprai, HK; Thani, NA | 1 |
| Abi-Jaoudeh, N; Avital, I; Beane, JD; Beresnev, T; Griffin, KF; Levy, EB; Pandalai, P; Rudloff, U; Shutack, Y; Webb, CC; Wood, B | 1 |
| Dia, VP; Gonzalez de Mejia, E; Johnson, JL; Wallig, M | 1 |
| Han, L; Li, W; Liu, J; Ma, J; Ma, Q; Reindl, KM; Wang, F; Wu, E; Wu, Z; Zhang, D | 1 |
| Bu, HQ; Huang, H; Jin, HM; Li, Y; Liu, DL; Zhao, JF | 1 |
| Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A | 1 |
| Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y | 1 |
| Asano, E; Funasaka, K; Goto, H; Hamaguchi, M; Hirooka, Y; Hyodo, T; Miyahara, R; Senga, T; Wong, M | 1 |
| Bechstein, WO; Brunner, TB; Bruns, C; Fietkau, R; Golcher, H; Grabenbauer, GG; Hohenberger, W; Jungnickel, H; Marti, L; Merkel, S; Meyer, T; Schreiber, S; Witzigmann, H | 1 |
| Alborzinia, H; Can, S; Cheng, X; Holenya, P; Ott, I; Rubbiani, R; Wölfl, S | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Distler, AM; Hill, EG; Lemasters, JJ; Manevich, Y; Mieyal, JJ; Nieminen, AL; Qanungo, S; Shaner, B; Townsend, DM; Uys, JD | 1 |
| Chao, YJ; Hsu, HP; Shan, YS; Sy, ED | 1 |
| Al-Wadei, HA; Al-Wadei, MH; Banerjee, J; Dagnon, K; Schuller, HM | 1 |
| Bouvet, M; Fujimura, K; Kaushal, S; Kelber, JA; Klemke, RL; Lowy, AM; Metildi, C; Strnadel, J; Wright, T | 1 |
| de la Fuente, M; Jones, MC; Marimuthu, P; Mirenska, A; Santander-Ortega, MJ; Schätzlein, A; Uchegbu, I | 1 |
| Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y | 1 |
| Andersson, R; Ansari, D; Bauden, MP; Ek, F; Hilmersson, KS; Olsson, R; Urey, C | 1 |
| Abel, EV; Balis, UG; Blau, JL; Craig, R; Greenson, JK; Griffith, KA; Khan, GN; Kim, EJ; Sahai, V; Simeone, DM; Takebe, N; Zalupski, MM | 1 |
| Chan, K; Coyle, D; Ko, YJ; Lam, H; Lien, K; Shah, K | 1 |
| Bachet, JB; Cros, J; Demetter, P; Fléjou, JF; Maréchal, R; Svrcek, M | 1 |
| Hong, WD; Huang, QK; Liu, Y; Sun, XC; Wu, JM | 1 |
| Li, HY; Li, N; Li, Q; Li, X; Shen, XH; Sun, HH; Wei, W | 1 |
| Blandino, G; Cordani, M; Di Agostino, S; Donadelli, M; Fiorini, C; Padroni, C | 1 |
| Bahra, M; Denkert, C; Dörken, B; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K | 2 |
| Du, W; Ke, QH; Lei, Y; Liang, G; Luo, F; Yang, JY; Zhou, SQ | 1 |
| De Toni, EN; Gallmeier, E; Göke, B; Guo, Y; Hocke, S; Kampmann, E; Ochs, S; Ziesch, A | 1 |
| Liu, GL; Luo, HY; Wang, DS; Wang, ZQ; Xu, RH; Zeng, ZL; Zhang, Y | 1 |
| George, TJ; Liu, C; Lu, Z; Ostrov, DA; Puszyk, WM; Robertson, KD; Zhao, X | 1 |
| Li, HY; Liao, Y; Mu, GG; Yu, HG; Zhang, LL | 1 |
| Alexander, DB; Fukamachi, K; Futakuchi, M; Hagiwara, Y; Hino, O; Iigo, M; Shibata, K; Suzui, M; Tsuda, H | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, YC; Shen, WC; Tsang, NM; Yang, TS | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Bouvet, M; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, AA | 1 |
| Fu, M; Huang, H; Wang, C; Xie, J; Yang, A; Zhang, W | 1 |
| Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
| Burkhart, C; Commane, M; Fleyshman, D; Garrigan, J; Gurova, KV; Kohrn, R; Kurbatov, V; Martello, L; Ramachandran, R; Toshkov, I | 1 |
| Lu, L; Xie, J; Yuan, J | 1 |
| Béjot, JL; Berthommé, H; Biollay, C; Buscail, L; Cordelier, P; Epstein, AL; Gayral, M; Hanoun, N; Lulka, H; Sèlves, J; Trempat, P; Vignolle-Vidoni, A | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Konishi, K; Marubashi, S; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K; Yoshioka, Y | 1 |
| Ferrari, M; Koay, EJ | 1 |
| Abbruzzese, JL; Baio, FE; Bhosale, PR; Chatterjee, D; Chen, R; Chen, Y; Court, L; Crane, CH; Cristini, V; Ferrari, M; Fleming, JB; Gottumukkala, VN; Javle, M; Kang, Y; Katz, MH; Koay, EJ; Lee, JE; Maitra, A; Ondari, A; Plunkett, W; Qayyum, A; Rozner, MA; Shen, H; Tamm, EP; Thomas, RM; Truty, MJ; Varadhachary, GR; Wang, H; Wolff, RA; Zhang, J | 1 |
| Billadeau, DD; Deng, ZH; Gomez, TS; Osborne, DG; Phillips-Krawczak, CA; Zhang, JS | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Caron, J; Couvreur, P; Desmaële, D; Maksimenko, A; Mougin, J | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Alkharfy, KM; Bhattacharya, S; Chari, ST; Dutta, SK; Elkhanany, A; Lau, JS; Mukhopadhyay, D; Pal, K; Patel, TC; Sanyal, A; Sharma, AK; Spaller, MR; Wang, E; Yan, IK | 1 |
| Kitanaka, C; Okada, M; Sato, A; Seino, M; Seino, S; Shibuya, K; Suzuki, S; Takeda, H; Yoshioka, T | 1 |
| Addington, C; Cartwright, C; Gagea, M; Kim, SJ; Kundra, V; Lee, HJ; Newman, RA; Pan, Y; Ravoori, MK; Rhea, P; Tan, L; Yang, P | 1 |
| Cardwell, J; Chatterjee, D; Fleming, JB; Kang, Y; Katz, MH; Li, SQ; Roife, D; Suzuki, R; Thomas, RM; Truty, MJ; Wang, H; Wang, Y; Zhang, R | 1 |
| Cress, AE; Dorr, RT; Landowski, TH; Patel, C; Patel, H; Pond, E; Pond, KW; Samulitis, BK; Wisner, L | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Jaidev, LR; Krishnan, UM; Sethuraman, S | 1 |
| Bold, RJ; Daylami, R; Muilenburg, DJ; Virudachalam, S | 1 |
| Butler, H; John, P; Saif, MW | 1 |
| Duchêne, B; Jonckheere, N; Tréhoux, S; Van Seuningen, I | 1 |
| Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE | 1 |
| Cai, QP; Feng, D; Huang, HJ; Wang, CM; Yang, DJ; Zhang, X | 1 |
| Chung, N; Kim, EJ; Park, SH; Sung, JH | 1 |
| Han, D; Jin, J; Kim, Y; Min, H; Yi, EC | 1 |
| Aloia, T; Balachandran, A; Conrad, C; Cooper, AB; Evans, DB; Fleming, JB; Fogelman, D; Garg, N; Holmes, HM; Katz, MH; Lee, JE; Ngo-Huang, A; Parker, N; Petzel, M; Slack, R; Varadhachary, G; Vauthey, JN | 1 |
| Awasthi, N; Brekken, RA; Hinz, S; Schwarz, MA; Schwarz, RE | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Huang, P; Ju, HQ; Wu, M; Yanaga, K; Zhuang, ZN | 1 |
| An, SG; Jang, AL; Kim, DU; Song, GA | 1 |
| Deng, Y; Li, J; Qin, S; Zhang, Z | 1 |
| Cordani, M; Donadelli, M; Fiorini, C; Gotte, G; Picone, D | 1 |
| Chang, DT; Columbo, LA; Dholakia, AS; Fisher, GA; Goodman, KA; Griffith, ME; Hacker-Prietz, A; Herman, JM; Iacobuzio-Donahue, CA; Koong, AC; Laheru, DA; O'Reilly, E; Pai, JS; Pawlik, TM; Raman, SP; Rosati, LM; Sugar, EA; Wild, AT; Wolfgang, CL; Zheng, L | 1 |
| Chen, J; Gao, S; Hao, J; Huang, C; Jia, L; Li, J; Qian, D; Ren, H; Wang, X; Xin, W; Yan, F; Zhao, T | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Naruge, D; Okano, N; Takasu, A | 1 |
| Lee, JK; Lee, KH; Lee, KT; Rhee, JC; Yang, MH; Yang, S | 1 |
| Hirano, Y; Homma, S; Ito, Z; Kajihara, M; Kan, S; Kobayashi, H; Koido, S; Matsumoto, Y; Misawa, T; Mori, M; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Takami, S; Yoshida, K | 1 |
| Bhattacharjee, V; Yen, TJ; Zhou, Y | 1 |
| Boroujerdi, M; Kohan, HG | 1 |
| Cafferata, EG; Curiel, DT; Gidekel, M; Haab, GA; Podhajcer, OL; Rotondaro, C; Salvatierra, E; Sganga, L; Weber, HL; Werbajh, S | 1 |
| Bendell, J; Burke, W; Burris, H; Chau, I; Fielding, A; Hochster, H; Middleton, MR; O'Reilly, EM | 1 |
| Chiorean, EG; Ferrara, S; Ganju, V; Goldstein, D; Hingorani, SR; Infante, JR; Penenberg, DN; Ramanathan, RK; Romano, A; Scheithauer, W; Tabernero, J; Von Hoff, DD; Weekes, C | 1 |
| Bridges, E; Harris, AL | 1 |
| Alrawashdeh, W; Cereser, B; Crnogorac-Jurcevic, T; Demircioglu, F; Elia, G; Ghazaly, E; Hagemann, T; Hodivala-Dilke, KM; Kocher, HM; McDonald, S; Scudamore, CL; Stratford, MR; Wong, PP | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Marubashi, S; Mori, M; Nagano, H; Ogawa, K; Satoh, T; Takehara, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Gao, HQ; Liu, P; Yang, YM; Zhuang, Y | 1 |
| Guan, J; Liang, Z; Liu, T; Ren, X; Shi, X; Wang, L; Wu, H; Zhang, H | 1 |
| Azevedo, S; Bach, BA; Bodoky, G; Carrato, A; Fuchs, CS; Gansert, JL; Haddad, V; Ikeda, M; Lipton, LR; Loberg, R; Melichar, B; Moore, MJ; Nemecek, R; Ohkawa, S; Okusaka, T; Peeters, M; Riess, H; Świeboda-Sadlej, A; Szczylik, C; Tjulandin, SA; Van Cutsem, E; Van Laethem, JL | 1 |
| Bae, KH; Han, BS; Jung, H; Kim, DS; Kim, JM; Kim, JS; Kim, WK; Lee, HJ; Lee, SC; Oh, KJ; Park, SG; Seo, YS | 1 |
| Aiura, K; Fujita, T; Hamamoto, Y; Higuchi, H; Itano, O; Kawakami, Y; Kitagawa, Y; Kitago, M; Matsuda, T; Mayanagi, S; Okamoto, M; Sakurai, T; Sunamura, M; Taguchi, J; Takaishi, H; Takeuchi, H | 1 |
| Hirata, T; Ishikawa, O; Kawaguchi, Y; Konishi, K; Nishiyama, K; Ogawa, K; Ohigashi, H; Otani, K; Takahashi, H; Teshima, T; Tomita, Y | 1 |
| Choi, HJ; Han, Z; Hwang, YS; Je, S; Kang, D; Kang, S; Kim, JH; Kim, SY; Song, JJ | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 1 |
| He, C; Lin, W; Liu, D; Lu, K; Poon, C | 1 |
| Cheng, L; Fang, B; Ma, C; Ma, J; Pang, H; Shi, Y; Wang, H; Wang, Z; Xia, J; Yin, B; Zeng, F | 1 |
| El-Maraghi, RH; Goldstein, D; Hammel, P; Heinemann, V; Kunzmann, V; Lu, B; Penenberg, DN; Romano, A; Sastre, J; Scheithauer, W; Siena, S; Tabernero, J; Teixeira, L; Tortora, G; Van Laethem, JL; Von Hoff, DD; Young, R | 1 |
| Baba, T; Furukawa, K; Li, YY; Matsugo, S; Mukaida, N; Sasaki, S; Song, Y; Tanabe, Y | 1 |
| Sui, YN; Wang, F; Wang, LS; Wang, YH; Yan, K; Zhou, JH | 1 |
| Boku, N; Bycott, P; Fujii, Y; Furuse, J; Ioka, T; Kamei, Y; Namazu, K; Ohkawa, S; Okusaka, T; Sawaki, A; Takahashi, S; Umeyama, Y | 1 |
| Erkan, M; Esposito, I; Friess, H; Hong, X; Jäger, C; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Valkovska, N; Wu, W | 1 |
| Dredge, K; Hammond, E; Jung, DB; Jung, JH; Kim, B; Kim, EO; Kim, J; Kim, SH; Mukhopadhyay, D; Shridhar, V; Wang, E; Yun, M | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Patel, M; Shrotriya, S; Somasagara, RR | 1 |
| Cao, F; Cui, Y; Li, F; Li, J; Liu, S; Sun, H | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Aboagye, EO; Barwick, T; Challapalli, A; Howell, EC; Mauri, F; Maxwell, RJ; Merchant, S; Pearson, RA; Sharma, R; Sumpter, K | 1 |
| Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A | 1 |
| Bidaut, G; Borge, L; Calvo, E; Garcia, S; Gayet, O; Gouirand, V; Guillaumond, F; Guimaraes, C; Iovanna, JL; Lac, S; Lavaut, MN; Loncle, C; Nigri, J; Olivares, O; Ouaissi, M; Pinault, M; Roques, J; Servais, S; Staels, B; Tailleux, A; Tomasini, R; Vasseur, S | 1 |
| Lee, KH | 1 |
| Chen, J; Hao, J; Li, F; Li, Y; Nie, G; Ren, H; Wang, H; Zhao, X | 1 |
| Bajor, DL; Byrne, KT; Clendenin, C; Evans, RA; Furth, EE; Meyer, AR; Odorizzi, PM; Stanger, BZ; Vonderheide, RH; Wherry, EJ; Winograd, R | 1 |
| Gao, S; Hua, YQ; Liu, LM; Pan, Y | 1 |
| O'Reilly, EM; Yang, A | 1 |
| Funazaki, H; Ichida, Y; Ikeda, M; Kobayashi, M; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Saitoh, S; Shimizu, S; Shinohara, A; Takahashi, H; Takahashi, K | 1 |
| Buyse, M; Ding, K; Parulekar, WR; Péron, J; Roche, L; Roy, P | 1 |
| Fujiwara, Y; Futagawa, Y; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Cioffi, M; Costello, E; Erkan, M; Greenhalf, W; Heeschen, C; Hidalgo, M; Kleeff, J; Sainz, B; Trabulo, S | 1 |
| Bansal, SS; Celia, C; Cosco, D; Ferrari, M; Fresta, M; Kirui, DK; Molinaro, R; Shen, H | 1 |
| Chen, H; Chen, L; Chen, Z; Liu, L; Meng, Z; Pan, Y; Shen, Y; Xu, L | 1 |
| Buettner, GR; Button, A; Cieslak, JA; Cullen, JJ; Doskey, CM; Du, J; Rawal, M; Schroeder, SR; Strother, RK; Wagner, BA | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Ohashi, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Deguchi, S; Goto, W; Inoue, T; Ishikawa, A; Kanazawa, A; Kotsuka, M; Kurihara, S; Mori, Y; Nakajima, T; Nishiguchi, Y; Ohira, G; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tashima, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y; Yoshii, M | 1 |
| Ishii, J; Kaneko, H; Katagiri, T; Koda, T; Kubota, Y; Maeda, T; Otsuka, Y; Shibuya, K; Tamura, A; Tsuchiya, M | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Osawa, S; Sawada, S; Shibuya, K; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Aisu, Y; Andoh, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Abe, T; Egawa, S; Fukase, K; Hayashi, H; Karasawa, H; Katayose, Y; Kawaguchi, K; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naito, T; Nakagawa, K; Okada, R; Okada, T; Sakata, N; Taniguchi, H; Unno, M; Yabuuchi, S; Yoshida, H | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Nakayama, A; Ohta, T; Shoji, M; Tajima, H; Takamura, H | 1 |
| Fukui, H; Ito, M; Maegawa, Y; Miyoshi, K; Nakamura, M; Suemura, S; Tanaka, E; Tatsumi, O; Terabe, F; Ueda, T | 1 |
| Hirai, K; Igarashi, T; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yamazaki, H; Yokoo, H; Yoshinari, D | 1 |
| Bauer, C; Bauernfeind, F; Dauer, M; Duewell, P; Endres, S; Hees, C; Lehr, HA; Mak'Anyengo, R; Noessner, E; Schnurr, M; Sterzik, A; Trauzold, A; Wank, R | 1 |
| Du, Q; Han, C; Tu, M; Wang, Q; Xu, D; Xu, L; Zhang, J; Zhu, Y | 1 |
| Collins, DC; Morris, PG | 1 |
| Chang, CH; Ji, Z; Liu, H; Liu, X; Meng, H; Nel, AE; Situ, A; Wang, M; Wu, B | 1 |
| Basso, SM; Bidoli, E; Foltran, L; Lo Re, G; Lumachi, F; Santeufemia, DA | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Du, Z; He, X; Li, Q; Tang, R; Wen, F; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Jiang, Z; Li, Y; Liu, G; Sun, J; Zhang, L | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A | 1 |
| Chen, D; Hu, J; Huang, W; Li, N; Wan, Z; Wang, L; Xue, P; Yang, H; Zhu, L | 1 |
| Duconseil, P; Dusetti, N; Garcia, S; Gasmi, M; Gayet, O; Gilabert, M; Iovanna, J; Loncle, C; Lopez-Millan, MB; Molejon, MI; Moutardier, V; Ouaissi, M; Poizat, F; Tellechea, JI; Turrini, O | 1 |
| Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H | 1 |
| Bain, BJ; Erblich, T; Hill, PD; Tomlinson, J | 1 |
| Bang, S; Chang, JS; Chung, JB; Chung, MJ; Kang, H; Oh, TG; Park, JY; Park, SW; Seong, J; Song, SY | 1 |
| Ettrich, TJ; Perkhofer, L; Seufferlein, T | 1 |
| Iida, M; Miyazawa, H; Nanjo, H; Shibata, S; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshida, M; Yoshioka, M; Yoshioka, T | 1 |
| Katoh, M; Kubota, K; Shimizu, T; Shimoda, M | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Akiyama, S; Chijiiwa, K; Furukawa, T; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Pastor-Anglada, M; Pérez-Torras, S; Shinsato, Y; Tabata, S; Takahashi, H; Tsujikawa, K; Yamada, K; Yamamoto, M; Yasuo, T; Zhang, S | 1 |
| Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gara, RK; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N; Zhao, H | 1 |
| Bamezai, RN; Manvati, S; Pandita, A; Singh, SK; Vaishnavi, S | 1 |
| Oon, CE; Östman, A; Prakash, J; Strell, C; Yeong, KY | 1 |
| Cheung, WY; Gill, S; Ho, M; Lim, HJ; Peixoto, RD; Renouf, DJ; Ruan, JY | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Madnick, DL; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Fortunato, F; Giese, NA; Gladkich, J; Gross, W; Hackert, T; Herr, I; Hinz, U; Liu, L; Ryschich, E; Strobel, O; Zhang, Y | 1 |
| An, Y; Ding, F; Gao, Q; Liang, C; Wang, L; Yuan, C; Zhang, D; Zhang, H | 1 |
| Kamada, T; Kamijo, T; Sai, S; Shirai, T; Vares, G; Wakai, T; Yamada, S | 1 |
| Kamada, Y; Minehira, T; Miyoshi, E; Nakayama, K; Sobajima, T; Takamatsu, S; Terao, N | 1 |
| Motoi, F; Unno, M | 1 |
| Shimizu, S | 1 |
| Acin, Y; Atkins, J; Demarchi, M; Deplanque, G; Dubreuil, P; Flynn, P; Hammel, P; Hebbar, M; Hermine, O; Mansfield, CD; Melichar, B; Moussy, A; Moyé, L; Nowara, E; Piquemal, D; Ritter, D | 1 |
| Baron, B; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Wang, Y | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Petrelli, F | 1 |
| Faure, R; Forestier, J; Hubault, M; Lombard-Bohas, C; Pivot, C; Walter, T | 1 |
| Boku, N; Fukutomi, A; Furukawa, M; Ikeda, M; Ishii, H; Maguchi, H; Miyazawa, M; Mizuno, N; Nishio, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Tani, M; Togashi, Y; Tsunoda, T; Ueno, H; Yamao, K; Yamaue, H | 1 |
| Amano, M; Asada, H; Ikeda, F; Kato, H; Kinugasa, H; Kuwaki, K; Miura, Y; Miyahara, K; Morimoto, Y; Nakahara, T; Nakamura, S; Nishimura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Bobustuc, GC; Frick, J; Konduri, SD; Patel, A; Srivenugopal, KS; Thompson, M; Weese, J | 1 |
| Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
| Chen, D; Dong, X; Hao, F; Liu, Z; Lu, X; Ni, G; Wang, M | 1 |
| Abeni, C; Aroldi, F; Bertocchi, P; Di Biasi, B; Meriggi, F; Ogliosi, C; Rizzi, A; Rosso, E; Rota, L; Savelli, G; Zaniboni, A | 1 |
| Brandes, F; Geissler, EK; Lang, SA; Redekopf, J; Schlitt, HJ; Schmidt, K; Wagner, C | 1 |
| Bouvet, M; Hoffman, RM | 1 |
| Aicher, A; Cioffi, M; Dorado, J; Hahn, S; Heeschen, C; Hidalgo, M; Lonardo, E; Miranda-Lorenzo, I; Ramirez, JC; Reis Vieira, C; Sainz, B; Sanchez-Ripoll, Y; Trabulo, SM | 1 |
| Beatty, GL; Clendenin, C; Evans, RA; Gladney, WL; Guirnalda, PD; Knoblock, DM; Lee, JW; Long, KB; Luque, SL; Vonderheide, RH; Winograd, R | 1 |
| Chen, H; Chen, R; Fu, Z; Gao, W; Li, H; Li, W; Li, Z; Liu, Y; Song, Y; Wang, Y; Ye, H; Zeng, J; Zhao, X; Zheng, S; Zhou, Q; Zhou, Y; Zhuang, B | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Rieken, S; Springfeld, C; Werner, J | 1 |
| Duchêne, B; Jonckheere, N; Skrypek, N; Van Seuningen, I; Vasseur, R; Vincent, A | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Bahary, N; Bao, P; Bartlett, DL; Boone, BA; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Moser, AJ; Normolle, DP; Singhi, AD; Wu, WC; Zeh, HJ; Zureikat, AH | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Cheng, S; Eliaz, I; McClintick, JN; Sandusky, GE; Sliva, D; Swanson, K | 1 |
| Assenat, E; Azria, D; Bibeau, F; Bleuse, JP; Crapez, E; Delord, JP; Guimbaud, R; Larbouret, C; Mollevi, C; Pèlegrin, A; Portales, F; Robert, B; Samalin, E; Smith, D; Tubiana-Mathieu, N; Ychou, M | 1 |
| Chatzitheoklitos, E; Lambropoulou, M; Pitiakoudis, M; Polychronidis, A; Romanidis, K; Simopoulos, C; Tsaroucha, AK; Tsiaousidou, A | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Akahori, T; Hasegawa, M; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Ohbayashi, C; Sho, M; Tamamoto, T; Tanaka, T | 1 |
| Bahra, M; Boas-Knoop, S; Denecke, T; Klein, F; Neuhaus, P; Pelzer, U; Pratschke, J; Puhl, G; Pullankavumkal, JR; Riess, H; Sinn, M | 1 |
| Ampie, L; Bade, NA; Hartley, ML; Marshall, JL; Prins, PA | 1 |
| Coppola, D; Crochiere, M; Husain, K; Kashyap, T; Kazim, S; Landesman, Y; Mahipal, A; Malafa, MP; Rashal, T; Sullivan, DM; Zibadi, S | 1 |
| Honma, Y; Kato, N; Miyake, T; Suzumiya, J; Urano, T | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Izzedine, H; Perazella, MA | 1 |
| Bria, E; Cognetti, F; Garufi, C; Melisi, D; Milella, M; Nuzzo, C; Reni, M; Scarpa, A; Sperduti, I; Tortora, G; Vaccaro, V; Vari, S | 1 |
| Erlichman, C; Foster, NR; Kim, GP; McWilliams, RR; Pedersen, KS; Wang-Gillam, A | 1 |
| Abe, H; Baghdadi, M; Higuchi, K; Hirano, S; Inoko, K; Nakamura, T; Nakanishi, S; Sato, S; Seino, K; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T; Usui, Y; Wada, H | 1 |
| Kashino, G; Kobashigawa, S; Mori, H; Morikawa, K | 1 |
| Aishima, S; Baba, H; Harimoto, N; Hualin, W; Itoh, S; Maehara, Y; Shirabe, K; Takeishi, K; Uchihara, T; Yamashita, Y; Yoshizumi, T | 1 |
| Dobbelstein, M; Li, Y; Saini, P | 1 |
| Arora, S; Bhardwaj, A; Carter, JE; Khan, MA; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T | 1 |
| Gao, C; Han, B; Li, Y; Meng, L; Shan, D; Wu, X; Yan, Y | 1 |
| Benedit, P; Carrato, A; García, P; Gostkorzewicz, J; López, R; Macarulla, T; Pérez-Alcántara, F; Rivera, F; Sastre, J | 1 |
| Tempero, MA | 1 |
| Ding, Q; Matsubara, S; Miyazaki, Y; Takao, S; Tsukasa, K; Yoshimitsu, M | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Anota, A; Artru, P; Bonnetain, F; Dubreuil, O; Dupont-Gossart, AC; Fein, F; Gauthier, M; Lecomte, T; Mouillet, G; Paget-Bailly, S; Taieb, J; Trouilloud, I; Zaanan, A | 1 |
| Basson, MD; Ito, H; Ono, H | 2 |
| Lin, ZQ; Luo, RJ; Wu, W; Xia, Q; Xue, P | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Bujanda, L; Er, TK; Herreros-Villanueva, M | 1 |
| Chao, Y; Chen, MH; Hung, YP; Kuo, CY; Lee, WP; Li, CP; Luo, JC; Shyr, YM; Wang, JP; Wu, CY; Wu, YY; Yeh, YC | 1 |
| Bahra, M; Bläker, H; Denkert, C; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Bruynzeel, AM; Giovannetti, E; Jacobs, MA; Kazemier, G; Meijer, OW; Meijerink, MR; van der Vliet, HJ; van Tienhoven, G; van Zweeden, AA; Verheul, HM; Wilmink, JW | 1 |
| Alexandrow, MG; Bryant, VL; Elias, RM; McCarthy, SM; Yeatman, TJ | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Anderson, K; Au, A; Bailey, P; Biankin, A; Carter, CR; Chang, D; Erler, JT; Evans, TR; Jamieson, NB; Karim, S; Leach, J; Marais, R; McGarry, L; McGhee, E; McKay, C; Miller, BW; Morton, JP; Oien, K; Pinese, M; Sansom, OJ; Saturno, G; Shanks, E; Springer, C; Steele, C; Timpson, P | 1 |
| Aisner, DL; Bajaj, R; Baranda, JC; Bathini, V; Berlin, J; Boles, J; Cho, JK; Cohen, DJ; Cohen, SJ; Coveler, L; Cusnir, M; Fanta, P; Fehrenbacher, L; Gomes, CL; Granfortuna, J; Jimeno, A; Ma, WW; Maguire, R; Maniar, M; McRee, AJ; Menter, AR; Messersmith, WA; Nazemzadeh, R; O'Neil, BH; Olowokure, OO; Phillip, P; Radford, J; Rarick, M; Scott, AJ; Tejani, MA; Wilhelm, F | 1 |
| Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T | 1 |
| Hong, SM; Jang, JJ; Jung, Y; Kang, MG; Kim, DJ; Kim, JA; Kim, MJ; Koo, H; Lee, KB; Park, KC; Park, YS; Yeom, YI; You, YM | 1 |
| Li, HY; Li, YY; Liang, C; Wang, Z; Yu, BH; Zhang, F | 1 |
| Belfiore, G; Belfiore, MP; De Lucia, G; Di Gennaro, TL; Gallo, C; Ianniello, GP; Marsicano, C; Romano, F; Ronza, FM | 1 |
| Bendaoud, S; de Mestier, L; Hammel, P; Hentic, O; Lekhal, C; Neuzillet, C | 1 |
| Hirano, K; Nagata, T; Okumura, T; Shimada, Y; Tsukada, K; Watanabe, T; Yamaguchi, T | 1 |
| Akada, J; Kitagawa, T; Kuramitsu, Y; Nakamura, K; Tokuda, K; Tokunaga, M; Wang, Y | 1 |
| Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
| Fulp, WJ; Jump, H; Kim, R; Mahipal, A; Shibata, D; Siegel, EM; Springett, GM; Suleiman, Y | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| de Prado-Otero, DS; Poves-Alvarez, R; Trueba-Arguiñarena, FJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K | 1 |
| Boyce, RJ; Boyle, RG; Courtin, A; Jodrell, DI; Koh, SB; Richards, FM | 1 |
| Coffey, M; Gill, G; Mahalingam, D; Nawrocki, ST; Nuovo, G; Patel, S; Selvaggi, G | 1 |
| Eagle, T; Fang, CX; Feng, M; Hart, D; Kimmel, GW; Lawrence, TS; Minter, RM; Schipper, MJ; Shen, J; Simeone, DM; Vainshtein, J; Zalupski, MM; Zhou, J | 1 |
| Lv, W; Wu, XZ; Yan, T; Zhang, JH; Zhang, WL | 1 |
| Brachmann, CB; Heise, C; Hidalgo, M; Illei, P; Lopez-Casas, PP; Lopez-Rios, F; Menendez, C; Musteanu, M; Pierce, D; Plaza, C; Romano, A; Tabernero, J; Von Hoff, DD; Wei, X | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Akiyama, T; Doi, T; Hirano, S; Hirata, K; Homma, H; Kogawa, K; Mezawa, S; Morii, K; Ohi, M; Takahashi, M; Takeuchi, M; Tanaka, S | 1 |
| D'Aronzo, M; Graziano, P; Mazza, T; Panebianco, C; Pazienza, V; Pereira, SP; Saracino, C; Vinciguerra, M | 1 |
| Bianco, T; Borgida, A; Bristow, RG; Cao, P; Cheung, M; Gallinger, S; Hedley, DW; Holter, S; Ibrahimov, E; Kumareswaran, R; Lohse, I; Pintilie, M; Tsao, MS | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Cieslak, JA; Cullen, JJ | 1 |
| Humm, JL; Kramer, RM; Russell, J | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Aguilar-Saavedra, JR; Beane, JD; Crean, CD; Dumas, RP; Matos, J; Schmidt, CM; Suvannasankha, A; Waters, JA; Yip-Schneider, M | 1 |
| Bai, X; Chen, BW; Chen, W; Hu, L; Liang, C; Liang, T; Shen, J; Wen, L; Xue, F; Zhi, X; Zhou, Y | 1 |
| Arshad, A; Cooke, J; Dennison, A; Isherwood, J; Mann, C; Metcalfe, M; Morgan, B; Pollard, C; Runau, F; Steward, W | 1 |
| Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K | 1 |
| Cheung, SS; Hasman, D; Ou, D; Tai, J; Warnock, GL | 1 |
| Fillat, C; José, A; Maliandi, MV; Mato-Berciano, A; Roué, G; Sobrevals, L | 1 |
| Amini, M; Azizi, M; Daman, Z; Gilani, K; Montazeri, H; Ostad, SN; Rezaie, F | 1 |
| Goodstal, S; Hagemann, T; Hartley, JA; Hochhauser, D; Li Causi, E; Rodriguez-Justo, M; Vena, F | 1 |
| Bielli, P; Calabretta, S; Capurso, G; Fave, GD; Fendrich, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| Liu, F; Ouyang, HQ; Pan, ZY; Xie, GR; Yan, ZC | 1 |
| Gall, TM; Jiao, LR; Tsakok, M; Wasan, H | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS | 1 |
| Jusko, WJ; Straubinger, RM; Zhu, X | 1 |
| Husain, K; Kim, R; Malafa, M; Sebti, S; Yamauchi, T | 1 |
| Aoyama, T; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Morimoto, M; Morinaga, S; Murakawa, M; Shiozawa, M; Ueno, M; Yamaoku, K | 1 |
| Beesetty, Y; Caprioli, R; Castellanos, JA; Chen, X; Merchant, NB; Moses, HL; Nagathihalli, NS; Reyzer, ML; Shi, C; Skala, MC; Walsh, AJ | 1 |
| Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A | 1 |
| Ding, YC; Huang, T; Luo, SX; Ma, C; Meng, B; Wang, Q; Yu, W | 1 |
| Abe, T; Kamiie, J; Kawaguchi, K; Motoi, F; Ohmine, K; Ohtsuka, H; Ohtsuki, S; Terasaki, T; Unno, M | 1 |
| Chen, B; Tang, JY; Tang, QH; Wang, XJ; Xu, M; Xu, MZ; Zhang, H | 1 |
| Cao, C; Luo, J; Mo, W; Ran, Y; Sun, L; Yang, Z | 1 |
| Abakar-Mahamat, A; André, T; Arsene, D; Ciccolini, J; Dahan, L; Deplanque, G; Desramé, J; Fein, F; François, E; Gagnière, J; Guerin-Meyer, V; Guillet, P; Guimbaud, R; Lecomte, T; Legoux, JL; Lepage, C; Montérymard, C; Seitz, JF; Serdjebi, C; Volet, J | 1 |
| Li, YY; Qian, KQ; Tu, C; Wang, JY; Zheng, F | 1 |
| Burki, M; Cohen, SJ; Egleston, B; Hoffman, JP; Meyer, JE; Shaikh, T; Wang, LS | 1 |
| Bi, Z; Chen, C; Chen, R; Fan, X; Li, D; Li, Z; Liu, Y; Zhou, Y | 1 |
| Arai, T; Ishiwata, T; Matsuda, Y; Ushijima, T; Yamashita, S; Yoshimura, H | 1 |
| Andersson, R; Ansari, D; Sasor, A; Vaz, J | 1 |
| Chen, M; Ding, XW; Huang, SL; Lv, Y; Shen, SS; Zhang, S; Zhang, XQ; Zou, XP | 1 |
| Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA | 1 |
| Akahori, T; Kawaguchi, C; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Sho, M; Tanaka, T; Yasuda, S | 1 |
| Cui, L; Dang, S; Fan, X; Lv, L; Ma, X; Mao, Z; Qu, J; Wang, X; Zhang, J | 1 |
| Dosch, JS; Rehemtulla, A; Sebolt-Leopold, JS; Shettigar, A; Ziemke, EK | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| Ryu, JK | 1 |
| Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X | 1 |
| Geyer, AI; Kelly, DW; O'Reilly, EM; Sahin, IH | 1 |
| Guo, Q; Qin, W | 1 |
| El-Rayes, BF; Murata, T; Shoji, M; Yamaguchi, M | 1 |
| Gong, FR; Li, W; Liu, ZY; Shen, M; Tao, M; Wang, WJ; Wu, MY; Zhi, Q | 1 |
| Du, F; Huang, J; Liu, S; Lu, W; Meng, H; Xu, Y; Yu, J | 1 |
| Crowder, C; Hamner, JB; Singh, G; White, M | 1 |
| Behrns, KE; Delitto, D; George, TJ; Gonzalo, DH; Graves, CL; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Moldawer, LL; Perez, C; Pham, K; Thomas, RM; Trevino, JG; Wallet, SM | 1 |
| Bian, Q; Hu, XG; Jin, G; Jing, W; Li, G; Liu, AA; Liu, R; Shao, CH; Song, B; Zhang, YJ; Zhou, YQ | 1 |
| Artyukhin, AB; Brekken, RA; Christie, AL; Cruz, VH; Hale, MA; Heath, BR; Kollipara, RK; Lorens, JB; Ocal, O; Pashkov, V; Swift, GH; Tsoulfas, P; Wilkie, TM; Zolghadri, Y | 1 |
| Bai, L; Chen, LZ; Chiao, PJ; Deng, W; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zeng, JB | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Ahmed, AK; Duncan, MD; Fushida, S; Harmon, JW; Kamigaki, T; Kitagawa, H; Makino, I; Miki, K; Miyashita, T; Nakagawara, H; Ohta, T; Tajima, H; Takamura, H | 1 |
| Bazhin, AV; Brecht, R; Fritz, J; Karakhanova, S; Nachtigall, I; Werner, J | 1 |
| Agostoni, V; Anand, R; Couvreur, P; Gref, R; Lampropoulou, M; Maksimenko, A; Monti, S; Rodriguez-Ruiz, V; Yannakopoulou, K | 1 |
| Eils, R; Giese, N; Krammer, PH; Lavrik, IN; Pietkiewicz, S | 1 |
| Chiu, TJ; Hou, YC; Shan, YS; Tung, HL; Wang, HC; Yang, MC | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H | 1 |
| Bode, AM; Byun, S; Cho, YY; Dong, Z; Farrand, L; Jung, SK; Kwon, YJ; Lee, E; Lee, HJ; Lee, J; Lee, KW; Lee, SY; Shin, SH; Sin, HS; Tsang, BK; Um, SJ; Zhang, C | 1 |
| Andersson, R; Ansari, D; Kölby, D; Sasor, A; Thilén, J | 1 |
| Chen, Y; Han, H; Ji, J; Jin, Q; Wang, Y | 1 |
| Craven, KE; Gore, J; Korc, M; Palam, LR; Wilson, JL | 1 |
| Fujiwara, K; Hiraoka, K; Nagase, H; Nakamura, M; Ozaki, T; Sang, M; Shimozato, O; Shinohara, K; Sugimoto, H; Yoda, H | 1 |
| Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Alessandri, G; Bondiolotti, G; Bonomi, A; Cavicchini, L; Ceserani, V; Ciusani, E; Coccè, V; Dossena, M; Dugnani, E; Parati, E; Pascucci, L; Pessina, A; Piemonti, L; Piovani, G; Sisto, F; Sordi, V | 1 |
| Choi, EK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Lee, DH; Lee, EY; Lee, JS; Lee, WK; Moon, JH; Park, SJ; Shin, JS; Shin, YJ | 1 |
| Arakawa, H; Ito, Z; Kajihara, M; Kanai, T; Kobayashi, H; Koido, S; Matsumoto, Y; Odahara, S; Ohkusa, T; Okamoto, M; Saito, K; Sugiyama, H; Sumiyama, K; Takakura, K; Takami, S; Tsukinaga, S; Uchiyama, K | 1 |
| Alejandre, MJ; Delgado, JR; Linares, A; Palomino-Morales, RJ; Perales, S; Torres, C | 1 |
| Li, CZ; Liu, Z; Song, Z; Sun, FL; Sun, J; Sun, JZ; Xu, LY | 1 |
| Aguilar, M; Chiao, PJ; Fan, X; Fleming, JB; Fu, J; Gocho, T; Iida, T; Iwakura, Y; Ju, HQ; Lee, H; Li, H; Li, M; Li, Z; Ling, J; Melisi, D; Wu, M; Xu, K; Zhou, H; Zhuang, Z | 1 |
| Arrowsmith, C; BeGora, M; Cleary, S; Connor, AA; Crawford, HC; Gallinger, S; Holtzinger, A; Huang, L; Jagan, I; Kalloger, SE; Keller, G; Lohse, I; Muthuswamy, LB; Muthuswamy, SK; Ngai, N; Nostro, C; Renouf, DJ; Roehrl, M; Schaeffer, DF; Tsao, MS; Wang, R | 1 |
| Baron, B; Kitagawa, T; Kuramitsu, Y; Tokuda, K; Tokunaga, M | 1 |
| Hirajima, S; Ichikawa, D; Ikoma, H; Imamura, T; Kawaguchi, T; Komatsu, S; Konishi, H; Miyamae, M; Morimura, R; Ochiai, T; Ohashi, T; Okajima, W; Okamoto, K; Otsuji, E; Shiozaki, A; Taniguchi, H | 1 |
| Cao, C; Chen, J; Kuang, M; Tang, C; Xu, W; Zhang, X | 1 |
| Lariño Noia, J | 1 |
| Bahary, N; Catenacci, DV; Cohen, D; de Sauvage, FJ; Henderson, L; Horiba, MN; Junttila, MR; Karrison, T; Kindler, HL; Kozloff, M; Kumar, P; Lenz, HJ; Marsh, R; Nattam, SR; Rajdev, L; Salgia, R; Sleckman, B; Stadler, WM; Stiff, P; Takebe, N; Wade, J; Wallace, J; Wang, X; Xu, P | 1 |
| Abrams, RA; Blazeby, JM; Bridges, S; Bridgewater, J; Crosby, T; Dutton, P; Falk, S; Griffiths, G; Hurt, CN; Johnson, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Staffurth, J | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Ishii, M; Kitamura, K; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Shimizu, S; Yoneyama, K; Yoshida, H | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Dong, Y; Li, D; Li, H; Tian, G; Wang, L; Yuan, Y | 1 |
| Chiarelli, M; Cioffi, U; De Simone, M; Gabrielli, F; Gerosa, M; Guttadauro, A; Marando, A | 1 |
| Chen, N; Cui, J; Guo, R; Hu, JF; Jin, H; Li, W; Wang, G; Wang, H; Yin, H | 1 |
| Davis, MA; Karnak, D; Kausar, T; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Schreiber, JS; Zhao, L | 1 |
| Di, Y; Fu, D; He, H; Jin, C; Li, H; Lu, W; Pu, X; Song, Y; Xie, C; Yu, X | 1 |
| Al Yaghchi, C; Alusi, G; Lemoine, NR; Wang, Y; Zhang, Z | 1 |
| Ando, Y; Ebata, T; Fujita, K; Maeda, O; Mitsuma, A; Nagino, M; Sasaki, Y; Shibata, T; Shimokata, T | 1 |
| Al-Batran, SE; Kullmann, F; Kunzmann, V; Oettle, H; Plentz, R; Riess, H; Siveke, J; Springfeld, C; Vogel, A | 1 |
| Dennison, AR; Garcea, G; Haqq, J; Howells, LM | 1 |
| Jusko, WJ; Koch, G; Miao, X; Straubinger, RM | 1 |
| Dhayat, SA; Haier, J; Hummel, R; Mardin, WA; Matuszcak, C; Mees, ST; Seggewiß, J; Senninger, N; Ströse, AJ | 1 |
| Chen, Y; Han, H; Ji, J; Jin, Q; Li, Z; Wang, H; Wang, Y | 1 |
| Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Kumar, V; Mahato, RI; Mondal, G; Shukla, SK; Singh, PK | 1 |
| Li, B; Shen, ZT; Wang, L; Wu, XH; Zhu, XX | 1 |
| Ashida, R; Ioka, T; Katayama, K; Sakon, M; Takahashi, H; Teshima, T | 1 |
| Bai, R; Ding, T; Lan, X; Liu, S; Yin, L; Yu, Y; Zhang, L; Zhao, J | 1 |
| Ferrara, S; Goldstein, D; Greeno, E; Liu, H; Lu, B; Macarulla, T; Moore, M; Pilot, R; Ramanathan, RK; Tortora, G; Von Hoff, DD | 1 |
| Billadeau, DD; Chini, CC; Chini, EN; Escande, C; Espindola-Netto, JM; Guerrico, AM; Mondal, G; Nin, V; Sola-Penna, M; Zhang, JS | 1 |
| Amiji, M; Mattheolabakis, G; Singh, A; Xu, J | 1 |
| Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
| Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M | 1 |
| Jiang, H; Pan, S; Sun, B; Wang, Y; Wu, X; Zhou, Y | 1 |
| Behrns, KE; Black, BS; Delitto, D; George, TJ; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Lu, X; Sarosi, GA; Thomas, RM; Trevino, JG; Vlada, AC; Wallet, SM; Zhang, D | 1 |
| Borzomati, D; Coppola, R; D'Angelillo, RM; Fiore, M; Floreno, B; Ippolito, E; Ramella, S; Trecca, P; Trodella, L; Trodella, LE; Valeri, S | 1 |
| Dambrauskas, Z; Gulbinas, A; Jakstaite, A; Kmieliute, K; Maziukiene, A; Silkuniene, G | 1 |
| Deng, M; Evans, D; Fang, Y; Gao, B; Kim, J; Lee, S; Liu, T; Lou, W; Lou, Z; Niu, N; Qin, B; Wang, L; Xie, F; Yu, J; Zhang, H | 1 |
| Choi, HJ; Eom, CY; Han, Z; Je, S; Kim, JH; Lee, S; Song, JJ | 1 |
| Baba, H; Boku, N; Fukutomi, A; Fukuzawa, K; Furukawa, M; Furuse, J; Hyodo, I; Iguchi, H; Ikeda, M; Ioka, T; Isayama, H; Komatsu, Y; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Shimada, K; Sugimori, K; Takeuchi, M; Ueno, M | 1 |
| Cui, YQ; Gao, CC; Gong, BG; Jiang, H; Li, F; Liu, S; Sun, HC; Xu, PY; Xu, XL; Zheng, YM | 1 |
| Binenbaum, Y; Gil, Z; Na'ara, S | 1 |
| Bekaii-Saab, T; Blazer, M; Lundberg, J; Phillips, G; Reardon, J | 1 |
| Cohen, SJ; Conkling, P; Hersh, E; Lee, FC; Ma, WW; Modiano, M; Nugent, F; Pascual, R; Wong, L; Zalupski, MM | 1 |
| Arumugam, T; Cao, J; Deng, D; Li, Z; Logsdon, CD; Ramachandran, V; Xu, L; Yang, J | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Hwang, HK; Kang, CM; Kim, H; Kim, MJ; Lee, SH; Lee, WJ; Seong, J; Song, SY | 1 |
| Natsui, M; Seino, S; Tsuchiya, A | 1 |
| Dong, SX; Han, P; Qi, J; Ren, ZG | 1 |
| Fu, S; Ma, G; Sun, Y | 1 |
| Abbruzzese, JL; Abrams, RA; Chang, P; Crane, C; Freedman, GM; Guha, C; Hoffman, JP; Li, D; Liu, C; Moughan, J; Regine, WF; Safran, H; Winter, KA | 1 |
| Buscail, L; Cordelier, P; Gayral, M; Hanoun, N; Pointreau, A | 1 |
| Egawa, S; Hara, K; Hijioka, S; Imaoka, H; Kou, T; Mizuno, N; Shimizu, Y; Tanaka, M; Yamao, K; Yazumi, S | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Chuong, P; Fouts, BL; Gurka, MK; McNally, LR; McNally, MW; Mezera, M; Pender, D; Sobelov, A; Woo, SY | 1 |
| Apte, MV; Biankin, AV; Goldstein, D; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Baldwin, GS; He, H; Lowy, AM; Nikfarjam, M; Patel, O; Yeo, D | 1 |
| Colloca, G; Guarneri, D; Venturino, A | 1 |
| Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| He, X; Shen, X; Shi, M; Wang, J; Wei, W; Xin, B; Zhang, T | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Arena, FP; Bathini, VG; Chiorean, EG; Clingan, PR; Goldstein, D; Infante, JR; Ko, A; Kunzmann, V; Lu, B; Mainwaring, PN; McGovern, D; Muldoon, RT; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD; Wood, TE | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 2 |
| Fukada, T; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
| Amano, K; Ebihara, T; Hiraki, Y; Hoshino, H; Ikeda, N; Inoue, T; Kamigaki, S; Kato, F; Kawada, M; Kimura, Y; Makari, Y; Mikami, J; Munakata, S; Nakata, K; Nakata, Y; Nishi, H; Ohzato, H; Sasamatsu, S; Shimizu, K; Tsujie, M; Yamamoto, T; Yamamura, J; Yoshimura, J | 1 |
| Egawa, C; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S | 1 |
| Fujiwara, H; Hatakeyama, T; Ichikawa, D; Ikoma, H; Imamura, T; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Hirose, Y; Kameyama, H; Kobayashi, T; Kosugi, S; Minagawa, M; Miura, K; Morimoto, Y; Nagahashi, M; Sakata, J; Sato, R; Soma, D; Takano, K; Takizawa, K; Wakai, T; Yuza, K | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
| Adachi, S; Kozawa, O; Okuno, M; Shimizu, M; Yasuda, I | 1 |
| Araki, N; Ishikawa, O; Ito, Y; Kawaguchi, Y; Konishi, K; Nishiyama, K; Ohigashi, H; Oshima, K; Otani, K; Takahashi, H; Teshima, T | 1 |
| Chang, DT; Chiu, W; Heestand, G; Hellendag, MG; Koong, AC; Moore, MJ; Ng, K; Pai, J; Parulekar, WR; Shultz, DB; Tu, D | 1 |
| Beck, JT; Berdov, BA; Devoe, CE; Dychter, S; Gladkov, OA; Harris, WP; Hingorani, SR; Holcombe, RF; Jiang, P; Korn, R; Pshevlotsky, EM; Raghunand, N; Shepard, HM; Tjulandin, SA; Wagner, SA | 1 |
| Kim, JH; Kim, SJ; Lee, J | 1 |
| Abukiwan, A; Amponsah, PS; Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Nwaeburu, CC; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Buchsbaum, D; Grizzle, W; Hidalgo, M; Kim, H; Kovar, J; Lopez-Casas, P; Oelschlager, D; Samuel, S; Warram, J; Zinn, K | 1 |
| Broussolle, C; Gerfaud-Valentin, M; Guillet, M; Noel, A; Pouteil-Noble, C; Rogier, T; Sève, P; Taleb, A | 1 |
| Cong, M; Li, H; Liu, B; Lu, A; Wang, C; Xu, W; Xu, X; Yin, J; Zhuang, B | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nakajima, TE; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Hirooka, S; Inoue, K; Kon, M; Kotsuka, M; Matsui, Y; Michiura, T; Ryota, H; Satoi, S; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Anajafi, T; Choi, Y; Mallik, S; Qian, SY; Scott, MD; Yang, X; You, S | 1 |
| Hasumi, K; Imaizumi, A; Kawamoto, M; Morisaki, T; Onishi, H; Umebayashi, M; Yamasaki, A | 1 |
| Bockhorn, M; Brockmöller, J; Gaedcke, J; Ghadimi, BM; Güngör, C; Hackert, T; Hank, T; Haubrock, M; Izbicki, JR; Johnsen, SA; Lüske, CM; Pflüger, R; Rapp, J; Roppel, S; Schaudinn, A; Schirmer, MA; Strobel, O; Werner, J; Zimmer, C | 1 |
| Bhagwandin, VJ; Bishop, JM; Shay, JW; Wright, WE | 1 |
| Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S | 1 |
| Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
| Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF | 1 |
| Assadi, RK; Dholakia, AS; Ellsworth, SG; Ford, E; Grossman, SA; Hacker-Prietz, A; Herman, JM; Jaffee, EM; Laheru, DA; Lu, Y; Moningi, S; Pawlik, TM; Rosati, LM; Saeed, AM; Tran, PT; Weiss, MJ; Wild, AT; Wolfgang, CL; Ye, X | 1 |
| Gao, X; Liao, Q; Liu, Q; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zhou, L | 1 |
| Cherubini, G; Halldén, G; Lemoine, NR; Pantelidou, C | 1 |
| Li, Y; Liao, Q; Liu, Q; Lu, Z; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zong, Y | 1 |
| Honda, H; Kamada, T; Saisho, H; Shinoto, M; Shioyama, Y; Terashima, K; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Ames, P; Berlin, J; Catalano, PM; Cohen, SJ; Davies, A; Horan, J; Leichman, L; McKinley, M; O'Neil, BH; Weekes, CD | 1 |
| Fuchs, JR; He, F; Highfill, CA; Ji, M; Li, K; Li, L; Lian, J; Lin, J; Marquez, RT; Tang, W; Wu, X; Xu, L | 1 |
| Alborzinia, H; Cheng, X; Duvaci, T; Eisenbrand, G; Fredebohm, J; Ghafoory, S; Hafezi, M; Hoheisel, JD; Holenya, P; Kim, JY; Mehrabi, A; Merz, KH; Rafiee, R; Saffari, A; Theobald, J; Wölfl, S | 1 |
| Cuneo, KC; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM; Zabludoff, SD | 1 |
| Ahmad, N; Karki, A; Kong, Y; Konieczny, SF; Li, J; Liu, X; Schweickert, PG; Wang, R; Yang, Y | 1 |
| He, J; Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Adachi, S; Doi, S; Hirose, Y; Iwashita, T; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakashima, M; Okuno, M; Shimizu, M; Yasuda, I; Yoshimi, N | 1 |
| Alvarez, R; Caruso, R; Diaz, E; Duran, H; Fabra, I; Ferri, V; Hidalgo, M; Ielpo, B; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
| Aggarwal, BB; Gupta, SC; Prasad, S; Sung, B; Tyagi, AK; Yadav, VR | 1 |
| Carrassa, L; Falcetta, F; Lupi, M; Ubezio, P | 1 |
| Ahn, DW; Chai, JW; Chun, JY; Kim, YA; Lee, JM; Shin, K | 1 |
| Huang, S; Li, Q; Liu, Z; Miao, X; Ouyang, G; Wen, Y; Xiong, L | 1 |
| Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V | 1 |
| Mantripragada, KC; Safran, H | 1 |
| Aarons, L; Mistry, H; Ogungbenro, K; Wendling, T | 1 |
| Borowa-Mazgaj, B | 1 |
| Epperla, N; Strouse, C | 1 |
| Besselink, MG; Boerma, D; Bonsing, BA; Busch, OR; de Hingh, IH; de Vos-Geelen, J; Dohmen, MA; Erdmann, JI; Festen, S; Groothuis, KB; Klaase, JM; Molenaar, IQ; Patijn, GA; Punt, CJ; Rasch, CR; Suker, M; Ten Tije, AJ; van der Harst, E; van der Kolk, MB; van Eijck, CH; van Tienhoven, G; Versteijne, E; Zwinderman, AH | 1 |
| Barile, E; Das, SK; De, SK; Emdad, L; Fisher, PB; Morvaridi, SK; Pandol, SJ; Pellecchia, M; Quinn, BA; Sarkar, D; Stebbins, JL; Wang, S | 1 |
| Buczkowski, AK; Chung, SW; Kozlowski, P; Kyle, AH; Minchinton, AI; Ng, SS; Owen, DA; Scudamore, CH; Tso, J; Valdez, SM; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Altaf, K; He, D; Ke, N; Li, A; Liu, X; Tan, C; Tang, J; Wang, Y; Xiong, J; Zhang, H | 1 |
| Paxton, JW; Wu, Z; Xu, H | 1 |
| Aoyama, T; Atsumi, Y; Kobayashi, S; Miyagi, Y; Morimoto, M; Morinaga, S; Murakawa, M; Nakamura, Y; Ueno, M; Yamaoku, K; Yokose, T | 1 |
| Bikhchandani, M; Dawson, DW; Donahue, TR; Duong, M; Gawlas, I; Kadera, BE; Li, L; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Dutta, R; Karaca, M; Mahato, RI; Ozsoy, Y | 1 |
| Chen, Y; Li, C; Liu, X; Wang, X; Yang, X; Zhou, G | 1 |
| Kim, JK; Park, JS; Yoon, DS | 1 |
| Ai, J; Algül, H; Barenboim, M; Campbell, A; Demir, IE; Diakopoulos, KN; Doglioni, C; Görgülü, K; Hagemann, T; Jodrell, D; Karpathaki, AP; Kurkowski, MU; Lesina, M; Neesse, A; Protti, MP; Rose-John, S; Ruess, D; Sansom, O; Schmid, RM; Song, L; Wörmann, SM | 1 |
| Li, D; O'Reilly, EM | 1 |
| Baldwin, GS; Beutler, JA; He, H; Huynh, N; Nikfarjam, M; Yeo, D | 1 |
| Fan, Y; Gan, Y; Gu, J; Li, G; Tu, H; Wang, Q; Wu, Y; Yao, M; Yuan, H; Zhang, J | 1 |
| Chan, AL; Leung, HW; Muo, CH | 1 |
| Ahn, HK; Cho, EK; Choi, SJ; Hong, J; Kim, YS; Lee, JH; Park, I; Park, J; Shin, DB; Shin, YJ; Sym, SJ | 1 |
| Ishiwata, T; Matsuda, Y; Matsushita, A; Naito, Z; Nakamura, Y; Sumiyoshi, H; Uchida, E | 1 |
| Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Daley, D; Engle, D; Giao Ly, NN; Greco, SH; Hajdu, C; Hundeyin, M; Mani, VR; Miller, G; Ochi, A; Pansari, M; Pergamo, M; Rendon, M; Seifert, L; Tippens, D; Tiwari, S; Torres-Hernandez, A; Werba, G; Zambirinis, CP | 1 |
| Azzi, L; Bachet, JB; Bartholin, L; Bernard, D; Cros, J; de la Fouchardière, C; Dubus, P; Gout, J; Griveau, A; Guitton, J; Le Calvé, B; Maréchal, R; Payen, L; Svrcek, M; Vindrieux, D; Wiel, C | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Arumugam, P; Bapiro, TE; Carapuça, EF; Delvecchio, FR; Feig, C; Gemenetzidis, E; Grose, RP; Kocher, HM; Lemoine, NR; Richards, FM; Williams, MD; Wilson, AS | 1 |
| Bekaii-Saab, T; El-Rayes, BF; Flowers, CR; Goldstein, DA; Krishna, K; Noonan, AM | 1 |
| Kinoshita, A; Koike, K; Koyama, M; Nishino, H; Tanaka, K | 1 |
| Asai, K; Asayama, Y; Honda, H; Matsumoto, K; Nakamura, K; Nishie, A; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Boeck, S; Haas, M; Heinemann, V; Kruger, S; Westphalen, CB | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Apers, S; Capistrano, R; Dockx, Y; Lardon, F; Pauwels, P; Pieters, L; Staelens, S; Stroobants, S; Vangestel, C; Wouters, A | 1 |
| Chayahara, N; Imamura, Y; Kiyota, N; Kotake, T; Minami, H; Mukohara, T; Nishimura, M; Saito, K; Saito, Y; Takenaka, K; Toyoda, M; Tsuji, A | 1 |
| Blake, A; Hayes, JP; Helenowski, I; Huang, J; Kim, T; McGinn, CJ; Mulcahy, M; Rakhra, S; Robertson, J; Small, W; Strauss, JB | 1 |
| Lee, HS; Park, SW | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Bachet, JB; Pernot, S; Portal, A; Taieb, J | 1 |
| Katata, Y; Okawaki, M; Sawaki, A; Yamaguchi, Y; Yamamura, M | 1 |
| Akaike, M; Godai, T; Higuchi, A; Katayama, Y; Masuda, M; Morinaga, S; Numata, K; Numata, M; Rino, Y; Sawazaki, S; Shiozawa, M | 1 |
| André, T; Artru, P; Bonnetain, F; Borbath, I; Bouché, O; Chibaudel, B; Glimelius, B; Goldstein, D; Hammel, P; Huguet, F; Louvet, C; Mineur, L; Shannon, J; van Laethem, JL | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Koide, S; Matsuo, Y; Morimoto, M; Saito, K; Sato, T; Shamoto, T; Takahashi, H; Takeyama, H; Tsuboi, K | 1 |
| Camara, SN; Cao, B; Duan, Q; Shen, Q; Shi, P; Wang, C; Yin, T; Zhang, Z; Zhao, H | 1 |
| Alexander, HR; Bergmann, F; Bernhardt, M; Funamizu, N; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Ried, T; Satoskar, AR; Schetter, A; Tang, W; Uwagawa, T; Wang, J; Werner, J; Yanaga, K; Yang, S | 1 |
| Chan, DE; Freeman, JW; Ghosh, R; Gong, J; Kumar, AP; Muñoz, AR; Payton-Stewart, F; Pingali, S | 1 |
| Armbrecht, N; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Dombrowski, F; Esposito, I; Fleischmann-Mundt, B; Gürlevik, E; Kleine, M; Kloos, A; Kubicka, S; Kühnel, F; Manns, MP; Oettle, H; Ostroumov, D; Ribback, S; Saborowski, M; Steiger, K; Wirth, TC; Woller, N; Yevsa, T | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Chiao, PJ; Fan, XQ; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zhou, HJ; Zhuang, ZN | 1 |
| Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
| Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Mattern, J; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D | 1 |
| Hirooka, S; Inoue, K; Kon, M; Matsui, Y; Michiura, T; Miyasaka, C; Ohe, C; Ryota, H; Satoi, S; Tanigawa, N; Uemura, Y; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Futamata, Y; Noguchi, J; Okabe, M; Yoshida, A | 1 |
| Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Bailey, P; Balkwill, F; Barry, ST; Biankin, AV; Bryson, S; Candido, JB; Carter, CR; Chang, DK; Clarke, M; Connelly, J; Eberlein, C; Evans, TRJ; Foth, M; Jamieson, N; Karim, SA; Leach, JDG; McDaid, K; Morton, JP; Nibbs, RJB; Nixon, C; Rishi, L; Sansom, OJ; Steele, CW; Strathdee, D; Upstill-Goddard, R; Wilson, Z | 1 |
| Chang, K; Chen, C; Freeman, JW; Jagirdar, J; Karnad, A; Kumar, AP; Zhao, S | 1 |
| Hoang, NT; Kadonosono, T; Kizaka-Kondoh, S; Kuchimaru, T | 1 |
| Buchsbaum, DJ; Christein, JD; Cooper, SJ; Davis, NS; Gertz, J; Greeno, EW; Grizzle, WE; Heslin, MJ; Johnston, BE; Kirby, MK; Myers, RM; Oliver, PG; Posey, JA; Ramaker, RC; Sexton, KC; Vickers, SM | 1 |
| Cai, Q; Fu, H; Hu, Z; Shi, J; Wei, Z; Xu, J; Yan, R; Yang, D; Zhang, Y | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Goda, Y; Hara, H; Irie, K; Kobayashi, S; Morimoto, M; Moriya, S; Ohkawa, S; Okusaka, T; Tanaka, M; Tezuka, S; Ueno, M | 1 |
| Choi, Y; Haldar, MK; Kulkarni, P; Mallik, S; You, S | 1 |
| Bajor, J; Balázs, A; Czakó, L; Czimmer, J; Farkas, G; Gódi, S; Halász, A; Hegyi, P; Izbéki, F; Kahán, Z; Kelemen, D; Kui, B; Lakatos, G; Leindler, L; Papp, R; Pár, G; Szabó, I; Szentesi, A; Szentkereszty, Z; Szepes, Z; Szmola, R; Szücs, Á; Takács, T; Vincze, Á | 1 |
| Baba, T; Mukaida, N; Song, Y | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Chiorean, EG; El-Maraghi, R; Goldstein, D; Harris, M; Li, JS; Liu, H; Lu, B; Ma, WW; Manax, V; Reni, M; Romano, A; Tabernero, J; Von Hoff, DD; Whorf, R | 1 |
| Büchler, MW; Hackert, T; Hinz, U; Jäger, D; Michalski, CW; Sachsenmaier, M; Schneider, L; Springfeld, C; Strobel, O; Ulrich, A | 1 |
| Guo, J; Han, X; Hu, GF; Liu, LY; Tang, N; Wang, X; Wang, Y; Wang, ZH; Zhang, QQ | 1 |
| Brooks, A; Guo, B; Miskimins, KW; Qian, SY; Xu, Y; Yang, X | 1 |
| Dawson, DW; Fernandez-Zapico, ME | 1 |
| DeNardo, DG; Hawkins, WG; Hegde, S; Herndon, JM; Jiang, H; Knolhoff, BL; Meyer, MA; Nywening, TM; Pachter, JA; Shapiro, IM; Wang-Gillam, A; Weaver, DT; Zhu, Y | 1 |
| Asimakopoulos, AG; Boroujerdi, M; Davis, PJ; Kannan, K; Kohan, HG; Mousa, SA; Muralidharan-Chari, V; Sell, S; Sudha, T | 1 |
| Agle, S; Bhutiani, N; Li, S; Li, Y; Martin, RC | 1 |
| Chen, H; Deng, X; Gu, J; Li, Y; Peng, C; Shen, B; Shi, M; Wang, D; Wang, X; Wei, G; Zhan, Q; Zhang, J; Zhu, Y | 1 |
| Kwon, H; Lee, KH; Park, CM; Shin, S | 1 |
| Alexander, HR; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Lee, DH; Ried, T; Schetter, AJ; Wang, J; Yang, S; Yfantis, HG | 1 |
| Bang, S; Chung, JB; Chung, MJ; Lee, HS; Lee, YI; Moon, do C; Park, JY; Park, SW; Song, SY | 1 |
| Bendas, G; Bisht, S; Brossart, P; Feldmann, G; Holdenrieder, S; Nolting, J; Rupp, A; Schlesinger, M; Schubert, R; Wenzel, J | 1 |
| Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S | 1 |
| Biederman, L; Blanco, F; Brody, JR; Jimbo, M; Jing, Y; Londin, E; Rigoutsos, I; Telonis, AG; Xia, NL; Zhou, H | 1 |
| Bernier, M; Singh, NS; Wainer, IW | 1 |
| Li, Y; Meng, Z; Ning, Z; Wang, H; Zhu, X | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Camphausen, K; Griffith, KA; Kim, EJ; Ruch, JM; Sahai, V; Savage, JE; Simeone, DM; Zalupski, MM; Zhen, DB | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP | 1 |
| Gu, M; Qian, Y; Xiong, Y; Yang, B | 1 |
| Bahra, M; Bläker, H; Denkert, C; Dörken, B; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Akita, H; Fijiwara, Y; Ishikawa, O; Kobayashi, S; Ohigashi, H; Sakon, M; Takahashi, H; Tomokuni, A; Yano, M | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Bak, YT; Choi, SJ; Kim, HJ; Kim, JS | 1 |
| Albert, AC; Bürtin, F; Graffunder, J; Jaster, R; Kumstel, S; Müller, S; Radecke, T; Schönrogge, M; Shih, HY; Vollmar, B; Zechner, D; Zhang, X | 1 |
| Lopez, CD; Vaccaro, G | 1 |
| Fernando, M; Goldstein, D; Ritchie, GE | 1 |
| Azakami, T; Eguchi, N; Hayashi, H; Matsumoto, K; Shimamoto, F; Sumida, T; Sumii, M; Sumimoto, K; Tamura, T; Uraoka, N | 1 |
| He, Z; Jia, Z; Shi, Y; Xu, C | 1 |
| Adsay, V; Brutcher, E; Chen, Z; El-Rayes, B; Ethun, CG; Kooby, DA; Maithel, SK; Postlewait, LM; Sarmiento, JM; Staley, CA | 1 |
| Di, Y; Fu, D; He, H; Jin, C; Song, Y; Yu, X | 1 |
| Lewis, CS; Smith, CD; Voelkel-Johnson, C | 1 |
| Askin, G; Buchy, E; Cayre, F; Couvreur, P; Desmaele, D; Gouazou, S; Mougin, J; Mura, S; Sobot, D; Stella, B; Valetti, S | 1 |
| Huguet, F; Mornex, F; Orthuon, A | 1 |
| Adiseshaiah, PP; Crist, RM; Hook, SS; McNeil, SE | 1 |
| Chen, LT; Hsu, MC; Hung, WC; Luo, CW; Pan, MR; Shan, YS | 1 |
| Li, Z; Lu, Z; Su, J; Ye, D; Zhan, Y | 1 |
| Chen, ZN; Fu, ZG; Jiang, JL; Li, L; Meng, Y; Wu, B; Wu, XQ; Xu, BQ; Xu, L | 1 |
| Duan, Q; Liu, T; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 1 |
| Chang, X; Dai, M; Shi, N; Xing, C; Zhao, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Cao, Z; Hu, Y; Huang, H; Wang, T; Xiong, G; Xu, J; You, L; Zhang, T; Zhao, Y; Zheng, L; Zhou, L | 1 |
| Adamson, DJ; Arif, SS; Bidoli, P; Carroll, KJ; Chang, D; Cheeseman, S; Dalgleish, AG; Diaz-Beveridge, R; Fernandez-Martos, C; Gaya, A; Glynne-Jones, R; Granetto, C; Martín, AJ; Massuti, B; McAdam, K; McDermott, R; Mudan, SS; Papamichael, D; Pazo-Cid, R; Stebbing, J; Vieitez, JM; Wagle, S; Zaniboni, A | 1 |
| Huang, M; Huang, Q; Lin, X; Xie, F; Yang, J; Zhou, H | 1 |
| Bahary, N; Hogg, ME; Poruk, KE; Steve, J; Weiss, MJ; Wolfgang, CL; Wright, GP; Zeh, HJ; Zenati, MS; Zuriekat, AH | 1 |
| Bernanke, AG; Blobe, GC; Hesler, RA; Huang, JJ; McCall, SJ; Nixon, AB; Starr, MD; Treboschi, VM; White, RR | 1 |
| Akladios, C; Aprahamian, M; Ignat, M; Mutter, D | 1 |
| Beaudoin, A; Cano, P; Cripps, C; Dhesy-Thind, S; Do, T; Dowden, S; Gill, S; Grassin, H; Ko, YJ; Lam, WYH; Moore, M; Stewart, J; Zalewski, P; Zulfiqar, M | 1 |
| Gharios, J; Kattan, J; Kourie, HR | 1 |
| Korc, M; Kota, J; Kwon, JJ; Quirin, KA; Wek, RC; Willy, JA; Yin, XM | 1 |
| Andersson, R; Ansari, D; Bauden, M; Cebrián, MJ; Holdenrieder, S | 1 |
| Hwnag, YI; Jeon, J; Kang, JS; Kim, H; Kim, TW; Kim, Y; Lee, WJ; Park, JH; Park, JK | 1 |
| Cai, WJ; Dong, YY; Liu, Y; Zhuang, YH; Zou, WB | 1 |
| Chen, K; Chen, X; Duan, W; Gao, L; Jiang, Z; Lei, M; Ma, J; Ma, Q; Sun, L; Wang, Z; Zhou, C | 1 |
| Fishel, ML; Hill, R; Littlepage, LE; Richards, KE; Wu, J; Zeleniak, AE | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Esumi, H; Fujioka, R; Hasegawa, H; Hashimoto, Y; Ikeda, M; Kishino, S; Mitsunaga, S; Miyoshi, C; Mochizuki, N; Nomura, S; Ohno, I; Sato, A; Takahashi, H; Takahashi, R; Toyosaki, K; Tsuchihara, K; Yomoda, S | 1 |
| Du, L; Gao, F; Li, F; Liang, X; Lin, L; Liu, Y; Qiao, X; Qin, P; Xing, L; Zhang, J; Zhao, Q | 1 |
| Hiraoka, K; Nakamura, M; Ogata, T; Ozaki, T; Sang, M; Shimozato, O; Yoda, H | 1 |
| Fan, Z; Guo-Fang, T; Xiao-Huan, L; Yong-Xian, G | 1 |
| Fang, J; Huang, D; Luo, G | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Kataoka, K; Maeda, M; Matsubara, H; Okamura, S; Urano, F | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY | 1 |
| Biermann, M; Bjånes, T; Dimcevski, G; Gilja, OH; Gjertsen, BT; Hoem, D; Kotopoulis, S; McCormack, E; Molven, A; Postema, M; Schjøtt, J; Sorbye, H | 1 |
| Benson, AB; Bepler, G; Elsaleh, H; Farrell, JJ; Guha, C; Lai, R; Liu, X; Macdonald, JS; Moughan, J; Regine, WF; Schaefer, P; Wong, JL; Yen, Y; Zheng, Z | 1 |
| Bamlet, WR; Carlson, EE; Fridley, BL; Jenkins, G; Li, L; McWilliams, RR; Petersen, GM; Wang, L; Xie, F; Zhang, JW | 1 |
| Bachet, JB; Calomme, A; Demetter, P; Drouillard, A; Maréchal, R; Ouazzani, S; Puleo, F; Van Laethem, JL; Verset, G | 1 |
| Brunner, T; Fokas, E | 1 |
| Apers, S; Capistrano I, R; Fransen, E; Pieters, L; Staelens, S; Vangestel, C; Vanpachtenbeke, H | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Chen, QD; Ge, X; Jiang, BH; Lin, Y; Liu, LZ; Lu, Y; Shi, ZM; Wang, M; Wen, Y | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Álamo, P; Allavena, P; Avilés, P; Céspedes, MV; Cuevas, C; Gallardo, A; Galmarini, CM; Guillén, MJ; Hidalgo, M; López-Casas, PP; Mangues, R; Sarno, F | 1 |
| Arima, H; Aruga, A; Fujiwara, T; Furukawa, H; Hatori, T; Hayashi, H; Hazama, S; Hirakawa, K; Iguchi, H; Iida, M; Ikemoto, T; Ishizaki, H; Koki, Y; Matsui, H; Nagano, H; Nakamura, Y; Oka, M; Sakata, K; Shimada, M; Shimizu, R; Shindo, Y; Suzuki, N; Takenouchi, H; Tanaka, H; Ueno, T; Uesugi, K; Umeda, Y; Yoshimatsu, K; Yoshino, S | 1 |
| Li, C; Liu, R; Zhao, Z; Zhou, Z | 1 |
| Caperell-Grant, A; Cardenas, H; Fishel, M; Ivan, C; Jones, DR; Lee, J; Matei, D; Yakubov, B | 1 |
| Hanazaki, K; Kitagawa, H; Koyama, T; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Takezaki, Y | 1 |
| Lu, H; Lu, M; Stenzel, MH; Wang, YK; Xiao, P; Zhao, J | 1 |
| Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X | 1 |
| Chen, H; Fan, W; He, Y; Hu, H; Tang, S; Wang, P; Xu, P; Xu, Z; Yang, G; Yu, M; Zhang, Z; Zhao, X | 1 |
| Lin, Y; Qin, C; Su, Z; Xian, G; Zhang, Z; Zhao, J | 1 |
| Ferrara, S; Goldstein, D; Kunzmann, V; Liu, H; Lu, B; Ramanathan, RK; Renschler, MF; Von Hoff, DD | 1 |
| An, Y; Duan, J; Fan, S; Li, X; Pan, Y; Tie, L; Wang, X; Xiaokaiti, Y; Yang, H; Ye, M | 1 |
| Hirono, S; Imaoka, H; Ishii, H; Katanuma, A; Katsuda, M; Kawai, M; Maguchi, H; Miyazawa, M; Okada, KI; Ozaka, M; Yamao, K; Yamaue, H | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
| Cabezuelo, B; de la Vara Inesta, L; Illescas, ML; Jimeno García, L; López Rubio, ME; Lucas Guillén, E; Martinez Díaz, M; Mateo Bosch, E; Morales Albuja, ME; Rodado Martínez, R | 1 |
| Alberts, SR; Bamlet, WR; Burch, PA; Chari, ST; Farnell, MB; Gleeson, FC; Haddock, MG; Kendrick, ML; Levy, MJ; Oberg, AL; Petersen, GM; Takahashi, N | 1 |
| Bekaii-Saab, T; Chen, CS; Ding, LY; Henderson, SE; Huang, PH; Kulp, SK; Mo, X | 1 |
| Brody, JR; Buchler, M; Costello, E; Dabbish, N; Ghaneh, P; Greenhalf, W; Grigoli, A; Halloran, C; Jiang, W; Jimbo, M; Leiby, BE; Neoptolemos, JP; Palmer, D; Tatarian, T; Winter, JM; Yeo, CJ | 1 |
| Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A; Patel, H | 1 |
| Kitanaka, C; Kuramoto, K; Okada, M; Sakaki, H; Sanomachi, T; Seino, S; Suzuki, S; Takeda, H; Watarai, H; Yoshioka, T | 1 |
| Aguila, FN; Chambers, LW; Hu, H; Huang, X; Knoble, JL; Liu, H; Patel, T; Zeng, M | 1 |
| Çalış, S; Esendağlı, G; Gürbüz, MU; Öztürk, K; Tülü, M | 1 |
| Bridgewater, J; Cascinu, S; Childs, BH; Dueland, S; Garosi, VL; Giurescu, M; Haas, M; Jassem, J; Martens, UM; Melichar, B; Michl, P; Peeters, M; Rajagopalan, P; Riess, H; Ross, P; Roth, K; Saramak, P; Schmiegel, W; Schulz, A; Seidel, H; Teufel, M; Van Brummelen, D; Van Laethem, JL; Weekes, C; Zaniboni, A | 1 |
| Chen, W; Gu, Y; He, Y; Hu, B; Hu, H; Wang, Y | 1 |
| Bazin, IS; Bodoky, G; Deplanque, G; Elekes, A; Evans, TRJ; Harrison, M; Lin, C; Melichar, B; Moore, MJ; O'Dwyer, PJ; Pezet, D; Rock, E; Rosemurgy, A; Strauss, L; Van Cutsem, E | 1 |
| Biankin, A; Goldstein, D; Johns, A; Mawson, A; McCarroll, J; Nunez, A; Phillips, P; Sharbeen, G; Youkhana, J | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Maehara, SI; Maehara, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Arigami, T; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Mori, S; Natsugoe, S; Sakoda, M; Shinchi, H; Uchikado, Y; Ueno, S; Uenosono, Y | 1 |
| Park, K | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Shen, B; Shi, M; Tang, X; Wen, C; Zhang, Y | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Hori, Y; Nishiyama, T; Shimizu, K | 1 |
| Aicher, B; Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Leon, LG; Maftouh, M; Massihnia, D; Minutolo, F; Peters, GJ; Raktoe, R; Russo, A; van Krieken, A | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Kauffman, M; Landesman, Y; Mohammad, RM; Muqbil, I; Philip, PA; Senapedis, W; Shacham, S | 1 |
| Han, H; Ji, J; Jin, Q; Li, Z; Parak, WJ; Pelaz, B; Valdepérez, D; Wu, Y; Yang, B | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
| Alarcón Cano, D; Andrade G, A; Barajas, O; Butte, JM; Caglevic, C; Calderillo Ruiz, G; Carballido, M; Cuartero, V; De La Fuente, H; de la Torre, M; Díaz Romero, C; Gallardo, J; González M, P; Hoefler, S; Kon Jara, X; Lembach, H; Lingua, A; Lobatón, J; Mahave, M; Marsiglia, H; Mas López, L; Montenegro B, P; Morillas G, L; Moscoso, Y; Müller, B; O'Connor, JM; Padilla Rosciano, A; Pérez Encalada, V; Roa, JC; Roca, E; Rolfo, C; Schwartsmann, G; Solé, S; Torres, J; Ubillos, L; Yepes, A | 1 |
| Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C | 1 |
| Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
| Alis, H; Dagoglu, N; Gonenc, M; Karabulut, M; Karabulut, S; Serilmez, M; Tas, F; Usul Afsar, Ç | 1 |
| Are, C; Bhirud, AR; Lazenby, AJ; Lin, C; Ly, QP; Sasson, AR; Verma, V; Zheng, D | 1 |
| Bedel, A; Brillac, A; Buscail, E; Dabernat, S; de Verneuil, H; Moranvillier, I; Moreau-Gaudry, F; Peuchant, E; Rousseau, B; Vendrely, V | 1 |
| Binder, PS; Goedegebuure, SP; Hashim, YM; Hawkins, WG; Liu, J; Mach, RH; Sankpal, NV; Spitzer, D; Vangveravong, S | 1 |
| Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Choe, KA; Dhar, VK; Fu, B; Habib, DA; Hanseman, DJ; Kharofa, J; Kim, Y; Levinsky, NC; Olowokure, OO; Smith, M; Wang, J; Wilson, GC; Xia, BT | 1 |
| Avan, A; Fayazbakhsh, H; Hassanian, SM; Hosseini, M; Khazaei, M; Maftouh, M; Mohammadzadeh, E; ShahidSales, S | 1 |
| Han, SS; Hong, EK; Joo, J; Kim, MK; Kim, TH; Kim, YH; Kong, SY; Lee, JH; Lee, WJ; Moon, H; Park, B; Park, SJ; Woo, SM; Yoon, KA | 1 |
| Arkenau, HT; Moschetta, M; Uccello, M | 1 |
| Kaura, S; Khan, ZM; MacEwan, JP; Yin, W | 1 |
| Kang, R; Lotze, MT; Sun, X; Tang, D; Zeh, HJ; Zhang, Q; Zhu, S | 1 |
| Hagino, S; Nakayama, A; Sakamoto, K | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| Abe, T; Fukase, K; Hayashi, H; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Otsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Ando, S; Kamei, R; Kitamura, Y; Tokunou, K; Yamamoto, H; Yamamoto, T | 1 |
| Fujimoto, T; Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Ueno, T; Yoshino, S | 1 |
| Fukada, T; Hasegawa, A; Isozaki, M; Kametaka, H; Makino, H; Seike, K | 1 |
| Hoshino, H; Hosoda, Y; Kakita, N; Kawada, J; Kim, Y; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M | 1 |
| Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E | 1 |
| Ito, F; Kaneta, A; Miura, J; Otani, S; Saito, T; Tsuchiya, T | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Hosomi, S; Ishikawa, A; Miyamoto, M; Tanigawa, T | 1 |
| Cha, H; Cho, JM; Kim, SA; Kwon, SK; Lee, DY; Lee, HS; Park, SB; Ro, S; Song, SY | 1 |
| Birhanu, G; Javar, HA; Seyedjafari, E; Zandi-Karimi, A | 1 |
| Bhardwaj, A; Khan, MA; Khushman, M; Patel, GK; Patton, MC; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Hui, P; Ma, J; Meng, W; Wang, N; Xiang, S | 1 |
| Aicher, A; Aires, A; Cortajarena, AL; Heeschen, C; Trabulo, S | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Dou, QP; Peng, T | 1 |
| Agaimy, A; Akdemir, KC; Amin, S; Carugo, A; Chin, L; Colla, S; Corti, D; DePinho, RA; Dey, P; Draetta, GF; Fleming, JB; Garvey, J; Genovese, G; Ghosh, P; Giuliani, V; Goggins, MG; Gutschner, T; Heffernan, TP; Jiang, S; Kwong, LN; Leo, E; Li, L; Liu, CG; Maitra, A; Minelli, R; Molin, MD; Muller, F; Nezi, L; Pettazzoni, P; Roberts, CW; Robinson, FS; Seth, S; Sgambato, A; Svelto, M; Takahashi, K; Tepper, J; Toniatti, C; Viale, A; Wang, H; Wood, LD; Wu, CC; Ying, H; Zhang, J | 1 |
| Nanjappa, S; Pabbathi, S; Singh, V; Uttamchandani, S | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Miyazawa, M; Okada, KI; Shimizu, A; Ueno, M; Yamaue, H | 1 |
| Alemany, R; Fillat, C; Maliandi, MV; Mato-Berciano, A; Montoliu, L; Raimondi, G | 1 |
| Aoki, T; Hasegawa, K; Hoshikawa, M; Kakimi, K; Kokudo, N; Matsushita, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hasegawa, S; Kawamoto, K; Kishimoto, T; Mikamori, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Wada, H; Yamada, D | 1 |
| Bird, NT; Dodd, J; Elmasry, M; Ghaneh, P; Greenhalf, W; Jones, R; Kitteringham, N; Malik, H; Neoptolemos, JP; Palmer, D; Psarelli, E | 1 |
| Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
| Altendorf-Hofmann, A; Betzler, C; Bruns, C; Camaj, P; Däberitz, T; Jauch, KW; Knösel, T; Niess, H; Popp, F; Pozios, I; Seeliger, H; Settmacher, U; Wang, X; Zhao, Y | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Inoue, K; Kuroda, H; Ohtsuka, H; Ohtsuki, S; Tachikawa, M; Terasaki, T; Uchida, Y; Unno, M | 1 |
| Hara, A; Ichinoe, M; Imaizumi, H; Iwai, T; Kaizu, T; Kaneda, T; Kawamata, H; Kida, M; Kumamoto, Y; Nakamoto, S; Nishiyama, R; Okuwaki, K; Suzuki, E; Tajima, H; Watanabe, M; Yamauchi, H; Yokota, M | 1 |
| Gao, G; Yu, H; Yue, Q; Zheng, X; Zou, G | 1 |
| Arigami, T; Kijima, Y; Kurahara, H; Maemura, K; Mataki, Y; Matsushita, D; Natsugoe, S; Okubo, K; Sakoda, M; Uenosono, Y; Yanagita, S | 1 |
| Kusuhara, M; Sasaki, K; Serizawa, M; Todaka, A; Umehara, R; Urakami, K; Yamaguchi, K; Yasui, H | 1 |
| Bendell, J; Benson, AB; Dong, H; Hecht, JR; Kudrik, F; Vyushkov, D; Wainberg, ZA | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Chen, S; Dong, MS; Wang, Y; Zhang, JH; Zhang, WL | 1 |
| Andersson, B; Andersson, R; Ansari, D; Nilsson, J; Said-Hilmersson, K; Sasor, A; Urey, C | 1 |
| Cross, WE | 1 |
| Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL | 1 |
| Marasini, B; Sahu, RP | 1 |
| Avan, A; Funel, N; Giovannetti, E; Gomez, VE; Griffioen, AW; Leon, LG; Rovithi, M; Verheul, HM; Wurdinger, T | 1 |
| Chao, Y; Chi, KH; Huang, PI; Lee, RC; Li, CP; Shiau, CY; Wang, LW; Yen, SH | 1 |
| Brunner, TB; Cavallaro, A; Geiger, M; Grabenbauer, GG; Hohenberger, W; Lang-Welzenbach, M; Mantoni, TS; McKenna, WG; Sauer, R | 1 |
| Bajetta, E; Barone, C; Bycott, P; Chodkiewicz, C; Kim, S; Létourneau, R; Liau, K; Maurel, J; Pithavala, Y; Ricart, AD; Rixe, O; Spano, JP; Trask, P; Wasan, H; Wong, R | 1 |
| Grossbard, ML; Kozuch, P; Nieto, J | 1 |
| Rocha-Lima, C; Vulfovich, M | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Friess, H; Kleeff, J | 1 |
| Aiura, K; Ito, Y; Kitagawa, Y; Kitajima, M; Ueda, M | 1 |
| Vikram, B | 1 |
| Fujita, T | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C | 1 |
| Buclin, T; Chassot, PG; Decosterd, LA; Kuemmerle, A; Lejeune, F; Liénard, D; Mosimann, F; Stupp, R | 1 |
| Carbó, N; Casado, FJ; García-Manteiga, J; Mazo, A; Mercadé, E; Pastor-Anglada, M; Pérez-Torras, S | 1 |
| Jiang, JX; Liu, WS; Qin, RY; Shen, M; Shi, CJ; Tian, R; Wang, M; Yan, HJ | 1 |
| Bluethner, T; Caca, K; Haefner, M; Moebius, C; Mossner, J; Niederhagen, M; Wiedmann, M; Wittekind, C | 1 |
| Dorr, RT; Landowski, TH; Samulitis, BK | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 2 |
| Hayama, M; Konishi, Y; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N | 1 |
| Fujimori, N; Fujimoto, C; Funakoshi, A; Maruyama, Y; Niina, Y; Sumii, T | 1 |
| Fujimoto, K; Hara, T; Kurahashi, T; Muraki, Y; Nagata, M; Yamashita, Y; Yasuda, Y | 1 |
| Hirata, K; Kawasaki, H; Kukita, K; Mizushima, Y | 1 |
| Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Crane, CH; Evans, DB; Ho, L; Lano, EA; Lee, JE; Lenzi, R; Pisters, PW; Staerkel, GA; Sun, CC; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Abbruzzese, JL; Abdalla, E; Bhosale, PR; Crane, CH; Das, P; Evans, DB; Ho, L; Krishnan, S; Lee, JE; Lee, JH; Pisters, PW; Ross, WA; Staerkel, GA; Sun, CC; Tamm, EP; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA; Xiong, H | 1 |
| Hampton, T | 1 |
| Gout, PW; Ling, V; Lo, M; Wang, YZ | 1 |
| Ammerpohl, O; Fölsch, UR; Kalthoff, H; Koch, D; Müerköster, SS; Schäfer, H; Sipos, B; Tsao, MS; Werbing, V | 1 |
| Drebin, JA; Hawkins, WG; Hull, M; Linehan, DC; Malyapa, RS; Myerson, RJ; Picus, J; Strasberg, SM; Tan, BR; Tan, MC; Trinkaus, K | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Auroux, J; Brunetti, F; Delchier, JC; Fabre-Guillevin, E; Locher, C; Piedbois, P; Zelek, L | 1 |
| Cereda, S; Reni, M | 1 |
| Corsini, MM; Iott, MJ; Miller, RC | 1 |
| Arizumi, M; Arizumi, T; Hirano, K; Isayama, H; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T | 1 |
| Dabanaka, K; Hanazaki, K; Kobayashi, M; Kohsaki, T; Maeda, H; Nishimori, I; Nishioka, A; Ogawa, Y; Okabayashi, T; Onishi, S; Sugimoto, T; Yamashita, K | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Ioka, T; Kanemitsu, Y; Mizuno, N; Nakaizumi, A; Nakamura, T; Salem, AA; Sawaki, A; Takahashi, K; Tanaka, S; Ueda, R; Yamao, K | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Erkan, M; Friess, H; Giese, NA; Giese, T; Kleeff, J; Michalski, CW; Sartori, C; Sauliunaite, D; Stratmann, R | 1 |
| Brooks, KJ; Coleman, EJ; Vitetta, ES | 1 |
| Dobrila Dintinjana, R; Guina, T; Krznarić, Z | 1 |
| Amendt, C; Bruns, CJ; Eichhorn, ME; Ischenko, I; Jauch, KW; Kleespies, A; Mantell, O; Seeliger, H | 1 |
| Bang, S; Chung, JB; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Catane, R; Kundel, Y; Mendlovic, S; Pfeffer, R; Rabin, T; Symon, Z | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Arita, Y; Hisano, T; Igarashi, H; Ito, T; Kaku, T; Kawabe, K; Takayanagi, R | 1 |
| Moriwaki, H; Nakagawa, T; Shimizu, M; Shirakami, Y; Tatebe, H; Tsurumi, H; Yasuda, I | 1 |
| Azmi, AS; Burikhanov, R; Chen, J; Mohammad, RM; Rangnekar, VM; Sarkar, FH; Wang, G; Wang, S; Wang, Z | 1 |
| Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Klipin, M; Omoshoro-Jones, J; Smith, MD; Sparaco, A | 1 |
| Aerts, R; Bielen, D; Budiharto, T; Ectors, N; Goethals, L; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Vanbeckevoort, D; Verslype, C | 1 |
| Hoffe, SE; Springett, GM | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP; Wong, D | 1 |
| Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V; Wang, H | 1 |
| Donahue, B; Hiotis, SP; Hochster, HS; Marti, JL; Newman, E; Ryan, T | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Lohr, JM; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV | 1 |
| Kayahara, M; Kitagawa, S; Minato, H; Mouri, H; Ohta, T; Ohtsubo, K; Tsuchiyama, T; Watanabe, H | 1 |
| Bernhaus, A; Erker, T; Fritzer-Szekeres, M; Grusch, M; Handler, N; Horvath, Z; Jaeger, W; Jaschke, M; Krupitza, G; Lackner, A; Madlener, S; Ozsvar-Kozma, M; Saiko, P; Szekeres, T | 1 |
| Hagihara, A; Ikeda, M; Iwasa, S; Kojima, Y; Morizane, C; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Buchsbaum, DJ; Forero, A; Grizzle, WE; Kim, H; Long, JW; McNally, LR; Morgan, DE; Sellers, JC; Stockard, CR; Warram, JM; Zeng, H; Zinn, KR | 1 |
| Chan, CY; Chen, Y; He, ML; Jiang, L; Kung, HF; Li, JC; Lin, L; Lin, MC; Sung, JJ; Wang, X; Yew, DT | 1 |
| Almhanna, K; Kim, R | 1 |
| Granov, DA; Gulo, AS; Pavlovskiĭ, AV; Popov, SA; Shapoval, SV; Suvorova, IuV; Tlostanova, MS | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yoshida, H | 1 |
| Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O | 1 |
| Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K | 1 |
| Saif, MW; Wasif, N | 1 |
| Knisely, J; Ramos, J; Saif, MW | 1 |
| Cha, SW; Chung, JB; Kim, KW; Kim, MJ; Klotz, E; Lim, JS; Park, MS; Park, SW; Seong, J; Song, SY | 1 |
| Abrams, R; Ammar, A; Benson, AB; Cass, CE; Dicker, AP; Elsaleh, H; Farrell, JJ; Garcia, M; Lai, R; Macdonald, J; Mackey, JR; Regine, WF | 1 |
| Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Hamada, K; Horiuchi, R; Igarashi, R; Obayashi, K; Ohwada, S; Sunose, Y; Takeyoshi, I; Yamamoto, K | 1 |
| Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Abbruzzese, JL; Amos, CI; Chen, J; Evans, DB; Frazier, ML; Killary, AM; Li, D; Sen, S | 1 |
| Chan, A; Chan, F; Cosenza, SC; Cusatis, G; Donehower, RC; Hidalgo, M; Jimeno, A; Kulesza, P; Ramana Reddy, MV; Reddy, EP; Rudek, MA; Solomon, A; Wheelhouse, J; Zhang, X; Zhao, M | 1 |
| Twombly, R | 1 |
| Höhler, T; Oettle, H; Staib, L | 1 |
| Chang, HM; Cho, JY; Im, SA; Kim, BS; Kim, HK; Kim, JS; Kim, MK; Kim, YH; Lee, KH; Lee, MA; Lim, HY; Ryoo, BY; Song, HS; Zang, DY | 1 |
| Beck, AW; Brekken, RA; Carbon, JG; Dineen, SP; Mamluk, R; Miller, AF; Sullivan, LA; Wong, H | 1 |
| Ko, AH; Tempero, MA | 3 |
| Abrams, T; Allen, B; Blaszkowsky, LS; Chan, JA; Clark, JW; Enzinger, PC; Fuchs, CS; Hezel, AF; Meyerhardt, JA; Ryan, DP; Wolpin, BM | 1 |
| Heinemann, V | 5 |
| Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J | 1 |
| Izuishi, K; Kakinoki, K; Maeba, T; Okamoto, Y; Okano, K; Suzuki, Y; Usuki, H; Wakabayashi, H | 1 |
| Bae, SH; Eun, JR; Hyun, MS; Jang, BI; Kim, MK; Kim, TN; Lee, KH; Lee, SA; Ryoo, HM | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Kim, YT; Lee, JL | 1 |
| Ikeuchi, N; Ishii, K; Itoi, T; Itokawa, F; Kurihara, T; Moriyasu, F; Sofuni, A; Tsuchiya, T; Tsuji, S | 1 |
| Arumugam, T; Ji, B; Levin, PA; Logsdon, CD; Lopez-Berestein, G; McConkey, DJ; Pan, X; Ramachandran, V; Sood, AK; Vivas-Mejia, PE; Yamamoto, T | 1 |
| Dilulio, J; Ganju, V; Khamly, K; Leong, T; Matera, A; Michael, M; Milner, AD; Muller, A; Ngan, SY; Price, T; Strickland, AH; Zalcberg, JR | 1 |
| Adamson, DJ; Ali, CW; Highley, MS; Kaye, TF; Polignano, FM; Tait, IS | 1 |
| Bhure, U; Clavien, PA; Hany, TF; Heinrich, S; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Doiuchi, T; Inoue, T; Ito, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Aiba, T; Aoyagi, Y; Baba, Y; Ban-Nai, H; Furukawa, K; Iiri, T; Ishizuka, K; Isokawa, O; Maruyama, Y; Mori, S; Motoyama, N; Nakamura, A; Natsui, M; Ohta, H; Seki, K; Shioji, K; Suzuki, Y; Watanabe, K; Yanagi, M | 1 |
| Hirota, M; Ichihara, T; Okamoto, K; Sato, T; Yagi, Y; Yamashita, K | 1 |
| Ebuchi, M; Koide, A; Koike, T; Maruyama, M; Maruyama, S; Ohinata, R; Sakoma, T; Sanada, T; Satoh, E; Shima, Y | 1 |
| Aoki, T; Hamada, H; Kenno, S; Oba, G; Okuda, K; Shimada, S; Shimokuni, T; Takada, J | 1 |
| Iida, M; Tokairin, Y; Yamazaki, S | 1 |
| Kim, DH; Nakamura, Y; Ogawa, K; Otani, T; Shiozawa, S; Tsunoda, T; Usui, T; Yoshimatsu, K | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Becker, J; Bharthuar, A; Deeb, G; Egloff, L; George, M; Iyer, RV; Lohr, JW | 1 |
| López-Tarruella, S; Rivera, F; Salcedo, M; Vega-Villegas, ME | 1 |
| Imada, H; Korogi, Y; Morioka, T; Nakano, K; Narisada, H; Ohguri, T; Yahara, K | 1 |
| Abrams, RA; Leslie, WT; Mahon, B; Shah, A; Shah, AP; Strauss, JB | 1 |
| Booth, RJ; Canman, CE; Denny, WA; Kraker, AJ; Lawrence, TS; Maybaum, J; Morgan, MA; Palmer, BD; Parsels, JD; Parsels, LA; Tanska, DM | 1 |
| Chen, N; Fong, Y; Galanis, C; Szalay, AA; Woo, Y; Yu, YA; Zhang, Q | 1 |
| Bornmann, C; Esser, N; Graeser, R; Hopt, UT; Jantscheff, P; Massing, U; Schaechtele, C; Unger, C; von Dobschuetz, E; Ziroli, V | 1 |
| Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Bentrem, DJ; Ding, XZ; McGill, JJ; Melstrom, LG; Milam, BM; Salabat, MR; Strouch, MJ; Ujiki, MB | 1 |
| Angelova, AL; Aprahamian, M; Balboni, G; Dinsart, C; Giese, NA; Grekova, SP; Hajri, A; Herrmann, A; Leuchs, B; Raykov, Z; Rommelaere, J | 1 |
| Esser, N; Fichtner, I; Graeser, R; Kratz, F; Unger, C; Unger, H; Zhu, A | 1 |
| Jeong, CY; Ju, JH; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Kim, TH; Lee, GW | 1 |
| Crane, CH; Evans, DB; Fleming, JB; Settle, SH; Varadhachary, G; Wolff, RA | 1 |
| Feldmann, G; García-García, E; Hidalgo, M; Jimeno, A; López-Ríos, F; Maitra, A; Matsui, W; Rasheed, Z; Rubio-Viqueira, B; Solomon, A; Suárez-Gauthier, A; Zou, GM | 1 |
| Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT | 1 |
| Barten-Van Rijbroek, AD; Kal, HB; Leen, R; Rodermond, HM; Van Bree, C; Van Kuilenburg, AB | 1 |
| Aho, U; Andersson, R; Nilsson, BI; Pastor-Anglada, M; Peters, GJ; Rasch, W; Sandvold, ML | 1 |
| Jia, L; Liu, YH; Wei, CG; Xie, Q | 1 |
| Davies, D; Halldén, G; Leitner, S; Lemoine, NR; Miranda, E; Oberg, D; Sweeney, K | 1 |
| Hirohata, S; Horita, K; Niki, T; Nishisaki, H; Tsuda, M; Yamamoto, Y | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Foo, KF; Wang, ML | 1 |
| Lluís, F | 1 |
| Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Mori-Iwamoto, S; Nakamura, K; Okita, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T | 1 |
| Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
| Bulotta, A; Calimeri, T; Celia, C; Cosco, D; Costa, N; Fresta, M; Neri, P; Paolino, D; Perri, G; Tagliaferri, P; Tassone, P; Ventura, M | 1 |
| Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M | 1 |
| Abbruzzese, JL; Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Gallick, GE; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Goto, H; Hara, K; Hirooka, Y; Ishigami, M; Ishikawa, T; Itoh, A; Kaneko, T; Kasugai, T; Katano, Y; Kawashima, H; Matsubara, H; Nieda, M; Niwa, Y; Nonogaki, K; Ohmiya, N; Ohno, E; Yamamoto, K; Yokokawa, K | 1 |
| Bitzer, M; Fend, F; Finkenwirth, P; Gregor, M; Horger, MS; Lauer, UM; Schick, D | 1 |
| Hoimes, C; Saif, MW; Strimpakos, AS | 1 |
| Hoimes, CJ; Saif, MW; Strimpakos, AS | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Clark, JW; Goulart, BH; Grenon, N; Lauwers, GY; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Gäbele, E; Harder, J; Hinke, A; Hollerbach, C; Hollerbach, S; Kullmann, F; Messmann, H; Trojan, J | 1 |
| Hasegawa, R; Ikeda, M; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yoshida, T | 1 |
| Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J | 1 |
| Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL | 1 |
| Bekaii-Saab, TS; Fortune, BE; Kosuri, KV; Li, X; Thomas, JP; Weatherby, LM | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL; Young, J | 1 |
| Ch'ang, HJ; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Huang, CL; Hwang, TL; Jan, CM; Lin, JT; Shiah, HS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; Mach, RH; McDunn, JE; Simon, PO; Vangveravong, S | 1 |
| Hirata, K; Ishikawa, O; Kimura, W; Kinoshita, H; Kurashina, K; Nagai, H; Nagakawa, T; Nakao, A; Ohta, T; Oka, M; Sata, N; Shimada, H; Tanaka, M; Yasuda, H | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS | 1 |
| Baserga, R; Belmontes, B; Beltran, PJ; Cajulis, E; Calzone, FJ; Chung, YA; Ho, J; Kendall, R; Lu, J; Mitchell, P; Radinsky, R; Tsai, MM; Vonderfecht, S; Zhu, M | 1 |
| Bousquet, C; Brizuela, L; Cuvillier, O; Davenne, L; Delisle, MB; Guilbeau-Frugier, C; Guillermet-Guibert, J; Pchejetski, D; Saint-Laurent, N; Susini, C | 1 |
| Ishibashi, Y; Ito, Y | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Jacobs, MJ; Saidi, RF | 1 |
| Buchsbaum, DJ; Grizzle, WE; Li, J; Oelschlager, DK; Tian, DA; Wan, M; Wang, P; Wang, Y; Yang, C; Zheng, Y | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; McDunn, JE; Simon, PO | 1 |
| Hedley, DW; Mamaghani, S; Patel, S | 1 |
| Barthet, M; Calvo, EL; Dagorn, JC; Delpero, JR; Iovanna, JL; Legoffic, A | 1 |
| Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM | 1 |
| Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM | 1 |
| Chun, SG; Yee, NS; Zhou, W | 1 |
| Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Alfieri, S; Antinori, A; Cellini, N; Crucitti, A; D'Agostino, GR; Di Lullo, L; Doglietto, GB; Ippolito, E; Luzi, S; Mantini, G; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V | 1 |
| Chen, Y; Guo, Q; Kang, M; Wu, Y; Xie, Q; Zhang, B | 1 |
| Dalgleish, AG; Liu, WM; Nizar, S | 1 |
| Mizumoto, K; Moriyama, T; Nabae, T; Nagai, E; Ohuchida, K; Sato, N; Takahata, S; Tanaka, M; Toma, H; Yu, J | 1 |
| Adachi, S; Handa, O; Ishikawa, T; Kokura, S; Naito, Y; Okayama, T; Takagi, T; Yoshikawa, T | 1 |
| Freeman, JW; Giles, FJ; Wang, Y | 1 |
| Pawlega, J; Zygulska, AL | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Fairweather, WR; King, CR; Murugesan, SR; O'Reilly, EM; Osborn, R; Thornton, MO; Wei, LL | 1 |
| Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Sorscher, SM | 1 |
| Borbath, I; Boterberg, T; de Hemptinne, B; Demols, A; Hendlisz, A; Laurent, S; Mahin, C; Monsaert, E; Peeters, M; Polus, M; Scalliet, P; Van Laethem, JL | 1 |
| Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Morita, S; Nishimura, T; Sasaki, T; Yanagihara, K; Yasuda, H; Yazumi, S | 1 |
| Adams, J; Allard, D; Caldwell, ME; Chang, A; Combs, C; Davidson, CJ; Davies, SE; Denicola, G; Dhara, M; Egorin, M; Feig, C; Frese, KK; Goldgraben, MA; Gopinathan, A; Griffiths, J; Grützmann, R; Hingorani, SR; Honess, D; Howat, WJ; Hruban, RH; Huang, P; Iacobuzio-Donahue, C; Ireland-Zecchini, H; Izeradjene, K; Jacobetz, MA; Madhu, B; McGovern, K; McIntyre, D; Olive, KP; Pilarsky, C; Plunkett, W; Reichelt, S; Rückert, F; Tuveson, DA; Wang, L; Whitebread, N; Winter, SP | 1 |
| Amitani, R; Hatano, K; Ikeda, A; Kawakami, H; Kimura, T; Kita, R; Maruo, T; Matsuo, H; Nakatsuji, M; Nishijima, N; Nishikawa, H; Okabe, Y; Osaki, Y; Saito, S; Tsumura, T | 1 |
| Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Gorospe, M; Keen, JC; Kennedy, EP; Kuwano, Y; Witkiewicz, AK; Yeo, CJ | 1 |
| Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J | 1 |
| Chan, F; Hidalgo, M; Jimeno, A; Lin, SH; Rajeshkumar, NV; Rubio-Viqueira, B; Solomon, A; Tan, AC; Wheelhouse, J | 1 |
| Bartenstein, P; Berger, F; D'Haese, JG; Ellwart, JW; Heeschen, C; Hermann, PC; Hidalgo, M; Huber, S; Jauch, KW; Leicht, SF; Mueller, MT; Mustafa, M; Rubio-Viqueira, B; Schoenberg, MH; Witthauer, J | 1 |
| Aspe, JR; Galloway, NR; Sellers, C; Wall, NR | 1 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Bijelic, L; Kamath, A; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Arora, S; Azorsa, DO; Basu, GD; Bisanz, KM; Choudhary, A; Gonzales, IM; Henderson, MC; Kiefer, JA; Mousses, S; Trent, JM; Von Hoff, DD | 1 |
| Hanahan, D; Olson, P | 1 |
| Ko, CJ; Li, J; Saif, MW | 1 |
| Arakawa, T; Ashida, R; Hirakawa, K; Mizuno, N; Nakata, B; Sawaki, A; Shigekawa, M; Yamao, K | 1 |
| Antúnez, A; García-Mata, J; Mellado, JM; Villar, JL; Zambrana, F | 1 |
| Gold, DV; Goldenberg, DM; Leon, E; Modrak, DE | 1 |
| Banerjee, S; Kong, D; Sarkar, FH; Wang, Z | 1 |
| Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V | 1 |
| Mistafa, O; Stenius, U | 1 |
| Abe, T; Ikeda, K; Koeda, K; Minakawa, Y; Nitta, H; Obuchi, T; Otsuka, K; Sasaki, A; Shimooki, O; Wakabayashi, G | 1 |
| Aono, T; Fushimi, H; Iwase, K; Koma, M; Matsuda, C; Nishikawa, K; Nomura, M; Shimada, K; Takeda, S; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Akita, H; Bepler, G; Doki, Y; Dono, K; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Takemasa, I; Zheng, Z | 1 |
| Eguchi, H; Ishikawa, O; Nakagawa, H; Nakamura, Y; Nishiyama, K; Ohigashi, H; Takahashi, H; Takehara, A; Tomita, Y; Uehara, R; Yano, M | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Banerjee, S; Kaseb, AO; Kong, D; Mohammad, M; Mohammad, RM; Padhye, S; Sarkar, FH; Wang, Z | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Eguchi, H; Gotoh, K; Ishikawa, O; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H; Yamada, T; Yano, M | 2 |
| Bigand, C; Hajri, A; Parmentier, C; Réjiba, S | 1 |
| Cance, WG; Golubovskaya, VM; Hochwald, SN; Magis, A; Massoll, NA; Nyberg, C; Ostrov, D; Wood, C; Zheng, D; Zheng, M | 1 |
| Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F | 1 |
| Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
| Alberts, S; Benson, AB; Berlin, J; Catalano, P; Cella, D; Feng, Y; Haller, D; Hochster, H; Mitchell, E; O'Dwyer, P; Poplin, E; Rothenberg, ML | 1 |
| Sherman, WH | 1 |
| Choi, DW; Choi, SH; Heo, JS; Lee, HG; You, DD | 1 |
| Abbruzzese, JL; Arumugam, T; Choi, W; Fournier, KF; Gallick, GE; Logsdon, CD; Marquis, L; McConkey, DJ; Ramachandran, V; Wang, H | 1 |
| Bang, S; Hong, SP; Park, S; Song, SY; Wen, J | 1 |
| Abbassi, S; Doan, NB; Iwanski, GB; Koeffler, HP; Lin, P; Okamoto, R; Said, JW; Song, JH; Thoennissen, NH; Toh, M; Xie, WD; Yin, D | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Lin, XB; Wang, FH; Xu, RH | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Awasthi, N; Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 2 |
| Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA | 1 |
| Ali, S; Kong, D; Li, Y; Philip, PA; Sarkar, FH; VandenBoom, TG; Wang, Z | 1 |
| Bakshandeh-Bath, A; Homann, N; Peters, SO; Stölting, S; Stoltz, AS; Wagner, T | 1 |
| Chiao, PJ; Gocho, T; Hirohara, S; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Seki, Y; Ueno, H | 1 |
| Aubert, S; Fauquette, V; Huet, G; Jonckheere, N; Pigny, P; Porchet, N; Saint-Laurent, N; Stechly, L; Susini, C; Van Seuningen, I | 1 |
| Antman, KA; Chabot, JA; Chen, C; Fine, RL; Grann, VR; Kumah, CK; Tsai, WY | 1 |
| Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT | 1 |
| Doi, R; Egawa, S; Hatori, T; Kanemitsu, K; Kosuge, T; Matsuyama, Y; Monden, M; Nakao, A; Shimada, M; Tanaka, M; Ueno, H; Yamamoto, J | 1 |
| Hirotsune, H; Inoue, A; Komori, K; Matsuyama, K; Miyamoto, A; Nakamori, S; Oike, M; Satomi, E; Sekiyama, R; Sueta, K; Todaka, K; Tsujinaka, T; Ueno, H; Yoshida, T | 1 |
| Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A | 1 |
| Hara, K; Hoki, N; Ito, S; Kawai, H; Kobayashi, Y; Matsumoto, K; Mizuno, N; Nakamura, T; Sawai, Y; Sawaki, A; Tajika, M; Takagi, T; Yamao, K | 1 |
| Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L | 1 |
| Alkis, N; Aslan, UY; Benekli, M; Buyukberber, S; Camci, C; Celenkoglu, G; Coskun, U; Er, O; Ozkan, M; Ozturk, B; Sevinc, A; Tokluoglu, S; Uner, A; Yildiz, R | 1 |
| Barone, C; Chodkiewicz, C; Kim, S; Maurel, J; Ricart, AD; Rosbrook, B; Spano, JP; Springett, GM; Wasan, HS; Wong, R | 1 |
| Chen, Y; Smith, BJ | 1 |
| Hagihara, A; Hashimoto, K; Ikeda, M; Kojima, Y; Kondo, S; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Esau, C; Lee, EJ; Park, JK; Schmittgen, TD | 1 |
| Chen, W; Cui, L; Fu, DL; Hou, HM; Jin, C; Li, JM; Lu, WY; Ni, QX; Wang, H; Yu, XJ | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Kaley, K; Peccerillo, J; Saadati, H; Saif, MW; Schilsky, ML | 1 |
| Bafna, S; Batra, SK; Kaur, S; Momi, N | 1 |
| Alvarez Sánchez, MV; Alvarez, M; Baltar Arias, R; Gómez Martínez, P; Soto Iglesias, S; Vázquez Astray, E; Vázquez Rodríguez, S | 1 |
| Ikeda, H; Mouri, H; Nakanuma, Y; Ohtsubo, K; Tsuchiyama, T; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Custodio, A; Díaz-Rubio, E; Puente, J; Sastre, J | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Halldén, G | 1 |
| Cass, CE; Paproski, RJ; Young, JD | 1 |
| Heike, Y; Hyodo, I; Ikeda, M; Makiyama, H; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Takahashi, N; Takaue, Y; Ueno, H; Yamagata, S | 1 |
| Bechi, P; Cipriani, G; Grifoni, R; Molinara, E; Neri, B; Pantaleo, P; Pantalone, D; Rangan, S; Taddei, A; Tonelli, P; Valeri, A; Vannini, A | 1 |
| Larsen, CJ | 1 |
| Liew, A; Magee, C; Phelan, PJ | 1 |
| Qian, C; Yao, J | 1 |
| Aboukameel, A; Banerjee, S; Chen, J; Choi, M; Mohammad, M; Mohammad, RM; Sarkar, FH; Wang, Z; Yang, D | 1 |
| Blackwelder, WC; Chawla, SP; Chua, VS; Fernandez, L; Gordon, EM; Hall, FL; Quon, D | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Mackenzie, RP; McCollum, AD | 1 |
| Barthet, M; Calvo, E; Cano, C; Closa, D; Dagorn, JC; Delpero, JR; Ferrés-Masó, M; Folch-Puy, E; Iovanna, J; Legoffic, A | 1 |
| Chiba, A; Fujii, T; Habiro, A; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Sasajima, J; Sugiyama, Y; Tanno, S | 1 |
| Fukada, I; Ikeda, H; Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Kanter, J; Strasberg, S; Wilson, DB | 1 |
| Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Booth, CM; Eisenhauer, EA; Ohorodnyk, P | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Hagmann, W; Jesnowski, R; Matthias Löhr, J | 1 |
| Ito, Y; Karasawa, K; Kazumoto, T; Nemoto, K; Nishimura, Y; Nishino, S; Ogawa, K; Ogawa, Y; Ogo, E; Okuno, Y; Onishi, H; Shibuya, H; Shibuya, K; Uchida, N | 1 |
| Chen, H; Jiang, H; Kong, R; Krissansen, GW; Pan, S; Sun, B; Sun, X; Wang, S | 1 |
| Azria, D; Bascoul-Mollevi, C; Ho-Pun-Cheung, A; Larbouret, C; Mach, JP; Morisseau, S; Navarro-Teulon, I; Pèlegrin, A; Penault-Llorca, F; Robert, B | 1 |
| Chiba, T; Hatano, E; Ishiguro, H; Kanai, M; Kawaguchi, Y; Kitano, T; Masui, T; Matsumoto, S; Matsumura, Y; Mori, A; Nakamura, E; Nishimura, T; Tada, S; Yanagihara, K | 1 |
| Furukawa, K; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimizu, H; Suda, K; Takano, S; Takayashiki, T; Takeuchi, D; Yoshidome, H; Yoshitomi, H | 1 |
| Boku, N; Endo, M; Igawa, S; Murakami, H; Nakamura, Y; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S | 1 |
| Kennedy, AM; Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Boeck, S; Boettcher, HD; Bruns, CJ; Fietkau, R; Flentje, M; Heinemann, V; Herbst, M; Hinke, A; Miethe, S; Ostermaier, S; Rau, HG; Sauer, R; Scholten, T; Wilkowski, R | 1 |
| Aggarwal, BB; Anand, P; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Pandey, MK; Sethi, G | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Hirono, S; Kawai, M; Miyazawa, M; Nakamura, Y; Ohsawa, R; Tani, M; Tsunoda, T; Yamaue, H | 1 |
| Gu, YH; Guo, RH; Lin, QF; Liu, LX; Shu, YQ; Wang, RS | 1 |
| Chang, CH; Gold, DV; Goldenberg, DM; Karacay, H; McBride, WJ; Ragland, DR; Rossi, EA; Sharkey, RM | 1 |
| Hirono, S; Ina, S; Noda, T; Yamaue, H | 1 |
| He, SM; Huang, YJ; Leng, TD; Li, Y; Ou, YQ; Qiu, PX; Xie, J; Xu, D; Yan, GM; Zheng, XK; Zhu, Wb | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kawashima, M; Kinoshita, T; Mitsunaga, S; Nakachi, K; Shimizu, S | 1 |
| Borbath, I; Caplin, ME; Coxon, F; Kato, H; Larvin, M; Meyer, T; Nagano, E; Palmer, DH; Peeters, M; Valle, JW; Waters, JS | 1 |
| Grützmann, R; Joensson, P; Pilarsky, C; Rückert, F; Saeger, HD | 1 |
| Koga, Y; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 1 |
| Huanwen, W; Kai, W; Tonghua, L; Xiaohua, S; Xinyu, R; Zhiyong, L | 1 |
| Wang, ZY | 1 |
| Abbruzzese, JL; Javle, M; Li, D; Okazaki, T; Tanaka, M | 1 |
| Akahori, T; Doh, J; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Nomi, T; Sho, M; Tamamoto, T; Tanaka, T; Yamada, T; Yamato, I | 1 |
| Kametaka, H; Koyama, T; Makino, H; Seike, K; Yasuno, K | 1 |
| Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T | 1 |
| Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K | 1 |
| Ami, K; Ando, M; Fukuda, A; Ganno, H; Hataji, K; Maruyama, M; Nagahama, T; Ohara, T | 1 |
| Doki, Y; Eguchi, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Ohmura, Y; Takeda, Y; Tanemura, M | 1 |
| Funada, N; Honda, G; Kurata, M; Tokashiki, T; Tsuruta, K; Watanabe, F | 1 |
| Fukunaga, M; Furukawa, H; Ikeda, H; Mabuchi, E; Matsumura, T; Miwa, H; Ohzato, H; Ota, K; Yamamoto, T | 1 |
| Heller, G; Panageas, KS; Schrag, D; Sima, CS | 1 |
| Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Mitsuno, M; Miyazaki, K; Nakamura, J; Noshiro, H; Ohtaka, K | 1 |
| Funamizu, N; Gocho, T; Kamata, Y; Manome, Y; Misawa, T; Okamoto, A; Uwagawa, T; Yanaga, K | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Chang, DT; Fisher, GA; Ford, JM; Goodman, KA; Graves, EE; Koong, AC; Kunz, P; Minn, AY; Quon, A; Schellenberg, D | 1 |
| Bossard, N; Chauffert, B; Girard, N; Mornex, F; Wautot, V; Ychou, M | 1 |
| Lillemoe, KD; Nakeeb, A; Simianu, VV; Zyromski, NJ | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Shoji, A; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Doi, R; Fujii, T; Hiraoka, M; Matsuo, Y; Mitsumori, M; Nakamura, A; Oya, N; Shibuya, K | 1 |
| Ceraulo, D; Cereda, S; Fugazza, C; Mazza, E; Reni, M; Rognone, A; Villa, E | 1 |
| Aziz, F; Ji, Y; Wang, D; Yang, G; Yang, Z; Yu, X; Zhang, Y; Zhao, H; Zhao, W; Zhong, B; Zhu, J | 1 |
| Lai, JI; Lin, PC; Tzeng, CH; Wang, WS | 1 |
| Chan, A; Hidalgo, M; Jimeno, A; Rajeshkumar, NV; Rubio-Viqueira, B; Solomon, A | 1 |
| Aronow, B; French, R; Hoffman, RM; Jaquish, D; Logan-Collins, J; Lowy, AM; McClaine, R; Mose, E; Stuart, W; Thomas, RM; Waltz, SE; Yu, P | 1 |
| Abbruzzese, JL; El-Rayes, BF; Ferris, AM; Hess, K; Javle, MM; Kaseb, AO; Philip, PA; Sarkar, FH; Shields, AF; Varadhachary, GR; Wolff, RA | 1 |
| Aprile, G; Berardi, R; Cereda, S; Cordio, S; Falconi, M; Mambrini, A; Milella, M; Pasetto, LM; Passardi, A; Pederzoli, P; Reni, M; Rognone, A; Sartori, N; Tronconi, MC | 2 |
| Jia, G; Zhang, WM; Zhou, J; Zhu, ZX | 1 |
| Hamano, H; Kobayashi, N; Orikawa, Y; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Hu, YD; Kong, YZ; Li, P; Ling, Y; Liu, YP; Wang, F | 1 |
| Bai, XW; Chen, H; Gao, Y; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Cheung-Lau, G; Dawson, DW; Dawson, NA; Farrell, J; Guha, C; Hines, OJ; Horvath, S; Kurdistani, SK; Manuyakorn, A; Paulus, R; Reber, H; Seligson, DB; Tze, S | 1 |
| Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD | 1 |
| Chen, R; Liu, E; Liu, X; Niu, J; Niu, W; Peng, C; Wang, J; Xu, K; Zhang, Z | 1 |
| Christians, K; Evans, DB; Lal, A | 1 |
| Backlund, DC; Berlin, JD; Parikh, AA | 1 |
| Cui, L; Egami, T; Hashizume, M; Mizumoto, K; Nagai, E; Ohuchida, K; Onimaru, M; Sato, N; Takayama, K; Tanaka, M; Uchino, J | 1 |
| Brennan, D; Callery, M; Goldstein, M; Jain, S; Mahadevan, A; Miksad, R; Pleskow, D; Sawhney, M; Vollmer, C | 1 |
| Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N | 1 |
| Cao, Y; Gao, F; Liao, C; Liu, L; Tan, A; Wu, L | 1 |
| Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Todaka, A; Tomita, H; Yamazaki, K; Yasui, H | 1 |
| Albrecht, H; Boxberger, F; Hahn, EG; Hohenberger, W; Konturek, PC; Männlein, G; Ostermeier, N; Reulbach, U; Roehrig, S; Wein, A; Wolff, K | 1 |
| Benson, AB; Berlin, J | 1 |
| Cartenì, G; Cavanna, L; Ciaparrone, M; Colucci, G; Dapretto, E; Di Costanzo, F; Di Maio, M; Falconi, M; Gallo, C; Gebbia, V; Giuliani, F; Labianca, R; Maiello, E; Manzione, L; Massidda, B; Pederzoli, P; Perrone, F; Piazza, E; Sannicolò, M; Testa, A | 1 |
| Adachi, S; Itoh, F; Izawa, N; Katakura, Y; Kobayashi, M; Nakahara, K; Nakatsu, S; Noguchi, Y; Sato, Y; Takagi, R | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Corrie, P; Gounaris, I; Zaki, K | 1 |
| Richter, J; Saif, MW | 1 |
| Hiraya, D; Kagohashi, K; Kondo, T; Sakamoto, N; Satoh, H | 1 |
| Bader, T; Bertucci, F; Castéran, N; Dubreuil, P; Finetti, P; Hanssens, K; Hermine, O; Humbert, M; Iovanna, J; Letard, S; Mansfield, CD; Moussy, A | 1 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
| Ali, S; Campbell-Baird, C; Harvey, H; Lipton, A; Witters, L | 1 |
| Ambrosino, G; Casamassima, F; Costantin, G; Febbraro, A; Francescon, P; Guglielmi, R; Panizzoni, G; Polistina, F | 1 |
| Hall, PD; Teusink, AC | 1 |
| Dash, AK; Khurana, J; Nagvekar, AA; Trickler, WJ | 1 |
| Alvarez, EM; Archange, C; Gonzalez, CD; Iovanna, JL; Lo Ré, A; Papademetrio, DL; Pardo, R; Ropolo, A; Vaccaro, MI | 1 |
| Chen, H; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, G; Wang, SJ; Xue, DB | 1 |
| Batra, SK; Chakraborty, S; Johansson, SL; Mimeault, M; Momi, N; Senapati, S | 1 |
| Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD | 1 |
| Bardeesy, N; Brekken, RA; Carbon, JG; Dineen, SP; Greer, R; Gupta, P; Minna, JD; Roland, CL; Sun, H; Toombs, JE; Williams, N | 1 |
| Hayashi, N; Hayashi, Y; Iijima, H; Inoue, T; Kitagawa, T; Konishi, K; Nishida, T; Takeda, Y; Tsujii, M; Tsutsui, S; Yamamoto, K; Yoshioka, Y | 1 |
| Hirose, K; Ikeda, T; Imai, N; Ishikawa, T; Kawata, N; Mizutani, Y; Taga, M; Takeda, K; Utsunomiya, S; Yoshida, S | 1 |
| Garber, K | 1 |
| Dorr, RT; Landowski, TH; Roman, NO; Samulitis, BK; Wisner, L | 1 |
| Denda, T; Hara, T; Ishihara, T; Nakamura, K; Sudo, K; Yamaguchi, T; Yokosuka, O | 1 |
| McIntosh, D; Shaukat, A | 1 |
| Cooke, EW; Hazard, L | 1 |
| Nugent, FW; Stuart, K | 1 |
| Mehta, SP | 1 |
| Kato, Y; Katori, M; Koga, R; Kokudo, N; Saiura, A; Sakamoto, Y; Seki, M; Yamaguchi, T; Yamamoto, J | 1 |
| Deplanque, G; Hammel, P; Hermine, O; Kinet, JP; Levy, P; Mitry, E; Mornex, F; Moussy, A; Raymond, E; Rougier, P; Seitz, JF | 1 |
| Aboukameel, A; Almhanna, K; Azmi, AS; Banerjee, S; Goustin, AS; Mohammad, RM; Philip, PA; Sarkar, FH; Wang, Z; Yang, D; Zafar, SF | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Di Marco, M; Macchini, M; Nobili, E; Vecchiarelli, S | 1 |
| An, Y; Cai, HH; Chen, P; Dai, CC; Ji, ZL; Jiang, KR; Lu, ZP; Miao, Y; Qian, ZY; Wei, JS; Wu, JL; Xu, ZK; Yao, J | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Ahmad, A; Ali, S; Banerjee, S; Dominiak, K; Padhye, S; Philip, PA; Sarkar, FH; Schaffert, JM; Wang, Z | 1 |
| Cui, L; Egami, T; Hashizume, M; Matsumoto, K; Mizumoto, K; Nagai, E; Ohuchida, K; Onimaru, M; Tanaka, M; Toma, H | 1 |
| Glimelius, B | 2 |
| Moore, M; Renouf, D | 1 |
| Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S | 1 |
| Imawari, M; Ito, N; Kiuchi, Y; Kobayashi, M; Kogo, M; Konishi, K; Kurihara, T; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Azmi, AS; Banerjee, S; Baruah, JB; Mohammad, RM; Padhye, S; Philip, PA; Sarkar, FH; Singh, MW | 1 |
| Hidalgo, M | 1 |
| Aviram, A; Escalon, E; Melnick, SJ; Ramachandran, C; Resek, AP | 1 |
| Fietkau, R; Heinemann, V; Knoefel, WT; Oettle, H; Tannapfel, A | 1 |
| Brand, RE; Singh, SV; Stan, SD | 1 |
| Chakerian, P; Kaley, K; Lamb, L; Saif, MW | 1 |
| Jensen, BV; Ladekarl, M; Pfeiffer, P | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| Bock, PR; Friedel, WE; Matthes, H; Zänker, KS | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Alpaugh, RK; Astsaturov, IA; Burtness, BA; Cheng, JD; Cohen, SJ; McLaughlin, S; Meropol, NJ; Rogatko, A; Watson, JC; Weiner, LM; Xu, Z | 1 |
| Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Erozenci, LA; Falcone, A; Funel, N; Giovannetti, E; Groen, A; Leon, LG; Peters, GJ; Pollina, LE; Vasile, E; Verheul, HM | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Abbruzzese, J; Baker, AF; Dragovich, T; Green, S; Guillen, JM; Kirkpatrick, L; Pestano, LA; Ramanathan, RK; Von Hoff, DD | 1 |
| Benson, AB; Catalano, PJ; Cooper, H; Harris, W; Hoffman, J; Landry, J; Staley, C; Talamonti, M; Xu, N | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Tsujino, T | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Fujisawa, T; Joshi, BH; Nakajima, A; Nakashima, H; Puri, RK | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 2 |
| Arumugarajah, S; Canman, CE; Davis, MA; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Normolle, DP; Parsels, JD; Parsels, LA; Simeone, DM; Zabludoff, SD; Zhao, L | 1 |
| Ai, KX; He, ML; Huang, XY; Li, A; Qin, HL; Wang, HC; Yuan, Z; Zheng, Q | 1 |
| Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM | 1 |
| Baker, JH; Buczkowski, AK; Cham, KK; Chang, CW; Chu, EM; Chung, SW; Flexman, JA; Kozlowski, P; Minchinton, AI; Ng, SS; Owen, DA; Reinsberg, SA; Scudamore, CH; Takhar, KS; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Alecci, C; Bertini, S; Danesi, R; Funel, N; Giancola, F; Giovannetti, E; Leon, LG; Macchia, M; Minutolo, F; Peters, GJ | 1 |
| Adachi, M; Hibi, T; Higuchi, H; Hozawa, S; Iizuka, H; Izumiya, M; Nakamura, S; Sakai, G; Takaishi, H; Yamagishi, Y | 1 |
| El-Rayes, BF; Hammad, N; Heilbrun, LK; Philip, PA; Shields, AF; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Kameda, R; Kobayashi, S; Miyagawa, K; Morinaga, S; Okawa, S; Ueno, M | 1 |
| Miyagawa, K; Sagara, Y; Yamaoka, N; Yata, Y | 1 |
| Dünschede, F; Galle, PR; Junginger, T; Möhler, M; Otto, G; Vahl, CF; von Langsdorf, C; Will, L | 1 |
| Brody, JR; Dasgupta, A; Kleer, CG; Potoczek, M; Toll, AD; Witkiewicz, AK; Yeo, CJ | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Jin, X; Koniaris, LG; Montero, AJ; Zimmers, TA | 1 |
| Eppinga, W; Lagerwaard, F; Senan, S; Slotman, B; Verbakel, W | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Christein, J; Eloubeidi, M; Frolov, A; Greeno, E; Jhala, N; Keene, K; Oster, R; Posey, J; Russo, S; Varadarajulu, S; Vickers, SM; Wood, T | 1 |
| Bokemeyer, C; Castor, B; Doan, NB; En-Gal, S; Iwanski, GB; Koeffler, HP; Lee, DH; Said, JW; Thoennissen, NH; Toh, M; Vogt, M | 1 |
| Kadish, SP; McDade, TP; Piperdi, B; Piperdi, M; Shim, JK; Sullivan, ME; Tseng, JF; Whalen, GF | 1 |
| Benson, AB; Bentrem, DJ; Mulcahy, MF; Rademaker, A; Small, W; Talamonti, MS; Weitner, BB | 1 |
| An, X; Ding, PR; He, YJ; Jiang, WQ; Li, YH; Shi, YX; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Araki, H; Denda, T; Hara, T; Hatano, K; Imagumbai, T; Ishihara, T; Ito, H; Kawakami, H; Nakamura, K; Sakai, M; Sudo, K; Tawada, K; Uno, T; Yamaguchi, T; Yokosuka, O | 1 |
| Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J | 1 |
| Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS | 1 |
| Bhargava, P; Goldberg, RM; Hollis, D; Hurwitz, H; Innocenti, F; Kindler, HL; Mayer, RJ; Mulcahy, MF; Niedzwiecki, D; O'Reilly, E; Picus, J; Schilsky, RL; Schrag, D; Sutherland, S; Wozniak, TF | 1 |
| Benedetti, J; Blanke, CD; Flynn, PJ; Goldman, B; Lippman, SM; Millwood, B; Moinpour, CM; O'Reilly, EM; Philip, PA; Redman, MW; Rowland, KM; Seay, TE; Vaught, NL; Wong, RP | 1 |
| Abbruzzese, JL; Atkins, JN; Benedetti, J; Blanke, CD; Corless, CL; Fenoglio-Preiser, CM; Flynn, PJ; Goldman, B; Khorana, AA; Mirtsching, BC; O'Reilly, EM; Philip, PA; Rivkin, SE; Rowland, KM; Wong, R | 1 |
| Lavi, S; Leitner, O; Lindzen, M; Yarden, Y | 1 |
| Lemoine, NR; Wong, HH | 1 |
| Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Bai, XW; Chen, H; Jiang, HC; Kong, R; Li, J; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R | 1 |
| Arakawa, A; Hisama, S; Kimura, M; Matsushita, H; Nishimura, T; Okamura, S; Saitoh, S; Shimokawa, Y; Tanaka, Y; Toyama, H | 1 |
| Mo, JZ; Sun, HL; Wu, SM; Xiong, GS | 1 |
| Hou, J; Ji, Y; Jin, DY; Lou, WH; Niu, GM; Wang, DS | 1 |
| Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Fujiwara, K; García-García, E; Hidalgo, M; López-Ríos, F; Matsui, WH; Rajeshkumar, NV; Rasheed, ZA | 1 |
| Brown, DB; Carr, BI; Gonsalves, CF; Witkiewicz, AK; Yeo, CJ | 1 |
| Itoh, K; Komatsu, N; Kwon, AH; Mine, T; Noguchi, M; Satoi, S; Shiomi, H; Tani, T; Toyokawa, H; Yamada, A; Yamamoto, T; Yanagimoto, H | 1 |
| Abbruzzese, JL; Dong, X; Eng, C; Javle, M; Li, D; Tanaka, M | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL | 1 |
| Bassett, MR; Bedolla, G; Campbell, AD; Davis, AT; Koo, HM; Luttenton, CR; Melnik, MK; Monroe, TJ; O'Rourke, TJ; Richardson, PJ; Stein, P; Szczepanek, CM; Truszkowski, KJ; Van Brocklin, MW; Vande Woude, GF; Webb, CP; Yost, KJ | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Du, Z; Peng, C; Qin, R; Shi, C; Tian, R; Wang, M; Wei, C | 1 |
| Gong, XG; Li, XQ; Lv, YF; Ma, QY; Xu, FG | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C | 1 |
| Flynn, G; Johnson, CS; Kong, RX; Ma, Y; Muindi, JR; Trump, DL; Yu, WD | 1 |
| Drukker, L; Epstein, A; Gabizon, A; Isacson, R; Keinan, A; Kelsen, D; Lowery, M; O'Reilly, EM; Rachkiman, M; Reissman, P; Rosengarten, O; Segal, A; Shah, MA; Smyth, E | 1 |
| Crea, F; Danesi, R; Del Tacca, M; Mey, V; Nannizzi, S; Pasqualetti, G; Ricciardi, S | 1 |
| Guerra, B; Kreutzer, JN; Ruzzene, M | 1 |
| Fukami, T; Funakoshi, A; Kuroki, M; Miyamoto, S; Yagi, H; Yoshizato, T; Yotsumoto, F | 1 |
| Brody, JR; Cozzitorto, JA; Freydin, B; Gonye, G; Grenda, D; Kennedy, EP; Richards, NG; Rittenhouse, DW; Rui, H; Witkiewicz, AK; Yeo, CJ | 1 |
| Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
| Ku, Y; Mukubou, H; Sasaki, R; Tsujimura, T | 1 |
| Akan, B; Ba'ssalamah, A; Eisenhut, A; Gnant, M; Goetzinger, P; Jakesz, R; Koellblinger, C; Kuehrer, I; Peck-Radosavljevic, M; Sahora, K; Teleky, B; Zielinski, C | 1 |
| Hu, Y; Liao, Q; Zhang, Q; Zhao, YP; Zhou, T | 1 |
| Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN | 1 |
| Hagmann, W; Jesnowski, R; Löhr, JM | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Sarkar, FH; Sethi, S; Wang, Z | 1 |
| Chin, K; da Cunha Santos, G; Dhani, N; Kamel-Reid, S; Ludkovski, O; Moore, MJ; Parulekar, W; Squire, J; Tsao, MS; Tu, D | 1 |
| Azria, D; Budach, V; Collette, L; Hammel, P; Haustermans, K; Lutz, M; Mauer, M; Mornex, F; Peeters, M; Polus, M; Praet, M; Van Cutsem, E; Van Laethem, JL; Van Tienhoven, G; Vergauwe, P | 1 |
| Fukui, H; Kou, C; Matsumoto, M; Matsumoto, T | 1 |
| Abe, S; Akaboshi, S; Baba, H; Beppu, T; Eto, S; Furuhashi, S; Horino, K; Ida, S; Nakahara, O; Ozaki, N; Takamori, H; Tanaka, H | 1 |
| Huang, XE; Tang, JH; Xu, HX; Yao, CY | 1 |
| Sahoo, SK; Vandana, M | 1 |
| Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K | 1 |
| Erkan, M; Friess, H; Kleeff, J; Michalski, CW; Quan, L; Raggi, MC; Reiser-Erkan, C; Wang, W; Yupei, Z | 1 |
| Aggarwal, BB; Deorukhkar, A; Dey, S; Diagaradjane, P; Gelovani, JG; Guha, S; Koca, C; Krishnan, S; Kunnumakkara, AB; Ravindran, J; Sung, B; Tong, Z; Yadav, VR | 1 |
| Bai, CM; Cheng, YJ; Zhang, ZJ | 1 |
| Chen, ZH; Ishigaki, Y; Motoo, Y; Nakagawa, H; Nakajima, H; Shimasaki, T; Takegami, T; Xia, QS; Zhao, X | 1 |
| Cardenes, HR; Chiorean, EG; Helft, P; Howard, TJ; Johnson, CS; Loehrer, PJ; Moore, AM; Stephens, AW; Tai, DF; Vinson, J; Yu, M | 1 |
| Ishii, H; Kamei, A; Kuraoka, K; Matsuyama, M; Ozaka, M; Takano, K; Yukisawa, S | 1 |
| Backer, JM; Backer, MV; Buhr, HJ; Hotz, B; Hotz, HG | 1 |
| Fujita, H; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Abolhassani, M; Baronzio, G; Behzadi, M; Campion, F; Fiorentini, G; Guais, A; Mainini, C; Montagnani, F; Sanders, E; Schwartz, L | 1 |
| Baba, N; Inaba, T; Ishikawa, H; Ishikawa, S; Kawai, K; Miyoshi, M; Nagano, T; Senoh, T; Takaguchi, K; Watanabe, S; Wato, M | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K; Zhang, X | 1 |
| Komori, S; Matsui, S; Mori, R; Osada, S; Sanada, Y; Takahashi, T; Tokuyama, Y; Tomita, H; Yamaguchi, K; Yoshida, K | 1 |
| Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Bellone, G; Brondino, G; Ciuffreda, L; Cristiano, C; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Diamond, DJ; Ellenhorn, JD; Ishizaki, H; Manuel, ER; Song, GY; Srivastava, T; Sun, S | 1 |
| Horneber, M | 1 |
| Meier, JJ; Ritter, PR; Schmidt, WE; Tischoff, I; Uhl, W | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Gordian, E; Miller, H; Ramachandran, K; Rocha-Lima, C; Singal, R | 1 |
| Cao, L; Liu, D; Que, R; Wang, G; Wang, L; Xie, D; Yu, J | 1 |
| Fleming, JB; Katz, MH; Lee, JE; Pisters, PW | 1 |
| Bhardwaj, A; Owen, LB; Singh, AP; Singh, S; Srivastava, SK | 1 |
| Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y | 1 |
| Assi, C; Bedenne, L; Jouve, JL; Lepage, C; Sgro, C | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA | 1 |
| An, Y; Cai, HH; Dai, CC; Lu, ZP; Miao, Y; Qian, ZY; Wei, JS; Xu, ZK; Yao, J | 1 |
| Badmaev, V; Bar-Sela, G; Epelbaum, R; Schaffer, M; Vizel, B | 1 |
| Mohelníková-Duchonová, B; Soucek, P | 1 |
| Ahad, A; Jacobs, MJ; Nalbantoglu, I; Saidi, RF; Tilak, J | 1 |
| Arlt, A; Müerköster, SS; Schäfer, H | 1 |
| Goedegebuure, P; Hawkins, WG; Hornick, JR; Mach, RH; Mitchem, JB; Spitzer, D; Tu, Z; Vangveravong, S; Xu, J | 1 |
| Katoh, M; Kita, J; Kubota, K; Sawada, T; Shimoda, M | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Mori-Iwamoto, S; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K | 1 |
| Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T | 1 |
| De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC | 1 |
| Holzman, DC | 1 |
| Chewaproug, D; Khanmoradi, K; Kung, SC; Melin, A; Ortiz, J; Pontinen, T; Varadi, G; Zaki, R | 1 |
| Barron, MR; Bentrem, DJ; Dangi-Garimella, S; Grippo, PJ; Heiferman, MJ; Krantz, SB; Munshi, HG; Shields, MA | 1 |
| Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Takaue, Y; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
| Bildzukewicz, NA; Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Einstein, L; Gonye, GE; Gorospe, M; Keen, JC; Richards, NG; Rittenhouse, DW; Williams, TK; Witkiewicz, AK; Yeo, CJ | 1 |
| Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Davis, C; Haefele, A; Hammons, G; Lyn-Cook, BD; Mohammed, SI; Wang, H; Word, B | 1 |
| Boggi, U; Campani, D; Del Chiaro, M; Falcone, A; Funel, N; Giovannetti, E; Scarpa, A; Vasile, E | 1 |
| Hisatome, I; Kanki, K; Kurimasa, A; Matsuura, S; Nishio, R; Shiota, G; Tsuchiya, H; Yasui, T | 1 |
| d'Adhemar, C; Kelly, ME; Kinsella, J; Ridgway, PF; Swan, N | 1 |
| Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R | 1 |
| Fisher, WE | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Ohba, A; Sanada, T; Tanaka, K; Tsubomoto, T; Wakabayashi, M | 1 |
| Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N | 1 |
| Murata, K; Nagase, H; Ota, H | 1 |
| Amano, R; Doi, Y; Hirakawa, K; Iwauchi, T; Nakamoto, K; Ohira, G; Ohira, M; Yamada, N | 1 |
| Bai, Z; Guo, W; Ma, X; Tang, K; Wang, Y; Zhang, Z | 1 |
| Chakrabarti, D; Khanna, A; Mahalingam, K; Periyasamy, G | 1 |
| Awasthi, N; Brekken, RA; Kirane, A; Schwarz, MA; Schwarz, RE; Toombs, JE | 1 |
| Arpicco, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Franchini, M; Palmieri, M; Scarpa, A; Zaniboni, T | 1 |
| Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E | 1 |
| Fujita, H; Hayashi, A; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Liu, TG; Zhu, H; Zhu, WY | 1 |
| Jiang, J; Kim, R; Lai, KK; Liu, X; Rybicki, LA; Tan, A; Wang, Y | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Abrams, RA; Benson, AB; Hoffman, JP; Konski, AA; Lustig, R; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morita, S; Morizane, C; Nakachi, K; Okusaka, T; Tanaka, K; Ueno, H | 1 |
| Hattori, H; Russell, P; Skoulidis, F; Venkitaraman, AR | 1 |
| Azzariti, A; Bocci, G; Chiarappa, P; Del Bufalo, D; Del Tacca, M; Fioravanti, A; Mangia, A; Paradiso, A; Porcelli, L; Quatrale, AE; Sebastian, S; Simone, GM; Sini, P | 1 |
| Chen, H; Guo, Y; Lin, S; Liu, A; Liu, J; Tan, W; Tong, H; Wang, Z; Wei, W | 1 |
| Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS | 1 |
| Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Goto, H; Ko, SB | 1 |
| Aparicio, T; Azzedine, A; Barhoumi, M; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Chang, D; Du, HZ; You, L; Zhao, YP | 1 |
| Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY | 1 |
| Araki, K; Kobayashi, T; Kubo, N; Kuwano, H; Raz, A; Shimura, T; Suzuki, H; Tsutsumi, S; Wada, W; Yajima, T | 1 |
| Hikichi, T; Ikeda, T; Imamura, H; Irisawa, A; Obara, K; Ohira, H; Sato, A; Sato, M; Shibukawa, G; Suzuki, R; Takagi, T; Takahashi, Y; Terashima, M; Wakatsuki, T | 1 |
| Arriví, A; Company, M; Cuadrado, A; Dolz, C; Falcó, E; García Bonafe, M; González de Cabo, M; Morales, R; Noguera, JF; Riera, J; Socías, A; Vicens, JC; Vilella, A | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
| Fujita, H; Hashizume, M; Kayashima, T; Mizumoto, K; Moriyama, T; Nagai, E; Ohtsuka, T; Ohuchida, K; Tanaka, M; Ueda, J | 1 |
| Gill, S; Kim, C; Owen, D | 1 |
| Coban, I; El-Rayes, BF; Kauh, JS; Kneuertz, PJ; Kooby, DA; Maithel, SK; Sarmiento, J; Staley, CA; Volkan Adsay, N | 1 |
| Hu, Y; Liao, Q; Si, S; You, LL; Zhang, Q; Zhao, YP | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Hanyu, F; Harada, N; Hayashi, T; Kaji, S; Koike, N; Morishita, K; Suzuki, M; Suzuki, S; Takeo, Y | 1 |
| Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K | 1 |
| Chung, WG; Cui, Z; DiGiovanni, J; Kiguchi, K; Lansakara-P, DS; Li, D; Proteau, PJ; Sandoval, MA; Sloat, BR | 1 |
| Brady, H; Heise, C; Kelter, G; Maier, A; Richard, N; Sung, V | 1 |
| Chen, G; Dong, J; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Chang, BW; Saif, MW | 1 |
| Makrilia, N; Saif, MW; Syrigos, KN | 2 |
| Dimou, AT; Saif, MW; Syrigos, KN | 1 |
| Kang, SP; Saif, MW | 2 |
| Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD; Zhou, SW | 1 |
| Gu, FY; Hu, XY; Li, MD; Shen, H; Yuan, Y; Zhong, X | 1 |
| Carrió, M; Cascante, A; Fillat, C; García-Ribas, I; Garcia-Rodríguez, L; Mazo, A; Pérez-Torras, S | 1 |
| Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J | 1 |
| Chen, C; Cubas, R; Li, M; Yao, Q; Zhang, S | 1 |
| Arnold, D; Dörken, B; Herrenberger, J; Kindler, M; Korsten, FW; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stieler, J | 1 |
| Chalmers, B; Chen, P; Chen, Q; Drisko, J; Espey, MG; Levine, M; Sun, AY | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Aboukameel, A; Ali, S; Banerjee, S; Bao, B; Kong, D; Padhye, S; Philip, PA; Sarkar, FH; Sarkar, SH; Wang, Z | 1 |
| Bigand, C; Couvreur, P; Hajri, A; Parmentier, C; Reddy, LH; Réjiba, S | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W | 1 |
| Bachet, JB; Boussaha, T; Dubreuil, O; Landi, B; Lepère, C; Taieb, J; Trouilloud, I; Zaanan, A | 1 |
| Beatty, GL; Chiorean, EG; Fishman, MP; Huhn, RD; Li, D; O'Dwyer, PJ; Saboury, B; Sharp, LL; Song, W; Sun, W; Teitelbaum, UR; Torigian, DA; Vonderheide, RH | 1 |
| Al-Leswas, D; Al-Taan, O; Arshad, A; Dennison, AR; Metcalfe, M; Stephenson, J; Steward, WP | 1 |
| Hu, J; Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC; Zhao, G | 1 |
| Brioschi, M; Ceraulo, D; Cereda, S; Fugazza, C; Ghidini, M; Nicoletti, R; Reni, M; Rognone, A; Villa, E | 1 |
| Egawa, S; Katayose, Y; Maeda, S; Morikawa, T; Motoi, F; Naitoh, T; Onogawa, T; Rikiyama, T; Sakata, N; Shigeru, O; Takadate, T; Unno, M | 1 |
| Berlin, JD; Cardin, DB; Castellanos, EH | 1 |
| Buettner, GR; Cullen, JJ; Spitz, DR | 1 |
| Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C | 1 |
| Abbruzzese, JL; Bennett, B; Bullock, S; Cunningham, P; Fogelman, D; Jafari, M; Lin, E; Morris, J; Ozer, H; Varadhachary, GR; Wolff, RA; Xiong, H | 1 |
| Abacioğlu, U; Atasoy, BM; Cağlar, H; Cıngı, A; Dane, F; Turhal, NS; Uçüncü Kefelı, A; Yeğen, C | 1 |
| Li, J; Yao, W; Yuan, Y; Zhang, L; Zhang, R; Zhou, L | 1 |
| Arumugarajah, S; Brown, JL; Gross, M; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Parsels, JD; Parsels, LA; Qian, Y; Simeone, DM; Tanska, DM; Zabludoff, SD; Zhao, L | 1 |
| Aggarwal, S; Gupta, S; Yadav, S | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Berlin, J; Cardin, DB; Castellanos, E | 1 |
| Di, Y; Fu, D; Hu, J; Jiang, Y; Jin, C; Li, J; Ni, Q; Wang, C; Yang, D; Yang, F | 1 |
| Fineberg, N; Grizzle, WE; Kim, H; Knowles, JA; Rosenthal, EL; Shah, N; Stockard, CR; Zhai, G; Zhou, T; Zinn, KR | 1 |
| Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Cui, L; Egami, T; Fujita, H; Matsumoto, K; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Tanaka, M; Yasui, T; Zhao, M | 1 |
| Park, JY | 1 |
| Fujii, M; Harada, R; Hirao, K; Ishida, E; Kato, H; Kawamoto, H; Kurihara, N; Mizuno, O; Noma, Y; Ogawa, T; Sakakihara, I; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Gnant, M; Goetzinger, P; Koelblinger, C; Kuehrer, I; Sahora, K; Schindl, M | 1 |
| Abbruzzese, A; Bifulco, M; Caraglia, M; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Marra, M; Palmieri, M; Scarpa, A; Scupoli, MT; Zaniboni, T; Zappavigna, S | 1 |
| Dhesy-Thind, B; Doyle, L; Goffin, JR; Hedley, D; Krzyzanowska, MK; Major, P; Moore, MJ; Renouf, DJ; Tang, PA; Wang, L | 1 |
| Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D | 1 |
| Arora, S; Azorsa, DO; Choudhary, A; Gonzales, IM; Henderson, MC; Mousses, S; Trent, JM; Von Hoff, DD | 1 |
| Hu, YS; Ke, PY; Lin, SZ; Liu, A; Tang, LL; Wang, ZH | 1 |
| Brümmer, F; Gebhard, MM; Gross, W; Herr, I; Kallifatidis, G; Klöppel, A; Liu, L; Ottinger, S; Rausch, V | 1 |
| Chang, DT; Christman-Skieller, C; Chun, CL; Columbo, LA; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Hsu, A; Kim, J; Koong, AC; Kunz, PL; Maxim, PG; Norton, J; Quon, A; Schellenberg, D; Van Dam, J; Xing, L | 1 |
| Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H | 1 |
| Acharya, S; Arya, G; Sahoo, SK; Vandana, M | 1 |
| Jenks, S | 1 |
| Ciombor, KK; Ferrell, A; Flores, A; Levi, J; Lopes, G; Macintyre, J; Merchan, JR; Ribeiro, A; Rocha-Lima, CM; Sleeman, D | 1 |
| Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP | 1 |
| Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Sugimoto, K; Utsunomiya, T | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Adler, M; Dörken, B; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Stieler, J | 1 |
| Doki, Y; Endo, W; Hasuike, Y; Masutani, S; Monden, M; Mori, M; Morimoto, T; Nakamori, S; Ozato, H; Shibata, T; Takeda, Y; Tohno, K | 1 |
| Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y | 1 |
| Galizia, MS; Miller, FH; Mulcahy, MF; Rezai, P; Small, W; Tochetto, SM; Yaghmai, V | 1 |
| Guo, K; Liu, H; Ma, Q; Shan, T; Wang, F; Wu, E; Zhang, D | 1 |
| Chen, YX; Lin, Y; Shi, J; Xie, WF; Zhu, CP | 1 |
| Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C | 1 |
| Avital, I; Davis, JL; Langan, RC; Levy, E; Pandalai, P; Ripley, RT; Steinberg, SM; Toomey, MA; Walker, M | 1 |
| Gattuso, P; Groh, V; Kaufman, HL; Plate, J; Prinz, RA; Rao, GS; Spies, T; Xu, X | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Fujiwara, H; Homma, S; Ito, M; Iwamoto, T; Koido, S; Komita, H; Mineno, J; Nagasaki, E; Nishida, S; Ochi, T; Sagawa, Y; Shiku, H; Sugiyama, H; Tajiri, H; Takahara, A; Yasukawa, M | 1 |
| Liu, A; Tong, HF; Zeng, Y | 1 |
| Cao, W; Chen, Q; Liu, X; Wang, Y; Wang, Z; Xia, C; Yan, B; Zhang, K; Zhang, L; Zhang, S | 1 |
| Appelbaum, L; Goldberg, Y; Hubert, A; Kadouri, L; Peretz, T; Sagi, M; Sonnenblick, A | 1 |
| Gunn, JR; Korc, M; Sempere, LF | 1 |
| Fujita, H; Kurata, N; Mahawithitwong, P; Manabe, T; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Sakai, H; Tanaka, M | 1 |
| Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM | 1 |
| Bae, K; Dicker, AP; Elsaleh, H; Farrell, JJ; Guha, C; Wong, J | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Ellinger, S; Henne-Bruns, D; Klapperstueck, T; Knippschild, U; Kreyes, A; Landfester, K; Udelnow, A; Walther, P; Wohlrab, J; Würl, P | 1 |
| Ballal, S; Dicke, K; Gurtler, J; Katz, T; Kayaleh, O; Keaton, M; Ko, AH; Lenz, HJ; Rowinsky, EK; Youssoufian, H | 1 |
| An, Y; Chen, P; Ji, ZL; Jiang, KR; Lu, ZP; Miao, Y; Wie, JS; Wu, JL; Xu, ZK; Yao, J | 1 |
| Bockhorn, M; Effenberger, KE; Güngör, C; Izbicki, JR; Kalinina, T; Vashist, YK; Yekebas, E; Zander, H | 1 |
| Cabarcas, SM; Farrar, WL; Hurt, EM; Jaffee, EM; Mathews, LA; Zhang, X | 1 |
| Bornschein, J; Kuester, D; Mönkemüller, K | 1 |
| Blackstock, AW; Fuchs, CS; Goldberg, RM; Hollis, D; Mamon, HJ; Mayer, RJ; Niedzwiecki, D; Tan, BR; Tepper, JE | 1 |
| Buchbinder, E; Bullock, A; Callery, M; Goldstein, M; Kent, T; Mahadevan, A; Miksad, R; Pleskow, D; Sawhney, M; Sullivan, R; Vollmer, C | 1 |
| Favaudon, V; Fernet, M; Huguet, F; Monnier, L; Touboul, E | 1 |
| Alvero, AB; Brown, DM; Husband, AJ; Kim, KH; McKernan, R; Mor, G; Saif, MW; Thompson, JA; Tytler, EM; Wang, X; Whiting, A | 1 |
| Kim, S; Moore, MJ; Pithavala, YK; Ricart, AD; Rixe, O; Spano, JP | 1 |
| Anzai, N; Azuma, S; Goto, H; Ishiguro, H; Kamimura, K; Ko, SB; Mizuno, N; Yamamoto, A | 1 |
| Gou, S; Shi, P; Wang, C; Wei, H; Yang, Z; Yin, T; Zhao, G | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y | 1 |
| Bando, E; Kanemoto, H; Kinugasa, Y; Mizuno, T; Sugiura, T; Terashima, M; Uesaka, K | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, JO; Park, K; Park, SH; Park, YS; Yi, JH | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Fleming, JB; Haque, W; Hobbs, BD; Javle, MM; Krishnan, S; Lee, JE; Safran, H; Staerkel, GA; Varadhachary, GR; Wolff, RA; Yordy, JS | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Arora, S; Bhardwaj, A; McClellan, S; Singh, AP; Singh, S; Srivastava, SK; Wang, B | 1 |
| Deslattes Mays, A; Kim, SE; LaConti, JJ; Marshall, JL; Peran, I; Preet, A; Riegel, AT; Shivapurkar, N; Wellstein, A | 1 |
| de Oliveira, E; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jimeno, A; Karikari, C; Laheru, D; Maitra, A; Rajeshkumar, NV; Rubio-Viqueira, B; Salomon, A; Sharma, R; Tan, AC; Taylor, G; Uson, M; Villaroel, MC | 1 |
| Abbruzzese, JL; Budillon, A; Carbone, C; Chiao, PJ; Ling, J; Melisi, D; Moccia, T; Paradiso, G; Xia, Q | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, HB; Liu, JX; Ni, ZL; Tan, W; Tong, HF; Wang, ZH; Wei, WT | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Hawkes, EA; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Alvarez, H; Bannerji, R; Bisht, S; Brossart, P; Dadon, T; Feldmann, G; Fendrich, V; Garrido-Laguna, I; Hidalgo, M; Karikari, C; Maitra, A; Matsui, W; Mishra, A; Nelkin, BD; Ottenhof, NA; Rajeshkumar, NV; Rasheed, Z | 1 |
| Obeid, KM; Venugopal, AA | 1 |
| Abelson, J; Chang, DT; Daly, ME; Koong, AC; Murphy, JD; Nelson, LM; Yeung, HN | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y | 1 |
| Brunner, TB; Fietkau, R; Sauer, R | 1 |
| Barth, BM; Cabot, MC; Cheng, H; DiVittore, NA; Fox, TE; Fritz, JL; Heakal, Y; Jiang, Y; Kaiser, JM; Kester, M; Shanmugavelandy, SS; Staveley-O'Carroll, KF; Tagaram, HR; Tran, MA | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Chen, X; Hormigo, A; Liu, A; O'Reilly, E; Pentsova, E; Rosenblum, M | 1 |
| Lowery, MA; O'Reilly, EM | 1 |
| Kamei, H; Katoh, T; Kiura, K; Shiote, Y; Suwaki, T; Takigawa, N; Umemura, S; Yamane, H; Yano, T | 1 |
| Bachellier, P; Berrevoet, F; Clavien, PA; Delpero, JR; Dufour, P; Heinrich, S; Lang, H; Laurent, S; Lesurtel, M; Moehler, M; Pestalozzi, B; Raoul, JL; Rogiers, X; Weber, A | 1 |
| Cerullo, V; Hemminki, A; Jalonen, H; Jokinen, M; Kanerva, A; Kangasniemi, A; Kangasniemi, L; Kiviluoto, T; Koski, A; Koskinen, M; Parviainen, S; Pesonen, S; Pisto, T | 1 |
| Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR | 1 |
| Kato, H; Kobayashi, N; Meyer, T; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Ando, M; Hirohata, M; Imagawa, A; Kato, H; Kawamoto, H; Matsumoto, K; Miyake, Y; Nakatsu, M; Toyokawa, T; Yamamoto, K | 1 |
| Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Dosch, J; Hynes, M; Li, C; Pasca di Magliano, M; Sarkar, B; Simeone, DM; Welling, TH; Wu, JJ | 1 |
| Boylan, JF; Deng, X; Ewton, DZ; Friedman, EA; Hoffman, AF; Hu, J; Luk, KC; Polonskaia, A; Vilenchik, M; Zipf, K | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Harder, J; Hartmann, A; Hollerbach, S; Kullmann, F; Kutscheidt, A; Messmann, H; Stöhr, R; Trojan, J; Troppmann, M | 1 |
| Chan, HL; Chen, JY; Chen, YH; Chen, YW; Chou, HC; Fan, CY; Huang, PC; Huang, SH; Kuo, CC; Law, CH; Li, JM; Lin, ST; Liu, JY; Lu, YC; Lyu, PC; Wu, CL; Wu, JY | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Omueti-Ayoade, K; Yang, M; Zemtsov, A; Zemtsov, R | 1 |
| Akaike, M; Kameda, Y; Mikayama, H; Miyagi, Y; Morinaga, S; Nakamura, Y; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Abe, Y; Aoki, T; Itoi, T; Kasuya, K; Nagakawa, Y; Nagao, T; Serizawa, H; Shimazu, M; Suzuki, M; Tsuchida, A | 1 |
| Funamizu, N; Kamata, Y; Lacy, CR; Manome, Y; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Aggarwal, BB; Deorukhkar, A; Dey, S; Diagaradjane, P; Gelovani, JG; Guha, S; Koca, C; Krishnan, S; Kunnumakkara, AB; Ravindran, J; Sung, B; Tong, Z | 1 |
| Dreyer, C; Hammel, P; Hentic, O; Lévy, P; Raymond, E; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Adachi, S; Itani, M; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakamura, M; Nakashima, M; Yamauchi, T; Yasuda, I; Yoshioka, T | 1 |
| Beger, C; Buurman, R; Focken, T; Heyn, H; Schlegelberger, B; Schreek, S | 1 |
| Brody, JR; Witkiewicz, AK; Yeo, CJ | 1 |
| Cui, L; Fujita, H; Kozono, S; Maeyama, R; Mizumoto, K; Ohuchida, K; Tanaka, M; Toma, H; Tominaga, Y; Zhao, M | 1 |
| Lyn-Cook, BD; Wang, H; Word, BR | 1 |
| Alberts, SR; Benson, AB; Brell, JM; Cardenes, H; Cella, D; Crane, CH; Feng, Y; Flynn, P; Loehrer, PJ; Ramanathan, RK; Wagner, L | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Francois, RA; Husain, K; Malafa, MP; Perez, M; Sebti, SM; Yamauchi, T | 1 |
| Murakami, Y; Sudo, T; Uemura, K | 1 |
| Kosuge, T | 1 |
| Azizi, A; Emami, AH; Farshid, P; Mbalisike, E; Naguib, NN; Vogl, TJ | 1 |
| Bu, HJ; Chen, Y; Liu, QH; Ni, CY; Yu, DH; Zhang, J; Zhao, CY; Zhu, MH | 1 |
| Chen, J; Gu, YM; Ma, YH; Zhao, WG | 1 |
| Bae, I; Duong, HQ; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Adachi, S; Hirose, Y; Itani, M; Kawaguchi, J; Kozawa, O; Matsushima-Nishiwaki, R; Moriwaki, H; Nakashima, M; Yamauchi, T; Yasuda, I; Yoshioka, T | 1 |
| Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Werner, J | 1 |
| Andriulli, A; Bassi, C; Botteri, E; Festa, V; Koch, M; Maisonneuve, P; Sebastiano, PD; Valvano, MR | 1 |
| Acunzo, J; Andrieu, C; Baylot, V; Garcia, S; Garrido, C; Giusiano, S; Gleave, M; Iovanna, J; Katsogiannou, M; Rocchi, P; Taieb, D | 1 |
| Hirokawa, N; Ito, Y; Karasawa, K; Kokubo, M; Nemoto, K; Nishimura, Y; Ogawa, K; Ogo, E; Onishi, H; Saito, T; Shibuya, H; Shibuya, K | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE; Yen, PL | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Wo, JY; Zhu, AX | 1 |
| Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T | 1 |
| Dovzhanskiy, DI; Felix, K; Giese, NA; Krysko, DV; Welsch, L; Welsch, T; Werner, J | 1 |
| Ikegami, A; Imawari, M; Inoue, K; Katsumoto, E; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Yoneyama, K; Yoshikumi, H | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH | 1 |
| Aftab, BT; Campbell, NR; Chenna, V; Hong, SM; Hu, C; Karikari, C; Khan, SR; Maitra, A; Pramanik, D; Rudek, MA; Rudin, CM; Zhao, M | 1 |
| Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Reiter, C; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D | 1 |
| Chen, G; Chen, SP; Kang, T; Liang, Y; Zhang, GN; Zhang, TP; Zhao, YP; Zhou, LJ | 1 |
| Balasubramaniam, A; Cho, J; Kennedy, MA; Lewis, KB; Sheriff, S; Tinch, SL; Watanabe, M | 1 |
| Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Motoo, Y; Nakajima, H; Nakamura, Y; Nakaya, N; Sato, I; Shimasaki, T; Takata, T; Takegami, T; Tanaka, T; Tomosugi, N; Zhao, X | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kim, EJ; Kim, JO; Lee, EM; Lee, JK; Lee, KH; Lee, KT; Min, SY; Park, YG | 1 |
| Celli, JP; Hasan, T; Liang, A; Pereira, SP; Solban, N | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Aggarwal, BB; Park, B; Prasad, S; Sung, B; Yadav, V | 1 |
| Hamada, T; Isaji, S; Kishiwada, M; Mizuno, S; Ohsawa, I; Sakurai, H; Tabata, M; Usui, M | 1 |
| Kotek, A; Parlak, C; Pehlivan, B; Topkan, E; Yapar, AF | 1 |
| Bahra, M; Boas-Knoop, S; Esendik, U; Hartmann, W; Heppner, F; Kamphues, C; Koch, A; Lippert, S; Neuhaus, P; Pietsch, T; Schüller, U; Waha, A | 1 |
| Han, S; Hu, G; Jiang, Z; Li, F; Ouyang, K; Qin, X; Tang, X; Wang, K; Wen, D; Xie, F; Zhang, L; Zhu, M | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Bozas, G; Ettelaie, C; Fyfe, D; Gardiner, E; Lofts, F; Maraveyas, A; Propper, D; Roy, R; Sgouros, J; Waters, J; Wedgwood, K | 1 |
| Archer, L; Basch, E; Kindler, HL; Niedzwiecki, D; Romanus, D; Schrag, D; Weeks, J | 1 |
| Barlett, B; Dalgleish, AG; Fryer, RA; Galustian, C | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T | 1 |
| Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM | 1 |
| Furuse, J; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shinichi, O; Suzuki, E; Ueno, H; Ueno, M; Yamaguchi, T | 1 |
| Doki, Y; Eguchi, H; Gotoh, K; Ishikawa, O; Nagata, S; Ohigashi, H; Takahashi, H; Tomita, Y; Yamada, T; Yano, M | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Fritzer-Szekeres, M; Golakoti, T; Graser, G; Jaeger, W; Krupitza, G; Madlener, S; Saiko, P; Schwarz, S; Somepalli, V; Szekeres, T | 1 |
| Conroy, T; Mitry, E | 1 |
| Ackland, SP; Borg, M; Brown, C; Bydder, S; Carroll, S; Cummins, MM; Gebski, VJ; Goldstein, D; Harvey, J; Horvath, L; Hruby, G; Porter, IW; Selva-Nayagam, S; Shapiro, J; Spry, N; Underhill, C; van Hazel, GA; Wratten, C | 1 |
| Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S | 1 |
| Cox, NL; Evans, P; Friedman, P; Giacomini, KM; Glubb, D; Goldberg, RM; Hollis, D; Hurwitz, H; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; Li, L; McLeod, HL; Mushiroda, T; Nakamura, Y; Owzar, K; Ratain, MJ; Schilsky, RL; Wang, L; Zembutsu, H | 1 |
| Arazi, L; Bittan, H; Cooks, T; Efrati, M; Horev-Drori, G; Keisari, Y; Kelson, I; Lazarov, E; Schmidt, M | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Bu, H; Chen, H; Guo, HC; Li, H; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH | 1 |
| Inoue, K; Kamata, M; Kitade, H; Kwon, AH; Matsui, Y; Ohe, C; Sakaida, N; Satoi, S; Tanigawa, N; Toyokawa, H; Uemura, Y; Yamamoto, T; Yanagimoto, H | 1 |
| Lee, M; Yee, NS; Yee, RK; Zhou, W | 1 |
| Bjerregaard, JK; Jensen, HA; Mortensen, MB; Nielsen, M; Pfeiffer, P | 1 |
| Li, B; Song, K; Sun, WJ | 1 |
| Lau, PC; Ng, WT; Yu, SC; Zheng, SF | 1 |
| Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC | 1 |
| Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S | 1 |
| Ge, Y; Guo, Y; Qi, W; Wang, G; Xie, C; Xu, X; Zhang, A | 1 |
| Akashi, M; Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kawashima, Y; Kinoshita, H; Kitazato, Y; Mikagi, K; Nogita, H; Okabe, Y; Shirouzu, K | 1 |
| Aoyagi, H; Hasegawa, K; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Takahata, T; Yoshida, T | 1 |
| Akashi, M; Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kawashima, Y; Kinoshita, H; Kitasato, Y; Mikagi, K; Nogita, H; Shirouzu, K | 1 |
| Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
| Hasegawa, Y; Ikeda, M; Ito, N; Matsuo, T; Nishizuka, S; Nitta, H; Sugitachi, A; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
| Danno, K; Imaoka, S; Inadome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Watanabe, A | 1 |
| Ben-Josef, E; Desai, S; Feng, FY; Francis, IR; Griffith, KA; Hunter, KU; Lawrence, TS; Murphy, JD; Zalupski, MM | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT | 1 |
| Camp, ER; Cole, DJ; Little, EC; Wang, C; Watson, DK; Watson, PM | 1 |
| Li, S; Liu, J; McFadden, G; Mona, M; Rahman, MM; Wennier, ST | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Iizawa, H; Kakizaki, Y; Motoi, F; Okada, T; Sakurai, N; Tamura, G; Unno, M; Yamamoto, K | 1 |
| Abhari, BA; Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Stadel, D; Vucic, D; Zobel, K | 1 |
| Ausseil, F; Cordelier, P; Dedieu, L; Ducommun, B; Dufau, I; Frongia, C; Sicard, F; Valette, A | 1 |
| Egawa, N; Hanada, K; Hijioka, S; Hirose, Y; Ikari, T; Ikeda, T; Ishii, H; Itoi, T; Kimura, Y; Maetani, I; Matsumura, Y; Mouri, H; Nakajima, T; Ohoka, S; Okabe, Y; Omuro, Y; Ozaka, M; Sofuni, A; Suyama, M; Tani, M; Watanabe, R | 1 |
| Abdalla, EK; Balachandran, A; Crane, CH; Fleming, JB; Fogelman, DR; Katz, MH; Lee, JE; Pisters, PW; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wolff, RA; Xiao, L | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
| Pan, SH; Sun, B; Wang, SJ; Wang, YW; Zhou, YN | 1 |
| Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G | 1 |
| Heike, Y; Okusaka, T; Sato, T; Ueno, M | 1 |
| Alexander, R; Goloubeva, O; Hanna, N; Herman, JM; Laheru, D; Maidment, BW; Pandya, N; Regine, WF; Schulick, R; Wolfgang, C; Yovino, S | 1 |
| Chang, JS; Chung, Y; Koom, WS; Seong, J; Song, SY; Wang, ML; Yoon, HI | 1 |
| Guo, F; Luo, F; Mao, X; Wang, J; Wang, Z | 1 |
| Abe, M; Demizu, Y; Fujii, O; Hashimoto, N; Hishikawa, Y; Jin, D; Kitajima, N; Mima, M; Murakami, M; Niwa, Y; Sasaki, R; Sirakawa, S; Sugimura, K; Takatori, K; Terashima, K; Yonson, K | 1 |
| Cha, YJ; Go, S; Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kwon, HC; Lee, GW; Lee, S; Oh, SY | 1 |
| Chen, D; Jiao, X; Liang, J; Niu, M; Zhang, D; Zhang, K | 1 |
| Ding, Q; Hayashi, T; Kuwahata, T; Maeda, K; Matsubara, S; Miyazaki, Y; Natsugoe, S; Obara, T; Takao, S | 1 |
| Burt, AD; Dasari, BV; Kelly, PJ; Loughrey, MB; Spence, R; Taylor, M | 1 |
| Cui, K; Li, L; Li, S; Niu, ZX; Sun, ZQ; Tian, H; Wang, AL; Wang, CL; Xue, Y; Zhang, B; Zhao, B; Zhou, WY | 1 |
| Guo, J; Hu, G; Jiang, Z; Li, F; Liang, J; Ouyang, K; Qin, X; Wang, K; Wen, D; Zhang, L; Zhu, M | 1 |
| Algin, E; Balakan, O; Benekli, M; Buyukberber, S; Colak, D; Dane, F; Dikiltas, M; Durnali, AG; Elkiran, ET; Geredeli, C; Goksel, G; Gumus, M; Harputoglu, H; Helvaci, K; Inal, A; Isikdogan, A; Kaplan, MA; Kos, FT; Kucukoner, M; Ozdemir, N; Ozkan, M; Uncu, D; Unek, IT; Yildiz, R | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Hirai, K; Katoh, R; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D | 1 |
| Asanuma, F; Atsuda, K; Morimoto, Y; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoneyama, H | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| Fu, J; Shankar, S; Srivastava, RK; Tang, SN | 1 |
| Bapiro, TE; Cook, N; Demuth, T; Frese, KK; Gopinathan, A; Howat, WJ; Jacobetz, MA; Jodrell, DI; Miller, JL; Rao, SS; Tuveson, DA | 1 |
| Alexander, HR; Funamizu, N; Gaedcke, J; Ghadimi, BM; Hanna, N; Hassan, R; He, P; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Yfantis, HG; Zhang, G | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Bu, HQ; Chen, H; Guo, HC; Li, HH; Li, W; Lin, SZ; Liu, DL; Luo, J; Tong, HF; Wang, ZH; Wei, WT; Wu, HY; Zuo, MM | 1 |
| Hiraoka, M; Matsuo, Y; Mizowaki, T; Nakamura, A; Nakamura, M; Shibuya, K; Shiinoki, T | 1 |
| Abdollahi, A; Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Hof, H; Kessel, K; Rieken, S; Schirmacher, P; Weitz, J; Welzel, T; Werner, J | 1 |
| Chahine, G; Farhat, F; Ghosn, M; Kattan, J; Nasr, F; Saroufim, A | 1 |
| Bae, I; Hong, YB; Hwang, JS; Kim, YJ; Seong, YS | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Eltawil, KM; Molinari, M; Renfrew, PD | 1 |
| Bae, I; Hong, YB; Kim, JS; Seong, YS; Yi, YW | 1 |
| Egawa, S; Kawaguchi, K; Motoi, F; Ohmine, K; Ohtsuki, S; Terasaki, T; Unno, M | 1 |
| Baschnagel, A; Jury, R; Margolis, J; Nadeau, L; Robertson, JM; Shah, C; Stein, J | 1 |
| Hiraki, Y; Iino, S; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Govindarajan, R; Hung, SW; Mody, HR | 1 |
| Ishikawa, O; Katayama, K; Kawada, N; Nagata, S; Nakamura, S; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H | 1 |
| Bao, Q; He, B; Pan, Y; Song, G; Tang, Z; Tian, F; Wang, S | 1 |
| Brody, JR; Holdbrook, T; Leiby, BE; Littman, SJ; Pequignot, E; Valsecchi, ME; Witkiewicz, AK; Yeo, CJ | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Chalasani, P; Jolivet, J; Kurtin, S; Mahadevan, D; Pretzinger, C; Ramanathan, RK; Rensvold, D; Von Hoff, DD; Weiss, GJ | 1 |
| Wolff, RA | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Innocenti, F; Soo, RA; Yong, WP | 1 |
| Bapiro, TE; Caldwell, ME; Chan, DS; Cook, N; Feig, C; Frese, KK; Frost, GI; Jacobetz, MA; Jiang, P; Jodrell, DI; Kultti, A; Lolkema, MP; Maneval, DC; Nakagawa, T; Neesse, A; Shepard, HM; Skepper, JN; Thompson, CB; Tuveson, DA; Zecchini, HI | 1 |
| Abe, S; Harada, M; Hiura, M; Kihara, Y; Miyagawa, K; Shimajiri, S; Taguchi, M; Yamamoto, M | 1 |
| Iwasaki, H; Kai, M; Katano, M; Morifuji, Y; Onishi, H; Suyama, K | 1 |
| Chen, N; Egawa, S; Fujimura, H; Fujiwara, S; Fukushige, S; Horii, A; Ishida, M; Jin, G; Kudo, Y; Lee, Y; Manabe, T; Mano, N; Motoi, F; Nakano, T; Nezhad, ZK; Oba, S; Saiki, Y; Shimada, M; Shimizu, H; Shimizu, S; Sunamura, M; Unno, M; Yoshino, Y | 1 |
| Chen, J; Gui, YZ; Long, HX; Sun, Y; Zhang, WH; Zhang, XY; Zhong, GC; Zhu, B | 1 |
| Hatakeyama, K; Kawachi, Y; Kitami, CE; Kurosaki, I; Minagawa, M; Nihei, K; Nomura, T; Takano, K; Tsuchiya, Y | 1 |
| Altwegg, R; Assenat, E; Caillo, L; Faure, S; Flori, N; Guillaumon, V; Mazard, T; Samalin, E; Senesse, P; Thezenas, S; Ychou, M | 1 |
| Cook, N; Davies, S; Halford, S; Jaki, T; Jodrell, D; Thygesen, H; Turner, H; Whitehead, J | 1 |
| Lee, SC; Ling, W; Sachdeva, P; Wong, AS; Zee, YK | 1 |
| Abe, T; Akada, T; Dendo, M; Ito, Y; Kato, H; Muto, R; Nakanishi, C; Ozawa, Y; Sakashita, K; Sato, K | 1 |
| Ahn, DW; Hwang, JH; Kim, YT; Lee, JK; Lee, SH; Ryu, JK; Seo, JK; Yoon, YB | 1 |
| Akasbi, Y; Arifi, S; Boutayeb, F; El Idrissi, M; El Mesbahi, O; El Mrini, A; Shimi, M | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mouri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yagioka, H; Yamamoto, K; Yamamoto, N | 1 |
| Chen, Y; Guo, Q; Kang, M; Lu, W; Wu, Y; Xie, Q; Zhang, B | 1 |
| Alexander, A; Anlauf, M; Knoefel, WT; Rehders, A; Riediger, R; Schmitt, M | 1 |
| Anant, S; Balakrishnan, A; Chakrabarti, D; Padigaru, M; Periyasamy, G; Ponnurangam, S; Sharma, S; Subramaniam, D; Sugumar, A; Weir, SJ | 1 |
| Borg, M; Goldstein, D; Halkett, G; Kneebone, A; Reece, W; Short, M; Spry, N; Zissiadis, Y | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Hadley, S; Khan, G; Lawrence, T; Leslie, W; Normolle, D; Schipper, M; Simeone, DM; Sonnenday, C; Ten-Haken, R; Zalupski, MM | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M | 1 |
| Chen, LH; Leung, PS; Liang, J; Lin, ZX; Liu, L; Zhao, M | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T | 1 |
| Guo, J; He, L; Hu, G; Jiang, Z; Li, F; Qin, X; Sun, L; Tang, X; Wang, K; Wang, T; Wen, D; Yao, J; Zhang, L | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Barth, RJ; Colacchio, TA; Davis, TH; Gardner, TB; Gordon, SR; Korc, M; MacKenzie, TA; McGowan, MM; Pipas, JM; Preis, M; Ripple, GH; Smith, KD; Srivastava, A; Suriawinata, AA; Sutton, JE; Tarczewski, SM; Tsapakos, MJ; Tsongalis, GJ; Zaki, BI | 1 |
| Gu, WJ; Li, Y; Liu, HL | 1 |
| Duchêne, B; Hebbar, M; Jonckheere, N; Leteurtre, E; Skrypek, N; van Seuningen, I | 1 |
| Clark, JW | 1 |
| Bapiro, TE; Cook, N; Frese, KK; Jodrell, DI; Lolkema, MP; Neesse, A; Tuveson, DA | 1 |
| Hou, J; Wang, L | 1 |
| Hong, SW; Hong, YS; Jin, DH; Jung, KA; Kim, KP; Kim, SM; Kim, TW; Lee, JL; Lee, JS; Shin, JS; Suh, C; Yoon, DH | 1 |
| Bahlo, M; Klapdor, R; Klapdor, S | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Fujita, K; Funamizu, N; Furukawa, K; Lacy, CR; Manome, Y; Misawa, T; Yanaga, K | 1 |
| Hu, H; Le, L; Li, J; Li, S; Qiu, P; Su, X; Wu, S; Yan, G; Zhu, W | 1 |
| Chen, Y; Liang, X; Lin, C; Luan, Q; Ma, F; Meng, X; Pei, W; Qian, H; Wang, H; Zhan, Q; Zhang, X; Zhao, P; Zhao, Z; Zhou, S | 1 |
| Beane, JD; Crooks, PA; Holcomb, BK; Schmidt, CM; Waters, JA; Yip-Schneider, MT | 1 |
| Avan, A; Crea, F; Danesi, R; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Marquez, VE; Paolicchi, E; Peters, GJ | 1 |
| Inaba, Y; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Tanaka, T | 1 |
| Chen, H; Chen, J; Jin, G; Ma, H; Shao, Z; Wang, Y; Xu, X | 1 |
| Li, J; Liang, X; Yang, X | 1 |
| Kaino, S; Kuramitsu, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Suenaga, S; Taba, K; Wang, Y | 1 |
| El-Rayes, BF; Zafar, SF | 1 |
| Auriemma, A; Bassi, C; Boz, G; Cantore, M; Frigerio, I; Giardino, A; Girelli, R; Mambrini, A; Orlandi, M; Salvia, R | 1 |
| Gress, TM; Michl, P | 1 |
| Jiang, W; Lin, J; Liu, X; Thomas, DG; Xie, H | 1 |
| Barlev, A; Bray, S; Butt, Z; Cella, D; Fuchs, CS; Kindler, HL; Oglesby, A | 1 |
| Liu, A; Luo, J; Zhang, JH | 1 |
| Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH | 1 |
| Abrams, RA; Benson, AB; Berger, AC; Freedman, GM; Hoffman, JP; Macdonald, J; Regine, WF; Safran, H; Willett, CG; Winter, K | 1 |
| Bae, I; Cho, CH; Hong, YB; Kim, YJ; Seong, YS | 1 |
| Hampole, H; Singh, A | 1 |
| Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S | 1 |
| Bray, SL; Chan, D; Feigal, EG; Fuchs, CS; Galimi, F; Garbo, LE; Garon, EB; Hei, Y; Kindler, HL; Kocs, DM; Loh, E; McGreivy, J; Richards, DA; Rocha-Lima, CM; Safran, H; Stephenson, JJ | 1 |
| André, T; Bachet, JB; Bardier-Dupas, A; Cass, CE; Closset, J; Couvelard, A; Dalban, C; Demetter, P; Devière, J; Dumontet, C; Emile, JF; Graham, K; Hammel, P; Jordheim, LP; Louvet, C; Mackey, JR; Maréchal, R; Matera, EL; Paye, F; Penna, C; Rougier, P; Salmon, I; Sauvanet, A; Svrcek, M; Van Laethem, JL | 1 |
| Bae, I; Duong, HQ; Hwang, JS; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Bu, HQ; Chen, H; Guo, HC; Li, HH; Lin, SZ; Luo, J; Wang, ZH; Zhang, JH | 1 |
| Jia, L; Jiang, SM; Wu, JH | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 2 |
| Furukawa, K; Kagawa, S; Kato, A; Kimura, F; Matsushita, K; Miyazaki, M; Nomura, F; Ohtsuka, M; Satoh, M; Shimizu, H; Takano, S; Yoshidome, H; Yoshitomi, H | 1 |
| Hashimoto, J; Koizumi, F; Kondo, S; Morizane, C; Okusaka, T; Tamura, K; Ueno, H | 1 |
| Costello, E; Greenhalf, W; Neoptolemos, JP | 1 |
| Jiang, J; Jiang, W; Kim, R; Liu, X; Wang, Y; Xie, H | 1 |
| Jiang, C; Li, YX; Shen, H; Yi, XP | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Maitra, A; Matsui, W; Mizuma, M; Omura, N; Puig, O; Rajeshkumar, NV; Rasheed, ZA; Yabuuchi, S; Zhang, Q | 1 |
| Tan, J; Zhou, X; Zhu, H | 1 |
| Akahori, T; Enomonoto, Y; Hasegawa, M; Hokuto, D; Kasai, T; Kawaguchi, C; Kichikawa, K; Kinoshita, S; Marugami, N; Nakajima, Y; Nishiofuku, H; Nomi, T; Sho, M; Tamamoto, T; Tanaka, T; Yamato, I; Yasuda, S | 1 |
| Bekaii-Saab, TS; Bloomston, M; Ellison, EC; Kleiber, B; Li, X; Martin, LK; Zalupski, M | 1 |
| Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL | 1 |
| Dahan, L; Delpero, JR; Esterni, B; François, E; Gasmi, M; Genre, D; Gilabert, M; Giovannini, M; Gonçalves, A; Lamy, R; Largillier, R; Moureau-Zabotto, L; Perrier, H; Raoul, JL; Re, D; Seitz, JF; Tchiknavorian, X; Turrini, O; Viens, P | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Aglietta, M; Campanella, D; Capussotti, L; Colombi, F; Gabriele, P; Gatti, M; Leone, F; Massucco, P; Regge, D; Sperti, E | 1 |
| Chang, DZ; Cohen, L; Garrett, CR; Huo, Y; Liu, L; Meng, Z; Ng, CS; Shen, Y; Spelman, AR; Yang, P; Zhao, Q | 1 |
| Hagihara, A; Kido, H; Kondo, S; Morizane, C; Okusaka, T; Tamura, T; Ueno, H | 1 |
| Ruan, JD; Sun, WJ; Wu, W; Xiong, Y; Zeng, J; Zhang, LB | 1 |
| Brody, JR; Burkhart, RA; Cozzitorto, JA; Gorospe, M; Leiby, B; Londin, ER; Pineda, DM; Rigoutsos, I; Rittenhouse, DW; Sachs, JN; Valley, CC; Weber, MC; Winter, JM; Witkiewicz, AK; Yeo, CJ | 1 |
| Bauer, TM; Bekaii-Saab, T; El-Rayes, BF; Hammad, N; Li, X; Philip, PA; Shields, AF; Zalupski, MM | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Simeone, DM; Venkatesha, VA; Zabludoff, SD; Zhao, L | 1 |
| Adesso, L; Barbagallo, F; Calabretta, S; Capurso, G; Delle Fave, G; Geremia, R; Pilozzi, E; Sette, C | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB | 1 |
| Alexander, HR; Back, TC; Chan, T; Funamizu, N; Gaedcke, J; Ghadimi, MB; Hanna, N; He, P; Hu, C; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Subleski, J; Weiss, JM; Yanaga, K; Yfantis, HG; Zhang, G | 1 |
| Brunner, TB; Charlton, PA; Fokas, E; McKenna, WG; Muschel, RJ; Pollard, JR; Prevo, R; Reaper, PM | 1 |
| Ando, T; Handa, O; Hattori, T; Imamoto, E; Ishikawa, T; Kamada, K; Katada, K; Kitagawa, K; Kokura, S; Konishi, H; Naito, Y; Okumura, Y; Oyamada, H; Sakagami, J; Sakamoto, M; Sakamoto, N; Takagi, T; Uchiyama, K; Yagi, N; Yasuda, H; Yoshida, N; Yoshikawa, T; Yoshinami, N | 1 |
| Choi, H; Jang, KT; Kim, KK; Kim, S; Lee, SY; Park, JO; Park, YS; Woo, HI; Yi, JH | 1 |
| Alami, M; Giessrigl, B; Gollinger, M; Hengstschläger, M; Huttary, N; Jäger, W; Kazlauskas, E; Kopf, S; Krieger, S; Krupitza, G; Maciuk, A; Matulis, D; Mazal, P; Messaoudi, S; Peyrat, JF; Rosner, M; Saiko, P; Szekeres, T | 1 |
| Chen, Y; Gao, L; Liu, QH; Ni, CY; Zhang, J; Zhao, CY; Zhu, MH | 1 |
| Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM | 1 |
| Goedegebuure, P; Hawkins, WG; Hornick, JR; Lockhart, AC; Mitchem, JB; Picus, J; Plambeck-Suess, S; Simon, PO; Sorscher, S; Suresh, R; Tan, B; Wang-Gillam, A | 1 |
| Bachet, JB; Demetter, P; Maréchal, R; Salmon, I; Van Laethem, JL; Verset, L | 1 |
| Joshi, K; Joshi, KS; Khanwalkar, H; Manohar, SM; Rathos, MJ | 1 |
| Kagohashi, K; Kurishima, K; Nakazawa, K; Satoh, H; Tamura, T | 1 |
| Andoh, H; Nakagawa, Y; Nanjo, H; Takahashi, T; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshioka, M; Yoshioka, T | 1 |
| Li, D; Liu, M; Lou, Y; Ren, Y; Sun, X; Zhang, C; Zhou, J | 1 |
| Gremeaux, L; Topal, B; Van den Broeck, A; Vankelecom, H | 1 |
| Choi, M; Kim, R; Razzaque, S | 1 |
| Berk, V; Buyukberber, S; Ciltas, A; Colak, D; Dane, F; Gumus, M; Inal, A; Isikdogan, A; Kos, FT; Ozdemir, NY; Ozkan, M; Unek, IT; Yildiz, R | 1 |
| Cao, WM; Wang, BH; Wang, XL; Yu, J | 1 |
| Akhisaroglu, M; Beckhove, P; Buchler, MW; Ge, Y; Grenacher, L; Haefeli, WE; Hohmann, N; Knebel, P; Koch, M; Leowardi, C; Lubenau, H; Mikus, G; Niethammer, AG; Schmitz-Winnenthal, FH; Springer, M; Weitz, J | 1 |
| Bourgaux, C; Couvreur, P; Desmaële, D; Lepeltier, E; Lepêtre, S; Maksimenko, A; Mougin, J; Mura, S; Sliwinski, E; Zouhiri, F | 1 |
| Hong, GB; Li, CY; Song, LQ; Sun, HB; Zhou, JX | 1 |
| Cui, X; Li, M; Liu, C; Long, J; Luo, G; Ni, Q; Satoh, K; Xiao, Z; Xu, J; Yu, X; Zhang, B | 1 |
| Bersani, S; Dalla Pozza, E; Dando, I; De Laurenzi, V; De Marco, M; di Mola, FF; di Sebastiano, P; Dijk, F; Donadelli, M; Fontana, A; Franco, R; Medema, JP; Palaia, R; Palmieri, M; Pezzilli, R; Rosati, A; Scarpa, A; Scognamiglio, G; Tavano, F; Turco, MC; Welling, L | 1 |
| Beviglia, L; Fischer, MM; Gurney, A; Hoey, T; Hynes, M; Kapoun, AM; Kim, E; Lewicki, J; Simeone, DM; Song, X; Wu, J; Yen, WC; Yeung, VP | 1 |
| Cheng, Z; Han, B; Jia, G; Jiang, H; Liu, J; Pan, S; Sun, B; Wang, Y; Zhou, H; Zhou, Y | 1 |
| Huang, ZL; Huang, ZM; Li, W; Pan, CC; Wu, PH; Yi, RY; Zhao, M | 1 |
| Akaike, M; Kameda, Y; Miyagi, Y; Morinaga, S; Nakamura, Y; Numata, M; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N | 1 |
| Hayashi, A; Ishigaki, Y; Motoo, Y; Shimasaki, T; Takata, T; Tomosugi, N; Tsuchida, H | 1 |
| Jiang, Y; Liu, F; Sun, S; Tang, Y; Zheng, C | 1 |
| Belli, C; Cereda, S; Reni, M | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Avan, A; Frampton, AE; Funel, N; Giovannetti, E; Maftouh, M; Nicolini, F; Pelliccioni, S; Peters, GJ; Quint, K; Schuurhuis, GJ | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Labianca, R; Merelli, B; Mosconi, S | 1 |
| Botta, C; Caraglia, M; Ciliberto, D; Correale, P; Rossi, M; Tagliaferri, P; Tassone, P | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Brogan, F; Chi, DC; Saif, MW; Schwartz, L; Turenne, I; Zelonis, S | 1 |
| Barcenas, J; Bohac, GC; Conlon, K; Davis, M; Deng, Y; Lamzabi, I; Leslie, W; Li, Y; Plate, JM; Watkins, L | 1 |
| Bachet, JB; Rougier, P; Seufferlein, T; Van Cutsem, E | 1 |
| Banerjee, D; Basu, S; Harfouche, R; Papa, AL; Sengupta, P; Sengupta, S | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yamamoto, N | 1 |
| Angst, E; Chen, M; Eibl, G; Go, VL; Hines, OJ; King, J; Li, G; Lu, QY; Lu, X; Moro, A; Park, JL; Reber, HA | 1 |
| Andersson, R; Ansari, D; Sun, C; Wu, DQ | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Forssell, H; Krona, H; Pröh, K; Wester, M | 1 |
| Anderson, MA; Gorospe, EC; Leggett, CL; Levy, M; Lutzke, LS; Sun, G; Wang, KK; Wong Kee Song, LM | 1 |
| Deng, LC; Shen, WS; Shu, ZQ | 1 |
| Alinger, B; Di Fazio, P; Lingelbach, S; Montalbano, R; Neureiter, D; Ocker, M; Quint, K; Rückert, F; Tonigold, M | 1 |
| Basu, B; Jodrell, D | 1 |
| Cheek, MA; Ellington, AD; Li, N; Ray, P; Sharaf, ML; Shaw, BR; Sullenger, BA; White, RR | 1 |
| Liu, Y; Shen, H; Su, Z; Wang, D; Yin, R; Zhang, Z; Zhu, H; Zhu, Y | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Liu, Y; Rabson, AB; Verano, M; Zheng, X | 1 |
| Belletrutti, MJ; Bhargava, R; Bigam, D; Grundy, P | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
| Pereira, S | 1 |
| Bandarchi, B; Leung, L; Organ, S; Panchal, D; Pintilie, M; Radulovich, N; To, C; Tsao, MS; Zhu, CQ | 1 |
| Cha, BH; Hwang, JH; Jeong, SH; Kim, JE; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, YS; Yoo, JY | 1 |
| Behrman, SW; Chitkara, D; Kumar, V; Mahato, RI; Singh, S | 1 |
| Beckham, TH; Beeson, CC; Beeson, G; Bielawska, A; Bielawski, J; Cheng, JC; Drake, RR; Jones, EE; Lewis, CS; Liu, X; Lu, P; Marrison, T; Norris, JS; Ogretmen, B; Ramshesh, VK; Szulc, ZM | 1 |
| Cheng, S; He, Y; Song, MM; Yuan, HS; Zhong, ZQ | 1 |
| Aiura, K; Itano, O; Kitagawa, Y; Matsuda, S; Suzuki, K; Takeuchi, O; Umezawa, K | 1 |
| Algül, H; Conradt, L; Henrich, A; Krämer, OH; Lesina, M; Reichert, M; Saur, D; Schmid, RM; Schneider, G; Wirth, M | 1 |
| Jiang, W; Liu, X; Xiao, SY; Xie, H | 1 |
| Albarello, L; Balzano, G; Braga, M; Capretti, G; Castoldi, R; Cereda, S; Di Carlo, V; Doglioni, C; Pecorelli, N; Reni, M | 1 |
| Fan, X; Liu, L; Zhang, D; Zhou, Q | 1 |
| Chen, G; You, L; Zhang, J; Zhang, TP; Zhao, YP; Zhou, B | 1 |
| Al-Wadei, HA; Banerjee, J; Schuller, HM | 1 |
| Azzariti, A; Carioggia, E; Leo, MG; Lioce, M; Mantuano, P; Paradiso, A; Porcelli, L; Quatrale, AE; Rolland, JF; Silvestris, N | 1 |
| Fujioka, M; Fukui, H; Kou, C | 1 |
| Boettcher, M; Eisen, C; Fredebohm, J; Gaida, MM; Giese, NA; Greulich-Bode, KM; Heller, A; Hoheisel, JD; Hotz-Wagenblatt, A; Keleg, S; Lathrop, M; Tost, J | 1 |
| Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Bottiglieri, S; Mehdi, S; Mo, JH; Patel, R; Tierson, N | 1 |
| Akasaka, H; Mizushina, Y; Sasaki, R; Takayama, I; Yamaguchi, T; Yoshida, H; Yoshida, K | 1 |
| Chen, H; Chen, Z; Fan, J; Liu, L; Luo, J; Meng, Z; Wang, K; Wang, P; Zhang, J; Zhuang, L | 1 |
| An, Y; Cai, B; Chen, J; Gao, W; Jiang, K; Li, Q; Lv, N; Miao, Y; Tang, D; Tu, M; Wei, J; Wu, J; Xue, X; Yao, J | 1 |
| Hirooka, S; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Chiorean, EG; Elzey, BD; Hazbun, T; Konieczny, SF; Kuang, S; Liu, X; Liu, XS; Ratliff, TL; Rice, SJ; Song, B | 1 |
| Krug, S; Michl, P | 1 |
| Alfieri, S; Antinori, A; Balducci, M; Crucitti, A; D'Agostino, GR; Deodato, F; Ippolito, E; Luzi, S; Macchia, G; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Cella, D; Ko, AH | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Chiorean, EG; Hardacre, JM; Krishnamurthi, S; Lenz, HJ; Mulcahy, M; Obel, J; Rocha-Lima, CS; Safran, H; Small, W; Talamonti, M | 1 |
| Bayry, J; Bazhin, AV; Karakhanova, S; Link, J; Shevchenko, I; Soltek, S; Umansky, V; Werner, J | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Andersson, R; Ansari, D; Tingstedt, B | 1 |
| Fang, H; Shen, J; Wu, A; Xu, C; Xu, L; Ye, J; Zhu, H | 1 |
| Abdel-Rahman, S; Berger, F; Dieterle, N; Issels, RD; Milani, V; Salat, C; Tschoep-Lechner, KE | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Uemura, K | 1 |
| Bui, DT; Couvreur, P; Harrisson, S; Maksimenko, A; Mougin, J; Nicolas, J | 1 |
| Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Khan, G; Lawrence, TS; Leslie, W; Schipper, M; Vainshtein, JM; Zalupski, MM | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Laubender, RP; Parhofer, KG; Schulz, C; Zeiss, K | 1 |
| Akahori, T; Hokutoh, D; Kinoshita, S; Nakajima, Y; Nomi, T; Sho, M; Yamato, I; Yasuda, S | 1 |
| Fukuda, S; Fukushima, Y; Hashimoto, K; Ide, Y; Kodama, K; Matsumoto, S; Matsuyama, J; Morimoto, T; Naito, A; Nomura, T; Sasaki, Y; Shiba, I; Takeda, M; Tokuoka, M; Toshiyama, R; Yokoyama, S | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Mitsuoka, A; Nakamura, H; Sanada, T; Watanabe, S; Yamamoto, Y | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Ku, Y; Matsumoto, I; Sawa, H; Shinzeki, M; Shirakawa, S; Takahashi, M; Tanaka, M; Toyama, H; Tsuchida, S; Ueno, K; Yamashita, H | 1 |
| Ashida, R; Ioka, T; Katayama, K; Kobayashi, N; Takakura, R; Tanaka, S; Taniai, H | 1 |
| Boggi, U; Campani, D; Caparello, C; Caponi, S; Cappelli, C; Costa, F; De Lio, N; Falcone, A; Funel, N; Ginocchi, L; Lencioni, M; Lucchesi, M; Mosca, F; Pollina, L; Ricci, S; Vasile, E | 1 |
| Ali, S; Banerjee, S; Deryavoush, T; Gupta, S; Parasramka, MA; Sarkar, FH | 1 |
| Fang, X; Liang, W; Lou, C; Yang, M; Zeng, W; Zhang, C; Zhang, F; Zhang, Y; Zhao, J | 1 |
| Brullé, L; Le Pape, A; Lerondel, S; Martel, E; Pouvesle, JM; Richard, S; Riès, D; Robert, E; Trichet, V; Vandamme, M | 1 |
| Ito, R; Kitamura, H; Miyake, R; Nojiri, T; Okui, N; Saito, R; Son, K; Toyama, Y; Usuba, T; Yanaga, K; Yoshida, S | 1 |
| Haruta, J | 1 |
| Centeno, BA; Chellappan, SP; Fulp, WJ; Kunigal, S; Pillai, S; Singh, S; Treviño, JG | 1 |
| Duan, X; Mao, X; Sun, W | 1 |
| Ji, S; Liu, C; Long, J; Ni, Q; Xu, J; Xu, W; Xu, Y; Yao, W; Yu, X; Zhang, B; Zhu, W | 1 |
| Bhutia, YD; Govindarajan, R; Hung, SW; Krentz, M; Lovin, D; Manoharan, R; Patel, D; Thomson, JM | 1 |
| He, LH; Niu, LZ; Xu, KC; Yang, ZZ; Zhou, L; Zuo, JS | 1 |
| Cui, X; Li, M; Liu, C; Liu, L; Liu, Z; Long, J; Luo, G; Shi, S; Xiao, Z; Xu, J; Yu, X | 1 |
| Huang, H; Jiao, Z; Kong, X; Li, L; Liu, Z; Xu, M; Xu, P; Zhang, Y | 1 |
| Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA | 1 |
| Cui, L; Eguchi, D; Fujiwara, K; Ikenaga, N; Kozono, S; Mizumoto, K; Ohuchida, K; Tanaka, M | 1 |
| Cao, LP; Li, YX; Song, JL; Yi, XP | 1 |
| Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J | 1 |
| Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K | 1 |
| Borghero, Y; Cassina, JC; Gabrielli, M; Galindo, J; Garrido, M; Guerra, JF; Jarufe, N; Madrid, J; Martínez, J; Roa, JC; Zoroquiain, P | 1 |
| Berg, DJ; Bodeker, KL; Buettner, GR; Cullen, JJ; Drisko, J; Du, J; Halfdanarson, TR; Levine, M; Roberts, LJ; van't Erve, TJ; Wagner, BA; Welsh, JL; Yee, NS; Zehr, PS | 1 |
| Buscail, L; Cordelier, P; Delpu, Y; Hanoun, N; Lopez, F; Lulka, H; Saint-Laurent, N; Sicard, F; Torrisani, J | 1 |
| Arpicco, S; Beghelli, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Scarpa, A; Scupoli, MT; Zoratti, E | 1 |
| Avan, A; Cantore, M; Caponi, S; Cereda, S; Giovannetti, E; Mambrini, A; Milella, M; Pacetti, P; Peters, GJ; Reni, M; Vaccaro, V; Vasile, E | 1 |
| Ke, XY; Liu, ZQ; Wang, Y; Xie, ZQ; Yang, DL; Zhang, CF; Zhao, Q | 1 |
| Dai, L; Hoffman, RM; Lin, Y; Liu, Y; Qi, M; Shi, Y; Sun, Y; Tian, Y; Tong, M; Wang, Z; Wu, Y; Yang, Z; Zhang, Y | 1 |
| Cazales, M; Ducommun, B; Frongia, C; Laurent, J; Lobjois, V; Mondesert, O | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Liu, S; Shi, X | 1 |
| Benson, AB; Berlin, JD; Catalano, P; Haller, DG; Kugler, JW; Thomas, JP | 1 |
| Akerman, P; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Quirk, D; Ramdin, N; Rich, T; Safran, H; Shah, S | 1 |
| Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G | 1 |
| Oettle, H; Riess, H | 1 |
| Jacobs, AD | 1 |
| Lawrence, TS; McGinn, CJ; Zalupski, MM | 1 |
| Abbruzzese, JL | 3 |
| Blagden, S; Blesing, C; Corrie, P; D'Ath, S; Mayer, A; Price, P; Shaw, J; Warner, N | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Cook, J; Herscher, LL; Kroog, GS; Mitchell, JB; Muir, C; Poggi, MM; Russo, A; Smith, J | 1 |
| Bruns, CJ; Ellis, LM; Harbison, MT; Hicklin, DJ; Jauch, KW; Portera, C; Radinsky, R; Shrader, M; Solorzano, CC | 1 |
| Kulke, MH | 3 |
| Fuxius, S; Mansouri, K; Mross, K; Unger, C | 1 |
| Epelbaum, R; Faraggi, D; Gaitini, D; Kuten, A; Mizrahi, S; Nasrallah, S; Rosenblatt, E | 1 |
| Feng, F; Jin, M; Li, Z; Ni, Q; Wang, X; Wu, Y; Zhao, Y | 1 |
| Bohlen, P; Bonner, JA; Buchsbaum, DJ; Carpenter, M; Grizzle, WE; Hicklin, DJ; Raisch, KP; Stackhouse, MA | 1 |
| Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE | 1 |
| Needle, MN | 1 |
| Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A | 1 |
| Bankhead, C | 1 |
| Donohue, CA; Kane, SE; Sadava, D; Schwarz, RE | 1 |
| Azria, D; Prost, P; Ychou, M | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Mornex, F | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Hayashi, H; Hayashi, Y; Kamata, T; Kanno, M; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, K; Takeda, T | 1 |
| Fujii, T; Maemura, M; Morishita, Y; Ohwada, S; Roppongi, T; Takeyoshi, I; Yamada, T | 1 |
| Aoyagi, S; Fukuda, S; Hara, M; Hiraki, M; Horiuchi, H; Ishikawa, H; Kinoshita, H; Koganemaru, M; Ohdo, M; Okuda, K; Shirouzu, K; Tamae, T; Uchida, S; Yasunaga, M | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 2 |
| Baum, U; Bautz, W; Brunner, TB; Grabenbauer, GG; Hohenberger, W; Klein, P; Papadopoulos, T; Sauer, R | 1 |
| Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M | 1 |
| Amano, H; Hanada, K; Hino, F; Hirota, Y; Kajiyama, G; Obayashi, M; Ooe, H; Sasao, S | 1 |
| Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S | 1 |
| Antolak, JA; Charnsangavej, C; Crane, CH; Evans, DB; Forster, KM; Janjan, NA; Lenzi, R; Papagikos, MA; Pisters, PW; Rosen, II; Wolff, RA | 1 |
| Chiao, PJ; Evans, DB; Fan, Z; Fujioka, S; Schmidt, C; Sclabas, GM | 1 |
| Barni, S; Beretta, GD; Cascinu, S; Catalano, G; Catalano, V; Ferraù, F; Foa, P; Frontini, L; Graziano, F; Labianca, R; Mare, M; Pancera, G; Priolo, D | 1 |
| Barone, C; Basso, M; Battelli, C; Cassano, A; Corsi, DC; Longo, R; Pozzo, C; Quirino, M; Schinzari, G | 1 |
| Abbruzzese, JL; Bedford, R; Freeman, SM; Hecht, JR; Kirn, DH; Lahoti, S; Reid, TR; Soetikno, RM | 1 |
| Haller, DG | 4 |
| Arlt, A; Fölsch, UR; Gehrz, A; Grohmann, F; Haye, S; Kalthoff, H; March, C; Müerköster, S; Schäfer, H; Wegehenkel, K; Witt, M | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Stoffregen, C; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Distel, L; Grabenbauer, GG; Sauer, R; Weiss, C | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Adachi, Y; Fujita, Y; Fujiwara, M; Horiki, N; Imoto, I; Maruyama, M; Sasaki, H; Shimomura, M; Suzuki, K; Suzuki, Y; Tanaka, T; Tanigawa, K | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakamori, S; Nakazuru, S; Okami, J; Sakon, M; Tsujie, M; Umeshita, K | 1 |
| Abramoff, R; Gansl, RC; Hoff, PM; Katz, A; Machado, MC; Saad, ED; Simon, SD; Tabacof, J; Wajsbrot, D | 1 |
| el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V | 1 |
| Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD | 1 |
| Joo, KR; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Yun, TK | 1 |
| El-Rayes, BF; Philip, PA | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 2 |
| Fitch, TR; Geeraerts, LH; Ghosh, C; Goldberg, RM; Haddock, MG; Keppen, MD; Martenson, JA; Pitot, HC; Sargent, DJ; Vigliotti, AP | 1 |
| Ehninger, G; Franz, T; Gross, P; Haufe, T; Kiani, A; Köhne, CH; Passauer, J; Schleyer, E | 1 |
| Bednarik, O; Bustova, I; Karasek, P; Kocakova, I; Melichar, B; Petruzelka, L; Skacel, T; Spurny, V; Trason, T | 1 |
| Berlin, JD; Rothenberg, ML | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Kumazawa, K; Ogawa, K; Shiozawa, S; Tsuchiya, A | 1 |
| Herfarth, Ch | 1 |
| Baker, CH; Bucana, CD; Evans, DB; Fidler, IJ; Hwang, R; Killion, JJ; Pisters, PW; Solorzano, CC | 1 |
| Balzer, JO; Berger, D; Eichler, K; Heller, M; Mack, MG; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Arlt, A; Fölsch, UR; Gehrz, A; Kruse, ML; Müerköster, S; Schäfer, H; Vorndamm, J | 1 |
| Yeo, CJ | 1 |
| Schramm, H | 1 |
| Gallagher, N; Smith, D | 1 |
| McGinn, CJ; Zalupski, MM | 1 |
| Hochster, HS | 1 |
| Closon, MT; Closset, J; Collette, M; Demols, A; Gastelblum, P; Gay, F; Gelin, M; Houbiers, G; Houtte, PV; Polus, M; Van Laethem, JL | 1 |
| Bland, KI; Bonner, JA; Buchsbaum, DJ; Huang, ZQ; Raisch, KP; Vickers, SM | 1 |
| Calvanese, A; Ceciarini, F; Cerretani, D; Correale, P; Di Palma, T; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Neri, A; Pellegrini, M; Petrioli, R; Pinto, E; Pozzessere, D; Sabatino, M | 1 |
| Adsay, V; Day, J; El-Rayes, BF; Heilbrun, LK; Jain, V; Philip, PA; Shields, AF; Vaishampayan, U; Zalupski, MM | 1 |
| Lawrence, TS; Shewach, DS | 1 |
| Abbruzzese, J; Hainsworth, J; Hochster, H; Lenzi, R; Plunkett, W; Ruiz Van Haperen, V; Tempero, M | 1 |
| Eriguchi, N; Funakoshi, A; Ito, T; Migita, Y; Mizumoto, K; Muranaka, T; Niyahara, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
| Crane, CH; Janjan, NA; Mason, K; Milas, L | 1 |
| Chan, WK; Chang, FY; Chao, Y; Chi, KH; Lee, RC; Lee, SD; Li, CP; Teng, HC; Yen, SH | 1 |
| Claude, L; Mornex, F | 1 |
| Aikawa, I; Matsuda, T; Taniguchi, F; Tsuda, T | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 2 |
| Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S | 1 |
| Colwell, B; Dagenais, M; Dancey, J; Eisenberg, PD; Fields, A; Greenberg, B; Hagan, K; Hamm, J; Humphrey, R; Moore, MJ; Ottaway, J; Seymour, L; Tu, D; Zee, B | 1 |
| Alfieri, S; Cellini, N; Costamagna, G; Doglietto, GB; Luzi, S; Macchia, G; Morganti, AG; Smaniotto, D; Trodella, L; Valentini, V | 1 |
| Bodoky, G | 1 |
| Cardillo, TM; Gold, DV; Modrak, D; Schutsky, K | 1 |
| Ito, H; Katoh, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimamura, F; Shimizu, H; Togawa, A; Yoshidome, H | 1 |
| Hirokawa, S; Masaki, T; Miyakawa, K; Ohkawa, S; Tamai, S; Tarao, K | 1 |
| Cooper, AJ; Johnson, CD; Whitehouse, PA | 1 |
| Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Sauerbruch, T; Schlie, C; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Haller, D; Sun, W | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Casado, FJ; García-Manteiga, J; Mazo, A; Molina-Arcas, M; Pastor-Anglada, M | 1 |
| Genet, D; Labourey, JL; Ly, K; Martin, J; Szelag, JC; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Garbrecht, M; Heinemann, V; Helmberger, T; Lamerz, R; Niebler, K; Schalhorn, A; Schermuly, MM; Stemmler, J; Stieber, P; Stoffregen, C; Szymala, AM; Wilkowski, R | 1 |
| Bai, YR; Chen, Y; Guo, WJ; Lu, DQ; Wu, GH; Wu, XD; Yao, Y; Zhou, RH | 1 |
| Aoyagi, S; Hara, M; Hayashi, K; Horiuchi, H; Ishikawa, H; Kinoshita, H; Kodama, T; Nishimura, K; Ogata, T; Ohdo, M; Okuda, K; Shirouzu, K; Uchida, S; Yasunaga, M | 1 |
| Matsumoto, G; Okamoto, A; Tsuruta, K | 1 |
| Arii, S; Baba, H; Endo, M | 1 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 2 |
| Eckel, F; Erdmann, J; Lersch, C; Mayr, M; Schmelz, R | 1 |
| Abe, H; Akada, M; Egawa, S; Fukuyama, S; Matsuno, S; Motoi, F; Ottomo, S; Sunamura, M; Takeda, K | 1 |
| Ahn, JH; Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JS; Lee, K | 1 |
| Maeyama, R; Manabe, T; Matsuda, T; Okino, H; Tanaka, M | 1 |
| Chayama, K; Iiboshi, T; Kariya, K; Kobayashi, K; Kuwada, Y; Kuwahara, K; Miyata, H; Morinaka, K; Murakami, M; Noma, B; Sasaki, T; Serikawa, M; Yamasaki, S | 1 |
| Cornelio, GH; Gordon, EM; Hall, FL; Levy, JP; Liu, L; Lorenzo, CC; Reed, RA | 1 |
| Calley, C; Fata, F; Ganjoo, KN; Loehrer, PJ; Picus, J; Schneider, BP; Seitz, DE; Stoner, C | 1 |
| Ashley, SW; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 3 |
| Brown, D; Hejna, G; Lawrence, T; McGinn, CJ; Muler, JH; Normolle, D; Zalupski, MM | 1 |
| Dianzani, C; La Cesa, A; Landi, D; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Granov, DA; Pavlovskiĭ, AV; Tarazov, PG | 1 |
| Christgen, M; Haye, S; Kalthoff, H; Kremer, B; Kurdow, R; Schniewind, B; Ungefroren, H | 1 |
| Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Behrens, P; Lee, KM; Märten, A; Mühlradt, PF; Sauerbruch, T; Schmidt, J; Schmidt, T; Schmidt-Wolf, IG; Schneider, C; Tiemann, K; Uhlinsky, V; Ziske, C | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Thoma, M; Wilkowski, R | 1 |
| Crane, CH | 1 |
| Arita, Y; Hisano, T; Ito, T; Kawabe, K; Nawata, H | 1 |
| Balasubramanian, S; Chandraratna, RA; Eckert, RL | 1 |
| Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K | 1 |
| Fujimoto, S; Fukiya, E; Funatsu, E; Hata, K; Ikezawa, S; Kimura, H; Kutsumi, H; Masuda, K; Nakamura, H; Nishida, K; Nobutani, K; Okuyama, Y; Otsuka, H; Shiomi, H; Sugeta, N; Suyama, Y; Suzuki, T; Yagi, N; Yashiro, H | 1 |
| Addeo, A; Bellone, G; Bertelli, GF; Bertetto, O; Chiappino, I; Heouaine, A; Merlano, M; Novarino, A; Ritorto, G | 1 |
| Habiro, A; Izawa, T; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakano, Y; Okumura, T; Osanai, M; Tanno, S | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| Láng, I | 1 |
| Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY | 1 |
| Bruns, CJ; Geissler, EK; Guba, M; Hoehn, A; Jauch, KW; Koehl, GE; Schwend, A; Seeliger, H; Steinbauer, M; Yezhelyev, M | 1 |
| Abbruzzese, JL; Li, D; Wolff, R; Xie, K | 1 |
| Abbruzzese, JL; McConkey, D; Pino, SM; Xiong, HQ | 2 |
| Fidler, IJ; Yokoi, K | 1 |
| Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D | 1 |
| Bansal, R; Friedlander, PA; Kemeny, N; Posner, J; Schwartz, L; Wagman, R | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Mey, V; Mosca, I | 1 |
| Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L | 1 |
| Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V | 1 |
| Chen, LT; Chen, SC; Chuang, WL; Su, YC; Wu, WC | 1 |
| Boige, V; Ducreux, M; Malka, D | 2 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Waseem, T; Whang, EE | 2 |
| Aerts, R; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Verslype, C | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Kehr, A; Schulz, J; Tuinmann, G; Zschaber, R | 1 |
| Koizumi, M; Nishiyama, K; Yamazaki, H | 1 |
| Aviles, V; Benson, AB; Berlin, JD; Harris, JE; Levy, DE; Shepard, RC; Stuart, K; Thomas, JP | 1 |
| Doi, R; Fujimoto, K; Imamura, M; Inui, K; Okuda, M; Onoue, M; Terada, T | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Katsuki, S; Machida, T; Mezawa, S; Murakami, K; Sato, T; Takanashi, K | 1 |
| Fujihara, M; Fujita, M; Furukawa, Y; Hattori, Y; Ishii, Y; Kuniki, H; Matsumoto, N; Yajima, T; Yamamoto, M; Yamaoka, Y | 1 |
| Hada, M; Mizutari, K | 1 |
| Abbruzzese, JL; Deutsch, J; LoBuglio, A; Needle, M; Rosenberg, A; Schmidt, W; Wolff, RA; Xiong, HQ | 1 |
| Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 2 |
| Bachem, MG; Berberat, P; Büchler, MW; di Mola, FF; Esposito, I; Friess, H; Giese, NA; Giese, T; Köninger, J | 1 |
| Allen, AM; Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Simone, D; Zalupski, MM | 1 |
| Alakavuklar, M; Coker, A; Oztop, I; Sagol, O; Tarhan, O; Yaren, A; Yavuzsen, T; Yilmaz, U | 1 |
| Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
| Hedley, DW; Lau, JP; Skalski, V; Weatherdon, KL | 1 |
| Aoki, K; Matsumura, Y; Okusaka, T | 1 |
| Abraham, NG; Gorschlüter, M; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Hatakeyama, K; Kurosaki, I; Shimizu, T; Tsuchiya, Y | 1 |
| Bhalla, KN; Gillespie, TW; Harris, WB; Kooby, D; Landry, J; Meyers, M; Small, W; Staley, CA | 1 |
| Allendorf, JD; Chabot, JA; Chen, J; Ennis, RD; Fine, RL; Fogelman, DR; Schreibman, SM; Schrope, BA | 1 |
| Maehara, S; Maehara, Y; Saito, Y; Shimada, M; Shirabe, K; Takahashi, K; Tanaka, S | 1 |
| Duan, XN; Liu, YH; Shen, WJ; Wan, YL; Wang, DM; Yang, YM; Yu, SP; Zhou, G | 1 |
| Blackstock, AW; Hollis, DR; Mayer, RJ; Niedwiecki, D; Tempero, MA; Tepper, JE | 1 |
| Cooper, H; Eisenberg, BL; Freedman, G; Hoffman, JP; Meropol, NJ; Pingpank, JF; Ross, EA; Sasson, AR; Wetherington, RW | 1 |
| Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F | 1 |
| Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R | 1 |
| Del Valle, J; Gómez, A; Ruiz, I | 1 |
| Elomaa, I; Joensuu, TK; Kärkkäinen, P; Kiviluoto, T; Kivisaari, L; Tenhunen, M; Vento, P; Westberg, R | 1 |
| Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S | 1 |
| Hidaka, S; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tanada, M; Tsubouchi, E; Tsuzuki, T; Yamauchi, Y | 1 |
| Bansback, N; Karnon, J; Ward, S | 1 |
| Davis, JJ; Fang, B; Jacob, D; Teraishi, F; Zhang, L; Zhu, H | 1 |
| Cass, C; Dabbagh, L; Dumontet, C; Glubrecht, D; Lai, R; Mackey, JR; Sangha, R; Spratlin, J; Young, JD | 1 |
| Baba, Y; Ishikawa, T; Kamimura, T; Mizuno, K; Oota, H; Watanabe, K; Yoshida, T | 1 |
| Lordick, F | 1 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 2 |
| Barauskas, G; Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Cardillo, TM; Gold, DV; Goldenberg, DM; Modrak, DE; Newsome, GA | 1 |
| Aoyagi, S; Hayashi, K; Horiuchi, H; Kinoshita, H; Koganemaru, M; Shirouzu, K; Toh, U; Uchida, S; Yamana, H | 1 |
| Funahashi, H; Manabe, T; Matsuo, Y; Okada, Y; Sakamoto, M; Sawai, H; Takahashi, H; Takeyama, H; Wakasugi, T; Yamamoto, M | 1 |
| Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Fujimori, Y; Furut, K; Hanazaki, K; Hasebe, O; Hayashi, K; Hisa, T; Hosokawa, K; Kajikawa, S; Kaneko, G; Kawa, S; Kiyosawa, K; Maejima, S; Matsuda, Y; Miwa, S; Miyagawa, S; Mukawa, K; Ochi, Y; Shikama, N; Tajiri, K; Takeuchi, N | 1 |
| Heinemann, V; Schauer, R; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Goldstein, L; Hesketh, P; Hughes, TM; Iannitti, D; Kennedy, T; King, T; Maia, C; Nauman, C; Pasquariello, T; Ramanathan, R; Rathore, R; Safran, H; Schwartz, JD; Steinhoff, M; Tantravahi, U; Tsai, JY; Wolff, R | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Hawkins, AE; Huang, ZQ; Khazaeli, MB; Kraus, MH; Vickers, SM | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Barge, A; Brabletz, T; Bruns, CJ; Fennell, M; Green, T; Guba, M; Jauch, KW; Koehl, G; Ryan, A; Yezhelyev, MV | 1 |
| Bang, SM; Chung, HW; Chung, JB; Kang, JK; Kim, JW; Lee, WJ; Park, SW; Seong, JS; Song, SY | 1 |
| Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Furuse, J; Ishii, H; Nagase, M; Yoshino, M | 1 |
| Alberts, SR; Erlichman, C; Fitch, TR; Foster, NR; Moore, DF; Nair, S; Rowland, KM; Schroeder, M; Steen, PD; Tschetter, LK | 1 |
| Maeyama, R; Manabe, T; Matsuda, T; Mizumoto, K; Okino, H; Tanaka, M | 1 |
| Biswas, S; Corrie, PG; Nik, S | 1 |
| Crnogorac-Jurcevic, T; Donadelli, M; Lemoine, NR; Missiaglia, E; Palmieri, M; Scarpa, A | 1 |
| Huang, WG; Jia, L; Yuan, SZ; Zhang, MH | 1 |
| Endou, M; Fujita, M; Hatano, M; Kuno, T; Mizuno, M; Nagata, T; Nakahara, N; Osawa, H; Tsukada, K; Tsuno, T; Yoshida, J | 1 |
| Matsuno, S | 1 |
| Dahan, L; Ries, P; Seitz, JF | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Ohkawa, S; Tarao, K; Ueno, M | 1 |
| Claude, L; Flandin, I; Khodri, M; Kubas, A; Mazeron, R; Mornex, F; Partensky, C; Wautot, V | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Cronk, M; Thomson, D; Walpole, E | 1 |
| Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C | 1 |
| Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ | 1 |
| Hedley, DW; Sutton, KL; Wheeler, JJ; Yau, CY | 1 |
| Bustamante, Fde T; Maffuz, A; Silva, JA; Torres-Vargas, S | 1 |
| Akutsu, Y; Endo, M; Hoshino, T; Matsubara, H; Ochiai, T; Ota, Y; Tsunoda, Y; Yoshinaga, Y | 1 |
| Inoue, S; Kitamura, M; Maeshiro, T; Matsuo, S; Miyamoto, S; Ohkubo, T; Ohmura, T; Tanaka, S; Umekita, N | 1 |
| Takeyama, O; Usui, Y | 1 |
| Androulakis, N; Aravantinos, G; Georgoulis, V; Mallas, K; Polyzos, A; Stathopoulos, GP; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Mai, M; Nishioka, K; Sawabu, N; Takahashi, Y | 1 |
| Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y | 1 |
| Bograd, S; Harris, JE; Plate, AE; Plate, JM; Shott, S | 1 |
| Bafaloukos, D; Bamias, A; Economopoulos, T; Efstathiou, E; Gogas, H; Kalofonos, H; Kastritis, E; Kosmidis, P; Onyenadum, A; Papacostas, P; Samantas, E; Samelis, G; Skarlos, D; Xiros, N | 1 |
| Büchler, MW; Erkan, M; Esposito, I; Friess, H; Giese, NA; Giese, T; Ketterer, K; Kleeff, J | 1 |
| Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R | 1 |
| Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C | 1 |
| Fujioka, A; Fukushima, M; Kazuno, H; Matsuda, A; Sakamoto, K; Sasaki, T | 1 |
| Aitini, E; André, T; de Gramont, A; Ducreux, M; Faroux, R; Hammel, P; Labianca, R; Lepere, C; Lledo, G; Louvet, C; Taïeb, J; Zampino, MG; Zaniboni, A | 1 |
| Choi, SB; Kim, SR; Lee, HY; Yuh, YJ | 1 |
| Abe, N; Atomi, Y; Sugiyama, M | 1 |
| Drebin, JA; Lin, LL; Linehan, DC; Myerson, R; Picus, J; Solis, J; Strasberg, SM; Tan, B; Thorstad, WL | 1 |
| Aldrighetti, L; Balzano, G; Bonetto, E; Bordonaro, R; Cordio, S; Di Carlo, V; Galli, L; Luppi, G; Milandri, C; Nicoletti, R; Oliani, C; Passardi, A; Passoni, P; Reni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T | 1 |
| Barauskas, G; Brasiūniene, B; Juozaityte, E | 1 |
| Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Smith, JP; Verderame, MF; Zagon, IS | 1 |
| Belcheva, A; Ellis, LM; Evans, DB; Fan, F; Gallick, GE; Gray, MJ; Klagsbrun, M; Liu, W; McCarty, MF; Somcio, R; Stoeltzing, O; Wey, JS | 1 |
| Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E | 1 |
| Akazawa, Y; Isomoto, H; Kohno, S; Mizuta, Y; Nakagoe, T; Ohara, H; Ohba, K; Ohnita, K; Omagari, K; Shiozawa, K; Shirono, K; Takeshima, F; Tanaka, K; Yasutake, T | 1 |
| Amano, R; Hirakawa, K; Inoue, M; Kosaka, K; Nakata, B; Nishino, H; Tendo, M; Yamada, N | 1 |
| Barletta, E; Carlini, P; Di Costanzo, F; Doni, L; Gasperoni, S; Iop, A; Massidda, B; Mattioli, R; Moscetti, L; Recchia, F; Tralongo, P | 1 |
| Lutz, MP | 1 |
| Brachtel, EF; Brugge, WR; Fernandez-del Castillo, C; Ryan, DP; Sahani, D; Willett, CG | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Hejna, GF; Lawrence, TS; McGinn, CJ; Normolle, DP; Schneider, BJ; Zalupski, MM | 1 |
| Abbruzzese, JL; Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP | 1 |
| McGee, PJ; Saif, MW | 1 |
| Calbó, J; Capellà, G; Cascalló, M; Fillat, C; Mazo, A; Pastor-Anglada, M | 1 |
| Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S | 1 |
| Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Aglietta, M; Capussotti, L; Faggiuolo, R; Gabriele, P; Gatti, M; Magnino, A; Massucco, P; Regge, D; Sperti, E | 1 |
| Addis, A; Balsari, A; Belluco, S; Menard, S; Petrangolini, G; Pratesi, G; Rossini, A; Rumio, C; Selleri, S; Tortoreto, M | 1 |
| Abbruzzese, JL; Chiao, PJ; Fidler, IJ; Hamilton, SR; He, J; Kim, SJ; Nam, DH; Sasaki, T; Sclabas, GM; Thaker, P; Yazici, S; Yokoi, K | 1 |
| Boterberg, T; Closon, MT; Closset, J; Demols, A; Gay, F; Honoré, P; Peeters, M; Polus, M; Van Houtte, P; Van Laethem, JL | 1 |
| Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Bernardini, N; Bocci, G; Collecchi, P; Danesi, R; Del Tacca, M; Fioravanti, A; Orlandi, P | 1 |
| Wang, XP; Wu, K; Xu, G; Zhao, S | 1 |
| Duquette, M; Galardi, E; Lawler, J; Parangi, S; Zhang, X | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Bria, E; Carboni, F; Carlini, P; Cognetti, F; Di Cosimo, S; Ettorre, GM; Gelibter, A; Giannarelli, D; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Arning, M; Fuchs, M; John, W; Kindler, HL; Oettle, H; Peeters, M; Ramanathan, RK; Richards, D; van Laethem, JL; Von Hoff, D; Zimmermann, A | 1 |
| Caca, K; Kronberg, J; Mossner, J; Schoppmeyer, K; Tannapfel, A; Wittekind, C | 1 |
| Christgen, M; Jueschke, A; Kalthoff, H; Schniewind, B; Ungefroren, H | 1 |
| Banerjee, S; Biliran, H; Bollig, A; Heng, H; Liao, JD; Sarkar, FH; Thakur, A; Wang, Y; Xu, H | 1 |
| Furuse, J; Gotohda, N; Ishii, H; Kinoshita, T; Konishi, M; Nakachi, K; Nakagohri, T; Suzuki, E; Takahashi, S; Yoshino, M | 1 |
| Fujimori, Y; Furuta, K; Hanazaki, K; Hasebe, O; Hayashi, K; Hisa, T; Hosokawa, K; Kajikawa, S; Kaneko, G; Kawa, S; Kiyosawa, K; Maejima, S; Matsuda, Y; Miwa, S; Miyagawa, S; Mukawa, K; Ochi, Y; Shikama, N; Tajiri, K; Takeuchi, N | 1 |
| Abbas, J; Al-Kutoubi, A; Bikhazi, AB; Chehal, AA; Habbal, MZ; Khalifeh, MJ; Malaeb, LA; Mourad, FH; Shamseddine, AI | 1 |
| Büchler, MW; Büchler, P; Eibl, G; Friess, H; Hines, OJ; Isacoff, WH; Reber, HA; Roth, MA | 1 |
| Burris, HA | 2 |
| Richards, DA | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L | 1 |
| Berlin, JD | 1 |
| Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN | 1 |
| Cunningham, D; Hill, A; Maisey, NR; Massey, A; Norman, AR; Oates, J | 1 |
| Abbruzzese, J; Ali, S; Banerjee, S; Bhuiyan, M; Chiao, PJ; Philip, PA; Sarkar, FH; Wang, Z; Zhang, Y | 1 |
| Abbruzzese, JL; Coombes, KR; Fidler, IJ; Hamilton, SR; Hawke, D; Kobayashi, R; Koomen, J; Li, D; Shih, LC; Yokoi, K | 1 |
| Hoshida, Y; Kawabe, T; Komatsu, Y; Nakai, Y; Omata, M; Otsuka, M; Tada, M | 1 |
| Abdollahi, A; Buchler, MW; Buechler, P; Debus, J; Didinger, B; Friess, H; Heeger, S; Herfarth, KK; Huber, PE; Krempien, R; Muenter, MW; Nill, S; Timke, C | 1 |
| Hatakeyama, K; Kurosaki, I | 1 |
| Fujii, M; Goubaru, M; Makino, Y; Ogata, M; Ohta, T; Tanaka, S | 1 |
| Fukuda, Y; Ishimoto, T; Kagawa, N; Matsugu, Y; Nakahara, H; Tanaka, T | 1 |
| Barge, A; Bruns, CJ; Friedrich, M; Jauch, KW; Kleespies, A; Köhl, G; Ryan, AJ | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| Barth, RJ; Bettmann, MA; Cates, JM; Colacchio, TA; Cole, BF; Gordon, SR; Marshall, JF; McDonnell, CE; Meyer, LP; Perez, RP; Pipas, JM; Redfield, N; Ripple, GH; Suriawinata, AA; Sutton, JE; Tsapakos, MJ; Zaki, B | 1 |
| Dachman, A; Friberg, G; Karrison, T; Kindler, HL; Kozloff, M; Locker, G; Nattam, S; Singh, DA; Stadler, WM; Taber, DA; Vokes, EE | 1 |
| Batra, SK; Brand, RE; Mimeault, M; Sasson, AA | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Adusumilli, PS; Chan, MK; Chou, TC; Eisenberg, DP; Fong, Y; Hendershott, KJ; Mullerad, M; Yu, Z | 1 |
| Chen, G; Li, LJ; Niu, BZ; Wu, YD; Zhao, YP | 1 |
| Dexheimer, TS; Fellows, IM; Gleason-Guzman, M; Hurley, LH; Schwaebe, M; Vankayalapati, H; Whitten, JP | 1 |
| Hirata, N; Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R; Yabu, K | 1 |
| Cleverly, A; de Lange, SM; Jensen, HA; Kroep, JR; Peters, GJ; Pfeiffer, P; van der Born, K; van Groeningen, CJ | 1 |
| Abbruzzese, JL; Baker, CH; Bucana, CD; Fan, D; Fidler, IJ; Kitadai, Y; Kuwai, T; Sasaki, T; Yokoi, K | 1 |
| Goker, E; Goksel, G; Karabulut, B; Sanli, UA; Sezgin, C; Uslu, R; Yuzer, Y | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yoshino, M | 1 |
| Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Sakai, T; Shirouzu, K; Uchida, S | 1 |
| Akiyama, T; Hirata, K; Homma, H; Kogawa, K; Koike, K; Mezawa, S; Takahashi, S | 1 |
| Arai, T; Baba, H; Ema, T; Hashimoto, T; Karasawa, K; Kawakami, M; Matsumoto, G; Nakanishi, C; Okamoto, A; Suzuki, Y; Tsuruta, K | 1 |
| Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Chien, PY; Khan, AR; Sheikh, S | 1 |
| Russo, S; Saif, MW; Sellers, S | 1 |
| Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Doi, R; Fujimoto, K; Hiraoka, M; Imamura, M; Mizowaki, T; Nagata, Y; Oya, N; Sakamoto, T; Shibuya, K | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Doi, R; Fujimoto, K; Ito, D; Kami, K; Kawaguchi, Y; Koizumi, M; Mori, T; Toyoda, E | 1 |
| Bang, S; Choo, YS; Chung, JB; Kim, HS; Park, SW; Song, SY | 1 |
| Airoldi, M; Cattel, L; Milla, P; Passera, R; Pedani, F; Zanon, C | 1 |
| Clayton, AJ; Hawkins, RE; Jones, ET; Mansoor, AW; Saunders, MP; Swindell, R; Valle, JW | 1 |
| Inadome, N; Maemondo, M; Matsumoto, K; Mizumoto, K; Murakami, M; Nagai, E; Nakamura, T; Nukiwa, T; Ogura, Y; Saimura, M; Tanaka, M | 1 |
| Kakizaki, I; Kon, A; Kudo, D; Morohashi, H; Nakazawa, H; Sasaki, M; Takagaki, K; Yoshihara, S | 1 |
| Flores, AM; Rocha Lima, CM | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 2 |
| Hyodo, M; Koizumi, M; Kurihara, K; Nagai, H; Sata, N; Shimura, K; Tsukahara, M; Yasuda, Y; Yoshizawa, K | 1 |
| Barnett, CC; Beck, AW; Brekken, RA; Conner, CR; Fleming, JB; Holloway, SE; Luster, TA; Miller, AF; Thorpe, PE | 1 |
| Moore, MJ | 2 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Aguilar, EA; Carbonero, AI; Delgado, FJ; Espinosa, JC; García López, JL; García Ribas, I; García, JJ; Guzmán, MC; Jericó, JF; Martos, CF; Mena, AC; Muñoz, ML; Plazas, JG; Rovira, PS; Santasusana, JM; Valera, JS | 1 |
| Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
| Archange, C; Barthet, M; Dagorn, JC; Gironella, M; Giroux, V; Iovanna, JL; Malicet, C; Vasseur, S | 1 |
| Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG | 1 |
| Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R | 1 |
| Aithal, GP; Anagnostopoulos, GK; Kaye, P; Ragunath, K; Rowlands, BJ | 1 |
| Bassi, C; Boz, G; De Paoli, A; Falconi, M; Innocente, R; Pederzoli, P; Rossi, C; Tosolini, GC; Trovò, MG | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Sakao, J; Souda, S | 1 |
| Lowy, AM | 1 |
| Guo, SS; Liang, HL; Wang, Y; Xie, de R | 1 |
| Fahlke, J; Florschuetz, A; Greiner, C; Hahnfeld, S; Hribaschek, A; Kettner, E; Klein, H; Kuhn, R; Lippert, H; Manger, T; Meyer, F; Ridwelski, K; Wilhelm, G | 1 |
| Attaluri, V; Colletti, LM; Freedman, GM; Hoffman, JP; Kinsella, TJ; McGinn, CJ; Mulcahy, MF; Philip, PA; Small, W; Talamonti, MS; Wayne, JD; Zalupski, MM | 1 |
| Hamada, S; Kanno, A; Kimura, K; Masamune, A; Satoh, K; Shimosegawa, T | 1 |
| Bekaii-Saab, TS; Chen, CS; Li, J; Melvin, WS; Muscarella, P; Zhu, J | 1 |
| Nagata, T; Tsukada, K; Yoshino, T | 1 |
| Ohkawa, S | 1 |
| Akiyama, T; Homma, H; Mezawa, S; Takahashi, S | 1 |
| Nakao, A; Takeda, S | 1 |
| Abe, H; Egawa, S; Motoi, F; Ohmura, N; Ottomo, S; Sunamura, M | 1 |
| Takahashi, Y; Yamashita, K | 1 |
| Funakoshi, A; Iguchi, H; Sumii, T | 1 |
| Hasegawa, T; Hirayama, A; Nagakawa, T; Nishino, S; Suga, T | 1 |
| Endoh, Y; Nagata, T; Ohnishi, Y; Tsukada, K; Yamagishi, F | 1 |
| Egawa, S; Fukuyama, S; Motoi, F; Sunamura, M; Unno, M | 1 |
| Izukura, M; Miyazaki, S; Nisijima, J | 1 |
| Ioka, T; Nakaizumi, A; Nishiyama, K; Tanaka, S; Yamazaki, H | 1 |
| Kim, DH; Ogawa, K; Shiozawa, S; Tsuchiya, A | 1 |
| Baron, D; Kluger, Y; Mayo, A | 1 |
| Feng, FY; Fu, M; Liang, X; Lin, C; Yang, Y; Yao, J; Zhang, XY | 1 |
| Abe, Y; Fujisawa, N; Fujisawa, T; Fujita, K; Inamori, M; Kawamura, H; Kirikoshi, H; Kobayashi, N; Kubota, K; Nakajima, A; Saito, S; Sakaguchi, T; Shimamura, T; Takahashi, H; Yoneda, M | 1 |
| Danquah, G; Jacobs, MJ; Mittal, VK; Ng, J; ReMine, SG; Saidi, RF; Williams, F | 1 |
| Amoh, Y; Bouvet, M; Hoffman, RM; Katsuoka, K; Li, L; Moossa, AR; Tsuji, K | 1 |
| Kitano, M; Kudo, M; Nakai, T; Ohyanagi, H; Sakamoto, H; Suetomi, Y; Takeyama, Y; Yasuda, C | 1 |
| Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Frazier, M; Hess, KR; Jiao, L; Li, D | 1 |
| Haye, S; Kalthoff, H; Kapischke, M; Kremer, B; Kruse, ML; Sipos, B; Tepel, J | 1 |
| Von Hoff, DD | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Crane, CH; Evans, DB; Pisters, PW; Varadhachary, G; Wolff, RA | 2 |
| Du, W; Posner, M; Schmidt, H; Shafaee, Z; Weichselbaum, R | 1 |
| Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
| de Jager, J; Stebbing, J | 1 |
| Algayres, JP; Béchade, D; Bredin, C; Defuentes, G; Desramé, J; Dourthe, LM; Duvic, C; Raynaud, JJ | 1 |
| Fujii, T; Habiro, A; Izawa, T; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakano, Y; Okumura, T; Osanai, M; Tanno, S; Yanagawa, N | 1 |
| Jiang, PH; Minamoto, T; Motoo, Y; Sawabu, N | 1 |
| Beck, AM; Carrigan, PE; Hayes, GM; Miller, LJ | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Iannopollo, M; Mey, V; Mosca, F; Nannizzi, S; Orlandini, C; Ricci, S | 1 |
| Boulikas, T; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Vougiouka, M | 1 |
| Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H | 1 |
| Graeven, U; Killing, B; Kremer, B; Rojo, F; Schmiegel, W; Südhoff, T; Tillner, J; Unal, C; Weber, D | 1 |
| Brueckl, WM; Brunner, TB; Grabenbauer, GG; Meyer, T; Sauer, R; Tinkl, D | 1 |
| Chen, Z; Jian, Z; Li, J; Li, X; Li, Y; Lv, X; Pei, H; Xia, K | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Arias de la Vega, F; Gómez Dorronsoro, ML; Jiménez, FJ | 1 |
| López Jiménez, A; Maestu Maiques, I; Oltra Ferrando, A; Pérez-Fidalgo, JA | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Ausania, F; Borzomati, D; Caricato, M; Coppola, R; Garberini, A; Rabitti, C; Tonini, G | 1 |
| Chang, JY; Chao, Y; Chen, LT; Cheng, AL; Chuang, TR; Hsu, C; Hsu, CH; Jan, CM; Liu, TW; Shiah, HS; Whang-Peng, J; Yu, WL | 1 |
| Hidalgo, M; Iacobuzio-Donahue, CA; Klein, A; Kulesza, P; Laheru, D; Ricci, F; Rubio-Viqueira, B; Rubio-Viquiera, B; Sebastiani, V; Yeo, CJ | 1 |
| Boehm, KA; Clark, M; Dasse, KD; Grove, W; Gulyas, S; Krishnamurthi, SS; Macdonald, K; Richards, DA; Rosemurgy, A; Wagener, DJ; Waterhouse, DM | 1 |
| Fakih, MG | 1 |
| Funakoshi, A; Sumii, T | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, LT; Cheng, AL; Hsu, C; Lin, JT; Liu, TW; Lu, YS; Shiah, HS; Wang, CC; Wang, HP; Whang-Peng, J | 1 |
| Eickhoff, A; Eickhoff, JC; Galle, PR; Hartmann, D; Jakobs, R; Martin, W; Möhler, M; Riemann, JF | 1 |
| Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Calabrò, F; Mancuso, A; Sternberg, CN | 1 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Mulholland, MW; Newman, EA; Simeone, DM | 1 |
| Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
| Baker, CH; Caron, A; Fidler, IJ; Gallick, GE; Nesbit, M; Summy, JM; Trevino, JG; Zhang, F | 1 |
| Abbruzzese, JL; Abdelrahim, M; Baker, CH; Safe, S | 1 |
| Abbruzzese, JL; Carr, K; Xiong, HQ | 1 |
| A-Hon, K; Kamiyama, Y; Komiyama, Y; Satoi, S; Takahashi, H; Takahashi, K; Takai, S; Terakawa, N; Yanagimoto, H | 1 |
| Adjei, AA | 1 |
| Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A | 2 |
| Kopchak, KV; Kopchak, VM; Romaniv, IaV | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Bruns, C; Heinemann, V; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C | 1 |
| Goldstein, D; Karapetis, C; Steer, CB; Strickland, A; Yip, D | 1 |
| Ishikawa, N; Mizumoto, K; Murakami, M; Nagai, E; Ogura, Y; Ohuchida, K; Tanaka, M; Yamada, D | 1 |
| Eichler, K; Hammerstingl, R; Heller, M; Hochmuth, K; Jacob, U; Scheller, A; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Aikawa, I; Matsuda, T; Minato, H; Nomura, H; Taniguchi, F; Tsuda, T | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Michalski, C | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K | 1 |
| Blackstock, AW; Case, LD; Descos, L; Kachnic, LA; Levine, EA; Limentani, SA; Melin, SA; Mishra, G; Mornex, F; Partensky, C; Tepper, JE | 1 |
| Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H | 1 |
| Neoptolemos, JP; Smith, DB | 1 |
| Cai, LZ; Fu, YW; Liang, QL; Liu, GX; Pan, DC; Xie, JR; Yang, Q; Yin, ZM | 1 |
| Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Altiok, S; Amador, ML; Bouraoud, N; Cusatis, G; Danenberg, K; Danenberg, PV; Eshleman, J; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Kulesza, P; Kuramochi, H; Maitra, A; Messersmith, W; Rubio-Viqueira, B; Salimi-Moosavi, H; Shi, C; Singh, S; Tanaka, K; Yeo, C; Zhang, X | 1 |
| Greer, K; McGinness, J | 1 |
| Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N | 1 |
| Hirakawa, K; Inoue, M; Kimura, K; Komatsu, M; Muguruma, K; Nishihara, T; Ohira, M; Sawada, T; Yamada, N; Yamashita, Y | 1 |
| Clemens, M; Einsele, H; Fleckenstein, D; Fuchs, M; Gesierich, W; Gieseler, F; Gonnermann, M; Haag, C; Heinemann, V; Heinrich, B; Hinke, A; Holstege, A; Neuhaus, H; Quietzsch, D; Rost, A; Schalhorn, A; Schönekäs, H; Uthgenannt, D; Vehling-Kaiser, U; Wilkowski, R | 1 |
| Hoffmann, D; Wildner, O | 1 |
| Bellone, G; Bertetto, O; Buffolino, A; Busso, V; Carbone, A; Emanuelli, G; Novarino, A; Scirelli, T; Smirne, C; Tosetti, L | 1 |
| Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV | 1 |
| Funahashi, H; Manabe, T; Okada, Y; Sawai, H; Takeyama, H; Tanaka, M; Yamamoto, M | 1 |
| Augé, JM; Ayuso, C; Cajal, R; Conill, C; Fernández-Cruz, L; Gallego, R; Gascón, P; Ginès, A; Marmol, M; Martin-Richard, M; Maurel, J; Miquel, R; Nadal, C; Navarro, S; Petriz, L; Sánchez, M | 1 |
| Nagaoka, S; Okabe, Y; Ono, N; Saito, F; Sata, M; Suga, H; Toyonaga, A; Tsuruta, O | 1 |
| Fujimori, N; Funakoshi, A; Horikawa, Y; Nakamura, T; Senju, T; Sumii, T | 1 |
| Baba, Y; Ishikawa, N; Ishikawa, T; Kamimura, T; Mafune, Y; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Ushiki, T; Watanabe, K; Yoshida, T | 1 |
| Machida, H; Suzuki, K; Toda, H; Ushida, S | 1 |
| Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS | 1 |
| Buscail, L; Cordelier, P; Drocourt, D; Ghénassia, L; Lulka, H; Pradayrol, L; Pyronnet, S; Souque, A; Tiraby, G; Vernejoul, F | 1 |
| Boeck, S; Fahrig, R; Hänel, M; Heinemann, V; Heinrich, JC; Krupitza, G; Liebert, A; Praha, C; Quietzsch, D; Schmid, RM; Sonntag, D | 1 |
| Dagorn, JC; Giroux, V; Iovanna, J | 1 |
| Behrens, R; Buechner-Steudel, P; Fleig, WE; Kleber, G; Kuss, O; Lindig, U; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Chatani, K; Kametani, T; Masuda, S; Shibata, K; Takase, M | 1 |
| Boku, N; Fukutomi, A; Yoshino, T | 1 |
| Eckel, F; Schmid, RM; Schneider, G | 1 |
| Baum, U; Brunner, TB; Grabenbauer, GG; Lambrecht, U; Sauer, R | 1 |
| Chen, G; Chen, H; Friess, H; Greenblatt, DY; Guo, J; Kleeff, J; Leung, PS; Liao, Q; Shen, S; Zhao, Y | 1 |
| Chen, G; Guo, JC; Jiang, H; Niu, BZ; Wu, WW; Zhang, LY; Zhao, YP | 1 |
| André, M; Bayle, S; Bideau, K; Labat, JP; Lagarde, N; Metges, JP; Robaszkiewicz, M | 1 |
| Fok, JY; Kumar, R; Manavathi, B; Mann, AP; Mehta, K; Verma, A; Wang, H | 1 |
| Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Furuya, T; Iizuka, N; Kawauchi, S; Oga, A; Oka, M; Sasaki, K; Toshimitsu, H; Yamamoto, K | 1 |
| Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Owen, OG | 1 |
| Aikou, T; Kitazono, M; Kubo, F; Maemura, K; Noma, H; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Guo, SS; Liang, HL; Wang, Y; Xie, DR; Yang, Q | 1 |
| Schmid, RM | 1 |
| Ashley, SW; Liau, SS; Whang, EE | 1 |
| Buchsbaum, DJ; DeRosier, LC; Huang, ZQ; Sellers, JC; Vickers, SM | 1 |
| Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, Y; Takemasa, I; Tsujie, M; Umeshita, K; Yamasaki, M; Yoshioka, S | 1 |
| Fujita, N; Horaguchi, J; Ito, K; Kobayashi, G; Noda, Y; Takasawa, O | 1 |
| Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T | 1 |
| Aoyagi, Y; Enomoto, T; Nakajima, M; Noguchi, M; Oda, T; Ohkohchi, N; Satake, M; Sugiura, S | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Balcke, P; Castellano, D; Davidson, N; Dittrich, C; Dobrowolski, F; Esteve, AA; Friess, H; Hawkins, R; Herzog, P; Hossfeld, DK; Katz, F; Kleeff, J; Kovar, A; Langrehr, JM; Neyns, B; Niedergethmann, M; Nippgen, J; Oettle, H; Piedbois, P; Raedle, J; Scheithauer, W; Stöger, H; Tempia-Caliera, AA; van Belle, S; Vermorken, J | 1 |
| Bang, S; Chung, JB; Jeon, TJ; Kim, MH; Park, JY; Park, SW; Song, SY | 1 |
| Ammerpohl, O; Griep, U; Grutzmann, R; Janssen, O; Kalthoff, H; Kloppel, G; Pilarsky, C; Saeger, HD; Schniewind, B; Sipos, B; Trauzold, A | 1 |
| Cengel, KA; Plastaras, JP | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V | 1 |
| Earle, CC; Krzyzanowska, MK; Kuntz, KM; Weeks, JC | 1 |
| Neifeld, JP | 1 |
| Akbulut, H; Büyükcelik, A; Cay, F; Demirkazik, A; Dincol, D; Icli, F; Isikdogan, A; Onur, H; Utkan, G; Yalcin, B | 1 |
| Brade, A; Brezden-Masley, C; Brierley, J; Cummings, B; Gallinger, S; Hedley, D; Maclean, M; Moore, M; Oza, A; Pond, GR; Townsley, C; Wong, S | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Arkus, N; Arnold, NB; Gunn, J; Korc, M | 1 |
| Baba, H; Karasawa, K; Kurata, M; Okamoto, A; Tsuruta, K | 1 |
| Izawa, T; Kohgo, Y; Koizumi, K; Minoguchi, M; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Tanno, S | 1 |
| Bechstein, WO; Burkart, C; Doerken, B; Fahlke, J; Gellert, K; Gutberlet, K; Kettner, E; Langrehr, J; Neuhaus, P; Niedergethmann, M; Oettle, H; Post, S; Ridwelski, K; Riess, H; Roll, L; Schmalenberg, H; Schmidt-Wolf, I; Schramm, H; Weigang-Koehler, K; Zuelke, C | 1 |
| Benson, AB | 1 |
| Boeck, S; Depenbrock, H; Fuchs, M; Heinemann, V; Kettner, E; Köhne, CH; Kröning, H; Lordick, F; Quietzsch, D; Steinmetz, T; Stötzer, O; Trojan, J; Weigang-Köhler, K; Zeuzem, S | 1 |
| Boeck, S; Heinemann, V; Holdenrieder, S; Schulz, C; Stieber, P; Weckbach, S | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Suzuki, E; Yoshino, M | 1 |
| Konduri, S; Schwarz, RE | 1 |
| Arnold, S; Doyle, A; Garofalo, MC; Hanna, N; Kataria, R; Mohiuddin, M; Regine, WF; Sims, J; Tan, M | 1 |
| Honma, S; Itoh, K; Kamiyama, Y; Mine, T; Mizoguchi, J; Nakahara, K; Oka, M; Satoi, S; Takahashi, K; Takai, S; Tanaka, M; Terakawa, N; Yamada, A; Yamamoto, K; Yanagimoto, H | 1 |
| Alvarez, H; Beaty, R; Bedja, D; Dhara, S; Feldmann, G; Fendrich, V; Gabrielson, KL; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Maitra, A; Matsui, W; Mullendore, M | 1 |
| Armour, EP; Feldmann, G; Herman, J; Karikari, CA; Maitra, A; Pinilla, C; Rakheja, D; Reed, JC; Roy, I; Tryggestad, E; Welsh, K; Wong, J | 1 |
| Zalatnai, A | 1 |
| Atmatzidis, K; Chrysogelou, E; Harlaftis, N; Livanis, J; Moschidis, A; Moschidis, E; Mourelatos, D; Papageorgiou, A; Tsalis, K; Tsavdaridis, D | 1 |
| Dalgleish, A; Hill, M; Lofts, F; Maraveyas, A; Michael, A | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Quivey, JM; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Alberts, SR; McWilliams, RR | 1 |
| Adusumilli, S; Ben-Josef, E; Griffith, KA; Lawrence, TS; Murphy, JD; Ray, ME; Zalupski, MM | 1 |
| Danenberg, PV; Endo, I; Fujii, Y; Ichikawa, Y; Ishikawa, T; Matsuyama, R; Mori, R; Shimada, H; Taniguchi, K; Togo, S; Ueda, M | 1 |
| Bauer, C; Bauernfeind, F; Dauer, M; Eigler, A; Endres, S; Lehr, HA; Orban, M; Schnurr, M; Sterzik, A | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS | 1 |
| Akahori, T; Azuma, M; Enomoto, K; Hamada, K; Kanehiro, H; Kubo, A; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Yagita, H | 1 |
| Ajiki, T; Fujino, Y; Kamigaki, T; Kamoda, Y; Kuroda, Y; Matsumoto, I; Takase, S; Ueda, T; Yasuda, T | 1 |
| Goto, H; Ishiguro, H; Ito, M; Ko, SB; Kondo, T; Naruse, S; Yamamoto, A; Yoshikawa, T | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Adler, G; Seufferlein, T; von Wichert, G | 1 |
| Boeck, S; Heinemann, V; Moosmann, N; Stemmler, HJ | 1 |
| Aggarwal, BB; Diagaradjane, P; Gelovani, J; Guha, S; Krishnan, S; Kunnumakkara, AB | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Fok, JY; Mehta, K | 1 |
| Ikemoto, T; Imura, S; Miyake, K; Morine, Y; Shimada, M; Yoshizumi, T | 1 |
| Bahra, M; Boas-Knoop, S; Davis, J; Jacob, DA; Langrehr, JM; Lippert, S; Neumann, UP; Schumacher, G; Stefaniak, R | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Bramhall, SR; Buckels, JA; Hassan, AB; Hewitt, H; Johnson, PJ; Markham, CE; Palmer, DH; Stocken, DD | 1 |
| Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Aprahamian, M; Hajri, A; Réjiba, S; Wack, S | 1 |
| Alberts, SR; Chari, ST; Gores, GJ; Kendrick, ML; Kim, GP; Martenson, JA; Roberts, LR; Rosen, CB | 1 |
| Kim, R; Saif, MW | 2 |
| Aikou, T; Kitazono, M; Maemura, K; Mataki, Y; Noma, H; Shinchi, H; Takao, S | 1 |
| Motoo, Y | 1 |
| Iishi, H; Ioka, T; Ishikawa, O; Koizumi, M; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Tanaka, E; Uehara, H; Yamazaki, H | 1 |
| Fukushima, N; Itoi, T; Itokawa, F; Kasuya, K; Kurihara, T; Moriyasu, F; Sofuni, A; Tsuchida, A; Tsuchiya, T | 1 |
| Moore, MJ; Welch, SA | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Cina, S; Dietrich, D; Figer, A; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, B; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Janjan, NA; Krishnan, S; Rana, V; Varadhachary, GR; Wolff, RA | 1 |
| Fukushima, M; Maruyama, R; Nio, Y; Toga, T | 1 |
| Adam, U; Bornmann, C; Esser, N; Graeser, R; Hopt, UT; Jantscheff, P; Keck, T; Massing, U; Schaechtele, C; Unger, C; von Dobschuetz, E; Ziroli, V | 1 |
| Burtness, B | 1 |
| Beghelli, S; Bonora, A; Budillon, A; Caraglia, M; Costanzo, C; Dandrea, M; Donadelli, M; Palmieri, M; Piacentini, P; Scarpa, A; Scupoli, MT | 1 |
| Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 1 |
| Cereda, S; Galli, L; Reni, M | 1 |
| Bussom, S; Cheng, YC; Lam, W; Leung, CH | 1 |
| Alberts, SR; Camoriano, JK; Foster, NR; Haddock, MG; Hauge, MD; Martenson, JA; Moore, DF; Schaefer, PL; Stella, PJ; Swaminathan, R; Tenglin, RC | 1 |
| Bria, E; Carlini, P; Cognetti, F; Cuppone, F; Gelibter, A; Giannarelli, D; Milella, M; Nisticò, C; Pino, MS; Ruggeri, EM; Terzoli, E | 1 |
| Shivnani, AT | 1 |
| Lowenfels, AB; Maisonneuve, P | 1 |
| Hirte, H; Johnson, C; Low, J; Mackenzie, MJ; Moore, MJ; Pond, G; Saltman, D | 1 |
| Joensuu, T; Kärkkäinen, P; Kivilaakso, E; Kiviluoto, T; Mustonen, H; Vento, P | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Bouffard, DY; Cass, CE; Clarke, ML; Damaraju, VL; Gourdeau, H; Grey, M; Leblond, L; Mackey, JR; Wong, CK | 1 |
| Choi, EH; Gang, J; Haam, S; Hyung, W; Kim, HS; Park, SB; Shul, YG; Song, SY; Wen, J | 1 |
| Füessl, HS | 1 |
| Fenoglio-Preiser, C; Hingorani, SR; Lowy, AM; Revelo-Penafiel, MP; Thomas, RM; Toney, K; Tuveson, DA; Waltz, SE | 1 |
| Cornfeld, D; Saif, MW; Shahrokni, A | 1 |
| Irisawa, A; Kanazawa, M; Ogata, T; Ohira, H; Ohto, H; Sato, Y; Takagi, T; Takenoshita, S | 1 |
| Gabata, T; Kayahara, M; Kitagawa, H; Matsui, O; Minato, H; Nakagawara, H; Nakamura, M; Ohnishi, I; Ohta, T; Tajima, H; Takamura, H; Tani, T; Zen, Y | 1 |
| Nimura, Y | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Baril, P; Bhakta, V; Caulee, K; Chelala, C; Harada, T; Lemoine, NR; Mahon, PC | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E | 1 |
| Heinemann, V; Hinke, A; Labianca, R; Louvet, C | 1 |
| Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF | 1 |
| Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W | 1 |
| Kibble, A | 1 |
| Büchler, MW; Jäger, D; Märten, A; Mühlradt, PF; Schmidt, J; Welsch, T | 1 |
| Gahr, S; Ganslmayer, M; Hahn, EG; Hartl, A; Herold, C; Leitner, S; Ocker, M; Okamoto, K; Zopf, S | 1 |
| Chen, W; Dang, C; Lee, W; Liu, D; Ma, Q; Zhang, Y | 1 |
| Blackstock, AW; Butler, J; Ove, R; Russo, S | 1 |
| Abou-Alfa, GK; O'Reilly, EM | 1 |
| Hagihara, A; Ikeda, M; Morizane, C; Ogura, T; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD | 1 |
| Guo, SS; Jiang, ZM; Liang, HL; Xie, DR; Yang, Q | 1 |
| Dillmann, S; Henne-Bruns, D; Keller, F; Klug, F; Mayer, JM; Stracke, S; Tuncyurek, P | 1 |
| Egberts, JH; Hinz, S; Kalthoff, H; Schniewind, B; Sipos, B; Tepel, J | 1 |
| Ito, H; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Sawada, S; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Klöppel, G; Kolb-van Harten, P; Layer, P; Rosien, U | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Kanazumi, N; Kasuya, H; Nakao, A; Nomoto, S; Nomura, N; Shikano, T; Shirota, T; Sugimoto, H; Takeda, S; Watanabe, I | 1 |
| Fujii, N; Takemura, N; Tanaka, T | 1 |
| Akada, M; Egawa, S; Fujimura, H; Furukawa, T; Horii, A; Ishida, M; Shibuya, E; Sunamura, M; Unno, M | 1 |
| Ammons, WS; Hoffman, RM; Tidmarsh, GF; Wang, JW; Yang, Z | 1 |
| Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E | 1 |
| André, T; Blanchard, P; Huguet, F | 1 |
| Atahan, IL; Cengiz, M; Gullu, IH; Gurkaynak, M; Yalcin, S; Zorlu, F | 1 |
| Hashmi, S; Saif, MW | 1 |
| Doi, T; Fujimi, A; Izumi, K; Kanisawa, Y; Kikuchi, S; Kitahara, T; Ohta, H; Okuda, T; Sato, Y | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Aderka, D; Ashkenazy-Voghera, M; Ben-Yosef, R; Greif, J; Lev-Ari, S; Starr, A; Vexler, A | 1 |
| Cao, P; Hedley, DW; Pham, NA; Tsao, MS | 1 |
| Hayashi, H; Igarashi, H; Ito, T; Kawabe, K; Kodama, M; Sakai, H; Takayanagi, R; Yoshinaga, M | 1 |
| Babcock, TA; Dekoj, TR; Espat, NJ; Garrean, S; Hering, J; Razzak, A; Saied, A; Trevino, J | 1 |
| Andrieu, JM; Banu, A; Banu, E; Chatellier, G; Fodor, A; Landi, B; Oudard, S; Rougier, P | 1 |
| Palmer, DH | 1 |
| Emori, Y; Eta, R; Hamano, H; Iino, Y; Kawasaki, D; Takei, M; Tanaka, T; Watson, SA; Yoshinaga, K | 1 |
| Goldstein, M; Miksad, RA; Schnipper, L | 1 |
| Egozi, Y; Elad-Sfadia, G; Haklai, R; Kloog, Y | 1 |
| Gallick, GE; Parikh, NU; Park, SI; Shah, AN; Summy, JM; Zhang, J | 1 |
| Antognoli, S; Berardi, R; Carbonari, G; Cascinu, S; Giampieri, R; Mariani, C; Pierantoni, C; Scartozzi, M; Silva, RR; Squadroni, M; Verdecchia, L | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Desai, SP; Francis, IR; Greenson, JK; Lawrence, TS; Normolle, DP; Simeone, DM; Zalupski, MM | 1 |
| Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C | 1 |
| Husain, SR; Kioi, M; Nakajima, A; Puri, RK; Royal, RE; Shimamura, T | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Bauer, RW; Böcher, E; Hammerstingl, RM; Heller, M; Jacob, U; Vogl, TJ; Zangos, S | 1 |
| Boeck, HP; Boeck, S; Geissler, M; Golf, A; Heinemann, V; Hochhaus, A; Hoehler, T; Kettner, E; Ko, Y; Kojouharoff, G; Lordick, F; Mahlberg, R; Neugebauer, S; Schmid, B; Schoppmeyer, K; Seipelt, G; Stauch, M; Wein, A | 1 |
| Kim, YT; Lee, KY; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yoo, JW; Yoon, YB | 1 |
| Fujimoto, M; Kuramitsu, Y; Maehara, S; Maehara, Y; Mikuria, K; Mori-Iwamoto, S; Nakamura, K; Okita, K; Ryozawa, S; Sakaida, I | 1 |
| Aprahamian, M; Hajri, A; Parmentier, C; Rejiba, S; Wack, S | 1 |
| Brasiūniene, B; Juozaityte, E | 1 |
| Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A | 1 |
| Abe, H; Endo, Y; Kurumi, Y; Kushima, R; Mekata, E; Miyake, T; Murata, S; Shimizu, T; Tani, T | 1 |
| Alken, RG; Bader, Y; Fritzer-Szekeres, M; Grusch, M; Hartmann, J; Heller, N; Horvath, Z; Krupitza, G; Madlener, S; Maier, S; Oehler, L; Saiko, P; Szekeres, T | 1 |
| Fukuyama, T; Hachiya, Y; Hirano, Y; Ishikawa, N; Maeyama, R; Morimatsu, K; Sako, T; Tamura, T | 1 |
| Alexander, HR; Bartlett, DL; Dedrick, RL; Egorin, MJ; Gamblin, TC; Herscher, LL; Lagattuta, TF; Libutti, SK; Russo, A; Zuhowski, EG | 1 |
| Dixon, J; Holcomb, B; Kennard, J; Mahomed, J; Matos, JM; Schmidt, CM; Sebolt-Leopold, J; Shanmugam, R; Yip-Schneider, MT | 1 |
| Arnoletti, JP; Ben-Josef, E; Bhargava, P; Casper, ES; Kim, P; Malafa, MP; Nakakura, EK; Shibata, S; Talamonti, M; Tempero, M; Wang, H; Willett, C | 1 |
| Bergmann, F; Büchler, MW; Friess, H; Gaida, MM; Giese, NA; Giese, T; Mayer, C; Michalski, CW; Wente, MN | 1 |
| Miller, JD | 1 |
| Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ | 1 |
| Aitini, E; Artale, S; Barni, S; Berardi, R; Cascinu, S; Dapretto, E; Di Costanzo, F; Falcone, A; Floriani, I; Labianca, R; Pierantoni, C; Rota, S; Scartozzi, M; Siena, S; Tonini, G; Zaniboni, A | 1 |
| Bjerregaard, JK; Pfeiffer, P | 1 |
| Ichihara, N; Kitanaka, A; Kubota, Y; Taminato, T; Tanaka, T | 1 |
| Heinemann, V; Wilkowski, R; Wolf, M | 1 |
| Arnoletti, P; Buchsbaum, DJ; Derosier, LC; Grizzle, WE; Huang, Z; Lobuglio, AF; Oliver, PG; Sellers, J; Stockard, CR; Vickers, SM; Wang, W; Zhou, T; Zinn, KR | 1 |
| Kim, YT; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| De Smet, D; Jochmans, K; Neyns, B | 1 |
| Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y | 1 |
| Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS | 1 |
| Berardi, R; Cantore, M; Cascinu, S; Cereda, S; Ferrari, VD; Grisanti, S; Mambrini, A; Mazza, E; Pasetto, L; Reni, M | 1 |
| Braguer, D; Cournede, A; Dahan, L; Duluc, M; Laquiere, A; Laugier, R; Ressiot, E; Ries, P; Seitz, JF | 1 |
| Benson, AB; Small, W; Wahl, AO; Wisinski, KB | 1 |
| Behringer, D; Gelos, M; Mann, B; Philippou, S | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Araki, H; Kamiyama, Y; Matsui, Y; Satoi, S; Sohgawa, M; Takahashi, K; Takai, S; Terakawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Aizawa, M; Ho Kim, D; Inose, S; Katsube, T; Naritaka, Y; Ogawa, K; Shiozawa, S; Tsuchiya, A; Usui, T; Yoshimatsu, K | 1 |
| Hashimoto, M; Matsuda, M; Watanabe, G | 1 |
| Hashimoto, M; Matsuda, M; Mine, S; Watanabe, G | 1 |
| Ammerpohl, O; Bohm, B; Brockschmidt, C; Eismann, T; Giamas, G; Henne-Bruns, D; Hillenbrand, A; Hirner, H; Huber, N; Kalthoff, H; Knippschild, U; Leithäuser, F; Radunsky, B; Trauzold, A | 1 |
| Morizane, C | 1 |
| Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J | 1 |
| Hayashida, H; Higaki, N; Hiura, Y; Ichihara, T; Kan, K; Murakami, M; Nakano, K; Sakon, M; Yamashita, S | 1 |
| Doi, K; Kudoh, K; Matsuo, A; Muranaka, T; Ogata, K; Ohchi, T; Ohtao, R | 1 |
| Gou, SM; Liu, T; Tao, J; Wang, CY; Wu, B; Wu, HS; Xiong, JX; Yang, M; Zhao, G; Zhou, F; Zhou, J | 1 |
| Boeck, S; Heinemann, V | 2 |
| Amos, KD; Arumugam, T; Evans, DB; Hwang, RF; Ji, B; Logsdon, CD; Moore, T; Ramachandran, V; Rivera, A | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Bajetta, E; Bodoky, G; Dietrich, D; Figer, A; Glimelius, B; Grawe, P; Herrmann, R; Hess, V; Ruhstaller, T; Saletti, P; Scheithauer, W | 1 |
| Arseneau, J; Caprioni, F; Corringham, R; De Boer, C; DeWitte, M; Friess, H; Lu, JD; Malfertheiner, P; Mantovani, G; Prabhakar, U; Qi, M; Richel, D; Ritch, P; Robinson, D; Van Cutsem, E; Von Hoff, D; Wiedenmann, B; Zhong, B | 1 |
| Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Takeda, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T | 1 |
| Dai, C; Du, Q; Gardner, K; Guo, X; Jacobs, JL; Jiang, K; Li, H; Li, QQ; Miao, Y; Qian, Z; Sun, G; Xu, Z; You, Y; Yu, C; Yuan, D; Zhang, X; Zhu, Y | 1 |
| Boku, N; Fukutomi, A; Kinoshita, T; Kondo, S; Maeda, A; Nagino, M; Uesaka, K | 1 |
| Attia, S; Eickhoff, J; Erlichman, C; Heun, J; Holen, KD; Huang, W; Kolesar, J; Laheru, D; Mahoney, MR; Pitot, HC | 1 |
| Benson, AB; Berlin, J; Chakravarthy, AB; Freedman, GM; Gill, JF; Hoffman, JP; Kinsella, TJ; Konski, AA; Lawrence, T; McGinn, CJ; Merchant, NB; Mulcahy, MF; Nicol, S; Philip, PA; Small, W; Talamonti, MS; Xu, RM; Zalupski, MM | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Dong, K; Li, B; Lin, F; Shen, JJ; Wang, R; Wang, X; Wei, SH; Zhang, HZ; Zhang, Q | 1 |
| Bang, S; Chung, JB; Hong, SP; Jeon, TJ; Lee, WJ; Park, JY; Park, MS; Park, SW; Seong, J; Song, SY | 1 |
| Afchain, P; André, T; Balosso, J; Dupuis, O; Huguet, F; Lledo, G; Louvet, C; Mineur, L; Moureau-Zabotto, L; Phélip, JM; Touboul, E; Vendrely, V | 1 |
| Gallick, GE; Kim, MP | 1 |
| Liau, SS; Whang, E | 1 |
| Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA | 1 |
| Kang, SP; Lacy, J; McLennan, B; Taddei, T | 1 |
| Arai, K; Honda, M; Iida, H; Kagaya, T; Kakinoki, K; Kaneko, S; Kitamura, K; Mizukosi, E; Nakamoto, Y; Sakai, A; Sakai, Y; Terashima, T; Yamashita, T | 1 |
| Arvanitaki, M; De Maertelaere, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Ames, MM; Bhattacharya, R; Buhrow, SA; Dutta, S; Katarya, A; Lau, JS; Muders, M; Mukherjee, P; Mukhopadhyay, D; Patra, CR; Reid, JM; Safgren, SL; Wang, E; Wang, S; Yaszemski, MJ | 1 |
| Correale, P; Francini, G; Miano, S; Montagnani, F; Pascucci, A; Petrioli, R; Sciandivasci, A; Tanzini, G; Testi, W | 1 |
| Capellà, G; Casanovas, O; Figueras, A; Galán, M; Germà, JR; Ginestà, MM; Lacasa, C; Laquente, B; Ribas, IG; Viñals, F | 1 |
| Chie, EK | 1 |
| Kim, YT | 1 |
| Leen, R; Medema, J; Rodermond, H; van Bree, C; van Kuilenburg, A | 1 |
| Persaud, R | 1 |
| Arvanitaki, M; de Maertelaer, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Chiba, T; Doi, R; Fukushima, M; Ishiguro, H; Kami, K; Kanai, M; Kawaguchi, Y; Kitano, T; Matsumoto, S; Misawa, A; Nishimura, T; Yamauchi, J; Yanagihara, K; Yasuda, H; Yazumi, S; Yoshikawa, K | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Fujino, Y; Kuroda, Y; Sakai, T | 1 |
| Boeck, S; Heinemann, V; Hinke, A; Labianca, R; Louvet, C | 1 |
| Hayashi, T; Homma, H; Ihara, H; Ishiwatari, H; Kato, J; Kawano, Y; Matsunaga, T; Miyanishi, K; Niitsu, Y; Okuda, T; Sato, Y; Takada, K; Takahashi, M; Takahashi, S; Takanashi, K | 1 |
| Armand, R; Kintner, J; Lewis, LD; Perez, R; Yeo, TK | 1 |
| Clarenbach, R; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt, T; Schmidt-Wolf, IG; Schmitz, V; Tiemann, K; Ziske, C | 1 |
| Burris, H; Rocha-Lima, C | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Ko, AH; Schillinger, B; Scott, J; Tempero, MA; Venook, AP; Wong, D; Xu, Z | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Abbruzzese, JL; Chang, P; Evans, DB; Jiao, L; Li, D; Okazaki, T | 1 |
| Alberts, SR; Carlson, SK; Foster, NR; Galanis, E; Grothey, A; Jatoi, A; Lowe, V; McWilliams, RR; Quevedo, F; Rubin, J | 1 |
| Van Laethem, JL | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Alvarez, I; Burris, H; Chow, S; Dragovich, T; Gordon, M; Green, S; Loehrer, P; Obregon, Y; Stratton, S; Von Hoff, DD | 1 |
| Chang, S; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Greco, R; Koong, AC; Kuo, T; Lee, F; Norton, J; Quon, A; Schellenberg, D; Yang, GP | 1 |
| Maples, PB; Nemunaitis, JJ; Wallraven, G | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
| Hilbig, A; Oettle, H | 1 |
| Arita, Y; Eriguchi, N; Funakoshi, A; Igarashi, H; Ito, T; Miyahara, T; Mizumoto, K; Muranaka, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Rocha-Lima, CM | 1 |
| Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Mohammad, RM; Rangnekar, VM; Sarkar, FH | 1 |
| Chen, J; Ou-Yang, ZG; Wu, SY; Zhen, YS | 1 |
| Ben-Josef, E; Lawrence, TS | 1 |
| Furuse, J; Ioka, T; Ishii, H; Ito, Y; Okusaka, T; Shibuya, K; Shinchi, H; Yamada, S | 1 |
| Aparicio, T; Azzedine, A; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Bauerfeind, P; Clavien, PA; Heinrich, S; Knuth, A; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Kuwahara, A; Masuda, T | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Mey, V; Mosca, F; Nannizzi, S; Pollina, LE; Ricciardi, S | 1 |
| Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W | 1 |
| Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C | 1 |
| Alschuler, L; Block, KI; Gyllenhaal, C; Kranz, S; Roddy, GD; Rubin, D | 1 |
| Nightingale, SL | 1 |
| Brown, TD; Casper, ES; Flombaum, CD; Green, MR; Heelan, RT; Kelsen, DP; Tarassoff, PG; Trochanowski, B | 1 |
| Andis, SL; Dudley, DE; Grindey, GB; Hertel, LW; Merriman, RL; Rutherford, PG; Schultz, RM; Tanzer, LR; Toth, JE; Zimmermann, JE | 1 |
| Blatter, J; Carmichael, J; Fink, U; Harris, AL; Russell, RC; Spiessi, G; Spittle, MF | 1 |
| Chang, EY; Hahn, TM; Hertel, LW; Lawrence, TS; Shewach, DS | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Moore, M | 1 |
| Lawrence, TS; Robertson, JM; Shewach, DS | 1 |
| Gelber, RD | 1 |
| Andersen, JS; Brown, TD; Burris, HA; Casper, ES; Cripps, MC; Green, MR; Moore, MJ; Portenoy, RK; Rothenberg, ML; Storniolo, AM; Tarassoff, PG; Von Hoff, DD | 1 |
| Rothenberg, ML | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Boder, GB; Grindey, GB; Hertel, LW; Houghton, JA; Houghton, PJ; Merriman, RL; Rutherford, PG; Schultz, RM; Tanzer, LR | 1 |
| Martin, C; Pollera, CF | 1 |
| Burris, H; Storniolo, AM | 1 |
| Andersen, J; Burris, HA; Cripps, MC; Dorr, FA; Green, MR; Modiano, MR; Moore, MJ; Nelson, R; Portenoy, RK; Rothenberg, ML; Stephens, CD; Storniolo, AM; Tarassoff, P; Von Hoff, DD | 1 |
| Goa, KL; Noble, S | 1 |
| John, WJ; Mohiuddin, M; Regine, WF | 2 |
| Rosenberg, L | 1 |
| Michael, M; Moore, M | 1 |
| Carmichael, J | 1 |
| Awada, A; Klastersky, J | 1 |
| Chaitchik, S; Merimsky, O | 1 |
| Caraceni, A; De Conno, F | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Brand, R; Capadano, M; Tempero, M | 1 |
| Adsay, V; Al-Katib, A; Joshi, U; Majumdar, AP; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Nori, D; Parikh, S | 1 |
| Kroep, JR; Merriman, RL; Peters, GJ; Pinedo, HM; Schultz, RM; Tanzer, LR; van Moorsel, CJ; Veerman, G; Voorn, DA; Worzalla, JF | 1 |
| Garcia, L; Goodwin, AL; Von Hoff, DD | 1 |
| Abrams, RA; Regine, WF | 1 |
| Blaszkowsky, L | 1 |
| Steward, WP; Thomas, A | 1 |
| Hejna, M; Raderer, M; Valencak, J | 1 |
| Adenis, A; Bugat, R; Dufour, P; Kayitalire, L; Kurtz, JE; Négrier, S; Ripoche, V; Trillet-Lenoir, V | 1 |
| Benedetti, F; Casper, ES; Erlandson, RA; Flombaum, CD; Mouradian, JA | 1 |
| Cascinu, S; Catalano, G; Graziano, F | 1 |
| Alonso, S; Castellano, D; Cortes-Funes, H; Diaz-Puente, M; Gravalos, C; Hidalgo, M; Hitt, R; Paz-Ares, L | 1 |
| Huhn, D; Oettle, H; Riess, H; Serke, S | 1 |
| Brown, CA; Enas, NH; Rothenberg, ML; Schilsky, R; Storniolo, AM; Voi, M | 1 |
| Coil, D; Davis, B; De Ipolyi, PD; Giovanella, BC; Natelson, EA; Stehlin, JS; Trojacek, A; Wallace, P; Wolk, D | 1 |
| Barton-Burke, M | 1 |
| Ali, N; Li, Y; Sarkar, FH; Singh, B | 1 |
| Taguchi, T; Tsukagoshi, S | 1 |
| Barni, S; Cascinu, S; Catalano, G; Cellerino, R; Frontini, L; Fusco, V; Giordani, P; Giuliodori, L; Labianca, R; Luporini, G; Pancera, G; Pessi, MA; Piazza, E; Silva, RR | 1 |
| Jeekel, J; van der Schelling, GP | 1 |
| Stucky-Marshall, L | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Baxter, D; Govindarajan, R; Wilson, C; Zent, C | 1 |
| Belotti, G; Cantù, A; Ciotti, R; D'Amico, A; Facchi, E; Gatti, C | 1 |
| Bauer, J; Kreil, A; Scheithauer, W | 1 |
| Brunet, R; Fonck, M | 1 |
| Choi, M; Göbel, U; Kettritz, R; Schneider, W; Woywodt, A | 1 |
| Ragnarson-Tennvall, G; Wilking, N | 1 |
| Adsay, V; Al-Katib, AM; Li, Y; Mohamed, AN; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Nanfro, JJ | 1 |
| Eisbruch, A; Fields, MT; Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Bernard, SA; Blackstock, AW; Case, LD; Eagle, KS; Poole, ME; Richards, F; Savage, PD; Tepper, JE | 1 |
| Arning, M; Diebold, T; Hochmuth, K; Huhn, D; Langrehr, J; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Schmidt, CA; Vogl, TJ | 1 |
| König, P; Kühr, T; Lhotta, K; Rumpelt, HJ; Thaler, J; Wöll, E | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Kalapura, T; Krishnamurthy, M; Reddy, CV | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA | 1 |
| André, T; Balosso, J | 1 |
| Halm, U; Keim, V; Mössner, J; Schiefke, I; Schumann, T; Witzigmann, H | 1 |
| Ely, G; Ferdinandi, ES; Joshi, SS; Liu, C | 1 |
| Adak, S; Berlin, JD; Blaszkowsky, L; Flinker, D; Harris, JE; Vaughn, DJ | 1 |
| Jolivet, J; Locas, C; Marty, J; Von Hoff, DD; Weitman, S | 1 |
| Abbruzzese, JL; Bruns, CJ; Davis, DW; Evans, DB; Harbison, MT; Hicklin, DJ; McConkey, DJ; Portera, CA; Radinsky, R; Tsan, R | 1 |
| Giaccone, G; Golding, RP; Linskens, RK; van Groeningen, CJ | 1 |
| Bianco, AR; Damiano, V; De Lorenzo, S; Fabbrocini, A; Libroia, A; Matano, E; Tagliaferri, P | 1 |
| Flórez, A; Peteiro, C; Rosón, E; Sánchez-Aguilar, D; Toribio, J | 1 |
| Abbate, A; Campisi, C; Di Cosimo, S; Di Sciascio, G; Gravante, G; Patti, G; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Abbruzzese, J; Bruns, CJ; Buchdunger, E; Fan, D; Fidler, IJ; Harbison, MT; Ozawa, S; Radinsky, R; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Depisch, D; Funovics, J; Greul, R; Haider, K; Kornek, GV; Krauss, G; Kwasny, W; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Haq, M; Rosemurgy, AS; Shafii, A; Zervos, EE | 1 |
| Au, E | 1 |
| Demeaux, H; Dilhuydy, MS; Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF | 1 |
| Yokoyama, A | 1 |
| Alabiso, O; Bortolini, M; Botta, M; Buosi, R; Chiappino, I; Clara, R; Grosso, M; Mussa, A; Satolli, A; Zai, S; Zanon, C | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Colarian, J; Fowler, D; Poolos, S; Schor, J | 1 |
| Geffen, DB; Horowitz, J | 1 |
| Johansson, M; Karlsson, A; Zheng, X | 1 |
| Beauchamp, RD; Benson, AB; Berlin, J; Catalano, PJ; Talamonti, MS; Vaughn, DJ; Whittington, R | 1 |
| Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG | 1 |
| Chow, S; Hedley, DW; Tsao, MS | 1 |
| Beger, HG; Blatter, J; Butzer, U; Kornmann, M; Link, KH | 1 |
| Brodowicz, T; Függer, R; Jakesz, R; Köstler, WJ; Steger, GG; Teleky, B; Tomek, S; Vaclavik, I; Wolfram, RM; Zielinski, CC | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Arotçarena, R; Bénichou, M; Berthelémy, P; Calès, V; Dujols, JP; Pariente, A | 1 |
| Arning, M; Arnold, D; Herrenberger, J; Huhn, D; Kindler, M; Korsten, EW; Langrehr, J; Musch, R; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stroszczynski, C | 1 |
| Barni, S; Cascinu, S; Catalano, G; Catalano, V; Curti, C; Farinati, E; Frontini, L; Graiff, C; Labianca, R; Pessi, MA; Picone, G; Zonato, S | 1 |
| Arnold, D; Oettle, H; Riess, H | 1 |
| Arning, M; Clemens, M; Fink, U; Heinemann, V; Illiger, HJ; König, H; Mergenthaler, HG; Possinger, K; Schalhorn, A; Wilke, H | 1 |
| Arnold, D; Hempel, C; Oettle, H; Riess, H | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP | 1 |
| Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H | 1 |
| Gershanovich, ML; Ignashov, AM; Ivanova, NE; Kokhanenko, NIu; Osipenko, SK; Rybakov, GV | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Löhr, JM | 1 |
| Furuse, J; Ikeda, M; Maru, Y; Okada, S; Okusaka, T; Ueno, H | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE | 1 |
| Brescia, FJ; Brunson, CY; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Geissler, M; Ness, T; Schmidt, D | 1 |
| Johnson, FM | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Meyer, F; Ridwelski, K | 1 |
| Calandri, C; Chiara, S; Corgna, E; Crinò, L; Mosconi, AM; Nobili, MT; Porrozzi, S; Tonato, M | 1 |
| Fine, RL; Sherman, WH | 1 |
| Günzburg, WH; Salmons, B | 1 |
| Crane, CH; Evans, DB; Wolff, RA | 1 |
| André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F | 1 |
| Glimelius, B; Hafström, L; Nygren, P; Permert, J | 1 |
| Ibrahim, SM; Koczan, D; Löhr, M; Müller, P; Ringel, B; Ringel, J; Schmidt, C; Thiesen, HJ | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 2 |
| Baranov, E; Bouvet, M; Hoffma, RM; Jiang, P; Lee, NC; Moossa, AR; Nardin, S; Rashidi, B; Wang, X; Yang, M | 1 |
| Bowry, C; Bramhall, SR; Brown, PD; Buckels, JA; Rosemurgy, A | 1 |
| Barth, RJ; Colacchio, TA; Lewis, LD; McDonnell, C; Meyer, LP; Mitchell, SE; Perez, RP; Pipas, JM; Rathmann, J; Vera-Gimon, R; Wagman, RS | 1 |
| Abbruzzese, JL; Charnsangavej, C; Evans, DB; Gravel, DM; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Wolff, RA | 1 |
| Baker, CH; Buchdunger, E; Cohen, P; Fidler, IJ; Killion, JJ; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Cole, DJ; Fraser, MM; Kelley, JR; Schweinfest, CW; Vournakis, JN; Watson, DK | 1 |
| Alberts, SR; Jacobson, SD; O'Connell, MJ | 1 |
| Crowell, PL; Jung, SH; Marshall, MS; Sweeney, CJ; Yip-Schneider, MT | 1 |
| Adsay, V; Arlauskas, P; Chaplen, R; Heilbrun, LK; Philip, PA; Shields, AF; Vaitkevicius, VK; Weaver, D; Zalupski, MM | 1 |
| Abbruzzese, JL; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Mason, K; Milas, L; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Abal, M; Agusto, S; Almira, E; Balbiani, L; Castilla, JL; Fein, L; Jovtis, S; Lewi, D; Marantz, A; Muiño, M; Pasccon, G; Pinckevicius, R; Reale, M; Uranga, G | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, A | 1 |
| Pützer, BM; Rödicker, F; Stiewe, T; Zimmermann, S | 1 |
| Colston, KW; Dalgleish, AG; Pettersson, F | 1 |
| Aebi, S; Büchler, MW; Friess, H; Kleeff, J; Korc, M; Solioz, M; Xu, Z | 1 |
| Tsukagoshi, S | 1 |
| Bansback, N; Calvert, N; Crellin, A; Forman, D; Larvin, M; Morris, E; Radstone, D; Ward, S | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Shureiqi, I; Smith, DC; Strawderman, M; Zalupski, MM | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Heinemann, V; Stoffregen, C; Wilkowski, R | 1 |
| Blumenthal, R; Cardillo, TM; Gold, DV; Ying, Z | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Buscail, L; Escourrou, J; Faure, P; Moreau, J; Pages, P | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Adsay, NV; El-Rayes, BF; Philip, PA | 1 |
| Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F | 1 |
| André, T; Bleiberg, H; Bouleuc, C; Cvitkovic, E; de Gramont, A; Flesch, M; Gamelin, E; Hammel, P; Lledo, G; Louvet, C | 1 |
| Beger, HG; Cammerer, G; Gansauge, F; Gansauge, S; Leder, G; Muehling, B; Pressmar, J; Ramadani, M; Stecker, K | 1 |
| Okada, S | 1 |
| Biglietto, M; Cigolari, S; Colucci, G; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Rabitti, P; Testa, A; Uomo, G | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
| Fu, D; Hua, Y; Ni, Q; Wang, L; Yu, X; Zhang, Q; Zhang, Y | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Delclos, M; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, AB | 1 |
| Davis, M; Lawrence, TS; McGinn, CJ; Symon, Z; Zalupski, MM | 1 |
| Fillet, G; Jerusalem, G; Polus, M; Sautois, B; Silvestre, RM | 1 |
| Fung, MC; Sakata, T | 1 |
| Günzburg, WH; Löhr, M; Salmons, B | 1 |
| Cuesta, MA; de Lange, SM; Giaccone, G; Langendijk, JA; Meijer, OW; Meijer, S; Peters, GJ; Pinedo, HM; Slotman, BJ; van Groeningen, CJ; van Riel, JM | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ryan, DP; Willett, CG | 1 |
| Ikeda, M; Okada, S; Okusaka, T; Tokuuye, K; Ueno, H | 1 |
| Büchler, MW; Friess, H; Solioz, M; Xu, ZW | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
| Ban, J; Weber, G | 1 |
449 review(s) available for gemcitabine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Cytotoxic Nitrobenzoyl Sesquiterpenoids from an Antarctica Sponge-Derived
Topics: Antarctic Regions; Antineoplastic Agents; Apoptosis; Aspergillus; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Sesquiterpenes | 2022 |
Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Risk Factors; Survival Analysis; Survivors | 2021 |
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Reactive Oxygen Species; Signal Transduction | 2021 |
Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.
Topics: Adipose Tissue; Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cachexia; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms | 2022 |
Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Pancreatic Adenocarcinoma Management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Neoadjuvant Therapy; Network Meta-Analysis; Pancreatic Neoplasms | 2023 |
Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antimetabolites; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |
[A Case of Pathological Complete Response Induced by Preoperative Gemcitabine plus S-1 with Concurrent Radiation Therapy Followed by Gemcitabine plus S-1 Therapy in Borderline Resectable Pancreatic Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |
Metastatic pancreatic ductal adenocarcinoma followed by a fatal diffuse large B-cell lymphoma: A rare case report and literature review.
Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Lymphadenopathy; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms | 2023 |
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
Topics: Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liposomes; Nanostructures; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Topics: Carcinogenesis; Cell Transformation, Neoplastic; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pharmaceutical Preparations | 2024 |
Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Deacetylases; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Untranslated; Signal Transduction; Tumor Microenvironment | 2019 |
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2019 |
Chemoresistance in Pancreatic Cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genome; Humans; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2019 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2019 |
Gemcitabine-induced pseudocellulitis: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2019 |
Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Topics: Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Developing effective combination therapy for pancreatic cancer: An overview.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA Damage; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Proteins | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complement Inactivating Agents; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2020 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery; Fluorouracil; Gemcitabine; Geriatric Assessment; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2021 |
The Application of Exosomal MicroRNAs in the Treatment of Pancreatic Cancer and Its Research Progress.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Genetic Therapy; Humans; MicroRNAs; Pancreatic Neoplasms | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Myositis; Paclitaxel; Pancreatic Neoplasms | 2021 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Publication Bias; Treatment Outcome | 2021 |
Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria; Carcinogenesis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Oncolytic Viruses; Pancreatic Neoplasms | 2021 |
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Surgical strategies and novel therapies for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Veins | 2017 |
Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy | 2017 |
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Ducts; Pancreatic Neoplasms; Signal Transduction | 2017 |
A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2017 |
Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2017 |
How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Frailty; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy | 2017 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoplasm Staging; Osteonectin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Permeability; Treatment Outcome | 2017 |
Current Standards of Chemotherapy for Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Topics: Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Osteonectin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pyridines; Stromal Cells; Survival Analysis; Treatment Outcome | 2018 |
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
Topics: Angiogenesis Inhibitors; Antigens, Tumor-Associated, Carbohydrate; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pleural Effusion, Malignant; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Tomography, X-Ray Computed; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2018 |
A look at the progress of treating pancreatic cancer over the past 20 years.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2018 |
[A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Topics: Antimetabolites, Antineoplastic; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Prognosis; Tumor Suppressor Protein p53 | 2018 |
Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Molecular Structure; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Survival Rate | 2018 |
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Scleroderma, Localized | 2018 |
Advances in oncolytic adenovirus therapy for pancreatic cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review.
Topics: Activating Transcription Factor 6; Animals; Antibodies; Carcinoma, Pancreatic Ductal; Communicable Diseases; Deoxycytidine; Diabetes Complications; Disease Models, Animal; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression Regulation; Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Pancreatitis, Chronic; Protein Serine-Threonine Kinases; Risk Factors; RNA, Small Interfering; Sulfones | 2018 |
Chemotherapy in Pancreatic Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic | 2018 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Tumor Burden | 2019 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Margins of Excision; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
Systemic treatment of pancreatic cancer revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2019 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; Early Detection of Cancer; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Pancreatic Neoplasms; Terminal Care | 2019 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Pancreatic Ductal Adenocarcinoma Derived From an Intraductal Papillary Neoplasm With Synchronous Incidental Glucagonoma: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Glucagonoma; Humans; Incidental Findings; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Treatment Outcome | 2019 |
Adjuvant treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2019 |
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Multicenter Studies as Topic; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate | 2003 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids | 2013 |
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome; Tumor Microenvironment | 2014 |
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival; Treatment Outcome | 2013 |
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
Topics: Animals; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2015 |
Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms.
Topics: Antineoplastic Agents; Bayes Theorem; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Stochastic Processes | 2014 |
Liposomal chemotherapeutics.
Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
[Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Tegafur; Treatment Outcome | 2013 |
Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Deoxycytidine; DNA Repair Enzymes; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Prognosis | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Signal Transduction; Time Factors; Treatment Outcome | 2014 |
Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2014 |
Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?
Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Immunotherapy; Myeloid Cells; Pancreatic Neoplasms | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Gemcitabine-induced cardiomyopathy: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Cardiomyopathies; Cardiotoxicity; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ultrasonography; Ventricular Dysfunction, Left | 2014 |
Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Databases, Bibliographic; Deoxycytidine; Gemcitabine; Humans; Male; Meta-Analysis as Topic; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2014 |
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2014 |
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inflammation Mediators; Pancreatic Neoplasms | 2014 |
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Mast Cells; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Tumor Microenvironment | 2014 |
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein Kinases | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Survival Analysis | 2014 |
The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur | 2015 |
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chi-Square Distribution; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Infusions, Parenteral; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Giant Cell; Cell Differentiation; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Mesenteric Vascular Occlusion; Mesenteric Veins; Neoplasm Invasiveness; Osteoclasts; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2015 |
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[A case of pancreatic cancer with distant metastasis successfully resected after neoadjuvant chemotherapy with a combination of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Pancreatic Neoplasms; Pleural Neoplasms; Stomach Neoplasms; Tegafur | 2014 |
[A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Time Factors | 2014 |
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, Vascular Endothelial Growth Factor | 2015 |
Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival | 2015 |
Pancreatic cancer, treatment options, and GI-4000.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Thrombotic microangiopathy, cancer, and cancer drugs.
Topics: Adrenal Cortex Hormones; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Kidney; Male; Neoplasms; Pancreatic Neoplasms; Plasmapheresis; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2015 |
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Treatment Outcome | 2015 |
[Pancreatic adenocarcinoma: 10 years of progress].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Precancerous Conditions | 2015 |
Treatment of Pancreatic Cancer with Pharmacological Ascorbate.
Topics: Animals; Antioxidants; Ascorbic Acid; Deoxycytidine; Gemcitabine; Humans; Hydrogen Peroxide; Oxidative Stress; Pancreatic Neoplasms | 2015 |
Pancreatic cancer: current management and treatment strategies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2015 |
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Pyrimidines; Survival Analysis | 2015 |
Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms; Prognosis; Signal Transduction; Treatment Outcome | 2015 |
[Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2015 |
Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms | 2015 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Odds Ratio; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Report; Tegafur; Treatment Outcome | 2015 |
[Latest advances in pancreatic tumours].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Deoxycytidine; Diagnosis, Differential; Disease Progression; Early Detection of Cancer; Elasticity Imaging Techniques; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatectomy; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatitis, Alcoholic; Prognosis; Risk | 2015 |
Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
Topics: Antineoplastic Agents; Cancer Vaccines; Deoxycytidine; Gemcitabine; Genetic Vectors; Humans; Immunotherapy, Active; Membrane Glycoproteins; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Vaccinia virus; Virus Replication | 2015 |
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Evidence-Based Medicine; Expert Testimony; Gemcitabine; Germany; Humans; Hyperbilirubinemia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleotide Reductases; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Molecular Chaperones; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
[Pancreatic cancer--mechanisms of chemoresistance].
Topics: Antineoplastic Agents; Apoptosis; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Tumor Microenvironment | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
Safety of palliative chemotherapy in advanced pancreatic cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Systemic Chemotherapy in Advanced Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
A case of ectopic pancreatic cancer in the mesentery of the jejunum.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Jejunum; Male; Pancreatic Neoplasms | 2016 |
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Pancreatic Neoplasms; Retrospective Studies; Rituximab | 2017 |
Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Carcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Delivery Systems; Extracellular Matrix; Gemcitabine; Hedgehog Proteins; Humans; Nanomedicine; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2016 |
Pancreatic carcinoma masked as fever of unknown origin: A case report and comprehensive review of literature.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fever of Unknown Origin; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?
Topics: Animals; Apoptosis; Autophagy; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, Tumor Suppressor; HMGB1 Protein; Humans; Mice; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Curcumin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Nanotechnology for delivery of gemcitabine to treat pancreatic cancer.
Topics: Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Nanotechnology; Pancreatic Neoplasms | 2017 |
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2017 |
Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2017 |
Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Biological Products; Combined Modality Therapy; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Metastatic pancreatic cancer 2008: is the glass less empty?
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Disease-Free Survival; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
Novel advances in pancreatic cancer treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Delivery Systems; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2008 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2008 |
Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Cause of Death; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Evidence-Based Medicine; Gemcitabine; Humans; Oncology Nursing; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Postoperative Care; Practice Guidelines as Topic; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Treatment Outcome | 2008 |
Borderline resectable pancreatic cancer: on the edge of survival.
Topics: Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
[Treatment of advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Platinum; Quinazolines; Terminal Care | 2008 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Management of a patient with borderline resectable pancreatic cancer. Case report and review.
Topics: Adenocarcinoma; Adult; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2009 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking | 2009 |
Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2009 |
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreatic Neoplasms; Radiography; Spinal Neoplasms; Vinblastine; Vinorelbine | 2009 |
Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Predictive Value of Tests; Prognosis; Research Design; Risk Assessment; Risk Factors; Salvage Therapy; Survival Analysis | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Novel agents for the treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Risk Factors; Survival Rate | 2009 |
[Complementary treatment for pancreas cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Pancreatic Neoplasms; Prognosis | 2009 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
[A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2010 |
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choice Behavior; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines | 2010 |
Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Congresses as Topic; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies | 2010 |
Curative radiation therapy for pancreatic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Adjuvant and neoadjuvant therapy in curable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radiotherapy, Adjuvant; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Evolution of systemic therapy for advanced pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Delivery Systems; Drug Design; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Survival | 2010 |
Pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Smoking | 2010 |
[New data on pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2010 |
Chemoprevention strategies for pancreatic cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Camellia sinensis; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Curcumin; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Isothiocyanates; Pancreatic Neoplasms; Phototherapy; Pyrazoles; Sulfonamides; Tea; Vitamin D; Vitamin E | 2010 |
Salirasib in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2010 |
One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Differentiation; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
[The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms | 2010 |
Targeting apoptosis pathways in pancreatic cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Histone Deacetylases; Humans; MAP Kinase Signaling System; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; ras Proteins; TOR Serine-Threonine Kinases | 2013 |
Cutaneous metastasis of pancreatic adenocarcinoma after kidney transplant: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Kidney Transplantation; Pancreatic Neoplasms; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Long-term recurrence-free survival in a patient with pancreatic carcinosarcoma: a case report with a literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence | 2012 |
Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2011 |
Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2011 |
Treatment of early-stage pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2011 |
Current treatment options for pancreatic carcinoma.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[Second line chemotherapy for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2011 |
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2011 |
Increased expression of DNA repair genes in invasive human pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Databases, Factual; Deoxycytidine; DNA Repair; DNA, Neoplasm; Gemcitabine; Gene Dosage; Gene Expression; Genes, BRCA1; Genomic Instability; Humans; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Rad51 Recombinase; Spheroids, Cellular | 2011 |
[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cystadenoma, Mucinous; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mutation; Neoplasm Proteins; Oncogenes; Pancreatic Neoplasms; Precancerous Conditions; Radiation Tolerance; Signal Transduction | 2011 |
Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Topics: Adenocarcinoma; Antineoplastic Agents; Chicago; Congresses as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Medical Oncology; Models, Biological; Pancreatic Neoplasms; Societies, Medical; United States | 2011 |
Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Edema; Female; Fever; Gemcitabine; Humans; Pancreatic Neoplasms; Sepsis; Skin Diseases; Tachycardia | 2013 |
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity | 2011 |
[Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2011 |
[Evidences for adjuvant therapy of resected pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2011 |
[Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Cooperative Behavior; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Interdisciplinary Communication; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Particle Accelerators; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2011 |
Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Premedication; Survival Rate; Treatment Outcome | 2012 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
[Meta-analysis of the efficacy between gemcitabine-alone and gemcitabine-based chemotherapy applied in advanced pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy | 2012 |
Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2012 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Evidence-Based Medicine; Gemcitabine; Humans; Molecular Targeted Therapy; Odds Ratio; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
What options are available for refractory pancreatic cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2012 |
Novel agents in early phase clinical studies on refractory pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Ipilimumab; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2012 |
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Signal Transduction | 2012 |
Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmacogenetics; Precision Medicine; Survival Rate | 2012 |
Soft-tissue metastasis revealing a pancreatic adenocarcinoma: one case report and a review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Soft Tissue Neoplasms; Thigh | 2012 |
Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Proteomics | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines | 2014 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; CD40 Antigens; Computational Biology; Deoxycytidine; Drug Therapy, Combination; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Gene Rearrangement; Hedgehog Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2012 |
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; ROC Curve; Treatment Outcome | 2013 |
Molecular changes in pancreatic cancer: implications for molecular targeting therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, CXCR4 | 2012 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2012 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Gemcitabine and platinum combinations in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2002 |
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
The pemetrexed/gemcitabine combination in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Survival Analysis | 2002 |
On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2002 |
New applications of gemcitabine and future directions in the management of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Signal Transduction | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Digestive System Diseases; Fluorouracil; Gastric Outlet Obstruction; Gemcitabine; Humans; Neoplasm Metastasis; Neuralgia; Palliative Care; Pancreatic Neoplasms; Risk Factors; Stents | 2002 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Europe; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Combined gemcitabine and radiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasms; Neoplasms, Experimental; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Tumor Cells, Cultured | 2002 |
Pemetrexed in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Folic Acid; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Thymidylate Synthase; Vitamin B 12 | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Future directions in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2002 |
[Gemcitabine treatment of pancreatic cancer peritonitis].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritonitis | 2003 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasm Proteins; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; United States | 2003 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Folic Acid; Gemcitabine; Hematinics; Humans; Leucovorin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2003 |
Systemic therapy for advanced pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Signal Transduction; Topoisomerase I Inhibitors | 2002 |
Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.
Topics: Adult; Aged; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2003 |
Chemotherapeutic advances in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Intraoperative Care; Metalloendopeptidases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organic Chemicals; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Phenylbutyrates; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Random Allocation; Time Factors | 2003 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
Advanced pancreatic cancer: is there a role for combination therapy?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes | 2003 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiography; Radiotherapy Dosage; Survival Rate | 2003 |
Dramatic improvement of psoriasis with gemcitabine monotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Psoriasis; T-Lymphocytes | 2003 |
[Conservative therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation | 2004 |
[Chemotherapy in pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms | 2004 |
Pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Risk Factors | 2004 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase Inhibitors; Deoxycytidine; Farnesyltranstransferase; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Matrix Metalloproteinase Inhibitors; Oligonucleotides, Antisense; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome | 2004 |
Gemcitabine-related radiation recall preferentially involves internal tissue and organs.
Topics: Adenocarcinoma; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Myositis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Radiation Injuries; Risk Assessment; Steroids | 2004 |
Emerging drugs in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Growth Inhibitors; Humans; Immunotherapy; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Receptors, Growth Factor; Risk Factors; Survival Rate; Treatment Outcome | 2004 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense | 2004 |
Systemic treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Duodenal Obstruction; Gemcitabine; Humans; Neoplasm Recurrence, Local; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Treatment Outcome | 2004 |
New approaches for pancreatic cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Infusions, Intra-Arterial; Japan; Pancreatic Neoplasms; Stem Cell Transplantation | 2004 |
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2004 |
[New horizon of the treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatectomy; Pancreatic Neoplasms; Registries; Survival Rate | 2004 |
Pemetrexed in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Thymidylate Synthase | 2004 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Stomach Neoplasms | 2004 |
Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal | 2005 |
[Recent important insights into treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Intraoperative Care; Lymph Node Excision; Lymphatic Metastasis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyridines; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Treatment Outcome | 2005 |
Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Pancreatic Ductal; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2005 |
Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Recent updates on the role of chemotherapy in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2005 |
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
Treatment of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2005 |
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.
Topics: Apoptosis; Biomarkers, Tumor; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; ErbB Receptors; Gemcitabine; Gene Expression Profiling; Hedgehog Proteins; Humans; Mucin-1; Mucin-4; Mucins; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Notch; Signal Transduction; Trans-Activators; Wnt Proteins | 2005 |
[Pancreatic carcinoma (ductal adenocarcinoma)].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal, Breast; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Radiography, Abdominal; Tomography, X-Ray Computed | 2005 |
Front-line therapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2005 |
Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
[Management of pancreatic cancer: current therapy and continued development].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Immunotherapy; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2006 |
[Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2006 |
[Combination chemotherapy in unresectable pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2006 |
[Adjuvant chemotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2006 |
[Therapeutics with replication--selective virus (RSV) for pancreatic cancer].
Topics: Adenoviridae; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genetic Therapy; Humans; Pancreatic Neoplasms; Viral Vaccines | 2006 |
[IMRD therapy for patients with metastatic pancreas cancer].
Topics: Antimetabolites, Antineoplastic; Contraindications; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Pancreatic Neoplasms; Quality of Life | 2006 |
[Multimodal therapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Liver Neoplasms; Palliative Care; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 2006 |
[Gene therapy of human pancreatic cancer cells by human interferon-beta gene].
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Interferon-beta; Liposomes; Pancreatic Neoplasms; Signal Transduction | 2006 |
[Chemoradiation therapy and immunotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Intraoperative Care; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2006 |
[Significance of thermo-chemotherapy for the patients with unresectable pancreas cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Mitomycin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2006 |
[Concurrent chemoradiation therapy with gemcitabine for advanced or relapsed pancreatic tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2006 |
[Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2006 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Radiotherapy Dosage | 2006 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
[Non-surgical treatment for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur | 2006 |
Current therapies and advances in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Incidence; Neoplasm Metastasis; Pancreatic Neoplasms; Remission Induction; Vascular Endothelial Growth Factor A | 2006 |
Adjuvant treatment strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholangiopancreatography, Endoscopic Retrograde; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Diagnostic Imaging; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms | 2006 |
Clinical studies of pemetrexed and gemcitabine combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Neoplasms; Pancreatic Neoplasms; Pemetrexed | 2006 |
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2006 |
Pancreatic cancer: from bench to 5-year survival.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticojejunostomy; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Administration Schedule; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Mesenteric Artery, Superior; Mitomycin; Pancreatic Neoplasms; Quality of Life; Radiography; Survival Rate | 2006 |
Pancreatic cancer: a review of recent advances.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cancer Vaccines; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2006 |
Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2006 |
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Hormone Antagonists; Hormones; Humans; Pancreatic Neoplasms; Prognosis | 2007 |
[Palliative treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Incidence; Nutrition Therapy; Pain Management; Palliative Care; Pancreatic Neoplasms; Quality of Life | 2007 |
[Molecular-based treatment concepts in advanced pancreatic cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Metalloproteases; Molecular Biology; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
Treatment options for hepatobiliary and pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Ethanol; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
[Diagnosis of and therapy for pancreatic neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur | 2007 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
[Treatment of pancreatic cancer--surgical point of view].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
Locally advanced pancreatic cancer: a review.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
Future chemoradiation strategies in pancreatic cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant | 2007 |
[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neutropenia; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms | 2007 |
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
Role of platinum agents in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms | 2007 |
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
Topics: Adenocarcinoma; Algorithms; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholestasis; Deoxycytidine; Disease Management; Drainage; Gastric Outlet Obstruction; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Radiotherapy, Adjuvant; Treatment Outcome | 2007 |
[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Survival Rate | 2007 |
Primary advanced unresectable pancreatic cancer.
Topics: Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2008 |
Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinosarcoma; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2008 |
The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis; Treatment Failure | 2008 |
Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Products; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Treatment Failure | 2008 |
[Radiation therapy in pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Topics: Aminoacridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
[Pancreatic cancer: ten years of systemic therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Gemcitabine in the treatment of metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Chemoradiotherapy for unresectable pancreatic cancer.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Forecasting; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Technology, Radiologic | 2008 |
Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Japan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2008 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1996 |
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Idoxuridine; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
New developments in chemotherapy for patients with advanced pancreatic cancer.
Topics: Analgesics; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pain; Pancreatic Neoplasms | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 1997 |
Current and emerging treatments for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 1997 |
Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Forecasting; Gemcitabine; Hormone Antagonists; Humans; Pancreatic Neoplasms; Somatostatin; Tamoxifen | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evaluation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Safety; Survival Rate; Treatment Outcome | 1997 |
Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1997 |
[Gemcitabine: a new chemotherapy agent for solid cancers].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1997 |
[Gemzar (gemcitabine)--a new chemotherapeutic agent for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 1997 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mitomycin; Neoplasm Metastasis; Nitrosourea Compounds; Pancreatic Neoplasms | 1998 |
Adjuvant therapy for pancreatic cancer: current status.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate | 1998 |
Chemotherapy in the treatment of cancer of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 1998 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Gemcitabine: a pharmacologic and clinical overview.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Nursing Care; Oncology Nursing; Pancreatic Neoplasms | 1999 |
[Clinical development in gemcitabine and its clinical pharmacological profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Survival Analysis | 1999 |
New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Oncology Nursing; Pancreatic Neoplasms | 1999 |
Radiosensitization by gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Ribonucleotide Reductases | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 1999 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2000 |
[Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Etoposide; Forecasting; Gemcitabine; Lung Neoplasms; Pancreatic Neoplasms | 2000 |
[Adjuvant therapy of pancreatic carcinoma].
Topics: Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Palliative Care; Pancreatic Neoplasms | 2001 |
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms | 2001 |
Alterations in taste sensation: a case presentation of a patient with end-stage pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dysgeusia; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Taste Disorders | 2001 |
Current options for palliative treatment in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2001 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Cancer Vaccines; Carcinoma; Clinical Trials as Topic; Cytochrome P-450 CYP2B1; Cytosine; Deoxycytidine; Dioxolanes; DNA, Antisense; Endopeptidases; Enzyme Inhibitors; Gemcitabine; Genes, p53; Genes, ras; Genetic Therapy; Heat-Shock Proteins; Humans; Ifosfamide; Multicenter Studies as Topic; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Pectins; Pilot Projects; Polyamines; Prospective Studies; Prostheses and Implants; Sesquiterpenes; Spiro Compounds; Tissue Extracts; Topoisomerase I Inhibitors | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2001 |
A systematic overview of chemotherapy effects in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Therapy for regionally unresectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2001 |
Pancreatic cancer in the older patient.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Cholestasis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pain; Pain Management; Palliative Care; Pancreatic Neoplasms | 2001 |
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2001 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life | 2001 |
Pancreatic cancer: the evolving role of systemic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2001 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Mutation; Neoplasm Recurrence, Local; Organophosphonates; Palliative Care; Pancreatic Neoplasms | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Radiotherapy and chemotherapy for unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage | 2002 |
[How I treat ... An advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
What's new in pancreatic cancer treatment?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
Novel treatments and therapies in development for pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Genetic Therapy; Hormones; Humans; Immunotherapy; Pancreatic Neoplasms | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
863 trial(s) available for gemcitabine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2021 |
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Topics: Adenocarcinoma; Albumins; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Japan; Markov Chains; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Neoadjuvant Therapy; Pancreatic Neoplasms | 2022 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Stromal Cells | 2021 |
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Repositioning; Female; Gemcitabine; Humans; Immunoglobulins; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tetrahydronaphthalenes; Treatment Outcome; Tumor Microenvironment; Young Adult | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2022 |
A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Mucin-1; Nanoparticles; Pancreatic Neoplasms | 2021 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Pancreatic Neoplasms; Treatment Outcome | 2022 |
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azepines; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoplasms; Pancreatic Neoplasms; Pyrimidines | 2022 |
A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |
Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies | 2022 |
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies | 2023 |
A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement.
Topics: Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2023 |
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2022 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Tyrosine Kinase Inhibitors | 2023 |
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Male; Middle Aged; Mucin 5AC; Paclitaxel; Pancreatic Neoplasms | 2023 |
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome | 2023 |
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms | 2023 |
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Edema; Female; Gemcitabine; Humans; Hypoalbuminemia; Male; Paclitaxel; Pancreatic Neoplasms | 2023 |
The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defin
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Quality of Life | 2023 |
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized
Topics: Adenocarcinoma; CA-19-9 Antigen; Carbohydrates; Chemotherapy, Adjuvant; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies | 2023 |
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2023 |
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Feasibility Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Gemcitabine; Humans; Hyperthermia, Induced; Paclitaxel; Pancreatic Neoplasms; Protons | 2023 |
ASO Visual Abstact: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Feasibility Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparat
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Gemcitabine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Quality of Life; Radiosurgery; Randomized Controlled Trials as Topic | 2023 |
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones; Survival Rate | 2019 |
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2019 |
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2019 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Non-Randomized Controlled Trials as Topic; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Patient Safety; Treatment Outcome | 2020 |
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Laparotomy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2019 |
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ipilimumab; Male; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors | 2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Topics: Aged; Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Pyridines; Treatment Outcome | 2020 |
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.
Topics: Adenocarcinoma; Aged; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors | 2020 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Preoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2020 |
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Heparitin Sulfate; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Rate | 2020 |
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-8; Irinotecan; Male; MAP Kinase Kinase Kinases; Mice; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Transcriptional Activation; Xenograft Model Antitumor Assays | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunoglobulin Fc Fragments; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Proteins | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2020 |
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Tomography, X-Ray Computed; Young Adult | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Analysis | 2021 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Capecitabine; Chemokine CCL5; Chemoradiotherapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Regression Analysis; ROC Curve; Treatment Outcome | 2021 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Japan; Kaplan-Meier Estimate; Male; Medical Oncology; Middle Aged; Multivariate Analysis; Neoplasm Staging; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2021 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2021 |
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Care; Prognosis; Survival Rate; Young Adult | 2021 |
Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Eicosapentaenoic Acid; Gemcitabine; Humans; Male; Pancreas; Pancreatic Neoplasms | 2022 |
Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.
Topics: Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms | 2021 |
Ultrasound and microbubble assisted drug delivery - A clinical pharmacological perspective.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreatic Neoplasms; Pharmacology, Clinical; Ultrasonic Therapy | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Standard of Care; Survival Analysis | 2022 |
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Gemcitabine; Guanidines; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Postoperative Period; Treatment Outcome | 2021 |
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA Copy Number Variations; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Signal Transduction; Treatment Outcome; Young Adult | 2021 |
A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Prospective Studies; Survival Rate; Treatment Outcome | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; China; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2021 |
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2021 |
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-G
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; GTP-Binding Proteins; Humans; Membrane Proteins; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2021 |
Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Four-Dimensional Computed Tomography; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Neoadjuvant Therapy; Observer Variation; Pancreatic Neoplasms; Radiation Oncology | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Smad4 Protein; Treatment Outcome | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2017 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survival Rate | 2017 |
Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis | 2017 |
Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2017 |
The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol.
Topics: Ablation Techniques; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Ethanol; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pancreatic Cyst; Pancreatic Neoplasms; Pennsylvania; Postoperative Complications; Prospective Studies; Risk Factors; Therapeutic Irrigation; Time Factors; Treatment Outcome | 2017 |
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Treatment Outcome; Young Adult | 2017 |
Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Sex Factors; Survival Rate | 2017 |
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2017 |
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Proto-Oncogene Proteins p21(ras); Survival Rate | 2017 |
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.
Topics: Aged; Antimalarials; Antimetabolites, Antineoplastic; Chloroquine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2017 |
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2018 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Margins of Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Analysis | 2019 |
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome; Young Adult | 2017 |
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Cell Proliferation; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Parenteral; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Endpoint Determination; Female; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyrimidines; Treatment Outcome | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cisplatin; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzene Derivatives; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Propionates; Receptors, Notch; Signal Transduction; Sulfones | 2018 |
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Tegafur | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tegafur; WT1 Proteins | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Complementary Therapies; Curcumin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phospholipids; Treatment Outcome | 2018 |
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Gemcitabine; Herpesvirus 1, Human; Humans; Injections, Intralesional; Male; Middle Aged; Mutation; Oncolytic Virotherapy; Oncolytic Viruses; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Ultrasonography, Interventional; Young Adult | 2018 |
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Receptors, Somatomedin; Survival Analysis; Treatment Outcome | 2018 |
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Arctium; Area Under Curve; Biomarkers; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Furans; Gemcitabine; Gluconeogenesis; Humans; Kaplan-Meier Estimate; Kidney; Lactic Acid; Lignans; Liver; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; Plant Extracts | 2018 |
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Geriatric Assessment; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Janus Kinase 1; Janus Kinase 2; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Pyrimidines; Tissue Distribution | 2019 |
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Cell Line, Tumor; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Receptors, Calcitriol; RNA, Messenger; Vitamin D | 2018 |
Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Febrile Neutropenia; Female; Gemcitabine; Humans; Infections; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period | 2018 |
Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemora
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2018 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Animals; Ascorbic Acid; Cell Line, Tumor; Cell Proliferation; Cell Survival; Collagen; Deoxycytidine; Disease-Free Survival; DNA Damage; Female; Gemcitabine; Glutathione; Humans; Male; Mice; Mice, Nude; Middle Aged; Oxidative Stress; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy; Recombinant Proteins; Treatment Outcome | 2018 |
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Paclitaxel; Pancreatic Neoplasms; Phenylthiohydantoin; Prognosis; Survival Rate; Tissue Distribution | 2019 |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Pyrazoles; Quinolines; Signal Transduction; Transforming Growth Factor beta | 2018 |
Clinical assessment of palliative radiotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Surveys and Questionnaires; Treatment Outcome | 2018 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2019 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; Polyethylene Glycols; Progression-Free Survival; Proportional Hazards Models | 2018 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies | 2018 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2019 |
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Radiotherapy; Treatment Outcome | 2019 |
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Topics: Administration, Oral; Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Multicenter Studies as Topic; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Young Adult | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Benzimidazoles; Blood Coagulation; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Factor VIIa; Female; Gemcitabine; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Time Factors | 2019 |
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Inflammation; Male; MicroRNAs; Pancreatic Neoplasms; Prognosis; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Survival Rate | 2019 |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Topics: Administration, Intravenous; Aged; Cytidine Deaminase; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prospective Studies | 2019 |
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Survival Rate; Tegafur; Young Adult | 2019 |
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Hydroxychloroquine; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2019 |
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cancer Vaccines; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Interferon-beta; Male; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Progression-Free Survival; Survivin; Vaccination; Vaccines, Subunit | 2019 |
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Repositioning; Gemcitabine; Humans; Maximum Tolerated Dose; Paclitaxel; Pancreas; Pancreatic Neoplasms; Patient Selection; Research Design; Response Evaluation Criteria in Solid Tumors; Tretinoin | 2019 |
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.
Topics: Acute Disease; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2019 |
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2019 |
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomiz
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2019 |
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Wnt Signaling Pathway | 2020 |
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Receptor, Notch2; Receptor, Notch3; Treatment Outcome | 2019 |
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Oximes; Pancreatic Neoplasms; Piperazines; Sulfonamides | 2013 |
Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitabine and intravenous ω-3 fish oil.
Topics: Administration, Intravenous; Adult; Aged; Complement System Proteins; Cytokines; Deoxycytidine; Fatty Acids, Omega-3; Female; Fish Oils; Gemcitabine; Humans; Male; Mannose-Binding Lectin; Middle Aged; Pancreatic Neoplasms | 2014 |
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Etanercept; Fatigue; Female; Gemcitabine; Humans; Immunoglobulin G; Interferon-gamma; Interleukin-10; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; GPI-Linked Proteins; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2013 |
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Radiosurgery; Treatment Outcome | 2013 |
Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.
Topics: Administration, Intravenous; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytokines; Deoxycytidine; Disease-Free Survival; Down-Regulation; England; Fatty Acids, Omega-3; Fibroblast Growth Factors; Gemcitabine; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Linear Models; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Time Factors; Treatment Outcome | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Radiotherapy | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2013 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2013 |
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Prospective Studies; Survival; Young Adult | 2013 |
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biphenyl Compounds; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tetrazoles; Treatment Outcome | 2013 |
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Receptor, IGF Type 1; Survival Analysis | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HLA Antigens; Humans; Immunoglobulins; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Precision Medicine; Prognosis; Survival Rate; Tegafur; Vaccination; Young Adult | 2013 |
Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Topics: Aged; Algorithms; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Prospective Studies | 2013 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2013 |
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate | 2013 |
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Quality-Adjusted Life Years; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Prospective Studies | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Macrophages; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Survival; Treatment Outcome | 2013 |
Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Gemcitabine; Heavy Ion Radiotherapy; Humans; Neoplasm Staging; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2013 |
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Risk Factors; Time Factors | 2013 |
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis | 2013 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Deoxycytidine; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Emulsions; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; ErbB Receptors; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Simvastatin | 2014 |
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Helicases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nerve Tissue Proteins; Pancreatic Neoplasms; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Europe; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kinesins; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome; Vaccines, Subunit | 2014 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Treatment Outcome | 2014 |
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Topics: Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Markers; Genetic Variation; Genome-Wide Association Study; Genotype; Humans; Linkage Disequilibrium; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Signal Transduction; Sulfotransferases | 2014 |
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Survival Rate | 2014 |
Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2014 |
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Osteonectin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2014 |
Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Topics: Aged; Antimetabolites, Antineoplastic; Biological Transport, Active; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Adducts; DNA, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Biological; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tomography, X-Ray Computed | 2014 |
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Serum Albumin; Survival Analysis | 2014 |
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Thromboembolism | 2014 |
Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation; Humans; Male; MicroRNAs; Neoplasm Proteins; Neoplasm Staging; Pancreatic Neoplasms; Receptor, IGF Type 1; RNA, Neoplasm; Tumor Cells, Cultured | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Blood Glucose; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Induction Chemotherapy; Liver; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancr
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drugs, Investigational; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Thrombocytopenia; Treatment Outcome | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Sucrose | 2014 |
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2014 |
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Survival Analysis | 2014 |
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2014 |
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Risk; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Epitopes; Female; Follow-Up Studies; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Vaccination; WT1 Proteins | 2014 |
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2016 |
Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Conformal | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Stomatitis; Survival Analysis; Tegafur; Treatment Outcome; Venous Thrombosis | 2014 |
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advance
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Catheterization; Deoxycytidine; Duodenal Diseases; Duodenum; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Ischemia; Male; Maximum Tolerated Dose; Middle Aged; Pancreas; Pancreatic Neoplasms; Perfusion; Splenic Artery; Treatment Outcome | 2015 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2014 |
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prevalence; Prospective Studies; Risk Factors; Sex Distribution; Survival Rate; Switzerland; Treatment Outcome | 2015 |
S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2014 |
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Topics: Actins; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Stromal Cells; Survival Rate; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2015 |
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate | 2015 |
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Prognosis; Survival Rate | 2015 |
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2015 |
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Time Factors; Treatment Outcome | 2015 |
Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Interleukin-8; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Pilot Projects; Treatment Outcome; Vaccination; WT1 Proteins | 2015 |
Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiation Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; International Cooperation; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Disease-Free Survival; European Union; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; North America; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Treatment Outcome | 2015 |
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tegafur; Young Adult | 2015 |
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Pharmacogenetics; Piperidines; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States | 2015 |
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Adenosquamous; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antirheumatic Agents; Autophagy; Biomarkers; CA-19-9 Antigen; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Safety; Survival Rate | 2015 |
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Receptor, ErbB-2; Salvage Therapy; Trastuzumab | 2015 |
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Deoxycytidine; Female; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Survival Analysis | 2015 |
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Taiwan; Time Factors; Treatment Outcome | 2015 |
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Rabbits; Survival Analysis; Watchful Waiting | 2015 |
Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Panitumumab; Radiation-Sensitizing Agents | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glycine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Sulfones; Tumor Suppressor Protein p53 | 2015 |
Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Electroporation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Somatostatin | 2015 |
Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2017 |
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Knockout; Neoplasm Metastasis; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
Intravenous ω-3 Fatty Acids Plus Gemcitabine.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Endpoint Determination; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2017 |
A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyridones; Pyrimidinones | 2015 |
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunologic Tests; Immunotherapy; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; WT1 Proteins | 2015 |
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Mice; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2015 |
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Fatigue; Feeding and Eating Disorders; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Health Status; Humans; Induction Chemotherapy; Male; Pancreatic Neoplasms; Quality of Life; Statistics, Nonparametric; Surveys and Questionnaires; United Kingdom | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal | 2015 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Genetic; RecQ Helicases; Reproducibility of Results | 2016 |
Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2016 |
Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Biomarkers, Pharmacological; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Risk factors for vertebral compression fractures in preoperative chemoradiotherapy with gemcitabine for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Epidemiologic Methods; Female; Fractures, Compression; Fractures, Spontaneous; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Preoperative Care; Spinal Fractures | 2016 |
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Placebos | 2016 |
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Russia; Treatment Outcome; United States | 2016 |
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polysaccharides; Survival Analysis; Treatment Outcome | 2016 |
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery | 2016 |
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2016 |
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Research Design; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Tegafur | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2016 |
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2016 |
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Pyridines; Survival Rate | 2016 |
Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2016 |
Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now?
Topics: Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Mortality; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Therapy, Combination; Endonucleases; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Treatment Outcome | 2016 |
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life | 2016 |
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; Ultrasonic Therapy | 2016 |
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Tumor Suppressor Proteins | 2016 |
[The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; HLA-A24 Antigen; Humans; Kinesins; Male; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; T-Lymphocytes, Cytotoxic; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2017 |
Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epitopes; Female; Gemcitabine; HLA-A24 Antigen; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Kinesins; Male; Middle Aged; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Peptide Fragments; T-Cell Antigen Receptor Specificity; T-Lymphocytes, Cytotoxic; Vaccines, Subunit; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cytoplasm; Deoxycytidine; Disease-Free Survival; ELAV-Like Protein 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Tissue Array Analysis; Treatment Outcome | 2018 |
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diphenylamine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2017 |
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2017 |
Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
Topics: Aged; Deoxycytidine; Duodenum; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2017 |
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Pancreatic Neoplasms; Thalidomide | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2017 |
Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Transplantation, Autologous | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Extracellular Matrix; Female; Gemcitabine; Humans; Immunoglobulin G; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Treatment Outcome | 2017 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Taiwan; Treatment Outcome | 2009 |
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Treatment Outcome | 2008 |
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Axitinib; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Topics: Abdominal Cavity; Aged; Antimetabolites, Antineoplastic; Ascites; Blood Gas Analysis; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Extracorporeal Circulation; Female; Gemcitabine; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Perfusion | 2009 |
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy, Adjuvant | 2008 |
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy | 2008 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms | 2008 |
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2009 |
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies | 2008 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate | 2009 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy | 2008 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; RNA, Messenger; Treatment Outcome | 2009 |
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Gemcitabine; Humans; Male; Middle Aged; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Swine; Venous Thromboembolism | 2008 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Regional Blood Flow; Treatment Outcome; Ultrasonography, Doppler, Color | 2008 |
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Morbidity; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron-Emission Tomography; Prospective Studies | 2008 |
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
Topics: Aged; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epitopes; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peptides; Receptors, Vascular Endothelial Growth Factor | 2008 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2009 |
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards; Survival Analysis; Treatment Outcome | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2009 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Severity of Illness Index; T-Lymphocytes, Cytotoxic; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2009 |
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2009 |
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Analysis | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage | 2010 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pilot Projects; Salvage Therapy; Survival Analysis | 2010 |
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Flow Cytometry; Gamma Rays; Gemcitabine; Humans; Lectins, C-Type; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis-Associated Proteins; Predictive Value of Tests; Radiotherapy, Adjuvant; Transfection | 2009 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; United States | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2009 |
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complementary Therapies; Deoxycytidine; Dietary Supplements; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Peptide Hydrolases; Proportional Hazards Models; Quality of Life; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphoramide Mustards; Safety; Survival Rate; Treatment Outcome | 2010 |
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2009 |
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2011 |
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Diastole; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Topics: Cyclin G1; Deoxycytidine; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae | 2010 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Cystine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Half-Life; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfhydryl Compounds; Tomography, X-Ray Computed | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2009 |
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Female; Gastrins; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Receptor, Cholecystokinin B; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2010 |
Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Thrombocytopenia; Tumor Burden; Young Adult | 2010 |
Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Safety; Survival Analysis | 2011 |
Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2009 |
Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Isoflavones; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Survival Rate | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome; United States | 2010 |
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Celecoxib; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demography; Deoxycytidine; Enhancer Elements, Genetic; Female; Fluorouracil; Gemcitabine; Genotype; Homozygote; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2011 |
Phase I trial of gemcitabine dose escalation with concurrent radiotherapy for patients with locally advanced pancreatic cancer.
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Chemotherapy followed by chemoradiotherapy for locally advanced non-metastatic pancreatic cancer - a new paradigm?
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiotherapy | 2010 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Pyridines; Survival Analysis; Thiazoles | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Plant Proteins; Retrospective Studies; Survival Analysis; Viscum album | 2010 |
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Blood Coagulation Factors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Disulfides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Mas; Survival; Thioredoxins; Treatment Outcome | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy; Safety; Survival Analysis | 2010 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2010 |
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2010 |
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cadherins; Cetuximab; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; ErbB Receptors; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Vimentin | 2011 |
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction | 2011 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Tegafur | 2011 |
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos | 2010 |
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mental Health; Middle Aged; Pain; Pancreatic Neoplasms; Quality of Life | 2010 |
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gastroesophageal Reflux; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Tegafur | 2010 |
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome | 2010 |
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vaccines; Deoxycytidine; Female; Gemcitabine; HLA Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome; Vaccines, Subunit | 2010 |
Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2010 |
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities | 2012 |
NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2010 |
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Canada; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2011 |
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; France; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Thalidomide; Treatment Outcome | 2011 |
Curcumin and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis | 2010 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Topics: Animals; Deoxycytidine; Disease Progression; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitomycin; Mutation; Nuclear Proteins; Pancreatic Neoplasms; Precision Medicine; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA Splicing Factors; Vaccines, Subunit | 2011 |
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Analysis | 2012 |
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Remission Induction | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gemcitabine; Health Status Indicators; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taiwan | 2011 |
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins | 2012 |
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Humans; Immunologic Surveillance; Macrophage Activation; Macrophages; Male; Mice; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes; Tumor Microenvironment; Young Adult | 2011 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy | 2011 |
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Taxoids | 2011 |
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Resistance, Neoplasm; Ethers, Cyclic; Female; Furans; Gemcitabine; Humans; Ketones; Macrolides; Male; Middle Aged; Pancreatic Neoplasms; Tubulin Modulators | 2012 |
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2011 |
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting | 2012 |
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Germany; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2011 |
Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Burden | 2011 |
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2012 |
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Maryland; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Research Design; Treatment Outcome | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2011 |
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2012 |
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant; Remission Induction; Research Design; Smad4 Protein; Treatment Outcome | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2012 |
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Translational Research, Biomedical | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2011 |
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2011 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; Bevacizumab; Blood Platelets; CD146 Antigen; Deoxycytidine; Drug Administration Schedule; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Immunophenotyping; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Regression Analysis; T-Lymphocytes; Treatment Outcome | 2011 |
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Dalteparin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Rate; Venous Thromboembolism | 2012 |
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pain; Palliative Care; Pancreatic Neoplasms; Prevalence; Quality of Life; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2012 |
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk | 2012 |
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Peripheral Nerves; Prognosis; Prospective Studies; Risk Factors | 2012 |
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
[A pilot study of intraperitoneal gemcitabine for reduction of peritoneal dissemination in advanced pancreatic cancer].
Topics: Aged; Deoxycytidine; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects | 2011 |
Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Retreatment; Tumor Burden | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome | 2012 |
Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplat
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Cisplatin; Combined Modality Therapy; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Nuclear Proteins; Pancreatic Neoplasms; Research Design; RNA Splicing Factors; Treatment Outcome; Vaccines, Subunit | 2012 |
Gemcitabine adsorbed onto carbon particles increases drug concentrations at the injection site and in the regional lymph nodes in an animal experiment and a clinical study.
Topics: Adsorption; Animals; Antimetabolites, Antineoplastic; Carbon; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Injections; Lymph Nodes; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Temperature; Time Factors; Tissue Distribution | 2011 |
A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Proton Therapy | 2012 |
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2012 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2012 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2013 |
[Efficacy evaluation of high intensity focused ultrasound combined with intra-arterial infusion of gemcitabine in the treatment of pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pain Management; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Ultrasonography | 2012 |
Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.
Topics: Adult; Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Tetrazoles | 2012 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Surveys and Questionnaires; Treatment Outcome | 2013 |
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organs at Risk; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Time Factors | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2012 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea | 2012 |
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.
Topics: Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Survival Rate | 2012 |
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Placebos; Receptor, IGF Type 1; Survival Rate; Treatment Outcome | 2012 |
Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Ribonucleotide Reductases; Sorafenib | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Amphibian Venoms; Animals; Antineoplastic Combined Chemotherapy Protocols; Anura; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Single-Blind Method | 2012 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2012 |
Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2012 |
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphocyte Activation Gene 3 Protein; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2013 |
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cancer Vaccines; Clinical Trials, Phase I as Topic; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Placebos; Randomized Controlled Trials as Topic; Salmonella typhi; Vaccines, DNA; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival; Survival Rate; Treatment Outcome | 2012 |
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Topics: Adaptive Immunity; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; CD8-Positive T-Lymphocytes; Cytotoxicity, Immunologic; Deoxycytidine; Female; Follow-Up Studies; Forkhead Transcription Factors; Gemcitabine; Glutamates; Guanine; Humans; Immunity, Innate; Immunologic Memory; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; T-Lymphocyte Subsets | 2012 |
[Curative effect of 3D-CRT combined with gemcitabine concurrently with addition of Kanglaite Injection in treatment of locally advanced pancreatic].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phytotherapy; Radiotherapy, Conformal; Young Adult | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy, Active; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Analysis; Treatment Outcome; Trisaccharides | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escala
Topics: Adenocarcinoma; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Sex Factors; Tumor Burden | 2013 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure | 2013 |
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Chromatography, High Pressure Liquid; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutathione; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Patient Compliance; Patient Safety; Sentinel Lymph Node Biopsy | 2013 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms | 2002 |
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2002 |
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis | 2002 |
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome | 2002 |
Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy | 2002 |
Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Statistics, Nonparametric; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2003 |
Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Cisplatin; Combined Modality Therapy; Deoxycytidine; Digestive System; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Radiotherapy Dosage | 2003 |
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Switzerland | 2003 |
Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2001 |
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Survival; Thrombocytopenia; Treatment Outcome | 2003 |
Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoviridae; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; In Situ Hybridization; Injections, Intralesional; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Safety; Treatment Outcome; Ultrasonography; Viral Vaccines | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival; Treatment Outcome | 2003 |
A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome; Vomiting | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2003 |
[Usefulness of gemcitabine in the treatment of advanced pancreatic cancer in terms of its clinical benefits].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2003 |
[Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Quality of Life; Survival Rate; Tomography, X-Ray Computed | 2003 |
A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis | 2003 |
Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Postoperative Care; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Failure | 2003 |
[Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Exanthema; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Vomiting, Anticipatory | 2003 |
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taiwan; Treatment Outcome | 2003 |
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Organic Chemicals; Pancreatic Neoplasms; Phenylbutyrates; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a phase I study.
Topics: Aged; Bile Duct Neoplasms; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hepatic Duct, Common; Humans; Infusions, Intravenous; Klatskin Tumor; Lymphatic Irradiation; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
[Experience with the treatment of advanced pancreatic cancer in Hungary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Kinetics; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2003 |
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quality of Life; Thrombocytopenia; Treatment Outcome | 2003 |
Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2002 |
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Hemodynamics; Humans; Infusions, Intravenous; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Retroviridae; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2003 |
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Endpoint Determination; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Tegafur; Uracil | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2004 |
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones | 2004 |
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Hospitals, University; Humans; Injections, Intravenous; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Pneumonia; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2004 |
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Failure; United States | 2004 |
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2004 |
Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2004 |
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
[Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Intraoperative Period; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Rate | 2004 |
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis | 2003 |
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Pancreatic Neoplasms; Prognosis; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiotherapy Dosage | 2004 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Survival Analysis | 2004 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2004 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2005 |
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Rate; Treatment Failure | 2005 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Greece; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quality of Life; Receptors, Platelet-Derived Growth Factor; Surveys and Questionnaires; Survival Rate | 2006 |
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
[A phase II study of combination chemotherapy with gemcitabine, 5-fluorouracil, and cisplatin for advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intestine, Small; Life Tables; Lymphatic Irradiation; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur; Treatment Outcome | 2005 |
[Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2005 |
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Endpoint Determination; Gemcitabine; Humans; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constipation; Cyclophosphamide; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome; Uracil | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Analysis; Thrombocytopenia | 2005 |
Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Ribonucleotide Reductases; Survival Rate | 2005 |
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
Topics: Adenocarcinoma; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Survival Rate | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Injections, Intra-Arterial; Injections, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2005 |
Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiotherapy, Intensity-Modulated; Time Factors; Treatment Outcome | 2005 |
Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Conformal; Taxoids | 2005 |
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
No evidence of gemcitabine accumulation during weekly administration.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 2005 |
Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Cell Count; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival | 2006 |
Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytotoxicity, Immunologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunity, Cellular; Interleukin-10; Killer Cells, Natural; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Reference Values; Vascular Endothelial Growth Factor A | 2006 |
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Time Factors | 2006 |
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Research Design; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Brief communication: a new combination in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Survival Rate | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Hyperbilirubinemia; Infusions, Intravenous; Male; Middle Aged; Mucositis; Neutropenia; Pancreatic Neoplasms; Patient Compliance; Quality of Life; Spain; Survival Analysis; Treatment Outcome | 2005 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Uracil | 2006 |
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Safety; Survival Rate; Treatment Outcome | 2006 |
Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes | 2006 |
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
Topics: Adenosine Triphosphatases; Adult; Aged; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Deoxycytidine; DNA Helicases; DNA Repair; DNA-Binding Proteins; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; RecQ Helicases; Tumor Suppressor Proteins | 2006 |
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prodrugs; Tegafur; Uracil | 2006 |
Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate | 2006 |
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phenylenediamines; Prognosis; Survival Rate | 2006 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2006 |
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Platelet Count | 2006 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; Middle Aged; Monocytes; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Tumor Necrosis Factor-alpha | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2007 |
[Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2006 |
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Survival Rate; Treatment Outcome | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Survival Rate | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance | 2006 |
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Gemcitabine; Humans; Interleukin-8; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor A | 2006 |
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2007 |
[Effect of combined treatment methods on quality of life in patients with pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Status; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Snake Venoms; Surveys and Questionnaires; Survival Rate | 2006 |
Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Korea; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Thromboembolism; Vomiting, Anticipatory | 2007 |
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis | 2007 |
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2007 |
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
Topics: Adult; Aged; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pemetrexed; Survival Rate; Treatment Failure | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2007 |
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulin G; Male; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines, Subunit | 2007 |
13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Isotretinoin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Pancreatic Neoplasms; Pilot Projects; Prognosis; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2007 |
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; California; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Michigan; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2007 |
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Failure | 2007 |
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Female; Gemcitabine; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Survival Rate | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2007 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Glucose; Half-Life; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards | 2008 |
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2007 |
Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Deoxycytidine; Female; Gemcitabine; Granzymes; Humans; Injections, Intralesional; Killer Cells, Natural; Lipopeptides; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Pancreatic Neoplasms; Survival Analysis; Time Factors; Toll-Like Receptor 2; Toll-Like Receptor 6; Treatment Outcome | 2007 |
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Survival Analysis; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Survival Rate | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2007 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Predictive Value of Tests; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2007 |
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2007 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Time Factors | 2007 |
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Ascitic Fluid; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Dialysis Solutions; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Dialysis; Pilot Projects; Survival Rate | 2008 |
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2008 |
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2008 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis | 2008 |
Improving treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Infliximab; Liver Neoplasms; Male; Pancreatic Neoplasms; Placebos; Prognosis; Survival Rate | 2008 |
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Injections, Intravenous; Japan; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Tegafur | 2008 |
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukopenia; Male; Middle Aged; Mouth Mucosa; Pancreatic Neoplasms; Polymorphism, Genetic; Pyridines; Ribonucleoside Diphosphate Reductase; Survival Rate; Thiosemicarbazones; Treatment Outcome | 2008 |
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome; Vomiting | 2008 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2008 |
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2008 |
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Drug Tolerance; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Treatment Outcome | 2008 |
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA Damage; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Radiotherapy | 2008 |
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Topics: Adult; Aged; CA-19-9 Antigen; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae; Stem Cells; Treatment Outcome | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Radiosurgery; Radiotherapy Dosage; Survival Analysis; Survivors | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
[Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2008 |
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
Phase II study of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Retreatment; Survival Rate; Treatment Outcome | 1996 |
Objective outcome measures of quality of life.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Pain; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 1996 |
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Male; Middle Aged; Morphine; Narcotics; Pain; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 1997 |
Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1997 |
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Survival Analysis | 1997 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Adjuvant therapy for pancreatic cancer: back to the future.
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1998 |
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Selection; Quality of Life; Survival Analysis; Tomography, X-Ray Computed | 1999 |
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Sweden | 1999 |
Phase I trial dosing of gemcitabine and concurrent involved field irradiation in patients with localized pancreatic carcinomas.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Gemcitabine; Humans; Pancreatic Neoplasms | 1999 |
Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 1999 |
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 1999 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; New England; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms | 2000 |
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Survival Analysis | 2000 |
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Patient Acceptance of Health Care; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
Phase I trial of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Gemcitabine in advanced pancreatic cancer: a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Pancreatic Neoplasms | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Hydroxamic Acids; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2001 |
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2001 |
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Survival Analysis | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome | 2002 |
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine Alkaloids; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Phenanthridines; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2002 |
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vomiting | 2002 |
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Pancreatic Neoplasms; Radiotherapy, High-Energy; Treatment Outcome | 2002 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
3107 other study(ies) available for gemcitabine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Cell Line, Tumor; Hepacivirus; Humans; Molecular Conformation; Pancreatic Neoplasms; Ribonucleosides; Structure-Activity Relationship; Triazoles; Virus Replication | 2009 |
Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; HSP27 Heat-Shock Proteins; Humans; Mice; Neoplasms, Experimental; Pancreatic Neoplasms; Ribonucleosides; Transplantation, Heterologous; Treatment Outcome; Triazoles | 2009 |
N-aryltriazole ribonucleosides with potent antiproliferative activity against drug-resistant pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Pancreatic Neoplasms; Ribonucleosides | 2010 |
A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleosides; Pancreatic Neoplasms; Triazoles | 2010 |
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Pancreas; Pancreatic Neoplasms; RNA; RNA Interference; Tumor Cells, Cultured | 2011 |
Synthesis, σ₁, σ₂-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes.
Topics: Adamantane; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Pancreatic Neoplasms; Receptors, sigma | 2012 |
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Crystallography, X-Ray; Cyclohexenes; Drug Screening Assays, Antitumor; Humans; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Thailand; Uvaria | 2012 |
Uvaridacols E-H, highly oxygenated antiausterity agents from Uvaria dac.
Topics: Antineoplastic Agents, Phytogenic; Cyclohexenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Plant Stems; Thailand; Uvaria | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Female; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neuralgia; Ovarian Neoplasms; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Protein Binding; Receptors, sigma; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Cytotoxic scalarane sesterterpenes from a Korean marine sponge Psammocinia sp.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Haplorhini; Humans; K562 Cells; Kidney Neoplasms; Mass Spectrometry; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Porifera; Sesterterpenes; Spectrophotometry, Infrared | 2013 |
Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Nigella sativa; Pancreatic Neoplasms; Structure-Activity Relationship | 2013 |
Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Neoplasms; Pancreas; Pancreatic Neoplasms; Structure-Activity Relationship | 2013 |
Discovery of 2-pyridineformamide thiosemicarbazones as potent antiausterity agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Formamides; Humans; Pancreatic Neoplasms; Pyridines; Thiosemicarbazones | 2014 |
Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
Topics: Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Humans; Mangifera; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Plant Bark; Triterpenes; Vietnam | 2016 |
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Mice; Pancreatic Neoplasms; Structure-Activity Relationship; Thiazoles | 2016 |
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice, SCID; Pancreas; Pancreatic Neoplasms; Prodrugs; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Drug Design; Endoplasmic Reticulum Chaperone BiP; Humans; Mice; Mitochondria; Oxidative Stress; Pancreatic Neoplasms; Quinazolinones; Reactive Oxygen Species; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2018 |
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Computational Biology; Computer Simulation; Deoxycytidine; DNA Damage; Down-Regulation; Drug Design; Drug Resistance, Neoplasm; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Syntheses and anti-pancreatic cancer activities of rakicidin A analogues.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combinatorial Chemistry Techniques; Humans; Lipopeptides; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides, Cyclic; Structure-Activity Relationship; Tumor Hypoxia | 2018 |
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Topics: Amiloride; Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Crystallography, X-Ray; Diuresis; Diuretics; Drug Discovery; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Models, Molecular; Molecular Structure; Pancreatic Neoplasms; Potassium; Protein Conformation; Sodium; Structure-Activity Relationship; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2018 |
Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Male; Mice, Nude; Pancreas; Pancreatic Neoplasms; Quinolines | 2019 |
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Thiadiazoles; Thiophenes; Tumor Cells, Cultured | 2020 |
Identification of a C3'-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth.
Topics: Amides; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Glycosylation; Humans; Mutation; Nitriles; Pancreatic Neoplasms; Phosphoric Acids; Proto-Oncogene Proteins p21(ras); Purines; Structure-Activity Relationship | 2020 |
Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; DNA; Drug Design; Drug Screening Assays, Antitumor; G-Quadruplexes; Humans; Mice; Pancreatic Neoplasms; Structure-Activity Relationship | 2020 |
Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Molecular Structure; Oxadiazoles; Pancreatic Neoplasms; Pyrimidines; Structure-Activity Relationship; Thiadiazoles | 2020 |
Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Calcitriol; Tumor Microenvironment | 2021 |
New indenopyrazole linked oxadiazole conjugates as anti-pancreatic cancer agents: Design, synthesis, in silico studies including 3D-QSAR analysis.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Oxadiazoles; Pancreatic Neoplasms; Pyrazoles; Quantitative Structure-Activity Relationship | 2021 |
Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; I-kappa B Kinase; Mice; Molecular Structure; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinoxalines; Structure-Activity Relationship; Urea | 2021 |
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Humans; Niacinamide; Pancreatic Neoplasms | 2022 |
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.
Topics: Cell Proliferation; Enzyme Inhibitors; Humans; Monoacylglycerol Lipases; Monoglycerides; Pancreatic Neoplasms | 2022 |
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Databases as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Paclitaxel; Pancreatic Neoplasms; Racial Groups; Retrospective Studies; Sex Factors; Treatment Outcome | 2021 |
Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Humans; Male; Mice, Knockout; Mice, Nude; Mucin 5AC; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
Topics: Animals; Calmodulin-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chitosan; Deoxycytidine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Binding; Protein Domains; Protein Stability; RNA, Long Noncoding; Transcription Factors; Ubiquitin-Protein Ligases | 2021 |
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2021 |
Use of
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Gemcitabine; Granulocytes; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Silencing; Genes, Homeobox; Hedgehog Proteins; Homeodomain Proteins; Humans; Mice; Pancreatic Neoplasms; Signal Transduction; Zinc Finger Protein GLI1 | 2022 |
Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Gene Silencing; Heterogeneous Nuclear Ribonucleoprotein D0; Humans; Inhibitory Concentration 50; MicroRNAs; Pancreas; Pancreatic Neoplasms; Ploidies; Proto-Oncogene Proteins c-akt; Transcription Factor RelA | 2021 |
Gemcitabine and nab-paclitaxel induced interstitial pneumonia.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Staging; Outcome Assessment, Health Care; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2021 |
Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome.
Topics: Aged; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enterobacteriaceae; Female; Gemcitabine; Humans; Male; Microbiota; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Stents; Tumor Microenvironment | 2021 |
Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Mutation; Pancreatic Neoplasms; Phenotype; Prognosis; Proto-Oncogene Proteins p21(ras); Reproducibility of Results; Risk Factors; ROC Curve; Survival Analysis | 2021 |
Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.
Topics: Alcohol Oxidoreductases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cytosol; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Ferroptosis; Flavonoids; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipid Peroxidation; Male; Mice; Mice, Nude; Molecular Docking Simulation; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptors, CXCR4; RNA, Small Interfering; Tissue Distribution | 2021 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors | 2022 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nomograms; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Probability; Proportional Hazards Models; ROC Curve; Sex Factors; Survival Rate; Tegafur | 2021 |
MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glucose; Humans; Molecular Targeted Therapy; Monocarboxylic Acid Transporters; Muscle Proteins; Pancreatic Neoplasms; Prognosis | 2021 |
Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Topics: Animals; Cells, Cultured; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; RNA-Binding Proteins; RNA, Circular; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice.
Topics: Animals; Deoxycytidine; Gastrointestinal Microbiome; Gemcitabine; Mice; Pancreatic Neoplasms; Probiotics; Transplantation, Heterologous | 2021 |
MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Self Renewal; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Analysis of the CONKO-001 trial: Is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; Transcription Factors; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2022 |
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blood Vessels; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Male; Middle Aged; Pain; Pancreatic Neoplasms | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Multimodal Imaging; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.
Topics: Animals; Cancer-Associated Fibroblasts; Caveolin 1; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia Inhibitory Factor; Mice; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Rho Guanine Nucleotide Exchange Factors; RNA Interference; RNA, Circular; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2022 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Progressive digital necrosis during gemcitabine/nab-paclitaxel chemotherapy in a patient with pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Necrosis; Paclitaxel; Pancreatic Neoplasms | 2022 |
The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Topics: Animals; Anthelmintics; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycogen Synthase Kinase 3 beta; Humans; Immune Evasion; Mice; Niclosamide; Pancreatic Neoplasms; Wnt Signaling Pathway | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proton Therapy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Time Factors | 2022 |
Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Ferroptosis; Gemcitabine; Glutathione Peroxidase; Humans; Magnetic Resonance Imaging; Pancreatic Neoplasms; Peroxidase; Reactive Oxygen Species | 2022 |
Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Response; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms | 2022 |
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; ERRalpha Estrogen-Related Receptor; Gemcitabine; Humans; MAP Kinase Signaling System; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Thiazoles; Xenograft Model Antitumor Assays | 2022 |
Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cinnamates; Deoxycytidine; Depsides; Gemcitabine; Humans; Orthosiphon; Pancreatic Neoplasms; Plant Extracts; Rosmarinic Acid | 2021 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Venous Thromboembolism | 2022 |
Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models.
Topics: Animals; Cell Line, Tumor; Collagen; Deoxycytidine; Disease Models, Animal; Gemcitabine; Heterografts; Humans; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
[A case of thrombotic microangiopathy during chemotherapy with gemcitabine in a patient with pancreatic cancer].
Topics: Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Renal Dialysis; Thrombotic Microangiopathies | 2022 |
Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; NF-E2-Related Factor 2; Pancreatic Neoplasms; Quassins; Survival Analysis; Transfection | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Tumor Microenvironment | 2022 |
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Endothelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Probability; Prognosis; Retrospective Studies | 2022 |
Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Methylenetetrahydrofolate Dehydrogenase (NADP); MicroRNAs; Minor Histocompatibility Antigens; Pancreatic Neoplasms; RNA, Circular | 2022 |
Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer.
Topics: Amlodipine; Animals; Antineoplastic Agents; Calcium Channel Blockers; Calmodulin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; United States | 2022 |
GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Receptor, Notch1; Transcription Factors | 2022 |
Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2022 |
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Molecular Docking Simulation; Neoplasm Proteins; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; rhoB GTP-Binding Protein; Signal Transduction | 2022 |
SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine.
Topics: Adenosine; Alternative Splicing; Deoxycytidine; DNA; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Long Noncoding; Serine-Arginine Splicing Factors | 2022 |
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Quality of Life; Risk Factors | 2022 |
The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Autophagy; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Receptor Subfamily 4, Group A, Member 2; Pancreatic Neoplasms; Receptors, Cytoplasmic and Nuclear | 2021 |
Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Hypoalbuminemia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2022 |
Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer.
Topics: Bacteria; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lipopolysaccharides; Pancreatic Neoplasms | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyethylene Glycols | 2022 |
FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Ubiquitins | 2022 |
Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models.
Topics: Animals; Bacteria; Butyrates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Pancreatic Neoplasms | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glycolysis; Humans; Pancreatic Neoplasms; Pentose Phosphate Pathway | 2022 |
Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tubulin | 2022 |
Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Triterpenes; Ursolic Acid | 2021 |
Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Laparoscopy; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2022 |
E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; E2F2 Transcription Factor; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Up-Regulation | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2023 |
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2022 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Thrombotic Microangiopathies | 2023 |
Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2022 |
microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplastic Stem Cells; NF-kappa B; Pancreatic Neoplasms | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; NF-E2-Related Factor 2; NF-kappa B; Pancreatic Neoplasms; Signal Transduction | 2023 |
Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Enbucrilate; Gemcitabine; Humans; Mice; Mice, Nude; Mucin-1; Pancreatic Neoplasms | 2022 |
A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Mice; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Serum Albumin, Human | 2022 |
Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dendrimers; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs | 2022 |
Sustained delivery of gemcitabine
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrogels; Pancreatic Neoplasms | 2022 |
Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Isoforms; Receptor, IGF Type 1; Transcription Factors; Up-Regulation | 2022 |
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft.
Topics: Animals; Cell Line, Tumor; Gemcitabine; Heterografts; Humans; Mice; Mice, Nude; Pancreatic Neoplasms | 2023 |
miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR/AKT/PI3K pathway in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Extracellular Vesicles; Gemcitabine; Macrophages; Mice; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Colchicine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; LIM Domain Proteins; Mice; Neoplasm Proteins; NF-kappa B; Nucleosomes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonuclease III; RNA, Small Interfering | 2022 |
Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Pancreatic Neoplasms; RNA, Long Noncoding; Tandem Mass Spectrometry | 2022 |
Long non-coding RNA SNHG16 decreased SMAD4 to induce gemcitabine resistance in pancreatic cancer via EZH2-mediated epigenetic modification.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; RNA, Small Nucleolar; Smad4 Protein | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life | 2023 |
Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Weight Loss | 2023 |
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.
Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Gemcitabine; Humans; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Tomography; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2022 |
Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Diphosphates; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proteomics; Ribonucleosides; S100 Calcium-Binding Protein A4 | 2022 |
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hypoxia; Mice; Oxidoreductases Acting on CH-CH Group Donors; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoembryonic Antigen; Deoxycytidine; Fatigue; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.
Topics: Aminoglycosides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Enediynes; ErbB Receptors; Gemcitabine; Humans; Ligands; NF-kappa B; Pancreatic Neoplasms; Smad4 Protein; TOR Serine-Threonine Kinases | 2022 |
Anti-tumour activity and toxicological studies of combination treatment of
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Eosine Yellowish-(YS); Gemcitabine; Heterografts; Humans; Ki-67 Antigen; Mice; Mice, Nude; Necrosis; Orthosiphon; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity.
Topics: Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15.
Topics: Anti-Inflammatory Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Receptors, Peptide; RNA, Small Interfering; Thrombomodulin | 2022 |
ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Topics: Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Epigenesis, Genetic; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Transcription Factors | 2022 |
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway.
Topics: Animals; Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Matrix Metalloproteinase 3; Mice; Pancreatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Streptozocin | 2022 |
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer.
Topics: Aminopeptidases; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Messenger | 2022 |
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Messenger | 2022 |
The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Topics: Activities of Daily Living; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2023 |
Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2022 |
ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells.
Topics: ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis | 2023 |
Nardoguaianone L Isolated from
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Nardostachys; Pancreatic Neoplasms; Proteomics; Reactive Oxygen Species; Signal Transduction | 2022 |
Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer.
Topics: Cell Line, Tumor; Cyclic AMP; Deoxycytidine; Gemcitabine; Humans; Metabolomics; Pancreatic Neoplasms | 2023 |
A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diet, Ketogenic; Female; Gemcitabine; Male; Mice; Pancreatic Neoplasms | 2022 |
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Signal Transduction | 2023 |
N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding; Up-Regulation; Wnt Signaling Pathway | 2022 |
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Topics: Apoptosis; Arsenic Trioxide; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Clusterin; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 1-beta; Humans; Mice; Pancreatic Neoplasms | 2022 |
RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway.
Topics: Animals; Cell Line, Tumor; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Topics: Animals; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Mice; Myeloid-Derived Suppressor Cells; Oncolytic Viruses; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53
Topics: Animals; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Disease Models, Animal; Gemcitabine; Mice; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2023 |
Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme System; Drug Interactions; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Plant Extracts; Warfarin | 2023 |
Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; East Asian People; Gemcitabine; Humans; Incidence; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Pancreatic Neoplasms; Transcriptome | 2023 |
Pharmacoinformatic screening of phytoconstituent and evaluation of its anti-PDAC effect using
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Ligands; Pancreatic Neoplasms | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Immunity; Insulins; Male; Metformin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; HeLa Cells; Humans; Pancreatic Neoplasms; Prodrugs | 2022 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemcitabine; Mice; Pancreatic Neoplasms | 2022 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2023 |
CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism.
Topics: Carcinoma, Pancreatic Ductal; Diclofenac; Gemcitabine; Humans; Nucleotidases; Pancreatic Neoplasms | 2023 |
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2023 |
A small Rho GTPase RAB25 with a potential role in chemotherapy resistance in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; rab GTP-Binding Proteins | 2023 |
Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway.
Topics: Animals; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Dendritic Cells; Gemcitabine; Immunity; Mice; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Hypoxia; Pancreatic Neoplasms | 2023 |
A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.
Topics: Animals; Biomimetics; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2023 |
Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Gemcitabine; Megakaryocyte-Erythroid Progenitor Cells; Mice; Pancreatic Neoplasms | 2023 |
Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.
Topics: Alginates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2023 |
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Stromal Cells | 2023 |
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2023 |
[A Case of Resected Pancreatic Adenosquamous Carcinoma with Early Hepatic Metastatic Recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2022 |
[Long-Term Survival following Multidisciplinary Therapy for Unresectable Pancreatic Body Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2022 |
[A Case of Giant Pancreatic Mucinous Cystic Neoplasm That Was Difficult to Preoperative Diagnosis].
Topics: Adult; Cystadenocarcinoma, Mucinous; Female; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Retroperitoneal Neoplasms | 2022 |
[A 10-Year Survivor with Multidisciplinary Treatment for Pancreatic Carcinoma That Recurred 17 Months after Pancreatoduodenectomy].
Topics: Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survivors | 2022 |
[A Case of Pathological Complete Response after Neoadjuvant Therapy for Resectable Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms | 2022 |
[Total Pancreatectomy for Remnant Pancreatic Cancer with Positive Washing Cytology after Conversion to Negative Cytology Following Gemcitabine plus Nab-Paclitaxel Therapy-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Humans; Middle Aged; Pancreatectomy; Pancreatic Neoplasms | 2022 |
Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Escherichia coli; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Gemcitabine; Humans; Male; Mutation; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Pancreatic Neoplasms | 2023 |
[A Case of Conversion Surgery after Long-Term Chemotherapy for Pancreatic Cancer with Peritoneal Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2023 |
DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; In Situ Hybridization, Fluorescence; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding; Tumor Suppressor Proteins | 2022 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
[A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Gemcitabine; Humans; Pancreatic Neoplasms; Peritoneal Lavage; Peritoneum | 2023 |
Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy.
Topics: Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering | 2023 |
Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta1 | 2023 |
Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Tumor Suppressor Protein p53; Ubiquitin-Conjugating Enzymes | 2023 |
Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Topics: Cachexia; Gemcitabine; Humans; Muscle, Skeletal; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer.
Topics: Acetylation; Antineoplastic Agents; Drug Resistance, Neoplasm; Extracellular Matrix; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Microenvironment | 2023 |
Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.
Topics: Cell Line, Tumor; Esters; Gemcitabine; Humans; Male; Organophosphates; Pancreatic Neoplasms; Phosphates; Prodrugs | 2023 |
Quantifying heterogeneity to drug response in cancer-stroma kinetics.
Topics: Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation.
Topics: Blood Proteins; Gemcitabine; Humans; Membrane Proteins; Metalloproteases; Mitochondria; Mitochondrial Proteins; Mitophagy; Pancreatic Neoplasms; Protein Kinases; Ubiquitin-Protein Ligases | 2023 |
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2023 |
Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing.
Topics: Acetyltransferases; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Immunity; Pancreatic Neoplasms | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Medicare; Pancreatic Neoplasms; Retrospective Studies; United States | 2023 |
In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrogels; Immunotherapy; Membrane Proteins; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
Topics: Adenosine; Animals; Carcinoma, Pancreatic Ductal; DEAD-box RNA Helicases; Gemcitabine; Humans; Lung Neoplasms; Methylation; Methyltransferases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger | 2023 |
A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Prodrugs; RNA, Small Interfering; Tumor Microenvironment | 2023 |
circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Circular; Signal Transduction | 2023 |
Targeting mitochondrial transcription factor A sensitizes pancreatic cancer cell to gemcitabine.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mitochondrial Proteins; Pancreatic Neoplasms | 2023 |
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Coenzyme A Ligases; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Ferroptosis; Gemcitabine; Humans; Mice; MicroRNAs; Pancreatic Neoplasms | 2023 |
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Topics: Artificial Intelligence; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Hypoxia; Mice; Pancreatic Neoplasms; Prodrugs; Recombinational DNA Repair | 2023 |
Supervised learning on impedance cytometry data for label-free biophysical distinction of pancreatic cancer cells versus their associated fibroblasts under gemcitabine treatment.
Topics: Biosensing Techniques; Cell Line, Tumor; Electric Impedance; Fibroblasts; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Mice; Mucin-1; Pancreatic Neoplasms; Receptors, Calcitriol | 2023 |
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms | 2023 |
Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Interleukin-13 Receptor alpha2 Subunit; Mice; Pancreatic Neoplasms | 2022 |
The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2022 |
Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant Therapy-Mimicking Pancreatic Cancer Xenograft Model.
Topics: Animals; Cytokine-Induced Killer Cells; Disease Models, Animal; Gemcitabine; Heterografts; Humans; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms | 2022 |
Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta | 2023 |
LncRNA GAS5 Regulates Gemcitabine Resistance in Pancreatic Carcinoma by Targeting miRNA-21.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2023 |
Chronic effects of pulsed high intensity focused ultrasound aided delivery of gemcitabine in a mouse model of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Topics: Cell Line, Tumor; Clinical Relevance; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Male; Neoplastic Stem Cells; Pancreatic Neoplasms | 2023 |
Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA, Mitochondrial; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2023 |
High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering | 2023 |
Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Treatment Outcome | 2023 |
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Prognosis | 2023 |
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Gemcitabine; Humans; Irbesartan; Mice; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nutritional Support; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Retrospective Studies; Weight Loss | 2023 |
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Leukocytes, Mononuclear; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2023 |
Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Heterografts; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2023 |
Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms | 2023 |
Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance.
Topics: Antibodies; Antineoplastic Agents; Biological Transport; Drug Resistance, Neoplasm; Fluorescence; Gemcitabine; Humans; Immunohistochemistry; Nucleosides; Pancreatic Neoplasms; Paraffin Embedding; Tissue Array Analysis; Tissue Fixation | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Japan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Serum Albumin | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Hsa_circ_0007401 regulates gemcitabine resistance of pancreatic cancer through the hsa-miR-6509-3p/fli1 axis.
Topics: Gemcitabine; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Circular; RNA, Messenger | 2023 |
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Protein; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Transforming Growth Factor beta; Transforming Growth Factors; Tumor Microenvironment | 2023 |
Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Topics: Angiopoietin-Like Protein 4; Apolipoprotein L1; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Transcriptome | 2023 |
Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mitochondria; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Immune Tolerance; Immunosuppression Therapy; Mice; Pancreatic Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |
Species-Deconvolved Proteomics for
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Heterografts; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Proteomics; Reproducibility of Results | 2023 |
Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulation.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Demethylation; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Humans; Lymphokines; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Ribonucleoside Diphosphate Reductase; Up-Regulation | 2023 |
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Topics: Afatinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Mucin-4; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2023 |
N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cdh1 Proteins; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Messenger | 2023 |
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2023 |
Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infant; Leucovorin; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Republic of Korea; Retrospective Studies | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin-7; RNA, Guide, CRISPR-Cas Systems; STAT5 Transcription Factor | 2023 |
Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Heat-Shock Response; Humans; Pancreatic Neoplasms; Pyruvaldehyde | 2023 |
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Topics: Gastrointestinal Diseases; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proton Therapy; Protons | 2023 |
Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy.
Topics: Animals; Cell Line, Tumor; Gemcitabine; Hydrogels; Mammals; Mice; Pancreatic Neoplasms; Polyethylene Glycols; Polyglactin 910; Sirolimus | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Mice; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polymers | 2023 |
A Ketogenic Diet in Combination with Gemcitabine Mitigates Pancreatic Cancer-Associated Cachexia in Male and Female KPC Mice.
Topics: Animals; Cachexia; Carcinoma, Pancreatic Ductal; Diet, Ketogenic; Female; Gemcitabine; Male; Mice; Pancreatic Neoplasms | 2023 |
Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-pac
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Hormones; Pancreatic Neoplasms | 2023 |
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Fibroblasts; Gemcitabine; Interleukin-2; Lymphocytes; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; Pancreatic Neoplasms; Up-Regulation | 2023 |
Knockdown of NF-κB activating protein promotes pancreatic cancer growth and metastasis through mTOR signaling pathway.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Repressor Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Thalidomide; Xenograft Model Antitumor Assays | 2023 |
Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel.
Topics: Animals; Gemcitabine; Humans; Hydrogels; Mice; Pancreatic Neoplasms; Ultrasonography, Interventional | 2023 |
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Topics: B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Oxidative Stress; Pancreatic Neoplasms; STAT3 Transcription Factor | 2023 |
hENT1 as a Predictive Biomarker in PDAC-Response.
Topics: Biomarkers; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Black Phosphorus as a Targeting PPAR-γ Agonist to Reverse Chemoresistance in Patient-derived Organoids, Mice, and Pancreatic Tumor Cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Organoids; Pancreatic Neoplasms; PPAR gamma; PPAR-gamma Agonists | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine.
Topics: Apoptosis; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Pyrroles; Sirtuins; Xenograft Model Antitumor Assays | 2023 |
Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hypoxia; Pancreatic Neoplasms; Up-Regulation | 2023 |
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Macrophages; Mice; Organoids; Pancreatic Neoplasms; Plicamycin; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Tumor Microenvironment | 2023 |
Chain length impact on the retro Diels-Alder mediated release of gemcitabine from hybrid nanoparticles towards pancreatic cancer therapy.
Topics: Gemcitabine; Hot Temperature; Humans; Nanoparticles; Pancreatic Neoplasms | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms | 2023 |
m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Stability; Ubiquitin-Specific Peptidase 7 | 2023 |
Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer.
Topics: Acyl-CoA Dehydrogenase; Fatty Acids; Ferroptosis; Gemcitabine; Humans; Lipid Metabolism; Pancreatic Neoplasms | 2023 |
USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
Topics: Drug Resistance, Neoplasm; Endopeptidases; Endosomal Sorting Complexes Required for Transport; Gemcitabine; Humans; NF-E2-Related Factor 2; Pancreatic Neoplasms; Signal Transduction; Ubiquitin Thiolesterase | 2023 |
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Topics: Gemcitabine; Humans; Pancreatic Diseases; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase | 2023 |
Efficacy and safety of gemcitabine plus S-1
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Sonodynamic Therapy of NRP2 Monoclonal Antibody-Guided MOFs@COF Targeted Disruption of Mitochondrial and Endoplasmic Reticulum Homeostasis to Induce Autophagy-Dependent Ferroptosis.
Topics: Antibodies, Monoclonal; Apoptosis; Autophagy; Cell Line, Tumor; Endoplasmic Reticulum; Ferroptosis; Gemcitabine; Humans; Metal-Organic Frameworks; Pancreatic Neoplasms; Reactive Oxygen Species | 2023 |
Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer.
Topics: Ataxia Telangiectasia; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine Kinase; ELAV-Like Protein 1; Gemcitabine; Humans; Pancreas; Pancreatic Hormones; Pancreatic Neoplasms; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2023 |
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
Topics: Animals; Carcinoma, Pancreatic Ductal; Core Binding Factor Alpha 2 Subunit; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Peptide Initiation Factors | 2023 |
Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Anticancer effect of umbelliferone on MKN-45 and MIA PaCa-2 cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Fibroblasts; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Umbelliferones | 2023 |
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Europe; Gemcitabine; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Topics: Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; T-Lymphocyte Subsets | 2023 |
Single-Cell Lipidomics Using Analytical Flow LC-MS Characterizes the Response to Chemotherapy in Cultured Pancreatic Cancer Cells.
Topics: Chromatography, Liquid; Gemcitabine; Humans; Lipidomics; Lipids; Pancreatic Neoplasms; Tandem Mass Spectrometry | 2023 |
The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glucose; Mice; NF-kappa B; Pancreatic Neoplasms | 2023 |
Matrix stiffness triggers chemoresistance through elevated autophagy in pancreatic ductal adenocarcinoma.
Topics: Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Pilot Projects | 2023 |
Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunization; Pancreatic Neoplasms; Stromal Cells; Tumor Microenvironment; Vaccines, DNA | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Receptor, Transforming Growth Factor-beta Type II; RNA, Circular | 2023 |
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2023 |
Tumor Microenvironment Responsive CD8
Topics: Animals; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Gemcitabine; Mice; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Topics: Amino Acid Transport Systems, Neutral; Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Glutamine; Humans; Mice; Pancreatic Neoplasms | 2023 |
Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway.
Topics: Apoptosis; Cell Line, Tumor; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Peptides; Proteome; Proteomics | 2023 |
Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms | 2024 |
FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Wnt Signaling Pathway; Wnt-5a Protein | 2023 |
Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Topics: Apoptosis; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; Niclosamide; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Ubiquitination; Wnt Signaling Pathway | 2023 |
Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
Topics: Animals; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2023 |
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Growth Inhibitors; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases | 2023 |
Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca‑2 and PANC‑1 cells.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Molecular Docking Simulation; Pancreatic Neoplasms; RNA, Messenger; Tumor Microenvironment | 2024 |
Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsaturated fatty acid metabolism.
Topics: Annexin A5; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Fatty Acids; Fatty Acids, Unsaturated; Ferroptosis; Gemcitabine; Humans; Pancreatic Neoplasms; Stearoyl-CoA Desaturase | 2023 |
LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Fructose-Bisphosphate Aldolase; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Pancreatic Neoplasms; Phenotype; Phosphatidylinositol 3-Kinases; Tumor Microenvironment | 2023 |
[Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Netherlands; Pancreatic Neoplasms | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Mice; Mucins; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms | 2023 |
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; DNA Damage; Gemcitabine; Hepatocyte Nuclear Factor 3-alpha; Humans; MicroRNAs; Mixed Function Oxygenases; Pancreatic Neoplasms; Proto-Oncogene Proteins; RNA Precursors; RNA, Circular | 2023 |
Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catechin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Enzyme Stability; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice, Inbred C57BL; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Burden | 2019 |
Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Synergism; Fibronectins; Gemcitabine; Humans; Myocytes, Cardiac; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dimerization; Drug Resistance, Neoplasm; Gemcitabine; Hexokinase; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Voltage-Dependent Anion Channels | 2019 |
Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma".
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
WEE1 kinase inhibitor shows promise.
Topics: Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones | 2019 |
Targeting WEE1 in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2019 |
Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2019 |
Computational modeling of therapy on pancreatic cancer in its early stages.
Topics: Anisotropy; Cell Death; Cell Division; Cell Line, Tumor; Cell Movement; Computer Simulation; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Hyaluronoglucosaminidase; Injections; Monte Carlo Method; Neoplasm Staging; Numerical Analysis, Computer-Assisted; Pancreatic Neoplasms; Stochastic Processes | 2020 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Long Noncoding; Scavenger Receptors, Class E; Transcriptome; Up-Regulation | 2019 |
ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Integrins; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptidomimetics; Xenograft Model Antitumor Assays | 2019 |
The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma.
Topics: Acanthaceae; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-bcl-2 | 2019 |
Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunosuppressive Agents; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polysaccharides; Strongylocentrotus; Toll-Like Receptor 4 | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
[A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Extracellular Matrix; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Nanoparticles; Pancreatic Neoplasms; Pyridones; Silicon Dioxide | 2019 |
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intestine, Small; Lab-On-A-Chip Devices; Microfluidic Analytical Techniques; Models, Biological; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Percutaneous stenting and chemotherapy for unresectable pancreatic cancer: Comparison of irradiation stents vs conventional metal stents.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract; Biliary Tract Surgical Procedures; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stents | 2019 |
Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Exercise; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Physical Conditioning, Animal; Vascular Remodeling; Xenograft Model Antitumor Assays | 2019 |
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Models, Biological; Mucin-1; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Deletion; Humans; Pancreatic Neoplasms; Smad4 Protein; Tumor Cells, Cultured | 2019 |
Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Green Fluorescent Proteins; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms | 2019 |
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Tegafur | 2019 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Compounding; Drug Design; ErbB Receptors; Female; Gemcitabine; Humans; Liposomes; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Polyethylene Glycols; Protein Kinase Inhibitors; Proteolysis; Xenograft Model Antitumor Assays | 2019 |
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Topics: Abnormalities, Multiple; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Keratoconus; Mice; Organophosphates; Pancreatic Neoplasms; Signal Transduction; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Receptors, Interleukin-17; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoglobulin G; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; THP-1 Cells; Xenograft Model Antitumor Assays | 2019 |
Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Topics: ADAM Proteins; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Datasets as Topic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Sequence Analysis, RNA; Up-Regulation | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Microfilament Proteins; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; RNA, Long Noncoding; Up-Regulation | 2019 |
YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Aporphines; Cell Cycle Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hydroxymethylglutaryl CoA Reductases; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Transcription Factors; Tumor Cells, Cultured | 2019 |
Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Endocytosis; Exosomes; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution | 2020 |
Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic Cancer Cells.
Topics: Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Porosity; Silicon Dioxide | 2020 |
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharmacokinetic and Pharmacodynamic Study.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Coix; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Plant Extracts | 2019 |
Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells.
Topics: Avena; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Ethanol; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts | 2019 |
ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2020 |
Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiosurgery; Retrospective Studies | 2020 |
Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer.
Topics: Adult; Aged; Animals; Cell Communication; Cell Line, Tumor; Connexin 43; Deoxycytidine; Female; Gap Junctions; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; In Situ Hybridization; Isothiocyanates; Male; Mice; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Sulfoxides | 2020 |
A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer.
Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Mice; Mice, Nude; Neoplasm, Residual; Pancreatic Neoplasms; Transplantation, Heterologous | 2019 |
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Mice; Mice, Inbred BALB C; Pancreas; Pancreatic Neoplasms; Prognosis | 2020 |
Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; MicroRNAs; Pancreas; Pancreatic Neoplasms; PC-3 Cells; RNA Helicases; RNA, Messenger | 2019 |
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Humans; Integrin alpha3; Integrin beta1; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Survival Rate; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Microscopy, Electron, Transmission; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Emergency Service, Hospital; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score; Treatment Outcome | 2020 |
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfones; Xenograft Model Antitumor Assays | 2020 |
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |
HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kelch-Like ECH-Associated Protein 1; Minor Histocompatibility Antigens; NF-E2-Related Factor 2; Pancreatic Neoplasms; RNA-Binding Proteins | 2020 |
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur | 2020 |
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Survival; Deoxycytidine; Diketopiperazines; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Rats, Wistar; Tubulin Modulators | 2020 |
CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Damage; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Naphthyridines; Pancreatic Neoplasms; RNA, Messenger; Spheroids, Cellular | 2019 |
Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleoproteins; Ribonucleoside Diphosphate Reductase; RNA-Seq; RNA, Messenger; Stromal Interaction Molecule 1; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Microenvironment; Ultrasonic Therapy | 2019 |
Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prognosis; Prospective Studies; Renal Insufficiency; Survival Rate | 2020 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2019 |
A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Pancreatic Neoplasms | 2019 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Deoxycytidine; Flow Cytometry; Gemcitabine; Glucagon-Like Peptide-1 Receptor; Humans; Immunohistochemistry; Liraglutide; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2020 |
ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germ-Line Mutation; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Topics: Albumins; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interferon-gamma; Killer Cells, Natural; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin Thiolesterase | 2020 |
Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2020 |
Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Nomograms; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Anti-tumor Activities of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors and Bisphosphonates in Pancreatic Cell Lines Which Show Poor Responses to Gemcitabine.
Topics: Alendronate; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Zoledronic Acid | 2020 |
Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer).
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation; Humans; Mice; Models, Molecular; Mucins; Pancreatic Neoplasms; Structure-Activity Relationship; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Dexamethasone; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, Glucocorticoid; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutaminase; Glutamine; Heterografts; Humans; Mice; Mice, Nude; Mutation; Neoplasm Proteins; NF-E2-Related Factor 2; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Random Allocation; Tissue Array Analysis; Up-Regulation | 2020 |
FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Deoxycytidine; Drug Synergism; Fibroblast Growth Factor 2; Gemcitabine; Humans; Magnetite Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Spheroids, Cellular | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Pancreatic Neoplasms; Recurrence; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Stromal Cells; Survival Analysis; Xenograft Model Antitumor Assays | 2020 |
Charging forward in locally advanced pancreatic cancer.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Stress, Physiological; Tumor Hypoxia; Up-Regulation | 2020 |
Polymeric modification of gemcitabine via cyclic acetal linkage for enhanced anticancer potency with negligible side effects.
Topics: Acetals; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Pancreatic Neoplasms; Polymers | 2020 |
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Liberation; Enzyme Inhibitors; Female; Gemcitabine; Imidazoles; Immunity; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Isoindoles; Mice, Inbred BALB C; Micelles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Prodrugs | 2020 |
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Metabolic Networks and Pathways; Models, Biological; Pancreatic Neoplasms | 2020 |
[Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Magnetite Nanoparticles; Male; Metformin; Mice, Inbred BALB C; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides | 2020 |
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Organoids; Pancreatic Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Pancreatic Neoplasms; Particle Size; Photothermal Therapy; Surface Properties; Theranostic Nanomedicine; Tumor Cells, Cultured | 2020 |
Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cetuximab; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Gold; Humans; Metal Nanoparticles; Nanoconjugates; Pancreatic Neoplasms; Pancreatic Stellate Cells; Polyethylene Glycols; Tumor Microenvironment | 2020 |
Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Ginsenosides; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Transfection; Tumor Burden; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
Topics: Animals; Antigens, CD; Cadherins; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Cyclin B; Cyclin D1; Deoxycytidine; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-cbl; Signal Transduction; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2020 |
PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; United States | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorodeoxyglucose F18; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2020 |
Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation; Prognosis; Survival Rate | 2020 |
Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doublecortin-Like Kinases; Gemcitabine; Hepatocyte Growth Factor; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pancreatic Stellate Cells; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.
Topics: Animals; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Dysbiosis; Gastrointestinal Microbiome; Gemcitabine; Hyperglycemia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms | 2020 |
Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression.
Topics: Bias; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Regression Analysis | 2020 |
Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Lipids; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polymers; Rats; Rats, Sprague-Dawley | 2020 |
An Unusual Gastric Lesion during Chemotherapy for Pancreatic Cancer.
Topics: Abdominal Pain; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Endoscopy, Gastrointestinal; Female; Gastritis; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Injuries; Tomography, X-Ray Computed | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-1; Male; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; STAT3 Transcription Factor | 2020 |
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Hexosamines; Humans; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2020 |
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proteomics; Tumor Microenvironment | 2020 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glucose; Glycolysis; Humans; Irinotecan; Lactic Acid; Leucovorin; Male; Mice, Nude; Mucin-1; Neoplasm Transplantation; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Deoxycytidine; Endosonography; Female; Ferric Compounds; Gemcitabine; Iron; Mice, Inbred C57BL; Microbubbles; Oxides; Pancreatic Neoplasms; Tumor Burden; Ultrasonic Therapy; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Suppressor Protein p53 | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphangiogenesis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Survival Rate; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
[42-year-old patient with renal insufficience, anemia and thrombocytopenia during chemotherapy].
Topics: Adult; Anemia; Antineoplastic Agents; Deoxycytidine; Erythrocytes; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms; Renal Insufficiency; Thrombocytopenia | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma.
Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin | 2020 |
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Topics: Anilides; Animals; Antimetabolites, Antineoplastic; Benzylamines; Cell Communication; Cell Survival; Coculture Techniques; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyridines; Reactive Oxygen Species; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction | 2020 |
Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor for Advanced Glycation End Products; Signal Transduction; Stilbenes | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells.
Topics: Amino Acid Transport Systems; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Metabolomics; Pancreatic Neoplasms; Tryptophan | 2020 |
Cisplatin Plus Gemcitabine as Standard of Care for Germline
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Standard of Care | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Linear Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bosentan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Endothelin A Receptor Antagonists; Gemcitabine; Humans; Pancreatic Neoplasms; Receptor, Endothelin A | 2020 |
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Sarcomatoid carcinoma of the pancreas with rare long-term survival: a case report.
Topics: Carcinosarcoma; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2020 |
CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoplasm; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Humans; Mice; Pancreatic Neoplasms; Prognosis; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53 | 2020 |
Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Jagged-1 Protein; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; RNA, Messenger; Signal Transduction | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Nanogels; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Phosphatidylserines; Xenograft Model Antitumor Assays | 2020 |
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Small Interfering; Tissue Inhibitor of Metalloproteinase-1 | 2021 |
Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Oxidative Stress; Pancreatic Neoplasms; Sesquiterpenes; Signal Transduction; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Nomograms; Outcome Assessment, Health Care; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reproducibility of Results | 2020 |
Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
Topics: Animals; Biomimetic Materials; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; Dimyristoylphosphatidylcholine; Gemcitabine; Liposomes; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Pancreas; Pancreatic Neoplasms; Prodrugs; Swine | 2020 |
Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Self Renewal; Deoxycytidine; Doxorubicin; Female; Gemcitabine; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Methyltransferases; Proto-Oncogene Proteins p21(ras); Trans-Activators; Transcriptional Coactivator with PDZ-Binding Motif Proteins | 2020 |
Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; CA-19-9 Antigen; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Radiation-Sensitizing Agents; Survival Analysis | 2020 |
MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Circulating MicroRNA; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2020 |
Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mutation; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Burden | 2020 |
Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Tapering; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pyrones | 2020 |
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Azepines; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Protein Domains; Proto-Oncogene Proteins c-fos; Transcription Factors; Triazoles | 2020 |
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Male; Middle Aged; Oncostatin M Receptor beta Subunit; Pancreatic Neoplasms; Sp1 Transcription Factor; Transcriptome; Young Adult | 2020 |
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Infusions, Intralesional; Infusions, Intravenous; Male; Mice; Pancreas; Pancreatic Neoplasms; Pressure; Tissue Distribution | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Prognosis | 2020 |
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Survival Rate; United Kingdom | 2020 |
A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS.
Topics: Antimetabolites, Antineoplastic; Autophagy; Biomarkers, Tumor; Deoxycytidine; E1A-Associated p300 Protein; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured | 2020 |
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.
Topics: Adenocarcinoma; Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Diagnostic Imaging; Dose Fractionation, Radiation; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Radiosurgery | 2020 |
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Drug Interactions; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Lymphocyte Activation; Oxaliplatin; Pancreatic Neoplasms; Thalidomide; Zoledronic Acid | 2021 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2020 |
Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Pancreatic Neoplasms; Prognosis; Tomography Scanners, X-Ray Computed | 2020 |
A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; G-Quadruplexes; Gemcitabine; Gene Expression Profiling; Humans; Imides; Ligands; Naphthalenes; Pancreatic Neoplasms; Repressor Proteins; Up-Regulation | 2020 |
One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer.
Topics: Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylserines | 2020 |
Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Ultrasonic Therapy; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2020 |
Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabine Administration: A Pilot Study.
Topics: Adenocarcinoma; Deoxycytidine; Fatty Acids, Omega-3; Gemcitabine; Humans; Pancreatic Neoplasms; Pilot Projects; Proteomics | 2021 |
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Purines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2020 |
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Autophagy; Autophagy-Related Proteins; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Binding; RNA Interference; RNA, Long Noncoding; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2020 |
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Europe; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Knockout Techniques; Humans; Indoles; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Pancreatic Neoplasms; Pyridines; Pyrimidines; Quinolines; RNA, Small Interfering; Sulfonamides; Sulfoxides; Xenograft Model Antitumor Assays | 2020 |
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2020 |
Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Immunotherapy; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.
Topics: Adenocarcinoma, Clear Cell; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Margins of Excision; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate | 2020 |
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Momordica charantia; Neoplasm Invasiveness; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Gemcitabine; Gene Expression; Gene Knockout Techniques; Humans; Letrozole; Leuprolide; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liposomes; Multidrug Resistance-Associated Proteins; Nitric Oxide; Pancreatic Neoplasms | 2020 |
[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].
Topics: Adenocarcinoma, Mucinous; Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Cavity; Positron Emission Tomography Computed Tomography | 2020 |
Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Pancreatic Neoplasms; Receptors, Cell Surface; Receptors, Death Domain; RNA, Small Interfering | 2020 |
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Cohort Studies; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Lipopolysaccharides; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Translational Research, Biomedical; Treatment Outcome | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brucea; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plant Oils; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Resveratrol; Tumor Cells, Cultured; Vascular Endothelial Growth Factor B; Xenograft Model Antitumor Assays | 2021 |
Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Topics: Animals; Apoptosis; Canagliflozin; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Glucose Transporter Type 1; Glycolysis; Humans; Lactate Dehydrogenase 5; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Retinoids | 2020 |
Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Plant Extracts; Poly (ADP-Ribose) Polymerase-1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2020 |
Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Topics: Animals; Apolipoprotein A-II; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lipoproteins, HDL; Male; Mice; Nanoparticles; Pancreatic Neoplasms; Particle Size; Prodrugs; Scavenger Receptors, Class B; Xenograft Model Antitumor Assays | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Interferon-beta; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Costs and Cost Analysis; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Health Resources; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Needs Assessment; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Thymidine Kinase; Thymidylate Synthase; Transcription, Genetic | 2020 |
Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Dual Delivery of Gemcitabine and Paclitaxel by Wet-Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation.
Topics: Adenocarcinoma; Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Tumor Burden | 2020 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate | 2021 |
Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2020 |
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Calcium Channel Blockers; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diltiazem; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Mechanical Control of Cell Proliferation Increases Resistance to Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Stress, Mechanical | 2020 |
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Transla
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Registries; Treatment Outcome | 2021 |
Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured | 2020 |
Precise and efficient silencing of mutant Kras
Topics: Amino Acid Substitution; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; Dependovirus; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Genetic Therapy; Genetic Vectors; Humans; Mice; Mutation; Pancreatic Neoplasms; Proof of Concept Study; Proto-Oncogene Proteins p21(ras); RNA, Guide, Kinetoplastida; Xenograft Model Antitumor Assays | 2020 |
Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; ATP Binding Cassette Transporter, Subfamily B; Cell Hypoxia; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Microenvironment | 2020 |
Toxic erythema of chemotherapy secondary to gemcitabine and paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Erythema; Female; Gemcitabine; Humans; Intertrigo; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2020 |
Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Intention to Treat Analysis; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
Topics: Antibodies, Blocking; Antineoplastic Agents; Antineoplastic Agents, Immunological; Deoxycytidine; Down-Regulation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Molecular Targeted Therapy; Mucins; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Interleukin-17; Tumor Cells, Cultured | 2020 |
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; CRISPR-Cas Systems; Deoxycytidine; Drug Development; Gemcitabine; Gene Knockout Techniques; Humans; Mice, Nude; Pancreatic Neoplasms; Protein-Arginine N-Methyltransferases; Xenograft Model Antitumor Assays | 2020 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Reproducibility of Results; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Metabolomics; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase | 2021 |
Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Pancreatic Neoplasms; Particle Size; Rats; Rats, Wistar; Structure-Activity Relationship | 2020 |
Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases as Topic; Deoxycytidine; Female; Gemcitabine; Hospitals; Humans; Insurance; Japan; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
MicroRNA-136-5p regulates gemcitabine resistance in pancreatic cancer via down-regulating ZNF32.
Topics: Antimetabolites, Antineoplastic; Cell Line; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2020 |
The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphoproteins; Prognosis; RNA-Binding Proteins | 2021 |
Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors | 2021 |
ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Ribonuclease III; Signal Transduction; Sp1 Transcription Factor; Transcriptional Activation; Xenograft Model Antitumor Assays | 2021 |
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Macrophages; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Transcriptome | 2021 |
Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Correlation of Data; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Frizzled Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation; Wnt Signaling Pathway; Wnt-5a Protein | 2021 |
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitinase-3-Like Protein 1; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Fibronectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Pancreatic Neoplasms; Pentoxifylline; Proteomics; Pyridones; Survival Analysis; Up-Regulation | 2021 |
Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Apolipoprotein E3; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Compounding; Gemcitabine; Gene Transfer Techniques; Humans; Lipids; Liposomes; Male; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Receptors, LDL; RNA, Small Interfering; RNAi Therapeutics; Xenograft Model Antitumor Assays | 2020 |
Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transcriptome | 2021 |
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Small Molecule Libraries; Vorinostat | 2020 |
Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights.
Topics: Anti-Bacterial Agents; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2021 |
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Topics: Acinar Cells; Adenocarcinoma; Animals; Antineoplastic Agents; Calcium; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Dedifferentiation; Cell Transformation, Neoplastic; Cells, Cultured; Ceruletide; Deoxycytidine; Disease Progression; Gemcitabine; GTP-Binding Proteins; Histone Deacetylase Inhibitors; Mice; Pancreatic Ducts; Pancreatic Neoplasms; Pancreatitis; Proto-Oncogene Proteins p21(ras); RGS Proteins; Signal Transduction | 2020 |
Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Macrophages; Mice; Pancreatic Neoplasms; Prognosis; Vascular Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays | 2020 |
Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogels; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Topics: Afatinib; Animals; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Gemcitabine; Hepatocyte Nuclear Factor 3-beta; Humans; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; SOX9 Transcription Factor | 2021 |
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxycytidine; Drug Resistance, Neoplasm; Electron Transport Complex I; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; PC-3 Cells; Phenformin; Xenograft Model Antitumor Assays | 2020 |
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2021 |
Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Repair; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pentacyclic Triterpenes; Tumor Suppressor p53-Binding Protein 1 | 2021 |
High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2021 |
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genes, ras; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Pancreatic Neoplasms; Peptides; Rats | 2020 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Markers; Glutathione Transferase; Humans; Pancreatic Neoplasms; RNA Interference | 2021 |
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Male; Mutation; Paclitaxel; Pancreatic Neoplasms | 2021 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microwaves; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2021 |
S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Coculture Techniques; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Targeting; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; S100 Proteins; Xenograft Model Antitumor Assays | 2021 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Taiwan; Tegafur; Treatment Failure | 2020 |
The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate | 2020 |
Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured | 2021 |
CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Cell Line, Tumor; Copper; Deoxycytidine; Gemcitabine; Mice; Nanoparticles; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, CCR2; Tumor Microenvironment | 2021 |
Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Tumor Cells, Cultured | 2021 |
[A case of advanced pancreatic cancer with oculomotor nerve palsy caused by herpes zoster after introduction of gemcitabine plus nab-paclitaxel].
Topics: Acyclovir; Aged; Albumins; Antiviral Agents; Deoxycytidine; Female; Gemcitabine; Humans; Oculomotor Nerve Diseases; Paclitaxel; Pancreatic Neoplasms | 2021 |
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Calcium Signaling; Carcinoma, Pancreatic Ductal; Cell Nucleus; Cell Proliferation; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Stromal Interaction Molecule 1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biocompatible Materials; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Male; Metal-Organic Frameworks; Pancreatic Neoplasms; Rats, Wistar; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoconjugates; Male; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2021 |
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed | 2021 |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Adult; Aged; Albumins; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pharmacogenomic Testing; Polymorphism, Genetic | 2021 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
[A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbon; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Sarcopenia; Tegafur; Treatment Outcome | 2021 |
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Membrane Transport Proteins; Mice; Mucin-4; Neoplasm Transplantation; Pancreatic Neoplasms; Polysaccharides | 2021 |
Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Silencing; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; RNA-Binding Proteins; RNA, Small Interfering; Stromal Cells; Tumor Cells, Cultured | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD27 Ligand; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2021 |
Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Tocotrienols | 2021 |
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Meningeal Neoplasms; Meningioma; Pancreatic Neoplasms | 2021 |
PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Proteins; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding; Signal Transduction | 2021 |
Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway.
Topics: Adenocarcinoma; Aged; Animals; Carcinogenesis; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Pancreatic Neoplasms; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; S100 Proteins; Tissue Array Analysis; Up-Regulation | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diet, Ketogenic; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Piperidines | 2021 |
Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Laminin; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Ferroptosis; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Signal Transduction; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2021 |
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Aggregation; Cell Division; Cell Movement; Cell Self Renewal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Organ Size; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Peritonitis | 2021 |
Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Apoptosis; Catechols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Radiation Tolerance; Signal Transduction; Transcription Factors; YAP-Signaling Proteins | 2021 |
Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Neoplasm Metastasis; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines; Wnt Signaling Pathway | 2021 |
Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells.
Topics: Adenosine Triphosphate; Albumin-Bound Paclitaxel; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome; Trimetazidine | 2021 |
Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Ketoglutarate Dehydrogenase Complex; Mice; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2021 |
pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; NIH 3T3 Cells; Pancreatic Neoplasms | 2021 |
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.
Topics: Albumins; China; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2020 |
Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; RNA-Binding Proteins | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients.
Topics: Aged; Databases, Nucleic Acid; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2021 |
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; Endosomes; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Topics: Deoxycytidine; Gemcitabine; Kinetics; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2021 |
Synergistic effect of the herbal mixture C5E on gemcitabine treatment in PANC‑1 cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorescein-5-isothiocyanate; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Herbal Medicine; Humans; Pancreatic Neoplasms; Plant Extracts | 2021 |
Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation.
Topics: Activating Transcription Factor 4; Cancer-Associated Fibroblasts; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Transforming Growth Factor beta1; Tumor Microenvironment | 2021 |
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Karyotyping; Mutation; Octamer Transcription Factor-3; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Suppressor Protein p53 | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Staining and Labeling | 2021 |
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment | 2021 |
Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles.
Topics: Copper Radioisotopes; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, CCR2; Tomography, X-Ray Computed | 2021 |
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Glucose; Humans; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Deoxycytidine; Drug Synergism; Gemcitabine; Liver Neoplasms; Male; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; HMGB1 Protein; Mice; Microtubule-Associated Proteins; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Receptor for Advanced Glycation End Products; Transplantation, Homologous | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Prognosis | 2021 |
Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gold; Humans; Nanoshells; Pancreatic Neoplasms; Photochemotherapy; Polymers | 2021 |
Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer.
Topics: alpha-Glucosidases; Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Lysosomes; Male; Mice; Mice, Nude; Pancreatic Neoplasms; RNA, Small Interfering; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
Topics: Animals; Cell Line, Tumor; Cytidine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Liposomes; Pancreatic Neoplasms; Rats | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2021 |
A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Drug Stability; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Assessment; Sialoglycoproteins | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Male; Mice; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Phospholipids; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2021 |
In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms | 2021 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Transcriptome | 2021 |
Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Cytoskeleton; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Microbubbles; Pancreatic Neoplasms; Ultrasonography | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nutrition Assessment; Nutrition Therapy; Nutritional Status; Oxonic Acid; Pancreatic Neoplasms; Phytotherapy; Polysaccharides; Shiitake Mushrooms; Tegafur; Treatment Outcome | 2021 |
Hypericin-mediated photodynamic therapy enhances gemcitabine induced Capan-2 cell apoptosis via inhibiting NADPH level.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; NADP; Pancreatic Neoplasms; Perylene; Photochemotherapy; Reactive Oxygen Species | 2022 |
Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.
Topics: Animals; Antimetabolites, Antineoplastic; Calcium; Calreticulin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoribonucleases; Gemcitabine; Gene Knockout Techniques; Gene Silencing; Heterografts; HSP47 Heat-Shock Proteins; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; NADPH Oxidases; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Unfolded Protein Response | 2021 |
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Topics: Aged; Cell Line, Tumor; Cell Survival; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Up-Regulation | 2021 |
Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Stents; Treatment Outcome | 2022 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Deoxycytidine; Female; Gemcitabine; Humans; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Tumor Cells, Cultured | 2021 |
Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Rose Bengal | 2021 |
Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Male; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Polyethylene Glycols; Rats | 2021 |
PMEPA1 interference activates PTEN/PI3K/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Membrane Proteins; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase | 2022 |
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents | 2021 |
Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2021 |
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferase, Cytoplasmic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Energy Metabolism; Enzyme Activation; Enzyme Activators; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sirtuins; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carcinoma, Pancreatic Ductal; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Gastrointestinal Microbiome; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Venous Thromboembolism | 2022 |
Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
Topics: Adult; Aged; Albumins; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Risk Factors | 2021 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Development and evaluation of a multi-functional organic-inorganic nanotheranostic hybrid for pancreatic cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Contrast Media; Deoxycytidine; Gemcitabine; Gold; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Pancreas; Pancreatic Neoplasms; Theranostic Nanomedicine | 2021 |
CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Topics: 5'-Nucleotidase; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Troglitazone; Xenograft Model Antitumor Assays | 2021 |
The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Coumarins; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression.
Topics: Aldehyde Dehydrogenase; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; NF-E2-Related Factor 2; Pancreatic Neoplasms; Piperidines; Quinazolinones | 2021 |
MASTL regulates EGFR signaling to impact pancreatic cancer progression.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; ErbB Receptors; Gain of Function Mutation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Loss of Function Mutation; Mice; Microtubule-Associated Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein Stability; Signal Transduction; Up-Regulation | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2021 |
An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surface Area; Canada; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lumbar Vertebrae; Male; Maximum Tolerated Dose; Middle Aged; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Predictive Value of Tests; Reference Values; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.
Topics: Apoptosis; Autophagy; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; HMGB1 Protein; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2021 |
T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Receptor, Transforming Growth Factor-beta Type I; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Allografts; Amino Acid Motifs; Animals; Apoptosis; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Synergism; Endocytosis; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Lysosomes; Mice; Microfilament Proteins; Molecular Targeted Therapy; NIMA-Interacting Peptidylprolyl Isomerase; Oncogenes; Organoids; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Survival Analysis; Toll-Like Receptor 2; Xenograft Model Antitumor Assays | 2021 |
The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Benzylisoquinolines; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Oleanolic Acid; Pancreatic Neoplasms; Trypsin Inhibitor, Kazal Pancreatic | 2021 |
New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results.
Topics: Adenocarcinoma; Animals; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Equipment Design; Gemcitabine; Hydrogel, Polyethylene Glycol Dimethacrylate; In Vitro Techniques; Injections, Intravenous; Pancreas; Pancreatic Neoplasms; Swine; Vascular Access Devices | 2017 |
Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Regional Blood Flow; Retrospective Studies; Survival Analysis; Tegafur | 2017 |
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Random Allocation; Relaxin; Xenograft Model Antitumor Assays | 2017 |
Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy.
Topics: Activating Transcription Factor 2; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2017 |
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Topics: Angiogenic Proteins; Animals; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Mice; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Mas; Proto-Oncogene Proteins c-jun; Ribonucleoside Diphosphate Reductase; Transcriptional Activation; Xenograft Model Antitumor Assays | 2017 |
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Male; Palliative Care; Pancreatic Neoplasms; Platelet Count; Prognosis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2017 |
Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Drug Monitoring; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Paclitaxel; Pancreatic Neoplasms | 2017 |
In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.
Topics: Animals; Cell Line, Tumor; Cytosine; Deoxycytidine; Female; Gemcitabine; Humans; Mice, Nude; Mice, Transgenic; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |
USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.
Topics: Antimetabolites, Antineoplastic; Carcinogenesis; Cell Line; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction; Tacrolimus Binding Proteins; Tissue Array Analysis; Ubiquitin Thiolesterase | 2017 |
Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Curcumin; Cyclohexanones; Deoxycytidine; Drug Interactions; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Uridine | 2017 |
Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chitosan; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Nanoparticles; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate | 2017 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Biosensing Techniques; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Collagen; Deoxycytidine; Disease Progression; Extracellular Matrix; Gemcitabine; Humans; Liver; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Treatment Outcome | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells.
Topics: Adipose Tissue; Adiposity; Animals; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Fatty Acids; Gemcitabine; Humans; Lipolysis; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Retrospective Studies | 2017 |
Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Melitten; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Comparison of Preparation Efficiency and Therapeutic Safety between Generic Products of Gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drugs, Generic; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Pancreatic Neoplasms; Pyrimidines; Ribonucleotide Reductases; Tumor Suppressor Protein p53 | 2017 |
Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Topics: Animals; Deoxycytidine; Drug Carriers; Female; Ferric Compounds; Gemcitabine; Genetic Therapy; Humans; Hyaluronan Receptors; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Nanomedicine; Oligonucleotides, Antisense; Pancreatic Neoplasms; Polyethylene Glycols; Polyethyleneimine; Precision Medicine; Single-Chain Antibodies; Xenograft Model Antitumor Assays | 2017 |
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Survival Rate | 2017 |
miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cell Line; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Sequence Homology, Nucleic Acid; Snail Family Transcription Factors; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemoradiotherapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thymidylate Synthase | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; MicroRNAs; Pancreatic Neoplasms; Prognosis; RNA-Binding Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2017 |
Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Topics: Aerosols; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Routes; Drug Delivery Systems; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pressure; Prospective Studies; Treatment Outcome | 2017 |
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caveolin 1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Injections, Intravenous; Ki-67 Antigen; Male; Mice; Micelles; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Polymers; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antineoplastic Agents; Azetidines; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2017 |
Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Japan; Male; Pancreatic Neoplasms; Risk Factors; Survival Rate | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proto-Oncogene Proteins p21(ras); Translational Research, Biomedical | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2017 |
Pancreatic cancer heterogeneity and response to Mek inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Heterogeneity; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Paclitaxel; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Serum Albumin; Survival Rate; Time Factors | 2017 |
BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Helicases; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Janus Kinase 2; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transcription Factors; Transfection; Xenograft Model Antitumor Assays | 2017 |
Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Imaging, Three-Dimensional; Mice; Mice, SCID; Pancreatic Neoplasms; Radiofrequency Therapy | 2017 |
Unique cellular interactions between pancreatic cancer cells and the omentum.
Topics: Adipocytes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cells, Cultured; Chromatography, High Pressure Liquid; Culture Media, Conditioned; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Omentum; Pancreatic Neoplasms; Tandem Mass Spectrometry; Transplantation, Heterologous | 2017 |
miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Topics: Aged; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2017 |
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Gemcitabine; Humans; Isocitrate Dehydrogenase; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenotype; Protein Processing, Post-Translational; Survival Analysis; Transcriptional Activation; Transfection; Up-Regulation | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Calcium Compounds; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphorylation; Silicates; Xenograft Model Antitumor Assays | 2017 |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-mdm2; Survival Analysis | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms; Perioperative Period; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Albumin-Bound Paclitaxel; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Time Factors; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Successful pregnancy after mucinous cystic neoplasm with invasive carcinoma of the pancreas in a patient with polycystic ovarian syndrome: a case report.
Topics: Adenocarcinoma; Adult; Chemoradiotherapy; Cystadenocarcinoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Infertility, Female; Magnetic Resonance Imaging; Ovary; Ovulation; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Radiation-Sensitizing Agents; Ultrasonography | 2017 |
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Postoperative Period | 2017 |
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
Topics: Carbon; Deoxycytidine; Digoxin; Drug Resistance, Neoplasm; Gemcitabine; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mucin-1; Pancreatic Neoplasms; Pentose Phosphate Pathway; Prognosis; Pyrimidines; Signal Transduction | 2017 |
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Age Factors; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Preoperative Period; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2017 |
Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cytoplasmic Dyneins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; RNA, Long Noncoding; Transplantation, Heterologous; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2017 |
Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Interleukin-17; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome | 2017 |
Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm, Residual; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron Emission Tomography Computed Tomography; Time Factors | 2017 |
EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Survival; Cetuximab; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Humans; Micelles; MicroRNAs; Pancreatic Neoplasms; Polyethylene Glycols; Polymers | 2017 |
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fructose-Bisphosphatase; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; ras GTPase-Activating Proteins; Signal Transduction; Transfection | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Drug Stability; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Phospholipids; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Toxicity Tests | 2017 |
Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice
Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endopeptidases; Gastrins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survivin; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; F-Box-WD Repeat-Containing Protein 7; Gemcitabine; Humans; Lysosomes; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Up-Regulation | 2017 |
A cascade enzymatic reaction activatable gemcitabine prodrug with an AIE-based intracellular light-up apoptotic probe for in situ self-therapeutic monitoring.
Topics: Apoptosis; Caspase 3; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fluorescent Dyes; Gemcitabine; Humans; Microscopy, Fluorescence; Molecular Structure; Pancreatic Neoplasms; Prodrugs; Protein Aggregates; Stilbenes; Structure-Activity Relationship | 2017 |
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD3 Complex; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Integrin beta4; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; T-Lymphocytes, Cytotoxic | 2017 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Damage; Fluorouracil; Gemcitabine; Gene Expression; Genomic Instability; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phthalazines; Piperazines | 2017 |
Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cattle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Particle Size; Serum Albumin, Bovine; Surface Properties | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Dipeptides; Drug Delivery Systems; Drug Liberation; Drug Stability; Enzyme Activation; Esters; Gemcitabine; Humans; Pancreatic Neoplasms; Permeability; Prodrugs; Thymidine Phosphorylase | 2017 |
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Xanthones; Xenograft Model Antitumor Assays | 2017 |
Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Floxuridine; Fluorescent Dyes; Gemcitabine; Heterografts; Humans; Indoles; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Surface Properties; Theranostic Nanomedicine; Tissue Distribution | 2017 |
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diazooxonorleucine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glutamine; Humans; Metabolic Networks and Pathways; Oxidation-Reduction; Pancreatic Neoplasms; Proteomics | 2017 |
Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Liposomes; Matrix Metalloproteinase 2; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides; Pyridones; Tumor Cells, Cultured | 2017 |
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gemcitabine; Humans; Lipids; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Heterografts; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pyrimidines; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2017 |
Gemcitabine-induced chronic systemic capillary leak syndrome.
Topics: Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Deoxycytidine; Edema; Female; Gemcitabine; Humans; Hypoalbuminemia; Hypotension; Middle Aged; Pancreatic Neoplasms | 2017 |
ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase 1 Family; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha Chains; Isoenzymes; Pancreatic Neoplasms; Prognosis; Retinal Dehydrogenase; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2017 |
Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells.
Topics: Adenosine Triphosphatases; Antimetabolites, Antineoplastic; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Calcitriol; Calcium Channel Agonists; Carrier Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Silybin; Silymarin | 2017 |
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luciferases; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fibrin Tissue Adhesive; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2017 |
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Gammaproteobacteria; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mycoplasma hyorhinis; Neoplasms, Experimental; Pancreatic Neoplasms | 2017 |
PEGylated thermosensitive lipid-coated hollow gold nanoshells for effective combinational chemo-photothermal therapy of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Gold; Humans; Hydrophobic and Hydrophilic Interactions; Infrared Rays; Lipids; Nanoshells; Pancreatic Neoplasms; Phototherapy; Polyethylene Glycols; Temperature | 2017 |
Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Contrast Media; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gadolinium; Gemcitabine; Hot Temperature; Liposomes; Magnetic Resonance Imaging; Mice, Nude; Models, Biological; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Particle Size; Phantoms, Imaging; Viscosity | 2017 |
Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pentoxifylline; Phosphodiesterase Inhibitors; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Hot Temperature; Humans; Lasers; Maleimides; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Tumor Burden | 2017 |
HINT2 triggers mitochondrial Ca
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Calcium Channels; Deoxycytidine; Gemcitabine; Heterografts; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Mitochondrial Proteins; Pancreatic Neoplasms | 2017 |
NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; I-kappa B Kinase; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Peptide Fragments; Peptides; Protein Domains; Random Allocation; Xenograft Model Antitumor Assays | 2017 |
Acinar Cell Carcinoma in the Background of Chronic Calcific Pancreatitis.
Topics: Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis, Chronic; Treatment Outcome; Viscera | 2019 |
CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGA2 Protein; Humans; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Receptors, CXCR4 | 2017 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyesters; Survival Rate; Transdermal Patch; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
Topics: AC133 Antigen; Aged; Animals; Anoikis; Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Pancreatic Neoplasms; Phenotype; RNA, Messenger; Spheroids, Cellular; Transcription Factors; Vimentin | 2017 |
Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Photochemotherapy; Serum Albumin, Human; Xenograft Model Antitumor Assays | 2017 |
Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CCL5; Chemokine CXCL1; Chemotaxis, Leukocyte; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-12 Subunit p35; Interleukin-8; Interleukins; Macrophages; Mice, SCID; Microvessels; Minor Histocompatibility Antigens; Monocytes; Neovascularization, Pathologic; Pancreatic Neoplasms; Paracrine Communication; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Gold; Humans; Metal Nanoparticles; Pancreatic Neoplasms; Peptides; Plectin | 2017 |
Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Ontology; Humans; Isotope Labeling; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphoproteins; Proteomics; Signal Transduction; Tandem Mass Spectrometry; Translational Research, Biomedical | 2017 |
Pancreatic cancer: Intra-tumour bacteria promote gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Bacteria; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens.
Topics: Algorithms; Cell Line, Tumor; Cell Proliferation; Databases, Genetic; Deoxycytidine; DNA Repair; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Kinase Inhibitors; Transcription, Genetic | 2017 |
ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anoctamins; Anti-Bacterial Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Humans; Male; Membrane Proteins; Mice; Middle Aged; Neoplasm Transplantation; Pancreatic Neoplasms; Phospholipid Transfer Proteins; Prognosis; RNA, Messenger; Survival Rate; Tumor Stem Cell Assay | 2017 |
The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Neoplasm Invasiveness; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Flavanones; Gemcitabine; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Taxoids | 2017 |
Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Primary Cell Culture; Prognosis; Rho Guanine Nucleotide Exchange Factors; Xenograft Model Antitumor Assays | 2017 |
miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Nuclear Proteins; Pancreatic Neoplasms; rho GTP-Binding Proteins; Twist-Related Protein 1 | 2017 |
Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2017 |
Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzodiazepinones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Doublecortin-Like Kinases; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction | 2017 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Development and
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; In Vitro Techniques; Liposomes; Mucin-4; Pancreatic Neoplasms; Tumor Cells, Cultured | 2017 |
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Splenic Artery | 2017 |
Comment on: MicroRNA Expression as a Predictive Marker for Gemcitabine Response After Surgical Resection of Pancreatic Cancer.
Topics: Deoxycytidine; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2017 |
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase Inhibitors; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyaluronan Receptors; Limonins; Mitochondria; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors; Tumor Suppressor Protein p53 | 2018 |
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2017 |
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation | 2018 |
Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells.
Topics: 3' Untranslated Regions; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Polyadenylation; Polyribosomes; Ribonucleoproteins; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation?
Topics: Aged; Antineoplastic Agents; Carcinoma, Acinar Cell; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; Tomography, X-Ray Computed | 2018 |
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2019 |
Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Peptide Fragments; Protein Kinase C; T-Lymphocytes | 2018 |
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Heterografts; Humans; Keratins; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Neuroendocrine Cells; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-myc; Synaptophysin | 2017 |
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Perioperative Care; Prognosis; Survival Rate; Tumor Cells, Cultured | 2018 |
3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Conformation; S Phase | 2017 |
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Topics: Antimetabolites, Antineoplastic; beta-D-Galactoside alpha 2-6-Sialyltransferase; Cell Line, Tumor; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunoblotting; Neuraminidase; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Sialyltransferases; Tumor Suppressor Proteins | 2018 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gas Chromatography-Mass Spectrometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lactic Acid; Male; Metabolomics; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2018 |
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carboxymethylcellulose Sodium; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Immunity, Cellular; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Poly I-C; Polylysine; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Deoxycytidine; Diterpenes; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Signal Transduction; Vimentin | 2018 |
Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Line, Tumor; Cyclin A2; Cyclin D1; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Random Allocation; RNA, Messenger; Triterpenes; Xenograft Model Antitumor Assays | 2018 |
Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Genes, p53; Male; Mice; Mutation; NF-E2-Related Factor 2; Oxidative Stress; Pancreatic Neoplasms; Precancerous Conditions; Proto-Oncogene Proteins p21(ras) | 2017 |
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.
Topics: Adrenergic Agents; Animals; Carcinoma in Situ; Catecholamines; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice, Transgenic; Nerve Growth Factors; Pancreatic Neoplasms | 2018 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
Topics: Actins; Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; CA-19-9 Antigen; Cancer-Associated Fibroblasts; Collagen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Stromal Cells | 2018 |
CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CDC2 Protein Kinase; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2018 |
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Eflornithine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Pancreas; Pancreatic Neoplasms; Polyamines; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Proliferation; Cell Transformation, Neoplastic; Chemokine CXCL10; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesenchymal Stem Cells; Mice; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, CXCR3; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Pancreatic Neoplasms; Prognosis; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured | 2018 |
Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Janus Kinase 1; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; STAT Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Thymidine Monophosphate; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2018 |
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin | 2018 |
A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Physiological Phenomena; Deoxycytidine; Female; Gemcitabine; Humans; Hyaluronan Receptors; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Nanoconjugates; Pancreatic Neoplasms; Particle Size; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Ontology; Humans; Methyltransferases; Pancreatic Neoplasms; Radiation Tolerance | 2018 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; China; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2018 |
miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins; Snail Family Transcription Factors | 2018 |
Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fibrosis; Gemcitabine; Humans; Interleukin-1 Receptor-Associated Kinases; Interleukin-1beta; Mice; Mice, Knockout; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2018 |
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Pancreatic Neoplasms | 2018 |
Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.
Topics: Antineoplastic Agents; Ascites; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Assessment of Anticancer Drug Effects on Pancreatic Cancer Cells under Glucose-Depleted Conditions Using Intracellular and Extracellular Amino Acid Metabolomics.
Topics: Amino Acids; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Glucose; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Discriminant Analysis; Extracellular Fluid; Gemcitabine; Glucose; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemia; Intracellular Fluid; Least-Squares Analysis; Metabolomics; Pancreatic Neoplasms; Principal Component Analysis; Pyrvinium Compounds; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Nude; Oligopeptides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
[Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2017 |
[Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors | 2017 |
[A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2017 |
[A Case of Unresectable Locally Advanced Pancreatic Cancer Resulted in R0 Surgery after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2017 |
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms | 2017 |
[A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritoneal Neoplasms; Treatment Outcome | 2017 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Indoles; Lysine; Methylation; Pancreatic Neoplasms | 2018 |
CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chloroquine; Deoxycytidine; Gemcitabine; Humans; Lysosomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Metabolomics; Mice; Mice, Nude; Microbiota; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Time Factors | 2018 |
Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Deoxycytidine; Enzyme Inhibitors; Esterification; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Sterol O-Acyltransferase | 2018 |
Circulating Microvesicles from Pancreatic Cancer Accelerate the Migration and Proliferation of PANC-1 Cells.
Topics: Antimetabolites, Antineoplastic; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell-Derived Microparticles; Deoxycytidine; Gemcitabine; Gene Expression Regulation; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Phosphatase 2; Proteome; Tumor Suppressor Protein p53 | 2018 |
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2018 |
You cannot miss it: Pancreatic mucoepidermoid carcinoma: A case report and literature review.
Topics: Antineoplastic Agents; Carcinoma, Mucoepidermoid; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Diagnosis, Differential; Drug Monitoring; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hyperthermia, Induced; Pancreatic Neoplasms | 2018 |
Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells.
Topics: Adenylate Kinase; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2018 |
Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; United States | 2019 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyridones; Pyrimidinones | 2018 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2018 |
The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hedgehog Proteins; Heme Oxygenase-1; Humans; Pancreatic Neoplasms; Protoporphyrins; Signal Transduction; Up-Regulation; Veratrum Alkaloids | 2018 |
Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
Topics: Cell Culture Techniques; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Silencing; Humans; Mutation; Pancreatic Neoplasms; Signal Transduction; Spheroids, Cellular; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2018 |
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Injections, Intraperitoneal; Male; Methionine; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Recombinant Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chick Embryo; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Simvastatin | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
[A Case of Successful Treatment with Gemcitabine plus Nab-Paclitaxel Therapy for Nonresected Pancreatic Body Cancer(Stage IVb)].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Male; Mice, SCID; Microbubbles; Pancreatic Neoplasms; Rose Bengal; Ultrasonic Therapy; Xenograft Model Antitumor Assays | 2018 |
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms | 2018 |
A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2018 |
Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2018 |
Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Gemcitabine; Hepatocytes; Humans; Pancreatic Neoplasms | 2018 |
[Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Weight Loss | 2018 |
Suppression of
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Pancreatic Neoplasms; RNA, Small Interfering | 2018 |
dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Topics: Acetylcysteine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Cysteine Ligase; Glutathione; Humans; Kelch-Like ECH-Associated Protein 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-E2-Related Factor 2; Pancreatic Neoplasms; Plasmids; Reactive Oxygen Species; Up-Regulation | 2018 |
Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Intracellular Signaling Peptides and Proteins; Mitomycin; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction | 2018 |
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Proportional Hazards Models; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Metastasis from pancreatic adenocarcinoma to the cheekbone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exophthalmos; Female; Gemcitabine; Humans; Middle Aged; Orbital Neoplasms; Pancreatectomy; Pancreatic Neoplasms; Plastic Surgery Procedures; Tomography, X-Ray Computed; Vinorelbine; Vision Disorders; Zygoma | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Messenger | 2018 |
Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Terpenes; Xenograft Model Antitumor Assays | 2018 |
Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Indoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Pyrroles; Tumor Suppressor Protein p53 | 2018 |
Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Immunoglobulin Fragments; Liposomes; Microscopy, Confocal; Microscopy, Electron, Transmission; Paclitaxel; Pancreatic Neoplasms; Particle Size; Proto-Oncogene Proteins c-bcl-2 | 2018 |
How Do We "Validate" a QSP Model?
Topics: Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Proteomics | 2018 |
Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Mitochondria; NF-E2-Related Factor 2; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Resveratrol; Ribonucleoproteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Stilbenes | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Tumor Hypoxia | 2018 |
Analysis of the cytotoxic effects of combined ultrasound, microbubble and nucleoside analog combinations on pancreatic cells in vitro.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Fluorocarbons; Gemcitabine; Humans; In Vitro Techniques; Microbubbles; Pancreatic Neoplasms; Ultrasonic Therapy | 2018 |
Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Microarray Analysis; Pancreatic Neoplasms; RNA; RNA, Circular; RNA, Messenger; Signal Transduction | 2018 |
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Mice, Nude; Oxygen; Pancreatic Neoplasms; Prodrugs; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Mesenteric Veins; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Nude; MicroRNAs; Microtubule-Associated Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Thiolester Hydrolases; Transplantation, Heterologous; Ubiquitin Thiolesterase | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flavonols; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc | 2018 |
Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-E2-Related Factor 2; Pancreatic Neoplasms; Quassins; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Topics: Analysis of Variance; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Replication; Gemcitabine; Histones; Humans; Nucleosides; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Roscovitine; Staining and Labeling | 2018 |
Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Deoxycytidine; Diterpenes; Gemcitabine; Humans; Isodon; MAP Kinase Signaling System; Pancreatic Neoplasms; Phosphorylation; Plant Extracts; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase | 2018 |
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carbon-Sulfur Lyases; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Recombinant Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Heterografts; Humans; Male; Mice, Inbred BALB C; Middle Aged; Neoplasm Transplantation; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Signal Transduction; Tripartite Motif Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2018 |
Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Immunoconjugates; Mice; Mice, Nude; Oligopeptides; Oxaliplatin; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2018 |
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Pancreatic Neoplasms; Quality-Adjusted Life Years; United States | 2018 |
Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Inhibitory Concentration 50; Models, Biological; Neoplastic Stem Cells; Paclitaxel; Pancreatic Neoplasms; Trifluoperazine | 2018 |
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding | 2018 |
Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience.
Topics: Adult; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; United Kingdom; Venous Thromboembolism | 2018 |
Tissue-Penetrating, Hypoxia-Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Heterografts; Humans; Lactates; Male; Mice, Nude; Microsomes, Liver; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Rats; Tumor Hypoxia | 2018 |
Combination Effects of Hispidin and Gemcitabine
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyrones | 2018 |
Neoadjuvant
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Healthcare Disparities; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Rural Health; Rural Population; Urban Health; Urban Population | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Humans; Irinotecan; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Signal Transduction | 2018 |
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Snail Family Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gemcitabine; Heat-Shock Proteins; Humans; Ki-67 Antigen; Mice, Inbred C57BL; Multivesicular Bodies; Pancreatic Neoplasms; Sunitinib; Survival Analysis; Tumor Burden; Unfolded Protein Response; X-Box Binding Protein 1 | 2018 |
miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-fyn; Signal Transduction; Time Factors | 2018 |
Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Databases, Factual; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Hyperbilirubinemia; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cyclin D2; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
[Two Case Reports of Chemotherapy-Induced Radiation Myositis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Myositis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2018 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
A case of gemcitabine-related acute lipodermatosclerosis.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Deoxycytidine; Dermatitis; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Scleroderma, Localized | 2019 |
Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Transfer Techniques; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Pancreatic Neoplasms; rab27 GTP-Binding Proteins; Tumor Microenvironment; Up-Regulation | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Homeodomain Proteins; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mutation; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Trans-Activators; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2018 |
A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; MAP Kinase Signaling System; Methyltransferases; Pancreatic Neoplasms; Proto-Oncogene Proteins B-raf; Signal Transduction; Thioguanine; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Hedgehog Proteins; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Lung Neoplasms; Matrix Metalloproteinases; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Transcription Factors | 2018 |
Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms | 2018 |
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome | 2018 |
Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dipeptides; Female; Gemcitabine; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Pancreatic Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Celiac Plexus; Chemoradiotherapy; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Models, Biological; Pancreatic Neoplasms; Proteomics; Signal Transduction | 2018 |
Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Histidine; Humans; Hydrogels; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred NOD; Pancreatic Neoplasms; Polyglutamic Acid | 2018 |
Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunomodulation; Macrophage Activation; Macrophages; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyanoacrylates; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyridines; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2018 |
An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Humans; Mice; Pancreas; Pancreatic Neoplasms | 2018 |
BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Genes, bcl-2; Humans; Mice; Pancreatic Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcineurin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Discovery; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Mice; Mice, Nude; Neoplasm Transplantation; NFATC Transcription Factors; Pancreatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-mdm2; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2018 |
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA2 Protein; Humans; Mice; Mice, Knockout; Pancreatic Neoplasms; Prognosis; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2018 |
Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Tegafur | 2019 |
Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Topics: Animals; Antimetabolites, Antineoplastic; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Integrin beta1; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Survival; Coculture Techniques; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Risk Factors; Sensitivity and Specificity; Stromal Cells; Tumor Cells, Cultured | 2018 |
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; rab GTP-Binding Proteins; Signal Transduction; Up-Regulation | 2019 |
Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dietary Supplements; Gemcitabine; Genes, p53; Genes, ras; Humans; Magnetic Resonance Imaging; Male; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; S100 Calcium Binding Protein beta Subunit; Smad4 Protein; Survival Rate; Terpenes | 2018 |
Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Topics: Animals; Antibodies, Monoclonal; Basigin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2018 |
Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cells, Cultured; Deoxycytidine; Ferric Compounds; Fibrosis; Gemcitabine; Humans; Male; Mice, SCID; Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, G-Protein-Coupled; Receptors, Peptide; Relaxin; Transforming Growth Factor beta; Treatment Outcome | 2018 |
Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Cytosol; Deoxycytidine; Deoxyglucose; Gemcitabine; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Mutation; Pancreatic Neoplasms; Protein Kinases; Protein Transport; Signal Transduction; Sirtuin 1; Tumor Suppressor Protein p53 | 2018 |
A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drainage; Female; Gemcitabine; Health Care Costs; Humans; Male; Metals; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Plastics; Retrospective Studies; Stents; Treatment Outcome | 2019 |
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2018 |
Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Kynuramine; Melatonin; Pancreatic Neoplasms | 2018 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2018 |
Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Topics: Amino Acids; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Chromatography, Liquid; Chromatography, Thin Layer; Deoxycytidine; Disease Models, Animal; Drug Monitoring; Drug Stability; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Pancreatic Neoplasms; Prodrugs; Tandem Mass Spectrometry; Threonine; Xenograft Model Antitumor Assays | 2018 |
Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering; TRPM Cation Channels | 2018 |
Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interleukin-6; Mice, SCID; Neoplasm Grading; Neoplasm Invasiveness; Pancreatic Neoplasms; Resistin; STAT3 Transcription Factor; Toll-Like Receptor 4 | 2019 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Nanoparticles; Pancreatic Neoplasms; Quercetin | 2019 |
Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Matrix Attachment Region Binding Proteins; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lipids; Mice; Mice, Transgenic; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Resveratrol; RNA Interference; RNA, Small Interfering; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Xenograft Model Antitumor Assays | 2019 |
Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Mas; RNA, Long Noncoding | 2018 |
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Palliative Care; Pancreas; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors | 2018 |
Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2019 |
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Neutralizing; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Nude; Neutralization Tests; NF-kappa B; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Survival Analysis | 2018 |
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2018 |
Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphocytes; Neutrophils; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2020 |
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Vaccinia virus; Xenograft Model Antitumor Assays | 2019 |
Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Activating Transcription Factor 2; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Survival Rate; Up-Regulation | 2019 |
Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform.
Topics: Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Microenvironment | 2019 |
The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
Topics: Animals; Binding Sites; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2019 |
Dihomo-γ-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Delta-5 Fatty Acid Desaturase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Fatty Acid Desaturases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2019 |
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mice, Transgenic; MicroRNAs; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.
Topics: Aggregatibacter actinomycetemcomitans; Animals; Chronic Periodontitis; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Gammaproteobacteria; Gemcitabine; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Mice; Pancreatic Neoplasms; Pathology, Molecular; Porphyromonas gingivalis; Receptor, Notch1 | 2018 |
Hyaluronic Acid-Based Multilayer Films Regulate Hypoxic Multicellular Aggregation of Pancreatic Cancer Cells with Distinct Cancer Stem-Cell-like Properties.
Topics: Cell Aggregation; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Nanostructures; Neoplastic Stem Cells; Pancreatic Neoplasms; Polyamines | 2018 |
CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.
Topics: Actins; Antigens, CD; Antigens, Neoplasm; Blotting, Western; Cell Adhesion Molecules; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Polysaccharides | 2018 |
Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Fibrinolytic Agents; Gemcitabine; Ginkgolides; HEK293 Cells; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Xenograft Model Antitumor Assays | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Long Noncoding | 2020 |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Neoplasms, Experimental; Pancreatic Neoplasms; Peptides; Phthalazines; Piperazines | 2018 |
Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Monitoring; Female; Gemcitabine; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Micelles; Nanoparticles; Pancreatic Neoplasms; Polycarboxylate Cement; Polyethylene Glycols; Polymers; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Cell Survival; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Membrane Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Phosphorylation; Primary Cell Culture; Protein Domains; Signal Transduction; Unfolded Protein Response | 2019 |
HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.
Topics: Animals; Annexin A5; Antibodies; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Nanostructures; Neoplasms, Experimental; Pancreatic Neoplasms; Peptides; RNA, Small Interfering | 2019 |
Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)".
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiotherapy; Reoperation; Retrospective Studies; Survival Rate | 2019 |
LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Long Noncoding; Up-Regulation | 2018 |
Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Sodium; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2018 |
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Mice; Mice, Nude; Monensin; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
A Glimmer of Hope for Pancreatic Cancer.
Topics: Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2018 |
Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice, Nude; MicroRNAs; Nanostructures; Pancreatic Neoplasms | 2019 |
Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell-Derived Microparticles; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Sphingomyelin Phosphodiesterase | 2018 |
Antipancreatic cancer effect of DNT cells and the underlying mechanism.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transplantation; Coculture Techniques; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; T-Lymphocyte Subsets | 2019 |
Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Microscopy, Fluorescence; Models, Biological; Necrosis; Oxidative Stress; Pancreatic Neoplasms; Sonication; Spheroids, Cellular | 2018 |
Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Humans; Pancreatic Neoplasms; Proteome; Receptor, EphA2 | 2018 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MicroRNAs; Pancreatic Neoplasms | 2019 |
Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2019 |
Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Emulsions; Gemcitabine; Humans; Inhibitory Concentration 50; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Simvastatin | 2019 |
Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Leptin; Male; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2019 |
Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Glutathione; Heme Oxygenase-1; Humans; Male; Mice, Nude; Models, Biological; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Stromal Cells | 2019 |
Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Interferon Type I; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
FOLFIRINOX goes adjuvant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Random Allocation; Survival Analysis; Treatment Outcome | 2019 |
Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Gels; Gemcitabine; Humans; Mice; Mice, Nude; Nanostructures; Pancreatic Neoplasms; Platinum; Polymers | 2019 |
S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Janus Kinase 2; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; S-Adenosylmethionine; Signal Transduction; STAT3 Transcription Factor; Tumor Burden | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Renal Dialysis | 2018 |
[A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2018 |
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Biological Variation, Population; Biomarkers, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Inflammation; Male; Malnutrition; Middle Aged; Neutrophils; Nutritional Status; Pancreatic Neoplasms; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies | 2019 |
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA Repair; Epithelial-Mesenchymal Transition; Etoposide; Forkhead Box Protein M1; Gemcitabine; HEK293 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Mice; Mice, Knockout; Pancreas; Pancreatic Neoplasms; Protein Isoforms; Transcription, Genetic | 2019 |
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Topics: Animals; Antimetabolites, Antineoplastic; Data Interpretation, Statistical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Mice; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Topics: 5'-Nucleotidase; Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; Mice, Transgenic; Models, Biological; Pancreatic Neoplasms; Prognosis; Xenograft Model Antitumor Assays | 2019 |
Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Nerve Tissue Proteins; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2019 |
Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cells, Cultured; Clonal Evolution; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Heterogeneity; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome | 2019 |
Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Nuclear Proteins; Pancreatic Neoplasms; RNA, Long Noncoding; Transcription Factors | 2019 |
SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2019 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2019 |
EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Initiation Factors; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2019 |
[Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms | 2019 |
MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway.
Topics: Aged; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Snail Family Transcription Factors; Survival Rate; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Topics: 3' Untranslated Regions; Albumins; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Sequence Homology, Nucleic Acid | 2019 |
STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gemcitabine; Humans; Interferon-gamma; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide.
Topics: Adenocarcinoma; Cell Line, Tumor; Cytotoxins; Delayed-Action Preparations; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Nitric Oxide; Pancreatic Neoplasms | 2019 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Mice; Mice, Nude; Neutrophils; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrimidines; RAW 264.7 Cells; Xenograft Model Antitumor Assays | 2019 |
Insights into gemcitabine resistance and the potential for therapeutic monitoring.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Gemcitabine; Humans; Metabolome; Pancreatic Neoplasms; Tumor Cells, Cultured | 2018 |
Macrophages throw tumour cells a lifeline.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Mice; p21-Activated Kinases; Pancreatic Neoplasms; Treatment Outcome; Tretinoin; Xenograft Model Antitumor Assays | 2019 |
[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms | 2019 |
Topics: Animals; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Copper Radioisotopes; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Female; Gemcitabine; HCT116 Cells; Humans; Injections, Intraperitoneal; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Radioimmunotherapy; Radiotherapy, Adjuvant; Treatment Outcome | 2019 |
WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; WT1 Proteins | 2019 |
Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; STAT3 Transcription Factor | 2019 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Monitoring; Female; Gemcitabine; Humans; Immunotherapy; Magnetic Resonance Imaging; Magnetite Nanoparticles; Maximum Tolerated Dose; Mice; Pancreas; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Tumor Microenvironment | 2019 |
Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liposomes; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; RNA, Small Interfering | 2019 |
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms | 2019 |
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; RNA, Antisense; RNA, Long Noncoding | 2019 |
Metabolite crosstalk could modulate chemotherapy response in pancreatic cancer.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
The distinct role of CD73 in the progression of pancreatic cancer.
Topics: 5'-Nucleotidase; Animals; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Male; Mice, Nude; MicroRNAs; Middle Aged; Models, Biological; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor, Type II; RNA, Messenger; Signal Transduction | 2019 |
Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
Topics: 14-3-3 Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Polarity; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Macrophages; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2019 |
The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; JNK Mitogen-Activated Protein Kinases; Ki-67 Antigen; Magnetite Nanoparticles; Mice, Nude; Pancreatic Neoplasms; Peptides; Phenotype; S Phase; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Folic Acid; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Pantothenic Acid; Plant Extracts; Solutions; Vitamin B 12; Vitamin B 6; Zinc Sulfate | 2019 |
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Methylprednisolone; Paclitaxel; Pancreatic Neoplasms | 2019 |
Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers.
Topics: Carcinoma, Hepatocellular; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreas; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; RNA Interference; RNA, Small Interfering | 2019 |
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Paclitaxel; Pancreatic Neoplasms; Peritoneal Dialysis; Tomography, X-Ray Computed | 2019 |
Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Curcumin; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Ferric Compounds; Gemcitabine; Humans; Magnetite Nanoparticles; Mice; Microscopy, Confocal; Nanoparticles; Pancreatic Neoplasms; Receptors, CXCR4 | 2019 |
Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Neovascularization, Pathologic; Pancreatic Neoplasms | 2019 |
Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT S
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lactones; Mitochondria; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Sesquiterpenes, Guaiane; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Diamines; Drug Carriers; Drug Delivery Systems; Gemcitabine; Liposomes; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss | 2019 |
Macrophage manipulation.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2019 |
Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Liposomes; Male; Mice, SCID; Pancreatic Neoplasms; Rats | 2019 |
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Fendiline; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Verteporfin; YAP-Signaling Proteins | 2019 |
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Hepatocyte Nuclear Factor 1-alpha; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Protein Binding | 2019 |
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms | 2019 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome | 2020 |
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
Topics: Animals; Annexin A1; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase 4; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase C; Signal Transduction | 2020 |
Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC.
Topics: Calibration; Cell Line, Tumor; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Limit of Detection; Linear Models; Metabolome; Pancreatic Neoplasms; Reference Standards | 2019 |
Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor.
Topics: Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Spheroids, Cellular; Tumor Microenvironment; Vimentin | 2019 |
Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gemcitabine; Homeodomain Proteins; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Receptor, EphB2; RNA, Long Noncoding; RNA, Neoplasm; Signal Transduction; Transcription Factors | 2019 |
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2019 |
[A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Mice; Microtubules; Paclitaxel; Pancreatic Neoplasms; Protein Multimerization; Tubulin Modulators; Xenograft Model Antitumor Assays | 2019 |
Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Brief Psychiatric Rating Scale; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Endocytosis; Gemcitabine; Glycerol; Humans; Hydrogen-Ion Concentration; Nanoparticles; Pancreatic Neoplasms; Polycarboxylate Cement; Polymers; Proton Magnetic Resonance Spectroscopy; Spheroids, Cellular; Tissue Scaffolds | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Standard of Care | 2019 |
Reply to I. Pecora et al.
Topics: Albumin-Bound Paclitaxel; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms | 2019 |
Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route.
Topics: Aged; Albumin-Bound Paclitaxel; Deoxycytidine; Drug Therapy, Combination; Frail Elderly; Gemcitabine; Group Processes; Humans; Nanoparticles; Pancreatic Neoplasms | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hydrogen Peroxide; Mice; Mice, Nude; Pancreatic Neoplasms; Prodrugs; Reactive Oxygen Species; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Matrix; Fibronectins; Flavonoids; Gemcitabine; Humans; MAP Kinase Signaling System; Oligopeptides; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Safety; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Circulating Tumor DNA; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liquid Biopsy; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras) | 2019 |
p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Carcinoma, Pancreatic Ductal; Class Ia Phosphatidylinositol 3-Kinase; Class Ib Phosphatidylinositol 3-Kinase; Deoxycytidine; Diet, High-Fat; Disease Models, Animal; Drug Resistance, Neoplasm; Fatty Acids, Omega-6; Female; Gemcitabine; Glucose; Humans; Lipid Metabolism; Liver; Male; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Up-Regulation | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biosensing Techniques; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Hydrogen Peroxide; Irinotecan; Luminescence; Mice, SCID; Nanotubes, Carbon; Pancreatic Neoplasms; Spectrum Analysis, Raman; Xenograft Model Antitumor Assays | 2019 |
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interleukin-6; Leukemia Inhibitory Factor; Mice; Mutation; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2019 |
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Computational Biology; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Pancreatic Neoplasms; Prognosis; Protein Interaction Maps; Survival Rate; Tumor Cells, Cultured | 2019 |
Tumor-specific delivery of gemcitabine with activatable liposomes.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liposomes; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Temperature | 2019 |
Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2020 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreas; Pancreatic Neoplasms; Phenotype; Zinc Finger E-box-Binding Homeobox 1 | 2019 |
Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carrier Proteins; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Signal Transduction | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2020 |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptome | 2019 |
Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Theoretical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2019 |
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Nanocapsules; Nanotechnology; Pancreatic Neoplasms; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2013 |
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays | 2013 |
Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Xenograft Model Antitumor Assays | 2013 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma in Situ; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Xenograft Model Antitumor Assays | 2013 |
miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transfection; Xenograft Model Antitumor Assays | 2013 |
Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.
Topics: Animals; Autophagy; Biomarkers, Pharmacological; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Organ Specificity; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2013 |
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Liver Neoplasms; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Receptors, Transferrin; Single-Chain Antibodies; Tumor Burden | 2013 |
Chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Fluids; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Designer Drugs; Disease Models, Animal; Gemcitabine; Gold; Humans; Immunohistochemistry; Light; Male; Metal Nanoparticles; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoconjugates; Pancreatic Neoplasms; Scattering, Radiation; Static Electricity; Treatment Outcome | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Receptor, Notch3; Receptors, Notch; Retrospective Studies; RNA, Messenger | 2013 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Molecular analysis of the inhibitory effect of N-acetyl-L-cysteine on the proliferation and invasiveness of pancreatic cancer cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Mitomycin; Pancreatic Neoplasms; Reactive Oxygen Species | 2013 |
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Topics: Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Up-Regulation | 2013 |
Evolving panorama of treatment for metastatic pancreas adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Protocols; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Prosthesis Design; Sphincterotomy, Endoscopic; Stents | 2014 |
Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Medicine, Chinese Traditional; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Cycle; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Indoles; MicroRNAs; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Survival Analysis; Treatment Outcome | 2013 |
ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Butadienes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Nitriles; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Tumor Burden | 2013 |
Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Transfection; Xenograft Model Antitumor Assays | 2014 |
Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lentivirus; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2013 |
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Mice; Mice, Mutant Strains; NF-kappa B; Pancreatic Neoplasms; Sesquiterpenes | 2013 |
Drug combination extends late-stage pancreatic cancer survival in Phase III clinical trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; T-Lymphocytes, Regulatory; Tumor Burden | 2013 |
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Sulfasalazine; Tomography, X-Ray Computed | 2013 |
Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Drug Utilization; Female; Gemcitabine; Humans; Male; Medicare; Multivariate Analysis; Neoplasm Staging; Pancreatic Neoplasms; SEER Program; United States | 2013 |
Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium Chloride; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Signal Transduction; Transcription Factors; Zinc Finger Protein GLI1 | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Diffusion; Folic Acid; Gemcitabine; Humans; Materials Testing; Nanocapsules; Pancreatic Neoplasms; Porosity; Treatment Outcome | 2013 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Towards a tailored therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Receptors, CXCR4 | 2013 |
A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Mice, Nude; Nanofibers; Nanotechnology; Neoplasms, Experimental; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tissue Scaffolds; Tumor Cells, Cultured | 2013 |
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Topics: Anilides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; SOXB1 Transcription Factors; Stem Cells | 2013 |
Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer.
Topics: Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Pancreaticoduodenectomy; RNA, Small Interfering | 2013 |
Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Plant Extracts; Trees; Xenograft Model Antitumor Assays | 2013 |
Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Signal Transduction | 2013 |
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Mitoxantrone; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Thiolester Hydrolases | 2013 |
Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.
Topics: Cell Line, Tumor; Collagen Type I; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Acetyltransferases; HMGA2 Protein; Humans; p300-CBP Transcription Factors; Pancreatic Neoplasms | 2013 |
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pyrimidines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cattle; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Gemcitabine; Liposomes; Pancreatic Neoplasms; Pyrazoles; Pyrroles | 2013 |
An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptors, CXCR4; Transcription Factor RelA; Transcription, Genetic; Up-Regulation | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays | 2013 |
Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Polymers; Xenograft Model Antitumor Assays | 2013 |
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridazines; RNA, Small Interfering | 2013 |
Aggressive secondary surgery for local recurrence of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Reoperation; Tomography, X-Ray Computed | 2013 |
miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Transcription Factors; Transfection | 2013 |
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery | 2013 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Radiation-Sensitizing Agents; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2013 |
Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study.
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Ultrasonic Therapy | 2013 |
In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Carbon; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Heavy Ion Radiotherapy; Humans; Pancreatic Neoplasms; Photons; Relative Biological Effectiveness | 2013 |
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Survival Rate; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Protein; Cell Line, Tumor; Cell Movement; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation Mediators; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Serum Amyloid P-Component; Transfection; Treatment Outcome | 2013 |
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Time Factors | 2013 |
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.
Topics: Animals; Antibodies, Neoplasm; Basigin; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Drug Delivery Systems; Female; Gemcitabine; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Tumor Burden | 2014 |
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Connective Tissue Growth Factor; Deoxycytidine; Gemcitabine; Liver Neoplasms; Mice; Pancreatic Neoplasms; Survival Analysis; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytidine Deaminase; Deoxycytidine; Disease Progression; Gemcitabine; Genotype; Humans; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Count; Cell Cycle; Cell Line, Tumor; Coloring Agents; Cytochromes c; Deoxycytidine; Diterpenes; Drug Synergism; Flow Cytometry; Gemcitabine; Gentian Violet; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Endoscopy, Gastrointestinal; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Proton Therapy; Radiation Injuries | 2014 |
Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Furans; Gemcitabine; Humans; Hyaluronoglucosaminidase; Lignans; Mutation; Pancreatic Neoplasms; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recombinant Proteins; RNA Interference; Treatment Outcome | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Osteonectin; Pancreatic Neoplasms; Pharmacogenetics; Transcriptome; Treatment Outcome | 2013 |
Preclinical research in treatment of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Imidazoles; Mice; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach.
Topics: Antimetabolites, Antineoplastic; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Gemcitabine; Genome-Wide Association Study; Humans; Models, Statistical; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Reactive Oxygen Species | 2013 |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Nucleus; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Transcription Factor RelA; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2013 |
Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2014 |
[Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; LIM-Homeodomain Proteins; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2013 |
Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luteolin; Pancreatic Neoplasms; Signal Transduction; Transcription Factor RelA | 2013 |
Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; RNA Interference; Tumor Burden | 2013 |
Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, SCID; Microbubbles; Pancreatic Neoplasms; Reproducibility of Results; Sonication; Survival Analysis; Transducers; Tumor Burden; Ultrasonics; Xenograft Model Antitumor Assays | 2014 |
Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Prognosis; Pulmonary Eosinophilia; Tomography, X-Ray Computed | 2013 |
Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.
Topics: Blotting, Western; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Up-Regulation | 2013 |
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Gemcitabine; Immunohistochemistry; Mice; Mice, Nude; Naphthols; Pancreatic Neoplasms; Sirtuin 1; Survival Analysis | 2013 |
MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Signal Transduction; Wnt Signaling Pathway | 2013 |
A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.
Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Spheroids, Cellular | 2013 |
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Collagen; Deoxycytidine; Disease Models, Animal; Elasticity Imaging Techniques; Endosonography; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography | 2013 |
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; HEK293 Cells; Humans; Pancreatic Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptors, Glucocorticoid; Sequence Analysis, DNA; Survival Analysis; Tacrolimus Binding Proteins | 2013 |
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Delayed-Action Preparations; Deoxycytidine; DNA Methylation; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Nanoparticles; Nucleosides; Pancreatic Neoplasms; Xenopus | 2013 |
Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspases; Cell Line, Tumor; Cytochromes c; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Knockdown Techniques; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms | 2013 |
Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Biomarkers, Tumor; Body Weight; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Genes, ras; Genotype; Immunohistochemistry; Male; Mice; Mice, Transgenic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Random Allocation; Signal Transduction; Treatment Outcome; Vitamin E | 2013 |
Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Aspirin; Carcinoma, Pancreatic Ductal; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Forkhead Transcription Factors; Gemcitabine; Mice; Mice, Transgenic; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2013 |
[Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kidney Neoplasms; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Pancreatic Neoplasms; Taxoids | 2013 |
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Mice; Mice, Knockout; Pancreatic Neoplasms; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.
Topics: 14-3-3 Proteins; Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Line, Tumor; Chromium; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Damage; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Models, Biological; Pancreatic Neoplasms; Protein Biosynthesis; Proto-Oncogene Proteins; Remission Induction; Transcription, Genetic; Tumor Suppressor Protein p53 | 2013 |
Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Hydroxamic Acids; Membrane Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Structure, Tertiary; Thiophenes | 2013 |
Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Drug Synergism; Gemcitabine; Humans; Hypnotics and Sedatives; NF-kappa B; Pancreatic Neoplasms; Propofol | 2013 |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cadherins; Carcinogenesis; Caspase 3; Cell Survival; Claudin-1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease Models, Animal; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression; Genes, Suppressor; Heterozygote; Immediate-Early Proteins; Life Expectancy; Mice; Mice, Knockout; Mucin-1; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2014 |
In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; Indium Radioisotopes; Inhibitory Concentration 50; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Polymers; Receptor, ErbB-2 | 2014 |
In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Agents; Benzophenones; Biological Availability; Biotransformation; Carcinoma; Caspase 3; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression; Half-Life; Hepatocytes; Humans; Injections, Subcutaneous; Ki-67 Antigen; Mice; Mice, Nude; Pancreatic Neoplasms; Phloroglucinol; Primary Cell Culture; Terpenes; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2013 |
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis | 2013 |
Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms | 2013 |
Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Platinum; Retrospective Studies | 2014 |
Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2013 |
Effectivity of long antigen exposition dendritic cell therapy (LANEXDC®) in the palliative treatment of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell- and Tissue-Based Therapy; Cytokines; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Crizotinib; Deoxycytidine; Female; Gemcitabine; Humans; Inactivation, Metabolic; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Chemokine CXCL12; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Vascular Endothelial Growth Factor D; Vesicular Transport Proteins | 2013 |
Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.
Topics: 1-Methyl-3-isobutylxanthine; Amides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphodiesterase Inhibitors; Pyridines; Quinolones; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; rhoC GTP-Binding Protein; Vasodilator Agents | 2015 |
[Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2013 |
uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors.
Topics: AC133 Antigen; Adenoviridae; Adenovirus E1A Proteins; Animals; Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CD24 Antigen; Cell Adhesion Molecules; Deoxycytidine; Epithelial Cell Adhesion Molecule; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Oncolytic Virotherapy; Pancreatic Neoplasms; Peptides; Promoter Regions, Genetic; Receptors, Urokinase Plasminogen Activator; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Topics: Animals; Cell Line, Tumor; Collagen; Deoxycytidine; Drug Carriers; Drug Combinations; Endothelial Cells; Female; Gemcitabine; Humans; Laminin; Liposomes; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Polyethylene Glycols; Polyethyleneimine; Proteoglycans; Signal Transduction; Silicon Dioxide; Smad2 Protein; Transforming Growth Factor beta | 2013 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2014 |
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Metalloproteases; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carbon; Cell Cycle; Cell Line, Tumor; Cell Separation; Chemoradiotherapy; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Glioblastoma; Humans; Ions; Lung Neoplasms; Paclitaxel; Pancreatic Neoplasms; Photons; Propidium; Radiotherapy; Relative Biological Effectiveness; Time Factors | 2013 |
Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.
Topics: Aldehyde Dehydrogenase; Analysis of Variance; Animals; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disulfiram; Drug Delivery Systems; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction | 2013 |
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gabexate; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Serine Proteinase Inhibitors; Vascular Endothelial Growth Factor A | 2014 |
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Binding; Receptors, Tumor Necrosis Factor, Member 6b; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Tumor Necrosis Factor Ligand Superfamily Member 14; Xenograft Model Antitumor Assays | 2013 |
Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorescent Antibody Technique; Gemcitabine; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inositol Phosphates; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Oxygen; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Pulmonary; Paclitaxel; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Ultrasonography, Doppler | 2013 |
Chin tremors associated with paroxetine in a patient with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anxiety; Chemotherapy, Adjuvant; Chin; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tremor; Withholding Treatment | 2013 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.
Topics: 3' Untranslated Regions; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2014 |
Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Peroxiredoxins; Tumor Cells, Cultured | 2013 |
Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperbaric Oxygenation; In Vitro Techniques; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors | 2014 |
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors | 2015 |
Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression; Glycoproteins; Humans; Immunophenotyping; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phenotype; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Vaccination | 2014 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Quercetin | 2013 |
Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Topics: Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Notch; Signal Transduction | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms | 2013 |
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bombesin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; RNA, Small Interfering; Survivin; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2016 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pyrazoles; Pyrimidines; Recombinational DNA Repair; S Phase Cell Cycle Checkpoints; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrazones; Mice; NF-E2-Related Factor 2; Pancreatic Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
[Effect of high-intensity focused ultrasound combined with gemcitabine on subcutaneous pancreatic cancer in nude mice].
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2013 |
Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms | 2014 |
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antibody Specificity; Antimetabolites, Antineoplastic; B-Lymphocytes; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin; Pancreatic Neoplasms; Peptide Fragments; Tumor Escape | 2014 |
Gemcitabine-induced myopathy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Muscle, Skeletal; Muscular Diseases; Pancreatic Neoplasms; Quadriceps Muscle; Thigh | 2014 |
Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Topics: Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Dendritic Cells; Deoxycytidine; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic | 2014 |
[Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; T-Lymphocytes | 2013 |
[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
[Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
[A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2013 |
[A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2013 |
[Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines | 2013 |
MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells.
Topics: Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Transcription Factors; Tumor Suppressor Proteins | 2014 |
Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreatic Neoplasms; Polysaccharides; Tumor Cells, Cultured | 2014 |
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Signal Transduction; Transcription, Genetic; Xenograft Model Antitumor Assays | 2014 |
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Deoxycytidine; Drug Evaluation; Fatal Outcome; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Salvage Therapy; Treatment Outcome | 2014 |
Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Toll-Like Receptor 4; Xenograft Model Antitumor Assays | 2014 |
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Red Fluorescent Protein; Salmonella Infections; Salmonella typhimurium; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2014 |
Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Receptor, PAR-1; Signal Transduction; Stromal Cells; Tumor Cells, Cultured | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Histones; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Glycosides; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes | 2014 |
Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Forkhead Box Protein O3; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; rho GTP-Binding Proteins; RNA Interference; Sirtuin 1; Tumor Suppressor Protein p53 | 2014 |
Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Down-Regulation; Drug Synergism; Enzyme Activation; Gemcitabine; Glaucarubin; Humans; Mice; Mice, Nude; p21-Activated Kinases; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.
Topics: Adenocarcinoma; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Radio Waves; Xenograft Model Antitumor Assays | 2014 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Wortmannin | 2014 |
Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Female; Gelatin; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; Mice; Mice, SCID; Nanoparticles; Oxidation-Reduction; Pancreatic Neoplasms; Plasmids; Random Allocation; Xenograft Model Antitumor Assays | 2014 |
Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Discriminant Analysis; Drug Resistance, Neoplasm; Gemcitabine; Humans; Least-Squares Analysis; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Pancreatic Neoplasms; Principal Component Analysis | 2014 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Random Allocation; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microvessels; Naphthoquinones; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Male; Mice; Middle Aged; Neuropilin-1; Oligopeptides; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Histones; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cellulose; Deoxycytidine; Drug Carriers; Gemcitabine; Hyperthermia, Induced; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Up-Regulation | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Proteins; ORAI1 Protein; Pancreatic Neoplasms; RNA, Small Interfering; Stromal Interaction Molecule 1 | 2014 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pain Measurement; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Tegafur | 2014 |
Patients with advanced disease: the value of patient reported outcomes.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Pain; Pancreatic Neoplasms; Quality of Life | 2014 |
Is there a role for second line therapy in advanced pancreatic cancer?
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy; Drug Therapy, Combination; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; ELAV Proteins; ELAV-Like Protein 1; Fluorouracil; Follow-Up Studies; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Protein Transport; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Interactions; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2014 |
Long-term management of gemcitabine in a patient with advanced pancreatic cancer undergoing haemodialysis.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; CA-19-9 Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models | 2014 |
Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
(125)I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2014 |
CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Helicases; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Pancreatic Neoplasms; Proportional Hazards Models; Random Allocation; Survival Analysis; Xenograft Model Antitumor Assays | 2014 |
The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interferon Regulatory Factor-1; Interferon Regulatory Factor-2; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Drug Stability; Gemcitabine; Humans; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Surface Properties; Technology, Pharmaceutical | 2014 |
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nomograms; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Male; Middle Aged; Models, Statistical; Pancreatic Neoplasms; Platinum Compounds; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Venous Thromboembolism; Venous Thrombosis | 2014 |
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lactate Dehydrogenases; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2014 |
Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Topics: Adenocarcinoma; Age Factors; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2014 |
Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; NEDD8 Protein; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Processing, Post-Translational; Proteins; Proteome; Proteomics; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; Signal Transduction; SUMO-1 Protein; Tandem Mass Spectrometry; TOR Serine-Threonine Kinases; Ubiquitin; Ubiquitins; Wnt1 Protein | 2014 |
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Pyrimidines; Retinal Dehydrogenase; Thiazoles | 2014 |
Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Elastin; Feasibility Studies; Female; Gemcitabine; Humans; Hypothermia, Induced; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Recombinant Fusion Proteins; Retinoblastoma Protein; S Phase Cell Cycle Checkpoints; Time Factors; Xenograft Model Antitumor Assays | 2014 |
The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells?
Topics: AC133 Antigen; Animals; Antigens, CD; Biomarkers, Tumor; Carcinogenesis; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Spheroids, Cellular; Up-Regulation | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Immunohistochemistry; Losartan; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclophilins; Cyclosporine; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pancreatic Neoplasms; Peptidyl-Prolyl Isomerase F; Protein Conformation; Protein Serine-Threonine Kinases; Protein Transport; Reactive Oxygen Species | 2014 |
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Communication; Cell Proliferation; Connexin 43; Deoxycytidine; Drug Resistance, Neoplasm; Gap Junctions; Gemcitabine; Humans; Immunoenzyme Techniques; Isothiocyanates; Microscopy, Electron; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Spheroids, Cellular; Sulfoxides; Tumor Cells, Cultured | 2014 |
Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plant Extracts; Rauwolfia; Tumor Burden | 2014 |
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Deoxycytidine; Enzyme Inhibitors; Female; Fibrinolytic Agents; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2014 |
Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?
Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Recurrence | 2015 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2014 |
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Disease Progression; DNA; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; Treatment Outcome | 2014 |
Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Femoral Artery; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2014 |
HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Extracellular Matrix; Female; Gemcitabine; Glutathione; Humans; Hydrolysis; Lipid Bilayers; Lipopeptides; Matrix Metalloproteinase 9; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphatidylcholines; Polyethylene Glycols; Transport Vesicles | 2014 |
Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Stability; Gemcitabine; Humans; Immunohistochemistry; Ligands; Male; Mice, Nude; Micelles; MicroRNAs; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Polymers; Transfection; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Benzodiazepinones; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; DNA Damage; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Pyrazoles; Radioimmunotherapy; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Topics: Active Transport, Cell Nucleus; Animals; Antibiotics, Antineoplastic; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Smad4 Protein; Time Factors; Transfection; Up-Regulation | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Doxorubicin; Energy Metabolism; Gemcitabine; Glycolysis; Humans; Hydrogen; Metformin; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2014 |
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Choline; Deoxycytidine; Diphosphates; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured | 2014 |
Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Female; Gemcitabine; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Thiazolidinediones; Xenograft Model Antitumor Assays | 2014 |
Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Berberine; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; Receptor, Notch1; RNA, Messenger; Side-Population Cells; Signal Transduction; SOXB1 Transcription Factors | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
[Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Telomerase | 2014 |
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase | 2014 |
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Mucin-1; Pancreatic Neoplasms; RNA, Messenger; T-Lymphocytes, Cytotoxic; Transfection | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; Side-Population Cells; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2014 |
BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Helicases; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Nude; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Transfection; Xenograft Model Antitumor Assays | 2014 |
Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genes, p53; Genes, ras; Homeodomain Proteins; Mice; Mice, Transgenic; NF-kappa B; Pancreatic Neoplasms; Pancreatitis, Chronic; Phosphorylation; STAT3 Transcription Factor; Systemic Inflammatory Response Syndrome; Trans-Activators; Treatment Outcome | 2014 |
Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Doxorubicin; Drug Repositioning; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Nitriles; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Quinolines; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Models, Animal; Female; Gastrointestinal Hormones; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neuropeptides; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2014 |
Dynamic contrast-enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer.
Topics: Animals; Contrast Media; Deoxycytidine; Gemcitabine; Heterografts; High-Intensity Focused Ultrasound Ablation; Humans; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; Ribonucleotide Reductases; Transplantation, Heterologous; Treatment Outcome; Ultrasonography | 2014 |
The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Necrosis; Pancreatic Neoplasms; Pyrimidines; TOR Serine-Threonine Kinases | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Topics: Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Peptides; Prodrugs; Squalene | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
[Down-regulation of Notch1 by small interfering RNA enhances chemosensitivity to gemcitabine in pancreatic cancer cells through activating apoptosis activity].
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; Receptor, Notch1; RNA, Small Interfering; Signal Transduction | 2014 |
The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Diabetes Mellitus; Docetaxel; Fasting; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Paraneoplastic Syndromes; Retrospective Studies; Single-Blind Method; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Transgenic; Neoplastic Stem Cells; Nuclear Proteins; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors | 2014 |
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Chick Embryo; Deoxycytidine; Female; Gemcitabine; Glucose; Glycolysis; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Mice, Inbred Strains; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyruvates; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Histamine Agonists; Histamine H3 Antagonists; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Thiourea; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
[Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 2; Caspase 8; Caspase 9; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cysteine Endopeptidases; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Time Factors | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; NIH 3T3 Cells; Pancreatic Neoplasms; Random Allocation; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2014 |
Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.
Topics: bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Histones; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Tumor Suppressor Protein p53 | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
Phase 1 trials in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Pharmacogenetics in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Treatment Outcome | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
PARP-inhibitors in BRCA-associated pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Analysis; Treatment Outcome | 2014 |
Adjuvant treatment for pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Macrophage Colony-Stimulating Factor; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Random Allocation; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Cell Surface; Signal Transduction; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2015 |
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prevalence; Randomized Controlled Trials as Topic; United States; Vitamin D; Vitamin D Deficiency; White People | 2014 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines.
Topics: Antineoplastic Agents; Cell Line; Dendrimers; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Magnetite Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tretinoin; Tumor Cells, Cultured | 2014 |
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Topics: Biomarkers, Tumor; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cyclin G2; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms | 2014 |
Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Indiana; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Universities | 2017 |
Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endoglin; Gemcitabine; Humans; Ligands; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Pancreatic Neoplasms; Peptides; Random Allocation; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2014 |
DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; DNA-Activated Protein Kinase; Enzyme Activation; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2014 |
[The study of clinical value of transarterial chemical perfusion as second-line therapy for late stage pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2014 |
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Murine-Derived; Antihypertensive Agents; Antimetabolites, Antineoplastic; Blood Component Transfusion; Deoxycytidine; Disease Management; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension; Kidney Failure, Chronic; Nursing Assessment; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Rituximab | 2014 |
Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzoates; Benzylamines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Liver X Receptors; Male; Microarray Analysis; Middle Aged; Neoplasm Proteins; Orphan Nuclear Receptors; Pancreatic Neoplasms; Signal Transduction | 2014 |
Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clone Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2015 |
Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.
Topics: 14-3-3 Proteins; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Pancreatic Neoplasms; Ribonucleotide Reductases; Ubiquitin-Protein Ligases; Up-Regulation | 2014 |
Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Betulinic Acid; Carrier Proteins; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Membrane Proteins; Pancreatic Neoplasms; Pentacyclic Triterpenes; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Triterpenes; Tumor Cells, Cultured | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2014 |
Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Colorimetry; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Pancreatic Neoplasms; Photinia; Phytotherapy; Plants, Medicinal; Polyphenols | 2014 |
Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luteolin; Male; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Argininosuccinate Synthase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Hydrolases; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Diterpenes, Kaurane; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2014 |
[Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
Silencing of STRN4 suppresses the malignant characteristics of cancer cells.
Topics: Animals; Anoikis; Calmodulin-Binding Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Experimental; Nerve Tissue Proteins; Pancreatic Neoplasms; RNA, Small Interfering | 2014 |
A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Densitometry; Deoxycytidine; Drug Resistance, Neoplasm; Free Radical Scavengers; Gemcitabine; Homeostasis; Humans; Inhibitory Concentration 50; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Organogold Compounds; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Protein Binding; Reactive Oxygen Species; Thioredoxin-Disulfide Reductase; Thioredoxins | 2014 |
N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.
Topics: Acetylcysteine; Animals; Apoptosis; Cell Line, Tumor; Cysteine; Deoxycytidine; Gemcitabine; Glutathione; Humans; Male; Mice; Mice, Nude; NF-kappa B; Oxidative Stress; Pancreatic Neoplasms; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome | 2014 |
Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro.
Topics: Animals; Baclofen; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; GABA Agonists; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Deoxycytidine; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Humans; Lysine; Mice; Pancreatic Neoplasms; Peptide Initiation Factors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridones; ras Proteins; RNA-Binding Proteins | 2014 |
A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Polypropylenes; Repressor Proteins; RNA Interference; Ubiquitin-Protein Ligases | 2015 |
Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mucin-4; Pancreatic Neoplasms; Peptides, Cyclic; Small Molecule Libraries | 2014 |
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Rabbits; Sensitivity and Specificity; Tissue Array Analysis | 2015 |
WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein; RNA, Messenger; Wnt Proteins; Wnt-5a Protein | 2014 |
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Tumor Suppressor Protein p53 | 2015 |
Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Severity of Illness Index; Survival Rate; Tegafur | 2015 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Radiotherapy, Conformal; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreas; Pancreatic Neoplasms; S Phase | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; PPAR gamma; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2015 |
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Naphthoquinones; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survivin; Xenograft Model Antitumor Assays | 2015 |
Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Mice, Inbred BALB C; Mice, Nude; Nigella sativa; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; GPI-Linked Proteins; Male; Mesothelin; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Proportional Hazards Models; Renin-Angiotensin System; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Regulation; Genetic Engineering; Herpesvirus 1, Human; Humans; Injections, Intralesional; Mice; Mice, Nude; Neoplasm Transplantation; Oncolytic Virotherapy; Pancreas; Pancreatic Neoplasms; Promoter Regions, Genetic; Trans-Activators; Tumor Burden; Viral Proteins | 2015 |
Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancreatic Neoplasms | 2014 |
Transport Oncophysics in silico, in vitro, and in vivo. Preface.
Topics: Biophysics; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Medical Oncology; Nanomedicine; Pancreatic Neoplasms | 2014 |
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; DNA Adducts; DNA, Neoplasm; Drug Delivery Systems; Gemcitabine; Humans; Injections, Intravenous; Pancreatectomy; Pancreatic Neoplasms; Tissue Distribution; Tomography Scanners, X-Ray Computed; Tumor Microenvironment | 2014 |
Nuclear FAM21 participates in NF-κB-dependent gene regulation in pancreatic cancer cells.
Topics: Cell Line, Tumor; Cell Nucleus; Chromatin; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Microfilament Proteins; NF-kappa B; Nuclear Localization Signals; Pancreatic Neoplasms; Phosphate-Binding Proteins; Protein Binding; Proteins; Transcription Factor RelA | 2015 |
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Splenic Artery; Splenic Vein | 2015 |
Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Ki-67 Antigen; Mice; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Pancreatic Neoplasms; Prodrugs; Squalene; Xenograft Model Antitumor Assays | 2015 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Autophagy-Related Protein 7; Beclin-1; Biological Transport; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression; Glucose; Humans; Membrane Proteins; Metabolic Networks and Pathways; Neoplasm Proteins; Pancreatic Neoplasms; Stress, Physiological; Ubiquitin-Activating Enzymes | 2014 |
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Immunoblotting; MAP Kinase Kinase 4; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; RNA, Small Interfering; Transfection | 2015 |
PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway.
Topics: Animals; Cardiac Glycosides; Cell Cycle; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nerium; Pancreatic Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Heterografts; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Protein Array Analysis; Proteomics; Tumor Cells, Cultured | 2015 |
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Chromatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Pancreatic Neoplasms; Phenotype | 2015 |
Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; In Vitro Techniques; Lactic Acid; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanospheres; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; E2F1 Transcription Factor; Gemcitabine; Humans; Hydrolases; Mice, Nude; Pancreatic Neoplasms; Polyethylene Glycols; Ribonucleoside Diphosphate Reductase; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diuretics; Female; Gemcitabine; Heart Failure; Humans; Paclitaxel; Pancreatic Neoplasms | 2014 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Matrix Metalloproteinase 13; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mucin-1; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2015 |
Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Flow Cytometry; G1 Phase; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors | 2015 |
Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics | 2014 |
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weight; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate | 2015 |
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Indoles; Neoplasms, Experimental; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2015 |
Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Isothiocyanates; Mice; Mice, Inbred NOD; Mice, SCID; NF-E2-Related Factor 2; NF-kappa B; Oxidation-Reduction; Pancreatic Neoplasms; Reactive Oxygen Species; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
[Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Blood Urea Nitrogen; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate | 2014 |
A bioengineered murine model using CD24⁺CD44⁺ pancreatic cancer stem cells for chemotherapy study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomedical Engineering; Camptothecin; CD24 Antigen; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Tissue Scaffolds | 2014 |
Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Oncogene Protein v-akt; Pancreatic Neoplasms; Reactive Oxygen Species; Ribonucleases; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2015 |
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; HMGB1 Protein; Hypoxia-Inducible Factor 1, alpha Subunit; Immunization; Mice, Inbred C57BL; Mice, Nude; Microscopy, Fluorescence; Mustard Compounds; Pancreatic Neoplasms; Phenylpropionates; Phosphorylation; Survival Analysis; T-Lymphocytes; Transcription Factors; Tumor Burden | 2015 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Inflammation; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2015 |
KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Arsenites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gemcitabine; Humans; Matrix Metalloproteinase 2; Pancreatic Neoplasms; Sodium Compounds; Vascular Endothelial Growth Factor C | 2015 |
Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Cytokines; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Treatment Outcome; Vaccination; WT1 Proteins | 2015 |
A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Damage; Gemcitabine; Gene Library; Histones; Homologous Recombination; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Rad51 Recombinase; Receptors, Calcitriol; RNA Interference; RNA, Small Interfering; Tumor Suppressor p53-Binding Protein 1 | 2014 |
Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2015 |
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; cdc25 Phosphatases; Cricetinae; Deoxycytidine; Gemcitabine; Humans; Mesocricetus; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Promoter Regions, Genetic; Xenograft Model Antitumor Assays | 2015 |
Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Renal Insufficiency; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autocrine Communication; Cell Line, Tumor; Chemokine CXCL12; Culture Media, Conditioned; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Receptors, CXCR4; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2015 |
Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer.
Topics: Annexin A2; Calcium; Cell Line, Tumor; Cell Nucleus; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, Neoplasm; Humans; Intracellular Space; Pancreatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Protein Subunits; Protein Transport; Signal Transduction; Structure-Activity Relationship; Transcription Factor RelA; Transcription, Genetic; Tumor Necrosis Factor-alpha; Up-Regulation | 2015 |
Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; HSP27 Heat-Shock Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreas; Pancreatic Neoplasms; Phosphorylation | 2015 |
Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polymers; Tumor Burden | 2015 |
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2015 |
Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Reactive Oxygen Species; Treatment Outcome; Up-Regulation | 2015 |
BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression; Genetic Variation; Hepatocyte Nuclear Factor 1-alpha; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomimetic Materials; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Saponins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Momordica charantia; Oxygen Consumption; Pancreatic Neoplasms; Plant Extracts | 2015 |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Coculture Techniques; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Proportional Hazards Models; Rats; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factor HES-1 | 2015 |
3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Salvage Therapy | 2015 |
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clone Cells; Deoxycytidine; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lipoproteins; MAP Kinase Signaling System; Metabolic Networks and Pathways; Mice; Pancreatic Neoplasms; Phenotype; Prognosis; Receptors, LDL; Up-Regulation | 2015 |
[Chemo-sensitivity study in pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2014 |
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Delivery Systems; Endocytosis; Female; Gemcitabine; Gene Knockdown Techniques; Gene Transfer Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interferon-alpha; Interleukin-6; Kaplan-Meier Estimate; Lipids; Lysosomes; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polymers; RNA, Small Interfering; Serum; Static Electricity | 2015 |
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Combined Modality Therapy; CTLA-4 Antigen; Deoxycytidine; Female; Gemcitabine; Genetic Engineering; Humans; Immune Tolerance; Immunity, Cellular; Interferon-gamma; Lymphocyte Activation; Mice, Inbred C57BL; Pancreatic Neoplasms; T-Lymphocyte Subsets; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dermatologic Agents; Drug Eruptions; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Minocycline; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
Topics: Antimetabolites, Antineoplastic; Benzamidines; Deoxycytidine; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Silicates; Titanium; Tomography, X-Ray Computed | 2015 |
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Hybridomas; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Fever; Gemcitabine; Gold; Hyperthermia, Induced; Liposomes; Mice; Nanotubes; Pancreatic Neoplasms | 2015 |
Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction | 2015 |
Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Ascorbic Acid; Catalase; Catalysis; Deoxycytidine; Drug Synergism; Fluorescent Antibody Technique; Free Radical Scavengers; Gemcitabine; Histones; Humans; Hydrogen Peroxide; Metalloporphyrins; Mice; Mice, Nude; Oxidation-Reduction; Oxidative Stress; Oxygen Consumption; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy].
Topics: Antimetabolites, Antineoplastic; Arteries; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2014 |
[A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2014 |
[A case of resection for a huge pancreatic acinar cell carcinoma with tumor thrombus in the portal vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Prognosis; Tegafur; Thrombosis | 2014 |
[A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Laser Therapy; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[A case of pancreatic pseudocyst associated with pancreatic cancer successfully treated with endoscopic pseudocyst drainage, which allowed continuation of chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drainage; Endoscopy, Digestive System; Fatal Outcome; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Pseudocyst; Stents | 2014 |
[A case of advanced pancreas cancer successfully treated by using combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2015 |
Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cancer Vaccines; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; fas Receptor; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of pancreatic cancer cells.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytidine Deaminase; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipid Bilayers; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Porosity; Silicon Dioxide | 2015 |
Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Adult; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis; United Kingdom | 2015 |
A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tegafur; Treatment Outcome | 2015 |
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Growth Processes; Deoxycytidine; Gemcitabine; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Xenograft Model Antitumor Assays | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome; Vomiting | 2015 |
The complex morphology of acute kidney injury with microangiopathic hemolytic anemia and hyposplenism.
Topics: Acute Kidney Injury; Adenocarcinoma, Mucinous; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Blood Cells; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Microscopy; Middle Aged; Pancreatic Neoplasms; Splenectomy | 2015 |
Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2014 |
[Therapy in pancreatic cancer - and still it moves along!].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Colectomy; Deoxycytidine; Diazoxide; Disease Progression; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Hypoglycemia; Lung Neoplasms; Mitomycin; Nephrectomy; Octreotide; Pancreatectomy; Pancreatic Neoplasms | 2015 |
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleotide Reductases; Tumor Cells, Cultured | 2015 |
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Combined effect of microRNA, nutraceuticals and drug on pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Benzoquinones; Betulinic Acid; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dietary Supplements; Drug Synergism; Gemcitabine; Humans; MicroRNAs; Pancreas; Pancreatic Neoplasms; Pentacyclic Triterpenes; Transfection; Triterpenes | 2015 |
SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo.
Topics: Animals; Apoptosis; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Male; Mice; Micronucleus Tests; Pancreatic Neoplasms; Sirtuin 1 | 2015 |
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Eligibility Determination; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2017 |
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2015 |
Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chick Embryo; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells.
Topics: Albumins; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Pancreatic Neoplasms | 2015 |
Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.
Topics: Animals; Carbon; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemoradiotherapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Heavy Ion Radiotherapy; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.
Topics: Antimetabolites, Antineoplastic; CD24 Antigen; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fucose; Fucosyltransferases; Galactoside 2-alpha-L-fucosyltransferase; Gemcitabine; Glycosylation; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA Interference; Spheroids, Cellular; Transfection | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2015 |
Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Metformin; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation | 2015 |
[Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2015 |
Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glycoproteins; Glycosylation; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polysaccharides; Prognosis; Retrospective Studies; Survival Analysis | 2015 |
MGMT inhibition suppresses survivin expression in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; RNA Interference; Survivin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tumor Cells, Cultured | 2015 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2015 |
Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Paclitaxel; Pancreatic Neoplasms | 2015 |
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Topics: Activins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Self Renewal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p57; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Nodal Protein; Pancreatic Neoplasms; RNA, Long Noncoding; Signal Transduction; T-Box Domain Proteins; Transcriptome; Transforming Growth Factor beta1 | 2015 |
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Immunotherapy; Macrophages; Mice; Pancreatic Neoplasms | 2015 |
The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; Survival Analysis | 2015 |
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2015 |
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Male; Membrane Transport Proteins; Mice, SCID; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Pancreas; Pancreatic Neoplasms; Poria; Regulatory Factor X Transcription Factors; Signal Transduction; Taurochenodeoxycholic Acid; Transcription Factor CHOP; Transcription Factors; Triterpenes; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2015 |
Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Serum; Survival Analysis; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2016 |
Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Period; Prognosis; Retrospective Studies | 2015 |
Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Hydrazines; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gemcitabine; Glycosides; Humans; Lipid Peroxidation; Mice; Mice, Nude; Pancreatic Neoplasms; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Histones; Humans; Pancreatic Neoplasms; Valproic Acid | 2015 |
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Lymphocyte Activation; MAP Kinase Signaling System; Monocytes; Myeloid Cells; NF-kappa B; Pancreatic Neoplasms; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2015 |
Gemcitabine Induces Radiosensitization Through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; Gamma Rays; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2015 |
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Signal Transduction | 2015 |
Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Spain | 2015 |
Multidisciplinary management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2015 |
Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peptides; Snail Family Transcription Factors; Transcription Factors | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; S Phase | 2015 |
In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS- Mediated Signalling Pathways.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Capillary Leak Syndrome; Cell Line, Tumor; Cell Survival; Deoxycytidine; Electric Impedance; Flavanones; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Intercellular Adhesion Molecule-1; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; rac1 GTP-Binding Protein; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53; Vascular Cell Adhesion Molecule-1 | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Signal Transduction; Time Factors; Transcription Factors; Tretinoin | 2015 |
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane Permeability; Deoxycytidine; DNA Replication; Etoposide; Fluorouracil; Gemcitabine; Humans; Minichromosome Maintenance Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Treatment Outcome | 2015 |
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays; Zidovudine | 2015 |
Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carrier Proteins; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Tumor Cells, Cultured | 2015 |
miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Wnt Signaling Pathway | 2015 |
Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines.
Topics: Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; ras Proteins; RNA, Messenger; Tumor Suppressor Protein p53 | 2015 |
High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGB1 Protein; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Up-Regulation | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Drug Synergism; G2 Phase; Gemcitabine; Humans; Mitosis; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Tumor Suppressor Protein p53 | 2015 |
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Reoviridae | 2015 |
miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.
Topics: Cell Line; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Promoter Regions, Genetic; Transforming Growth Factor beta; Ubiquitin-Protein Ligases | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Culture Media; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fasting; Female; Fetal Blood; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Mice, Nude; Microscopy, Fluorescence; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; I-kappa B Proteins; Male; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Pancreatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Inhibition of Human Pancreatic Cancer Cell Proliferation by Devil's Club Oplopanax horridus and Its Polyacetylene Bioactive Compound.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Oplopanax; Paclitaxel; Pancreatic Neoplasms; Plant Extracts; Plant Roots; Polyynes; Signal Transduction | 2015 |
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Urokinase Plasminogen Activator; Virus Replication; Xenograft Model Antitumor Assays | 2015 |
Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Micelles; NIH 3T3 Cells; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Pyrans; Solubility; Surface Properties; Xenograft Model Antitumor Assays | 2015 |
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Knockdown Techniques; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Transplantation, Isogeneic; Tumor Burden; Tumor Suppressor Proteins; Ubiquitination | 2015 |
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Pyruvate Kinase | 2016 |
[A Retrospective Study of Chinese Herbal Medicine Combined with Systemic Chemotherapy and/or Regional Arterial Perfusion for Pancreatic Cancer with Liver Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Complementary Therapies; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins | 2015 |
Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Models, Theoretical; Pancreatic Neoplasms | 2015 |
Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Topics: Acenaphthenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribonucleotides; Staining and Labeling; Trypan Blue | 2015 |
Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Molecular Targeted Therapy; Neoplasm Staging; Osteonectin; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; STAT3 Transcription Factor; Stromal Cells; Time Factors; Transcription Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Transfection; Up-Regulation | 2015 |
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proteomics; Survival Rate; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2015 |
The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Membrane Proteins; Mice, SCID; Multiprotein Complexes; Pancreatic Neoplasms; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2015 |
Quercetin Mediates β-Catenin in Pancreatic Cancer Stem-Like Cells.
Topics: Antimetabolites, Antineoplastic; Antioxidants; beta Catenin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Microscopy, Confocal; Neoplastic Stem Cells; Pancreatic Neoplasms; Quercetin; Spheroids, Cellular | 2015 |
Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Radiation Injuries; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Risk Assessment; Survival Analysis | 2018 |
Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Nestin; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |
The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Interference; Snail Family Transcription Factors; Transcription Factors | 2015 |
Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Cell Count; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Smoking; Treatment Outcome | 2015 |
Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms | 2016 |
Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.
Topics: AC133 Antigen; Animals; Antigens, CD; Antigens, Ly; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD24 Antigen; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glycoproteins; Luciferases; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Peptides; Phenotype; Proto-Oncogene Proteins p21(ras); Pyrans; Spheroids, Cellular; Staining and Labeling; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Gene Knockdown Techniques; Glycoproteins; Humans; Metformin; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phosphorylation; Prognosis; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcohol-Related Disorders; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Pneumonia; Retrospective Studies; Risk Factors; Severity of Illness Index; Smoking | 2016 |
DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; beta Catenin; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Chemokines; Deoxycytidine; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice, Nude; Microscopy, Confocal; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coumaric Acids; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Signal Transduction | 2015 |
Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib.
Topics: Apoptosis; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphorylation; Signal Transduction | 2015 |
Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Topics: alpha-Tocopherol; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Stability; Drug Storage; Female; Gemcitabine; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Prodrugs; Vitamin E | 2015 |
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2015 |
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.
Topics: Adaptive Immunity; Cell Line, Tumor; Chemokine CXCL10; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; HLA Antigens; Humans; Interferon-gamma; Interferons; Pancreatic Neoplasms; Receptors, CXCR3; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation.
Topics: Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; In Vitro Techniques; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2015 |
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biological Assay; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; RGS Proteins | 2015 |
Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Melatonin; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Topics: Aged; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Immunity, Innate; Male; Middle Aged; Neoadjuvant Therapy; NK Cell Lectin-Like Receptor Subfamily K; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Receptors, IgG; Signal Transduction; T-Lymphocytes, Cytotoxic | 2017 |
In vitro immunomodulatory properties of gemcitabine alone and in combination with interferon-alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-1 Antigen; B7-2 Antigen; CD4-CD8 Ratio; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dendritic Cells; Deoxycytidine; Flow Cytometry; Gemcitabine; Interferon-alpha; Mice, Inbred C57BL; Pancreatic Neoplasms; Spleen; T-Lymphocytes; T-Lymphocytes, Regulatory | 2015 |
Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Crystallization; Deoxycytidine; Drug Liberation; Drug Stability; Drug Storage; Ferric Compounds; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Metal Nanoparticles; Organometallic Compounds; Pancreatic Neoplasms; Phosphates; Polymers; Prodrugs | 2015 |
Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Necrosis; Nuclear Pore Complex Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Signal Transduction; Tumor Cells, Cultured | 2015 |
Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured | 2015 |
[Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2015 |
The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-met; Receptor, ErbB-3; Retinoids; Signal Transduction; Transcriptional Activation; Tretinoin; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells.
Topics: Amino Acid Sequence; Antineoplastic Agents; Buthionine Sulfoximine; Cathepsin B; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Deoxycytidine; Dipeptides; Endocytosis; Fluorescent Dyes; Gemcitabine; Glutathione; Humans; Integrin alphaVbeta3; Oxidation-Reduction; Pancreatic Neoplasms; Prodrugs | 2015 |
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Acetamides; Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cyclohexylamines; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice, Nude; Neoplasm Proteins; Oxidative Stress; Pancreatic Neoplasms; Protein Biosynthesis; Protein Phosphatase 1; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Maytansine; Mice; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mesenchymal Stem Cells; Paclitaxel; Pancreatic Neoplasms | 2015 |
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Vorinostat | 2016 |
Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Interactions; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2016 |
The MRTF-A/B function as oncogenes in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Trans-Activators; Transcription Factors | 2016 |
IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Male; Mice; NF-kappa B; Pancreatic Neoplasms; Receptors, Interleukin-1; Xenograft Model Antitumor Assays | 2016 |
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Models, Biological; Mutation; Organoids; Pancreas; Pancreatic Neoplasms; Pluripotent Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; SOX9 Transcription Factor; Tissue Culture Techniques; Tumor Suppressor Protein p53 | 2015 |
Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Heat Shock Transcription Factors; Heat-Shock Proteins; HMGB1 Protein; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreatic Neoplasms; Polysaccharides; Transcription Factors; Tumor Cells, Cultured | 2015 |
Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Sequence Analysis, RNA; Up-Regulation | 2015 |
Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzothiazoles; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intracellular Space; Luciferases, Firefly; Luminescence; Luminescent Measurements; Mitoxantrone; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation | 2016 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies | 2015 |
C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Reproducibility of Results; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Phosphoproteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2016 |
An indeterminate mucin-producing cystic neoplasm containing an undifferentiated carcinoma with osteoclast-like giant cells: a case report of a rare association of pancreatic tumors.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Giant Cells; Humans; Neoplasms, Multiple Primary; Osteoclasts; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Ultrasonography | 2015 |
Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Interferon-alpha; Models, Molecular; Pancreatic Neoplasms; Peptides; Placenta Growth Factor; Pregnancy Proteins; Protein Conformation; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor | 2015 |
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; DNA Damage; Female; Flow Cytometry; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiation-Sensitizing Agents; Recombinational DNA Repair; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Particle Size; Serum Albumin; Subcutaneous Tissue | 2015 |
Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Fatty Acids, Omega-3; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Receptors, Platelet-Derived Growth Factor | 2016 |
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dioxoles; Drug Synergism; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2016 |
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cluster Analysis; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Genes, p53; Humans; MicroRNAs; Mutation; Pancreatic Neoplasms; Reproducibility of Results; RNA Interference; RNA, Messenger | 2015 |
Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2016 |
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2016 |
EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Carriers; ErbB Receptors; Gemcitabine; Humans; Mice; Micelles; Pancreatic Neoplasms; Peptides; Polyesters; Polyethylene Glycols; Polymers | 2016 |
Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Chromones; Deoxycytidine; Gemcitabine; Humans; Morpholines; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Lysosomes; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Sirtuin 1; Thiazoles | 2016 |
EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gelatin; Gemcitabine; Humans; Mice; Mice, SCID; Nanoparticles; Pancreas; Pancreatic Neoplasms | 2016 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Dioxolanes; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hepatocyte Growth Factor; Humans; Inhibitor of Differentiation Protein 1; Mice; Neoplasm Metastasis; Nicotine; Pancreatic Neoplasms; Paracrine Communication; Phosphorylation; Proto-Oncogene Proteins c-met; Signal Transduction; Smoking; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Enzyme Activation; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Pancreatic Neoplasms; RNA Interference; RNA Processing, Post-Transcriptional; Transfection | 2015 |
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Nude; Minor Histocompatibility Antigens; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphorylation; Random Allocation; Ribonucleosides; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2016 |
Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Survivin; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2016 |
Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lectins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2016 |
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Topics: Animals; Antigens, Surface; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2015 |
Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2015 |
A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Acinar Cell; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction | 2016 |
Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; S100 Calcium-Binding Protein A4; S100 Proteins | 2015 |
Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Genes, Reporter; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; HIV-1; Humans; Injections, Subcutaneous; Integrases; Lentivirus; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Viral Proteins | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2016 |
MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; MicroRNAs; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor alpha-Induced Protein 3 | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Topics: Animals; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Indocyanine Green; Ligands; Mice; Nanoparticles; Pancreatic Neoplasms; Particle Size; Photoacoustic Techniques; Porosity; Rats, Nude; Silicon Dioxide; Surface Properties; Theranostic Nanomedicine; Tissue Distribution; Tomography; Urokinase-Type Plasminogen Activator | 2016 |
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Hepatocyte Growth Factor; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2016 |
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Invasiveness; p21-Activated Kinases; Pancreatic Ducts; Pancreatic Neoplasms; Pyridones; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones | 2016 |
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2016 |
Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Pancreatic Neoplasms; Tumor Microenvironment | 2016 |
[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Recurrence; Tegafur | 2015 |
[R0 Resection of Locally Advanced Pancreatic Cancer after Combination Chemotherapy with Gemcitabine and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[A Case of Invasive Ductal Carcinoma in the Fat Replacement of the Pancreatic Body and Tail].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fats; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy | 2015 |
[Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Tegafur; Treatment Outcome | 2015 |
[A Case of Radical Resection for Locally Advanced Pancreatic Cancer with Positive Peritoneal Cytology Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro.
Topics: Cell Line, Tumor; Cell Movement; Databases, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Flavonoids; Gemcitabine; Gene Expression Regulation, Neoplastic; Glucosides; Humans; In Vitro Techniques; Pancreatic Neoplasms; Quercetin; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2016 |
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; Time Factors; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2016 |
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Mice; Microcirculation; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Thrombotic Microangiopathies; Treatment Outcome | 2016 |
Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Aptamers, Nucleotide; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Epoxy Compounds; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Phenanthrenes; Polyethylene Glycols; Polymers; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells.
Topics: Acridine Orange; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Microscopy, Electron, Transmission; Pancreatic Neoplasms; Polymers | 2016 |
Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hypoxia; Immunoenzyme Techniques; Leukemia Inhibitory Factor; Mediator Complex; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2016 |
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sp Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2016 |
The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas, Exocrine; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Propensity Score; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies | 2016 |
Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages.
Topics: Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Interleukins; Macrophages; Neoplasm Proteins; Pancreatic Neoplasms; U937 Cells | 2017 |
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Deoxycytidine; DNA Damage; Down-Regulation; Gemcitabine; Genes, Viral; Humans; Irinotecan; MRE11 Homologue Protein; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2016 |
Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Aspirin; Atorvastatin; Cell Line; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Macrophages; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heavy Ion Radiotherapy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2016 |
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Radiation Tolerance; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Survival Analysis | 2016 |
Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases | 2016 |
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin B1; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitosis; Nocodazole; Pancreatic Neoplasms; Thiophenes; Urea | 2016 |
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; S Phase; Thiophenes; Xenograft Model Antitumor Assays | 2016 |
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autoantigens; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Phosphoproteins; Ribonucleotide Reductases; Transcription Factors; Transfection; Up-Regulation; YAP-Signaling Proteins | 2016 |
The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inflammation; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes; Tumor Microenvironment; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms | 2016 |
Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gemcitabine; Humans; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Renal Dialysis | 2017 |
Optimizing initial chemotherapy for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2016 |
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tumor Burden | 2016 |
A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Creatinine; Deoxycytidine; Diagnosis, Differential; Erythema; Exanthema; Female; Gemcitabine; Humans; Leg; Leukocytosis; Middle Aged; Pancreatic Neoplasms; Withholding Treatment | 2017 |
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Receptor, EphA2; Xenograft Model Antitumor Assays | 2016 |
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; Mice, SCID; Microvessels; Necrosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Perfusion; Xenograft Model Antitumor Assays | 2016 |
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Gemcitabine; Half-Life; Hydrogen-Ion Concentration; Liposomes; Pancreas; Pancreatic Neoplasms; Particle Size; Pharmaceutical Solutions; Rats; Rats, Sprague-Dawley | 2016 |
Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Situ Hybridization; Male; MicroRNAs; Middle Aged; Oligonucleotides; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2016 |
Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inflammation; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2016 |
Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dodecanol; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Propane; Pyridines; Signal Transduction | 2016 |
Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; China; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Correlation of Early Recurrence With In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Pancreas Cancer With Postoperative Gemcitabine Chemotherapy.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Republic of Korea; Retrospective Studies; Tumor Cells, Cultured | 2016 |
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Janus Kinase 2; Mice; Mutation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT3 Transcription Factor | 2016 |
Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Glaucarubin; Mice; Neoplasms, Experimental; Pancreatic Neoplasms | 2016 |
Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Deoxycytidine; Fluorouracil; Gemcitabine; Housing, Animal; Male; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Stress, Psychological | 2016 |
Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Topics: Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Monte Carlo Method; Pancreatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Taiwan | 2016 |
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2016 |
Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; bcl-X Protein; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Small Interfering; STAT5 Transcription Factor | 2016 |
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immune Tolerance; Lectins, C-Type; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Necrosis; Pancreatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2016 |
Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Topics: Amino Acid Oxidoreductases; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Female; Fibrillar Collagens; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Tissue Distribution; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction | 2016 |
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2016 |
[A Case of Primary Cancer of the Pancreas and Colon Treated with the Combination of Gemcitabine and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Silicates; Titanium; Treatment Outcome | 2016 |
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Chemoradiotherapy; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Tomography, X-Ray Computed | 2016 |
Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using (18)F-FDG PET/CT for Monitoring Treatment Response.
Topics: Animals; Antimetabolites, Antineoplastic; Colchicine; Deoxycytidine; Drug Synergism; Female; Fluorodeoxyglucose F18; Gemcitabine; High-Throughput Screening Assays; Humans; Immunoenzyme Techniques; Liliaceae; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Plant Extracts; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Seeds; Toxicity Tests, Acute; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Frequency; HLA-B27 Antigen; HLA-DRB1 Chains; Humans; Infusions, Intravenous; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis | 2016 |
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Drug Combinations; Female; Gemcitabine; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome; Zoledronic Acid | 2016 |
Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Topics: Aminoquinolines; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Butylamines; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Female; Fibroblasts; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, CXCR4; Stromal Cells; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Gemcitabine; Gene Knockdown Techniques; Humans; Intracellular Membranes; Membrane Potential, Mitochondrial; Mice, Nude; Mitochondria; NF-kappa B; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Polycomb Repressive Complex 1; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Mice; Mice, Knockout; MicroRNAs; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Receptors, Mineralocorticoid; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2016 |
Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Berberine; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Pancreas; Pancreatic Neoplasms; Phellodendron; Plant Extracts; Signal Transduction; STAT3 Transcription Factor | 2017 |
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Killer Cells, Natural; Mice; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2016 |
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Topics: 3' Untranslated Regions; Acrylamides; Animals; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Glycolysis; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; MicroRNAs; NAD; Nicotinamide Phosphoribosyltransferase; Pancreatic Neoplasms; Piperidines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Survival; Clone Cells; Deoxycytidine; Diet; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phytochemicals; Quercetin; Sulfoxides | 2016 |
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Tegafur; Treatment Outcome | 2017 |
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Receptors, Interleukin-8B; Signal Transduction; Small Molecule Libraries; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Isoforms; RNA, Small Interfering | 2016 |
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Prodrugs; Recombinant Fusion Proteins; Silicates; Survival Analysis; Titanium; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
Topics: Adenocarcinoma; Aged; Angiopoietin-Like Protein 4; Angiopoietins; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; ROC Curve; Sequence Analysis, RNA; Survival Analysis; Time Factors | 2016 |
Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Pancreatic Ductal; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Integrin beta1; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Cells, Cultured | 2016 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Hypoxia; Pancreatic Neoplasms; Polymers; Tumor Cells, Cultured | 2016 |
Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neuroendocrine Tumors; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Smoking; Stents; Young Adult | 2016 |
Gemcitabine induces cell senescence in human pancreatic cancer cell lines.
Topics: Cellular Senescence; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; E1A-Associated p300 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering | 2016 |
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
Pancreatic Cancer Survival Increases with Chemo Combo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2016 |
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Topics: 8,11,14-Eicosatrienoic Acid; Antineoplastic Agents; Apoptosis; Biocatalysis; Caprylates; Cell Line, Tumor; Cyclooxygenase 2; Delta-5 Fatty Acid Desaturase; Deoxycytidine; Drug Resistance, Neoplasm; Fatty Acid Desaturases; Free Radicals; Gemcitabine; Gene Knockdown Techniques; Humans; Lipid Peroxidation; Pancreatic Neoplasms | 2016 |
Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Killer Cells, Natural; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Fibrosis; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Escape; Tumor Microenvironment | 2016 |
Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell-Derived Microparticles; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Microenvironment | 2016 |
Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Deoxycytidine; Electrochemotherapy; Gemcitabine; Immunocompromised Host; Mice; Mice, Nude; Pancreatic Neoplasms | 2016 |
Pancreatic cancer: cause for optimism?
Topics: Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2016 |
GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Kaplan-Meier Estimate; Male; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden | 2016 |
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Republic of Korea; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pancreatic Neoplasms | 2016 |
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2016 |
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
Topics: Animals; Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Compounding; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Injections, Subcutaneous; Liposomes; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Piperidones; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Topics: Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Binding; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis | 2016 |
Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; beta Catenin; Biomarkers, Tumor; Carrier Proteins; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fenoterol; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MCF-7 Cells; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; Signal Transduction; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2016 |
Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling.
Topics: Animals; Bufanolides; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibility Studies; Female; Fever; Fluorouracil; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Injections, Intra-Arterial; Intestinal Obstruction; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2016 |
Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Coix; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Emulsions; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Seeds; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Endoscopy, Digestive System; Erlotinib Hydrochloride; Female; Gastritis; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; Metformin; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hypoglycemic Agents; Metformin; Mice, Nude; Pancreas; Pancreatic Neoplasms | 2016 |
Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.
Topics: Albumins; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Peptides, Cyclic | 2016 |
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Topics: Acetylation; Adamantane; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase | 2016 |
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Indoles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
[Radiation therapy of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Neoadjuvant Therapy; Organs at Risk; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided | 2016 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histocompatibility Antigens; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Interleukin-8; Male; Mice; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Interleukin-8A; RNA, Small Interfering | 2016 |
Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Flavanones; Gemcitabine; Humans; Hyaluronic Acid; Lipids; Mice; Mice, Inbred C57BL; Nanostructures; Pancreatic Neoplasms; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tissue Array Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice, Nude; NADPH Oxidases; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplastic Stem Cells; NF-kappa B; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Reactive Oxygen Species; Signal Transduction; SOXB1 Transcription Factors; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
[S‑1 versus gemcitabine for adjuvant therapy in pancreatic cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enhancer of Zeste Homolog 2 Protein; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-pim-1; Signal Transduction; Survival Analysis | 2016 |
Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein.
Topics: ADAM10 Protein; Adult; Aged; Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Deoxycytidine; Down-Regulation; Female; Gemcitabine; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Tumor Escape | 2016 |
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis | 2016 |
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Line, Tumor; Coculture Techniques; Cysteine-Rich Protein 61; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction; Statistics, Nonparametric; Survival Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2016 |
Survival variability of controls and definition of imaging endpoints for longitudinal follow-up of pancreatic ductal adenocarcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Follow-Up Studies; Gemcitabine; Longitudinal Studies; Male; Pancreatic Neoplasms; Rats, Inbred Lew; Survival Rate; X-Ray Microtomography | 2017 |
Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2017 |
Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.
Topics: Autophagy; Autophagy-Related Proteins; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Membrane Proteins; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vesicular Transport Proteins | 2016 |
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gemcitabine; Humans; Male; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Topics: Adenine Nucleotide Translocator 1; Adenosine Monophosphate; Adenosine Triphosphate; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cyclophilins; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pancreatic Neoplasms; Peptidyl-Prolyl Isomerase F; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Pancreatic Neoplasms; Phosphoproteins; Resveratrol; RNA Interference; Signal Transduction; Stilbenes; Transcription Factors; YAP-Signaling Proteins | 2016 |
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.
Topics: Actins; Antimetabolites, Antineoplastic; Biomarkers; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Humans; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Signal Transduction; Snail Family Transcription Factors; Vimentin | 2017 |
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Adhesion Molecules; Cell Cycle; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Membrane Proteins; Mutation; Pancreatic Neoplasms | 2016 |
Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2016 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Adenosquamous; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Intraoperative Care; Laparotomy; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Genetic Association Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenomic Variants; Survival Analysis; Treatment Outcome | 2016 |
DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Receptor, Notch1; Receptor, Notch3 | 2016 |
Coadministration of a Gloriosa superba extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Colchicine; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Glycosides; Herb-Drug Interactions; Humans; Liliaceae; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Seeds | 2016 |
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Pancreatic Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Topics: Adenocarcinoma; Animals; Apoptosis; Carbolines; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; DNA Damage; Down-Regulation; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Macrophages; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.
Topics: Autophagy; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Membrane Proteins; MicroRNAs; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; RNA, Long Noncoding; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2016 |
Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Fibroblasts; Gemcitabine; Gene Expression; GTP-Binding Proteins; Humans; Laminin; Mice; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Xenograft Model Antitumor Assays | 2016 |
Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Furans; Gemcitabine; Humans; Ketones; Pancreatic Neoplasms | 2016 |
PEG Grafted-Nanodiamonds for the Delivery of Gemcitabine.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanodiamonds; Pancreatic Neoplasms; Polyethylene Glycols | 2016 |
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Complement Activation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Etanercept; Female; Gemcitabine; Humans; Infliximab; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proportional Hazards Models; Stromal Cells; Time Factors; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2016 |
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Connective Tissue Growth Factor; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Simvastatin; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Curcumin; Deoxycytidine; Diarylheptanoids; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Pancreatic Neoplasms; Prohibitins; Protein Deglycase DJ-1; Protein Interaction Maps; Repressor Proteins; RNA Interference; Signal Transduction; Transcription Factor CHOP; Transfection | 2016 |
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2017 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |
Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Function Tests; Male; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Treatment Outcome | 2017 |
EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Endosonography; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate; Ultrasonography, Interventional | 2017 |
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Mice, Transgenic; Muscle, Skeletal; Pancreatic Neoplasms; Phenylbutyrates; Tumor Burden; Wasting Syndrome; Xenograft Model Antitumor Assays | 2016 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Rate | 2017 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Guanidines; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Markov Chains; Models, Econometric; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; United States | 2017 |
Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Survivin | 2016 |
Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colitis; Deoxycytidine; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Treatment Outcome | 2016 |
Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dendrimers; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Surface Properties; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2017 |
micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine.
Topics: Antagomirs; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Chromones; Deoxycytidine; DNA-Activated Protein Kinase; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; MicroRNAs; Morpholines; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation | 2017 |
MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Glycosylases; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Paclitaxel; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Hypoxia; Tumor Microenvironment; Vincristine; Xenograft Model Antitumor Assays | 2017 |
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Topics: Androstadienes; Cell Line, Tumor; Cell Survival; Chromones; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Wortmannin | 2017 |
Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreas; Pancreatic Neoplasms; Sonication; Ultrasonography | 2016 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Processing, Post-Transcriptional; RNA, Long Noncoding | 2017 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 10; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Topics: Aged; Apoptosis; Biopsy; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2017 |
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; p21-Activated Kinases; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Matrix Metalloproteinase 9; Nanoparticles; Pancreatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Consensus Development Conferences as Topic; Deoxycytidine; Disease Management; Gemcitabine; Humans; Latin America; Pancreatic Neoplasms; Practice Guidelines as Topic | 2016 |
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Triphosphate; Deoxycytidine; Fibroblasts; Floxuridine; Gemcitabine; Humans; Liver; Liver Neoplasms; Mice; Pancreatic Neoplasms; Primary Cell Culture; Tumor Microenvironment | 2018 |
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Interleukin-18; L-Lactate Dehydrogenase; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2017 |
Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsaicin; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Resveratrol; Signal Transduction; Stilbenes | 2017 |
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tertiary Care Centers | 2017 |
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2017 |
Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
Topics: Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2017 |
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2017 |
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells.
Topics: Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Gemcitabine; Glutathione Peroxidase; Heat-Shock Proteins; Humans; Lipid Peroxidation; Mice; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase | 2017 |
[Experience with Gemcitabine plus Nab-Paclitaxel Therapy for Advanced Metastatic Pancreatic Cancer in Our Hospital].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
[A Study of Gemctabine plus Nab-Paclitaxel Therapy for Advanced Local Progressive Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer with Hepatic Arterial Variation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2016 |
[A Case of Remnant Pancreatic Cancer after Pancreatoduodenectomy Successfully Treated Using Chemotherapy and Carbon-Ion Radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heavy Ion Radiotherapy; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Treatment Outcome | 2016 |
[A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[Long-Term Survival in Response to Multimodality Therapy in a Patient with Invasive Pancreatic Cancer with Cyst Formation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cysts; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2016 |
[A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
Topics: Aged; Albumins; Celiac Artery; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2016 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2016 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
[Two Year Recurrence Free Survival after Resection of Cutaneous Metastasis from Pancreatic Cancer - A Case Report].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Recurrence; Skin Neoplasms; Thalamus; Time Factors | 2016 |
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Naphthalenes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Topics: 3' Untranslated Regions; Catalase; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Dynamic Light Scattering; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Reactive Oxygen Species; Superoxide Dismutase | 2017 |
Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ku Autoantigen; Mice; Mice, SCID; Pancreatic Neoplasms | 2017 |
Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Gemcitabine; Humans; Magnetics; Magnetite Nanoparticles; Nanomedicine; Neoplastic Stem Cells; Pancreatic Neoplasms; Surface Properties; Tumor Cells, Cultured | 2017 |
Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
Topics: Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; M Phase Cell Cycle Checkpoints; Neoplasm Proteins; Pancreatic Neoplasms | 2017 |
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoplasmic Reticulum Stress; Female; Gemcitabine; Genes, myc; Genes, ras; Humans; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mesoderm; Mice; Mosaicism; Oncogene Protein p55(v-myc); Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); SMARCB1 Protein; Transcriptome | 2017 |
Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2017 |
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplastic Stem Cells; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Receptors, Notch; Receptors, Urokinase Plasminogen Activator; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Microdissection; MicroRNAs; Pancreatic Neoplasms; Prognosis; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Topics: Catalysis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Tretinoin; Up-Regulation | 2017 |
[Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Clinical impact of circulating tumor cells and therapy response in pancreatic cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Multivariate Analysis; Neoplasm Staging; Neoplastic Cells, Circulating; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2017 |
Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Glycolysis; Humans; Metabolome; Mutation; Paclitaxel; Pancreatic Neoplasms | 2017 |
Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Topics: Aerobiosis; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Doublecortin-Like Kinases; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Up-Regulation | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Phenotype; Receptors, Notch; Ribonucleoside Diphosphate Reductase; Signal Transduction; Tumor Suppressor Proteins; Up-Regulation; Zinc Finger Protein GLI1 | 2017 |
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mucin-4; Pancreas; Pancreatic Neoplasms; Survival Analysis; Sweden | 2017 |
Ecological Factors in Human Development.
Topics: Capecitabine; Deoxycytidine; Friends; Gemcitabine; Humans; Pancreatic Neoplasms; Social Identification | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2017 |
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
Topics: Adenocarcinoma; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chickens; Chorioallantoic Membrane; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Drug Evaluation, Preclinical; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 6; Luminescent Measurements; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Sequence Analysis, DNA; SOX9 Transcription Factor; Tumor Cells, Cultured | 2017 |
Targeting angiogenesis in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Imidazoles; Indazoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor | 2008 |
Nonmetastatic pancreatic cancer: many trials, little progress.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms | 2008 |
Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gemcitabine; Interleukin-2; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Portal Vein; T-Lymphocytes | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatic Neoplasms; Survival Analysis | 2008 |
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Genetic Vectors; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Biosynthesis; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Uridine; Xenograft Model Antitumor Assays | 2008 |
siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Pancreatic Neoplasms; Plasmids; RNA, Small Interfering; Survivin; Transfection | 2009 |
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Ki-67 Antigen; Mice; Mice, Nude; Pancreatic Neoplasms; Panobinostat; Time Factors | 2008 |
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Hexanones; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors | 2009 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
[Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2008 |
[A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Clinical trials probe new therapies for some difficult-to-treat cancers.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Everolimus; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Pancreatic Neoplasms; Sirolimus | 2008 |
New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Meta-Analysis as Topic; Mucin-1; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Rate | 2008 |
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Herbal Medicine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Plant Preparations | 2008 |
The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cystine; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Immunohistochemistry; Microscopy, Fluorescence; Oxidative Stress; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Topics: Animals; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Nucleus; Coculture Techniques; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Etoposide; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; STAT1 Transcription Factor; Transfection | 2008 |
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Taxoids | 2008 |
Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2008 |
Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2008 |
Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tegafur; Treatment Outcome | 2009 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymerase Chain Reaction | 2008 |
The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Prostatic Neoplasms; Transplantation, Heterologous | 2008 |
Nutritional and pharmacologic support in patients with pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Appetite Stimulants; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Megestrol Acetate; Middle Aged; Nutritional Support; Pancreatic Neoplasms; Weight Loss | 2008 |
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Conformal; Registries; Retrospective Studies; Survival Analysis | 2008 |
CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2008 |
Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oncogene Protein p21(ras); Pancreatic Neoplasms; Retinoids | 2009 |
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; Protein Transport; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Acinar cell carcinoma--a rare tumour of the pancreas.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Male; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Splenectomy; Tomography, X-Ray Computed | 2008 |
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Down-Regulation; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proteins; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Prospective Studies; Warfarin | 2008 |
Postoperative adjuvant treatments for biliary tract cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
[An autopsy case of pancreatic cancer with poor performance status due to peritonitis carcinomatosa treated successfully with continuous infusion of low-dose 5-FU with octreotide].
Topics: Antimetabolites, Antineoplastic; Ascites; Autopsy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Peritonitis | 2008 |
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Molecular Structure; Pancreatic Neoplasms; Ribonucleotide Reductases; Stilbenes; Tumor Cells, Cultured | 2009 |
Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays | 2008 |
Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; RNA, Small Interfering; Stathmin; Transforming Growth Factor beta; Tumor Cells, Cultured | 2009 |
[Neoadjuvant intra-arterial oil chemoembolization and adjuvant selective intra-arterial chemoinfusion in the combined treatment of pancreatic cancer].
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Treatment Outcome | 2008 |
Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Cholangitis; Cholecystitis; Cholestasis; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Prosthesis Design; Prosthesis-Related Infections; Retrospective Studies; Stents; Time Factors; Treatment Outcome | 2008 |
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin | 2008 |
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Deoxycytidine; Duodenitis; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Pancreatic Neoplasms; Radiodermatitis; Stomach Ulcer | 2008 |
Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Volume; Combined Modality Therapy; Contrast Media; Deoxycytidine; Extracellular Fluid; Female; Fluid Shifts; Follow-Up Studies; Gemcitabine; Humans; Iopamidol; Male; Middle Aged; Pancreatic Neoplasms; Plasma Volume; Portography; Prospective Studies; Radiotherapy Dosage; ROC Curve; Tomography, Spiral Computed; Treatment Outcome | 2009 |
[Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiosurgery; Remission Induction; Survival Rate; Tegafur | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystadenoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiography | 2008 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; Cyclin B1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glycine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Predictive Value of Tests; Sulfones; Xenograft Model Antitumor Assays | 2009 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Europe; Fluorouracil; Gemcitabine; Humans; Incidence; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; United States | 2008 |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Personalized medicine for pancreatic cancer: a step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms | 2009 |
A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Digestive System Surgical Procedures; Drug Administration Schedule; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2009 |
[Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis; Treatment Failure | 2008 |
Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Male; Mice; Pancreatic Neoplasms; RNA, Small Interfering; Transcription Factor RelA | 2008 |
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; CA-19-9 Antigen; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
Topics: Adult; Aged; Aged, 80 and over; Data Collection; Deoxycytidine; Female; Gemcitabine; Hospitals; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
[A long survival case of unresectable pancreatic cancer by chemoradiotherapy with gemcitabine as key drug].
Topics: Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case report of intra-operative radiotherapy and gemcitabine for unresectable pancreatic body cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms | 2008 |
[S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Prohibitins; Tegafur; Tomography, X-Ray Computed | 2008 |
[Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2008 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Immunologic Factors; Middle Aged; Pancreatic Neoplasms; Plasmapheresis; Retrospective Studies; Rituximab; Vincristine | 2009 |
Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2008 |
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Topics: Biocatalysis; Carbazoles; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Rad51 Recombinase | 2009 |
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.
Topics: Animals; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Viral; Genetic Markers; Humans; Inflammation; Injections, Intravenous; Male; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Vaccinia; Vaccinia virus; Viral Proteins; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Liposomes; Luciferases; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Peritoneal Neoplasms; Transduction, Genetic | 2009 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Analysis | 2009 |
The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apigenin; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; G2 Phase; Gemcitabine; Humans; Mitosis; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; S Phase | 2009 |
Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oncolytic Viruses; Pancreatic Neoplasms; Parvovirus; Rats; Rats, Inbred Lew | 2009 |
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Doxorubicin; Female; Gemcitabine; Humans; Hydrazones; Inhibitory Concentration 50; Mice; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Biomarkers, Tumor; CD24 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Hyaluronan Receptors; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase; Xenograft Model Antitumor Assays | 2009 |
Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Cytidine; Cytidine Triphosphate; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Rats; Rats, Inbred BN | 2009 |
Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Photochemotherapy | 2009 |
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Topics: Adenocarcinoma; Adenoviridae; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Deletion; Genetic Therapy; Genetic Vectors; Humans; Immunoblotting; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S Phase; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
[Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
[A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
[Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Interferon-gamma; Molecular Chaperones; Pancreatic Neoplasms | 2009 |
In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, SCID; Microscopy, Confocal; Pancreatic Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tandem Mass Spectrometry | 2009 |
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Topics: Antimetabolites, Antineoplastic; Calcium-Binding Proteins; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Membrane Proteins; Mesoderm; NF-kappa B; Pancreatic Neoplasms; Phenotype; Proto-Oncogene Proteins; Receptor, Notch2; Receptor, Notch4; Receptors, Notch; RNA, Messenger; RNA, Small Interfering; Serrate-Jagged Proteins; Signal Transduction; Transfection | 2009 |
[Thrombotic microangiopathy under an effective treatment with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Deoxycytidine; Erythrocytes; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male; Palliative Care; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Treatment Outcome | 2009 |
Pancreatic cancer: translating lessons from mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genotype; Humans; Mice; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribonucleotide Reductases | 2009 |
Advancements in the management of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2009 |
Therapeutic tools in pancreatic cancer.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Haptoglobins; Humans; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity | 2009 |
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Humans; Logistic Models; Male; Mass Spectrometry; Middle Aged; Neutropenia; Pancreatic Neoplasms; Phenotype; Thrombocytopenia | 2009 |
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Survivors | 2009 |
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Asian People; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2009 |
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Interphase; Ligands; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms; Receptors, sigma; Survival Analysis | 2009 |
The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Health Surveys; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Binding; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Topics: Blotting, Western; Cell Proliferation; Cell Survival; Ceramides; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; Sphingosine; Tumor Cells, Cultured | 2009 |
[A case of drug induced interstitial pneumonitis after gemcitabine treatment for pancreatic carcinoma].
Topics: Aged; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2009 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Interferons; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2009 |
Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; COP9 Signalosome Complex; Curcumin; Deoxycytidine; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Male; Pancreatic Neoplasms; Peptide Hydrolases; Polyethylene Glycols | 2009 |
Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation Tolerance; tat Gene Products, Human Immunodeficiency Virus; Thiolester Hydrolases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Glycogen Synthase Kinase 3; Humans; NF-kappa B; Pancreatic Neoplasms; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha | 2009 |
Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromosome Mapping; Chromosomes, Human; Chromosomes, Human, X; Comparative Genomic Hybridization; Deoxycytidine; Drug Resistance; Gemcitabine; Genetic Variation; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome | 2009 |
Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Tumor Stem Cell Assay; Vorinostat | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positive T-Lymphocytes; Cisplatin; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-12 Subunit p40; Killer Cells, Lymphokine-Activated; Lipopolysaccharides; Liver Neoplasms; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects; Prognosis; Survival Rate; T-Lymphocytes; Treatment Outcome | 2009 |
Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Caspase 3; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Drug Synergism; Emodin; Gemcitabine; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Muscle, Skeletal; Pancreatic Neoplasms; Rats; Reverse Transcriptase Polymerase Chain Reaction; Suppression, Genetic; Survivin | 2009 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lenalidomide; Pancreatic Neoplasms; Thalidomide | 2010 |
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2009 |
Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; NF-kappa B; Pancreatic Neoplasms | 2009 |
Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Vorinostat | 2009 |
Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2009 |
Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome; Vitamin B Complex | 2009 |
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2009 |
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Stromal Cells; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2009 |
[Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers].
Topics: Aged; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Injury; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2009 |
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Pancreatic Neoplasms; RNA-Binding Proteins; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2009 |
Characterizing DNA methylation patterns in pancreatic cancer genome.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line; Cluster Analysis; CpG Islands; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reproducibility of Results; Transplantation, Heterologous | 2009 |
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Protein Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Veratrum Alkaloids | 2009 |
Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Pancreatic Neoplasms; RNA Interference; Survivin; Time Factors; X-Linked Inhibitor of Apoptosis Protein | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Topics: Aged; Alkaloids; Antimetabolites, Antineoplastic; Carbazoles; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Electric Impedance; Enzyme Inhibitors; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinases; Reproducibility of Results; RNA Interference; RNA, Small Interfering; Transfection | 2009 |
Cancer. Breaching the cancer fortress.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Fibroblasts; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Stromal Cells | 2009 |
Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Deoxycytidine; Diagnosis, Differential; Erythema Nodosum; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Recurrence; Vasculitis, Leukocytoclastic, Cutaneous | 2009 |
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Proteins; Ultrasonography | 2009 |
Sarcoidosis as a diagnostic pitfall of pancreatic cancer.
Topics: Abdominal Pain; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Carcinoma; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Female; Gallium Radioisotopes; Gemcitabine; Granuloma; Humans; Laparotomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Sarcoidosis; Trigeminal Neuralgia | 2009 |
Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cellular Senescence; Ceramides; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Sphingomyelins | 2009 |
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytochromes c; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Uracil | 2009 |
A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Cystadenocarcinoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Peritoneum; Tomography, X-Ray Computed | 2009 |
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
The usefulness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2009 |
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cytochromes c; Deoxycytidine; Dinoprostone; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred ICR; Mice, SCID; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Perfusion; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Treatment Outcome | 2009 |
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Nude; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms; Prodrugs; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2009 |
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Topics: Aniline Compounds; Animals; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Treatment Outcome | 2009 |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Deoxycytidine; Drug Synergism; Gemcitabine; Losartan; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: alpha 1-Antichymotrypsin; alpha 1-Antitrypsin; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Probability; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Survival Analysis | 2009 |
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Cluster Analysis; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Immunohistochemistry; Mesoderm; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Giant Cells; Humans; Janus Kinases; Mice; Molecular Structure; Pancreatic Neoplasms; Signal Transduction; STAT Transcription Factors; Time Factors; Triterpenes; Xenograft Model Antitumor Assays | 2009 |
[Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Remission Induction; Survival Rate | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2009 |
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Cell Dedifferentiation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Indoles; Isoflavones; Mesoderm; MicroRNAs; Pancreatic Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2009 |
Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2009 |
Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamidines; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Gemcitabine; Guanidines; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Ribonucleotide Reductases; Serine Proteinase Inhibitors; Tumor Cells, Cultured | 2009 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constriction, Pathologic; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Portal; Liver Diseases; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Stents; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; Mice, Nude; Microscopy, Confocal; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Transcription Factor AP-2; Transfection; Xenograft Model Antitumor Assays | 2009 |
[A case of unresectable advanced pancreatic cancer treated by gemcitabine-based chemotherapy following cancer pain alleviation by low-dose matrix-type transdermal fentanyl].
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fentanyl; Gemcitabine; Humans; Pain, Intractable; Pancreatic Neoplasms | 2009 |
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2010 |
Clinical impact of radiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2009 |
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bayes Theorem; Bevacizumab; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Models, Statistical; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Research Design | 2009 |
Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; G1 Phase; Gemcitabine; Humans; MicroRNAs; Oligonucleotides, Antisense; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2009 |
Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Nanocapsules; Nanospheres; Pancreatic Neoplasms; Serum Albumin, Bovine; Tumor Cells, Cultured | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2009 |
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Cell Line, Tumor; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mucin-4; Pancreatic Neoplasms; Receptor, ErbB-2; Signal Transduction | 2009 |
Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Pancreatic Neoplasms | 2009 |
Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine.
Topics: Biological Transport; Cell Line, Tumor; Deoxycytidine; Dideoxynucleosides; Fluorine Radioisotopes; Gemcitabine; Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Protein Binding | 2010 |
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Cancer Vaccines; CD11c Antigen; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-4; Killer Cells, Natural; Lipopolysaccharide Receptors; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pancreatic Neoplasms | 2009 |
[The inhibition of the Sonic Hedgehog (SHh) pathway improves the effects of chemotherapy in a model of ductal carcinoma of the pancreas in mice].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Hedgehog Proteins; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Veratrum Alkaloids | 2009 |
A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hypertension; Pancreatic Neoplasms; Stroke; Thrombotic Microangiopathies | 2009 |
Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Notch3; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction | 2010 |
Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gossypol; Humans; Membrane Proteins; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2010 |
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prodrugs; RNA-Binding Proteins; Treatment Outcome | 2009 |
The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lectins, C-Type; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Pancreatitis-Associated Proteins | 2009 |
[Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Uracil | 2009 |
[A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Recurrence; Tegafur; Tomography, X-Ray Computed | 2009 |
Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy.
Topics: Adolescent; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Papillary; Cystadenoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Periodicals as Topic; Sensitivity and Specificity; Survival Analysis; Total Quality Management; Treatment Outcome | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2009 |
Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Pancreatic Neoplasms | 2010 |
Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Surveys; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2010 |
Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; DNA; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transcription Factor RelA | 2010 |
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Deoxycytidine; Dexamethasone; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Premedication; Secondary Prevention | 2010 |
Features of gemcitabine-related severe pulmonary toxicity: patients with pancreatic or biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Diseases; Male; Middle Aged; Pancreatic Neoplasms; Pneumonia | 2009 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Micelles; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Red Fluorescent Protein; Transfection; Ultrasonography; Xenograft Model Antitumor Assays | 2010 |
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Resveratrol; Stilbenes; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Tegafur | 2009 |
The effect of endostatin and gemcitabine combined with HIFU on the animal xenograft model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Endostatins; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microvessels; Pancreatic Neoplasms; Random Allocation; Ultrasonic Therapy; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2009 |
Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cytokines; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitins | 2010 |
Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2010 |
Functional analysis of LOXL2 in pancreatic carcinoma.
Topics: Amino Acid Oxidoreductases; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; E2F5 Transcription Factor; Epithelium; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Mesoderm; Pancreatic Neoplasms; RNA, Small Interfering; Stress, Physiological; Transfection | 2010 |
Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Drug Delivery Systems; Enzyme Inhibitors; Female; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2010 |
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Laminin; Pancreatic Neoplasms; Phosphorylation; RNA Interference | 2009 |
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Treatment Outcome | 2010 |
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period | 2009 |
[The effectiveness of reduction surgery and gemcitabine for multiple bowel obstructions due to peritoneal dissemination of pancreatic carcinoma with liver metastasis--a case report].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2009 |
[A case report of un-resectable pancreas body carcinoma successfully treated by chemoradiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
[A case of locally advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Pancreatic Neoplasms; Radiotherapy | 2009 |
[A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Tegafur | 2009 |
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Diffusion of Innovation; Drug Approval; Drug Utilization; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Quality of Health Care; SEER Program; United States; United States Food and Drug Administration | 2010 |
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Immunoenzyme Techniques; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; ortho-Aminobenzoates; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases | 2010 |
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Nucleoside Deaminases; Pancreatic Neoplasms; Tetrahydrouridine; Transfection; Up-Regulation | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Fluorodeoxyglucose F18; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Retrospective Studies | 2010 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Early Detection of Cancer; Endosonography; Fluorouracil; Gemcitabine; Humans; Jejunostomy; Laparoscopy; Magnetic Resonance Imaging; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Calibration; Carcinoma, Pancreatic Ductal; Deoxycytidine; Early Detection of Cancer; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2010 |
A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Situs Inversus; Treatment Outcome | 2011 |
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biopsy, Fine-Needle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Treatment Outcome | 2010 |
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Immunoblotting; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Italy; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
[Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed | 2010 |
Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
Topics: Animals; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Topics: Aged; Algorithms; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate | 2010 |
[Effect of human telomerase reverse transcriptase gene antisense oligonucleotide on sensitivity of gemcitabine in pancreatic cancer cell].
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Oligonucleotides, Antisense; Pancreatic Neoplasms; RNA, Messenger; Telomerase | 2009 |
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Growth Processes; Cell Survival; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Gemcitabine; Histones; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2010 |
Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Division; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; G2 Phase; Gemcitabine; Gene Silencing; Humans; Integrins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2010 |
Update on adjuvant trials for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2010 |
Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Telomerase; Transfection; Virus Replication; Xenograft Model Antitumor Assays | 2010 |
Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Duodenum; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Movement; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2010 |
Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2010 |
[Gemcitabine therapy for unresectable pancreatic cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Pneumonia; Radiography | 2010 |
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Piperidines; Pyridines; Thiazoles | 2010 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate; Treatment Outcome | 2010 |
Toxicities of gemcitabine in patients with severe hepatic dysfunction.
Topics: Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Diseases; Male; Neoplasms; Pancreatic Neoplasms; Platelet Count; Retrospective Studies | 2010 |
Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment.
Topics: Cell Survival; Chitosan; Deoxycytidine; Emulsions; Gemcitabine; Glycerides; Humans; Inhibitory Concentration 50; Nanostructures; Pancreas; Pancreatic Neoplasms | 2010 |
Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells.
Topics: Adenine; Apoptosis; Autophagy; Caspase 3; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Knockdown Techniques; Humans; Membrane Proteins; Pancreatic Neoplasms; Vacuoles | 2010 |
[An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; RNA, Small Interfering; Transcription Factor RelA; Transfection; Xenograft Model Antitumor Assays | 2010 |
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucin-4; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms | 2010 |
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Biomimetic Materials; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Mice, Transgenic; Mitochondrial Proteins; Pancreatic Neoplasms; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; X-Linked Inhibitor of Apoptosis Protein | 2010 |
[A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Middle Aged; Mucin-1; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Hexanones; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Pancreatic Neoplasms; Ribonucleotide Reductases; Xenograft Model Antitumor Assays | 2011 |
Improved survival of left-sided pancreas cancer after surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2010 |
Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Immunoprecipitation; Indoles; Ku Autoantigen; Mice; Mice, Inbred ICR; Mice, SCID; Pancreatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-mdm2; RNA Interference; Sirtuin 1; Spiro Compounds; Surface Plasmon Resonance; Time Factors; Transfection; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2010 |
Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; CD24 Antigen; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Curcumin; Deoxycytidine; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; NF-kappa B; Oligonucleotides, Antisense; Pancreatic Neoplasms; PTEN Phosphohydrolase; Transfection; Triterpenes; Vascular Endothelial Growth Factor A | 2010 |
Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cytomegalovirus; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Hepatocyte Growth Factor; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Promoter Regions, Genetic; Transgenes | 2010 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2011 |
[Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2010 |
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, SCID; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prostaglandins E; Structure-Activity Relationship | 2010 |
Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoblotting; Interleukin-8; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT3 Transcription Factor | 2010 |
First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 2010 |
Options for the treatment of gemcitabine-resistant advanced pancreatic cancer: are we there yet?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2010 |
[Oncological treatment of patients with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2010 |
Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-13; Interleukin-13 Receptor alpha2 Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cells, Cultured; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Rate; Xenograft Model Antitumor Assays | 2010 |
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; DNA Repair; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase; Gamma Rays; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Flow Cytometry; Gemcitabine; Genes, bcl-2; Growth Inhibitors; Humans; I-kappa B Proteins; Mastic Resin; NF-kappa B; Pancreatic Neoplasms; Resins, Plant | 2010 |
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Ceramides; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Pancreatic Neoplasms | 2010 |
Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[A case of abdominal wall metastasis from pancreatic cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Remission Induction; Tegafur | 2010 |
Treatment of metachronous and simultaneous liver metastases of pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2010 |
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Neoplasm, Residual; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Pennsylvania; Polycomb Repressive Complex 2; Survival Rate; Transcription Factors | 2010 |
Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2011 |
Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cytokines; Deoxycytidine; Gemcitabine; Humans; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Rate | 2010 |
Volumetric modulated arc therapy for advanced pancreatic cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Film Dosimetry; Gemcitabine; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Intestines; Kidney; Liver; Neoplasm Staging; Pancreatic Neoplasms; Radiation Injuries; Radiation Tolerance; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Spinal Cord; Stomach; Tomography, X-Ray Computed | 2010 |
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Stem Cells; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Complications; Radiotherapy, Adjuvant | 2010 |
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom | 2010 |
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antibody Specificity; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Heparin-binding EGF-like Growth Factor; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Pancreatic Neoplasms; Transforming Growth Factor alpha | 2010 |
Novel therapies for pancreatic cancer: setbacks and progress.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction | 2010 |
[Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Matrix Metalloproteinase 9; Mice; Nanoparticles; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Polymers; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2010 |
[A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering | 2010 |
Survival analysis of pancreatic and periampullary collision cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Topics: Aged; Deoxycytidine; Disease-Free Survival; Eukaryotic Initiation Factor-3; Female; Gemcitabine; Gene Expression Profiling; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2010 |
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Isoforms; Up-Regulation | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
Topics: AC133 Antigen; Animals; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; CD24 Antigen; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; Peptides; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Survivin; Vimentin | 2011 |
Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Topics: Alternative Splicing; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Recombinant Proteins; RNA, Small Interfering; Tenascin; Transcription Factor RelA | 2010 |
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcitriol; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Liver; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; Humans; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2010 |
Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2010 |
Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
Topics: Amphiregulin; Antibodies; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; EGF Family of Proteins; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Glycoproteins; Humans; Immunoblotting; Intercellular Signaling Peptides and Proteins; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Biomarkers, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; ELAV Proteins; ELAV-Like Protein 2; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Microarray Analysis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation.
Topics: Adenine; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; Humans; Immunohistochemistry; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Microtubule-Associated Proteins; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Time Factors; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Spheroids, Cellular | 2010 |
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Time Factors; Up-Regulation | 2010 |
Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Immunohistochemistry; In Vitro Techniques; Mice; Mice, Inbred ICR; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
[S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Ultrasonography | 2010 |
[Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer].
Topics: Acute Disease; Aged; Amino Acids, Branched-Chain; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hepatic Encephalopathy; Hepatitis B; Humans; Lactulose; Liver; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2010 |
Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2010 |
Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms | 2010 |
Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Homeodomain Proteins; Humans; Male; Pancreas; Pancreatic Neoplasms; Prognosis; RNA Interference | 2010 |
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Chromans; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inflammation; Inflammation Mediators; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; Tumor Cells, Cultured; Vitamin E; Xenograft Model Antitumor Assays | 2010 |
[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation; Wortmannin | 2011 |
Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2011 |
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Endothelium, Vascular; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shiga Toxins; Signal Transduction; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Adenosquamous; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Citrates; Deoxycytidine; Energy Metabolism; Female; Gemcitabine; Humans; Methotrexate; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics; Up-Regulation | 2010 |
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Inhibitory Concentration 50; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; RNA Interference; Thymidylate Synthase | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pilot Projects; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2010 |
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Cancer Vaccines; CD11b Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genetic Vectors; Inhibitor of Apoptosis Proteins; Interferon-gamma; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Peptide Library; Receptors, Cell Surface; Remission Induction; Repressor Proteins; Survivin; Vaccination; Vaccinia virus | 2011 |
Treatment effect or secret nature: long-term remissions in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2010 |
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Silencing; Humans; Pancreatic Neoplasms; Promoter Regions, Genetic; Taxoids; Transfection | 2010 |
Evaluation of the effectiveness of a chemoprevention model of pancreatic adenocarcinoma using protein chip technology.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Chemoprevention; Deoxycytidine; Diagnostic Techniques, Endocrine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2011 |
Current status of adjuvant therapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Topics: Antimetabolites, Antineoplastic; Benzylamines; beta Catenin; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Heterocyclic Compounds; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Injections, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Perioperative Period; Survival Rate; Treatment Outcome | 2011 |
Chronic anemia resistant to erythropoietin in a patient treated with gemcitabine showing a hemolytic uremic syndrome (HUS).
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Chronic Disease; Deoxycytidine; Erythropoietin; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Treatment Failure | 2010 |
[Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell].
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
The expression of interferon receptor α/β in human pancreatic cancer in nude mice is essential for tumor response to interferon α treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Interferon-alpha; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Receptor, Interferon alpha-beta | 2012 |
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Receptors, sigma | 2010 |
The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Deoxycytidine; Drug Synergism; Estradiol; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Tubulin Modulators | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Benzhydryl Compounds; Deoxycytidine; Down-Regulation; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 2011 |
Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bile; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2010 |
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Collagen Type I; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Matrix; Gemcitabine; HMGA2 Protein; Humans; Matrix Metalloproteinase 14; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; HEK293 Cells; Humans; Pancreatic Neoplasms; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger | 2010 |
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Indoles; Male; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sex Factors | 2010 |
Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Gemcitabine; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms | 2011 |
A rare case of thyroid metastasis from pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2011 |
Medical therapy for advanced pancreatic cancer: work in progress.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents; Biomedical Research; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gemcitabine; Humans; Hydrogen-Ion Concentration; Losartan; Lovastatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Forecasting; Gemcitabine; Genetic Association Studies; Human Genome Project; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Precision Medicine; Risk Factors; Sequence Analysis, DNA; Survival Rate; Treatment Failure | 2011 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms; Radiosurgery | 2010 |
[Two cases of pancreatic cancer with fairly good prognosis].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Duodenum; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2010 |
[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
Topics: Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Tegafur | 2010 |
[The case of a person who let to umbilicus metastasis at a year after PD].
Topics: Abdominal Neoplasms; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lymph Node Excision; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Umbilicus | 2010 |
[A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2010 |
Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Caspase 3; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Vectors; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Matrix Metalloproteinase 1; Pancreatic Neoplasms; Proto-Oncogene Protein c-ets-1; RNA Interference; RNA, Small Interfering; Time Factors; Urokinase-Type Plasminogen Activator | 2011 |
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mitochondrial Proteins; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Survival Analysis; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Thiocarbamates | 2011 |
High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Survival Analysis; Up-Regulation | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Young Adult | 2011 |
Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
Topics: Animals; Blotting, Western; BRCA2 Protein; Cell Line; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; HEK293 Cells; Humans; Mice; Mutation; Pancreatic Neoplasms; Protein Kinases; ras Proteins; RNA Interference; Transfection; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Nude; Organophosphates; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Drug Synergism; Emodin; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2011 |
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms | 2011 |
How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Transposable Elements; Drug Resistance, Neoplasm; Gemcitabine; Genome-Wide Association Study; Humans; Mutagenesis; Pancreatic Neoplasms; Proteins; RNA, Long Noncoding | 2011 |
Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Galectin 3; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Transfection; Tumor Cells, Cultured | 2011 |
ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration.
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Cell Survival; Cells, Cultured; Deoxycytidine; Disease-Free Survival; Endosonography; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2011 |
Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Colectomy; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Care Team; Prospective Studies; Stents; Survival Rate | 2011 |
Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Interferon-beta; Pancreatic Neoplasms; Receptor, Interferon alpha-beta; RNA, Messenger | 2011 |
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2011 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Canada; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genotype; Humans; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2011 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
[Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer].
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2011 |
[A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Screening Assays, Antitumor; Excipients; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Stearic Acids; Time Factors | 2011 |
Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Histone Deacetylase Inhibitors; Humans; Immunoblotting; Pancreas; Pancreatic Neoplasms; Pyrimidines | 2011 |
Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2011 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2011 |
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Connective Tissue Growth Factor; Deoxycytidine; Enzyme Inhibitors; Factor VIIa; Gemcitabine; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Treatment Outcome | 2011 |
Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mutation; Pancreatic Neoplasms; Translational Research, Biomedical; Treatment Outcome | 2011 |
Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Linear Models; Male; Meta-Analysis as Topic; Middle Aged; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2011 |
Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Connexin-26 is a key factor mediating gemcitabine bystander effect.
Topics: Animals; Bystander Effect; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexin 26; Connexin 43; Connexins; Deoxycytidine; Gap Junction beta-1 Protein; Gap Junctions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Phosphorylation; RNA, Messenger | 2011 |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies; Antigens, Neoplasm; Cancer Vaccines; Cell Adhesion Molecules; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunization; Immunotherapy, Active; Interferon-gamma; Interleukin-10; Macrophages; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Proteins; Recombinant Proteins; Survival Rate; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Vaccines, Virus-Like Particle | 2011 |
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carcinoma; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Aggregation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Nanomedicine; Nanoparticles; Pancreas; Pancreatic Neoplasms; Squalene | 2011 |
Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Salvage Therapy | 2011 |
Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Injections, Intravenous; Mice; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Fingers; Gangrene; Gemcitabine; Humans; Ischemia; Male; Necrosis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Raynaud Disease; Scleroderma, Systemic; Tegafur; Toes | 2011 |
Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Retrospective Studies | 2011 |
Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy.
Topics: Adenoviridae; Angiotensin-Converting Enzyme 2; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptidyl-Dipeptidase A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Histones; Humans; Mice; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Transplantation, Heterologous; Urea; Xenograft Model Antitumor Assays | 2011 |
EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Compounding; ErbB Receptors; Gemcitabine; Humans; Lactic Acid; Nanocapsules; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Treatment Outcome | 2011 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Carriers; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lymph Nodes; Lymphatic Metastasis; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanotubes, Carbon; Necrosis; Pancreatic Neoplasms | 2011 |
(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
Topics: Adenosine Triphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Basigin; Cell Death; Cell Line, Tumor; Contrast Media; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Injections, Intravenous; Mice; Mice, SCID; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Green Fluorescent Proteins; Hepatocyte Growth Factor; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transgenes | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cannabinoids; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Endoplasmic Reticulum; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stress, Physiological; Transcription, Genetic; Transplantation, Heterologous | 2011 |
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Platelets; Bone Marrow; Cell Movement; Chemokine CXCL12; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Neoadjuvant Therapy; Neovascularization, Physiologic; Pancreatic Neoplasms; Stem Cells; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Fetal Proteins; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Pancreatic Neoplasms; Protein-Tyrosine Kinases; RNA, Small Interfering | 2011 |
[Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Emodin; Female; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Survivin; Tumor Burden | 2011 |
Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Crambe Sponge; Deoxycytidine; Endothelial Cells; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Prostatic Neoplasms | 2012 |
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitosan; Deoxycytidine; Drug Delivery Systems; Gemcitabine; HEK293 Cells; Humans; Nanoparticles; Pancreas; Pancreatic Neoplasms; Trastuzumab | 2011 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interferon alpha-2; Interferon-alpha; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Repressor Proteins; Trans-Activators; Valproic Acid | 2011 |
[A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Salvage Therapy; Tegafur | 2011 |
β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction.
Topics: Adrenergic beta-2 Receptor Antagonists; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Propanolamines; Proto-Oncogene Proteins c-bcl-2; Receptors, Adrenergic, beta-2 | 2011 |
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; DNA Damage; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Uric Acid; Xanthine Dehydrogenase | 2011 |
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Topics: Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Gemcitabine; Gene Expression; Genes, T-Cell Receptor; HLA-A24 Antigen; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; RNA, Messenger; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Transduction, Genetic; Up-Regulation; WT1 Proteins | 2011 |
[Effect of emodin combined gemcitabine on the growth and apoptosis of pancreatic cancer cell line BxPC-3 in vitro].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Emodin; Gemcitabine; Humans; Pancreatic Neoplasms | 2011 |
Clusterin confers gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clusterin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Cisplatin; Deoxycytidine; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2011 |
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; RNA, Messenger | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Coatomer Protein; Deoxycytidine; Fluorouracil; Gemcitabine; Golgi Apparatus; Humans; Lysosomal Membrane Proteins; Lysosomes; Magnetic Resonance Spectroscopy; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Omeprazole; Pancreatic Neoplasms; Ultracentrifugation | 2011 |
Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Topics: AC133 Antigen; Antigens, CD; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins; Pancreatic Neoplasms; Patched Receptors; Peptides; Receptors, Cell Surface; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Smoothened Receptor; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2011 |
Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Midkine; Pancreatic Neoplasms; Receptor, Notch2; RNA Interference; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2011 |
A man with a testicular mass and a colon stenosis. Diagnosis: Metastatic pancreatic adenocarcinoma to the gonads.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Colonic Diseases; Colonoscopy; Constriction, Pathologic; Deoxycytidine; Endoscopy, Digestive System; Gemcitabine; Humans; Immunohistochemistry; Intestinal Obstruction; Krukenberg Tumor; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed | 2011 |
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
Topics: Adult; Aged; Aged, 80 and over; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2011 |
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Flow Cytometry; Gemcitabine; Humans; Isoflavones; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer.
Topics: Acute Kidney Injury; Antineoplastic Agents; Crystallization; Deoxycytidine; Fluid Therapy; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms | 2011 |
Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; CD24 Antigen; Cell Line; Cell Movement; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Polycomb Repressive Complex 1; Vimentin | 2011 |
[Postoperative adjuvant treatment for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Postoperative Period | 2011 |
A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Biomarkers, Tumor; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Survival Rate; Treatment Outcome | 2011 |
Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Gemcitabine; Humans; Lignans; NF-kappa B; Pancreatic Neoplasms; Protein Transport | 2011 |
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer.
Topics: Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2011 |
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Transplantation, Heterologous; Treatment Outcome | 2011 |
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Silencing; Humans; Irinotecan; MAP Kinase Kinase Kinases; Mice; Mice, Nude; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Emodin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Tumor Burden; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2011 |
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Indolizines; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Pyridinium Compounds; ral GTP-Binding Proteins; Receptors, Notch; Retinoblastoma Protein; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Radiosurgery; Radiotherapy; Radiotherapy, Intensity-Modulated; Severity of Illness Index; Survival Rate; Treatment Outcome | 2012 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ceramides; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Glucosyltransferases; Humans; Liposomes; MAP Kinase Signaling System; Mice; Mice, Nude; Morpholines; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Radiotherapy; Thigh | 2012 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Risk Factors | 2011 |
Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Topics: Adenoviruses, Human; Animals; Antibodies, Neutralizing; Capsid; Capsid Proteins; Cell Line, Tumor; Combined Modality Therapy; Cricetinae; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Silica Gel; Transfection | 2012 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cytopathogenic Effect, Viral; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Deletion; Gene Expression Regulation, Viral; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Virus; Retinoblastoma Protein; Virus Replication; Xenograft Model Antitumor Assays | 2011 |
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Receptor, Cholecystokinin B; Signal Transduction; Vascular Endothelial Growth Factor A | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Therapy, Combination; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines | 2011 |
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cisplatin; Deoxycytidine; DNA Damage; Drug Synergism; Dyrk Kinases; Exons; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Resting Phase, Cell Cycle | 2011 |
Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Protein Interaction Mapping; Proteome; Proteomics; Two-Dimensional Difference Gel Electrophoresis | 2011 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Livedo Reticularis; Middle Aged; Pancreatic Neoplasms | 2012 |
Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models | 2012 |
Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Sequence Analysis, DNA | 2011 |
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Topics: Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hydroxyurea; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA Interference; Snail Family Transcription Factors; Transcription Factors; Vimentin; Zinc Finger E-box-Binding Homeobox 1 | 2012 |
Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Plant Extracts; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine in elderly patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Ultraviolet Rays | 2011 |
MicroRNA miR-548d is a superior regulator in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Databases, Genetic; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; Transfection | 2012 |
Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Deoxycytidine; Diphosphonates; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2012 |
Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Indoles; Pancreatic Neoplasms; RNA, Messenger; Treatment Outcome | 2011 |
Locally advanced pancreatic cancer: where should we go from here?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2011 |
Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Up-Regulation; Vitamin E; Xenograft Model Antitumor Assays | 2011 |
Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Retrospective Studies; Treatment Outcome; Tumor Burden | 2011 |
Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2012 |
Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; beta Catenin; Cell Line, Tumor; Cell Proliferation; Chemokines; Deoxycytidine; DNA Methylation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger | 2011 |
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Triazines | 2012 |
Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Molecular Chaperones; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Serine | 2011 |
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorylation; Prognosis; Xenograft Model Antitumor Assays | 2011 |
Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Tumor Burden | 2012 |
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Inhibitors; Female; Fibroblasts; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinolines; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2012 |
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2012 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Cytokines; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Macrophages; Pancreatic Neoplasms; Phagocytosis; Phenylbutyrates | 2012 |
Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Odds Ratio; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2011 |
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Hedgehog Proteins; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Transcription Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Glycoproteins; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Pyrans; Xenograft Model Antitumor Assays | 2011 |
HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Cell Line, Tumor; Deoxycytidine; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Transfection; Xenograft Model Antitumor Assays | 2012 |
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Urea; Xenograft Model Antitumor Assays | 2012 |
[MicroRNA expression pattern in intraductal papillary mucinous neoplasm].
Topics: Adenocarcinoma, Mucinous; Adenoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Papillary; Cell Line; Deoxycytidine; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Up-Regulation | 2011 |
Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Verteporfin | 2011 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Triterpenes; Xenograft Model Antitumor Assays | 2011 |
Pancreaticoduodenectomy with resection of the splenic artery and splenectomy for pancreatic double cancers after total gastrectomy. Preservation of the pancreatic function via the blood supply from the posterior epiploic artery: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Deoxycytidine; Gastrectomy; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Splenectomy; Splenic Artery; Stomach Neoplasms | 2012 |
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genes, Reporter; Hedgehog Proteins; Humans; Mice; Mice, Nude; Middle Aged; Mutation; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Signal Transduction; Time Factors; Transcription Factors; Transfection; Tumor Burden; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karyotype; Mice; Mice, SCID; Microsatellite Repeats; Neoplastic Stem Cells; Pancreatic Neoplasms; Transplantation, Heterologous | 2012 |
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Proportional Hazards Models; Tegafur | 2012 |
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Stem Cell Assay | 2012 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lenalidomide; Nitriles; Pancreatic Neoplasms; Phosphorylation; Thalidomide; Tumor Cells, Cultured | 2011 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Combination effects of digalloylresveratrol with arabinofuranosylcytosine and difluorodeoxycytidine in human leukemia and pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cytarabine; Deoxycytidine; Gallic Acid; Gemcitabine; HL-60 Cells; Humans; Leukemia; Pancreatic Neoplasms; Stilbenes; Tumor Stem Cell Assay | 2011 |
[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2011 |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Genome-Wide Association Study; Humans; Interleukin-17; Kaplan-Meier Estimate; Linkage Disequilibrium; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2012 |
Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Brachytherapy; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radium | 2012 |
Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Emodin; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2012 |
Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Statistics, Nonparametric; Tegafur | 2012 |
Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Exodeoxyribonucleases; Gemcitabine; Humans; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RecQ Helicases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Werner Syndrome Helicase | 2012 |
Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate | 2012 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Metformin; Pancreatic Neoplasms; Receptor, IGF Type 1; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; S Phase Cell Cycle Checkpoints | 2012 |
[A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[An example case that chemoradiotherapy was succeeded for unresectable pancreas cancer].
Topics: Antimetabolites, Antineoplastic; Biopsy; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[A novel gemcitabine delivery system].
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmaceutical Solutions | 2011 |
[Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Signal Transduction | 2012 |
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunocompetence; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Severity of Illness Index; Spleen; Survival Rate | 2012 |
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Luminescent Measurements; Mice; Mice, Nude; Microscopy, Fluorescence; Myxoma virus; Oncolytic Viruses; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
[A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Molecular Mimicry; NF-kappa B; Pancreatic Neoplasms; Tumor Necrosis Factor-alpha | 2011 |
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinolines; Quinuclidines; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Down-Regulation; Drug Synergism; Escin; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Failure | 2012 |
High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Humans; Interferon-alpha; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides | 2012 |
Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Pancreatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Neoplasm Transplantation; NF-kappa B; NM23 Nucleoside Diphosphate Kinases; Pancreatic Neoplasms | 2012 |
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
[A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; S Phase; Tegafur | 2012 |
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor | 2012 |
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Gemcitabine; Humans; Hypoxia; Mice; Mice, Mutant Strains; Necrosis; Pancreatic Neoplasms; Protease Inhibitors; Receptors, Notch; Signal Transduction; Thiadiazoles; Translational Research, Biomedical | 2012 |
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Dipeptidases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; GPI-Linked Proteins; Humans; Male; MAP Kinase Signaling System; Maryland; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Reproducibility of Results; Treatment Outcome | 2012 |
Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Emodin; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Survivin; Tumor Burden; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2012 |
Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Duodenum; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Intestine, Small; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiation Injuries; Radiography; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Stomach; Tumor Burden | 2012 |
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2012 |
Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinoxalines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta | 2012 |
Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2012 |
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metabolomics; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proteomics | 2012 |
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis | 2012 |
[A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed | 2012 |
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Ribonucleotide Reductases | 2012 |
CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
Topics: Basigin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Symporters | 2012 |
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2012 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Survival Rate | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Pancreatic Neoplasms; Recombinant Proteins; Tissue Array Analysis; Treatment Outcome | 2013 |
Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Hedgehog Proteins; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; RNA Interference; Smoothened Receptor; Transcription Factors; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering | 2012 |
Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Prospective Studies; Treatment Outcome | 2013 |
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies | 2012 |
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzene Derivatives; Clinical Trials, Phase II as Topic; Computer Simulation; Deoxycytidine; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Propionates; Research Design; Sample Size; Sulfones | 2012 |
Unprecedented case of tumor lysis syndrome in a patient with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Tumor Lysis Syndrome | 2012 |
[The evaluation of chemotherapy for patients over eighty-years-old].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2012 |
Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA; Drug Synergism; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Pregnenediones; Xenograft Model Antitumor Assays | 2012 |
DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Oncogene Proteins; Pancreatic Neoplasms; Protein Deglycase DJ-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Young Adult | 2012 |
Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2012 |
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oncogenes; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Brucea; Camptothecin; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; Drugs, Chinese Herbal; Gemcitabine; Hepatocytes; Humans; Membrane Potential, Mitochondrial; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quassins; Stem Cells | 2012 |
Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells.
Topics: Base Sequence; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; NM23 Nucleoside Diphosphate Kinases; Pancreatic Neoplasms; Promoter Regions, Genetic; Regulatory Sequences, Nucleic Acid; Sequence Analysis, DNA; Sp1 Transcription Factor; Sp3 Transcription Factor; Transcription Initiation Site; Transcription, Genetic; Transcriptional Activation | 2012 |
Induction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; Gene Expression; Histone Chaperones; Humans; Nuclear Proteins; Pancreatic Neoplasms; RNA, Small Interfering; Transfection | 2012 |
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Membrane Transport Proteins; Middle Aged; Models, Biological; Mucin-4; Multigene Family; Pancreatic Neoplasms | 2013 |
Drug interactions: the importance of looking inside cancer cells.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Paclitaxel; Pancreatic Neoplasms | 2012 |
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2012 |
FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleosides; Tacrolimus Binding Proteins; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Naphthoquinones; Pancreatic Neoplasms; RNA, Small Interfering; Survivin | 2012 |
Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Quinazolines | 2012 |
Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Tetrahydrouridine | 2012 |
Triptolide cooperates with Cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Diterpenes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epoxy Compounds; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Pancreatic Neoplasms; Phenanthrenes; RNA, Small Interfering; Transfection | 2012 |
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Fluorouracil; Gemcitabine; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Tumor Burden; Tumor Suppressor Protein p53 | 2012 |
Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Sesquiterpenes | 2012 |
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Topics: AC133 Antigen; Adenosine; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Topics: Antimetabolites, Antineoplastic; Contrast Media; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Radiography, Interventional; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemokine CX3CL1; Chemotherapy, Adjuvant; CX3C Chemokine Receptor 1; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Receptors, Chemokine; Retrospective Studies; Survival Analysis; Tissue Array Analysis; Up-Regulation | 2012 |
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Random Allocation; Signal Transduction; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Treatment Outcome | 2012 |
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Adhesion Molecules; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Recombinant Proteins | 2012 |
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Ohio; Pancreatectomy; Pancreatic Neoplasms; Paraffin Embedding; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome | 2012 |
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Outcome Assessment; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Symptom Assessment | 2013 |
[Emodin combined gemcitabine inhibited the growth of pancreatic cancer in vitro and in vivo and its mechanisms study].
Topics: Animals; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Emodin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2012 |
Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases | 2012 |
Gemcitabine associated pseudocellulitis.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Follow-Up Studies; Gemcitabine; Humans; Lower Extremity; Male; Pancreatic Neoplasms; Risk Assessment | 2012 |
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome | 2013 |
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biotransformation; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; France; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering | 2012 |
Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes, Kaurane; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Random Allocation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Carcinoma; Cell Line, Tumor; Deoxycytidine; Eating; Gemcitabine; Humans; Mianserin; Mice; Mice, Inbred BALB C; Mice, Nude; Mirtazapine; Nutritional Status; Pancreatic Neoplasms; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells.
Topics: Aged; Annexin A2; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Receptor, Notch1; Thiadiazoles; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colorimetry; Cytomegalovirus; Deoxycytidine; Down-Regulation; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Telomerase; Time Factors; Transfection | 2012 |
Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid | 2012 |
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2013 |
Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pericardial Effusion; Pleural Effusion | 2012 |
The antitumor activity of recombinant antitumor antiviral protein and the associated molecular mechanism in pancreatic tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Interferons; Mice; Mice, Nude; Pancreatic Neoplasms; Recombinant Proteins; Xenograft Model Antitumor Assays | 2012 |
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytoplasm; Deoxycytidine; ELAV Proteins; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Pancreatic Neoplasms; Protein Transport; Proteolysis; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Processing, Post-Transcriptional; RNA, Messenger | 2012 |
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Checkpoint Kinase 1; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; RNA Splicing; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Signal Transduction | 2013 |
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Neoplasms; Pancreatic Neoplasms; Sirolimus | 2012 |
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Macrophage Migration-Inhibitory Factors; Male; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA Interference; Transplantation, Heterologous | 2013 |
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation-Sensitizing Agents; Signal Transduction; Sulfones | 2012 |
Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genetic Association Studies; Haplotypes; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
Topics: Benzoquinones; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Novobiocin; Pancreatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Mas | 2012 |
Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: comparative proteomic analyses.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Male; Mass Spectrometry; Middle Aged; Pancreatic Neoplasms; Proteome | 2012 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2013 |
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
Topics: Base Sequence; Cell Line, Tumor; Cyclin-Dependent Kinases; Deoxycytidine; DNA Primers; Flavones; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Cavitary pulmonary metastases of pancreas cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 2013 |
Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombus.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Disease Progression; Female; Gemcitabine; Giant Cells; Humans; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Remission Induction; Thrombectomy; Tomography, X-Ray Computed; Venous Thrombosis | 2012 |
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chlortetracycline; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2012 |
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Male; Mice; Mice, SCID; Middle Aged; Pancreatic Neoplasms; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivors | 2012 |
Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2012 |
Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Random Allocation; Terpenes; Xenograft Model Antitumor Assays | 2013 |
Development of a unique mouse model for pancreatic cancer lymphatic metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cluster Analysis; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphatic Metastasis; Mice; Pancreatic Neoplasms; Transplantation, Heterologous | 2012 |
Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Survival Analysis | 2012 |
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Anti-Idiotypic; Calcium-Binding Proteins; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Pentacyclic Triterpenes; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes | 2012 |
Efficacy of minimally invasive therapies on unresectable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Catheter Ablation; Chemoembolization, Therapeutic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2013 |
The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Histones; Humans; Immunohistochemistry; Lysine; Male; Methylation; Middle Aged; Pancreatic Neoplasms | 2012 |
Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lactoferrin; Neoplasm Proteins; Pancreatic Neoplasms; Proteomics; S100 Proteins; Transferrin | 2012 |
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clusterin; Deoxycytidine; Flavonoids; Gemcitabine; Gene Knockdown Techniques; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Thionucleotides | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatography, Liquid; Crizotinib; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mass Spectrometry; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2013 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Platinum | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Gemcitabine-induced pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pneumonia | 2012 |
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Deoxycytidine; Gemcitabine; Humans; Lactic Acid; Liposomes; Microscopy, Electron, Transmission; Nanotechnology; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2012 |
Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Comorbidity; Deoxycytidine; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2013 |
The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Luciferases, Firefly; Luminescent Measurements; Mice; Mice, Nude; Pancreatic Neoplasms; Quercetin; Time Factors; Transduction, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
Tumor size as measured at initial X-ray examination, not length of bile duct stricture, predicts survival in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Bile Ducts; Cholangiopancreatography, Endoscopic Retrograde; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Chlorophyll; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Photochemotherapy; Photosensitizing Agents | 2012 |
Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Reproducibility of Results; RNA Interference; RNA, Messenger; Wound Healing | 2012 |
Progress in pancreatic cancer: moving beyond gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Base Sequence; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Endocytosis; ErbB Receptors; Fluorescent Dyes; Gemcitabine; Humans; Microscopy, Fluorescence; Molecular Sequence Data; Pancreatic Neoplasms; Staining and Labeling | 2012 |
CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Intermediate Filament Proteins; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Tissue Proteins; Nestin; Octamer Transcription Factor-3; Pancreatic Neoplasms; Polymerase Chain Reaction; Stem Cells | 2013 |
Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; MAP Kinase Kinase 4; Mice; Mice, Nude; Pancreatic Neoplasms; Tetradecanoylphorbol Acetate; Xenograft Model Antitumor Assays | 2012 |
Use of gemcitabine with multi-stage surgical resection as successful second-line treatment of metastatic pancreatoblastoma.
Topics: Antimetabolites, Antineoplastic; Child; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Tomography, X-Ray Computed | 2013 |
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Pyrazoles; Random Allocation; Receptor, IGF Type 1; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2012 |
Photodynamic therapy for pancreatic and biliary tract cancer: the United Kingdom experience.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Photochemotherapy; Survival Rate; Treatment Outcome; United Kingdom | 2012 |
Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Lipocalins; Mice; Pancreatic Neoplasms | 2012 |
Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: does chemotherapy affect stent patency?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Deoxycytidine; Duodenal Obstruction; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intestinal Obstruction; Male; Palliative Care; Pancreatic Neoplasms; Prognosis; Pylorus; Stents; Stomach Neoplasms | 2013 |
miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms | 2013 |
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; Carbocyanines; Cell Death; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Coloring Agents; Cytochromes c; Deoxycytidine; Female; Gemcitabine; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrum Analysis; Xenograft Model Antitumor Assays | 2013 |
Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2012 |
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Movement; Cell Proliferation; Cyclohexanones; Deoxycytidine; Disease Models, Animal; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Interleukin-8; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Synergism; Etoposide; Gemcitabine; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Topoisomerase II Inhibitors | 2013 |
High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survivin; Up-Regulation | 2013 |
Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
Topics: Adenocarcinoma; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Hemorrhage; Time Factors; Treatment Outcome | 2013 |
Preparation and characterization of gemcitabine liposome injections.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Electrochemistry; Gemcitabine; Injections; Liposomes; Microscopy, Electron, Transmission; Pancreatic Neoplasms; Particle Size | 2012 |
Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Caspase 3; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Indoles; Pancreas; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2013 |
[Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2012 |
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Alleles; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Glycoproteins; GPI-Linked Proteins; Humans; Isoenzymes; Keratins; Male; Mesothelin; Mice; Middle Aged; Mutation; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Polyploidy; Retinal Dehydrogenase; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
Gemcitabine-induced gouty arthritis attacks.
Topics: Aged; Antimetabolites, Antineoplastic; Arthritis, Gouty; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cattle; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Directed DNA Polymerase; Drug Synergism; Enzyme Inhibitors; Galactolipids; Gemcitabine; Humans; Isoenzymes; Kinetics; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Pancreatic Neoplasms; Plant Extracts; Rats; Spinacia oleracea | 2013 |
The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Fas Ligand Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Pancreas; Pancreatic Neoplasms; Prognosis | 2013 |
MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Kruppel-Like Transcription Factors; MAP Kinase Kinase Kinases; Nuclear Proteins; Pancreatic Neoplasms; Transcription Factors; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2013 |
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Time Factors | 2013 |
Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model.
Topics: Actins; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Immunohistochemistry; Male; Myofibroblasts; Neoplasms, Experimental; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Ribonucleotide Reductases; Transforming Growth Factor beta1; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Acetyltransferases; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Origin Recognition Complex; Pancreatic Neoplasms; Phosphorylation; Polo-Like Kinase 1; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Pteridines; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2013 |
Achieving the best of both worlds.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Quality of Life | 2013 |
Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Topics: Adenoviridae; Analysis of Variance; Animals; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Guanidines; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2013 |
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Lymphocyte Count; Mice; Neoplasms, Experimental; Pancreatic Neoplasms; Survival Analysis; T-Lymphocytes, Regulatory | 2013 |
Pancreatic cancer - cost for overtreatment with gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nucleoside Transport Proteins; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Sweden | 2013 |
Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melatonin; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gem
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Free Radicals; Gemcitabine; Humans; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polymerization; Polymers; Prodrugs; Transplantation, Heterologous | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Glycation End Products, Advanced; HMGB1 Protein; Humans; Pancreatic Neoplasms; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2013 |
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Glucose Tolerance Test; Humans; Insulin; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis | 2013 |
[Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[Total pancreatectomy for pancreatic head cancer accompanied with multiple lesions].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Jaundice; Male; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[A case of simultaneous resection of pancreatic tail and transverse hematogenous metastasis].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[A case of interstitial lung disease associated with gemcitabine treatment in a patient with locally advanced pancreatic cancer following proton beam radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemorrhage; Humans; Lung Diseases, Interstitial; Pancreatic Neoplasms; Proton Therapy | 2012 |
Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Observation; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Prospective Studies; Treatment Outcome | 2013 |
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2013 |
Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Interleukin-8; Matrix Metalloproteinase 9; Microarray Analysis; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Phenotype; Signal Transduction; Terpenes; Vascular Endothelial Growth Factor A; Wound Healing | 2013 |
Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.
Topics: Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Antagonists; Flavanones; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Wound Healing | 2012 |
Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Tracking; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Luciferases, Firefly; Mice; Pancreatic Neoplasms; Plasma Gases; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2012 |
Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Survival Rate | 2013 |
[Questions on "gemcitabine plus S-1 combination therapy (G-S therapy) for pancreatic cancer with accentuated hepatic metastasis" (by Matsumoto, T. et al) published on Japanese Journal of Gastro-enterology Vol. 108, N0. 12].
Topics: Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Differentiation Protein 1; Kaplan-Meier Estimate; Mice; Mice, SCID; Nicotine; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcription, Genetic | 2012 |
ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.
Topics: ADAM Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Protein Structure, Tertiary; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2013 |
Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Topics: Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Cadherins; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirtuin 1; Survival; Transcription Factors; Transcriptional Activation; Twist-Related Protein 1; Up-Regulation | 2013 |
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Topics: Antineoplastic Agents; Cell Line; Cells, Cultured; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Chaperones; Humans; MicroRNAs; Oncogene Proteins; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA-Binding Proteins; Transcription Factors | 2013 |
[Percutaneous cryoablation and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2012 |
Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Receptors, CXCR4; Veratrum Alkaloids | 2013 |
ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
An integrative network inference approach to predict mechanisms of cancer chemoresistance.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Biotransformation; Cell Line, Tumor; Computational Biology; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Markov Chains; Metabolic Networks and Pathways; Models, Statistical; Pancreatic Neoplasms; Stochastic Processes; Time Factors | 2013 |
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Pyridones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured | 2013 |
Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate | 2013 |
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2013 |
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; MicroRNAs; Pancreatic Neoplasms; Proteome; Proteomics; Xenograft Model Antitumor Assays | 2013 |
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glycine; Humans; Lysine; Male; Middle Aged; Pancreatic Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Xeroderma Pigmentosum Group D Protein | 2013 |
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Topics: Adult; Antimetabolites, Antineoplastic; Cell Proliferation; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Middle Aged; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2013 |
VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Gene Silencing; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lymphangiogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Vascular Endothelial Growth Factor C; Xenograft Model Antitumor Assays | 2013 |
Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Culture Techniques; Cell Cycle Checkpoints; Cytotoxins; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Ribonuclease, Pancreatic; Tumor Cells, Cultured | 2002 |
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cells; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Cycle; Cell Division; Cell Survival; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retreatment | 2002 |
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2002 |
Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Division; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured | 2003 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
[A case of vulval extramammary Paget's disease associated with pancreatic cancer that was successfully treated with chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Paget Disease, Extramammary; Pancreatic Neoplasms; Vulvar Neoplasms | 2002 |
[A case of pancreatic tail cancer with peritoneal carcinosis treated with gemcitabine hydrochloride].
Topics: Antimetabolites, Antineoplastic; Ascitic Fluid; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peritonitis | 2002 |
[Intra-arterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2002 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
[Gemcitabine in elderly patients with unresectable pancreas cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Pancreatic Neoplasms | 2002 |
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2003 |
Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Division; Cetuximab; Deoxycytidine; DNA; Electrophoretic Mobility Shift Assay; ErbB Receptors; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Signal Transduction; Tumor Cells, Cultured | 2003 |
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Sulfasalazine; Tumor Cells, Cultured | 2003 |
[Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed | 2003 |
Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Radiation; Electrophoresis; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured | 2003 |
[A case of liver metastasis of pancreatic duct carcinoma successfully treated with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quality of Life | 2003 |
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Gemcitabine; Humans; Life Tables; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2002 |
Gemcitabine therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate | 2002 |
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis | 2003 |
[Pancreatic carcinoma--overcome technically but not oncologically].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Risk Factors | 2003 |
Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Endothelium, Vascular; Fibroblast Growth Factor 2; Gemcitabine; Humans; Implants, Experimental; Interferon-alpha; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Morpholines; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2003 |
[Pancreatic cancer--diagnostics and therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Neoadjuvant Therapy; Pancreatic Neoplasms | 2003 |
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Division; Cetuximab; Cobalt Radioisotopes; Deoxycytidine; Electrophoresis, Polyacrylamide Gel; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; GRB2 Adaptor Protein; Humans; Immunosorbent Techniques; Iodine Radioisotopes; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
It's what's inside that counts.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms | 2003 |
[A case of advanced pancreatic cancer treated with gemcitabine hydrochloride].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2003 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Luminescent Proteins; Male; Mice; Mice, Nude; Models, Animal; Neoplasm Metastasis; Pancreatic Neoplasms; Predictive Value of Tests; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured | 2003 |
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Radioimmunotherapy; Time Factors; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line.
Topics: Brefeldin A; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
[A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Karnofsky Performance Status; Liver Neoplasms; Pancreatic Neoplasms | 2003 |
Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; gamma-Linolenic Acid; Gemcitabine; Pancreatic Neoplasms | 2003 |
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Membrane; Deoxycytidine; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Membrane Transport Proteins; Pancreatic Neoplasms; Poly A; Polymerase Chain Reaction; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Time Factors; Transfection | 2003 |
Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fingers; Gangrene; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Iloprost; Male; Middle Aged; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Vasodilator Agents | 2003 |
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2003 |
[Chemoradiation therapy for stage IV pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Intraoperative Care; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate | 2003 |
[Novel chemoradiotherapy for locally advanced pancreatic cancer using arterial infusion chemotherapy following the alteration of peripancreatic blood flow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Intraoperative Care; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Survival Rate | 2003 |
[Gemcitabine infusion via splenic artery for advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Pancreatic Neoplasms; Quality of Life; Remission Induction; Splenic Artery | 2003 |
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA; RNA Interference; RNA, Small Interfering; Transfection | 2003 |
Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Gelatin; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution; Transplantation, Heterologous | 2003 |
Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Ascites; Ascitic Fluid; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Time Factors; Transplantation, Heterologous | 2004 |
[Arterial oil chemoembolization: a new method of treatment for pancreatic cancer].
Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspase 9; Caspases; Cytochromes c; Deoxycytidine; Drug Resistance, Neoplasm; fas Receptor; Female; Gemcitabine; Intracellular Signaling Peptides and Proteins; Membrane Potentials; Mice; Mice, Inbred BALB C; Mice, SCID; Mitochondria; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Tumor Cells, Cultured | 2004 |
Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Flow Cytometry; Gemcitabine; Lipopeptides; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligopeptides; Pancreas; Pancreatic Neoplasms; Spleen; Survival Analysis; Ultrasonography | 2004 |
In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Irradiation; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Deoxycytidine; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interferon-gamma; Ligands; Pancreatic Neoplasms; Plasmids; Protein Binding; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Time Factors; Transcription Factors | 2004 |
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
[Outcomes of treatment with gemcitabine for unresectable pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2004 |
Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerases; Pyridines | 2004 |
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Cell Death; Cell Division; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Sirolimus; Transplantation, Heterologous | 2004 |
Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Phospholipid Ethers; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction | 2004 |
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Ribonucleoside Diphosphate Reductase; src-Family Kinases; Transcription Factors; Tyrosine | 2004 |
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine | 2004 |
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Ribonucleotide Reductases | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Pancreatic Neoplasms; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Heart Neoplasms; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction | 2004 |
A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Caspase 3; Caspases; Cell Adhesion Molecules; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Cytochromes c; Deoxycytidine; Drug Resistance, Viral; Enzyme Activation; Gemcitabine; Gene Silencing; GPI-Linked Proteins; Humans; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; src-Family Kinases; Transfection | 2004 |
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Small Interfering; src-Family Kinases; Tumor Cells, Cultured | 2004 |
[Concurrent chemoradiotherapy using full-dose gemcitabine for patients with unresectable pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2004 |
Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms | 2004 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Heart Failure; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Stents; Survivors; Tegafur; Uracil | 2004 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Infusions, Intravenous; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thalidomide | 2004 |
Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Decorin; Deoxycytidine; Drug Interactions; Extracellular Matrix; Extracellular Matrix Proteins; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2004 |
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Retroviridae; Ribonucleoside Diphosphate Reductase; RNA Interference | 2004 |
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Kinetics; Oligonucleotides, Antisense; Pancreatic Neoplasms; Transfection | 2004 |
Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA, Complementary; Female; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Interferon-alpha; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Retroviridae; Transgenes | 2004 |
[Role of postoperative adjuvant chemotherapy with gemcitabine for pancreatic cancer: feasibility and anti-tumor effect].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Retrospective Studies; Survival Rate; Vomiting, Anticipatory | 2004 |
Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Humans; Interferon-gamma; Muscle Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protein Biosynthesis; Proteins; Reactive Oxygen Species; Selenoprotein P; Selenoproteins; Tumor Cells, Cultured | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fibrosis; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2003 |
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Gemcitabine and haemolytic-uraemic syndrome.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2004 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Dipyridamole; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms | 2004 |
[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Survival Rate | 2004 |
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; United Kingdom | 2004 |
Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter.
Topics: Adenoviridae; Animals; Apoptosis Regulatory Proteins; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; Genetic Therapy; Humans; Liver; Liver Neoplasms; Membrane Glycoproteins; Mice; Mice, Nude; Oligopeptides; Pancreatic Neoplasms; Promoter Regions, Genetic; Telomerase; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2005 |
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms; Quality of Life; Tegafur; Uracil | 2004 |
[Pancreatic carcinoma: progress in therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2004 |
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; NF-kappa B; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Retrospective Studies; Survival Analysis; Time Factors | 2004 |
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Ceramides; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Glucosyltransferases; Humans; Pancreatic Neoplasms; Sphingomyelin Phosphodiesterase; Sphingomyelins | 2004 |
[Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Transfusion, Autologous; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Killer Cells, Natural; Liver Neoplasms; Male; Pancreatic Neoplasms; Treatment Outcome | 2004 |
[The QOL of the patient with advanced pancreatic carcinoma was changed for the better with combination therapy consisting of arterial chemotherapy and injection of interferon].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Quality of Life | 2004 |
[A case of unresectable pancreatic cancer showing tumor dormancy treated with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Palliative Care; Pancreatic Neoplasms; Treatment Outcome | 2004 |
[Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Surveys and Questionnaires | 2004 |
Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Conformal | 2004 |
Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gemcitabine; Genes, erbB; Humans; Immunoblotting; Mice; Pancreatic Neoplasms; Phosphorylation; Rabbits; Radiation-Sensitizing Agents; Receptor, ErbB-4; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Male; Mice; Mice, Nude; NIH 3T3 Cells; Pancreatic Neoplasms; Ribonucleotide Reductases; src-Family Kinases | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2004 |
Impact of gemcitabine on the treatment of metastatic pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2005 |
New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Elastomers; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Polyurethanes; Prognosis; Secondary Prevention; Time Factors | 2005 |
Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Coronary Artery Disease; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Failure; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema | 2004 |
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Decitabine; Deoxycytidine; DNA Methylation; DNA Modification Methylases; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interferons; Pancreatic Neoplasms; Signal Transduction | 2005 |
Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyclohexanes; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; O-(Chloroacetylcarbamoyl)fumagillol; Pancreatic Neoplasms; Sesquiterpenes; Transplantation, Heterologous | 2005 |
Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cations; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Combined Modality Therapy; Culture Media, Conditioned; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Humans; Immunoprecipitation; Interferon-beta; Liposomes; Pancreatic Neoplasms; Plasmids; ras GTPase-Activating Proteins; Signal Transduction; SOS1 Protein; Time Factors; Transfection | 2005 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Pancreatic Neoplasms; Polysaccharides; Prognosis; Pyridines; Survival Analysis; Survival Rate; Tegafur; Ultrasonography | 2005 |
Unusual liver abscess.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Abscess; Liver Neoplasms; Male; Pancreatic Neoplasms; Seminoma; Testicular Neoplasms; Tomography, X-Ray Computed | 2005 |
Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenograf
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2005 |
Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas.
Topics: Adult; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed | 2005 |
[A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life | 2005 |
[Local recurrence of pancreatic cancer successfully treated with gemcitabine].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
[Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Quality of Life; Survivors | 2005 |
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antimetabolites, Antineoplastic; B-Lymphocytes; CD4-CD8 Ratio; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; T-Lymphocytes | 2005 |
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; RNA, Small Interfering; Survival Rate | 2005 |
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinases; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Serine; Transfection | 2005 |
Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytidine; Deoxycytidine; Deoxyribonucleotides; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Ribonucleotides; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Impact of different treatment methods on survival in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Stents; Survival Analysis; Time Factors | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enkephalin, Methionine; Fluorouracil; Gemcitabine; Growth Substances; Humans; Male; Mice; Mice, Nude; Naloxone; Narcotics; Pancreatic Neoplasms; Receptors, Opioid; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Humans; Mitogen-Activated Protein Kinases; Neuropilin-1; Pancreatic Neoplasms; Phenotype; Signal Transduction; Transfection; Tumor Cells, Cultured; Up-Regulation | 2005 |
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Time Factors | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiotherapy; Smoking; Tomography, X-Ray Computed | 2005 |
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Analysis | 2005 |
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; beta-Galactosidase; Colorimetry; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2005 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CpG Islands; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Female; Gemcitabine; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Oligonucleotides; Pancreatic Neoplasms; Receptors, Cell Surface; Toll-Like Receptor 9; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; ErbB Receptors; Exons; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor | 2005 |
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.
Topics: 5'-Nucleotidase; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Gemcitabine; Genes, ras; Humans; Immunoblotting; Immunohistochemistry; Indoles; Male; Mevalonic Acid; Mice; Mitogen-Activated Protein Kinase 1; Mutation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins p21(ras); rho GTP-Binding Proteins | 2005 |
[Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Celecoxib; Cell Cycle; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, SCID; Microcirculation; Microscopy, Fluorescence; Molecular Sequence Data; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein Structure, Tertiary; Recombinant Proteins; Thrombospondin 1; Time Factors | 2005 |
Predictive value of heparanase expression in the palliative therapy of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Biomarkers; Deoxycytidine; Female; Gemcitabine; Germany; Glucuronidase; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2005 |
Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspase 8; Caspases; Deoxycytidine; Enzyme Activation; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Gemcitabine; Genes, Dominant; Humans; Pancreatic Neoplasms; Retroviridae; Ribonucleotide Reductases; Transfection; Tumor Cells, Cultured | 2005 |
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Culture Media; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; NF-kappa B; Pancreatic Elastase; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2005 |
Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
[Survey of gemcitabine treatment for advanced pancreatic cancer in 20 hospitals of Nagano Prefecture].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2005 |
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Topics: Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Recombinant Proteins; Taxoids; Time Factors; Trastuzumab | 2005 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
In focus: advanced pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Meta-Analysis as Topic; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chronic Disease; Deoxycytidine; Diterpenes; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mitochondria; Oxidative Stress; Pain; Pancreas; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; TRPV Cation Channels | 2006 |
Pancreatic cancer combo treatment promising.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Italy; Pancreatic Neoplasms; Treatment Outcome | 2005 |
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Mice, Inbred ICR; Mice, Nude; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2005 |
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Staging; Neoplasms, Experimental; Pancreatic Neoplasms; Random Allocation; Sensitivity and Specificity; Serum Amyloid A Protein; Transplantation, Heterologous | 2005 |
Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms | 2005 |
[Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Stents; Tegafur | 2005 |
[Combined systemic and intraarterial chemotherapy with gemcitabine and concomitant external-beam radiotherapy in patients with liver metastasis from pancreatic cancer--report of two cases].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage | 2005 |
Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Coloring Agents; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunohistochemistry; Liver; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Organophosphorus Compounds; Pancreatic Neoplasms; Tetrazolium Salts; Thiazoles; Tubulin; Umbilical Veins | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; Humans; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2005 |
[Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine].
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Thioredoxin-Disulfide Reductase | 2005 |
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Cell Line, Tumor; Deoxycytidine; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Epoxy Compounds; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Leukemia; Lymphoma; Mice; Mice, Nude; Models, Chemical; Models, Molecular; Pancreatic Neoplasms; Stereoisomerism; Time Factors; Xanthones | 2005 |
[A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Edema; Furosemide; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisolone; Spironolactone | 2005 |
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endothelial Cells; ErbB Receptors; Gemcitabine; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Health Status Indicators; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
[A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2005 |
[Intraperitoneal and intrapleural gemcitabine in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pleural Cavity; Pleural Neoplasms | 2005 |
[Gemcitabine concurrent with radiation for locally advanced pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2005 |
[A case of advanced pancreatic cancer treated with chemoradiation].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2005 |
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; HT29 Cells; Humans; Leukemia P388; Leukocyte Count; Mice; Mice, SCID; Neutropenia; Nucleoside Transport Proteins; Pancreatic Neoplasms; Thioinosine; Xenograft Model Antitumor Assays | 2006 |
Gemcitabine-related radiation recall in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Injuries | 2006 |
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinases; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2006 |
Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Genetic Vectors; Hepatocyte Growth Factor; Humans; Injections; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Hymecromone; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Outcome | 2006 |
[An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatic Neoplasms | 2005 |
Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylserines; Transplantation, Heterologous | 2006 |
p8 is a new target of gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Squamous cell carcinoma of the pancreas: report of a case and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Gemcitabine; Humans; Incidence; Male; Neoplasm Staging; Pancreatic Neoplasms; Prognosis | 2006 |
Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate | 2006 |
[A case of drug-induced interstitial pneumonitis after gemcitabine treatment for advanced pancreatic cancer].
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Methylprednisolone Hemisuccinate; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Prednisolone; Pulse Therapy, Drug; Tomography, X-Ray Computed | 2006 |
Putting the chemo in chemoradiation for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation Dosage | 2006 |
MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Enzyme Activation; Gemcitabine; Homeodomain Proteins; Humans; Pancreatic Neoplasms | 2005 |
A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Ribonucleotide Reductases; Sulfonamides; Tetrazolium Salts; Thiazoles | 2006 |
[Arterial infusion chemotherapy and radiotherapy after vascular supply distribution for pancreatic carcinoma].
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2006 |
Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
[The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Naphthoquinones; Pancreatic Neoplasms; RNA, Messenger | 2005 |
[Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Survivors | 2006 |
Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Interferons; Pancreatic Neoplasms; Receptors, Interferon | 2006 |
Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Green Fluorescent Proteins; Humans; Immunohistochemistry; Intermediate Filament Proteins; Mice; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Transfection; Transplantation, Heterologous | 2006 |
Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
Topics: Adenocarcinoma; Animals; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; HCT116 Cells; Hedgehog Proteins; Humans; Paclitaxel; Pancreatic Neoplasms; Radiation, Ionizing; Time Factors; Veratrum Alkaloids | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
[Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Mass Screening; Mesothelioma; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms | 2006 |
Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heat-Shock Proteins; Humans; Lectins, C-Type; Pancreatic Neoplasms; Pancreatitis-Associated Proteins; RNA, Messenger | 2006 |
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transfection | 2006 |
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Transcriptional Activation; Treatment Outcome; Tumor Suppressor Proteins | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Survival Rate | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Time Factors | 2006 |
XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antimetabolites, Antineoplastic; Arm; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Diagnostic Errors; Female; Gemcitabine; Humans; Keratins; Neoplasm Proteins; Neprilysin; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphopyruvate Hydratase; Soft Tissue Neoplasms; Subcutaneous Tissue; Vimentin | 2006 |
Primary carcinoid tumour of the pancreas.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diagnostic Errors; Gemcitabine; Humans; Liver Neoplasms; Liver Transplantation; Male; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction | 2006 |
Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cerebellar Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2006 |
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Pancreatic Neoplasms; Survival Analysis | 2006 |
Gemcitabine-induced rectus abdominus radiation recall.
Topics: Abdominal Muscles; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Myositis; Pancreatic Neoplasms; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Tomography, X-Ray Computed | 2006 |
[Present and future home therapy in advanced stage of pancreatic cancer].
Topics: Ambulatory Care; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Home Care Services, Hospital-Based; Humans; Neoplasm Staging; Pain; Pancreatic Neoplasms; Quality of Life | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases | 2006 |
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Deoxycytidine; Electrophoretic Mobility Shift Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Laser Scanning Cytometry; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; ortho-Aminobenzoates; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp Transcription Factors; Sp1 Transcription Factor; Sp3 Transcription Factor; Sp4 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Staging; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fibrin Tissue Adhesive; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatectomy; Pancreatic Neoplasms; Rhodamines; Transplantation, Heterologous | 2006 |
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA, Messenger; Tegafur; Uracil; Xenograft Model Antitumor Assays | 2006 |
[Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Disease Progression; fas Receptor; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Remission Induction | 2006 |
An in vivo platform for translational drug development in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Kinetics; Mice; Mice, Nude; Pancreatic Neoplasms; Predictive Value of Tests; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Malignant acanthosis nigricans and tripe palms associated with pancreatic adenocarcinoma.
Topics: Acanthosis Nigricans; Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Hand Dermatoses; Humans; Pancreatic Neoplasms | 2006 |
Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Female; Gemcitabine; Genetic Vectors; Humans; Membrane Fusion Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Pancreatic Neoplasms; Survival Rate; Transduction, Genetic; Tumor Cells, Cultured | 2006 |
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2.
Topics: Antimetabolites, Antineoplastic; Caspase 2; Caspase Inhibitors; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kinetics; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Anticoagulants; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Injections, Intra-Arterial; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; Warfarin | 2006 |
Combined gemcitabine and alpha-interferon therapy for pancreatic cancer: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Interferon-alpha; Liver Neoplasms; Male; Pancreatic Neoplasms | 2006 |
[Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms | 2006 |
[Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2006 |
[A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Cricetinae; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Therapy; Genetic Vectors; Male; Mesocricetus; Neoplasms, Experimental; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms | 2006 |
RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.
Topics: Adult; Aged; Bromodeoxyuridine; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Killer Cells, Natural; Middle Aged; Pancreatic Neoplasms | 2006 |
Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Genome, Human; Humans; Pancreatic Neoplasms; Phosphotransferases; RNA, Small Interfering | 2006 |
[A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pleural Effusion, Malignant; Tomography, X-Ray Computed | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning.
Topics: Adenocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Imaging, Three-Dimensional; Lymph Nodes; Lymphatic Vessels; Male; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiography, Abdominal; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt | 2006 |
[A pilot study on the impact of the drug resistance on the radioresistance in human pancreatic cancer cell lines].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Tolerance | 2006 |
[Treatment of squamous cell carcinoma of the pancreas with gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome | 2006 |
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; GTP-Binding Proteins; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Transglutaminases | 2006 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms | 2006 |
Molecular features linked to the growth-inhibitory effects of gemcitabine on human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
Exatecan and gemcitabine: no better than gemcitabine only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2006 |
[A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survivors; Tegafur; Uracil | 2006 |
[Pancreatic cancer].
Topics: Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Palliative Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Tomography, X-Ray Computed; Tumor Suppressor Protein p53 | 2006 |
Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Lentivirus; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference | 2006 |
Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
Topics: Animals; Annexin A5; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Antisense; RNA, Messenger; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2007 |
Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drainage; Gemcitabine; Humans; Jaundice, Obstructive; Lower Body Negative Pressure; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Stents; Survival Analysis | 2006 |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous | 2006 |
Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Injections, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Pancreatic Neoplasms; Portal Vein; Rats; Rats, Nude; Transplantation, Heterologous | 2006 |
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
Topics: Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 8; Cell Communication; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gap Junctions; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Phenylbutyrates; Time Factors; Tumor Cells, Cultured | 2007 |
Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin | 2006 |
Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chromatography, Affinity; Cromolyn Sodium; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Reporter; Immunoprecipitation; Luciferases; Mice; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins | 2006 |
Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Markov Chains; Medicare; Models, Economic; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2007 |
Adjuvant therapy for pancreatic cancer: a time that has not yet come.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Deoxycytidine; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Up-Regulation; Vorinostat | 2007 |
[Low-dose gemcitabine concurrent with radiation therapy for locally advanced pancreatic carcinoma].
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage | 2006 |
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biomarkers; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Adjuvant therapy for pancreatic cancer: one small step forward.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2007 |
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2007 |
Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Treatment Failure | 2007 |
Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Coumestrol; Deoxycytidine; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Gemcitabine; Genistein; Humans; In Vitro Techniques; Pancreatic Neoplasms; Predictive Value of Tests; Tamoxifen | 2007 |
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Veratrum Alkaloids; Xenograft Model Antitumor Assays | 2007 |
Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; Ligands; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; X-Linked Inhibitor of Apoptosis Protein; X-Rays | 2007 |
Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2007 |
Gemcitabine plus cisplatin in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome | 2007 |
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Pancreatic cancer: an update on a 'stealth' cancer. Treatment advances have been slow in coming. What makes this cancer so intractable?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Early Diagnosis; Family Health; Gemcitabine; Humans; Mice; Pancreas; Pancreatic Neoplasms | 2007 |
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunologic Memory; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Survival Analysis; T-Lymphocytes, Cytotoxic; Treatment Outcome; Vaccination | 2007 |
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2007 |
Acute tubulointerstitial nephritis associated with long-term gemcitabine therapy.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Nephritis, Interstitial; Pancreatic Neoplasms | 2007 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Calcimycin; Calcium Channels; Carcinoma, Pancreatic Ductal; Cell Death; Cell Differentiation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Ionophores; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Tumor Cells, Cultured | 2007 |
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Japan; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Time Factors | 2007 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |
K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Silencing; Genes, ras; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plasmids; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic; Transfection; Transplantation, Heterologous | 2007 |
[A resected case of effective treatment with gemcitabine for advanced pancreatic cancer with peritoneal metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Node Excision; Male; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Splenectomy; Tomography, X-Ray Computed | 2007 |
Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2007 |
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Protein Subunits; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis | 2007 |
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2007 |
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Capillary Permeability; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Compounding; Evans Blue; Gemcitabine; Liposomes; Luciferases; Luminescence; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Permeability | 2008 |
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Reactive Oxygen Species | 2007 |
Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Cell Division; Cell Line, Tumor; Deoxycytidine; Dihydrotestosterone; Drug Therapy, Combination; Flutamide; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Androgen; Testosterone; Xenograft Model Antitumor Assays | 2007 |
The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphoglycerate Kinase; Rhabdomyosarcoma | 2007 |
Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms | 2007 |
Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2007 |
Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Treatment Outcome | 2007 |
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Deoxycytidine; Dioxolanes; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Treatment Outcome; Tritium; Tumor Cells, Cultured; Uridine; Xenograft Model Antitumor Assays | 2007 |
Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Ferrosoferric Oxide; Gemcitabine; Humans; Magnetics; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyesters; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
[MMW drug award for gemcitabine. Cytostatic drug with growing indications].
Topics: Antimetabolites, Antineoplastic; Awards and Prizes; Deoxycytidine; Drug Approval; Gemcitabine; Germany; Neoplasms; Pancreatic Neoplasms; Treatment Outcome | 2006 |
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Humans; Matrix Metalloproteinase Inhibitors; Models, Biological; Pancreatic Neoplasms; Platinum Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Cirrhosis; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms | 2007 |
Endoscopic ultrasound-guided fine-needle injection of immature dendritic cells into advanced pancreatic cancer refractory to gemcitabine: a pilot study.
Topics: Adult; Antimetabolites, Antineoplastic; Dendritic Cells; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopy; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pilot Projects | 2007 |
A pure invasive micropapillary carcinoma of the pancreatic head: long disease-free survival after pancreatoduodenectomy and adjuvant chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Duodenum; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms | 2007 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2007 |
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proto-Oncogene Proteins; RNA Interference; S100 Calcium-Binding Protein A4; S100 Proteins; Time Factors; Transfection | 2007 |
Pancreatic cancer: new studies, new treatments. "Periodontal disease,", "gemcitabine" and "adjuvant therapy" are the new buzzwords.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Periodontal Diseases; Radiotherapy, Adjuvant; Smoking | 2007 |
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras) | 2007 |
siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Proto-Oncogene Mas; Receptor, trkA; RNA, Small Interfering; Transfection | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2007 |
Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Deoxycytidine; Drug Synergism; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Mycophenolic Acid; Pancreatic Neoplasms; Sirolimus | 2007 |
Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Mice, SCID; Neoadjuvant Therapy; Neoplasm Transplantation; Pancreatectomy; Pancreatic Neoplasms; Transplantation, Heterologous | 2007 |
Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mitomycin; Pancreatic Neoplasms | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Oncolytic Viruses; Pancreatic Neoplasms; Simplexvirus; Virus Replication | 2008 |
Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: a case treated with gemcitabine.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Skin Neoplasms | 2007 |
Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; Treatment Outcome | 2007 |
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Topics: Alkylating Agents; Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Glucose; Ifosfamide; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2008 |
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Calcium Gluconate; Deoxycytidine; Diphenhydramine; Female; gamma-Aminobutyric Acid; Gemcitabine; Histamine H1 Antagonists; Humans; Magnesium Sulfate; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pregabalin; Psychomotor Agitation | 2008 |
[A case of unresectable advanced pancreatic cancer with peritoneal dissemination responding to continuous dose S-1 monotherapy after chemo-radiation therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Cavity; Peritonitis; Quality of Life; Tegafur | 2007 |
Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms | 2007 |
Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays | 2007 |
Successful management of multiple liver metastases from pancreatic neuroendocrine tumor by hepatic arterial administration of cisplatin powder.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pancreaticoduodenectomy; Powders; Remission Induction | 2007 |
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fatty Acids, Omega-3; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured | 2007 |
Trial of adjuvant gemcitabine for pancreatic cancer: the jury is still out.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms | 2007 |
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gastrins; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Cholecystokinin B; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; United States | 2007 |
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry | 2008 |
Development and characterization of gemcitabine-resistant pancreatic tumor cells.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhesion; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Immunoblotting; Membrane Proteins; Mesoderm; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured | 2007 |
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Green Fluorescent Proteins; Humans; Interleukin-4; Leukocidins; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Interleukin-4; Recombinant Fusion Proteins; Transfection; Xenograft Model Antitumor Assays | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
[Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intra-Arterial; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Outpatients; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2007 |
Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2008 |
Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Needle; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Molecular Chaperones; Neoplasm Proteins; Pancreatic Neoplasms; Proteomics | 2007 |
Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer.
Topics: Adenoviridae; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Mice; Models, Genetic; Pancreatic Neoplasms; Promoter Regions, Genetic; Telomerase; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic | 2008 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Clinical potential of an antitumor drug sensitivity test and diffusion-weighted MRI in a patient with a recurrent solid pseudopapillary tumor of the pancreas.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography | 2007 |
Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Deuterium Oxide; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Stem Cell Assay | 2008 |
[A long-term survivor case with good quality of life due to biliary bypass and gemcitabine for advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survivors | 2007 |
Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromones; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Gemcitabine; Humans; MAP Kinase Signaling System; Morpholines; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2008 |
CXCL14 expression and potential function in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Chemokines, CXC; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Messenger; Time Factors; Transcription Factor RelA; Up-Regulation; Vascular Endothelial Growth Factor A | 2008 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Serum; Signal Transduction; src-Family Kinases; Transfection | 2008 |
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Immunoprecipitation; Mice; Mice, SCID; Pancreatic Neoplasms; Radiography | 2007 |
Survival and prognostic factors of unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hospitals, Teaching; Humans; Injections, Intravenous; Korea; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Prognosis; Radiotherapy; Retrospective Studies; Social Support; Survival Rate; Treatment Outcome | 2008 |
Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis | 2008 |
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2008 |
[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Deoxycytidine; Edema; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2007 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Platinum Compounds; Tomography, X-Ray Computed | 2007 |
Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
[A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer].
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
[A case of salvage chemotherapy with gemcitabine hydrochloride and nedaplatin for gemcitabine-refractory pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms; Salvage Therapy; Treatment Failure | 2008 |
[Fatal liver failure associated with gemcitabine hydrochloride therapy].
Topics: Aged; Deoxycytidine; Gemcitabine; Humans; Liver Failure; Male; Pancreatic Neoplasms; Treatment Failure | 2008 |
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; fas Receptor; Gemcitabine; Humans; Indoles; Lymphatic Metastasis; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Phloroglucinol; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
[A case of gemcitabine-based chemo-radiation therapy for unresectable pancreatic cancer with liver metastases].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2007 |
[Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2007 |
Persistence of side population cells with high drug efflux capacity in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Line, Tumor; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms | 2008 |
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Enzyme Activation; Fibroblasts; Gemcitabine; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Stromal Cells | 2008 |
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Topics: Angiotensin II; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2007 |
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Genetic Vectors; Humans; Inverted Repeat Sequences; Mice; Mice, Nude; Molecular Sequence Data; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Specific Pathogen-Free Organisms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Survival Rate | 2008 |
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy | 2008 |
Gemcitabine resistance in pancreatic cancer: picking the key players.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms | 2008 |
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; HMGA1a Protein; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Tumor Cells, Cultured | 2008 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and management.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Diuretics; Drug Therapy, Combination; Female; Gemcitabine; Humans; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
[Unresectable pancreatic cancer in the Hokuriku area].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Utilization; Female; Gemcitabine; Humans; Japan; Male; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Surveys and Questionnaires; Survival Rate | 2008 |
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Weight Loss | 2007 |
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Gold; Humans; Immunoconjugates; Metal Nanoparticles; Pancreatic Neoplasms | 2008 |
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms | 2008 |
Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cytidine; Cytidine Triphosphate; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents | 2008 |
Inhibition of proliferation to omega-3 fatty acids in chemoresistant pancreatic cancer cells: mechanism of action may be more complex.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Fatty Acids, Omega-3; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; STAT3 Transcription Factor | 2008 |
Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2008 |
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Tegafur | 2008 |
Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hospitals, University; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Lactic Acid; Mitochondria; Pancreatic Neoplasms; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Time Factors; Ultrasonography, Interventional | 2008 |
Compassionate approval process for experimental gene-based products.
Topics: Adult; Aged; Cancer Vaccines; Deoxycytidine; Drug Approval; Empathy; Female; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; Li-Fraumeni Syndrome; Male; Pancreatic Neoplasms; Terminal Care; Therapies, Investigational; Time Factors; United States; United States Food and Drug Administration; Viral Vaccines | 2008 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Receptors, Thrombin; Signal Transduction; Up-Regulation | 2008 |
Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
Topics: Aminoglycosides; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Carbocyanines; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Synergism; Enediynes; Fluorescent Dyes; Gemcitabine; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Pancreatic Neoplasms; RNA, Messenger | 2008 |
Protein kinase C: a target for therapy in pancreatic cancer.
Topics: Adenocarcinoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Pancreatic Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Reference Values | 2008 |
[A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiography; Tegafur | 2008 |
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lasers; Male; Microdissection; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Messenger; Tetrazolium Salts; Thiazoles | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors | 2007 |
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Topics: Aged; Budgets; Deoxycytidine; Drug Costs; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; United States | 2008 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Naturopathy; Pancreatic Neoplasms; Pastoral Care; Physical Therapy Modalities | 2008 |
FDA expands access to gemcitabine for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Humans; Pancreatic Neoplasms; United States; United States Food and Drug Administration | 1995 |
From the Food and Drug Administration.
Topics: Abciximab; Acquired Immunodeficiency Syndrome; Angioplasty; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Growth Hormone; Humans; Immunoglobulin Fab Fragments; Nonprescription Drugs; Pancreatic Neoplasms; Platelet Aggregation Inhibitors; Recombinant Proteins; Spermatocidal Agents; United States; United States Food and Drug Administration | 1995 |
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Sulfonylurea Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
ODAC recommends full approval for Gemzar for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Pancreatic Neoplasms; United States; United States Food and Drug Administration | 1995 |
Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.
Topics: Adenosine Triphosphate; Cell Cycle; Cell Survival; Cytidine Triphosphate; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Guanosine Triphosphate; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Thymine Nucleotides; Tumor Cells, Cultured | 1996 |
Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 1996 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Gemcitabine for treatment of pancreatic cancer.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 1996 |
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Pancreatic Neoplasms; Transplantation, Heterologous; Treatment Outcome | 1996 |
Gemcitabine: safety profile unaffected by starting dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Kidney Function Tests; Liver Function Tests; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Ribonucleotide Reductases; Vomiting | 1996 |
[Oncology--a common language, new perspectives. Lilly Oncology Global Medical Conference, Indianapolis, 1996].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Medical Oncology; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 1996 |
Analgesic effects of chemotherapy?
Topics: Analgesics; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pain; Pancreatic Neoplasms | 1998 |
Clinical benefit as a primary efficacy endpoint.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 1998 |
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, Inbred ICR; Mice, SCID; Oligopeptides; Pancreatic Neoplasms; Transplantation, Heterologous | 1998 |
Unresectable pancreatic adenocarcinoma treated with palladium-103 implant and chemoradiation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Brachytherapy; Deoxycytidine; Fatal Outcome; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palladium; Pancreatic Neoplasms; Radioisotopes; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1998 |
Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Nucleoside Deaminases; Pancreatic Neoplasms; Thymidine Kinase; Transplantation, Heterologous | 1998 |
Gemcitabine--a major advance?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Pancreatic Neoplasms | 1998 |
Anal pruritus after cancer chemotherapy with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Pruritus Ani | 1999 |
[Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 1999 |
Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Creatinine; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Hemoglobins; Hemolytic-Uremic Syndrome; Humans; Kidney; Male; Microcirculation; Pancreatic Neoplasms; Thrombosis | 1999 |
Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.
Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Duodenal Neoplasms; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms; Reticulocyte Count; Thrombocytopenia | 1999 |
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 1999 |
Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Oligopeptides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Vancomycin-induced thrombocytopenia.
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bacteremia; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Platelet Count; Staphylococcal Infections; Thrombocytopenia; Vancomycin | 1999 |
Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Heart; Humans; Liver Neoplasms; Lung; Male; Pancreatic Neoplasms; Respiratory Distress Syndrome; Ventricular Fibrillation | 1999 |
[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Bryostatins; Deoxycytidine; DNA Mutational Analysis; Ethers, Cyclic; Gemcitabine; Genes, p53; Genes, ras; Humans; Karyotyping; Lactones; Macrolides; Male; Mice; Mice, SCID; Neoplasm Transplantation; Oligopeptides; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Needle; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis; Ribonucleotide Reductases | 1999 |
Acute myocardial infarction following gemcitabine therapy--a case report.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Male; Middle Aged; Myocardial Infarction; Pancreatic Neoplasms | 1999 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Incidence; Liver; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Retrospective Studies; Stents | 2000 |
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Sex Factors; Survival Analysis; Time Factors | 2000 |
Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Bile; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Immunologic Factors; In Vitro Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Spleen; T-Lymphocytes; Tissue Extracts | 2000 |
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cetuximab; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Severe acute lung injury induced by gemcitabine.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung; Lung Injury; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema; Severity of Illness Index | 2000 |
Solitary cutaneous metastasis on the buttock: a disclosing sign of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Buttocks; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Skin Neoplasms | 2000 |
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Atrial Fibrillation; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2000 |
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Deoxycytidine; Down-Regulation; Endothelium; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2000 |
Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Chromatography, Affinity; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pancreatic Neoplasms; Phenylalanine; Thiophenes; Time Factors; Tumor Cells, Cultured | 2000 |
[Splenic vascular occlusion in the course of pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Infarction; Middle Aged; Pancreatic Neoplasms; Spleen; Tomography, X-Ray Computed | 2000 |
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Jaundice; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Cyst; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2000 |
Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contracture; Deoxycytidine; Drug Interactions; Edema; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisone; Ribonucleotide Reductases | 2000 |
Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Arabinonucleosides; Bromodeoxyuridine; Catalysis; Cell Division; Cell Nucleus; Cladribine; Cytarabine; Deoxycytidine; Drosophila melanogaster; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Osteosarcoma; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Promoter Regions, Genetic; Retroviridae; Substrate Specificity; Thymidine; Thymidine Kinase; Transduction, Genetic; Tumor Cells, Cultured | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Urinary Tract Infections | 2000 |
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Adenocarcinoma; Androstadienes; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Wortmannin | 2000 |
Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kinetics; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
[Severe ischemic myopathy localized in an irradiated area following gemcitabine therapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Pancreatic Neoplasms; Radiotherapy | 2000 |
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
[Experience with chemotherapy for advanced pancreatic carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Cotton-wool spots associated with pancreatic carcinoma.
Topics: Adrenal Gland Neoplasms; Biomarkers, Tumor; Bone Neoplasms; Deoxycytidine; Eye Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Vision Disorders | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Arabidopsis Proteins; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspases; Computer Systems; Deoxycytidine; Fas Ligand Protein; fas Receptor; Fatty Acid Desaturases; Flow Cytometry; Gemcitabine; GPI-Linked Proteins; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Receptors, Tumor Necrosis Factor, Member 6b; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2001 |
Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrimidines; Pyrroles; Ribonucleotide Reductases; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Gemcitabine; Genetic Therapy; Humans; In Situ Nick-End Labeling; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 2001 |
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Sulindac; Tumor Cells, Cultured | 2001 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis | 2001 |
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Nude; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2001 |
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Alitretinoin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Tretinoin; Tumor Cells, Cultured | 2001 |
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Tumor Cells, Cultured; Wortmannin; Xenograft Model Antitumor Assays | 2001 |
Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Blotting, Northern; Blotting, Western; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Oligonucleotides, Antisense; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Gemcitabine (Gemzar) and radiotherapy--is it feasible?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies | 2002 |
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2002 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Selection; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2001 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |
[Regional intra-arterial infusion chemotherapy for pancreatic cancer: an experimental study].
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Dogs; Gemcitabine; Infusions, Intra-Arterial; Kidney; Male; Pancreatic Neoplasms; Tissue Distribution | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2002 |
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic.
Topics: Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Ribonucleotide Reductases; Tetracyclines; Transfection; Tumor Cells, Cultured | 2002 |
Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; IMP Dehydrogenase; Kinetics; Leukemia, Promyelocytic, Acute; Liver Neoplasms, Experimental; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Ribavirin; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Stem Cell Assay | 1992 |